"study_alias","study_desc","nct_number"
I8F-MC-GPHM,Weight Loss Maintenance after Intensive Lifestyle Lead-in,"04657016"
I3Y-MC-JPCW,Ph III - Abemaciclib - Adjuvant,"04752332"
I6T-MC-AMBT,Miri Reformulation PK (BE) HV,"05515601"
I5T-MC-AACQ,"Multi-center, randomized, double-blind phase 3b study in adults with early symptomatic Alzheimer's disease","05738486"
J1I-MC-GZBM,CWM3 - High-Risk Obesity Pts Eligible for Bariatric Surgery,"05882045"
F3Z-MC-IORW,OUS Pen Platform Clinical Trial #2,"05893797"
I8F-MC-GPIT,High Dose Tirzepatide,"06037252"
J2P-MC-LXBD,Phase 2b evaluation of LY3556050 in DPNP,"06074562"
J2A-MC-GZGW,Add-on to basal insulin,"06109311"
I7S-MC-HBEO,Phase 2b study to evaluate the efficacy and safety of mevidalen in patients with mild to moderate AD,"06538116"
J3E-MC-EZDC,Clinical Trial (Phase 2b),"06598631"
I1F-MC-RHCG,EMA Pediatric PsA Regulatory Commitment Study,NA
I3Y-MC-JPCE,Ph 1b - Abemaciclib + I/O agent - NSCLC,NCT02779751
I3Y-MC-JPCF,MONARCH E_Ph III - Abemaciclib - Adj High Risk Breast - HR+,NCT03155997
I3Y-MC-JPCS,Ph1b - Chemo + Abema – Pediatric Solid Tumors,NCT04238819
J4B-MC-OKAA,PRV-FTD-101; Ph 1/11 PR006A FTD,NCT04408625
I5T-MC-AACH,Open Label N3pG1 for I5T-MC-AACG Placebo Completers,NCT04640077
I8F-MC-GPHL,Weight Management in T2DM,NCT04657003
I8F-MC-GPHN,Randomized Withdrawal,NCT04660643
I6T-MC-AMAZ,"Peds, OLE for UC and CD",NCT04844606
I8F-MC-GPID,Tirzepatide vs placebo in obesity-related HFpEF,NCT04847557
I4V-MC-KHAB,Baricitinib in Children with COVID-19,NCT05074420
I8F-MC-GPGV,Pediatric Study,NCT05260021
J2T-MC-KGBO,Open Label in moderate to severe AD prev treated with Dupi,NCT05369403
J2T-MC-KGBP,Open Label in mod to severe AD in pts with skin of color,NCT05372419
I8H-MC-BDCY,BIF Ph3 MDI T1DM 12 month vs Degludec,NCT05463744
J3Z-MC-OJAE,PRV-GD-101; Ph 1/11 PR001 GD,NCT05487599
I5T-MC-AACO,Donanemab IMCT + EU,NCT05508789
I6T-MC-AMAY,Peds Phase 3 CD,NCT05509777
J1A-MC-KDAF,Phase 2b Rheumatoid Arthritis study,NCT05516758
I8F-MC-GPIJ,Morbidity and Mortality in Obesity,NCT05556512
I8F-MC-GPIH,Switch from GLP-1 RA to TZP,NCT05564039
J3E-MC-EZDB,Ph2 study for the treatment of heart failure,NCT05592275
J4D-MC-EZFA,FHD POC Cardiovascular & Vascular Diseases Pts/HV,NCT05609825
H0P-MC-OA05,Intervention Specific Appendix - OA,NCT05620563
H0P-MC-NP05,Intervention Specific Appendix - CLBP,NCT05620576
H0P-MC-BP05,Intervention Specific Appendix,NCT05630196
I8H-MC-BDCW,BIF Ph3 T2DM Insulin Naive Fixed Dose 12 mo vs. Glargine,NCT05662332
I8F-MC-GPIM,Addition of TZP in T2DM on insulin glargine,NCT05691712
I6T-MC-AMBZ,Open Label Miri Trial in a Bowel Urgency Enriched Population,NCT05767021
I6T-MC-AMBA,Peds Phase 3 UC,NCT05784246
J2A-MC-GZGS,High risk CV,NCT05803421
I8F-MC-GPHJ,H2H vs Sema 2.4mg,NCT05822830
J3P-MC-FTAF,Adaptive Ph2a/2b RA,NCT05848258
J2G-MC-JZPB,BCRP DDI Trial HV,NCT05906836
J1I-MC-GOA1,"A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants without Type 2 Diabetes who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1) J1I-MC-GOA1",NCT05929066
J1I-MC-GZBJ,Chronic Weight Management -1 (without T2DM),NCT05929066
J1I-MC-GSA1,"A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants without Type 2 Diabetes who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1) J1I-MC-GSA1",NCT05929066
J1I-MC-GZBN,CWM + OA Standalone: Non-T2DM,NCT05931367
J1I-MC-GZBU,Renal MoA,NCT05936151
I7P-MC-DSAF,Phase 2 POC in Hidradenitis Suppurativa,NCT06046729
I8F-MC-GPIQ,Weight Maintenance Dose Trial,NCT06047548
J2N-MC-KLAA,Phase 2 Study Evaluating Efficacy of LY in Adults with MS,NCT06104683
W8M-MC-CWMM,Chronic Weight Management Master Protocol,NCT06143956
J1I-MC-GZBZ,Clinical Trial (H2H Sema w/ ext),NCT06260722
J5C-MC-FOAA,SAD/MAD Ethnicity Study in JP/CN Participants HV,NCT06311656
J1I-MC-GZBW,Energy Expenditure MoA Pts,NCT06313528
J2T-MC-KGBT,Clinical Trial (Ph3 Trial PAR 56wk),NCT06339008
I8F-MC-GPIV,Tirzepatide + Mibavademab,NCT06373146
J1I-MC-GZBO,"TRIUMPH Outcomes Trial: Cardiovascular Risk, CVOT",NCT06383390
J2T-MC-KGBY,Clinical Trial (Device Usability),NCT06444165
J5F-MC-OOAA,Clinical Trial (SAD/MAD) LM non-Oncology,NCT06565195
J4F-MC-CYAB,Clinical Trial (Ph2b Trial 4: DR DPNP) LM,NCT06566170
J2A-MC-GZPN,Weight Maintenance Dose Trial,NCT06584916
I1F-MC-RHDC,Ixekizumab and Tirzepatide Concomitantly Administered in Adult Participants with Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: Phase 3b Study (TOGETHER- PsO),NCT06588283
I1F-MC-RHDB,"Ixekizumab and Tirzepatide Concomitantly Administered in Adult Participants with
Active Psoriatic Arthritis and Obesity or Overweight: Phase 3b Study (TOGETHER-PsA)",NCT06588296
J4G-OX-JZVC,Definitive Food Effect HV,NCT06641037
J4Z-MC-GIDF,Clinical Trial (24 wk CWM in non-T2D pts),NCT06643728
J1G-MC-LAKI,Clinical Trial (Ph3 Trial 1: AD DM; LY v Pbo w/OLE) LM,NCT06653153
J1I-MC-GZBP,CWM4 - H2H,NCT06662383
J1P-MC-KFAD,MAD Atopic Dermatitis Pts,
I3Y-NS-L002,Phase 1/2 trial: STX-478 + abemaciclib + fulvestrant arm in PIK3CA mutant HR+HER2- metastatic breast cancer,
J4Z-VR-G004,BA and RoA bridging study (IV and SC) in healthy elderly,
J4Z-VR-G010,PoC study in cancer cachexia patients,
J3M-NS-L001,Single-arm open label Ph1b/2 olomorasib in combination with VVD Ras-PI3K,
I3Y-NS-L001,Abemaciclib in combination with PI3K inhibitor,
J1P-MC-KFAJ,Phase 2 Trial in SLE,
H8H-MC-B001,Pregnancy Registry,
J1L-AM-Y001,This is a Named Patient Use Program for patients transitioning from J1L-AM-JZGA A Phase 1 Study for Pegilodecakin to Named Patient Use ( compassionate use),
J5B-MC-FHAC,RBA/DDI#3/FE HV,
I3Y-MC-JPEH,Abema Peds HGG,
H0P-MC-BP07,Clinical Trial (Ph2a 8wk CLBP (Chronic Low Back Pain) NEW,
I8X-MC-JECA,FHD_Ph I/Ib - TGFb Inhib II - Solid Tumors,
H0P-MC-NP07,Clinical Trial (Ph2a 8wk DPNP/CPMP (Diabetic Peripheral Neuropathy/Chronic Pain) NEW,
I3Y-MC-JPCY,Ph II-Abemaciclib-Prostate Cancer,
J5B-MC-FHAF,ADME no costs,
H0P-MC-OA07,Clinical Trial (Ph2a 8wk OA (Osteoarthritis)) New,
I6E-AV-I068,Department of Defense Alzheimer’s Disease Blood-Testing Initiative (DoD-ADBI),
I8F-MC-GPI2,Obstructive Sleep Apnea Appendix TZP with PAP therapy,
J2P-MC-LXBE,Metformin DDI at lowe dose,
J4H-MC-FVAD,C14 ABA HV,
I4V-MC-B003,US_EU RA Long-Term Safety Study,
I3Y-MC-JPCM,Ph II/III - Abiraterone with or without abema in mCRPC,
I8F-MC-GPIG,Tirzepatide Mechanism of Action Study on Renal Function (TREASURE - CKD),
I4V-GH-B021,China PMSS,
J3R-MC-YDAD,China PK Study HV,
J5C-MC-FOAF,DDI #2 no costs,
J3P-MC-FTAD,Methotrexate DDI and CYP cocktail DDI (2-part study),
J2N-MC-E008,"A PHASE 3 MULTICENTER, RANDOMIZED, PROSPECTIVE, OPEN-LABEL TRIAL
 OF FIXED-DURATION (12 MONTHS) VENETOCLAX/OBINUTUZUMAB VS.
FIXED-DURATION (15 MONTHS) VENETOCLAX/PIRTOBRUTINIB VS.
MRD-GUIDED VENETOCLAX/PIRTOBRUTINIB
IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL)
AIMING TO ESTABLISH MEASUREMENT OF INDIVIDUAL RESIDUAL DISEASE FOR ADADPTION OF TREATEMENT DURATION TO IMPROVE OUTCOMES",
J2A-MC-GZGM,Multi-dose study with LY3502970 and clarithromycin HV,
J2A-MC-GZPH,CWM H2H with Rybelsus,
J4I-AV-_001,"18F-LY3950321-01",
H6O-MC-GCEK,Chronic Weight Management Prescreening Protocol,
J2G-JE-B009,JP PMSS,
I4C-MC-JTBB,p2 NSCLC 1st line EGFR mutant population,
I1F-IN-RHCZ,"Assessing AEs, SAEs & efficacy w/Ixekizumab for PsO & PsA",
J1I-MC-GZQF,Response of participants with type 2 diabetes mellitus on once-weekly retatrutide to hypoglycemia MOA Pts,
I8F-MC-GPHE,Early Type 2 Diabetes,
I8F-JE-GPHZ,Weight Management in Non-T2DM overweight or obese JP patient,
J2G-GH-B003,China PMSS-PhIV-RET Inhibitor-NSCLC+MTC+Thyroid,
I8H-MC-BDDD,Injection Site T2DM HV,
J3H-MC-GZNC,"C14, ABA, HV",
I4V-JE-B034,Non-Interventional Safety Study of JP Patients with AA,
J1I-MC-GZBL,Renal Impairment Study Pts/HV,
J4E-MC-FR01,AtD Ph2b POC,
I1F-US-I002,"An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum",
J1I-MC-GZBY,Clinical Trial (Monotherapy),
I1F-EW-B008,Badbir (UK & Ireland) & PsoBest & Rabbit Registry (Germany),
I8F-MC-GPHH,MoA Functional MRI in Overweight/Obese (non DM) Pts,
I5Q-MC-Y001,Cluster Headache Expanded Access Program,
J2Y-MC-JZSA,nsq-NSCLC Bridging Study,
I6T-IN-AMCC,Clinical Trial (India Phase IV PMR),
I6T-MC-AMCE,Clinical Trial (TZP/miri combo trial) LM,
J3R-MC-YDAA,FHD SAD/MAD (12 week MAD),
I8F-MC-GPIP,BE of Multi-use Prefilled Pen vs Autoinjector in HV,
J2T-MC-KGBR,Clinical Trial (Ph3 Trial PEDS Combined),
I6E-AV-_A28,Evaluation of reader training processes by comparing clinical interpretations to centralized expert reads,
J2O-MC-EKBF,SAD/MAD | MoA | HV,
I4V-MC-JAIN,AtD EU Access & Reimbursement Study,
J1P-MC-KFAE,Phase 2 Trial in AtD,
I8F-MC-GPHR,Ph2B w Biopsy for NASH Resolution/NAS Score Reduction,
I4T-NS-I039,Ph 1 trial evaluating EO-3021 (CLDN18.2 ADC) in combination with Cyramza in Gastric Cancer,
I9X-MC-MTAF,Neurodegenerative Diseases OGA C14,
J4Y-AV-S002,Biospecimen Collection for Neurodegeneration Biomarker Research and Assay Development,
I8P-MC-OXAJ,Incretins in Imm- Mazdutide monotherapy,
"27310",Clinical Trial (60-wk PBO Controlled Trial),
F1D-MC-B041,Olz LAI Registry,
I8F-MC-GPIA,Efficacy & Safety of TRZ 1x/wk in pts w/out T2DM w/obesity,
J5C-MC-FOAC,DDI#3 PGP no costs,
J1I-MC-GZBR,Paediatric participant study (12 - <18 years) w/obesity,
I7E-AV-_A17,"18F-AV-1451-A17: LEARN Tau",
J4M-MC-PWMP,Clinical Trial (Ph3 Trial 7: Peds 1 (age 12-17) LM,
I3Y-IN-JPEC,Ph4-Abemaciclib-MBC,
J2G-KL-B005,"Selpercatinib RET+ NSCLC, MTC, TC PMSS – Korea",
I1F-MC-B019,Taltz PsA Observational Study,
J4E-MC-IMMB,Atopic Dermatitis Master Protocol Ph2a/b,
J4E-MC-KK02,GITR AtD Ph2a POC,
J2T-MC-KGBS,Clinical Trial (Ph3 Trial PAR 16wk),
J5B-MC-FHAA,SAD/MAD Ethnicity Study in JP/CN Patients HV,
I1F-MC-B007,Long Term Prospective RWE,
J2J-MC-JZLK,Oncology DDI#3 study in female healthy volunteers of NCBP,
I7E-AV-E145,The San Antonio Heart and Mind Study,
J4Z-NS-E001,"Effects of tirzepatide and bimagrumab on body composition, insulin sensitivity, and bone in adults with obesity",
I8R-MC-IGBO,SAD T1DM Pediatric 1-4 Pts,
J2N-MC-JZNJ,LOXO-305 China Only Phase 1/2 Study,
I4V-JE-B030,Non-Interventional Safety study of JP patients with AD,
J3G-MC-S002,Nocturnal Pruritis Identification Using Passive Data,
J2N-OX-JZNU,LOXO-BTK-20030-BRUIN-314-Ph3-Pirtobrut+Ibrutinib-H:H 1L CLL,
J3O-MC-LSBA,SAD PET HV,
J1R-MC-GZFC,MAD PK HV,
I8F-JE-B004,Observational Study Obesity Japan Post Marketing Safety Study,
J2G-MC-JZJX,PhIII-RET Inhibitor-NSCLC,
I8F-MC-GPIW,Clinical Trial of Chinese RBA TZP Kwikpen vs AI,
I8F-IN-B017,Clinical Trial (Trial 18 PMR India),
J1R-MC-GZFB,MAD Safety Study Pts,
J1I-MC-GZBV,DDI with Oral Contraceptives HV,
J2A-MC-GZPG,Multi-dose study of LY3502970 as perpetrator and multiple DDI in HV,
I1F-US-I003,Ixekizumab in the treatment of patients with pityriasis rubra pilaris (PRP),
J4C-OX-JZUD,LOXO-PIK-23009-Ph1-PI3K-DDI: Cholestyramine,
J2J-MC-JZLJ,Relative Bioavailability (RBA) Food Effect HV,
I7E-AV-E146,Tau Twin Study: Genetic and environmental contributions to longitudinal tau trajectories,
J5C-MC-FOAB,Clinical Trial (Ph2 in Pso),
J2T-MC-KGBW,IMCT for AtD patients,
J3L-MC-EZEG,Clinical Trial (China PK),
J4Y-MC-B001,A phase IV non-drug interventional study to evaluate the impact of p-Tau 217 on patient management.,
J3H-MC-GZNE,Incretins in Imm- GIP-GLP study in mild to mod pts,
I4X-IE-JFCC,SQUIRE-CP11-0806:R-Ph3-11F8+Gemzar+Cis-Sq-NSCLC,
I3Y-MC-JPBM,Monarch 3_R-PhIII CDK 4/6+Aromatase vs Aromatase-MBC-1st Ln,
I5B-MC-JGDJ,R-Ph III-Olaratumab vs Placebo-Soft Tissue Sarcoma,
I4V-MC-JAHU,sJIA pediatric trial,
I1F-JE-B011,Post-marketing safety study of Ixekizumab with Ankylosing Sp,
I9Y-OX-JDHB,LOXO-IDH-20001-Ph1-IDH1-AML,
J2O-JE-EKBB,FHD MAD Safety in Healthy Volunteers,
I8H-MC-BDCU,BIF Ph3 T2DM Basal Switch 18 month degludec controlled trial,
I4V-EW-B032,"2019-9084 UK AD Registry (A-STAR)",
I1F-MC-RHDA,Connected Autoinjector Patient Experience Study,
J2A-MC-GZPF,Clinical Trial (Ph3 Trial 3:T2DM Monotherapy H2H vs Dapa) SM,
J2O-MC-EKBE,Renal Impairment Hybrid Pt/HV,
J4Z-VR-G008,Extension of CBYM338E2202,
I8F-MC-GPHP,Pediatric (Age 12-17),
J4Z-JE-GIDE,Clinical Trial Japan Pts Overwt / Obese,
J1G-MC-LAKB,MAD Alzheimer's Pts/HV,
I8F-MC-GPGM,High Risk H2H Basal,
I5B-MC-Y001,Lartruvo Patient Access Program,
I8R-MC-B007,Post Marketing China Nasal Glucagon Study,
J2G-JE-JZJN,JP PMS-Ph IV-Ret Inhibitor-mutant MTC,
J2A-MC-GZGH,RBA HVA,
I5T-MC-AACM,Donanemab Ph3 for Pre Clinical AD,
I5Q-MC-B004,Galcanezumab GHORWE observational Study,
J3M-OX-JZQI,LOXO-RAS-23006-Ph1-Pilot Food Effect,
I4V-JE-B033,Post Marketing Safety Study of Baricitinib in COVID-19 Japan,
H6O-MC-O017,Investigate Continuous Heart Rate Monitoring Using Biosensor,
H9X-IN-B012,Prospective Non Interventional Dulaglutide India PMS Study,
J1P-MC-KFAL,ISR/PK Study,
I4V-NS-O037,Susceptibility for Transition of Progression to Psoriatic Arthritis (STOP-PsA) trial,
W8M-MC-BIM1,Clinical Trial (Ph2 TZP/Bima Lean Muscle),
J5R-MC-OPAA,FHD SAD/MAD incl. JP/CN HVs,
I8F-MC-GPJA,Clinical Trial (Ph3 Trial in T1DM pts),
J1A-MC-KDAE,SAD and PK in HV + Japanese - New Formulation,
J1P-GH-KFAK,China PK Study HV,
H7I-MC-S028,EET CIPN Natural History Study (EPIPHANY) PT,
J3W-MC-S001,NASH Diabetes,
J2O-MC-EKBD,Human C14 HV,
I1F-AY-O003,Phase II study of ixekizumab for chronic wound healing,
I3Y-MC-E021,Phase 1/2 trial of neoadjuvant darolutamide and abemaciclib in intermediate/high-risk prostate cancer.,
J3K-MC-KIAB,Phase 2a Multiple Sclerosis Study,
I8F-MC-GPIS,BE of Fixed Dose 15 mg Multiuse Pen vs AI in HV,
J4M-MC-WM01,Efficacy and Safety of Tirzepatide Once Weekly versus Placebo in Adolescents with Obesity and Weight-Related Comorbidities,
J2T-MC-B002,Clinical Trial (Observational Priority E short),
I8H-MC-BDDG,Pharmacokinetic Hyporecovery Clamp Pts,
"26606",This is a real-world prospective follow-up study of SURMOUNT-CN trial participants after trial termination. the aim of the study is to examine weight and waist circumferences change after treatment cessation in 3 monthly interval for 6 months.,
I4T-MC-JVCY,RELAY_R-PhIII-Erlotinib+Ram vsErlotinib+Placebo-NSCLC 1st Ln,
I4V-MC-JAIO,"Pediatric Alopecia Areata trial, ages 6 to <18",
J4H-MC-FVAC,DDI HV,
I4V-MC-JAJD,Randomized Controlled Pragmatic Trial,
J2G-MC-JZJZ,BE study in LY3527723,
I8F-MC-GPI1,Obstructive Sleep Apnea Appendix TZP without PAP therapy,
I5T-AV-_002,CSF Concordance - Flortaucipir,
J2T-AP-KGBX,This alias will be for the Almirall-run Lebrikizumab trial ADlong which is the extension to Lebri's KGAA trial.  Almirall is the EU-partner for Lebrikizumab.,
I8F-IN-GPIZ,Clinical Trial Indian TZP T2DM and Obesity,
I6E-AV-ADND,ADNI-DOD: Effects of TBI and PTSD on AD Veterans,
I6T-MC-AMAN,Ulcerative Colitis Phase III: Induction trial 1,
I6T-MC-AMAX,Crohn's Disease Long Term Extension (LTE),
I1F-NS-O013,Brain inflammation in patients with psoriasis and comorbid depression: a [11C](R)-PK11195 positron emission tomography (PET) study,
J2N-OX-JZNO,LOXO-BTK-20022-BRUIN-322-Ph3-Pirtobrutinib-R/R CLL (combo),
J5B-MC-FHAG,Clinical Trial (Ph2b Trial: Pso) SM (no cost),
J2A-MC-GZPA,Pediatric study for CWM (age 6-11),
J4M-MC-WMMP,A Platform Trial for Pediatric Participants with Obesity or Overweight,
J4W-MC-KUAA,"A first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of LY3876358 in
healthy participants",
I8F-MC-B016,Clinical Trial (Prospective Pregnancy Exposure Registry),
J3M-MC-JZQC,KRAS G12C China PK study,
J2J-MC-JZLG,Oncology Hepatic Pts,
,Clinical Trial (Ph3 DPNP; Registration 1) SM Grants,
I3Y-MC-JPBB,FED Mantle Cell Lymphoma,
I3X-MC-JHTB,"FED, JAK2 Ph 2 trial in MPD",
I4V-KL-B007,Baricitinib RA PMSS - Korea,
J2A-MC-GZGE,Phase 2 T2DM GLP-1 Non-Peptide Ag I,
H9X-IN-GBGR,India Trulicity Ph IV Post Approval Commitment Study,
J2A-MC-GZGQ,Adult Participants with Obesity or Overweight and Type 2 Diabetes,
I5T-MC-AACP,A Phase I Donanemab (LY3002813) PK study,
I5Q-US-I001,Anti-CGRP neutralizing antibody for modulation of neurogenic inflammation in trigeminal pain associated with small fiber neuropathy/fibromyalgia,
J4Z-VR-G006,Extension of CBYM338B2203,
J4H-MC-FVAA,Randomized Phase 2a in patients with Psoriasis,
I8F-JE-B013,I8F-JE-B013 2023LMP - T-BEAT (JP observational study TZP vs Rybelsus I8F-JE-B013),
I3Y-MC-JPCG,Ph II - Abema Benefit/Risk - Breast,
H6O-MC-O012,EET to evaluate SU withdrawal / institution in T2DM Pts,
J2T-MC-KGBJ,Long-Term Extension Lebri vs Placebo in moderate to severe AD pediatrics,
J2D-JE-CVAD,Japan Phase 1,
J3L-MC-EZEH,Clinical Trial (Hepatic) | Confirmatory | Pts,
I8I-MC-JY05,Continued Access of LY3023414,
J1G-MC-LAKD,N3PG IV Phase 3 Clinical Efficacy,
I8P-MC-OXAG,MAD Obese HV,
J2T-AP-KGBQ,"Dble blind trial in pts cyclosporine failure

This is the Almirall trial ADvantage",
I8F-MC-GPIN,Tirzepatide Excretion in Breast Milk Study PK HV,
J2A-MC-GZPJ,DDI Moderator Inducer HV,
B3D-MC-B030,Forsteo Device Post Market Clinical Follow Up (PMCF) Survey Study,
J5N-OX-JJEA,Clinical Trial (Ph1/2 SM) Accel,
I6E-AV-I067,"Diabetes Prevention Outcomes AD Study (""DPPOS"")",
J2N-OX-JZNP,LOXO-BTK-20023-BRUIN-313-Ph3-Pirtobrutinib-Untreated CLL,
J2U-MC-YBAB,Ph2a KHKII 12 wk T2DM NAFLD Dose Finding,
I3Y-MC-B013,"2019-9039: RWE multi-site based study into Verzenios ES CSP",
I5Q-JE-B007,"Non-interventional, mandatory post marketing database study",
I5Q-MC-CGBD,interventional trial,
I5T-MC-AACN,H2H Donanemab,
J3F-MC-EZCB,AngPTL3 siRNA Ph2 study for ASCVD,
J4Z-VR-G011,PoC in COPD muscle dysfunction,
I8F-MC-B010,US study annual incidence medullary thyroid carcinoma/MTC,
I8F-MC-B012,China Tirzepatide T2DM Post Marketing Safety Study,
I8F-MC-GPIX,Clinical Trial (Ph3 New WMO1),
I4V-MC-JAHX,JIA Open label extension trial,
I8F-MC-GPGL,GIP/GLP-1 VS Semaglutide,
J2G-OX-JZJA,RET Inhibitor FHD  Libretto-001   LOXO-RET-17001,
I8F-MC-GPIY,Clinical Trial (Ramadan Study),
J2R-MC-YAAC,GI Tolerability w/ 2 Parts in HV,
,Clinical Trial (CYP 3A4),
,Clinical Trial (Pilot Food Effect),
I8X-MC-E002,Request for LY3300054 (PD-L1 antibody),
F3Z-MC-I031,Investigating How Time-in-Range Influences Quality of Life in T1D Adults,
J2G-GH-JZJK,LOXO-292 China FHD Study,
J2N-OX-Y001,LOXO-305 Expanded Access Protocol,
H8H-MC-B003,"2020-9158Survey to understand tx patterns&burden of migraine",
I5T-MC-AACK,China PK Pts,
J3T-OX-JZTA,Loxo-NGR-21001-Ph1-RET Inhibitor II-Thyroid-NSCLC,
J1I-MC-GZBI,DDI HV,
I4V-JE-B040,Japan PMSS,
I9J-MC-DIPC,Formulation Development Study (Quotient),
,Clinical Trial (BE/Device Bridging) LM,
J2A-MC-GZGP,CWM in obese population,
J2A-MC-GZGO,Mictrotracer C14 Trial Pts,
J2A-GH-GZGX,OFG_Obesity_China PK Pts,
J2A-MC-GZPI,BE Study Tablet vs Capsules T2DM HV,
I3Y-MC-JPEI,Clinical Trial (Ph1b – Darolutamide plus Abemacilib in mCRPC,
I3Y-JE-B016,"2023LMP - TR 05 - Nyupage study",
H6O-MC-O018,Screening protocol,
,Clinical Trial (Pilot Food Effect),
B9R-SB-B004,"",
,National registry (Tau PET/Amyloid PET/BBM),
J2T-JE-KGAL,Lebri comb study in Japanese pts with moderate to severe,
J3L-MC-EZEA,A FHD trial for LY3819469 in treatment of Atherosclerosis,
J3P-MC-FTAC,MAD study in Japanese and non-Japanese HV,
J3V-MC-KKAA,FHD SAD HV and Multi Dose Atopic Derm Hybrid Pt/HV,
I8B-MC-ITSN,I8B-MC-ITSN- Insulin Only Tandem Luymjev Closed Loop Safety Study,
,Japan Validation Study,
J4L-MC-KMAA,FHD SAD/MAD Dose Escalation Pts/HV,
J2A-MC-GZGY,Pediatric study in T2DM,
J2T-MC-KGBU,Clinical Trial (Ph3 Trial CRSwNP 56wk Preferred),
I5B-MC-JGDQ,Ph Ib - Olaratumab + PD1(external) - Solid Tumors,
I6T-MC-AMAM,Crohn's Disease Phase III Study,
,Device Trial,
,Clinical Trial (JZQH part A-not linked in Vault),
J2N-MC-JZNX,"A Phase 2, Open-label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib",
J4X-MC-LWCB,C14/ABA,
,Clinical Trial (Ph1/2 LM St Dose Esc/Expan/Reg: 240 pts./25 cyc/35 sites/28 m,
J3D-MC-FNAA,"FHD SAD,MAD,DDI,FE in HV",
H8H-MC-B006,Lasmiditan Exposure and Driving,
J2T-MC-KGBI,Lebri vs Placebo in moderate to severe AD pediatrics with TCS,
J3P-MC-FTAE,C14 HV,
H8H-MC-B011,Non-inter mandatory post mktg db stdy JP pts/migraine,
J3Z-MC-OJAD,PRV-GD2-EAP; GD Type 2; Center 2,
J1I-MC-GZBT,Hepatic Impairment Study Pts,
J4R-MC-KRAA,FHD SAD in HV and MD in RA Pts,
,Clinical Trial (Ph2 Demonstrate Slowing of Motor Progression),
,Clinical Trial (Ph2 Trial 1: HFpEF 6 Month) LM,
J2T-AP-KGCB,"A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis 

This is the Almirall Trial ADHope-2; M-17923-34",
H7I-AV-S032,The use of alpha synuclein skin biopsy test to evaluate the relationship between rapid clearance versus longer clearance of amyloid in relation to alpha synuclein positivity/levels and to evaluate the trajectories/rate of amyloid re-accumulation related to alpha synuclein positivity/levels,
,Clinical Trial (Observational Study),
I3Y-MC-JPBH,Met Breast Cancer study with combo therapies,
I4V-MC-JAHO,Ph2/Ph3 LY vs PBO in pts with Alopecia Areata,
I1F-MC-B010,Prospective Pregnancy Registry per FDA request,
J2G-OX-JZJJ,RET Inhibitor Pediatric Trial  Libretto-121  LOXO-RET-18036,
,Clinical Trial (C14+ABA),
J3G-MC-S004,EET HV,
I5Q-NS-O001,Definition of neuroimaging and blood biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine,
H9X-MC-GBGS,Clinical Trial (PMR Peds 3/4.5 mg)),
I4V-MC-B026,Obs prospective study compares Baricitinib-biologic Trmt AD,
I5T-MC-AACI,N3pG Phase 3 Safety and Efficacy in AD Patients,
I9X-MC-MTAE,"Assessment of Safety, Tolerability, and Efficacy of LY337268",
I8H-MC-BDDF,Bioequivalence Study Comparing 2 Formulations of LY3209590 in Healthy Participants,
I4T-MC-B012,Ph4-PMSS of Cyramza in China,
J1P-MC-KFAM,"Phase 1, Open-label PK study of LY3471851 Following SC Administration to Participants with Impaired Renal Function",
I8F-MC-GPIL,Switching to Tirzepatide from GLP-1RA,
I6T-MC-PIBD,IBD PLATFORMPBCRD3001/I6T MC PIBD,
,Clinical Trial (Ph2 Trial: Cognition; LY v Pbo) SM,
H9X-MC-B023,Trulicity/ KwikPen Device Post Market Clinical Follow Up Survey Study,
I8F-MC-B006,IBU Persistence and Real-World Usage: TZP vs Ozempic,
,Clinical Trial (Pregnancy Registry Study),
,Clinical Trial (CYP 3A4),
J5D-MC-FPAA,Clinical Trial (EET-Assessing PD in HV with a skin model ),
I6T-MC-B006,Pregnancy Registry Study,
,Clinical Trial (Ph1a/b SM St Dose Esc/Expan: 240 pts 20 cyc 35 sites 25 mo Stand,
J2T-AP-KGCC,Patient-assessed long-term control of moderate-to-severe Atopic eczema treateD with LebrIkizumab in a real-liFE setting (AD-LIFE),
I6E-AV-AVBE,Evaluation of Effectiveness of Amyvid Reader Training,
I1F-MC-B018,Nail and Scalp PMS,
I8F-MC-GPIF,Obstructive Sleep Apnea Master Protocol,
I6E-AV-I012,Diagnosing Dementia with Lewy Bodies and Parkinson’s Disease Dementia,
,Clinical Trial Ph2 Miri Combo in Moderate to Severe UC,
I8I-MC-JY01,AKT-1 Inhib I - CONTINUED ACCESS -  Solid Tumors,
J3R-MC-YDAC,QW SAD/MAD Initial Combo HV,
J1A-MC-KDAI,RBA Bridging PK - Ph3 EP formulation vs Ph2 vial HV,
J4V-MC-OMAA,FHD SAD/MAD Pts/HV,
J5B-MC-FHAD,DDI #1 no costs,
I6T-MC-AMBG,Ulcerative Colitis PhaseIII Maintenance,
I6E-AV-I059,AV-45-IIT-059 (LEARN),
,Clinical Trial (Ph2 Trial: RA) SM,
J1I-MC-GZQA,Clinical Trial (Add on to Insulin),
J2J-MC-JZLI,Oncology DDI,
J3T-OX-Y001,LOXO-NGR-Single Patient Protocol,
,Clinical Trial (Ph3B #1Trial) ,
J4Z-VR-G007,DRF study in Sarcopenia,
I1F-MC-B009,Obs prospective study compares Ixekizumab-biologic Trmt PsA,
J2L-MC-EZBB,SAD in heart failure in reduced ejection fraction Pts,
J2T-DM-KGAA,Long-term Extension Study,
J2G-OX-Y049,RET Inhibitor-NSCLC,
J3G-MC-S001,Exploratory nocturnal scratching in atopic dermatitis,
J3W-MC-GZOA,FHD SAD NASH/NAFLD Pts,
I3Y-MC-JPEF,Ph3-Abema-MBC Post Progression Sequencing,
I8H-MC-BDCV,BIF Ph3 MDI T2DM 6 Month vs Glargine,
I3Y-MC-JPEG,Ph3-Abemaciclib-mHSPC,
J2G-CA-O001,Profiling RET fusions in a Canadian papillary thyroid cancer cohort and establish samples for a future RET fusion quality assurance program,
J1G-MC-LAKC,N3PG IV Phase 3 Plaque Lowering,
H7I-MC-S030,Measure gait with wearable sensor devices in chronic pain,
I6E-AV-_A27,The feasibility and reliability of utilizing commercially available quantitative analysis software as an adjunct to the clinical qualitative interpretation of Amyvid brain scans,
,Pediatric study for CWM (age 6-11),
"27210","A Phase 1/2 Open-Label, Dose-Escalation, Safety, Tolerability,
and Efficacy Study of SIG-001 in Adult Patients with Severe or Moderately-Severe
Haemophilia A Without Inhibitors (SIG-001-121)",
H8A-US-B004,GERAS - US Study,
I5Q-US-X003,TOGETHER STUDY: Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study,
,Clinical Trial (SAD/MAD) LM non-Oncology,
J5V-MC-ORAA,FHD SAD/MAD,
,Clinical Trial (Ph2 Trial 1: CWM) LM,
J2G-MC-JZPA,Food Effect study in LY3527723,
H7I-AV-S029,ADDI Precision,
J2A-MC-GZGV,LY vs PBO on a background of SGLT2 +/- metformin,
J4N-MC-YFAA,Phase 1 Single-Ascending Dose in Participants with Dyslipidemia and Repeat-Doses in Participants with NAFLD,
J4O-MC-EZHA,FHD SAD/MAD Pts/HV,
J1G-MC-LAKH,BE/Device Bridging HV,
J4P-MC-IYAA,FHD SAD/MAD Pts/HV,
,Clinical Trial (Ph2 Reduction in Craving Prevent Relapse),
,Japan PMSS,
,Clinical Trial (Ph2 PsA Mixed Population 3LY doses vs PBO),
I9M-MC-ONAA,Biomarker Pts,
J5H-MC-KVAA,SAD/MAD SM non-Oncology HV,
I3Y-MC-Y001,Ph 2 - Abemaciclib - OUS Named Patient Use Program,
I4V-MC-JAJA,Safety Post Marketing Registration Study,
J2G-MC-JZJC,RET Inhibitor NSCLC Phase III,
I5Q-NS-O003,"A pilot study to identify responders to galcanezumab in patients with fibromyalgia and its relationship with sensory profiling, CGRP innervation and function (Galfibro)",
,Clinical Trial (Ph1a/b SM St Dose Esc/Expan: 240 pts 20 cyc 35 sites 25 mo Stand,
,Clinical Trial (Ph2 Trial 3: POC DPNP) SM,
W8M-MC-BIM2,Clinical Trial (T2D CWM bima+TZP),
J1P-MC-KFAN,Single-dose Study of the PK of LY3471851 Following SC dosing,
I8H-MC-BDCT,BIF IADA - Device Feasibility,
J4C-OX-JZUA,LOXO-PIK-21001-Ph1-PI3K,
I8F-MC-B007,US Persistence and Real-World Usage: TZP vs Ozempic,
J1G-MC-LAKG,Relative Bioavailability HV,
J4Q-MC-KQAA,FHD TNF-GC HV,
I4V-JE-B037,"Post Approval Safety Study (Preg, Safety,  etc) - JP",
I3Y-JE-B015,"2023LMP - TR 04 - Abemaciclib physician & patient survey",
"25436","A first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of LY3876358 in
healthy participants",
B3D-US-X033,PTH on Craniofacial Osseous Regeneration in Bone,
B3D-US-X032,Stem Cell Recruitment Anabolic v Antiresorptive therapy,
B3D-US-X034,Randomized controlled trial of teriparatide of idiopathic osteoporosis in premenopausal women,
I3Y-IT-B018,"This study evaluates the real-world use of Abemaciclib as adjuvant therapy in high-risk early breast cancer. It’s a retro-prospective observational study conducted across ~15 sites. The primary objectives are to describe the demographic and clinical characteristics of patients and the persistence, discontinuation rate, and reasons for Abemaciclib discontinuation at 6 months post-initiation. Secondary objectives evaluate Abemaciclib treatment effectiveness, adherence, persistence, discontinuation rate, and reasons for discontinuation at various time points post-initiation. Exploratory objectives aim to assess the benefit of Abemaciclib treatment in terms of QoL, health status, and work impairment. Participation will be offered to patients already in treatment with Abemaciclib for no more than 30 days, as per clinical practice. The study will collect data from ~6 assessment visits scheduled according to clinical practice: Baseline, 2-month, 5-month, 11-month, 17-month, 23-month.",
I5B-KL-B002,KR_Ph IV-PMS–Olara+Doxorubicin-Adv Soft Tissue Sarcoma,
I4V-MC-JAIR,Ph3 LY vs PBO in pts with Alopecia Areata,
J4Y-MC-B002,A phase IV non-drug interventional study to evaluate the impact of p-Tau 217 on patient management,
,Clinical Trial (DDI 1),
I8F-JE-B005,Observational Study＿Japan PMSS,
H8H-MC-LAHW,Ph 3 OLT Safety Trials with Lasmiditan in Children,
J4Z-VR-G013,sIBM Open Label Extension CBYM338X2205E1,
I6T-MC-AMCD,Clinical Trial (Ph3 TZP/miri combo UC) LM,
,"Post Approval Safety Study (Preg, Safety,  etc) - CN",
J1S-MC-JAAA,CAMPFIRE - Ph II - MultiCmpd Peds Protocol - Solid Tumors,
J2G-MC-JZJB,RET Inhibitor MTC Phase III,
J2A-JE-GZGB,SAD MAD Pts,
J2W-MC-PYAB,COVID-19 Program,
J2A-MC-GZGT,"Monotherapy in T2D - Orforglipon 3, 12, 36 vs placebo QD
•	optional pre-screening visit
•	up to 4 weeks of screening and lead-in period
•	40-week treatment period (52w in Japan) : dose escalation + dose maintenance
•	2-week safety follow-up period",
J4K-MC-LALA,FHD IL-34 Alzheimer's Disease,
I5T-AV-_001,External Bridging Study between CE-Marked CSF Test and Amyloid PET Trial Criteria,
I7E-AV-_A27,Tauvid Japan Reader Study,
J4Y-AV-S001,"This clinical validation Study includes participants from Study I5T-MC-AACI (AACI) with early symptomatic cognitive impairment, including Alzheimer's Disease. The participants were selected based on their clinical status as well as amyloid and tau status determined by PET scan findings. Data from these participants includes demographic variables, genetic markers such as apolipoprotein E (ApoE), a panel of biomarker   assays from stored plasma samples, and historical amyloid and tau PET scans. Primary objective: to explore the relationship between plasma P-tau217 and amyloid PET. Secondary objectives: 1) to explore the ability of variables such as demography, genetic biomarkers (e.g., APOE), and a panel of biomarker assays, when added to P-tau217, to predict amyloid PET, and 2) to explore plasma AB 42/40 vs amyloid PET.",
I4V-MC-B041,RABBIT RA Registry,
J2T-KL-B004,Post-Marketing Safety Study on EBGLYSS(Lebrikizumab) for Patients in Korea with moderate to severe atopic dermatitis,
J5B-MC-FHAJ,DDI and PGP - no costs,
J5B-MC-FHAI,Clinical Trial (ABA) no costs,
J4Z-VR-G001,FIH (SAD) with POC in disuse atrophy,
W8M-MC-LAA3,Clinical Trial Mono QM,
J4Z-VR-G005,"RESILIENT, sIBM Ph 3",
I8H-MC-BDCI,Recovery from Hypoglycaemia with T2DM PTs,
I8F-MC-GPGN,CVOT,
I5Q-KL-B006,Galcanezumab Cluster Headache PMSS - Korea,
J2A-MC-GZGK,Evaluate tolerability of different dosing regimens,
J2A-MC-GZGU,H2H vs Rybelsus,
I1F-US-X002,Cognitive dysfunction in psoriasis due to decreased cerebral perfusion,
J1B-MC-FRCJ,Relative Bioavailability (RBA) HV,
,Clinical Trial (Ph2a/b Trial: Adult UC) LM,
I8I-MC-JY06,Continued Access LY3023414 from Study CBBA,
I6E-AV-_A26,A study to evaluate the improvement in reader accuracy when using a read method that incorporates commercially available quantitative analysis software as an adjunct to the clinical visual interpretation of Amyvid brain scans,
I3Y-CR-JPBQ,R-Ph III-CDK 4/6 +AI vs Placebo + AI - MBC - 1st line,
I6E-AV-_A23,"18F-AV-45-A23: Brain Health Registry",
I4V-MC-B012,EU RA registries RABBIT (Germany) and BSRBR (UK),
J1I-MC-GZQG,Insulin Secretion and Insulin Sensitivity Pts/HV,
I1F-FH-O015,A Basket Trial of the Safety and Efficacy of Ixekizumab in Participants with Autoimmune Inflammatory Skin Diseases,
J2A-MC-GZPB,Hepatic Organ Impairment Study Pts,
,Clinical Trial (JZQB Part A -not linked to Vault),
J4Z-VR-G002,Diet profiling study,
W8M-MC-LAA1,Clinical Trial Mono QW,
J3Z-MC-OJAA,PRV-PD101 Ph 1/11 PR001A PD-GBA,
J1I-MC-GZBS,RBA Injection Site Study (with ABA) HV,
J1G-MC-LAKF,N3PG 4 Phase 3 Clinical Efficacy,
J3L-MC-EZED,Renal Hybrid Pt/HV Renal,
J4S-MC-KSAA,SAD/MAD HV,
J3L-MC-EZEF,Clinical Trial Ph3 CV Outcomes,
J2T-MC-KGBZ,BE Formulation Comparability HV,
J4B-MC-OKAB,Clinical Trial (Ph3 Trial 1: AD DM; LY v Pbo w/OLE) LM,
J3L-MC-EZEI,Device RBA study HV,
J2T-AP-KGCA,"This is the Almirall trial ADhope

A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis ",
J5U-MC-YGAA,FHD SAD/MAD Pts/HV,
I4V-MC-JAHW,Pediatric Uveitis trial,
I4V-MC-JAHN,"AtD Blinded LTE Rollover for JAHL,JAHM",
J1S-MC-JV01,CAMPFIRE - Ph II - MultiCmpd Peds Ram+Vino+Cyclo - DSRCT,
I7P-MC-DSAD,Phase 2 POC in HS,
I1F-US-I001,Taltz (Ixekizumab) in the Treatment of Bullous Pemphigoid (BP),
I4V-NS-O029,BARICIVID,
I4V-NS-O020,"A pilot study of the use of Janus Kinase Inhibitor, Baricitinib, in the treatment of COVID-19-related pneumonia: a two-step, proof of concept clinical trial 
Baricitinib for coRona virus pnEumonia: a THerapeutic trial 
(BREATH trial)",
I4V-US-X001,"An open-label, pilot study of baricitinib for cutaneous dermatomyositis (DM)",
I1F-NS-E001,Axial Spondyloarthritis International Outcome Assessment (AXIOMA),
J2N-OX-JZNM,LOXO-BTK-20019-BRUIN-321-Ph3-BTK-MCL,
,PMR1 - UK Registry,
J1I-MC-GZBG,C14 Metabolism study HV,
J3X-MC-LYGA,"FHD, SAD/MD HV",
J1G-GH-LAKE,Pharmacokinetic/China PK/Alzheimers/HV,
J1I-MC-GSA2,Chronic Weight Management -2 (with T2DM) OSA DSA,
I4V-MC-B035,Pregnancy Registry Study,
J2A-MC-GZGZ,"Pediatric study for CWM (age 12-17)

Trial alias has been changed to PW01, therefore this record is being canceled.",
J2A-MC-GZPK,BE Study - Blended vs dual-filled capsules HV,
J5X-MC-YJAA,FHD SAD/MAD HV,
J5A-OX-JZWA,LOXO-ENC-23001-Ph 1a/b-ETx-22-Urothelial Carcinoma,
J5B-MC-FHAB,SAD/MAD SM HV/PSO Pts,
H9H-MC-Y001,"Named Patient Use program for the treatment of glioblastoma using galunisertib in continued access patients transitioning from the following trials, H9H-MC-JBAL and H9H-MC-JBAH.",
I3Y-MC-JPBK,JUNIPER_R-Ph III-CDK 4/6 Dual Inhib vs Erlotinib-NSCLC,
I3O-MC-JSBF,R-PhII-Merestinib or Ram + Gem/Cis- Cholangiocaracinoma,
I1F-KL-B006,Ixekizumab PMS - Korea,
I5Q-MC-B005,Pregnancy Registry,
I9S-MC-BTAC,Proof of Signal Psoriasis Pts,
I1F-NS-O008,Ixekizumab Diabetes Intervention Trial (I-DIT),
J2P-MC-LXBF,Clinical Trial (Proof of signal in DSP population),
J2G-OX-Y001,LOXO-292 Expanded Access Protocol LOXO-RET-18037,
J2G-JE-JZJM,JP PMS-Ph IV-Ret Inhibitor-Fusion NSCLC,
I9Y-OX-JDHC,LOXO-IDH-20002-Ph1-IDH1-CCA,
I8H-MC-BDDC,China-PK,
J2A-MC-GZGN,Capsule vs Tablet Formulation RBA Study Pts,
J1I-MC-GZBX,RBA - KwikPen vs. Autoinjector HV,
J2N-OX-Y002,LOXO-305 Single Patient Protocols,
I1F-MC-B020,Taltz Device Post Market Clinical Follow Up (PMCF) Survey Study,
J4H-MC-FVAB,"J/C PK,  High Dose Study HV",
J2O-MC-EKBC,Phase 2 study in patients with elevated Lp(a),
I8F-MC-GPHV,Obese Pediatric PK 6 to 11 yo Pts,
,Clinical Trial (Phase 2 POC in Mild to Moderate CD),
I1F-NS-O017,Assessment of microscopic bowel inflammation variation at six months in spondyloarthritic patients treated or not by a biologic treatment,
I1F-US-X001,"Open Label Study Evaluating Taltz in combination with EnstilarÂ® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% in Psoriasis Patients.",
I1F-NS-O014,Pressure pain threshold and itch sensitivity in psoriasis patients before and under therapy with IL-17A blockers compared to healthy controls,
I1F-US-X004,Open-label Study of Ixekizumab for the Treatment of Nail Psoriasis (PsO),
I1F-US-I008,Ixekizumab for the management of refractory non-infectious uveitis: a proof of concept study,
I1F-NS-O006,"Association of genital psoriasis, stigmatization and sexuality - new insights for optimized disease management",
I1F-NS-O010,Next generation sequencing of patients enrolled in the German Psoriasis Registry PsoBest to individualize and optimize management of patients with psoriasis (PsoBest Bioscience),
I1F-NS-O016,Clinical and ultrasound assessment of the therapeutic response to Ixekizumab in PsA dactlylitis,
I1F-NS-O004,Mapping of Immunopathological Characteristics and Immunocellular Mechanisms in patients with Psoriatic Arthritis (PsA) in Treatment with Interleukin 17 inhibitor (Ixekizumab) or Tumour Necrosis Factor-Î± inhibitor (Adalimumab),
I1F-OE-O001,Exploring the proliferative response of human dendritic cells induced by T-cells or therapeutic antibodies,
J2N-KL-B009,Observational Study on Jaypirca(Pirtobrutinib) for the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma(MCL) who have received a prior BTK inhibitor,
J4Z-VR-G003,Cardiac safety study in older adults,
J2A-MC-GZPO,OFG Ph3 Tablet Master Protocol,
I1F-US-I006,Skin Microbiome of Inverse Psoriasis,
I1F-NS-O005,UItrasound-based early diagnosis of psoriasis arthritis focused on dactylitis. Validation of ultrasound as a tool for measuring dactylitis,
I1F-US-I005,"A pilot study of a single, easily measurable outcome for psoriasis",
I1F-NS-O012,USE OF ANTI-IL17A IN SARS AND MAS ASSOCIATED WITH NEW CORONAVIRUS (SARS-CoV-2) INFECTION.,
I1F-US-I009,Radiographic progression in patients with ankylosing spondylitis treated with Ixekizumab,
I3O-MC-E001,A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations,
I3O-MC-E003,Merestinib on Bone Metastases in Breast Cancer,
I3O-MC-E002,Merestinib with LY2874455 in Relapsed or Refractory Acute Myeloid Leukemia,
I5B-BP-O003,Making a difference to the health-related quality of life of sarcoma patients,
I5B-US-I002,Phase I Trial of Olaratumab with Sorafenib for Desmoid Tumors,
I5B-US-I001,A phase II trial of doxorubicin +olaratumab in the treatment of recurrent or persistent carcinosarcoma of the uterus or ovary or fallopian tube,
I5B-SB-O002,OLAREDO: Safety and efficacy of olaratumab and doxorubicin rechallenge in anthracycline pretreated metastatic sarcoma patients. An exploratory phase-II study,
I5B-US-X001,A phase 2 study of doxorubicin and olaratumab in chondrosarcoma,
I5Q-NS-O002,CGRP LEVELS AND MABs,
I5Q-US-X001,Novel insight into migraine pathophysiology and galcanezumab mechanisms of action,
I1F-NS-O011,IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY,
H0P-MC-CPMP,Pain Master Protocol,
I5B-XM-O001,Phase I/ II clinical trial of Olaratumab plus Trabectedin in patients with soft-tissue sarcoma,
I1F-US-X003,The effect of IL-17A inhibition on the natural history of idiopathic subglottic stenosis,
I1F-NS-O007,Interleukin-17 and osteoclastogenesis in psoriatic arthritis: The effects of IL-17 blockade,
I1F-NS-O020,"Objective evaluation, using ultra high frequency ultrasound (UHFUS), of nail psoriasis in patients treated with ixekizumab",
I6E-AV-I054,An investigation of the interaction between amyloid accumulation and neuroinflammation in post-stroke cognitive impairment using Florbetapir and 18F-FEPPA.,
I6E-AV-I066,Imaging of Islet Amyloid in Humans,
I6E-AV-I065,"Focused Imaging for the Neurodegenerative Disease - Chronic Traumatic Encephalopathy (""FIND-CTE"")",
I6E-AV-I014,"Amyloid Imaging with Florbetapir in dementia, MCI, and Healthy Aging",
I6E-AV-I053,Diagnostic Utility of Florbetapir F18 in Peripheral Nerve Amyloidosis,
I6E-AV-I007,Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients with Significant White Matter Disease,
J2G-NS-O009,The ROME trial from histology to target: the road to personalize  target therapy and immunotherapy,
J2G-CA-O003,TAPESTRY-NGS,
J2G-CA-O002,Upfront Comprehensive Molecular Profiling for Lung Cancer Patients,
J2G-CA-O004,Community-based delivery of  rapid plasma and tissue next-generation sequencing in non-small cell lung cancer.,
J2G-NS-O010,‘The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile’,
J2G-US-X001,RET Fusion Diagnostics:  Comparing the Sensitivity and Specificity of Available Assays,
J2G-US-JZJH,S1900B and S1900F LungMAP Phase II Carboplatin and Pemetrexed with or without Selpercatinib in NSCLC previously treated with RET-directed therapy,
J2G-US-I002,Restoration of Radioiodine Uptake by Selpercatinib in Radioiodine-Refractory RET-Fusion Thyroid Cancer,
J2G-NS-O008,ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on Genomic Profiling,
J2G-JE-E001,Phase II Study of Selpercatinib in Patients with Advanced Non-Small-Cell Lung Carcinoma harboring RET Rearrangement detected by Liquid Biopsy,
J2G-CA-O005,Implementation of a Provincial Collaborative Clinical Genomics Network for Prospective Screening of Actionable Alterations in Lung Cancer in Quebec,
J2G-NS-O007,Improving public cancer care by implementing precision medicine in Norway,
J2G-US-I001,Neoadjuvant/Adjuvant Treatment with Loxo 292 in RET-altered Thyroid Cancers,
J2G-OX-JZJW,Pediatric Match,
J2G-NS-I003,"A Multicenter Thyroid Oncology Group (ITOG) Phase 2 Study of Selpercatinib in Patients with Completely Resected, Non-Metastatic, RET-Mutated Medullary Thyroid Cancer and Rapid Calcitonin and/or CEA Doubling Times",
J2G-US-X003,Screening Patients with Suspected Early-Stage Lung Cancers for Actionable Oncogene Targets,
J2G-US-X002,Fusion detection program in aggressive solid tumors,
J2G-US-I004,"Selpercatinib to enhance RAI avidity in children, adolescents, and young adults with newly diagnosed differentiated thyroid cancers harboring RET fusions",
J2G-NS-O006,"A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile. The Drug Rediscovery Protocol (DRUP trial)",
J2G-US-I005,Phospho-Proteomics Basket Trial: Selecting Therapeutics Using Phosphoproteomics (STUPP) ,
I4T-US-I031,A phase 1/2 study of combination lorlatinib and ramucirumab in patients with advanced ALK-rearranged lung cancers,
H6D-HL-O014,Retrospective data:Tadalafil in ED  clinical population,
B3D-BP-O044,Teriparatide vs. Standard care for severe Osteoporosis,
B3D-BP-O046,Teriparatide followed by Zoledronic acid versus placebo,
I8B-NS-I004,"A randomized, controlled, crossover trial to assess a fully automated, dual-hormone (insulin-and-pramlintide) delivery system without carbohydrate counting in regulating glucose levels in adults with type 1 diabetes.",
B9E-SB-O370,Multizentrische Phase I/II-Studie zur Wirksamkeit einer kombinierten Rituximab/Gemcitabin/Oxaliplatin-Therapie bei rezidivierten indolenten niedrigmalignen Lymphomen,
B9E-SN-O507,"An open labeled, multicentre, randomized phase II trial of combination Gemcitabine and Carboplatin",
B3D-AY-O033,PTH on Craniofacial Osseous Regeneration in Bone,
B9E-SB-O459,Prospective randomized study to compare extensive versus limited pelvic lymphadenectomy in urinary bladder carcinoma surgery.,
B3D-CA-O038,Effect of 2yr of Teriparatide on Fracture healing in Women,
B9E-BP-O364,BTOG 2: A British Thoracic Onc  Grp PHIII trial of gemcitabine+cisplatin at 50 mg/m2 versus gemcitabine plus cisplatin at 80 mg/m2 or gemcitabine plus carboplatin AUC 5 in stage IIIB/IV NSCLC,
Alias1234,title,
B9E-SB-O506,"SUCCESS B-Trial: Randomized phase III trial benefits of adjuvant FEC followed by docetaxel single agent vs. combinded docetaxel gem  based chemotherapy in early, HER2-neu positiveBC",
H6O-AY-O011,Preventing diabetic ketoacidosis in new patients with T1DM,
H8O-FR-O022,Intravenous exenatide (ByettaÂ®) versus insulin for perioperative glycemic control in cardiac surgery: the open-labeled randomized phase II/III ExStress study.,
F1D-XB-O335,IIT Encephaography,
I6T-NS-O001,Development and validation of the fecal URGENcy index Through two European cohorts (The URGENT Index),
I4X-US-I006,A Phase 1 Study of Osimertinib and Necitumumab and Tucatinib in Advanced EGFR-mutant NSCLC with Acquired Resistance to Osimertinib,
B4Z-XM-O028,NEUROPSYCHOLOGICAL EVALUATION OF THE EFFICACY ATX IN ADHD,
B3D-SZ-O030,Effect of 1-34 rh-PTH teriparatide in Anorexia Nervosa Pts,
H6D-IT-O021,"IIT Tadalafil  Double-Bind, Placebo-Controlled Study",
F1D-JE-O340,BP dep olanzapine plus antidepressant,
B9E-IH-O481,Randomized phase III trial benefit of adjuvant chemotherapy w/ gem+cis in nasopharyngeal carcinoma patients w/residual EBV DNA following radiotherapy with/without concurrent cisplatin,
B3D-CP-O032,Teriparatide in Patients with Osteogenes Imperfecta,
F1D-US-X318,Olanzapine vs. Placebo for Outpatients with Anorexia Nervosa,
H6O-PL-O013,A Multinational Study of Numeracy Skills in Children with Diabetes and Their Caregivers,
B3D-JE-O045,Effects of TPTD on bone microstructure and bone strength,
B3D-US-X014,A Mechanistic Study of Skeletal Actions of 1-34hPTH,
H6O-US-X002,Tailoring Preconception Counseling for Hispanic Adolescents,
B4Z-SZ-O036,"Atomoxetine, diurnal profiles of cortisol and Ã¡-amylase",
I8B-NS-I005,"A Randomized, Crossover, Pilot Trial to Compare Automated Lyumjev Delivery with Carbohydrate Counting, Qualitative Meal-Size Estimation, and Meal Detection in Type 1 Diabetes",
H7T-IT-O020,Elderly-2,
I4E-US-X022,"A Single Arm Phase II study of 5-Flourouracil based combination chemotherapy with Cetuximab in Second Line for Mutant APC, TP53 and Wild-type Pan-RAS patients with Metastatic Colorectal Cancer",
B3D-SO-O041,Parathyroid hormone treatment of osteoporosis in DK patients,
I5Q-US-X002,A Pilot Trial of Galcanezumab for Vestibular Migraine,
B3D-CA-O018,Forteo in Bone Geometry in PM Women with Osteoporosis,
B3D-OE-O042,IIT Terafrap studyTeriparatide for fracture repair in humans,
F1D-US-X320,Sustaining Remission of Psychotic Depression,
B3D-US-X039,PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial,
B3D-CP-O035,Postoperative treatment with Forteo in elderly patients,
F3Z-FR-O084,Prognosis Associated with an Early Screening for Gestational Diabetes Mellitus,
I1A-MC-E001,The effects of an estrogenn receptor (ER) beta agonist (Lilly Compound LY500307) on estradiol-withdrawal-induced mood symptoms in women with past perimenopausal depression,
B3D-CP-O002,DK Database of patients in PTH-treatment for osteoporosis,
B9E-BP-O504,"Neo-ESCAPE:Extended chemotherapy with neoadjuvant carboplatin, then surgery followed by adjuvant paclitaxel and gem vs neoadjuvant gem+carbo+surgery, followed by paclitaxel",
B3D-JE-O043,OP patients w or w/o TPTD treatment after the first hip fx,
H6D-SO-O023,Insulin resistance-inflammation;novel PDE5 inhibit.strategy,
I7E-AV-E061,Neuroimaging Correlates of Social Cognition in Frontotemporal Dementia,
I4E-US-I009,RANDOMIZED TRIAL OF CONSOLIDATION TARGETED ADJUVANT THERAPY WITH ENCORAFENIB AND CETUXIMAB VERSUS USUAL CARE FOR PATIENTS WITH STAGE II/III BRAF V600E COLON CANCER,
H3E-CA-O083,A CLINICAL AND MOLECULAR RISK-DIRECTED THERAPY FOR NEWLY DIAGNOSED MEDULLOBLASTOMA (SJMB12),
B3D-US-X038,Development of chondro-regenerative therapy for osteoarthritis,
H3E-EW-O039,Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIA NSCLC,
B4Z-US-X057,Targeted Pharmacologic Interventions for Autism,
B3D-BP-O027,Teriparatide (Forsteo) treatment in postmenopausal women,
I3Y-NS-O034,"Neo-AGILE: A phase II window-of-opportunity trial of giredestrant and abemaciclib in patients with hormone-receptors-positive (HR+), HER2-negative (HER2-) early breast cancer",
I8S-MC-E006,A Phase 0/2 Study of LY3214996 (ERK inhibitor) in combination with Abemaciclib (CDK4 and 6 inhibitor) in  Recurrent Glioblastoma Participants Scheduled for Resection  to Evaluate Central Nervous System (CNS) Penetration,
I8S-MC-E003,The study of the safety and efficacy of ERK 1/2 Inhibitor in AML,
I8S-MC-E005,"A Phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1",
J2N-MC-JZNZ,Clinical Trial (Ph1a/b SM St Dose Esc/Expan: 65 pts 28 sties  Stand,
I8S-MC-E001,Phase II Trial of ERK Inhibition Alone and in Combination with Autophagy Inhibition in Patients with Metastatic Pancreatic Cancer,
I4V-NS-X010,"A Phase IIa, Single-Site, Open-Label Trial of Baricitinib in Patients with Cardiac Sarcoidosis",
I8S-MC-E010,A Window of Opportunity Strategy for Targeted PARP or MEK/ERK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma,
I8F-NS-O005,THE POTENTIAL OF TIRZEPATIDE IN PATIENTS WITH POSTBARIATRIC TREATMENT FAILURE,
H6D-US-I002,A Phase I/II Study of Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,
I5Q-MC-CGAS,LY2951742 vs placebo in episodic pediatric migraine patients,
J2Y-GH-O001,Exploratory clinical study of Sintilimab combined with GP regimen in the treatment of advanced lung lymphoid epithelioid carcinomaï¼ˆLELCï¼‰,
H9H-MC-E001,paclitaxel/carboplatin +/-  LY2157299 in stage I-IV or recurrent Uterine Carcinosarcoma,
H9H-MC-E005,TGFb R1 kinase inhibitor with nab-paclitaxel in triple negative metastatic breast cancer,
H9H-MC-E003,TGFb Type I Receptor Inhibitor with Neoadjuvant Chemoradiation in Rectal Adenocarcinoma,
H9H-MC-E008,Galunisertib Plus Stereotactic Body Radiation Therapy in Advanced HCC,
H9H-MC-E006,Phase II Study of LY2157299 and Radiotherapy in Metastatic Breast Cancer,
I6A-MC-E006,LY3023414 and pembrolizumab in advanced NSCLC whose tumors express PD-L1,
I6A-MC-E007,LY3023414 followed by prexasertib in metastatic triple negative breast cancer,
I6A-MC-E004,"Phase II clinical trial of LY3023414, a PI3K/mTOR inhibitor, in patients with recurrent osteosarcoma",
I6A-MC-E002,LY3023414 in Recurrent or Persistent Endometrial Cancer,
I8F-NS-I003,"Phase II Study of Adjuvant Tirzepatide plus Standard of Care Endocrine Therapy in Overweight or Obese Patients with Hormone Receptor-positive, HER2-negative, Node-positive Early Breast Cancer, with Molecular Residual Disease (MRD), as Determined by Circulating Tumor DNA (ctDNA)",
I8F-US-X002,TERMINATED: Effect of Tirzepatide plus Diet Therapy on body weight and metabolic health in Latinos with Obesity,
I8F-NS-I002,Investigator Initiated Study for the Treatment of Hidradenitis Suppurativa using TIirzepatide,
H9H-MC-E002,LY2157299 and enzalutamide after abiraterone in metastatic castration resistant prostate cancer,
I8F-NS-O004,Tirzepatide in the treatment of PCOS-related ovarian dysfunction - a prospective randomized placebo-controlled trial,
I8J-MC-JYCA,FHD  -Ph I - PD-L1 Antibody - Dose Escalation,
I8F-US-X003,Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Obese Humans,
J2N-NS-I020,"Phase 1b/2, Open-Label Study to Evaluate Safety
and Tolerability of Epcoritamab in Combination
with Anti-Neoplastic Agents in Subjects with Non-
Hodgkin Lymphoma",
I8F-NS-I006,Efficacy and Safety of Tirzepatide versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder: A Randomized Clinical Trial,
I8F-US-X001,Effect of Tirzepatide on progression of coronary atherosclerosis using MDCT (TIRZ-PLAQUE),
I8F-NS-O001,Optimising body composition in middle-age to prevent cardiovascular diseases: The Tirzepatide and Resistance EXercise (T-REX) study,
I8F-NS-I004,Tirzepatide for Idiopathic Intracranial Hypertension Trial (TIIHT),
I8F-US-X004,Tirzepatide and AFIB,
J2N-NS-I015,PRT2527 in Combination with Pirtobrutinib in Aggressive BCLs,
J2N-US-I013,A phase 2 study of Glofitamab as monotherapy or in combination with Polatuzumab Vedotin or Pirtobrutinib in Richter’s Transformation,
J2N-US-I017,Immune Profiling of CLL/SLL Treated with First-Line Pirtobrutinib,
J2N-US-I003,A phase II randomized study of pirtobrutinib plus obinutuzumab vs. pirtobrutinib monotherapy in CLL,
I7E-AV-E089,"Evaluating the effects of the novel GLP-1 analogue, liraglutide, in patients with Alzheimer’s disease (ELAD study)",
I8F-NS-O003,"Tirzepatide Once Weekly in Patients with Obesity and Knee Osteoarthritis: A Randomised, Placebo Controlled Trial.",
J2N-NS-I014,Pirtobrutinib post acalabrutinib in CLL,
J2N-US-I008,Phase II single center study of pirtobrutinib-rituximab in previously untreated low/medium risk patients with mantle cell lymphoma,
J2N-US-I009,A phase II study of Pirtobrutinib with Venetoclax in treatment naïve patients with Waldenström’s Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL),
J2N-MC-E007,"An open-label, single-arm, phase 1-2 trial of GlOfitamab anD pIrtobrutinib (LOXo-305) in patients with mantle cell lymphoma and prior exposure to a BTK inhibitor",
J2N-MC-E002,A Phase II study evaluating venetoclax and pirtobrutinib in previously treated WaldenstrÃ¶m Macroglobulinemia,
J2N-NS-O005,"A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Rich-ter Transformation",
J2N-US-I006,A multicenter phase II study of pirtobrutinib in combination with rituximab for first line treatment of marginal zone lymphoma – A risk adapted approach.,
J2N-NS-O003,Glofitamab Combined With Pirtobrutinib in Relapsed/Refractory Patients with Mantle Cell Lymphoma Followed by an Extension in Treatment Naïve Patients (PLATO),
J2N-NS-I012,Ph1/2 Mosun + Pirto in R/R CLL.,
J2N-MC-E003,Phase II study of Pirtobrutinib with Venetoclax  in relapsed-refractory MCL (mantle cell lymphoma) patients,
J2N-NS-O006,PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL),
J2N-NS-O004,"Single-Arm phase 2 trial of pirtobrutinib treatment (24 cycles) with 
18 cycles of epcoritamab in patients with relapsed or refractory 
chronic lymphocytic leukemia or Small Lymphocytic Lymphoma",
,Clinical Trial (Trial 19 PMR Korea),
,Clinical Trial (P-Tau217 Patient Management Study),
J2N-MC-E009,A Study of Pirtobrutinib in CLL After Previous Treatment with Zanubrutinib,
J2N-US-I019,Pirtobrutinib and Mosunetuzumab for Patients with Relapsed/Refractory Follicular Lymphoma,
J2N-MC-E005,"Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients with Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)",
J2N-MC-E001,Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated with Venetoclax,
J2N-US-I016,A Phase 2 trial of Single-Agent Pirtobrutinib for Elderly Patients with CLL.,
J2N-NS-I011,Ph 1 study evaluating pirtobrutinib in combination with ZN-d5 (BCL-2 inhibitor) in R/R MCL,
J2N-MC-E004,"A phase 2 study of MRD guided, fixed duration therapy for previously untreated chronic lymphocytic leukemia with LOXO-305 and venetoclax",
,PMR2-Clinical Trial (PASS-US) Algorithm study,
J2N-US-I018,Pirtobrutinib plus R-CHOP vs. R-CHOP for patients with previously untreated Richter Transformation (RT),
I4V-JE-O042,"A Phase 4, Multicenter Study to Evaluate the Dose titration n and Drug Holiday Safety and Efficacy of Baricitinib in RA Patients who achieved Remission.",
I4V-NS-O035,"Tolerance and efficacy of a janus kinase 1-2 inhibitor, baricitinib, in systemic sclerosis: a randomized, controlled versus placebo, phase II study",
I4V-XM-O003,Response of ultrasound-detected synovitis to baricitinib monotherapy and baricitinib combined with methotrexate as compared to adalimumab,
I4V-MC-I002,Donated Pharmaceutical Agents Agreement,
I4V-NS-O027,CREDID COVID-19 ADAPTIVE PLATFORM - RANDOMIZED CLINICAL TRIALS (CCAP-RCT),
I4V-US-X005,Safety and Efficacy of baricitinib for the treatment of frontal fibrosing alopecia,
I4V-MC-I001,Janus Kinase Inhibitor (Baricitinib) for Aicardi GoutiÃ¨res Syndrome,
I4V-NS-O031,Phase II proof of concept study of baricitinib in individuals who are considered at risk of developing inflammatory arthritis: Baricitinib ExIST,
I4V-US-I008,Neurodegenerative Alzheimer’s Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Proof of Concept Trial including Asymptomatic Individuals using Baricitinib,
I7E-AV-E097,Tau PET imaging in Neurodegenerative Diseases (TaPINDS Phase 2),
I4V-US-X002,An open label pilot trial of baricitinib in the treatment of adults with  Pyoderma Gangrenosum (PG),
I4V-NS-O041,EFFICACY AND SAFETY OF BARICITINIB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS WHO HAVE FAILED OR PRESENT CONTRAINDICATIONS TO THERAPY WITH DUPILUMAB,
I4V-US-I010,"Safety and Efficacy of Baricitinib, a JAK1/JAK2 Inhibitor, on Cardiovascular Risk in Treated HIV Infection: A Randomized Placebo Controlled Trial (BRAVO-HIV)",
I4V-NS-O024,TREATMENT OF MODERATE TO SEVERE CORONAVIRUS DISEASE (COVID-19) IN HOSPITALIZED PATIENTS,
I4V-MC-E001,"A Phase 1/2 study of baricitinib, a JAK1/2 inhibitor, in chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (SCT)",
I4V-US-X003,Baricitinib for the Treatment  of Ocular Mucous Membrane Pemphigoid,
I4V-NS-O040,BARICITINIB IN CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE – A PROOF OF CONCEPT PHASE II CLINICAL TRIAL,
I4V-SB-O008,CALIRA - CArtiLage Investigation in Rheumatoid Arthritis,
I4V-NS-O010,"(BANDIT) A phase 2, randomized, placebo-controlled study investigating the safety, tolerability and efficacy of baricitinib (Olumiant) in new-onset type 1 diabetes mellitus",
I4V-US-I006,Baricitinib in Lichen Planus,
I4V-FR-O009,Efficacy and tolerance of the association of Baricitinib (4mg) and phototherapy versus phototherapy in adults with progressive vitiligo : a randomized double blind prospective study (BARIVI),
I4V-NS-O012,Exploiting leading edge 7 Tesla MRI brain imaging to decipher Olumiantâ€™s mode of analgesic action in rheumatoid arthritis,
I4V-NS-O015,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricitinib as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects with New-Onset Polymyalgia Rheumatica",
I4V-NS-O017,Combination of baricitinib and adalimumab vs. baricitinib in patients with rheumatoid arthritis: a randomized phase 3 trial,
I4V-NS-O045,MOLLI-B,
I4V-US-I007,Baricitinib as Novel Therapy for APOL1 Nephropathy,
I7E-AV-E027,PET Imaging of tau burden in neurodegenerative diseases,
I4V-FR-O002,Baricitinib in early Onset Polymyalgia Rheumatica,
I4V-NS-O011,ICEA Induction of Cure in Early Arthritis,
I4V-UT-O005,Pragmatic trial baricitimib vERsus First biological in Tight Control PatiEnTs suffering from Rheumatoid Arthritis (PERFECT),
I4V-NS-O034,Deciphering complexity of atopic dermatitis by assigning deep clinical phenotyping to lesional skin transcriptome ,
I4V-BP-O004,A proof of concept study of baricitinib in the treatment of idiopathic inflammatory myopathy,
I4V-US-O007,An Investigator Initiated Study to Evaluate the Efficacy of Baricitinib in Treatment of Delayed-Type Hypersensitivity versus Irritant Skin Reactions in Healthy Adult Male Subjects,
I4V-NS-O026,PANCOVID,
I4V-US-X007,Combination baricitinib plus oral minoxidil vs baricitinib monotherapy for treatment of alopecia areata,
I4V-NS-O032,CHARACTERIZATION OF BARICITINIB EFFECTS ON THE PRO-THROMBOTIC AND CARDIOVASCULAR RISK PROFILE OF RHEUMATOID ARTHRITIS PATIENTS,
I4V-NS-O023,CORIMMUNO - NESTED JAKOVID,
I4V-US-I003,Baricitinib in REfractory juvenile Dermatomyositis (BRED),
I4V-US-X004,Mechanistic phase II study of baricitinib for HIV persistence in the central nervous system,
I4V-GH-O039,"A multi-center, prospective, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients",
I4V-NS-O046,"A multi-center, prospective, open-label, randomized study to explore efficacy and safety of baricitinib in refractory intestinal Behçet's Syndrome patients",
I4V-NS-O018,JAK/STAT-inhibition to induce immunological remission by silencing ACPA-expressing B cells in Rheumatoid Arthritis,
I4V-US-X006,Efficacy and Safety of Baricitinib in Oral Lichen Planus: A Proof-of-Concept Study,
I4V-FR-O006,"BARIcitinib: Cognitive Emotional and Neural signaTuRE
BARICENTRE",
I4V-JE-O014,Cross-sectional analysis of changes in the fine articular structure by JAK inhibitor using HR-pQCT in rheumatoid arthritis,
I7E-AV-E069,Korean brain aging study for early diagnosis and prediction of Alzheimer’s disease (KBASE),
I4V-NS-O044,Baricitinib to stop acute exacerbation of alopecia areata,
I4V-NS-O019,"A parallel group, randomized, double-blind, placebo-controlled, multiple dose, investigator initiated (IIT) study to investigate the effect of orally administered baricitinib on thromboembolic events in healthy subjects and in patients with rheumatoid arthritis under Methotrexate (MTX) treatment alone or in combination with tumour necrosis factor-alpha (TNF-α) inhibitors.",
I4V-NS-O036,"The JAKIPRA Study (JAK Inhibition in PReclinical Arthritis) A prospective, randomized controlled, double-blind, single-center clinical trial in adult subjects with ACPA-positive Arthralgia",
I4V-NS-O025,mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 (TACTIC),
I4V-SB-O001,"Evaluation of structural bone change in patients with Rheumatoid Arthritis treated with baricitinib vs. adalimumab: single center, mode of action study (BARE BONE)",
I4V-NS-O030,"A randomized, double-blind, placebo-controlled, parallel-group, phase 2 study of Baricitinib as add-on therapy in the antipsychotic treatment of schizophrenia patients with chronic peripheral inflammation",
I4V-JE-O038,RA-Be in Remission Study,
I7E-AV-E110,Neuroimaging of CVD and AD Pathology in the Transition to Old Age (Heart SCORE Neuroimaging Study)  ,
I7E-AV-E038,"Longitudinal imaging of tau accumulation in the earliest stages of AD (""LUNAR"")",
I7E-AV-E116,"Tau, Amyloid and White Matter in the Aging Brain",
I7E-AV-E057,Alzheimer's Disease Biomarker Consortium - Down Syndrome,
I7E-AV-E094,Longitudinal Early-Onset Alzheimer's Disease Study (LEADS),
I7E-AV-E135,Characterization of relationship between tau pathology and neurodegeneration in Alzheimer's disease using multimodal imaging,
I7E-AV-E049,"Structural, Functional, and Molecular Brain Imaging in Aging and Early Dementia",
I7E-AV-E024,An open-label study evaluating the diagnostic accuracy of [18F]AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau,
I7E-AV-E120,Health and racial disparities in Alzheimer's Disease in the Southeastern United States,
I7E-AV-E125,"Neurologic Function across the Lifespan: A Prospective, LONGitudinal, and Translational Study for Former National Football League Players (NFL LONG)",
I7E-AV-E140,Alzheimer's Disease Neuroimaging Initiative 4,
I4V-NS-O033,QUALITY OF LIFE IN YOUNG CHILDREN WITH DERMATOLOGICAL DISEASES: VALIDATION OF THE GERMAN INFANTS AND TODDLERS DERMATOLOGY QUALITY OF LIFE (INTODERMQOL),
I7E-AV-E123,Neuroimaging in Health Aging and Senile Dementia,
I7E-AV-E046,F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction due to Alzheimer Disease,
I7E-AV-E138,Mayo Clinic Study of Aging - Jacksonville (MCSA - Jax),
I7E-AV-E100,Longitudinal effects of cerebrovascular and amyloid burdens on AV1451 uptakes,
I7E-AV-E131,Aging Brain Cohort Dedicated to Diversity Study (ABCD2),
I7E-AV-E117,Dominantly Inherited Alzheimer Network (DIAN) Observational Study (DIAN-O),
I7E-AV-E026,"An evaluation of tau aggregation by the novel tau tracer, [18F]T807 PET in mild cognitive impairment subjects: A preliminary PET study",
I7E-AV-E011,"PET Biomarker Imaging in Normal Aging, Mild Cognitive Impairment and Dementia at the Mayo Clinic",
I7E-AV-E126,The Impact of Depression and Preclinical Alzheimer Disease on Driving Among Older Adults ,
I7E-AV-E064,Alzheimer neuroimaging-biomarkers in pre-clinical cognitive decline from a population-based study (“MYHAT-Neuroimaging Study”),
I7E-AV-E102,Alzheimer's Disease Core Center ,
I7E-AV-E136,Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery (DISCOVERY),
I7E-AV-E077,Mechanisms of Spreading Disease in Human Tauopathy,
I7E-AV-E119,DIAN-TU OLE,
I7E-AV-E129, Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease (SToMP-AD),
I7E-AV-E004,Memory and Aging Study,
I7E-AV-E051,The structural and functional connectome across Alzheimer's disease subtypes,
I7E-AV-E052,Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD in Humans,
I7E-AV-E099,Tau Evaluation in Neurodegeneration and Dementia Research (TENDeR),
I7E-AV-E118,PET-AL: Vulnerable and resilient neural networks in early onset Alzheimer’s disease and its focal variants,
I7E-AV-E037,The Biological Basis of Cognitive Impairment due to Suspected Non-Alzheimer’s Pathology (SNAP) : Studying the interplay between amyloidosis and tau-related neurodegeneration,
I7E-AV-E002,T807 Tau PET Imaging of Alzheimer's Disease,
I7E-AV-E080,Tau PET Imaging in African Americans,
I7E-AV-E130,Sleep Trial to Prevent Alzheimer's Disease (SToP-AD) ,
I7E-AV-E022,Expansion of tau-pathology along functional networks of the brain in Alzheimer's Disease. A longitudinal multimodal imaging study (T-POT),
I7E-AV-E107,Relationship of Tau Burden as Assessed with AV-1451 to Phenotypic Profiles in Adults at Risk for Alzheimer’s Disease,
I7E-AV-E114,"Comprehensive Biomarker Panel for Trauma-Related Dementia: Mechanistic links among axonal injury, neuroinflammation, and neurodegeneration",
I7E-AV-E111,PET Imaging in the ADRC Neuroimaging Core Extension (ADRC PET Extension Study),
I7E-AV-E133,Neuroinflammation and Alzheimer's Disease Imaging Biomarkers in Midlife Obesity,
I7E-AV-E137,"The ADRC Consortium for Clarity in ADRD Research Through Imaging ""CLARITI""",
I7E-AV-E134,Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery,
I7E-AV-E087,Tau Imaging in Atypical Dementias,
I7E-AV-E132,Longitudinal multicenter head-to-head harmonization of tau PET tracers,
I7E-AV-E041,Tau Imaging in Mild Cognitive Impairment,
I7E-AV-E115,Prevalence of Brain Health versus Neurodegeneration in Professional Football Retirees,
I7E-AV-E068,Modulators of Medial Temporal Lobe Subregion Structure and Function in Normal and Pathological Aging,
I4V-JE-JAJE,Japan P2/3 for autoimflammatory Type1 interferonopathies,
I7E-AV-E073,Tau-Imaging in Tauopathies; Alzheimer’s disease and Non-AD dementias (TITAN),
I4X-US-I001,A Feasibility and Biomarker Study to Evaluate Necitumumab in the Neoadjuvant Setting with Gemcitabine and Cisplatin in Surgically Resectable Squamous Lung Cancer,
I4X-US-I005,"A Phase II Study of Osimertinib and Necitumumab in 
EGFR-mutant NSCLC harboring C797X Mutations after Progression on First Line Osimertinib",
I4X-MC-E001,AZD9291 and Necitumumab in EGFR-mutant Non-Small Cell Lung Cancer,
I4X-US-I003,Brigatinib plus Necitumumab for EGFR C797S-positive NSCLC,
I4X-MC-JFDB,"An Open-Label Multicentre, Multi-Drug, Biomarker-Directed, Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-line Therapy with the Epidermal Growth Factor Tyrosine Kinase Inhibitor, Osimertinib, to Assess the Safety, Tolerability, and Efficacy of Investigational Agents",
F3Z-US-X037,"Therapeutic Effect of Intranasal Insulin on Cognition, Funct",
F3Z-BP-O087,A retrospective study of patients receiving Humalog 200 units/ml KwikPen insulin in the UK,
I8B-NS-I002,Orbit 2.0 Extended Wear Pivotal Trial,
I8B-NS-I001,Bridging Algorithm Study ,
H9X-FR-O002,DIaMOND Dulaglutide and insulin MicrosecretiON in T1DM,
H9X-FR-O001,Effect of GLP-1 Agonist dulaglutide on Liver Steatosis (REALIST),
H9X-NS-O003,Safety and efficacy of dulaglutide in hemodialysis patients - a pilot study,
J3M-NS-I001,Olomorasib + Rybrevant in KRAS G12C+ NSCLC,
H3F-US-X003,A Multicenter Study of Outpatient Automated Blood Glucose Co,
B5K-US-X013,Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes (TN20) - B5K-US-X013,
H3F-US-X002,Closed-Loop Glucagon Administration for the Automated Treatment of Post-Bariatric Hypoglycemia,
H3F-US-X005,Set-Point: Eval Effects of Changing GLC Target - H3F-US-X005,
J2T-MC-X001,Molecular Mechanism(s) for long-term response to Lebrikizumab in Atopic Dermatitis,
I4D-MC-E008,"Prexasertib in combination with mitoxantrone, etoposide and cytarabine in relapsed/refractory acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) - a phase I trial.",
I4D-MC-E010,LY2606368 with Cyclophosphamide or Gemcitabine in pediatrics with Medulloblastoma Brain Tumors,
I4D-MC-E003,LY2606368 in Pediatric Patients with Solid Tumors including CNS tumors,
I4D-MC-E004,"LY2606368 and Olaparib, PARP inhibitor, in Advanced Solid Tumors",
I4D-MC-E002,LY2606386 with Cytarabine and Fludarabine in Acute Myelogenous Leukemia,
I4D-MC-E005,"Phase I Study of Prexasertib, CHK1 inhibitor, in combination with LY3300054, PD-L1 Antibody",
I4D-MC-E001,Chk1/2 inhibitor in BRCA1/2 mutation associated breast or ovarian cancer,
"0101815",Evaluation of CHK1-Â­independent homologous recombination-Â­mediated DNA repair as a mechanism of prexasertib resistance,
I4D-MC-E006,CHK1 inhibitor in solid tumors with replicative stress or homologous recombination repair deficiency,
I4T-US-X001,A phase II clinical trial of the safety and efficacy of the addition of ramucirumab to nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC),
I4T-SB-O015,A multicenter single-arm pilot study of ramucirumab in combi-nation with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors,
I4T-JE-O021,Phase II Study of 1st. line S-1+RAM for elderly patients with advanced gastric cancer.,
I4T-JE-O043,Phase II study to evaluate the efficacy of erlotinib plus ramucirumab in patients with previously untreated EGFR mutation-positive NSCLC and with malignant pleural effusion,
I4T-US-I031,A phase 1/2 study of combination lorlatinib and ramucirumab in patients with advanced ALK-rearranged lung cancers,
I4T-JE-O048,Prospective observational study evaluating profiling of T cell binding to anti-PD-1 antibody using peripHeral blood as signature for tumor response during ramucirumab and docetaxel after an anti-PD-1 antibody (ENHANCER),
I4T-JE-O036,Single arm study to evaluate the safety and efficacy of ramcirumab in patients with advancded hepatocellular carcinoma failed lenvatinib,
I4T-NS-I034,"S2302, PROJECT PRAGMATICA: A PROSPECTIVE, RANDOMIZED STUDY OF RAMUCIRUMAB (NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER IN STANDARD PRACTICE",
I4T-JE-O012,PhaseII study of the efficacy and safety of DOCETAXEL + RAMUCIRUMAB for NSCLC wIth brain meTAstasis: RAMNITA study,
I4T-JE-O023,Phase 1b study of ramcirumab in combination with cisplatin plus irinotecan for extensive small-cell lung cancer,
I4T-JE-O040,Multicenter Retrospective Study to Evaluate Docetaxel plus Ramucirumab after Combination Therapy with PD-1 Inhibitor and Chemotherapy in Advanced Non-Small Cell Lung Cancer,
I4T-US-I011,"TH-125: A Randomized Phase 2 Study of Nivolumab plus Ramucirumab in Patients with Recurrent, Advanced, Metastatic Non-Small Cell Lung Carcinoma",
I4T-NS-O037,Phase II study of pembrolizumab + ramucirumab in  metastatic GC as second-line treatment,
I4T-US-I006,Phase II study of ramucirumab with trastuzumab and capecitabine/cisplatin in patients with metastatic HER2-positive gastric cancer,
I4T-US-X002,Ramucirumab plus irinotecan in patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma,
I4T-JE-O042,Multicenter Retrospective Study of Ramucirumab-Containing Chemotherapy for previously treated Gastrointestinal Neuroendocrine Carcinoma,
I4T-KL-O014,Ram in combo with Trastuzumab and Weekly Pac in HER+ Gastric,
I4T-US-X003,"A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma",
I4T-NS-I028,"PHASE 2/3 STUDY OF TUCATINIB, TRASTUZUMAB, RAMUCIRUMAB AND PACLITAXEL VERSUS PACLITAXEL AND RAMUCIRUMAB IN PREVIOUSLY TREATED HER2+ GASTROESOPHAGEAL CANCER",
I4T-NS-I026,"A PHASE 2, MULTI-CENTER, OPEN-LABEL STUDY OF CINREBAFUSP ALPHA (PRS-343) IN COMBINATION WITH RAMUCIRUMAB AND PACLITAXEL IN PATIENTS WITH HER2-POSITIVE GASTRIC OR GASTROESOPHAGEAL (GEJ) ADENOCARCINOMA",
I4T-JE-O047,Ramucirumab plus Erlotinib versus Osimertinib as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR exon 21 L858R mutation: A multicenter retrospective observational cohort study in Japan,
I4T-FR-O019,Ph II study evaluation of ramucirumab alone or combined with chemotherapy in second line treatment of elderly patients with advanced gastric or gastro-oesophagal junction adenocarcinoma,
I4T-MC-JVDF,"AN OPEN LABEL, MULTICENTER, PHASE 1B/2 STUDY OF RAMUCIRUMAB PLUS PEMBROLIZUMAB (MK3475) IN PATIENTS WITH LOCALLY ADVANCED AND UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA, NON-SMALL CELL LUNG CANCER (NSCLC), OR TRANSITIONAL CELL CARCINOMA (TCC) OF THE BLADDER, URETHRA, URETER, OR RENAL PELVIS TUMORS.",
I4T-JE-O025,Docetaxel plus Ramucirumab with pegylated granulocyte-colony stimulating factor support for elderly patients with advanced non-small cell lung cancer: A multicenter prospective single arm phase II study: DRAGON study,
I4T-NS-O038,"A pilot study of ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy",
I4T-IT-O008,Platinum-Etoposide With or Without Ramucirumab in First Line Treatment of Extensive Disease Small Cell Lung Cancer (SCLC),
I4T-GR-O009,Ramucirumab combined with standard nab-paclitaxel and gemcitabine as first-line chemotherapy in patients with advanced pancreatic adenocarcinoma,
I4T-US-I017,An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC,
I4T-JE-O032,A phase II trial of ramucirumab plus irinotecan for patients with advanced gastric cancer with early relapse after docetaxel plus Sâ€‘1 adjuvant therapy,
I4T-NS-I021,"Open-label, single-arm trial to evaluate antitumor activity, safety, and pharmacokinetics of SAR408701 used in combination with ramucirumab in metastatic, nonsquamous, non–small-cell lung cancer (NSQ NSCLC) patients with CEACAM5-positive tumors, previously treated with platinum-based chemotherapy and an immune checkpoint inhibitor",
I4T-JE-O044,A Phase II Trial of EGFR-TKI + Ramucirumab for Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer Patients with brain metastasis,
I4T-SB-O005,"Ram+Irinotecan / Leucovorin / 5-FU versus Ram+Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or GEJ, who failed one prior line of palliative chemotherapy",
I4T-NS-I030,"A PHASE 2/3 STUDY OF ALX148 IN PATIENTS WITH ADVANCED HER2-OVEREXPRESSING 
GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (ASPEN-06)",
I4T-US-I009,Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma,
I4T-MC-I036,"Open-Label, Randomized Phase 2 Trial of Ramucirumab in Combination with Pembrolizumab versus Pembrolizumab Alone as First-Line Treatment of PD-L1 Positive, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma.",
I4T-JE-O013,Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer,
I4T-JE-O028,A phase II study of second line chemotherapy of FOLFIRI plus Ramucirumab in patients with anti-EGFR antibody refractory RAS wild type unresectable or recurrent colorectal cancer,
I4T-JE-O035,Phase II study of Docetaxel plus Ramucirumab in patient with non-small cell lung cancer after anti-PD-1/PD-L1 antibody +platinum based chemotherapy.,
I4T-US-I005,"A Phase II Study of Ramucirumab with Somatostatin Analog Therapy in Patients with Advanced, Progressive Carcinoid Tumors",
I4T-US-X004,A Phase II trial of Pembrolizumab and Ramucirumab in patients with progressive transitional cell carcinoma after treatment with an immune checkpoint inhibitor,
I4T-US-I007,"Phase II Randomized, Double-Blind Study of mFOLFIRINOX plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients HCRN GI14-198",
I4T-JE-O041,Phase III clinical trial comparing the combination of erlotinib plus ramucirumab with osimertinib for untreated advanced or recurrent non-squamous non-small cell lung cancer with EGFR L858R mutation,
I4T-NS-I035,S1900K: A RANDOMIZED PHASE II STUDY OF TEPOTINIB WITH OR WITHOUT RAMUCIRUMAB IN PARTICIPANTS WITH MET EXON 14 SKIPPING POSITIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY) ,
I4T-JE-O026,Phase III study of Ramucirumab plus docetaxel versus Immune checkpoint inhibitors for 2L treatment of stage IV NSCLC after disease progression on platinum-based therapy,
I4T-US-I013,"Ã¢â‚¬Â¢	Salvage Therapy with Carboplatin, Weekly taxane (Nab-Paclitaxel or Sb-Paclitaxel) and Ramucirumab in Advanced NSCLC after PD on Maintenance Pemetrexed or Pembrolizumab",
I4T-NS-O046,"An open label, single-arm, multicenter phase Ib/II study to evaluate the safety and efficacy of T-Dxd in combination with ramucirumab in patients with HER2 low gastric or gastroesophageal junction (GEJ) adenocarcinoma",
I4T-JE-O029,Phase I study of EGFR-TKI in combination with ramucirumab in patients with previously untreated EGFR mutant NSCLC,
I4T-NS-I025,"A Randomized, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Sintilimab Combined with Ramucirumab as Compared to Chemotherapy for the First-line Treatment of Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma",
I5F-MC-E002,"GVAX Pancreas Vaccine (with Cyclophosphamide), Pembrolizumab and CSF1R in Adenocarcinoma",
I4T-BP-O003,Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial (PLATFORM Trial),
I4T-IT-O004,"""""Assessment of Ram+paclitaxel as switch MANteInance vs continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or GEJ cancers: the ARMANI PhIII study""""",
I4T-NS-I027,"A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)",
I4T-US-X005,AN INVESTIGATOR-SPONSORED PHASE 2 SINGLE ARM TRIAL OF RAMUCIRUMAB AND PEMBROLIZUMAB IN PATIENTS WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER,
I4T-IT-O006,"Titolo: RAMES: A double-blind, placebo controlled, Ph II Study evaluating Gemcitabine with or without Ramucirumab as II line treatment for advanced malignant pleural mesothelioma",
I4T-US-I014,A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.,
I4T-NS-I032,"Lung-MAP S1900G: A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV Non-Small Cell Lung Cancer",
I4T-SB-O001,Perioperative RAMucirumab in combination with FLOT versus FLOT alone for reSEctable eSophagogastric adenocarcinoma â€“ RAMSES - a phase II/III trial of the AIO and GOIM,
I4T-JE-O033,Phase II study of docetaxel and ramucirumab for previously treated non-small cell lung cancer patients with malignant pleural effusion (PLUERAM),
I4T-NS-I018,A PHASE II STUDY EVALUATING COMBINATION TREATMENT OF TAS-102 AND RAMUCIRUMAB IN PATIENTS WITH METASTATIC GASTRIC CANCER,
I4T-NS-O045,"A phase II study of Ramucirumab (Cyramza®), nal-IRI (ONIVYDE®) and and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL study).",
I4T-US-I016,Ramucirumab and atezolizumab after progression on any immune checkpoint blocker in NSCLC (RamAtezo-1),
I4T-JE-O039,Real World Data of Systemic Therapy for Hepatocellular Carcinoma -Prospective observational study of systemic therapy for HCC in Japan (PRISM)-,
I4T-US-X006,"Systemic management of brain metastases from non-small cell carcinoma of the lungs by using upfront chemotherapy, immunotherapy and anti-angiogenic therapy, a Phase I/II study",
I4T-MC-JVDL,"AN OPEN LABEL, MUL TICENTER, PHASE 1 STUDY WITH EXPANSION COHORTS OF RAMUCIRUMAB OR NECITUMUMAB IN COMBINATION WITH AZD9291 IN PATIENTS WITH ADVANCED T790M-POSITIVE EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PROGRESSION ON FIRST-LINE EGFR TKI THERAPY",
I4T-JE-O024,Phase II study of ramucirumab and irinotecan combination therapy as second line treatment in metastatic or advanced gastric cancer patients; HGCSG 1603.,
I4T-JE-O034,A randomized controlled phase II trial of Nutrition counseling in Japanese patients with advanced gastric cancer receiving paclitaxel and ramucirumab.,
I4T-US-I037,"Open-Label, Randomized Phase 2 Trial of Ramucirumab in Combination with
Pembrolizumab versus Pembrolizumab Alone as First-Line Treatment of PD-L1 Positive,
Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (RM-HNSCC)",
I4T-JE-O016,A phase Ib study of osimertinib plus ramucirumab in EGFR mutated lung cancer patients.,
I4T-NS-I033,S1900I: A Randomized Phase II study of Mobocertinib (TAK-788) with or without Ramucirumab in Participants with Previously Treated EGFR Exon 20 Insertion Non-Small-Cell Lung Cancer (LUNG-MAP SUB-STUDY) ,
I5F-MC-E001,A Phase I/II Study of LY3022855 with BRAF/MEK Inhibition in Patients with Melanoma,
I4T-CA-O007,Eligibility of Patients with Unresectable and Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma for Second Line Therapy in Clinical Practice,
I4T-IT-O010,Phase II Study of carboplatin and paclitaxel in combination with ramucirumab in advanced thymic carcinoma and B3 thymoma,
I4T-US-I022,A Phase II study of poziotinib and ramucirumab in EGFR exon 20 mutant advanced non-small cell lung cancer (NSCLC),
I4T-US-I004,"A Phase II Study of Ramucirumab for Advanced, Pre-treated Biliary Cancers",
I4T-JE-O011,Randomized Ph III Trial of Continuation of Ramucirumab in Combination With Irinotecan in Patients With Advanced Gastric Cancer who Have Experienced Disease Progression on Ramucirumab,
I4T-US-I023,Neoadjuvant ramucirumab plus nivolumab in patients with borderline resectable/locally advanced HCC,
I4T-US-X007,"A Phase II, single-center, open-label study of Ramucirumab, Atezolizumab and N-803 after progression on any immune checkpoint blocker in NSCLC (RAN)",
I4T-NS-I038,IBI 343 (Claudin18.2 ADC) in combination with cyramza in gastric cancer,
I4T-US-I024,Combination of ramucirumab and TAS-102 in patients with recurrent metastatic gastric/gastroesophageal junction adenocarcinoma,
I4T-JE-O049,A Phase II Study of Ramucirumab and Erlotinib in EGFR exon19 deletion mutation positive treatment-naïve Non-Small Cell Lung Cancer Patients with high tumor PD-L1 expression,
I4T-JE-O027,A study of Ramucirumab in combination with Osimertinib in Participants with EGFR Mutation-Positive Metastatic NSCLC,
I4T-US-I015,LungMAP S1800A: a phase II randomized study of ramucirumab plus MK3475 (pembrolizumab) versus standard of care for patients previously treated with immunotherapy for stage IV or recurrent NSCLC (Non-Matched Sub-Study),
I4T-SB-O031,The Phase III Portion of the RAMIRIS study,
I4T-NS-I029,A Phase 2 study in Gastric Cancer CEACAM5 high expressor patients with SAR408701 used in combination with ramucirumab in CEACAM5.,
I4T-KL-O002,Phase II ramucirumab/paclitaxel as second-line treatment in metastatic gastric or GEJ adenocarcinoma with integrative genomic analysis,
I4T-JE-O017,Phase II study of FOLFIRI+Ramucirumab with early recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine,
I4T-SB-O020,"Ph II trial of Pac+ Ram vs Pac alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combo therapy with Fluoropyrimidine and Platinum-based drugs",
I4T-SB-O022,Phase III study of Ramucirumab in combination with TAS102 vs. TAS102 monotherapy in chemotherapy refractory metastatic colorectal cancer patients - RAMTAS,
,Clinical Trial (SAD/MAD incl. JP/CN HVs) LM non-Oncology,
I8B-MC-ITSY,I8B-MC-ITSY- Insulin Only Medtronic Lyumjev Closed Loop Pump Safety Study,
H7K-GH-O004,Single-agent fruquintinib as maintenance therapy after induction of first-line treatment of metastatic colorectal cancer,
H7K-GH-O007,Fruquintinib Combination Chemotherapy for Stage Ⅳ Colorectal Cancer in Preclinical Drug Evaluation,
H7K-GH-O001,Frukuintinib as the second-line treatment for metastatic biliary tract adenocarcinoma,
H7K-AQ-O006,呋喹替尼联合5氟尿嘧啶/亚叶酸钙（5FU/LV）在呋喹替尼治疗进展后的转移性结直肠癌(mCRC)中的Ib/II期研究,
H3E-IT-O060,"Study comparing PEM+GEM testing the efficacy of the addition of cisplatin in elderly patients with non squamous advanced, metastatic or recurrent NSCLC. -MILES 4",
H3E-FR-O076,WINTHER  A study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies,
H3E-CA-O081,PHASE II TRIAL OF SELUMETINIB with PEMETREXED AND CISPLATIN CHEMOTHERAPY FOR THE TX OF ADVANCED OR METASTATIC KRAS WILDTYPE OR UNKNOWN NON-SQUAMOUS NSCLC,
H3E-OE-B017,Evaluation of health related qualit of life during consolidation therapy in patients with advanced non-small cell lung cancer (NSCLC),
H3E-EZ-O089,A randomized phase II study of pleurectomy/decortication (P/D) preceded or followed by chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205-LCG),
H3E-BP-O030,CONCEPT: Concurrent chemoradiotherapy  for stage III NSCLC followed by consolidation Pemetrexed: a phase II study,
H3E-GH-O086,Randomized phase II study of pemetrexed alone vs pemetrexed plus cisplatin in patients with EGFR mutation-positive advanced NSCLC after first line EGFR-TKIs failure,
H3E-XM-O020,Study of pemetrexed disodium plus cisplatin as first-line therapy in patients with advanced non-squamous cell lung cancer: a phase IIA pharmacogenomic trial,
H3E-FR-O056,Phase II trial with concurrent pemetrexed cisplatin plus cetuximab regimen and combining chest radiotherapy for patients with non-squamous locally advanced NSCLC,
H3E-US-X083,"Phase II trial of Preoperative Pemetrexed and Carboplatin in Patients with Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer",
H3E-CA-O077,A phase Ib study of selumetinib in patients with previously treated or untreated advanced /metastatic  NSCLC who are receiving standard chemotherapy regimens,
H3E-US-X090,Retrospective analysis of the genomic landscape of non-small cell lung cancer (NSCLC) prior to Pemetrexed,
H3E-US-X065,Phase I/II Trial of Gemcitabine/Pemetrexed Combination in patients with advanced cutaneous T-cell lymphoma,
H3E-US-X059,"A Multicenter Phase Study of the Treatment of Recurrent Primary CNS Lymphoma with Alimta (Pemetrexed), a Novel Anti-Folate",
H3E-US-X087,"Randomized Phase III Study of Maintenance Therapy with Bev  Pem , or a Combination of Bev  and Pem  Following Carboplatin, Paclitaxel and Bevacizumab for Adv Non-Squamous NSCLC",
H3E-US-I037,A Phase IB Study of Pembrolizumab in Combination with Pemetrexed and Oxaliplatin in Subjects with Chemo-refractory Metastatic Colorectal Cancer,
H3E-UT-O028,Phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected nonsmall-cell lung cancer patients with high-risk for recurrence: NVALT- 8B.,
H3E-PL-O071,Molecular targeted pemetrexed therapy in advanced NSCLC: an effect of thymidylate synthase gene locus mutations,
H3E-JE-O064,Randomized Phase III Study of Cisplatin + Pemetrexed and Cisplatin + Vinorelbine for Completely Resected Non-squamous Non-Small Cell Lung Cancer,
H3E-MC-I040,"Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy with Osimertinib,Carboplatin and Pemetrexed for Untreated Patients with Advanced Non-squamous Non-Small Cell Lung Cancer With concurrent EGFR and TP53 Mutations",
H3E-US-I027,Phase I/II Clinical Trial of Combined Re-irradiation with Pem+Erlotinb Followed By Maintenance Erlotinib  Recurrent and Second Primary SCCHN,
H3E-UT-O065,"Dose escalation by boosting radiation dose within primary tumor on the basis of a pre treatment FDG-PET-CT scan in stage IB, II-III NSCLC: A randomised Phase II Trial.",
H3E-NS-O090,DARWIN2 Study (NCT02314481),
H3E-SZ-O057,"SAKK 19/09. Bevacizumab, pemetrexed and cisplatin, or erlotinib and bevacizumab for advanced non-squamous NSCLC stratified by EGFR mutation status. (BIO-PRO trial).",
H3E-FR-O067,Phase II trial evaluatingcarbo+pem in Human Immunodeficiency Virus positive (HIV+) patients w/ stage III (not amenable to radiation or inoperable) or stage IV nonsquamous NSCLC,
H3E-FR-O075,"Phase III trial comparing brain radiotherapy followed by chemo  with chem  alone in patients with non-epidermoid, NSCLC with asymptomatic brain metastases",
H3E-SB-O069,Randomized Phase-II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous NSCLC,
H3E-US-X088,"Phase II Study of Pemetrexed with Sorafineb in advanced, HER2 Negative breast cancer",
H3E-XM-O054,Study of pemetrexed disodium plus oral vinorelbine in patients with advanced non-squamous cell lung cancer: a phase I/II trial,
H3E-MK-I038,"A Phase3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)",
H3E-BP-O082,Platinum and pemetrexed rechallenge in patients with malignant pleural mesothelioma (MPM).,
H3E-UT-O085,First line chemotherapy in KRAS mutated non-small cell lung cancer patients: a Phase III comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22,
H3E-GH-O087,Phase II study of adjuvant chemotherapy with pemetrexed and cisplatin followed by pemetrexed single-agent consolidation in patients with completely resected stage II/IIIA lung adenocarcinoma,
H3E-US-X091,Pemetrexed for Progressive Chordoma,
H3E-SB-O015,phase 2 of alimta combined with paclitaxel in thyroid cancer,
H3E-MK-I039,"A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)",
I2V-MC-E001,Phase 1b Study of LY251092 in Combination with Idarubicin and Cytarabine in AML,
I3Y-US-I034,A phase 1/2 study of abemaciclib and docetaxel for patients with SMARCA4-mutant lung cancer,
I3Y-NS-O007,Abemaciclib in combination with fulvestrant and/or trastuzumab in patients with breast cancer accompanied by brain metastasis,
I3Y-US-I025,"Multicenter, open-label, phase Ib followed by three arm, randomized phase II neoadjuvant trial evaluating DS8201a versus DS8201a plus endocrine therapy versus DS8201a plus abemaciclib and endocrine therapy in women with hormone receptor positive, HER2-low",
I3Y-US-X012,GENOMICALLY-GUIDED TREATMENT TRIAL IN BRAIN METASTASES,
I3Y-MC-I051,Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT),
I3Y-MC-E017,A PHASE 1 TRIAL OF SELUMETANIB PLUS ABEMACICLIB FOR METASTATIC RAS MUTATED MALIGNANCIES,
I3Y-JE-O028,Innovation of the 1st line strategy optimized as abemaciclib with endocrine therapy based on the ESR1 mutation of ctDNA for HR-positive HER2-negative advanced metastatic breast cancer patients(JBCRG-M08) - Multi-institutional phase 2 trial -,
I6A-MC-E005,"A Phase 2, Two-Group, Two-Stage, Study of LY3023414 and Abemaciclib with or without Letrozole in Recurrent or Persistent Endometrial Cancer",
I3Y-MC-E009,Phase II study of abemaciclib in recurrent GBM patients with CDKN2A/B loss and intact RB,
I3Y-RH-I014,"A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH HORMONE RECEPTORPOSITIVE HER2-NEGATIVE BREAST CANCER (MORPHEUS-HR BREAST CANCER",
I3Y-NS-I033,"A Phase 1b Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LP-118 and Abemaciclib in Relapsed or Refractory Acute Myeloid Leukemia

",
I3Y-US-X003,"Immune Modulation by Abemaciclib in HPV-Negative Head and Neck
Squamous Cell Carcinoma (HNSCC): A Phase II Window Trial",
I3Y-NS-JPEB,"A PHASE 1B STUDY OF ZN c5 IN COMBINATION
WITH ABEMACICLIB IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED BREAST CANCER",
I3Y-NS-O021,Perceptions and Experiences of Abemaciclib and Endocrine TherapY,
I3Y-MC-I042,A single arm phase 1/2 trial of abemaciclib + VS-6766 + fulvestrant in metastatic HR+/HER2- breast cancer,
I3Y-MC-E020,I-SPY 2 EOP,
I3Y-US-I030,"A phase I study of ruxolitinib plus abemaciclib for patients 
with primary or post-polycythemia vera/essential 
thrombocythemia myelofibrosis",
I3Y-MC-E005,Phase IIA clinical trial of Abemaciclib in CDKN2A deleted Mesothelioma,
I3Y-US-I011,"Modulation of High-Grade Glioma Microenvironment with Pembrolizumab Combined with Pemetrexed, Abemaciclib, or ValloVax.",
I3Y-NS-O005,"ADAPTLAte: A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk,
HR+/HER2- early breast cancer",
I3Y-NS-O012,"Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast cancer patients",
I3Y-US-X022,A PHASE II STUDY OF THE COMBINATION OF GEMCITABINE AND CISPLATIN WITH ABEMACICLIB,
I3Y-MC-E006,Phase 2 Study of Abemaciclib in Dedifferentiated Liposarcoma,
I3Y-MC-E004,A phase II Study to Investigate the Efficacy of Abemaciclib in Advanced Biliary Tract Carcinoma,
I3Y-US-X020,"Analysis of ctDNA in Patients with Hormone-Receptor Positive, HER2-Negative Breast Cancer Receiving Adjuvant Abemaciclib and Endocrine Therapy",
I3Y-NS-I055,Verzenio in combination with PRMT5 inhibitor in MTAP del tumors with a GBM arm.,
I3Y-US-X007,Efficacy of Abemaciclib (CDK4/6 inhibitor) in Small Cell Lung Cancer,
I3Y-US-I016,A Phase II Trial of Abemaciclib with or without Atezolizumab in Metastatic Castration Resistant Prostate Cancer,
I3Y-GH-O033,Precision Treatment of HR+ HER2- Metastatic Breast Cancer Based on Molecular Subtyping,
I3Y-US-X008,A Phase I/II Study of the Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas,
I3Y-US-X010,Abemaciclib+ Hydroxychloroquine (HCQ) in refractory malignancies.,
I3Y-NS-JPCZ,"An Open, Multicenter, Single Arm Safety Study Evaluating the Safety and Tolerability of the Combination of Lasofoxifene and Abemaciclib for the Treatment of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer",
I3Y-US-I045,The TRADE study:  A Phase 2 Trial to Assess the ToleRability of Abemaciclib Dose-Escalation in Patients with Early-Stage HR-positive and HER2-negative Breast Cancer,
I3Y-MC-E015,Fulvestrant in Combination with Abemaciclib in ER positive Endometroid Adenocarcinoma,
I3Y-US-I012,Phase II trial of abemaciclib and pembrolizumab for recurrent glioblastoma,
I3Y-NS-O020,Efficacy and response prediction for combined CDK4/6 inhibitor and endocrine therapy  in low-grade serous ovarian cancer–  a collaborative phase II trial of the AGO study group,
I3Y-US-I039,"A Phase 2 Multicenter, Double-blind, Randomized-controlled Study of Abemaciclib (CDK4 and 6 inhibitor) in Newly Diagnosed RB-proficient Grade 3 Meningioma Participants",
B9R-US-X020,Growth Hormone Therapy in Osteogenesis Imperfecta,
I3Y-IT-O002,"An exploratory, Phase 2, single arm trial evaluating the activity and safety of Abemaciclib+ Aromatase Inhibitors (AIs) after 1st-line treatment with High-Dose Fulvestrant (HD-FUL) in HR+/HER2- advanced breast cancer patients – The HERMIONE-7 trial",
I3Y-US-I052,"Ph2 trial of irradiation alone vs. irradiation plus abemaciclib in RB-intact high-risk meningioma 
",
I3Y-US-X013,A Phase II Clinical Trial of Neo-adjuvant Abemaciclib with Fulvestrant in patients who develop localized recurrence while on adjuvant endocrine therapy with molecular evidence of endocrine resistance,
I3Y-NS-O004,"An open-label, multi-center phase IB/II study of abemaciclib with paclitaxel for CDK4/6 pathway activated tumors",
I3Y-JE-O023,The prospective trial of patient-proposed healthcare services with multiple targeted agent based on the result of gene profiling by multigene panel test,
I3Y-US-I054,A phase 1/2 study of CB-103 (oral pan-NOTCH inhibitor) with Abemaciclib or Lenvatinib in Combination in patients with NOTCH activated Adenoid cystic carcinoma (CALCulus),
I3Y-US-I008,A pilot neoadjuvant biomarker study to test whether abemaciclib + AI + a checkpoint inhibitor can change immunologically cold hormone receptor positive breast cancer to immunologically hot tumors after 12 weeks of therapy.,
I3Y-JE-O010,A randomized Phase II study of Probiotics plus supportive care vs. supportive care plus Trimebutine maleate for Abemaciclib-induced diarrhea in patients with ER-positive and HER2-negative advanced breast cancer (MERMAID),
I3Y-NS-O017,"A RANDOMIZED, TWO-ARM, OPEN-LABEL, PHASE II STUDY OF ABEMACICLIB  COMBINED WITH ENDOCRINE THERAPY (LETROZOLE OR FULVESTRANT) WITH OR WITHOUT A SHORT COURSE OF INDUCTION CHEMOTHERAPY WITH PACLITAXEL AS FIRST-LINE THERAPY IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HR-POSITIVE/HER2-NEGATIVE BREAST CANCER WITH AGGRESSIVE DISEASE CRITERIA",
I3Y-US-X021,Phase I/II Study of CDK4/6 Inhibition with Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy,
I3Y-NS-O031,"A multicenter uncontrolled, open label, prospective phase II study with bicalutamide (an antiandrogen) in combination with abemaciclib (an oral CDK 4/6 inhibitor) in 4 cohorts of locoregionally advanced inoperable or metastatic AR+ TNBC.",
I3Y-MC-E014,Multiorgan Metabolic imaging response assessment of Abemaciclib: the MiMe-A trial,
I3Y-NS-O008,Pilot ‘Window of Opportunity’ Neoadjuvant Study of Abemaciclib in Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC),
I3Y-US-I026,Multicenter open label phase Ib/II trial of abemaciclib and elacestrant in patients with brain metastasis due to HR+/Her2- breast cancer.,
I3Y-US-I021,A phase Ib of abemaciclib in combination with PT2977 in advanced clear cell renal cell carcinoma,
I3Y-US-X018,Phase II Study of Abemaciclib in Combination with Letrozole in Recurrent or Metastatic Endometrioid Endometrial Cancer,
I3Y-US-I009,Phase I/II Study of Abemaciclib +/- Ramucirumab in Metastatic Esophageal/Gastroesophageal Junction Carcinomas,
I3Y-US-I028,"Phase Ib study to investigate the safety and efficacy of CDK4/6 inhibitor, Abemaciclib combined with oral SERD, AMCENESTRANT in recurrent ER+ low grade endometrial or low grade serous ovarian cancers with prior therapy with aromatase inhibitors",
I3Y-MC-I043,A phase I study assessing safety and efficacy of giltertinib + abemaciclib for relapsed/refractory FLT3 mutant AML,
I3Y-NS-O013,Impact of abemaciclib on patients' roles and responsibilities (Impactor),
I3Y-NS-O018,Abemaciclib in patients with hormone receptor positive HER2 negative breast cancer with locally advanced or metastatic disease The Minerva trial - A phase IV Trial,
I3Y-NS-I047,"
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination with Select Targeted Therapies in Subjects with Locally Advanced or Metastatic Solid Tumors with Oncogene Amplifications
",
I3Y-US-I049,"Randomized, phase II trial of maintenance Letrozole/Abemaciclib after combination chemotherapy in patients with advanced or recurrent ER positive TP53-wildtype endometrial cancer (EC)",
I3Y-MC-E011,Abemaciclib in patients with head and neck squamous cell carcinoma,
I3Y-US-I004,MyDRUG: Myeloma-Developing Regimens Using Genomics (Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen),
I3Y-JE-O019,Liquid molecular analysis of CDK4/6 inhibitor re-challenge upon Progression to a Abemaciclib combination in ER-positive Metastatic Breast Cancer Patients,
I3Y-US-I035, A multi-center retrospective study to evaluate biomarkers and association with clinical outcomes with abemaciclib monotherapy following prior CDK4/6i progression among patients with Hormone Receptor positive (HR+)/HER2- metastatic breast cancer.  ,
I3Y-NS-I046,Abema + camizestrant in eBC or mBC,
I3Y-US-X015,"MONARCH-PRECISION PROGRAM: A Prospective, Randomized, Open Label, Phase II study of Abemaciclib combined with fulvestrant vs. abemaciclib in patients with molecularly defined subtypes of hormone-receptor positive (HR+), HER-2 negative metastatic breast cancer",
I3Y-MC-E003,Randomizedpre-surgical study to assess the effects of abemaciclib in early breast cancer patients,
I3Y-NS-I056,Abemaciclib + Endoxifen in recurrent ovarian & endometrial cancer,
I3Y-US-I031,"MULTICENTER RANDOMIZED PHASE II TRIAL OF FULVESTRANT PLUS ABEMACICLIB WITH OR WITHOUT RUN-IN OF FULVESTRANT IN ER-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER AFTER FAILURE OF A CDK4/6 INHIBITOR IN COMBINATION WITH AN AROMATASE INHIBITOR",
I3Y-GH-O029,Efficacy and tumor shrink pattern analysis of neoadjuvant Abemaciclib and aromatase inhibitor in HR+/HER2- breast cancer with a high Ki67 after 2 weeks preoperative endocrine therapy.,
I3Y-NS-I037,abemaciclib + giredestrant in ovarian cancer,
I3Y-MC-E001,"Abemaciclib (IND# 127912) in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors",
I3Y-MC-E007,"A Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB monotherapy in patients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-EGFR-based therapy and harboring an homozygous deletion of CDKN2A, and/or an amplification of CCND1 and/or of CDK6 ",
I3Y-US-I005,A phase Ib study of abemaciclib and tucatinib for HER2+ metastatic breast cancer,
I3Y-US-I053,Phase 1B trial of CB-103 in combination with CDK 4/6 inhibition and endocrine therapy in endocrine-resistant metastatic breast cancer.,
I3Y-MC-E012,A phase II study of the CDK4/6 inhibitor abemaciclib in patients with solid tumors harboring genetic alterations in genes encoding D­type cyclins or amplification of CDK4 or CDK6,
I3Y-MC-E010,A Phase 2 Study of Abemaciclib in Patients with Recurrent Primary Brain Tumors,
I3Y-MC-E002,INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT),
I3Y-MC-E016,Abemaciclib followed by radical cystectomy in patients urothelial carcinoma,
I3Y-NS-O022,‘The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile’,
I3Y-JE-O024,Clinical utility of LINE-electronic patient reported outcomes for breast cancer patients treated with abemaciclib,
I3Y-US-I001,Phase II clinical trial of abemaciclib in combination with androgen deprivation therapy for locally advanced prostate cancer,
F3Z-IT-O086,Sapienza University Mortality and Morbidity Event Rate (SUMMER) Study in Diabetes,
J2T-NS-L001,Phase 2 Trial of Lebrikizumab for Keloids,
I3Y-US-X001,Combination abemaciclib and sunitinib in Renal Cell Carcinoma,
I3Y-US-I007,abemaciclib in gastroenteropancreatic neuroendocrine tumors (GEP NETs),
I3Y-SB-O001,"IIMPLEMENTING PATIENTS ́ COMPETENCE IN ORAL BREAST CANCER THERAPY
A randomized, controlled study of standardized patient coaching versus patient management according to local practice for patients with hormone receptor positive HER2 negative metastatic breast cancer treated with Abemaciclib",
I3Y-US-I015,PHASE II TRIAL OF SMO/AKT/NF2 INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2/CDKx/CCNx MUTATIONS,
I3Y-JE-O015,NESTED CASE CONTROL STUDY OF  ABEMACICLIB-INDUCED INTERSTITIAL LUNG DISEASE (NOSIDE),
I3Y-US-I032,"SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib versus Placebo in
Patients with Advanced Dedifferentiated Liposarcoma",
I3Y-NS-O016,The Drug Rediscovery Protocol (DRUP trial),
I3Y-NS-I038,A Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm in Combination with Abemaciclib (Enobosarm Combination Group) compared to Estrogen Blocking Agent (Control Treated Treatment Group) for the Second Line Treatment of ER+HER2- Metastatic Breast Cancer in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent plus Palbociclib ,
I3Y-US-I023,A Phase 1 Study of Abemaciclib and Niraparib as Neoadjuvant Therapy in Hormone Receptor Positive (HR+) HER2 Negative (HER2-) Breast Cancer,
I3Y-US-X009,"Phase II Trial of Abemaciclib and T-DM1 in Women and Men with HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment with a Taxane, Trastuzumab and Pertuzumab",
I3Y-NS-O009,"AMBRE Open-label, randomized, multicenter, phase III study, comparing standard chemotherapy to Endocrine Therapy   + Abemaciclib combination as initial metastatic treatment among patients with visceral metastasis of ER+ Her2- breast cancer, high burden disease",
I3Y-NS-I033,NCI CRADA - Master Portal record,
I3Y-NS-O006,Pre-Operative Endocrine Therapy for Individualised Care with Abemaciclib,
I3Y-NS-I044,":  An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation",
I3Y-US-I010,Abemaciclib for the Rb indpendent inhibition of SNAIL1 and EMT in Surgically Resectable Chemotherapy Resistant TNBC,
I3Y-US-I050,Phase 1b/2 study of abemaciclib plus cabozantinib in IO-pretreated metastatic clear cell RCC,
,Clinical Trial (Underrepresented Populations),
I3Y-US-X011,Surgical Window of opportunity Study of Abemaciclib and Letrozole versus Letrozole for Endometrioid Adenocarcinoma of the Endometrium,
I3Y-JE-O011,Prospective Cohort Study of Abemaciclib for Chemotherapy-Treated Metastatic or Advanced Breast Cancer,
I3Y-JE-O014,Utilizing Tumor Immune Microenvironment and Gut Microbiome Signature to Identify Abemaciclib (LY2835219) Response Predictors and Factors Causing Diarrhea for Patients With ER+/HER2- Metastatic Breast Cancer,
I3Y-US-I018,"A randomized phase 2 study of abemaciclib, trastuzumab, and pembrolizumab in patients with advanced HER2+ breast cancer",
I3Y-NS-I040,Phase II – Endocrine therapy for male breast cancer,
I3Y-NS-O027,Abemaciclib and letrozole in estrogen receptor positive rare ovarian cancer,
I3Y-NS-O034,"Neo-AGILE: A phase II window-of-opportunity trial of giredestrant and abemaciclib in patients with hormone-receptors-positive (HR+), HER2-negative (HER2-) early breast cancer",
B5K-SB-O459,Fr1da Insulin INTERVENTION,
B5K-MC-IBDS,Epidemiology of diabetes intervention and complications:EDIC,
B5K-SB-O458,PRE-POINT-EARLY STUDY -PILOT STUDY USING ORAL INSULIN AT EARLY AGE FOR IMMUNE EFFICACY IN PRIMARY PREVENTION OF TYPE 1 DIABETES,
B5K-SB-O461,POInT - Primary Oral Insulin Trial Prevention of Diabetes Autoimmunity with Oral Insulin Therapy,
B5K-SB-O460,PINIT,
I4E-US-X030,A phase 2 trial of safety and efficacy of trastuzumab deruxtecan in combination with cetuximab in HER2-low metastatic colorectal cancer that has progressed on standard therapies,
I4E-US-X004,RTOG1016 Phase III Trial of Radiotherapy Plus Cetuximab versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer,
I4E-MC-X025,"Open-label Phase 2 Study of VS-6766 (RAF/MEK Clamp) in Combination with Cetuximab in Patients with Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer",
I4E-IE-W893,USOR 04-070 - Randomized phase II study of weekly irinotecan/carboplatin (ICb) with or without cetuximab  (Erbitux) in patients with metastatic breast cancer,
I3Y-US-I013,A Phase II Trial of Osimertinib and Abemaciclib with a Focus on Non-Small Cell Lung Cancer Patients with EGFR Activating Mutations with Osimertinib Resistance,
I4E-NS-I022,Ph /1b study for cetuximab + KRAS G12D inhibitor and/or RAS MULTI inhibitor in RAS mutant CRC and PDAC and KRAS G12D mutant CRC and PDAC,
I4E-MC-X026,Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination with Cetuximab and Encorafenib in Patients with Unresectable or Metastatic Colorectal Cancer who have previously received EGFR or BRAF-directed therapy,
I4E-US-I014,A phase Ib study of ALX148 in combination with cetuximab and pembrolizumab in patients with refractory microsatellite stable metastatic colorectal cancer,
I4X-US-I006,"A PHASE 1 STUDY OF OSIMERTINIB, CETUXIMAB, AND TUCATINIB IN ADVANCED EGFR-MUTANT NSCLC WITH ACQUIRED RESISTANCE TO OSIMERTINIB ",
I4E-US-X006,"S0819, A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",
I4E-US-X013,Randomized Phase II Trial Contrasting Weekly PCC with   Cetuximba-TPF) in Previously Untreated Patients with Locally Advanced SCHHN-Correlative Biomarkers,
I4E-US-I010,A Phase II Trial of Cetuximab for Patients with EGFR-expressing Advanced or Metastatic Chordoma,
I4E-NS-I017,HERKULES-3:ERAS-007 (ERKI) IN COMBINATION WITH ENCORAFENIB + CETUXIMAB IN BRAF V600E COLORECTAL CANCER.,
I4E-US-X021,Randomized Phase II Trial of Radiotherapy with Concurrent Cisplatin +/- Concurrent Cetuximab for HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) in KRAS-variant Patients,
I4E-NS-I021,Addition of a Cetuximab arm in the Strata PATH™ (Precision Indications for Approved Therapies) (Strata PATH) Ph 2 Trial,
I4E-US-I024,"Phase 1b First-in-Human Trial of Autologous HER3-primed Dendritic Cells Combined with Cetuximab Followed by Standard Chemotherapy for the Treatment of Early-Stage T1b-T3, N0 Triple Negative Breast Cancer",
I4E-US-I005,SWOG 1403  A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-NaÃ¯ve Patients with Advanced EGFR Mutation Positive Non Small Cell Lung Cancer,
I4E-US-I012,"APK MUTANT: A Single Arm Phase II study of Cetuximab in Third Line for Mutant APC, TP53 and RAS patients with Refractory Metastatic Colorectal Cancer",
I4E-US-X028,Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination with Cetuximab and Encorafenib in Patients with Unresectable or Metastatic Colorectal Cancer who have previously received EGFR or BRAF-directed therapy ,
I4E-NS-I016,"Randomized Phase 2 Trial of Encorafenib and Cetuximab plus Pembrolizumab versus Pembrolizumab Alone in Participants with Previously Untreated BRAF V600E-mutant, MSI-H /dMMR mCRC.",
I4E-NS-I020,"Erbitux + SAR444881 (ILT blocking Ab) in 3L+, any RAS, CRC in Ph 1/2 trial",
I4E-NS-I025,Ph3 study evaluating cetuximab + toripalimab vs pembrolizumab in 1L R/M HNSCC,
I4E-US-X022,"A Single Arm Phase II study of 5-Flourouracil based combination chemotherapy with Cetuximab in Second Line for Mutant APC, TP53 and Wild-type Pan-RAS patients with Metastatic Colorectal Cancer",
I4E-NS-I015,NKTR-255 (IL2)+cetuximab,
I4E-US-X012,Utilization of Low Level Laser Therapy for Mitigation of Cetuximab and Radiation-Induced Dermatitis in Patients Receiving Definitive Therapy for SCHNC,
I4E-NS-I019,"An open-label, multi-center Phase 1/1b dose escalation and expansion study of ERAS-601 SHP2 inhibitor as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumors (FLAGSHP-1)",
I4E-US-X024,A Phase 1b/2 Study of VS-6766 and Cetuximab in patients with advanced KRAS mutated colorectal cancer,
I4E-US-X020,Exploratory Correlative Studies to Evaluate Potential Biomarkers of Response to Cetuximab in Patients Enrolled in NCT01099358 and NCT01063075,
I4E-US-I011,Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer,
I4E-US-X023,EGFR Inhibition in Advanced Refractory Colorectal Cancer with RAS Loss,
I4E-NS-I018,Ficlatuzumab and Cetuximab vs. Cetuximab in HPV- 2L/3L R/R HNSCC,
I4E-US-I009,RANDOMIZED TRIAL OF CONSOLIDATION TARGETED ADJUVANT THERAPY WITH ENCORAFENIB AND CETUXIMAB VERSUS USUAL CARE FOR PATIENTS WITH STAGE II/III BRAF V600E COLON CANCER,
I4E-US-X009,A Phase III study of postoperative radiation therapy (IMRT) +/- Cetuximab for locally advanced resected head and neck cancer,
I4E-NS-I013,"AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E MUTANT COLORECTAL CANCER",
I4E-IE-I004,"Randomized Phase II Study of Irinotecan+ Cetuximab With/Without Ramucirumab, in Adv, K-ras Wild-Type CRC Following Progression on Bevacizumab-Containing Chemotherapy",
,Clinical Trial (Ph2 Trial: AtD) SM,
,Clinical Trial (Ph2 Alcohol Use Disorder Non AUD),
I4E-NS-I026,A PHASE II STUDY OF NEOADJUVANT CETUXIMAB AND CEMIPLIMAB IN PATIENTS UNDERGOING SURGERY FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA,
I4E-NS-I027,"Phase 1, first-in-human, open-label, dose escalation and dose optimization study of BND-35 administered alone and in combination with nivolumab or with cetuximab in patients with advanced solid tumors",
I4E-US-I008,A PHASE I/II STUDY OF CONCURRENT CETUXIMAB AND NIVOLUMAB IN PATIENTS WITH RECURRENT AND/OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA,
,CCTA Imaging Study,
,Clinical Trial (Ph2 Trial 1: NILEX#3),
,Clinical Trial (Hepatic),
,THE POTENTIAL OF TIRZEPATIDE IN PATIENTS WITH POSTBARIATRIC TREATMENT FAILURE,
,Clinical Trial (CYP3A4 DDI),
,Clinical Trial (Ph3 Trial 1: bDMARD-IR (LY vs Rinvoq vs Pbo),
,Intervention Specific Appendix,
,Placeholder for Versanis-Novartis Trial 1,
,Placeholder for Versanis-Novartis Trial 2,
I6E-AV-I064,"Research Protocol for Exploratory Study of Entire-body PET Scans for Multiple Sclerosis (""ESPMS"")",
B5K-GH-O446,Clin Obs of Treat for Type 2 diabetes by insulin pump,
"10136", future Humalog IIT (France),
F1D-US-A128,Synaptic Plastic Action of Zyprexa,
H3E-MC-V053,Inter-Plueral admin of pemetrex for malignant p effusion,
H6Q-MC-S001,Ph II-Enza-Solid Tumors,
H7U-JE-IDBB,JP Pulmonary insulin P-II/III (Type 1) - Pan Asian,
H9J-MC-EPCB,"Phase I Safety, Tolerabilty, PK/PD study of LY680697",
H6Q-MC-V004,Microarray analysis of B cell lymphoma cell lines with enzas,
F1D-SZ-O284,The impact of spironolacton on eating behavoir in patients w,
B7A-LL-A014,Efs of RBX on VGEF expression in diabetic rat kidney,
F1D-MC-I007,OLANZAPINE IN DEMENTED PATIENTS WITH BEHAVIORAL AGITATION,
I1F-MC-RHAA,"SDSS LY2439821 (NHV, 4 dose levels) IV Administration",
H3E-MC-V069,Evaluation of Antifols in the Treatment of Human Breast Canc,
B9E-MC-V285,Cytotoxic action of gemcittabine on L1210/F cells,
H3E-US-I010,PhI Cetuximab & Pemetrexed w/ radiation in head/neck cancer,
"10707",Ph2 Tarceva v  Tarceva/Ali v Alim non/never smoke 2nd NSCLC,
H3E-MC-JMID,Ph 3 Alimta v Taxotere in 2nd line NSCLC (China Reg),
,Lactation Study Post Launch,
,Clinical Trial (Ph3 SM St Registration: 500 pts 12 cyc 250 sites 70 mo),
,Clinical Trial (Ph2 study for Parkinson's Disease),
,Clinical Trial (Ph3 Trial 4: LTE RA) LM,
,Paediatric participant study (6-11 years) w/obesity,
,Clinical Trial (Ph3 SM St Registration: 500 pts 12 cyc 250 sites 70 mo),
,Clinical Trial (Ph3 Trial 2: csDMARD-IR (LY vs Humira vs Pbo),
,Clinical Trial (SAD/MAD) SM non-Oncology,
,Clinical Trial (ESAD Dona/OGA Concurrent Ph3),
,Clinical Trial (SAD/MAD) SM non-Oncology,
,Clinical Trial (Ph3 Trial 1: AD DM; LY v Pbo w/OLE) LM,
,Clinical Trial (EP Coform vs Coadmin RBA),
,Intervention Specific Appendix,
,Clinical Trial (Ph3b/4: CWM Weight Maintenance),
,Clinical Trial (DDI 1),
,Clinical Trial (Contraceptive),
,Clinical Trial (GGG Kwikpen vs PBO) LM,
,Clinical Trial (SAD/MAD incl. JP/CN HVs) SM non-Oncology,
,JP Lp (a) Epidemiological study ,
,Clinical Trial (Mixed Pop pts w/2 yr extension),
,Clinical Trial (Abuse Liability),
,Clinical Trial (Ph2 Trial:LN),
,Clinical Trial (Ph2 Trial 1: NILEX #2),
,Clinical Trial (Once Weekly Reta for MASH/MAFLD),
,Clinical Trial (Ph3 Trial 3: Humira-IR (LY vs Enbrel),
,Clinical Trial (Ph2/3 Trial: 500 pts 12 cyc 70 sites 37 mo Model B),
,Food Effect Placeholder,
,Clinical Trial LY CT Supply 48-week study (Part B2),
,Clinical Trial (SAD/MAD) SM non-Oncology,
,Clinical Trial (SAD/MAD) LM non-Oncology,
,Clinical Trial (Ph3 PBO Controlled Study (1:1) w/randomized withdrawal),
,Clinical Trial (SAD/MAD) LM non-Oncology,
,Clinical Trial (SAD/MAD) LM non-Oncology,
F1D-GH-O273,A clinical study of H2 receptor antagonist ranitidine preven,
B1Y-GH-O035,The survey of depression and quality of life of cancer patie,
F3Z-SB-O064,Postprandial insulin lispro vs insulin mixtures in T2 DM,
H3E-US-X041,"Ph II Alimta, Carboplatin, & Radiation in Adv. Esophageal CA",
H3E-US-X042,Ph II Pemetrexed/Cetuximab for NSCLC Refractory to Primary,
H3E-US-X044,Ph II Alimta combo Cisplatin in pts. with Head & Neck Cancer,
"10095",MDSS,
F1K-MC-EVDI,Sepsis Patient Registry- PROGRESS II,
H6D-MC-LVGW,Cialis PAH Study #2,
F1D-CA-S063,Zydis vs oral olanzapine for patients who have gained weight,
H4S-IT-O064,Early vs. Late Abciximab prior to PCI ,
,Clinical Trial (PASS -EU) Risk Minimization ,
H6Q-MC-A006,Role of PKCb in glioma progression,
"10343",Multiple dose safety study (MDSS) safety/PK,
F1D-SZ-O283,Differential psychopharmacological treatment in affect-domin,
"10369",Furlong-Stimulated Cell Migration in HMCs,
B9E-MC-V276,Structure determination of Gem diphospate with Rnr1,
H9U-JE-MDBG,JP Pruvan P-1 SDS/MDS,
H6Q-MC-V014,Potential of  enzastaurin to overcome drug resistance of ova,
B9E-SB-O467,GemOxaliDexaRituximab with 90Y-Zevalin consolidation in NHL,
B9E-MC-V292, Chemosensitivity of gem in pancreatic cancer cell,
"10522",Combination Therapy for Pan Ca Sensitising Tumour Mass Chemo,
"10528",Scale Validation,
H3E-MC-V086,Pemetrexed and gemcitabine in combination with radiation,
H3E-US-I008,Ph. II Alimta and carbo w/RT followed by Alimta + gem NSCLC,
H6Q-MC-A013,Enz effect in gastric and liver cancer,
H3E-SB-O022,Phase 1 with Alimta XELOX in colorectal Cancer,
F1K-BP-A018,APC on endothelial Protein C receptor,
H6L-MC-LFAU,LY450139 and Hepatic Dysfunction,
F1D-MS-HGCI,PHARMACOKINETIC INTERACTION OF FLUOXETINE ON OLANZAPINE,
"11781",China local IIT placeholder,
H6Q-MC-S025,Ph 2 Enza Single Agent Study (Ovarian),
H3E-MC-V093,ALIMTA and Radiotherapy,
H3E-MC-V105,ALIMTA efficacy in prostate cancer,
F1D-VI-HGCZ,EFFICACY AND SAFETY IN THE TREATMENT OF SCHIZOPHRENIC PAT.,
"10894", future local study with exenatide (france),
"10949",OSCAR: Obs study on psyco-social effect,
F1K-US-V021,Effect of APC on Nitric Oxide Generation by Endothelium,
H3E-MC-V128,Folate Receptor Binder for  Potential Rheumatoid Arthritis,
H6Q-MC-A021,"In vitro and in vivo enz, alimta and radiation in pancreas",
F1D-VI-B031,Factor - olanzapine observational study,
F1D-AY-O296,Employment / Vocational Service Options in Mental Illness,
"11139",ExNCR trial Dr. Blankenstein,
H3E-IT-V129,Pemetrexed and oxaliplatin interaction in colon cancer cells,
H7T-MC-TACD,Link IPA/MPA/Accumetrics to outcomes,
F1J-MC-HMAK,DULOXETINE VS PLACEBO IN PREVENTION OF RECURRENCE OF MAJOR D,
F1D-SB-O298,"Treatment of schizophrenica, patints' favoured antipsychotic",
"10029",Determine mechanism of resistance to gem in cancer cells,
F3Z-US-X028,Impact of Aggressive vs. Moderate Glycemic Control on Clinic,
H8L-MC-B001,Tempo Ease of Use,
H9P-MC-LNDO,ADHD pediatric NERI flex dosing vs. Concerta and PBO,
F1J-US-X039,Dulox Vs. Placebo in the Tx of BED & Comorbid Depressive Dis,
H6D-MC-V003,Assmnt of tadalafil n sildenafil on atrial trabecular muscle,
H6D-MC-V007,Characterization of effect of tadalafil on aromatase activit,
H3E-KL-B004,Alimta PMS in NSCLC and MPM,
H8O-JE-GWBX,JP Exenatide QW Phase 3 Insulin head-to-head study,
F2P-LC-LCAG,LY237733: ORAL DOSE-RANGING STUDY II,
F3Z-BL-IOEP,Ins Lispro vs Humulin R in  Patients with DIABETES TYPE I,
H6O-MC-GCEC,PET dosimetry study for CB1 target using [11C]MePPEP,
H6D-MC-LVHQ,NAION Epidemiology Study ,
F1D-JE-HGMS,Zyprexa bipolar depression OL extension study for Japan,
"11728",Studies of the IGF system in MPM,
B9E-CA-O499,Phase 3 Gem Cap vs Gem in Advanced Biliary Cancer,
F3Z-IT-IODT,OPTIMIZATION OF INS.THERAPY IN TYPE I WITH LYSPRO+HUMULIN I,
B4Z-US-X054,Comparing the Neurocognitive Effects of Atomoxetine and Meth,
H7T-MC-V022,Platelet Inhibition in pts w/T2 DM rec'g Clopidogrel,
"12039",Weight reduction POC study,
B9E-US-X447,Ph II Gemcitabine & Thalidomide for Metastatic Breast Cancer,
F1D-MC-HGCJ,A SAFETY AND EFFICACY STUDY OF OLANZ VS HALOP IN SCHIZ.,
"10129",Gem Taxotere vs Taxotere in MBC,
"10132",Placeholder for Alimta Ovary 2nd line ph. II CH,
I1K-BD-GLUA,FHD: LP10152 SDSS in Healthy Subjects,
H3E-US-X048,Ph II Alimta + Gem or Carboplatin in Malignant Mesothelioma,
F1D-MC-HGDG,"EFFECTS OF OLZ AND RISPERIDONE IN SZ, SPECT AND NEUROPSYCH",
F1D-MC-HGDI,OLANZAPINE OPEN-LABEL IN PTS FROM PREVIOUS US OLANZAPINE CT,
B9E-MC-V259,Gem on Invasive pancreatic cells,
B9E-MC-V263,Antitumor Effects on Interferons on Panc Cancer,
A6J-JE-C003,JP VCMJ P-IV PRSP Infection,
F1D-MC-HGFL,OLANZAPINE IN PATIENT WHO COMPLETED PREVIOUS OLANZAPINE STUD,
H3E-MC-V065,Effacacy of ALIMTA on Ovarian Cancer,
H6Q-MC-V013,Role of PKCb in the growth of human breast and colon cancer,
H3E-US-I006,Ph II Alimta in pts. w/ Adv. Transitional Cell Carcinoma,
H7U-MC-IDBE,AIR + basal insulin in patients with type 2 diabetes,
H3E-MC-V076,Comb of Trastuzumab w Pem for Breast Cancer Cells,
B9E-MC-V279,Nucleoside Transporter 2 Mutant  Mouse M5076 Ovarian Cells,
I4F-MC-CCAG,C14,
"12120",Human Experimental Pain Model validation study,
H7O-MC-S003,CMS to aqquire whole blood from subjects w/polycythemia vera,
B4Z-US-X059,"Atomoxetine, Placebo, and Parent Training in Autism",
F3Z-TW-IMAI,HUMALOG MONITORING SAFETY IN PATIENT TREATED LONG-TERM,
"12403",European Observational study EFOS 2,
B3D-US-X018,Teriparatide for tx of idiopathic osteo in premo fm,
"12431",CSF-Histamine Study,
"12463",PlaceHolder/LocaSupportMDD/DataMining HAMD&HMDGData-TSH,
"12509",Kappa OpRA Provocation study,
H8O-XM-B011,ECOBIM: Economic impact of BMI on cost associated DMII,
H8O-MC-A014,Enhancement of GT by Exen,
"12567",K+ challenge Methods Study (MR Antagonist II),
H3E-JE-JMIJ,JP ALM+CDDP P-I NSCLC ChemoRT ,
F1D-US-X313,Omega-3 Fatty Acids for Olanzapine,
H8Y-MC-HBCF,hPepT1 Probenecid,
"12684",DDI: Lithium - placeholder,
B3D-SB-O019,Acceleration of consolidation of regenerated bone,
H8O-MC-A027,Mechanisms of action of exendin-4 and GLP,
"10569",Safety of Pulmonary hGH in Patients with COPD,
H3E-MC-V075,Cyclooxygenase II Inhibitors and Alimta in Mesothelioma Cell,
B9E-MC-V331,Gemcitabine containing vesicular phospholipid gels (VPG),
H6Q-MC-A014,Liver cancer and enzastaurin,
"10658",Placeholder for Critical Care Europe ReoPro IITs,
"10687",Phase 2 Placeholder - VTE Treatment Study,
F1D-MS-E002,INTERACTIONS BETWEEN OLANZAPINE AND LEVOMEPROMAZINE,
"10716",Ph II Gemzar in Pediatric Pop with neuroblastoma or sarcoma,
B5K-US-V009,Auto-antigen vaccination in individuals with new onset T1DM,
B9E-MC-V301,Examine nucleoside transporters in the PK + PD,
F3Z-MC-IOOZ,Insulin Lisp vs Detemir  (basals) w/Humalog as bolus insulin,
B9E-MC-V339,DNA / Protein Profiles to Gem Mediated Radiosensitization,
H3S-IH-O134,Raloxifene in patients receiving chronic corticosteroid,
B4Z-US-X049,Combination Use of Atox & Olz trmt of ADHD,
H4S-US-X027,REVITALIZE cardiac stem cell study,
B9E-JE-C003,JP gem P-IV biliary tract cancer,
"11208",FHD for future Compound FC000078,
F1J-MC-X031,Effects on brain fmri response to emotionally valenced pic,
F3Z-MC-IOPR,Comparison of ILPS vs Glargine in T2DM patients on orals ,
I2K-MC-ZZBF,Obstructive Sleep Apnea,
I1Y-MC-JFBE,FED: R - Ph II -  LY2523355 vs Ixabepilone - Breast Cancer,
H2Q-MC-LZZT,SAF/EFF XANOMELINE TTS IN PTS. WITH MILD TO MODERATE ALZ,
H6L-MC-LFBI,China IMCT,
H8V-MC-B001,Seizures pediatric popn treated with atomoxetine (GPS Obs),
B1Y-EW-HCCQ,FLUOX. (20/40)/PLA: UK GERIATRIC DEPR DOSE RANGE,
H6D-MC-B014,"Codispensing Tadalafil, PDE-5 Inhibitors, and Nitrates",
H8O-MC-A020,Effect of Exenatide on Muscle Energetics,
I3E-JE-MSAG,JP_Dirucotide Ph2/3_SPMS and RRMS,
H3E-EW-S127,TS driven in 1st line Squamous NSCLC,
I2N-MC-GPBF,Human 14C Study,
"13280",CRH-1 Antagonist II (LY2371712) Hepatic impairment ,
B7A-MC-V004,Influence of PKC involvement of tetraspanins,
H6Q-FW-JCCC,PK study to support Enza local China registration,
H3S-JE-105J,A PHARMACOKINETIC STUDY OF LY139481 HCL IN THE ELDERLY,
H6N-MC-LEAZ,Healthy Elderly vs Healthy Young,
H6L-MC-LFAS,Ketoconazole  Interaction Study,
H3E-US-X064,PhII Oxaliplatin & Pemetrexed in Prostate Cancer,
B9E-IT-V353,Pharmacokinetic ph. II study of gem plus cisplatin in NSCLC,
H6Q-MC-V031,Enzastaurin in breast cancer and chronic leukemia,
B3D-US-X015,The effect of Teriparatide on Human Cancellous Bone Ingrowth,
H8O-MC-X032,"""MODEL"" or ""IDEAL"" study",
H6Q-MC-V034,Enz and metastasis invasion in lung cancer,
F1J-US-X040,Semi-INTR Dosing of Dulox for Tx of Premenstrual EX of DEPR,
H7T-MC-V008,In Vitro Clot Model,
"11475",Benefit of RBX on DR in Comb w/Fcl or Pan-Ret Laser Therapy,
H9X-MC-GBCX,GLP-1 IV-FC: DDI - Sudafed,
H6Q-MC-V036,Enz and Epstein Barr Virus,
H6O-MC-GCEB,PET Kinetic/Dosimetry Brain Study for CB1 target,
H6Q-US-S037,Enz/Gem/Carbo +/- Avastin in 1st line NSCLC,
H3E-CR-S112,"Phase II Alimta/Cis , Toptecan/Cis in Meta uterine cervix CA",
H8O-EW-B005,CHOICE Costs & QoL first 24 months exenatide therapy,
I1K-MC-GLUD,Multiple Ascending dose; Proof of Concept Study,
"11732",Schedule Dependent synergistic effect of Peme Plus Doce,
"13410",Absolute Bioavailability,
I2Y-EW-GHFM,Renal Impairment,
I1Q-MC-JDDF,Multiple Ascending Dose Study,
"13498","1st-line Treatment of NSCLC under Routine Conditions: Obs",
H3S-MC-GGGB,RALOXIFENE HCL VS ESTROGEN VS PLACEBO IN OSTEOPOROSIS,
B4Z-AY-O031,Physiological effects of atomoxetine on additional lapses AD,
B5K-US-IBHB,Hospital Hyperglycemia Study,
H3S-MC-GGGK,RALOX HCL TREATMENT OF POSTMEN. WOMEN WITH OSTEOPOROSIS,
H9B-MC-BCDT,Phase III Systemic Lupus Erythematosus,
B1Y-FP-0707,FLUOXETINE:  STUDY VERSUS CLOMIPRAMINE,
F1J-CA-O045,Cymbalta Pregnancy Registry,
I4O-MC-BACB,MAD BACE Inhibitor II,
I4O-MC-BACE,BACE Inhibitor II RENAL,
H8L-MC-IQAK,Evaluate design specs that influence wheal formation.,
"13832",Effect of the knockdown of SHIP2 and PTEN in vitro,
F1D-US-X308,Controlled trial of intranasal insulin adjunctive in olz,
H3E-EW-S116,Phase II Alimta Carbo in neo-adj non-responders (breast),
B9E-TW-O501,"Phase II, Gem+Tax tri-weekly/Gem+Tax weekly for MBC",
"11841",Ph II Alimta Vitamin supplementation Standard vs Bolus,
F3Z-MC-I008,INSULIN LISPRO SAFETY IN TREAT.OF PTS W/GESTATIONAL DIABETES,
"11850",Forteo after vertebroplaty or kyphoplaty,
H3E-MC-V135,Development of Alimta polygluatmate assay,
H8O-MC-GWCK,QW IMCT,
H7T-MC-TACO,Treatment of patients wirh ASA resistance,
F3Z-MC-IODK,LISPRO LM VS HUMULIN 20/80,
B4Z-JE-LYEH,Atomoxetine Asia Pilot Phase2,
H3E-JE-S117,JP ALM P-I Combination,
"12160",Relative Bioavailability of new formulation of BIL-Bridging,
F1J-JE-HMFX,JP Dulo DPNP P-III DB Study Managed by Shionogi,
H4Z-MC-GJAX,Comparison of Arzoxifene and BP Comparator on BMD,
H6E-XB-O016,Pioglitazone on intracel production of cytokines in  PBMC,
B5K-US-V010,"ExNCR, Insulin, immunoassay std.",
H3E-EW-V139,Pretherapeutic response evaluation of Alimta and further rel,
"12319",Exenatide BID on patients with OMA failure during Ramadan,
"12411",ADHD Adult Relapse Study,
I4T-IE-JVBH,CP12-0709: Ph 2-1121B+5FU/FA+Oxaliplatin(FOLFOX6)-CRC-1st Ln,
H8L-EW-IQAT,EQW Device Usability Simulation Study in Pts w/type 2 Diabet,
I4T-IE-JVBS,CP18-0601:R-Ph2-1121B or A12+Miltoxantron+Predn-Prostate-2nd,
I5B-IE-JGDC,CP15-0601: Ph 1 - 3G3 - Adv  solid Tumor - 2nd Line,
F3Z-CA-O077,"Randomized, double blind, placebo controlled trial evaluatin",
I5E-MC-TSAB,POC  Ejaculatory Dysfunction,
I2R-MC-BIAR,Pediatric T1DM,
"13999",Placeholder- Benefits of Applicator #1,
H3E-JE-JMIR,JP_Ph II - Alimta+Cisplatin+XRT - NSCLC,
"14049",Asian and Latin American Forteo Study ,
H9X-MC-GBDS,Definitive Bioequivalence,
H6Q-MC-V075,Pre Clinical - NSCLC Cell Lines - In vitro,
H8O-MC-GWDT,ENDURING Prospective observational trial in type 2 diabetes ,
H7T-MC-B015,Retrospective analysis using data collected prospectively by,
"14146",R-PhIII-Decetaxed +/- 18F1 - Bladder - 2nd line,
"12419",Phase 3 - LY2148936 2-yr Prevention Study (Placeholder),
H8O-KL-B010,Byetta PMS (Post Marketing Surveillance),
I2X-MC-JBBA,Phase 1 Dose escalation study of MAK Inhibitor in AML Pts.,
"12465",Placeholder PRA thales observatory of antidepressants,
"12472",CRH-1 Phase 2 Relapse Prevention,
F3Z-VI-IOCV,SAFETY AND EFFICACY OF INSULIN LISPRO VERSUS HUMULIN R IN PA,
F1D-US-A150,Behavioral Mechanisms of Action of Atypical Antipsychotics,
H6O-FW-GCEG,Insulin Secretagogue Effects on QTc During Hypo-andEuglycemi,
I2K-MC-ZZAL,Hypnion trial ZZAL,
H2G-LC-BZAA,LY213829: SINGLE & MULTIPLE DOSE REGIMEN & PHARMACOKINETICS,
H8C-MC-LQBL,C-14 Study,
H8O-MC-GWDE,QW vs Liraglutide,
H8Y-EW-HBCE,Renal,
H8C-MC-LQBK,iGluR5 Renal Impairment ,
H2Q-MC-LZCC,OPEN LABEL EXTENSION OF XANOMELINE REGISTRATION PHASE EFFIC,
I2K-MC-ZZBW,Phenobarb Interaction #1,
I2R-MC-BIAY,BIL + GLP Combination Use,
I5L-MC-TCAD,"810 Ph. 3, Single arm, long term safety study",
I5F-IE-JSCA,CP24-1001: PhI - CS4 - Solid Tumor,
H3E-MC-V152,Pre Clinical - TS Expression- Gene Copy #/Methylation Status,
I6D-FW-SMRA,SAD,
H4H-EW-LGAB,"LY300164 MULTIPLE DOSE SAFETY,PK,PD,PILOT FOOD INTERACTION",
H6D-MC-LVJE,CN Tadalafil Ph3 BPH China IMCT,
I5A-IE-X016,ADVL0813: Ph 1 - A12 + Temsirolimus - Solid Tumors,
I4K-MC-GPEE,Sarm I/Tadalafil for Erectile Dysfunction in Incomplete Resp,
"14510",DDI-Placeholder,
I2H-MC-A001,Pre Clinical - GSK Inh for Ras-Induced Cancers,
B1Y-JE-HCLW,JP Prozac Long term safety study,
I1V-MC-EIAO,The Effect of Evacetripib on the Pharmacodynamics of Warfari,
"14634",Phase 1b/2 in Pancreas,
H4S-MC-EEAA,RAPPORT:REOPRO IN ACUTE MI AND PRIMARY PTCA,
I4M-MC-MRAL,MR III plus Tadalafil Phase 2b in Resistant HTN,
H7T-EW-TADA,Bioequivalence,
H3E-CR-JMIL,R-Ph III-Alimta+Cis vs Gem+Cis-1st line NS NSCLC(China Reg),
H9B-MC-BCDO,"LY vs placebo safety & efficacy,6 mo S&Sx",
B3D-IT-O023,PTH vs. Alendronate on improving screw fixators,
H3E-US-X080,PhI of Ixabepilone/Pemetrexed in advanced solid tumors,
"13022",IC Study of mixed Humalog Mixtures with Insulin Mixtures DM2,
B4Z-CA-O027,Measuring Diagnostic Sensitivity CMHPS Screener,
F1D-XM-O098,Magnetoencephalography Schizophrenia according to LIDDLE,
H8C-MC-LQBM,Diet Ethnic Study,
I3T-MC-PRAB,LY2528263 Progesterone Receptor Modulator Multiple Dose,
B7A-AY-V003,Macrophage Signaling Mechanism in induce apoliprotein,
F1D-US-A159,Fenton - Olz in the rat for impaired cognitive control,
"13294",Growth Control Studies with Cultured Hepatocytes,
"13296",JP GPR119 Phase II,
F1D-JE-RACD,JP additional Ph3 for Zyp RAIM,
H6Q-MC-V069,Pre Clinical - NSCLC and HNC:Sensitivity to Enzastaurin,
H9D-MC-ITAG,Humalog Ultra Rapid PK/PD,
F1J-MC-B051,"2012-201_Adherence and Persistence to Dulox treatment ",
B4Z-MC-B021,"2012-468_ADHD medications used first  line vs. second line",
I6O-FW-BHBA,Phase 1 Trial in Healthy Volunteers,
H9H-MC-A008,Crosstalk between TGF-β and HER2-ErbB2-Signaling in Mammar,
"14944",COMPASSIONATE USE - Ph IV - 1121B - HCC - 2nd Line ,
I1D-MC-JIAN,Probenicib DDI in NHV or Patients,
I3G-MC-V003,P70 S6 Kinase as a critical node in cancer cell signaling,
H9H-MC-JBAR,Ph III - TGFb R1 Kinase Inhib-Gliobalstoma (GBM) Placeholder,
H6U-BX-I002,College mental Health Survey,
"15075",Aspirin Recovey Study,
F1D-OL-HGFS,Switching Psychotic Patients to Olanzapine; open-label study,
H6D-IT-V015,in vitro study onto primary cultures of human fetal skeletal,
I1V-MC-EIBO,CETP Inhibitor pH Effects,
I6K-EW-GLED,C14,
I5Q-MC-CGAB,"2b Migraine Prevention Dose Ranging ",
B9E-MC-X076,PHase 1 Study of Gemcitabine and Paclitaxel,
H7L-EW-S021,Randomised-controlled to assess impact of Conv Maps on 2DM,
F3Z-JE-PV05,JP_Humalog MirioPen (KwikPen)_Ph4_Observational study,
H3E-JE-HS01,JP_ALM_NSCLC_Special_PMS,
I4D-MC-JTJB,"Chk-1 II, ph 1, Combo in pancreatic",
"13416",JP iGlur5 Antagonist Ph2 DBT,
H6D-MC-LVIO,Peyronies Disease #2 OUS,
F1J-MC-HMGS,China Osteoarthritis registration study,
I1A-MC-BPAH,Safety and tolerability in hypogonadal men with BPH,
"13542",Ph I-Tasisulam-PK Pediatric Study-Sarcoma,
B7A-MC-A019,Beresewicz - Endothelin-induced superoxide production and en,
"13610",Effects of GIP and GLP-1 Infusion on Insulin/Glycemic Resp,
F1J-US-HMGU,MDD - Pain Replication Study,
H6D-JE-TD01,JP_Adcirca_PAH_special_PMS,
H8Y-MC-HBDD,Alcohol Interaction,
H6Q-MC-V043,Effect of LY317615 on cutaneous T-cell Lymphoma,
H9X-EW-GBDO,Hepatic Study,
I6E-JE-AVBG,Japan Mandatory PMS,
I6W-JE-TNAC,Japan Phase 1 Study,
I6K-EW-GLEH,RBA,
I7T-MC-RMAH,MRA III/Tadalafil Ph 2a Dose Ranging in Hypertension,
I4D-EW-JTJG,C14,
I2L-MC-ALCB,Relative Bioavailability of Phase III CT Material,
I7X-EW-LLCC,C14 Study,
I8C-MC-GSFA,IL-21 Antibody Phase 1 SAD study in HV,
I6E-AV-I004,AV-45-IIT-004: Memory & Aging Project - Amyloid Img Pilot,
I3G-MC-JGCH,"12 mth txt assessing safety & efficacy in dyslipidemia pts",
I6T-MC-AMAC,Phase 2 in UC,
I4E-IE-W828,Protocol CA225-075; A LIMITED ACCESS II TRIAL OF CETUXIMAB (,
I4E-IE-W875,Protocol CA225-054; II TRIAL OF INDUCTION THERAPY WITH C225 ,
"1594",Adult ADHD Efficacy - A,
H9H-MC-A038,Biomarker in ovarian cancer patients with suboptimally debul,
H4A-MC-V015,LY303366--CANDIDA BLOODSTREAM ISOLATES FROM MSG 33 & MSG 34,
I4L-MC-ABEE,PD Study BIV vs Glargine,
I4T-MC-JVBB,RAISE-CP12-0920:R-Ph3-FOLFIRI+Plcb vsFOLFIRI+1121B-CRC-2ndln,
I4U-MC-ELBA,Mexico PK/PD Study,
B1Y-FP-0712,FLUOXETINE VS CLOMIPRAMINE:TREATMENT MELANCOLIA,
I4X-IE-JFCA,CP11-0907: JP-Ph 1 - 11F8 - Solid Tumors,
H3E-US-I034,PHI/II Rel Thymidylate pts w NSCLC tx w Entinostat&Pemetrexe,
I5A-IE-JAEJ,CP13-0603: Ph 2 - A12 - Prostate - 1st Line,
"13952",R-Ph II/III-Tasi + Gem vs Gem - Pancreas-1st Line,
H9X-JE-GBDP,JP GLP-Fc Phase3 Lira-comparison Mono study,
H6D-CR-LVIZ,A comparison of Tadalafil and Sildenafil treatment preferenc,
"14036",sexual quality of life and PDE5 inhibitor treatment choice,
I4V-MC-JADW,Ph 3 RA TNF IR vs Plc trial,
I4V-MC-JADX,Ph 3 DMARD IR Signs and symptoms study,
I5L-MC-TCAI,Ped study (infant study 3-6 months),
I1D-MC-JIAG,Human C14 in Cancer Patients,
I8D-AZ-AZEW,AZD SAD Study (D5010C00001) ,
I7E-AV-E023,"18F-AV-1451-EXIST-023",
H2Q-MC-LZYI,Disease progression in elderly at risk of Alzheimers (S1),
I1F-MC-RHBW,Pivotal Ph3 AS Trial in bDMARD Experienced,
I4L-MC-ABEV,BIV U200 Combo Pilot/BE,
I4V-MC-JAHV,Polyarticular JIA trial,
"16296",Renal Impairment,
I4E-US-I007,CA225-229 NCI 6980 EGFR blockade w/Erlotinib/Cetuximab Colon,
I4T-KL-B004,KR_Ph IV - Ramucirumab-Gastric & Gastroesophogeal Junction,
I3O-JE-JSBG,JP_FHD - Ph I - Merestinib - Solid Tumors,
"16412",Ph III- Ram+Osimertinib v Osimertinib -NSCLC - 1L/2L EGFR,
"16436",P2 dose-finding study,
I9G-MC-CCBA,SAD ,
I8L-MC-IXAG,PK study in HVs to evaluate BC222,
I4V-MC-JAHQ,axSpA ,
I4T-IE-JVBZ,CP12-1031: Ph III - 1121B - Prostate,
I5L-MC-TCAB,"726 Phase III, Randomized, Safety & Efficacy",
F1D-MC-X275,MRS Measures of NAA in Schizophrenia,
H7T-IT-O015,SWITCH OVER,
"10072",Goetinck-Syndecan-4 medicated cell-matrix interactions,
F1J-JE-HMGX,JP Cymbalta P-III OA,
I3X-MC-JHTF,JAK2 Inhibitor Particle size,
B3D-EW-GHCX,Effect of teriparatide/strontium ranelate- bone histomorphic,
I4V-MC-JAGO,Relative Bioavailability,
B9E-MC-V333,PK CP study of Gem Pharmacodynamics in E6201,
I1V-MC-EIAR,Pk of evacetripib in Subj w Various Levels of Renal Impairme,
H6D-KL-B019,Cialis BPH KR PMS,
F1D-MC-HGCS,OPEN-LABEL TRIAL OF OLAN. IN CHILDREN W/CHILDHOOD ONSET SCHI,
I6E-US-AVBD,PH IV USMD customer answers,
"10121",Placeholder F1K-MC-EVBQ Local Resources,
F3Z-CR-IOQI,Comparison of Insulin Mix25_bid vs Mix50_bid vs Mix_50 bid,
F1D-CP-HGGK,OLANZAPINE VERSUS ZUCLOPENTHIXOL IN THE ACUTE TREATMENT OF S,
I9I-MC-LGDA,LA Glucagon/Dulaglutide Combo (LY900019) Combined SAD/MAD,
ZYY-MC-B006,"2016-1093:Consumer Health Activation Index-Diabetes (CHAI-D)",
I9D-MC-ROAD,RBA,
I9L-MC-JZCB,C14 Micro-Dose Study,
I8B-MC-ITSM,URLi Medtronic 670G Pilot Study,
I5T-MC-AACG,N3pG PhII Safety and Efficacy in AD Patients,
H7I-MC-S014,EET Feasibility Assessment Dev of a Digital Biomarker Pts,
I4V-MC-JAIU,China IMCT,
"17281",Atopic Dermatitis Head-to-Head with dupi ,
I7E-AV-E086,"18F-AV-1451-EXIST-086",
J1X-MC-GZHH,RBA-Food/Water-Effects Study (Gastric) HV,
H6O-MC-O014,EET Novel Biomarkers of Drug induced Acute Pancreatitis Pts,
J2G-OX-Y035,PhI-RET Inhibitor+Osimertinib-NSClC,
F3Z-BP-O001,"Effect on PP lipemia, insulin sensitivity, etc in type 2",
"17769",Temperature Study,
"11309",Combination therapy of pancreatic cancer in vivo wtih type 1,
B9E-UT-O473,PH II: comp. Gemzar +Nadroparine vs Gemzar in pancreatic pts,
"10142",Placeholder for Gemzar CTNR B9E-MC-S205,
H9V-MC-GFRA,LA307 (LY2382770) SDSS in stage 2-4 CKD,
B9E-MC-V255,Gem Novel cationic liposomes pancreatic cells,
B9E-MC-V260,Gem on Lung and Met Lymph node cells (CD-DST),
H3E-MC-V058,Reversal of Alimta Resistance,
B9E-IT-V245,PRECLINICAL COMBINATION STUDY WITH THE RUTHENIUM COMPLEX NAM,
H6Q-MC-A002,Nude mouse model of ovarian cancer study with enzastaurin,
H6Q-MC-A003,DLCBL studies for cancer gene expression,
F1D-MC-I002,OLANZAPINE VS. CLOZAPINE IN PET ASSESSMENT OF BLOOD FLOW,
F1K-BX-V017,Ex-vivo / In vitro IIT: Anti-inflammatory effect of Xigris,
I1F-MC-RHAD,"Phase 2, LY2439821, in RA patients",
"10590",China PK Study,
B4Z-CA-O009,Treatment Effectiveness for Children-Adolescents with ADHD,
"10652",Proposal for Analysis of Ghrelin Plasma Samples,
F1D-MC-X026,OLANZAPINE AUGMENTATION IN SRI-REFRACTORY OCD PATIENTS,
H6Q-MC-S019,Ph II Paclitaxel/Carbo +/- Enzastaurin - Ovarian,
H6Q-MC-V016,"Enz and alimta, in renal cell carcinoma cell lines",
H4R-CA-A001,LY309132:  KINETICS IN PIGS,
H3E-SB-O072,Evaluation of novel predictive biomarkers for pemetrexed ,
I6E-AV-_A21,Ph III safety/imaging subjects with new onset MCI,
I6J-MC-PRBC,C14,
H3E-XM-O073,Retrospective pharmacogenomic study of a gene signature,
I5M-MC-V001,Abnormalities in the hepcidin/ferroportin nexus drive inflam,
H9D-MC-ITAK,(CT-3) PK/PD Study - Aura ,
"15016",Japan NSOS DPNP trial,
"15020",Vasodilator Determination for Ultra Rapid Insulin,
F3Z-BP-B012,IIT - Dr Idris - Obs retro - Efficacy of Humalog Mix 50 TDS ,
"15094",COMBINED EFFECTS ON PROSTATE TUMOR CELL BONE METASTATIZATION,
"15121",Tadalafil for Duchenne Muscular Dystrophy,
I3Y-JE-JPBC,JP_PH I-CDK4/6 dual inhibitor-Advanced Tumors,
I6I-MC-LMRF,TZD interaction,
I2I-MC-V015,Id of syn.-lethal treatments in INPP4B-deficient ovarian can,
"15238",Food Effect in Healthy Subjects with Standard High Fat Meal,
I5E-MC-B003,The Risk of Venous Thrombotic Events among Hypogonadal Males,
I4D-MC-JTJF,PhIb-Chk1 InhII+chemotherapy/targeted agents-solid tumors,
B1Y-IT-9002,FLUOXETNE VS DESIPRAMINE IN PSYCHOTIC MAJOR DEPRESSION,
J2G-OX-Y075,RET Inhibitor-MTC,
J2G-OX-Y094,RET Inhibitor-MTC,
J2G-OX-Y103,RET Inhibitor-MTC,
J2G-OX-Y135,RET Inhibitor-NSCLC,
J2G-OX-Y142,RET Inhibitor-MTC,
J2G-OX-Y157,RET Inhibitor-NSCLC,
I4V-MC-JAJH,Illustrate the effect of Bari ,
J2G-OX-Y194,RET Inhibitor,
J2G-OX-Y209,RET Inhibitor,
"18106",CM&C Formulation Particle Size HV,
J2S-MC-GZMB,"3-day mini MAD HV",
I4V-MC-I004,NIH Bari Trial,
J1I-MC-GZBH,Ph2 GGG vs TZP Comparison Obesity Trial with NAFLD Addendum,
J2P-MC-LXBB,FHD SAD MAD HV,
J1I-MC-GPS2,Chronic Weight Management -2 (with T2DM) PCOS DSA,
"18684",Loxo-NGR-23012-Ph1-RET Inhibitor II-ADME,
J4J-MC-PYAK,Bebtelovimab ,
H3E-MC-V054,Effect of Alimta on Cell Lines,
H6D-BP-O022,Effect of tadalafil on blood flow of rat major pelvic gangli,
I6K-EW-GLEE,TQT,
I6E-AV-_A22,Calibrate Florbetapir(18F) PET Data to Centiloid Scale,
I7Q-FW-SLAA,Single-ascending dose study (SAD),
B1Y-MC-A007,Prenatal Antidepressants and Autism Spectrum Disorder,
I7W-MC-JQBA,FHD-Ph I/IB - Angiopoietin2 Antibody and Ram  - Solid Tumors,
I4D-MC-V002,Effect of LY on normal and malignant human urothellal cells,
"15634",RBA 2 - Formulation,
I7Z-FW-FLAA,Single and Multiple Dose Safety study for LY3104607,
"15660",DDI - Warfarin,
I7Z-MC-FLAB,Phase 2 3rd Line (add on to Met+ DPPIV),
I5Q-MC-CGAG,Ph3 acute episodic migraine prevention study #1,
I6A-MC-CBBD,Ph II - Enzalutamide+PI3 Kinase/mTor Dual Inhib - Prostate,
I4E-IE-W824,Protocol CA225-058; A randomized II trial of two dose schedu,
I4E-IE-W830,Protocol CA225-099; A Randomized Multicenter II Study of Tax,
I4E-IE-W886,Protocol CA225-079; II STUDY OF CETUXIMAB IN PATIENTS WITH U,
I4E-IE-W920,Protocol CA225-102; EVALUATION OF THE ROLE OF AN ANTI-EPIDER,
H3E-US-S096,Rand Ph II Alimta+Gemzar vs SOC in Relapsed Ovarian Cancer,
H3S-US-GGLK,Lasofoxifene Head to Head Comparison with Raloxifene,
B9E-MC-V306,Gemzar PGx,
B9E-MC-V311,T-cell assay for the oral Gemzar,
B9E-MC-V318,Gemzar triphosphate Measurements in PBMC's,
B9E-MC-V321,Gemzar to examine nculeoside transporters in vivo,
H3E-MC-V104,Evaluation of in invitro assays with ICOS chk-1 inhibitor,
F1D-VI-HGCL,EFFICACY AND SAFETY OF OLANZAPINE IN SAUDI ARABIA,
H3E-MC-V110,Folate receptor in uptake of Alimta tumor and normal tissue,
F1K-SB-A019,Activated protein C to treat SIRS after global hypoxia,
F1J-MC-HMFI,Duloxetine Bioequivalence Study for 90 and 120 mg Doses,
H9F-MC-GYAI,Opra I C14 Metabolism Study,
H6Q-MC-V018,TGEN Enz and RNAi technology,
F1D-IT-A134,Olanzapine on Glucose-Insuline homeostasis,
F1K-SB-V023,Effects of APC on LPS stimulated Endothelium & Blood Artmann,
H8O-MC-A001,Studies of Exendin's Metabolic Effects,
H8O-MC-A003,Exen and CVS; direct/vs indirect actions of GLP-1R,
"11105",Sample request,
"11136",Develop and characteriz of leukemic cells resistance to Gemz,
F1J-MC-X030,Dulox in Resilience and correlation w/ blockade of neuropine,
B1Y-MC-X149,RECOGNITION AND TREATMENT OF DEPRESSION IN CANCER PATIENTS,
F3Z-JE-M03H,lisp P-I sigl subcutaneous Inj.,
F3Z-MC-IOHV,Acute Hypoglycemia Awareness Study,
B9E-MC-S040,Ph II Gem+Carbo+Tax in ovarian,
F1K-LC-EVAH,F1K-LC-EVAH Pediatric Pharmacology,
F3Z-MC-IOHU,LM vs 30/70:  A test meal study in patients type II diabetes,
B1Y-LC-HCFM,FLUOXETINE BIOEQUIVALENCE: MANU LOT 60MG TABS VS 60MG CAPS,
"2126",Dose Ranging study using Somatropine in Pediatric Burns,
H4Z-LC-JWWE,Male Safety Study,
H3Z-MC-JNAU,Phase-I combination study:  LY295501 + Capecitabine,
B3D-MC-GHAU,Effects of LY333334 on BMD in early menopausal women,
F1D-SP-HGGS,"An obs, natural, ol to evaluate incidence of ae in schizo pa",
B9E-MC-S084,Ph II Gem+Cis - Met. Breast Cancer,
B9E-MC-S101,Ph III- Carbo+Tax vs triplet or sequential doublet - Ovarian,
B9E-MC-I143,PHASE I/II STUDYOF DOSE DENSE ALTER. CHEMO WITH FILGRASTIM,
"2560",Ph 2 ADHD peds,
B9E-MC-I005,PHASE 2 STUDY OF TAXOL AND GEMCITABINE IN METASTATIC NSCLC,
I4E-IE-W936,Protocol CA225-344; A II RANDOMIZED STUDY OF CETUXIMAB AT EI,
I8D-MC-AZEA,DDI Alcohol,
I4D-MC-JTJH,Phase 2 single agent LY2606368 in patients with SCLC,
I8D-MC-AZES,Amaranth study,
I4L-GH-ABET,China Ph 3 T2DM BIV vs. Lantus,
I8E-MC-APBB,MAD,
I5E-MC-B006,Testosterone Replacement Therary and Risk of Acute MI,
"16074",QT\TQT,
"16075",DDI,
"16076",RBA,
H2Q-MC-LZYF,Behaviors and cognition in severe Alzheimers (B3),
I6E-AV-I044,AV-45-IIT-044: Reconstruction,
F3Z-MC-ITCF,U100 Pilot PK,
I6E-MC-AVBI,Phase 3 China,
I8L-MC-IXAK,Blinded mealtime dosing in type 2 patients,
I4V-MC-JAHP,Pediatric PK study in Atopic Derm Age 2-<10,
H8O-MC-A028,Mesenchymal Stem Cell Islets,
"11370",GLP-FC vs Placebo vs Comparator,
F1K-MC-EVAC,R-ACTIVATED PROTEIN C DOSE-RANGING STDY IN APC RESISTANT PTS,
H9X-MC-GBCH,Absorption Study acetaminophen,
I1V-MC-EIAH,CETP - C14 study,
F1K-US-B008,Protein C levels and Morbidity following Liver Transplant,
F1J-US-HMFR,Cym vs. Plcb in Patients with MS Pain,
B4Z-KL-LYEC,Korean Strattera Registration Trial,
B9E-BP-O497,Ph I Gem/oxaliplatin plus Glivec in Gem-refractory pancreas,
H3E-MC-V140,Study of MTAP deletions in Mesothelioma tissue samples,
B4Z-KL-B009,Strattera PMS (Post Marketing Surveillance) in Korea,
"11778",Ph III Open Label Safety Study for LA294,
"11835",Central Biomarker study,
I2B-MC-S001,Vaso Serm Device Validation Study,
B9R-HL-GDGN,Open Label F-up study of Pts Who Participated in B9R-HL-GDDV,
B4Z-JE-J001,JP Atomoxetine Validation Study,
H3E-US-X070,Predictive Markers of Response to Pemetrexed Companion Study,
"2648",AECB Cefaclor AF (500mg) vs Roxithromycin,
H4Z-LC-JWXK,bioequivalence study,
B1Y-MC-X177,Utilizing PsychopharmTherapy to Extend Alcohol Abstience,
B1Y-MC-X173,TX of Depression in the Medically Ill: A Survey,
B3N-BL-EUDB,moxonidine vs anlopidine in hypertensive obese pat,
F1J-MC-SBAW,Open Label - Long Term Safety/Exposure (Trial #2687),
"2703",Humatrope in Pts with Genetic Short Stature (Global Study),
B3N-EW-EUBE,Dose ranging study with the CR formulation.,
H5W-BD-LQAD,Prophylactic effect,
H5X-BD-LTAA,First human dose (oral),
F3Z-MC-IOIA,Single arm transfer 30/70 to LM:  effects on HbA1c in type 2,
F1J-FW-SBAZ,PK study comparing Japanese & Caucasian subjects,
"2881",Amelioration of NIDDM,
B9R-JE-K01A,JP hGH P-III adult DBT,
H4Q-MC-ARRH,Void,
"2914",Exploratory-MDD with/without anxiety,
B9E-MC-I014,Gemcitabine and Docetaxel for Pancreatic Carcinoma,
B9E-MC-X170,Phase 2 Trial of Gemcitabine in Salivary Gland Carcinoma,
F3Z-SO-O079,Insulin protection and signalling in human coronary arteries,
I8K-MC-JPDH,Phase 2 in SLE PLUS long-term extension,
"16680",TANGO Feasibility Study 2,
I4V-MC-JAIE,US Pragmatic Baricitinib vs SOC cDMARD-IR RA Patients,
I8K-MC-JPDJ,Renal Impairment Study,
"16812",R-Ph III - Alimta + Platinum +/- Pemrolizumab - NSCLC,
I4D-MC-E007,Ph I - Prexasertib + VX-970 -Adv Solid Tumors,
H8H-CD-LAHK,SPARTAN 3 doses Lasmiditan vs Placebo in Acute Migraine,
"16915",FHD-Ph I - CD137 - Solid Tumors,
F3Z-MC-IOQZ,Connected Pen + CGM Clinical Trial,
"16931",DDI CYP2B6,
I9U-MC-JKEA,SAD/MAD/multi dose DDI,
I8F-MC-GPGI,GIP/GLP-1 Add on to Basal Insulin,
I9Z-MC-OGAC,MD-PET,
J1C-MC-JZDA,Ph 1 FHD - PD-L1/TIM-3 Bispecific in Combo - Solid Tumors,
J1M-MC-GZDA,SAD/MAD,
B9E-MC-I068,Gemcitabine (Prolonged Infusion) in GU Cancers,
A6J-MC-X001,CROATIAN OSTEOMYELITIS REGISTRY STUDY,
"12082",Biopharm QTc,
"12156",PK/PD Variability,
B5K-US-V008,"ExNCR, insulin ",
B4Z-GH-O019,research of altered reinforcement of ADHD in Children,
H8A-MC-LZAR,Renal Impairment ,
"12437",CTNR post Registration in Label Study,
B3D-IT-B014, Italian Study on Severe Osteoporosis (ISSO),
"12469",CETP DDI/PD,
I2Z-MC-LAFA,OpRA Kappa SDSS (FHD),
ZYY-MC-B003,Optimization of Minidose Midazolam as CYP3A Probe Drug CRU+,
F3Z-VI-IOFW,LONG-TERM COMPARISON PRE VERSUS POSTPRANDIALLY LISPRO,
H9P-EW-LNCA,Biopharm Renal Impairment Study,
H9P-EW-LNCI,Biopharm DDI Beta II agonist (oral),
H6E-KL-B004,ActosMet PMS,
H8C-MC-LQBR,OA Pain: DB pbo cntrlld fixed dose #3,
H2Q-LC-LZZK,XANOMELINE-TARTRATE:WITHIN AND BETWEEN SUBJECT VARIABILITY,
B4Z-US-A012,Methamphetamine Abuse and Inhibitory Control,
I8F-MC-GPHB,Tirzepatide DDI study with Sitagliptin in T2DM Patients,
I9N-MC-FCAC,Safety and Tolerability / PK Bridging Study,
"17259",Bolus Injector Crohn's Efficacy,
F3Z-CP-IOGH,OPTIMISING INSULIN THERAPY IN PATIENT WITH IDDM USING LISPRO,
I9R-MC-BSDI,Basal Insulin Acylated T1DM,
I1F-AV-O002,IXEHEAL PhII study of ixe for chronic wound healing,
I8R-MC-B004,"GHO_ Incidence, Prevalence, HCRU & Costs of T2DM Insulin",
I4V-JE-O013,MTX response and T2T strategy in RA,
J2G-OX-Y014,PhI-RET Inhibitor-PTC,
J2G-OX-Y045,PhI-RET Inhibitor-MTC+PTC,
H8L-MC-IQDE,Eval of Adhesive Properties on the skin of Healthy Humans,
B5K-MC-B015,"2019-8636_GHO_Consistent w/ Label Cohort- HbA1c, Hypogly...",
I8F-MC-GPIB,MoA 18F Fatty Acid Tracer PET Validation Study in T2DM Pts,
I7P-MC-DSAE,Single dose sc/ISR study in HV,
F3Z-US-X040,Insulin Only Bionic Pancreas Pivotal Trial,
B1Y-MC-HCIT,FLUOXETINE VERSUS SERTRALINE AND PAROXETINE-DISCONTINUATION,
F1D-SB-LOAY,"Olanzapine in Adolescent and Young Adult Pts., Open Label",
H5P-MC-BWWT,Pain Study,
H5P-MC-BWWU,Osteoarthritis Probe,
F1J-MC-SBBG,Cost of Illness Studies,
"3297",Protein C levels in malaria,
A6J-FW-ASCF,Investigation of Red Man Syndrome,
B9E-MC-X236,Phase 2 Gemcitabine for Relapsed CLL,
"3341","Phase II, MTA +Navel, 2nd line breast",
H5U-EW-HSAG,Pharmacokinetic study in female subjects,
B9E-VI-O038,"Phase II , Gemcitabine & Cisplatin, Metastatic Breast Cancer",
H3S-MC-I005,Study raloxifene in hyperprolactinemic women in menopause,
B9R-IT-GDFP,Effects of GH in pre-clinical models of ALS,
H6D-EW-LVAT,SSRI Interaction study,
B1Y-BP-HC24,FLUOXETINE/MIANSERINE/PLACEBO IN MDD,
B9E-SB-V023,Gemcitabine in isolated coloractal liver metastasis,
"3755",Statin interaction study,
H3S-US-GGJR,Use of Raloxifene on endothelial reactivity in healthy postm,
"3863",Decision phase ReoPro,
H8Y-MC-HBCV,Warfain,
H3E-FR-O046,IIT-customized treatment,
F1J-MC-B034,Cymbalta observational pregnancy exposure registry,
H8O-MC-X015,T2DM pts with heart failure and normal LV EF,
"12952","MK-0646 In StIIIB or IV Lung comb w/ Alimta/Cisplatin, PH II",
H3E-US-X079,Insulin GF1 in Stage IIB or IV Lung w Alimta/Cisplatin Ph II,
H3E-MC-JMAD,PHASE II TRIAL LY231514 IV Q 21 DAYS IN PANCREATIC CANCER,
H9B-MC-BCEA,MS Phase 3 Open Label Extention Study,
"12974",MS - LY vs Placebo vs Active Comparator & Open label,
F1D-TW-O322,Compare oldanzapine & lamotrigine for recurrence of Bipolar ,
I3I-JE-GFBA,JP Teplizumab Phase 1,
H8K-MC-JZAR,Tasisulam  drug -drug interaction CYP 2C9,
"13082",RADAR IPO STudy,
H3E-MC-I028,DRUG ONLY_Ph I/II-Alimta+Cis+Axitinib-NSCLC (non-squamous),
H6D-MC-LVIH,Ph 3 - Tadalafil Safety-Ped with PAH,
"13172",MDSS (Multiple Dose Safety Study),
"13212",LXR Beta Agonist SAD,
J1I-MC-GZBD,Phase II T2DM GGG Tri-Agonist,
I6T-MC-AMBW,UC PK device bridging (2x1mL PFS and a 2x1mL AI injector) HV,
J2G-OX-Y104,RET Inhibitor-MTC,
J2G-OX-Y124,RET Inhibitor-NSCLC,
J2G-OX-Y171,RET Inhibitor,
J2T-DM-KGBB,Single IV Dose-Escalation in HV (GB28613 / TNX-650.150),
J2G-OX-Y192,RET Inhibitor,
"18314",DIAB-Diabetes Device Bridging (AI to KwikPen),
J3O-MC-LSBB,FHD Dose Escalation HV,
"18409","PF AIIMIN-Autoimmune, DDI transporter substrate(s) study 1",
"18556",OXM3 + LAGIPRA Combination HV,
J3X-MC-LYGB,SARM 1 FED,
H3Z-MC-JNAL,Phase II Eval. of LY295501 for Treatment of Ovarian Cancer,
"18886",A phase IV non-drug interventional study to evaluate the imp,
B1Y-IT-M003,FLUOXETINE V MIANSERIN D.B. DEPRESSED PATIENTS,
B9E-MC-S027,Gem+Tax vs Gem+Dox vs Tax+Dox in breast-S027,
,Clinical Trial (DDI 1),
A6J-MC-I001,PK OF VANCO DOSING DURING CELLULOSE TRIACETATE HEMODIALYSIS,
H4S-MC-EWAY,ReoPro in Acute Coronary Syndromes- A Meta Analysis,
B1Y-MC-X088,FLUOXETINE IN PSYCHOTHERAPY NON-RESPONDERS,
F1D-CA-O039,Can a questionnaire identify positive response to Zyprexa,
F1D-CA-A040,Does Olanzapine spare cell death?,
B9E-MC-X165,"Gemcitabine, Cisplatin, 5-FU - Esophageal Cancer",
F1D-CA-O010,olanz vs hal on proc learning & striatal D2 rec-bind in schi,
H3E-MC-JMDW,MTA+Gem+Oxaliplatin,
B9E-MC-V018,In vitro pharmacokinetics and identification of metabolites,
F1D-CA-O048,Pilot study on exercise and weight gain with Olanzapine,
B9D-EW-GAAB,FHD,
"4131",Renal Impairment PK,
F1D-CA-O052,Use of Zyprexa in treatment of Dementia with Lewy Bodies,
B9E-MW-O108,Non-adjuvant chemotherapy of non small cell cancer at II-III,
B9E-MC-V047,Gemcitabine and Vinorelbine against NSCLC,
F1D-FP-S004,OL in open label: dose lowering vs dose >10 mg/d maintenance,
H4Z-MC-JWXG,FNA in Women with High Risk for Breast Cancer,
J4A-MC-EZZF,Sepsis  - Phase II Safety and Efficacy study,
H8O-BP-O018,Effects of Exenatide on EDS/ alertness in type 2 diabetes ,
H9C-MC-BBDK,"Safety, Tolerability and Efficacy of Subcutaneous LY2189102 ",
H3S-LC-GGGD,RALOXIFENE: PLASMA LEVELS OF METAB. AS A FUNCTION OF FORM.,
F3Z-MC-IOQC,Escalation from basal #1,
I4Q-MC-JLCA,AKT-1 Inhibitor Effort 5,
B7A-MC-A017,Role of mineralcorticoid receptor antag in rodent ,
H8A-MC-LZAT,Single Site (Dr. J. Snider) study; Brain Amyloid Imaging,
H8O-MC-X022,Exendin-4 for the Tx of neurodegenerative diseases,
B7A-MC-V016,Role of PKC-beta in Amphetamine-mediated dopamine re,
B9R-IT-O055,IGF-I role in premature babies at risk of neurol damage ,
B1Y-FP-0706,FLUOXETINE V AMINEPTINE  ACUTE MOD DEPRESS STATE,
H3S-MC-GGGH,RALOXIFENE/PLACEBO/PREMARIN IN PREVENTION OF OSTEOPOROSIS,
F1J-US-X056,Cent Noradrenergic resp to dulox measured by pupillography,
H9B-MC-BCDS,Phase 3 Systemic Lupus Erythematosus,
"13662",iGluR5 PPI/antacid DDI,
H6D-EW-LVIU,Obs study on Tadalafil oad,
F1D-MC-X054,Preventing of osteoporosis risk factors in chronic schizophr,
B9E-MC-S003,"Nav+Cis vs. Gem + Tax, NSCLC, Ph III",
B3N-MC-EUCX,Moxonidine Effect/Exercise Tolerance Compared/Carvedilol,
H4A-SB-V016,Phagocytosis and Killing of C. albicans by Human Phagocytes,
F3Z-US-IOHE,INSULIN DELIVERY USING A NEW LILLY 3.0ML DISPOSABLE PEN DEVI,
B5K-MC-IBEJ,"Bioavailability, Dose Calculation and Safety",
B5K-MC-IBEW,Inspiratory flow rate with PK/PD measures,
F1D-US-X096,Olz + Hal. in Decreasing Craving in Cocaine Dependent pts.,
F1D-US-A015,Functional + Neuroanatomic Effects of Chronic Olz. Treatment,
B9E-MC-S107,Ph II Radiotherapy+Gem after curative resection / Pancreatic,
F3Z-MC-IOGZ,"Russia, Romania and Taiwan local registration study",
B4G-EW-LCCZ,Parkinson / Adjunct / Pergolide vs COMT,
B9E-SB-O010,"Phase I/II, Gemcitabine & 5-FU (24H)  In Pancreatic Cancer",
"2512",BID Use in Self-Mixed Regimens with NPH (Latin America),
B4G-EW-LCDE,Parkinson Patch / Regulatory A (ClinPharm study),
F1D-US-X111,Olz. vs. Valproate in treatment of Affective Lability in BPD,
"2612",Effect of oral contraceptive on LY334370,
B1Y-MC-HCDZ,FLUOXETINE:  SPECIAL TESTS IN LONG-TERM PATIENTS,
"2672",Phase 2 Trial of LY309887 in Ovarian Cancer,
B1Y-BP-HC31,FLUOXETINE V DOTHIEPIN MAJOR DEPRESSIVE DISORDER,
"4409",AD Disease Progression Study,
B1Y-SB-4016,FLUOXETINE UNIPOLAR DEPRESSION VS MAPROTILINE,
"4575",Clinically Significant Macular Edema,
F1D-XS-O084,Quality of  Life Evaluation study in the Schizophrenia.,
F3Z-IN-IONB,lispro in diabetic patients with nephropathy,
B1Y-MC-X207,FLUOX IN INDIVIDUALS W/PATHOLOGICAL GAMBLING DISORDER,
B9E-MC-X282,Phase 2 Trial of Gemcitabine in NHL,
F1D-US-X186,Cognitive Effects of Risperidone vs. Olanzapine,
H6Q-MC-JCAG,Phase I Carbo/TX/(LY317615 NCIC,
B1Y-TW-0003,FLUOXETINE: OPEN CLINICAL-TRIAL STUDY OF LUOXETINE,
H6D-MC-LVDB,IIT,
"5054",LY466700 Single-Dose Study--Japan,
B1Y-UT-0291,"NEUROPSYCHOLOGICAL EFFECTS, FLUOXETINE IN ELDERLY DEPRESSED",
"5096",LY450108 Japan - first human volunteer study,
H4Q-LC-ARRP,LY333328 End Stage Renal Failure,
B9E-XM-S227,RANDOMIZED PHASE II GEM LONG INF-CIS VS GEM-CIS STANDARD,
B9E-MC-JHRM,Ph II Gem + Cis in NPC,
H3S-MC-GGGX,Assessment of Health Economics Endpoints with Raloxifene,
H6Q-MC-V048,Pre Clinical - Follicular Lymphoma Cells,
H6Q-MC-V063,Pre Clinical - Er and HER2 pathways in breast cancer,
H6Q-MC-V065,Pre Clinical  - Enz in Ocular Melanoma Cell Lines,
H7T-FR-O008,IIT Relationship between PRI following prasugrel LD ,
H8O-MC-I015,Exenatide and postprandial End Dysfunction,
H4A-BP-A004,LY303366 - NEUTRPENIC MURINE MODEL OF INVASIVE ASPERGILLOSIS,
H9X-JE-GBDQ,JP GLP-Fc Phase3 Safety study,
"14000",Placeholder- Benefits of Applicator #2,
H4A-CA-V007,PHARMACODYNAMICS OF ANTIFUNGAL LY303366,
I4V-MC-JADI,Particle Size,
"14020",EQW in pts with Stage I or II HTN,
"14021",B'pharm Increase of GI Transit CPD,
"14026",EQW in T2 pts for glucose control with HF,
H6D-US-X011,Immunochemoradiotherapy for Adv Pancreatic Adenocarcinoma,
H4A-MC-V011,LY303366--TREATMENT OF HISTOPLASMOSIS IN A MURINE MODEL,
I4L-JE-ABEJ,Japan Phase 1 study with Basal Insulin Analog V,
H3E-EW-S135,Rd Ph2 Alimta vs AlimtaCarbo vs Navelbine nonsqNSCLC Elderly,
B3T-MC-JTAI,LY335979/Docetaxel/neoadjuvant Ph 2/ Breast Cancer,
A6J-MC-I002,Association between Antecedent Antibiotic Treatment and VRE,
H5N-EW-GFFC,V8 GLP-1 Infusion study in Type II Diabetic Subjects,
H3E-US-X039,Brain Metastases from NSCLC with Radiation and Pemetrexed,
B9R-MC-GDFF,Turner Syndrome,
B7A-MC-MBBR,Peripheral neuropathy in patients with diabetes,
F1D-MC-X274,Brain Correlates of Olanzapine Treatment Response in BPD,
F3Z-PH-IOFD,SAFETY & EFFICACY OF LISPRO IN PATIENTS W/DIABETES MELLITUS,
B3D-IN-B008,Teriparatide (Forteo) - Post Marketing Surveillance Study,
H5N-MC-GFFJ,Phase 3  Pivotal 1 yr. Met Trial (Study C),
B9E-MC-V246,Effect of HSP90 disruption on gem cytoxicity,
"2900",GHS: Phase 1B Drug Interaction study,
F1D-MC-HGDH,OLANZAPINE VS HALOPERIDOL IN FIRST EPISODE PSYCHOSIS,
H3E-MC-JMDD,PH III 2nd/3rd line breast in anthra/tax failures,
H3E-MC-V049,Preclinical Research with LY289739 (ALIMTA),
"2956",Raloxifene Musculoskeletal Effects,
"10240",PK bridging study  Phase 1,
B9E-MC-X174,Gemcitabine and Docetaxel in Pancreatic Carcinoma,
A3Q-BL-O001,Cephalexin in Acute Pharyngotonsillitis - IIT,
"5298",GAD PANIC efficacy study #2,
F1D-US-I034,Double-blind study w/ OLZ for treat't of cocaine dependence,
B9E-VI-O198,Gem+Cis neoadj. in Bilharzial-relat bladder cancer Phase III,
B9E-MC-V109,study interaction bet gem + oxali re:toxicity&effic of combi,
B3D-EW-GHAK,RELATIVE BIOAVAILABILITY AND LUNG DEPOSITION OF LY333334 INH,
"5431",JP pulm hGH P-I MDSS,
B3M-MC-O002,Investigator Initiated PK/MEF Study,
B3M-GH-AJBS,Ceclor for treatment of URTI in children,
F1D-CA-O106,Is olanzapine effective in BPD,
B9E-GH-O222,preoperative chemo with 5-Fu+Gem +Carb for esophageal cancer,
B1Y-MC-X216,"Substance-Dependent, Deliquent-Depression",
B3M-MC-V050,invitro,
B5K-SN-S004,Swtich from intermediate acting insulin to Humulin 30/70: OS,
H6M-MC-LDAL,Phase 2 study in patients with Alzheimer's disease- AMPA I,
B1Y-MC-HCLF,Fluoxetine in the treatment of PMDD in Adolescence,
B9R-EW-GDFY,Pulm hGH safety and relative bioavailability,
"5850",Drug Interaction Study 3,
I2Y-EW-GHFU,Repeat GHFO biopharm. Skin irritation and sensitization stud,
I5G-IE-JBCA,CP23-1001: Ph I - 3C5 - Adv Solid Tumors,
"14256",Phase 2B Dose Ranging Study,
"14257",Sleep Maintenance Claim Study,
F1D-MC-V027,Zyprexa versus generic competitor study in vitro,
H8O-MC-GWEB,Observ type 2 DM comparing Exen. vs other antidiabetic drugs,
F3Z-US-X034,TODAY2 Phase 1 Immediate Post-Intervention,
H3E-MC-V153,Pre Clinical - TS in lung biopsies - Resectioning Specimens,
F1J-US-V004,Eff of NE transporter inhibitors on stability & purification,
B3D-SZ-O031,Drugs and fracture healing-healing of distal radius fracture,
I5A-IE-X007,"8121: Ph II - A12+Temsiroliums - Bone",
I5A-IE-X011,"8148: Ph II - A12 + Eriotinib - NSCLC",
I5A-IE-X027,S0727: Ph I - A12+Gem+Eriotinib vs Gem+Eriotinib-Pancreas,
H4M-LC-NRRS,LY307640 IN H PYLORI POSITIVE SUBJECTS,
"14447",RA - Phase 3 Head to Head Trial,
H4Q-MC-A001,LY333328 VS VANCOMYCIN--S AUREUS ENDOCARDITIS IN RABBITS,
H4Q-MC-A004,LY333328--INTRAVASCULAR CATHETER-RELATED BACTEREMIA IN RATS,
H3E-US-I001,Ph II Bevacizumab combo w/ Alimta as 2nd line in brain,
H3E-US-X049,Ph I/Pilot of Alimta and Cisplatin in extensive stage SCLC,
ZYY-MC-BPAB,ERbeta Ejaculate Method Study to support BI,
H6Q-MC-V003, Evaluate effect of enzastaurin on PKCbeta II signaling,
B9E-IT-O475,Ac vs Gem-TXT weekly no anthra MBC patients,
B9E-MC-V273,Mechanistic Analyse DNA Polymerase B Mut and Efficacy of Gem,
B9E-US-X450,Ph 2 Gem & Irinotecan in pts. with unknown primary carcinoma,
B9E-FP-O465,IIT-Hepatocellular carcinoma B9E-FP-O465 / ARMHV,
"10434",Proposal for a Clinical Audit and Educational Program,
B9E-US-I153,"Ph II Gem, Paclitaxel, Bevacizumab for breast cancer",
H3E-US-X053,PhII Trial of Alimta/Gem in Adv. Non-Clear Cell RCC,
H6D-MC-LVHB,Cialis BPH Asian Phase III,
F1J-AY-B014,Frequency of treatment emergent sexual dysfunction in MDD,
H7T-MC-TABH,High-dose Statin Interaction Study with Prasugrel,
H3E-US-X054,"Ph II rad, Alimta & Carbo w or w/o Cetuximab in Stg II NSCLC",
F1D-US-X285,Cerebral Morphometric Correlates in Schizophrenia & Diabetes,
B9E-MC-X179,Weekly Gemcitabine and Paclitaxel in Lung Cancer,
H3E-MC-JMDA,colorectal phsae III,
B9E-MC-X079,Phase 1 Trial of Gemcitabine and CPT-11,
"3167",Study of LY357584 in fibromyalgia,
B1Y-MC-I006,FLUOXETINE FOR RELAPSE PREVENTION OF ALCOHOLISM,
B7A-LC-MBBW,carbon 14 study,
H4Z-MC-GJAB,Safe. and Effic. of LY353381 in Pts. with Mild to Mod . AD,
F1D-MC-O026,Olanzapine in Treatment of Adults with BPD,
F1D-MC-A030,Preclinical Evaluation of Olanzapine as Antidepressant,
B1Y-MC-X184,EFFECTS OF FLUOX ON HIPPOCCAMPAL VOLUME,
F1D-MC-X133,Retrospective Chart Review of Olz + ECT vs Haldol + ECT,
B9E-XM-JHPL,"Phase II, Gemcitabine, Cisplatin & Dexamethasone, NHL",
B9E-MC-S132,Ph lll - Surgery vs. surgery + pre-op gem/cis NSCLC,
B9R-MC-X013,Assessment of Neurosecretion of GH,
B9E-VI-O067,"Phase II, Alternating Mode of tx w/ Gemcitabine, In NSCLC",
B9E-VI-O076,"Phase II, Study Gemcitabine Monotherapy & Clinical Benefit",
H6D-MC-LVBK,"Efficacy, safety in diabetics with MED",
H6D-MC-LVBM,Pivotal on demand therapy,
I4P-MC-GPFD,TQT,
H4S-MC-A001,BABOON RESTENOSIS STUDIES,
B1Y-FP-0734,FLUOXETINE LIQUID/ELDERLY DEPRESSED PATIENTS,
F1D-XL-O337,Study dysregulation 5HT2A/mGLU2 receptor psychotic disorder,
I4E-US-X001,Eval of sE-cad&proA15 as indicators of Cetuximab in Bladder,
I6B-MC-HZBF,Night time impairment,
H4W-LC-LLAC,MELATONIN:EFFECT ON SLEEP,
"14831",SUMMATIVE human factor study for IRMA,
"14946",Ph IV-1121B-Target population/treatment patterns-Gastric,
I2I-MC-V009,Molecular Pathways Leading to Optimal Efficacy of LY2606318,
H6Q-MC-JCCD,COMPASSIONATE USE - Enzastaurin - DLBCL maintenance,
H9H-MC-JBAS,R-PH 2- TGFb vs TGFb+Sorafenib vs Sorafenib- Adv HCC,
"15076",RBA (+Food Effect) Study,
B3D-OE-O039, Pathogenesis of Fractures in Diabetes Mellitus,
I3G-MC-V004,glucose and lipid metabolism in the liver and white adipose ,
H8L-MC-IQBV,BOLT and ePFS Formative - Ixekizumab,
H6D-IT-A020,Effect of tadalafil treatment on high fat diet-induced ,
H8L-MC-IQCC,BIL 60 KwikPen Formative Human Factors 2,
H4S-US-X013,Evaluation of Platelet Function,
B9R-XM-O015,PEDIATRIC PATIENTS WITH SHORT STATURE DUE TO NEUROSECRETORY,
B9E-UT-O288,"Induction therapy with Carbo and Gem, locally advanced NSCLC",
"6049",Validation of cognitive methodology in schizophrenia,
"6103",GLP-1 analogue - Drug/drug interaction 1,
"6113","Dose confirmation, Pulmonary Insulin",
H3E-MC-S003,"ALIMTA + GEM + Carbo, 1st line",
F1K-MC-EVCY,Acute Renal Failure ( Prevention/therapy),
H3E-US-S017,Ph 2 ALIMTA + GEM +  Herceptin in Breast,
"6200",Premeal humalog + actos vs. once daily glargine + amaryl,
H3E-MC-S033,Placeholder for Breast,
H7C-MC-LMBZ,GAD Venlafaxine Comparator #1 (QD w/Extension),
H7C-MC-LMCA,Geriatric Safety Study,
"6250",NIDA Cocaine Abuse Study,
H7C-JE-LMBH,JP mGluR2 P-I SDSS,
B5K-BC-L001,BERLINSULIN DRUG MONITORING INS2/97,
H4S-BL-O034,Reopro vs placebo in multiarterial intervention,
"6447","354",
H7X-MC-JVAH,Ph I - 2nd line - Alimta + Affinitak - NSCLC,
"10705",Ph3 Gem/Carbo/Avastin vs Taxol/Carbo/Avastin 1st Line NSCLC,
F1J-BL-O015,Duloxetine effects over axiety on depressed patients,
F1J-BL-O016,Duloxetine for premenstrual disorder,
H6D-US-LVHE,Patient and Partner Satisfaction,
B9E-MC-V308,PGx Analyses of Pt.Tissue Samples,
F1J-US-HMEY, Current Tx: Dulox add on vs. switch to pregabalin,
B9E-CA-O478,Concurrent Cispl and Gemcitabine plus RXT in cervical cancer,
"10902",IIT : patient with kidney insufficiency,
H7T-EW-TABW,CS747 Renal Impairment,
H8R-MC-S001,Alcohol craving study,
F3Z-US-X024,"50 Year Medalist Study - Humalog",
"11084",Epidemiologic study on microvascular complications (retinopa,
F1J-JE-HMFF,JP Dulox P-II DPNP Open-label study (Shionogi),
H4S-US-X025,IIT prevention of neointimal hyerplasia,
F1D-JE-V018,Effect of ola on the gene expression of serine,
"11122","Chemoimmuno with Cisplatin,Pemetrex and CD40 active in Meso",
"11135",G Protein-Coupled receptors: therapeutic Targets in Pancreat,
F1J-MC-X032,Pilot in psych resilience and correlation w/ blockade,
"11219",Human dosimetry study,
B1Y-MC-X068,DRUG AND COGNITIVE MAINTENANCE THERAPIES IN DEPRESSION,
F1D-MC-X150,"5HT2A Mechanisms in the Tx of Schizoaffective Dis.",
B4Z-LC-LYAK,Pilot Biodquivalence_IV_PM subjects,
"3901",MGlur2 - Antacid Interaction,
B9E-MC-X255,Adjuvant Gemcitabine/Cisplatin in Bladder Cancer,
"4013",Phase 3 polyneuropathy,
B1Y-MC-X098,TREATMENT OF BENGEING & WT. GAIN UPON SMOKING CESS. IN WOMEN,
H4Z-LC-JWXJ,pharmacokinetics of LY353381 in renal patients,
B1Y-MC-X114,FLUOXETINE VS PAXIL: WITHDRAWAL FROM SSRI'S BRAIN IMAGING,
B1Y-MC-X118,FLUOXETINE N HIGH UTILIZERS OF MEDICAL SERVICES,
B9E-MC-V036,p53 + gemcitabine combination in NSCLC,
B7A-MC-MBDB,LY333531inEarly Diabetic Retinopathy (Label Expansion Study),
B9E-MC-V041,Effect of PKC activator on gem in leukemia cells,
B9E-MC-V043,Use gem-dFdCDP as standard for analysis of nucleotide pool,
F3Z-FP-S005,Strategies to treat patients after NPH & Oral agent failure,
H5P-MC-BWXO,IBD Phase I,
F3Z-MC-IOMP,"Compassionate use of LM, MM and HM",
H8L-MC-IQCE,Formative Human Factors for U-500 Syringe,
H8L-MC-IQCG,Strattera Dosing Aids Summative Study #2,
I6K-MC-GLEC,GPR40 Agonist III Phase II Study,
I2Z-MC-E002,FAST-MAS2 ExIST 8 wk dosing for LY2456302(OpRa Kappa I)/PBO,
I4M-MC-MRAJ,MR III Ph 2a Dose Ranging in Hypertension,
I4M-MC-MRAR,DDI Study w/ 3A4 Inhibitor,
"15470",Blosozumab H2H BMD Study with Romosozumab,
H9H-MC-JBEB,PPI / Antiacid in Healthy Subjects,
H8L-MC-IQCT,U200 KwikPen Summative Human Factor Study 2,
"1564",Lorabid vs. Cefaclor; Comparative Study in Acute,
I8L-JE-IXAI,Japan Final Formulation PK,
I5Q-MC-CGAL,Ph 3 prophylactic treatment of Episodic Cluster Headache,
H9X-JE-GBGF,Japan PMS - Dula + Insulin,
H9H-MC-A037,Comb-targeting immunosuppression in pre-clin glioblastoma,
I4V-MC-JAHE,Expanded Access Protocol FSGS,
I4E-IE-W849,Protocol CA225-119; A II TRIAL OF CETUXIMAB IN UNRESECTABLE ,
I4E-IE-W892,CA225-114: Ph II-Cetuximab+/-Carbo - Met Breast,
B9E-MC-V158,HPLC Method for Ther Drug Mon of Gem in Cancer Pts,
H8H-MC-LACB,"5-HT1F  FED (IV)",
F1D-GN-O160,Cardiac Safety Indices in Antipsychotic Medication,
"6599",Compliance study,
"6619",Placeholder for Xigris IITs,
H3S-PL-V008,Influence of Ralox. on Collagen in Human Fibroblasts.,
F1D-US-X217,"Rehabilitation, brain function'g and early schizophrenia",
B9R-US-X035,Pituitary Tumor Database Prospective Study,
B9E-MC-V169,Pk of Gem when given in combination with BMS-214662,
ZYY-MC-GOAA, Obesity Biomarker - Method Study #1 - Fed and Fasted,
B9E-LA-S350,R - Ph II -  Cis + Gem - NSCLC,
"7035",AMPT Dosing Study,
B9E-US-S312,Phase II FDR Gem in Pan Ca Refractory to SDR Gem,
H3E-US-JMGB,Single Arm PhII Gemzar followed by Alimta in PS 0/1 NSCLC,
"7224","Placeholder B9E-MC-S062, -S175, -S274, -S307, -S351",
"7247",IIT Placeholder Humatrope,
"7274",Abeta time course effect and plasma level,
B9E-SB-O334,Chemoembolization with Gemcitabine: Liver mets in MBC,
B9E-MC-JHEI,GEMCITABINE COMPARE HIGH/LOW DOSE IN NON-SMALL CELL LUNG CA,
B1Y-BP-O007,Placebo vs SSRI augmentation of Rivastigmine in Alzheimer's,
ZYY-MC-PCAA,Hepatitis C Patients Observational Trial,
B9E-MC-V060,Effects of tumor suppresor expression before/after gemcitabi,
"4481",Assay correlate with clinical endpoints,
"4560",head to head comparison of Pioglitazone and Sulfonylurea,
B9E-SB-V075,MTA radiation interaction in Vitro,
H6K-MC-IIAE,Clamp Study in Normal Volunteers,
B9E-MC-S199,"Gem + Carbo vs Gem + Nav (NSCLC, 1st line)",
H3R-MC-I003,Analgesic Efficacy in Lumbar Monoradiculopathy,
B1Y-FP-O011,Early post accidental vascular cerebral depression,
B1Y-SP-E064,FLUOXETINE VS CLOMIPRAMINE MAJOR DEPRESSIVE DISORDERS,
B1Y-SZ-PK41,PROZAC IN THE TTT OF DEPRESSION IN A DAILY PRAXIS,
B9E-MC-I119,"Gemzar, 5-FU, and XRT in Surgically Resected Pancreatic Ca",
"4951",Clin Pharm Drug Interaction Study #3,
"4982",Single dose safety - Lilly Clinic,
"5012",Phase 2 Alzheimer's disease,
"5041",Schizophrenia POC / dosing study,
H6E-KL-GLAO,"Single Dose, Dose-Ranging Study to Assess PK of Actos",
"6383",Cialis Placeholder for business planning,
H6Q-MC-S065,Ph II Enz + Alimta/Cis in 1st line Meso,
"11223",Ph I/II Enza+ Sorafenib or Interferon-1st ln or Refract RCC,
H3E-US-X067,Predictive Markers of Response to Pemetrexed,
H8O-MC-GWBR,QW vs Lantus,
F1J-MC-HMAG,DULOXETINE VS PLACEBO IN MAJOR DEPRESSIVE DISORDER,
H9D-MC-ITAC,Phase II Injection Experience with the Aura Device,
H6O-FW-GCAY,Sensitivity of Beta Cell mass biomarker tool,
H9P-MC-LNBL,NERI IV Flex dose Depression Monotherapy,
H9P-MC-LNDP,ADHD pediatric NERI-IV flexible dosing vs. PBO,
"11372",GLP-1 IV-FC: Hypoglycemic recovery,
H9T-MC-NABI,Opra II phase 2 efficacy study,
I2A-MC-GABA,SDSS LY2148936 in men and PMP women,
H8O-JE-GWBW,JP Exenatide QW P-IB MDSS,
H3E-XM-S113,Alimta-cisplatin in 1st line for SCLC patients,
H6Q-MC-JCBV,Ph II Open-label safety study of ENZ for patients with glio,
F1J-MC-HMFJ,Chinese Cymbalta GAD Registration Study,
H6Q-MC-V038,Enzastaurin in prostate cancer,
I4E-IE-W927,Protocol CA225-215; A II STUDY OF CETUXIMAB (ERBITUX) IN PAT,
I8D-MC-AZEQ,China PK		,
B1Y-HL-E069,FLUOXETINE V MAPROTILINE-MAJOR DEPRESS DISORDER,
I4J-MC-E002,Ph Ib/II - Hedgehog+Paclitaxel+Carbo+XRT-Esophagus,
"16077",Renal,
H2Q-MC-LZYD,Behaviors in mod. Alzheimers-US/Canada (B1),
"16123",PET RO study of LY2491503,
I7E-AV-E029,"18F-AV-1451-EXIST-029",
I4T-MC-JVDK,Ph1a/1b Ram +other Lilly agents in specific advanced cancers,
I8L-MC-IXAD,BC3-CT013 Ph1b PK/PD T1DM BC222 Lispro vs. Lispro,
"16236",SAD in HV and SLE patients,
"16237",Formulation Support,
B1Y-IT-0001,"FLUOXETINE VS CLOMIPRAMINE IN MDD, COMPARISON STUDY",
"1633",LY33013-MC-xxxD Rheumatoid Arthritis Phase II/III,
I8O-MC-SBDD,MAD,
I8P-MC-OXAE,RBA - PK Formulation,
I8H-MC-BDCC,MOA Study,
F1D-EW-HGJO,"Prospective,observational health outcomes study (SOHO)",
B7A-MC-MBCQ,Long-Term Safety Diabetic Retinopathy Study,
B9E-GV-O200,Gem+Cis+Pacli in 2nd line Gem cell cancer,
H3S-US-X015,Prevention of BMD loss in high risk PM women using raloxifen,
B1Y-FP-S009,"Depression diagnosis in erdely patients, >75 years old in GP",
F1D-TW-O103,Combination use of Olanzapine and Haloperidol in Schizophren,
B9E-SN-O209,"phase II 5FU, Cis, folinic, gem: 2nd line in colon cancer",
B9E-MC-X322,PhII Gemzar/paclitaxel/carboplatin in urothelial tract,
B3M-LC-AJAF,CEFACLOR SUSPENSION: BIOEQUIVALENCE STUDY OF NEW FORMULATION,
B9E-JE-C002,JP gem P-IV pancreas,
B3M-MC-V051,Invitro,
"5689",invitro,
H3S-BX-S006,Raloxifene Effects on Atherosclerosis Process,
B3N-EW-EUBF,MOXONIDINE:PILOTSINGLE DOSE OF CR AND PK OF SR FORMS,
F1D-EW-S018,Obs-IM: Obs study of IM antipsy. in agitated schizo. pts.,
B9E-MC-O247,Neoadjuvant Gem-Oxali in Adv. Cervix Carcinoma,
B3N-HH-EUAI,Moxonidine and enalaprile in pts. with essential HTN,
"5903",Alzheimers Phase II Study,
"7365",Expanding Knowledge Study,
"7438",Severe sepsis in oncologic patients,
"7450",Gem+Alimta Colon study (Amadori proposal),
"7490",Placeholder IIT Evaluation of sleep in ADHD patients,
H3E-MC-JMGE,R-Ph II-Dbl  Blind-ALIMTA 600 vs Alimta 900-Breast-1st Line,
"7502",Uterine safety of raloxifene in women with uterine myoma,
F1J-FP-O004,Effect Duloxetine and Venlafaxine in mice,
H6D-EW-LVFF,Cialis/Sildenafil Placebo-Ctrl 3 Period X-Over Visual Study,
"7606",Methods Placeholder,
"7620",Ceclor Untitled IITs,
"7627",olanzapine side effects,
H3E-MC-JMGH,"Ph II, 2nd Line, Single Agent ALIMTA (Calvert) Ovarian",
F1D-PL-O201,Bipolar Mania,
"7762",IIT - 2003 (2) - Cymbalta,
"7786",Extracellular levels of monoamines in rats - Cymbalta,
"7800",Questionnaires Comparison in Tx w/Duloxetine,
F1K-HU-EVCQ,Data of Local Sepsis Patients Treated with Xigris,
"7883",IITs 2003 & 2004,
B3D-US-GHCL,Forteo vs alendronate bone biopsy (micro-architecture) study,
"8006",Neuroimaging: Neuropsych measures & cog tasks,
F1J-US-X037,Open trial of Dulox in Outpts w/IBS & Co-Morbid Maj Depress,
F1J-US-HMFS,MDD efficacy in depressive sympt improvements and usual fx,
F1D-CA-S068,Olanzapine and Olanzapine/Fluoxetine for agitated depression,
H3S-IT-V010,Effect of Raloxifene on vit D receptor sintesis,
B5K-US-I012,Primary Oral Insulin Trials (POINT),
F3Z-IT-IODV,EVAL.OF INS.THER.REG.IN DIAB.PTS. COMPARISON: LISPRO - HUM R,
H3E-EW-S115,Ph II Pemextred seond line  adv Metastatic Osteocarcoma,
I2F-FW-GHEA,Pulmonary Bioavailability Trial Phase 1,
I2N-MC-GPBC,MDSS Safety and Tolerability,
B1Y-FH-O038,SSRIs on cognitive function in patients with stroke,
H7T-MC-V017,Effect - P2Y12 inhib-plt thormbus formation under blood flow,
F3Z-EW-IOPJ,Basal/Bolus study: ILPS vs. glargine,
I2K-MC-ZZAD,Chronic Insomnia - Phase 2,
H8G-MC-EPBQ,Special Population Hepatic,
I2Q-FW-GMAG,Bioavailability Study,
B4Z-MC-LYEF,Atomoxetine Asia Pilot Phase2-China,
"16403",Ph II-Ramucirumab+LLY PD-L1 in MSI High Pts - CRC,
I8R-MC-IGBB,Assessment of Intranasal Glucagon in Children-Aolescents T1,
I8R-MC-B001,Observational Intranasal Administered Home or School Envirom,
I4T-US-I008,PhII Pembrolizumab+Ramucirumab Previously-Tx Mesothelioma,
I8R-MC-IGBH,Safety of single 3 mg dose inransally glucagon in adults,
I6T-MC-AMAI,Phase 3 placebo controlled trial in Psoriasis,
"16621",SAD,
I9F-MC-SCAC,RBA/Food Effect,
I9F-MC-SCAD,SAD/MAD,
I6E-AV-I052,AV-45-IIT-052: The Role of Florbetapir in the Early Detectio,
I6T-MC-AMBF,Cosentyx non-inferiority Trial,
H8H-MC-LAHA,"Effect of Age on PK, Safety, and Tolerabilily of Lasmiditan ",
I9H-MC-FFAC,Patient SAD,
I8K-MC-JPDM,Phase 2 in RRMS,
H8H-JE-LAIH,"JP PhII, Bridging study",
I8H-MC-BDCN,Hepatic Imaging/Biomarker 26 Week,
B3D-IT-O022,Prevalence of Osteoporosis in Internal Medicine (POINT),
H8K-JE-JZAH,JP ASAP Phase I,
"12177",U200 Clinical Trial,
H8K-MC-JZAJ,Phase I of LY573636 in Hematological malignancies - AML,
F1D-CR-S071,Olz Depot vs Olz Early on in pts w/Sch At High risk relapse,
"12370","2-year phase 3 obesity",
"12417",Tritiated Human study,
I2U-MC-H305,Obesity Proof of Concept,
I3G-MC-JGCA,"FHD p70 S6 Kinase (LY2584702 . Tosylate) Single Agent, Ph 1",
"12452",Phase II Study for LY2515682,
H8O-MC-O011,Effect of exenatide on beta-cell turnover ,
H9P-EW-LNDG,Biopharm China PK study,
I2K-MC-ZZAM,Long Term Open Label Extension & Safety Study,
I2K-MC-ZZAU,Mid-Term (3-month) PSG & PRO,
H2Q-EW-LKAA,XANOMELINE-TTS (FORMULATION E) MULTIPLE DOSE SAFETY IN ELDER,
H2Q-EW-LKAC,XANOMELINE-TTS (FORMULATION E) NIFEDIPINE INTERACTION STUDY,
"12746",iGluR5  OA Pain 9,
"12751",Radicular Pain Pbo Controlled #1,
H3S-SB-O012,RLX vs. Placebo w/wo dynamic power training,
H3S-XM-O016,Raloxifene in endotelial function,
"6045",Method study 1,
"6054",Olanzapine depot (Japan),
F3Z-MC-IOOA,Premeal Humalog+NPHvs twice daily NPH:  Acute Postprandial,
"6190",Pulmonary hGH: Phase III Pediatric GHD,
"6191",Pulmonary hGH: Phase III Adult Efficacy,
F1J-LC-HMCF,Second Food Effect Dose at High Dose,
B4G-SB-LBAJ,PERGOLIDE VS PLACEBO IN RESTLESS LEGS SYNDROME,
B9E-MC-S279,Ph II-Paclitaxel+Carbo+Gem - Ovary,
"6306",Miscellameous IIts Prozac,
B4G-UT-LBAX,PERGOLIDE IN ELDERLY PTS. WITH PARKINSONS DISEASE,
B9E-SZ-O281,PhIII - Gem + Capecitabine vs Gem - Pancreas,
H6D-MC-LVEP,Premature Ejaculation,
"6374",GDFC Placeholder for business planning,
"6392",J-MDSS 395,
B9E-MC-S286,Ph III XRT+/-Gemcitabine,
B1Y-ME-O021,Free L-Triptophane and N1/P2 segments as biological indicato,
"8032",PET Study,
"8033",PET Study,
F3Z-US-X018,Transition to Insulin Therapy in Type 2 Patients on OHAs,
B9E-US-X384,"Ph I Wkly Gem, comb w/Docetaxel in pts w/Adv Solid Tumors",
"8062",Genetic Prediction of Response to Tiazolidinediones in IGT,
H8O-FW-GWAF,Exendin-4: Digoxin PK,
"8125",MDSS Contingency Study,
F1D-AY-O227,New media training in mental health policy & service devt.,
F1K-US-V006,Eff. of Recombinant APC on Human Monocyte Bactericidal Activ,
"8231",Mamputu-Signaling Pathways Involved in Advanced Glycation...,
B9E-MC-V224,Lung in rat model of pulmonary adenocarcinoma w gem +XRT,
H3E-MC-S086,Ph I/II ALIMTA 2-arm (diff sched) Intravesical super bladder,
H4S-CA-O053,The Change protocol,
"8477",Dosimetry in Human Volunteers,
B1Y-BX-9201,PROZAC AND ANXIETY IN MAJOR DEPRESSIVE DISORDER,
B9R-MC-I012,EFFECTS OF GH ON THE HEALING OF FEMUR FRACTURES IN CHILDREN,
"8500",Other Anxiety Disorder Commercialization Trial #1,
H6D-FW-LVFU,China PK Study,
I7E-AV-_A24,"18F-AV-1451-A24: LMDC Pre-Screener",
B1Y-IT-0010,FLUOXETINE EVALUATION MULTICENTER STUDY(HARD II),
I9X-MC-MTAC,MAD 3 dose levels LY Women of nonchildbearing potential HV,
J1O-MC-JZHB,Ph 1b - AurA Kinase Inh - SCLC,
I3Y-MC-JPCU,Ph IV - Abema+Fulvestrant vs Chemo - mBC,
I7E-AV-E062,"18F-AV-1451-EXIST-062",
I8X-MC-JECD,Ph I - TGFb RI Kin Inhib + Pembro - Multiple Tumors,
I7E-AV-_PX1,AV-1451-PX-01,
I9J-MC-DIPB,Diabetes Initiation Polypill - China BE Study,
F3Z-MC-IORQ,Tango Remote Settings Update,
"17692",PhII Ram+TAS-102 Adv Gastric or GEJ Adenocarcinoma,
"17713",Rollover Protocol for Continued Assesment of drug LY3023414,
"17744",Multi-center Connected Care Innovation testing,
J2G-OX-Y084,RET Inhibitor-PTC,
J2G-OX-Y085,RET Inhibitor-NSCLC,
J2G-OX-Y102,RET Inhibitor-MTC,
H3S-XM-O124,BMD in femenine postmenopausal population of an area of Lugo,
F1D-FP-S029,olanzapine versus haloperidol and patient's outcome,
"6609",IIIB,
F1D-LA-S056,Olanzapine RAIM Study LA,
H6P-MC-A002,Preclinical regulation of CREB fxn in rat CNS after OFC,
"6705",Prozac in depression with tired fatigue unmotivated symptoms,
H6P-BL-O002,Epidemiol. study of Psychiatr disorders in SP State,
H6E-XM-O004,Pioglitazone effect on endothelial dysfunction in Type 2 DM,
B9E-US-X346,Ph I/II trial of Std-Dose Carbo/Gem+esc dose celecoxib nsclc,
H7G-MC-PDAC,Phase 2 Global Non-China Treatment,
B9E-MC-V164,Gem in Dogs w/ Carcinomas & Prev. Treated Lymphomas,
"6807",Single Dose Safety Study,
B9E-BP-O311,Gemecitabine and Capecitabine in Adv/Met Renal Cell Carcinom,
B9E-JE-N01D,PHASE I/II COMBINATION TRIAL WITH CISPLATIN FOR NSCLC,
B9E-MC-I001,PH I GEMCIT. COMB. WITH FLUORODEOXYURIDINE IN ADULT CANCER P,
B9E-MC-I021,GEMCITABINE AND 5-FLUORACIL IN SOLID TUMORS,
F1D-MC-HGKT,Olanzapine oral vs. risperidone depot in schizophrenia,
H7T-MC-TAAH,CS-747 Phase II Stent Study,
F1D-FP-S041,Observational study on use of Olanzapine zydis form,
I3E-MC-MSAF,Single Dose PK study in MS,
I1C-MC-JLBK,Gem Prodrug - C14 study,
H2Q-SB-LZZQ,XANOMELINE ORTHOSTATIC TOLERANCE OF ORAL AND TRANSDERMAL,
H7T-MC-TADH,DAPT in Stents,
H3S-US-I009,Effect of Antiestrogens on Hormone-independent breast cancer,
I1F-MC-RHAU,"Ph 3 RA 2LY, Plc (MXT bckgrd) TNF IR: 6 mo S&Sx ",
F3Z-KL-A001,prevent diabetic vascular complications,
H8O-CR-B012,IC OS Assessing Clinical Eff & Safety of pt initiating inj t,
"13089",Intensification of insulin therapy in oral failures,
F1D-US-A157,Effects of chronic olanzapine on peripheral and central omeg,
I3J-MC-LACI,"13C Leucine Study",
H6D-MC-X008,Tadalafil in Pts with Squamous Cell Carcinoma,
I4B-FW-GPCB,MADS (Multiple Ascending Dose Study),
"13233",Exenatide plasma metabolomes ,
"13357",The effects of slow-release or long-acting ins,
H7T-MC-V027,Reg of Purinergic Receptor by Rev & Irrev P2Y12 Ag,
B9E-AG-O395,Phase I Gem & Concurrent radiotherapy in esophageal carcinom,
H4Z-MC-GJAR,Comparator trial: Arzxoifene vs Evista in osteoporosis,
H3E-SB-JMGY,"Ph II, ALIMTA+Carbo+Radiotherapy in pts w/ inoperable NSCLC",
F1J-MC-O005,"duloxetine in animals, to study 5HT1-A and B in pain",
"8748",Ph II - Gem+Etop+Solumedrol-pts w/relapsed T-cell - Lymphoma,
"8762",Ph I/II - ALIMTA+Oxali+ novel agents (PKC-beta) - CRC,
H3E-MC-V037,Reversal of Alimta Resistance Invitro and Invivo,
H3E-MC-V036,Sensitivity of Bronchioloallveolar+Andenocarcinoma o,
"8815","Olan vs Risp: efficacy, safety, outcome, 6 months foolow-up",
"8837",Placeholder Trial,
"8839",Phase II Study,
"8862",Placeholder IIT duloxetine,
"8898",Ph III CRC Confirmatory Trial,
H7R-MC-GCCD,Efficacy in combination w/metformin,
F1J-US-HMDR,Comparison of Dulox Dosing Strategies in MDD patients,
F1J-BI-SBCO,Urge Registration study OUS,
"9033",Placeholder Actos (BUY UP),
"9080",Phase II GAD Low-Dose #2 (Buy-Up),
"9090",exenatide BID vs lantus among type 2  with OAD failure,
J2T-DM-KGAV,Lebri for pts w/ uncontrolled asthma on inhaled corticostero,
H3E-MC-JMBS,Ph I-Alimta+Taxol-solid tumors,
"18099",Renal Safety HV,
"18104",Midazolam DDI HV,
"18108",QTC HV,
I4X-MC-Y001,NPU-Necitumumab-Metastatic Squamous NSCLC,
H7I-AV-S026,ADDI Confirm EET - EXIST,
"18408", Placeholder DDI study,
"18461", China PK Study,
B9E-MC-I111,"GEMCITABINE, CISPLATIN AND METHORTREXATE IN BLADDER CANCER",
"18600",DDI study with Atorvastatin,
"18663",P-gp Placeholder ,
"18683",Loxo-NGR-23011-Ph1-RET Inhib II-DDI CYP384 Inhibitor/Inducer,
H3Z-MC-JNAO,P-II Eval of LY295501 in Treatment of 2nd-Line Colorectal Ca,
H4S-MC-EWAH,ReoPro for the Treatment of Acute Coronary Syndromes,
H4Y-MC-LJAO,Dose comparison of LY334370 vs placebo (tablet),
B9E-MC-S006,Taxol+Gem vs Nav + Cis vs Gem + Cis as XRT induct - NSCLC,
H6Q-IT-V041,Express. profile of Protein Kinase C isoforms in endo tumor,
"13430",Non Interventional Device Comp,
"13502",AKT/p70 Dual Inhibitor,
B7A-MC-V013,The involvement of PKC isozymes in cerebellar  ,
I2H-JE-JWYC,JP_GSK3_Phase_1,
I4G-MC-BIBC,MAD Study,
"13644",R-PhII-LY2334737[GemPro] vs Doxil-platinum resist-Ovary,
I4G-MC-ABDA,PK / PD Bioquivalence in T1DM,
H3S-MC-GGHX,A COMP OF RALOX CONTIN HRT AND PLACEBO ON CHD RISK MARKERS,
H9B-MC-BCDX,Ph III Lupus Extension study,
F1J-US-X058,"Dulox in Tx of Widespread, Non-Joint Pain in Rheum Arthritis",
I4E-MC-JXBE,Ph II-Erbitux+FOLFORI-1st Line-Colorectal,
B4Z-US-A013,Effects Atomox on binge-like alc drinking in C57BI/6J mice,
I4W-FW-HMJA,Single Ascending Dose,
H8O-EW-GWDS,EQW Device Usability Simulation Study in Pts w/Type 2 Diabet,
I1F-MC-RHAS,Phase 2 Trial in Multiple Sclerosis,
H6D-MC-LVIY,PK in Japanese subjects,
B9R-FP-GDGI,Children with ISS treated by hGH (Phoenix),
B9E-MC-JHDM,PHASE 2 STUDY OF GEMCITABINE IN PRETREATED NON-HODGKINS,
B1Y-GH-O028,The characteristic of regional cerebralmetabolism in patient,
B9E-MC-V204,Antitumor effect of gemcitabine in combination with older ch,
H6U-BL-LRAH,Brazilian observational study for depression,
"7355",survey with gynecologists,
"7437",Mortality data in CID patients,
H3E-MC-JMGF,Phase I AlLIMTA + oxal w/ vit CRCl cancer - 2 schedules,
H3E-US-S074,Ph. II Alimta + Oxal vs. 5-FU/LV + Oxal in Colorectal Cancer,
"7501",Local trials in Evista-AP,
F3Z-MC-IOOM,"24 Hour Lantus Profile",
F1D-MC-X226,Effects of Chronic Tx w/Olz. & Other Atypical Antipsychotics,
B9E-MC-JHFW,PHASE I GEMCITABINE + RADIOTHERAPY IN STAGE III NSCLC,
"7573",Duloxetine vs citalopran,
B9E-MC-JHKB,PH1 GEM + VINORELBINE COMB. THER. IN REFRACTORY SOLID TUMORS,
"7614",Alcohol Dependence Study,
"7624",Gemzar in NSCLC,
B9E-US-X376,Ph I of Pre-OP concomitant Gem & Ext-beam Rad soft tiss sarc,
F1K-US-V013,Role of rcombinant human aPC in CARS with Xigris,
H6D-FP-O003,IIT - Tadalafil effect on humain adipocytis function,
F1D-TW-O255,Olanzapine versus Valproate in the Treatment of Acute Mania,
"9355",use of forteo in severe osteoporosis local obs trial,
H3E-US-X007,Ph II pemetrexed/carbo stage IV or select stage IIIb NSCLC,
B9E-US-X430,"Ph II Dose Dense Gem, Epirubicin, Docetaxal in Breast CA",
F1D-OE-B015,Balance - bipolar longitudinal compliance obs study,
F1D-LC-HGAC,LY170053:  CLINICAL PHARMACOLOGY MULTIPLE DOSE STUDY,
F1D-CA-O260,Genetic Factors in Bipolar Disorder,
F3Z-XL-O060,Analyses of DM type MODY Characteristics,
B9E-BP-O438,Phase II Gem + Taxotere - 2nd line Cervical,
F1D-JE-DP02,JP ola Depot I/II,
B9E-US-X436,"Ph II Gem, Mitoxantrone, & Rituximab for MCL",
F1D-CA-S058,olanzapine vs. seroquel in bipolar manic/mixed state,
H6D-MC-X002,Tadalafil in Men with ED and Partial Response to Antidepress,
F1D-MC-A007,OLAN. AND OTHER ATYPICALS ON INGESTIVE BEHAVIOR IN THE RAT,
"9908",EMBRACE (Observational Study in Breast Cancer),
B9E-MC-S012,Ph II Gem + Carbo in Bladder Ca,
F3Z-JE-M02H,lisMix P-I Hmlg30-70 & HmlgMix25,
"2179",LY300164 as Monotherapy in DeNovo Pts with Parkinson's Dis.,
H4Y-MS-LJAS,Safety and tolerance with sumatriptan #1,
B9E-MC-S058,"Ph II Gem + Oxaliplatin, NSCLC & Ovarian cancer",
B3M-MC-V038,Streptococcus pyogenes Global Surveillance Study,
B9E-MC-S062,"Ph lll, Adj Gem vs Observation in Bladder Cancer",
"2295",Timing studies regarding onset of LY333334,
F1D-US-X098,Olz in Comm. Heath Setting: Focus on Psychosocial Outcomes,
B1Y-MC-X174,Fluoxetine in Major Depression in Youth with Bipolar II,
B9E-MC-S096,Gem single agent / Breast,
B9E-SB-O023,"Phase II, Gemcitabine,  Cisplatin, &  Hyperthermia, Pancreas",
B9E-MC-I117,"SEQUENTIAL GEMCITABINE, DOXORUBICIN, THEN PACLITAXEL + CISP",
F3Z-IT-I009,ACUTE EFFECTS OF LISPRO ON POST-PRANDIAL BGL NIDDM,
H5U-EW-HSAA,"Single dose escalation, safety and disposition in volunteers",
F1D-MC-HGEN,A d.b. comparison of olan and clozapine with respect to slee,
H4Y-LC-LJBM,Single dose PK - Elderly,
"7682",Gemcitabine and Taxoter in NSCLC,
"7684",IIT / Fellowship / Chair Placeholder for Humatrope,
"7747",Paed. Endo Dr. Huot,
"7791",Double-blind Rand Comparison Atomoxifene and Methylphenidate,
B9E-SB-V001,GEMCITABINE:FDG UPTAKE IN VITRO AND GLUCOSE CARRIER EXPRE.,
B9E-PL-O359,Gemzar+Taxotere in advanced NSCLC,
B9E-SB-V004,Gemcitabine In Liposomale Formulation,
H6D-SB-S001,German Obs Study,
"8123",Sibutramine Drug Interaction,
B9E-US-S337,Ph II Avastin+5FU/Leu/Gem vs. Avastin+FOLFOX4 Colrec Cnr,
F1D-AY-O221,Management of behavioural distrurbance in psychiatry,
B9E-US-X386,Ph II Study of Gem & Cisplatin Unknown Prim CA liver involve,
H3S-US-X026,Compare the Effects of Raloxifene to Donepezil,
H3E-US-S078,PhII Alimta + Gem in Advanced Urothelial Cancer,
"8313",Drug Interaction Trial,
"8424","Ph II, ALIMTA+XRT -> Gem+Cis in non-resectable pts-Pancreas",
"8427",ALIMTA + Trastuzmab in Breast Cancer,
"8432","Ph I/II, 1st Line ALIMTA+Cis -> ALIMTA+Gem q2wk in NSCLC",
B7A-FW-MBCE,Bioequivalence of ph 2 material-ph 3 material w/food effect,
I5D-IE-JRCA,CP21-0901: FHD-Ph I - RON8 - Adv Solid Tumors - 2nd line,
I5C-IE-JEBA,CP17-0801: Ph I - EB10 - Acute Myeloid Lukemia- 2nd Line,
H4A-EW-XBAB,"LY303366:MULTIDOSE SAFETY AND PHARMACOKINETICS,100MG V 400MG",
H3E-EW-S134,Alimta/cis vs Iressa on-sq NSCLC pts with EGFR mutations,
H4A-MC-A002,LY303366: ASPERGILLUS IN IMMUNOSUPPRESSED MICE--LUNG TARGET,
I5L-MC-TCAH,LY3031642 Phase 3 Parallel Study,
"14210",Ph 2 - c-Met Antibody - Uveal Melanoma -1st line ,
"14230",Cardiovascular Effects of Apelin Infusion,
I3W-MC-HHAN,Renal Study,
I3W-MC-HHAJ,DDI Transporter Study,
H7I-MC-MGDA,PET dosimetry and test/re-test study for mGlu5,
H9P-EW-LNDZ,Biopharm Effect of 2C19 genotype on NERI PK Study,
I5A-IE-X014,"8269: Ph I - A12 + AZD6244 - Adv Solid Malignancies",
H8Y-MC-HBDH,Maintenance Treatment Adolescent,
I6F-MC-JJCB,Ph1b/R-PhII - Notch Inhibitor II - Leukemia,
F1J-LC-SBAH,Multiple Dose PK - Renal Impaired,
F1D-MC-HGBK,OPEN LABEL OLANZAPINE IN TREATMENT-REFRACTORY SCHIZOPHRENICS,
F1D-PL-HGGG,DOUBLE-BLIND  OLANZ. VS PERPHENAZINE STUDY IN SCHIZOPHRENIA,
H9C-MC-BBDG,anti-IL 1 Ph2 Placebo Controlled RA Study (MTX background),
"10759",Lispro Mix 75/25 pump usage in pediatric population,
B9E-MC-V325,Analyze Gemzar treated lung cancer + metastic lymph nodes,
H3E-MC-V109,Thymeless Stress DNA Repair and Recombination,
I2B-MC-GACA,"Tolerability, PK, SDSS in Healthy Post Menopausal Women",
"10909",International Somatropin ISS Trial,
F1J-JE-1001,LY248686 SINGLE DOSE ADMINISTRATION STUDY,
H3E-MC-V127,Nucleoside transporters in the pharmacokinetics and pharmaco,
"11032",A Placebo Controlled Trial of Aripiprazole Added to Obese Ol,
B3D-BX-B010,Belgian registry : Forsteo 18-month prospective obs study,
F3Z-XM-B005,CADiNi-Analysis of quality of DM sanitary assistance Spain,
B9E-FR-O486,IIT-Pediatric cancer B9E-FR-O486 / IGR,
H9X-MC-GBCE,Body Composition Glp-FC,
F1J-MC-SAAF,DULOXETINE DOSE TITRATION FOR EFFICACY AND SAFETY IN URGE,
"11367",Phase III 2yr Obesity Crossover Study OpRa II,
"11368",Phase III 1yr Obesity Comparator Study OpRaII,
F1J-JE-1004,LY248686:PHASE I SINGLE DOSE STUDY (ENTERIC GRANULES),
H7L-MC-MDAD,Volume Study Support Device,
I4F-MC-CCAJ,RBA,
I6L-AV-_B03,"Imaging DLB, PD, AD",
I1V-MC-EIBD,Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib,
H3E-AY-JMIW,Australian Neoadjuvant Therapy Study,
"14745",Does Teriparatide Reverse Osteonecrosis of the Jaw ,
H7T-MC-B017,"2011-779_A2-9389 Pattern of Effient vs.Plavix Use ",
B5K-MC-B009,"2010-300_Real World U500 studies Economic charact of use",
I5S-MC-EFJF,PCSK9 Ph 2 High Dose Statin Combo Phase 2,
H8O-MC-B019,Post Marketing Surveillance Study ,
I1D-MC-JIAL,Hepatic Impairment in Cancer or Non Cancer Patients,
H8L-MC-IQBW,BOLT and ePFS Formative - Tabalumab,
I5E-MC-B002,Topical Solution for Topical Use CIII Risk Evaulation,
I6L-AV-_VMT,Imaging Brain Vesicular Monoamine Transporters (VMAT),
I3Y-MC-A004,Molecular PredictorsResponseTargeted Therapy in Glioblastoma,
B3D-US-A005,PTH Therapy Adjuvant for Structural Allografting (Schwarz),
B9U-MC-AZCW,LORABID VERSES BIAXIN:  SINUS TISSUE PENETRATION,
F1J-LC-SBAK,Theophyllin Interaction or ACE Inhibitors,
F1J-MC-SBAN,GP Validation Diagnosis of SUI in a Primary Care Setting,
B1Y-MC-HCEE,FLUOXETINE CAPSULES BIOEQUIVALENCE,
B9R-EW-GDFC,GeNeSIS: Paediatric Short Stature Observational Study,
"2725",LY354740:  Drug-Drug Interaction Study,
C2N-MC-JXAG,(J108) LY355703 + Capecitabine,
C2N-MC-JXAI,(J110) LY355703 in Metastatic Breast CA - 2nd line,
H4Z-MC-JWWO,(JW16)  Metastatic Br (SERM vs Tamoxifen) Ph III,
"2880",Effects on Dental Pain,
H4Z-MC-JWWX,(JW20) Ph 3 Trial of LY353381 vs. Megace in Endometrial Canc,
"2909",Neuroendocrine Test Paradigm Development,
B1Y-MC-HCFH,FLUOX/PLACEBO:SAFETY IN MDD PATIENTS WITH ARRHYTHMIA,
H3E-MC-JMCS,PH II MTA + Taxotere 1st line NSCLC,
B9E-MC-X180,Phase 2 Study of Gemcitabine in Hepatocellular Carcinoma,
B9E-MC-X184,Gemcitabine and Paclitaxel in Head and neck Cancer,
B9E-MC-X196,Gemcitabine and Vinorelbine in Relapsed NSCLC,
"3030",Gemcitabine and Docetaxel/Phase 2/SCLC,
H5U-EW-HSAF,Effect of LY367265 on ovulation of pre-menopausal women,
B3N-MC-EUDF,Sleep apnea in CHF patients (Solvay),
B9E-CA-O388,Ph II Cis+Gem Loc.Adv/Recurrent or Met. Salivary Gland Tumor,
"8489",training,
F1D-MC-HGLP,Schizoaffective Depressive Disorder for Zyprexa,
H4Z-MC-GJAD,Effects of Arzoxifene on Vertebral Fracture Incidence and In,
H4Z-MC-GJAM,Enterohepatic cycling study (ClinPharm),
"8646",Exendin-4: Interaction 3,
B3D-US-X005,Effects of pth on Bone Metabolism in HomeTPN Patients,
B9R-MC-X015,OVERNIGHT INTEGRATED GROWTH HORMONE ASSAYS IN GH DEFICIENCY,
H8O-JE-GWAV,JP Exenatide P-II dose finding study,
F1D-SZ-O247,"ETUDE CLINIQUE CONTROLEE ""APPLE-PIE GROUP""",
H3E-MC-V035,Invitro and Invivo Studies comparing Alimta and Methotrexate,
B9R-SO-GDDD,HUMATROPE VS PLACEBO. SUBSTITUTION IN ADULT HYPOPITUITARISM,
H6O-LC-GCAT,Single dose Sibutramine - Effect on Caloric Intake,
"8828",MDSS/PET,
"8873",mGlu1 antag II Biomarker Study #2,
"8895",Placeholder with Actos - local studies,
"9336",SWITCH FROM TYPICAL TO ATYPICAL,
I4T-MC-JVCU,RAINFALL - Ph III - Ramucirumab - Gastric - 1st line,
I3X-MC-V002,JAK/STAT inhibition in preclinical models of head and neck c,
I1D-MC-E001,Ph I/II - LY2228820+XRT+TMZ - Glioblastoma,
"15432",Phase 2 Study #2,
B9E-MC-I008,"Phase I/II Study of Gemcitabine, Navelbine, & Cisplatin",
H3E-CA-O078,"Phase I/II MEK 162, with carbo & pemetrex in lung pts ",
I4X-MC-JFCR,Ph I/II - Necitumumab+EGFR 3rd gen TKI - NSCLC - 2nd Line,
H9H-MC-V013,Assessing the anti-tumor activity of LY in gastric cancer,
I7E-AV-_A08,"Tau Imaging of Preclincal, Prodromal, Dementia Phases of PD",
H8L-MC-IQCV,u200 supplemental SHF ,
H8A-MC-B002,"2014-316 Projecting Solanezumab Clinical Efficacy to a RWE",
I5Q-MC-CGAI,Ph3 chronic migraine prevention study,
I4D-MC-V004,BRCA Mutant Breast And BRCA Mutant Ovarian Cancer,
H3E-KL-O080,"Ph II, Alimta/Cis intercalated with Iressa vs. Iressa in EGF",
B3D-MC-B026,Asia and Latin America Fracture Observational Study (ALAFOS),
B4G-SB-V004,Effect of pergolide on neurons in primary cell culture,
B9E-JE-N13D,Phase 1/2 NSCLC,
B1Y-MC-X150,Mirtazapine to Fluox to Fluox Alone in Depressed Pts.,
B9E-MC-I145,Phase 2 Trial of Gemcitabine and Paclitaxel in Germ Cell Tum,
B1Y-MC-X015,PROZAC IN PATIENTS WITH PANIC DISORDER,
F1D-US-A028,"Cognitive Effects of Olz:  Comparison w/Hal, Cloz, & Risp.",
H5Z-LC-LUAE,Phase I trial of R-fluoxetine at doses above 40mg per day,
"3436",Validation study for SPET scanner,
F1D-MC-X132,Efficacy of Olz in the Treatment of Obsessive Compulsive Pts,
B9E-XM-JHPP,"Phase II, Gemcitabine & Taxol,  Advanced NSCLC",
B3D-LC-GHBI,Absolute Bioavailability (SQ),
B1Y-MC-X189,Effects of Phentermine on MAO A Concentration in Human Brain,
B1Y-MC-X192,Effect of Fluoxetine on Psychoactive Neurosteroids in Panic,
B9R-US-X025,EFFECT OF GH REPLACEMENT ON PROTEIN METABOLISM IN PATIENTS,
B9R-US-X026,INTERMEDIARY METABOLISM OF GLUCOSE IN GROWTH HORMONE DEFICIE,
H6D-EW-LVAS,Single Dose Study Comparing Diabetics and Healthy Subjects,
J4A-LC-EZZC,Dose Escalation study in active RA patient,
B9E-UT-O415,Gastro/Esophageal: Gem/Cis +/- vitamines (Folic acid + B12),
B9U-MC-AZDA,LORABID VS ZITHROMAX: SINUS TISSUE PENETRATION,
H7R-LC-GCBU,Drug-Drug Interaction Study (LY/sulfonylurea),
F1K-US-V012,Inhibition of bacteria induced lymphocyte apoptosis,
H7T-EW-TAAP,CS-747:ECG study,
H7T-EW-TAAR,CS-747: Warfarin,
"9019",Stage IIIa/b NSCLC Alimta/Carbo/XRT,
H8Q-MC-GQAF,SERM GYN 1/ LY2066948 Phase 1b - POC 30 Day Dosing,
"9109",Phase 4 Cialis in  Patients Unsatisfied Sildenafil Response,
H6D-SB-B004,Cialis Observational Study Germany,
B9E-SB-O405,Kosten und Res. bei chemo. NW im KH,
F1K-XM-EVCW,Multidisciplinary medical intervention after ICU discharge,
B4Z-MC-X008,Pilot Study of Atomoxetine to enhance Cognition in Patients,
B9E-MC-V265,Pharmacogenomics nalyses of Patient Tissue Samples(GEM),
"9236",Local OS Trial with Humapen (PATH),
F1D-EW-E010,LY170053:OPEN LABEL SAFETY AND DOSE RANGING STUDY,
B9E-BL-B003,Pospective OS in Advanced NSCLC,
"9291",Zyprexa IIT placeholder,
"9334",DURAPAC,
I4E-IE-W930,CA225-260: PhII-Combined Modality Therapy in pts w/HIV-Anal,
B9E-MC-X046,Gemcitabine for Indolent Non-Hodgkins Lymphoma in Patients,
I4D-MC-JTJI,Ph Ib-Chk-1 InhibII + Cis or Cetux + XRT - H&N,
I4D-MC-JTJJ,R-Ph II/III- Chk-1 Inhib II - Anal,
I7E-AV-E013,AV-1451-EXIST-013,
I7C-MC-FEAC,BMP-6 CDK MAD Study,
I7E-AV-E001,"18F-AV-1451-EXIST-001",
"16107",Ph2B dose ranging study in Alzheimer Disease Psychosis,
H3E-JE-O084,IIT-CDDP+Pem+salazosulfapyridine PhaseI,
H3E-MC-B020,"2014-787-2:PhysDecisionMaking&Attitudes-NSCLC-Maint-PhySurve",
I7E-AV-E039,"18F-AV-1451-EXIST-039",
I8L-MC-IXAC,URI Biochaperone Phase III T1D Pump,
I4E-US-X010,CA225-296 Poetic09-014 RT+Cetux then Irinotecan+Cetux childr,
I4E-US-X014,CA225-241 E3205 PII Cetux+Cis+5FU+RT ImmunocomPTw Anal CA,
H3E-US-X089,PHII Eval Pem Responses MTAP gene met Urothelial Bladder Ca,
B9E-SB-V022,Interaction of gemcitabine and MTA in human cancer cell line,
B9E-VI-O060,"Phase II, Gemcitabine,  Pancreas Carcinoma",
H6D-EW-LVBV,Interaction study with Aspirin,
B9E-VI-O074,"Phase II, Gemcitabine & Cisplatin, In Adv. Cervical Cancer",
"3821",Healing of lower extremity ulcers in diabetic patients,
"3838",ReoPro in angioplasty,
F1D-MC-HGIJ,Nizatidine for Prevention of Olanzapine Assoc. Weight Gain,
"3869",ReoPro in Acute Coronary Sydrome,
B1Y-FP-HCKD,Patient satisfaction with antidep. treatment fluo vs parox,
F1D-MC-A038,Effects of OLZ on Cocaine Self-Administration,
F1D-CA-O036,Does Zyprexa normalize incentive learning in schizophrenics,
F1D-BX-O041,Effect of Olanzapine vs typical antipsychotics on cognitive,
H3E-MC-JMEC,MTA + XRT new schedule,
H5Z-LC-LUAL,R-fluoxetine Bioequivalence Study,
"4128",R-fluoxetine Drug Interaction Study 2,
"4169",COMBINATION GEMCITABINE & RADIOTHERAPY IN HEAD AND NECK,
B1Y-GH-O014,Fluoxetine in treatment of GI patients with depression,
B9E-MC-V042,Use gem as standard for analysis of nucleotide pool,
"7828",special access scheme,
H6L-FW-LFAK,Midazolam Drug Interaction,
"9391",Inhibition of Platelet P2 1/12 Receptor,
"9394",Local Observational Study:  Effectiveness and Compliance,
H7I-PU-O002,Glucose tolerance in drug-naive patients with schizophrenia,
F1J-US-X003,Duloxetine for Social Anxiety Disorder:  Prediction of Long,
B9E-SI-S371,phase II Gem Cis single vs. split dose in LA or MBC,
"9602",Daily Dosing for PRN Non-Responders,
"9617",Type 1 efficacy,
"9618",Compliance protocol #2,
"9661",Second study- dosing study in suboptimal responders,
B4Z-US-X027,Nurse Telecare Augmentation for Treating Attention,
H9Q-EW-LHBA,Atomoxetine V: SDSS/MDSS,
"9723",IIT-Place Holder B9E-MC-S307 Pujade TCG / AGO-GINECO,
F1D-CA-S059,Zydis vs. SOC for acute agitation,
H6Q-MC-S005,Ph I-Neo-adjuvant tx w Enza w/tissue samples -Colorectal,
F1J-IT-O010,Neuroplastic events in response to Duloxetine,
"9928",Evaluation of fracture reduction vertebroplasty,
"9999",CB1 Agonist Challenge,
F1J-JE-1005,LY248686:PHASE I STUDY(MEAL-ENTERIC GRANULES),
"1632",LY333013-MC-xxxC Rheumatoid Arthritis Phase II/III,
I8P-MC-OXAC,"Ph2 trial for T2DM, parallel, 24 week treatment with compara",
I4T-MC-JVDP,Ph III - Ramucirumab+Pembro v. Pembro NSCLC 1L PDL1>50%,
I6T-MC-AMAE,Relative Bioavailability in Healthy Subjects of Lyo vs PFS,
F3Z-MC-IOQQ,U200 in pumps,
I4V-MC-JAHJ,FRD: R-Ph III - Baricitinib - Acute/Chronic GVHD Treatment,
F1D-MC-HGGT,Olanzapine vs Quetiapine in the Treatment of Schizophrenia,
"16569",C14 in Healthy Volunteers,
"16626",JIA,
H3F-US-X006,Closed Loop Glucagon adminstration for automated Treatment,
I6T-MC-AMBC,Ulcerative Colitis Pediatric PK exposure,
"16827","2016-4569:PRO Dev to Measure Pain Symptoms in Pts w/Chron's",
I9O-MC-AABA,PH20/Halozyme-single dose and impact of dose level,
I4T-MC-JVDS,Ph2+Ram+Alt Backbone-1L Gastric Cancer,
I9S-MC-BTAA,FHD SAD HV,
I9U-MC-JKEB,RBA PK Bridging study,
H5N-EW-GFFB,"Dose ranging single dose PK and PD, SC use in type 2",
I5Q-MC-B003,Pregnancy Database Study (USA database) ,
F3Z-MC-IORG,TANGO Late Feasibility CT3 ,
F3Z-MC-IORM,TANGO T2 U200 Pivotal,
I6T-MC-AMBQ,PsO BE study Autoinjector HV,
"17275",AD preclinical combo trial,
I9R-MC-BSDH,Basal Insulin Acylated T2DM Bolus,
B9U-US-AZDH,BIOEQUIVALENCE OF LORABID CHEWABLE IN PEDIATRIC SUBJECTS,
I4V-MC-E004,CHOP Natural History Study-AGS,
H4F-MC-EWAD,"A PHASE II RANDOMIZED, OPEN LABEL ANGIOGRAPHIC TRIAL EVALUAT",
H4S-FP-EWAN,ANGIOSCOPIC EV. OF REOPRO IN PATIENTS WITH UNSTABLE ANGINA,
I4V-MC-JAJF,SLE Pediatric Trial-core treatment plus LTE,
B9R-MC-B005,Phase IV Somatropin US Observational study ,
J2G-OX-Y021,PhI-RET Inhibitor-MTC,
J2G-OX-Y032,PhI-RET Inhibitor-MTC,
J2G-OX-Y036,PhI-RET Inhibitor-PTC,
H7I-MC-S017,Cleveland Clinic Exploratory Study,
F1D-MC-HGIU,Olanzapine in juvenile mania,
"4408",AD Efficacy Study,
B1Y-SB-4008,FLUOXETINE SINGLE DOSE NEUROENDOCRINE EFF VOLUNTEERS,
B9E-MC-S151,Ph II study -standard vs dose rate constant gem in hepatoma,
F1D-PU-S006,Switching Schizophrenic patients from Haloperidol to Olanzap,
B1Y-SB-9028,"FLUOXETINE VS PLACEBO IN MDD, VIGILANCE & PERFORMANCE PARAM.",
B9E-FP-O149,ITT-PULMONARY CANCER NSCLC WITH SURGERY,
F1D-KL-O079,Olanzapine Vs Risperidone on hallucinstion,
B9E-MC-V069,Determine max tolerated dose of gem in comb w/oxal in pts w/,
B9E-MC-S164,Ph I/II Gem use in insitu bladder cancer refractory to BCG,
B1Y-MC-X205,PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION,
"4769",Vasomotor Symptoms and Endothelial Function,
B9E-SB-O164,Gemcitabin + 5FU + Irinitecan in GI-CA,
"4834","Multiple dose, dose escalation",
"4839",LY293111in Pancreatic Ca,
B9E-MC-X286,"Ph2 Gemzar, CI 5FU,Thalidomide in Metastatic Renal Cell CA",
B9E-MC-S171,Ph II - Carbo-->Docetaxel or Docetaxel/Gem - Ovarian,
F3Z-MC-IOHZ,"China local registration study, single arm transfer",
J2A-MC-GZGD,MAD PK Test Formulations HV,
"1779",Safety and Pharmacokinetics of the Tablet in Healthy Elderly,
I4T-MC-JVDU,Ph1-Ramucirumab-Advanced Solid Tumors,
J2D-MC-CVAC,PK,
J2G-OX-Y169,RET Inhibitor,
B5K-BP-0017,INSULIN DELIVERY USING A NEW LILLY 3.0ML PRE-FILLED PEN DEVI,
J2T-DM-KGAO,Lebri for pts w/ uncontrolled asthma on inhaled corticostero,
J2T-DM-KGBE,TNX-650 In Subjects With Refractory Hodgkins Lymphoma,
J2G-OX-Y208,RET Inhibitor,
J3H-MC-GZNA,FHD SAD/MAD HV,
H3E-MC-JMBT,Phase II Anthracyclline/Taxane refractory MBC,
I4V-MC-JAJI,Olumiant AD Chronic Hand Eczema,
B9E-MC-I061,PHASE I  OF GEM AND TAXOL FOR ADVANCED MALIGNANCIES,
I6Q-MC-BIFG,EET Injection Site Pain Buffer Matrix HV,
I4T-MC-B014,Ph4-PMSS of Cyramza in China,
I9Y-OX-JDHH,LOXO-IDH-21007-Ph1-IDH1-Hepatic,
"4996","LY900002 MDSS, DOSE/FORMULATION OPTIMIZATION",
"5117",LY333328 VRE Endocarditis in a Rabbit Model,
H3S-FP-A004,RALOXIFENE AND ATHEROSCLEROSIS,
B3D-LC-GHBN,Cardiac Conduction and Repolarization,
"5217",Olanzapine-ETC combination for resistant depression,
"5247",Phase Ia-Dose Escalation,
B1Y-VI-E051,FLUOX VS CLOMIPRAMINE MAJOR DEPRESSIVE DISORDERS,
B3C-BP-JQAB,CLIN. & PHARMACOKINETIC EVALUATION OF LY309887 ADMIN. WEEKLY,
B3M-KL-AJBR,Clinical outcome and Compliance for acute bronchitis,
B9E-SB-O216, Gemcitabine + Irinitecan + Carboplatin in SCLC,
B9E-SB-V123,Gemcitabin + Anti-VEGF-Antibody,
F1D-XM-O114,Neuropsychiatric disturbances in alzheimer,
B3M-HH-AJAL,"CEFACLOR AF SOLID, DRUG MONITORING",
F1D-SO-O118,Conventional neuroleptics vs olanzapine in schizophrenia,
F1D-MC-X203,Pharmacotheraphy of High Risk Bipolar Disorder,
F1D-EW-HGJW,PET Imaging Study of olanzapine pamoate monohydrate (depot),
H3S-BX-S005,Effect of EVISTA on Generalised and Periarticular Bone Loss,
B9E-FP-O240,IIT-Gemzar in the hodgkin disease relapse,
"6338",Clin Pharm Renal Study,
I9Y-OX-JDHI,LOXO-IDH-21008-Ph1-IDH1-Renal,
"18399",Placeholder DDI Methotrexate study,
"18406",DDI Oral contraceptive study,
"18464",Drug Drug Interaction,
J2Y-NS-I001,Recsectable ,
"18632",DDI - Oral Contraceptives - Placeholder,
I6T-JE-B002,Post Marketing Safety Study of Mirikizumab ,
"18660",Definitive BE Study HV,
F3Z-BP-O006,Impact of Type 1 Diabetes on Day to Day Living,
I7E-AV-_A25,Tauvid Diagnostic Thinking,
"1882","Male studies, Klibanski",
B1Y-IT-M002,FLUOXETINE MAJOR DEPRESSIVE DISORDER,
B9E-MC-I065,"GEMCITABINE, PACLITAXEL, AND CARBOPLATIN IN UROTHELIAL CANCE",
"1948",PP Dosing: Pt Function/Lifestyle by Age (>55 yrs),
B9R-MC-GDEI,Humatrope: phase II in elderly patients with burns,
H4Z-LC-SDAC,Multiple Dose Study in Healthy Postmenopausal Women,
B9E-MC-S030,Gem vs Gem/Tax in Anthra refr breast-S030,
B9E-MC-JHQI,"Ovary- Gemcitabine vs Topotecan, 2nd line, Ph III-- JH43",
F1J-US-HMCB,Duloxetine vs. Placebo for treatment of MDD with pain symp.,
B5K-SN-S003,Switch from OHAs to Humulin 30/70 : Observational study,
H8D-MC-EMBB,PPAR-alpha in patients with artherogenic dyslipidemia,
B9E-CP-O340,ph I-II comb treat w Xeloda + Gem in advanced colorecta canc,
B9E-SU-O250,"Phase II study, gemcitabine and paclitaxel IIIB, IV NSCLC",
"5849",Drug Interaction Study 2,
F3Z-XM-S014,EXTENSION OF QUESTIONNAIRE VALIDATION -HYPOGLICEMIC FEAR-,
B7A-XM-O001,PILOT STUDY- EFFICACY SCREENING PROCEDURE -MIDRIATIC machine,
B9R-JE-K03A,JP hGH p-III/IV Adult GHD,
B9E-SU-O267,"Phase II Gemcitabine, Paclitaxel,Her2 Metastatic Breast CA",
B9E-MC-S271,R Ph III-EC sequence Taxane vs ED sequence  Gem+Tax-Breast,
H3E-MC-JMFB,"ALIMTA x3 ->GEM x 3 vs GEM x3 -> ALIMTA x 3,1st Line",
"6162",Dose escalation,
B7A-MC-MBCW,Peripheral neuropathy with symptoms patients w/ diabetes II,
H3E-MC-JMFJ,Ph 2 ALIMTA Pharmacogenomics Follow-Up to Breast Study,
F1J-LC-HMCC,CYP1A2 STUDY,
H4S-US-X014,Washington Radiation in Diabetics,
F3Z-BP-O051,Effects of acute hyperglycaemia on cognitive function,
H4Y-MS-LJAI,"200 mg in migraineurs during and outside a migraine attack",
B9E-MC-S008,Ph lll Gem+Cis+Nav vs Gem+cis vs gem+Nav then ifos+Nav/NSCLC,
B9E-US-S009,Ph III G+Tax vs. G+Carbo vs. Carbo+Tax,
B9E-MC-S051,Ph III Gem + Carbo vs Etoposide+Cis in SCLC,
B1Y-LC-HCIF,PINDOLOL-FLUOXETINE MULTIPLE DOSE SAFETY STUDY,
H5P-MC-BWWD,RA PATIENTS WHO FAILED 2ND LINE DRUGS,
B1Y-MC-X154,WEIGHT LOSS COMPARISON BETWEEN A FLUOX/PHENTERMINE REGIMEN,
F1D-MC-X038,ZYPREXA IN SOCIAL PHOBIA,
B1Y-MC-HCJE,Fluoxetine vs placebo in childhood/adolescent depression,
H3Z-MC-JNAI,Phase-I Combination study: LY295501 + Mitozantrone,
H3Z-MC-JNAX,Phase-I combination study with LY295501 + MTA,
B1Y-MC-HCAQ,FLUOXETINE IN TREATMENT OF DYSTONIA PATIENTS,
F1D-MC-X108,A Pharmacoepidemiological study on the longitudinal use of a,
B9E-MC-S088,Gem+Carbo post AT/Breast ca,
B9E-MC-S090,Ph I/II Gem+Oxaloplatin / Breast,
B9E-MC-S097,Gem vs Capeciabine / Breast,
B9E-MC-S098,Gem+Dox post Taxanes / Breast,
B5K-MC-I007,DIABETES PREVENTION TRIAL (PART B - ORAL ANTIGEN PROTOCOL),
B9E-MC-S285,Ph II - Intravesical Gem - Bladder (pharmacokinetic),
F1K-US-EVCE,Safety Evaluation in Oncology Patients with Severe Sepsis,
B5K-FW-O009,Effect of fatty acid infusion on response to insulin,
B9E-MC-X341,PHII Bladder preservation using limited surgery-Gem+Tax+Carb,
B5K-MC-X004,A COMPARISON BETWEEN HUMULIN U AND HUMULIN N IN NIDDM,
B5K-CA-O010,Does an Interactive Ins. Adj. Prog. for the PC Improve Care?,
B5K-RC-IBDX,INSULIN DELIVERY USING HUMAMIX MODEL 1530,
F1D-AY-S027,Safety of IM Psychotropic Medication in Acutely Agitated Pts,
B9E-SB-O297,Gemzar + 5-FU/FA + Cisplatin in oesophagial carcinoma,
B5K-SB-IBOJ,HUMULIN APPLIED IN PENS,
"6546",Pharmacogenomic study on early stage NSCLC,
B5K-SE-9384,HUMULIN CLINICAL EXPERIENCE EVALUATION; OPEN LABEL,
F1K-SB-V002,Antiinflammatory & Profibrinolytic Mech. of Action of rhAPC,
B9E-IH-O303,GC MBS Phase II Study,
B3M-GH-S029,Ceclor SR for Treatment of Acute Sinusitis,
H6M-MC-LDAQ,Parkinson's Tolerability Study,
F3Z-SP-IOMC,MID OF INSULIN LISPRO+LM VS MID OF REGULAR+30/70 IN DIAB. I,
B9E-MC-X064,PHASE 1/2 STUDY OF GEMCITABINE AND RADIOTHERAPY,
F1J-FW-SBAS,Duloxetine- Detrol Combination,
B1Y-MC-HCED,FLUOXETINE V PLACEBO:MAINTAINING WEIGHT LOST PRE,
B9R-MC-GDFK,Bridging study for larger Humatrope vial size:Bioequivalency,
"2724",LY354740 in Special Population Study,
"2733",Device Bridging Study,
B9R-MC-GDFE,Adult replacement PRT - Emerging Market Countries,
H4A-MC-XBBB,IV vs. Azole in Candidemia,
"2886",Invest Initiated  Block &Strategic Support Studies -Cefaclor,
B1Y-MC-HCFD,FLUOX/NORTRIP:TREATMENT OF MDD IN CARDIAC PATIENTS,
H3E-MC-JMDO,"ALIMTA+ CPT-11, 2 cohorts, Phase I/II, 2nd line CRC",
"2951",Raloxifene - Cardiovascular Endothelial Function,
B9E-MC-X160,"Gemcitabine, 5-FU, and Folinic Acid in Gastric Cancer",
B9E-MC-X168,"Gemcitabine, Carboplatin, Paclitaxel, and Oral Etoposide",
H4Q-FP-A008,LY333328-GENTAMYCIN COMBINATION VERSUS VANCOMYCIN-RESISTANT,
B9E-MC-X172,Gemcitabine and Docetaxel in NSCLC,
H3S-MC-GGJD,Raloxifene 60mg in pre-menopausal women,
B9E-MC-X140,Gemcitabine and Mitomycin-C in Breast Cancer,
"6772",Adolescent and Primary HSV,
"6774",Low Frequency of Recurrences,
"6779",MOA Labeling Study,
B9E-MC-S296,Bladder Cancer  Placeholder,
"6852",Drug Interaction - Probe Drugs,
B9E-KL-S304,Gem-Navelbine  OS,
H8E-MC-KBAB,Roll-over Study 1423-RESI,
H6D-EW-LVER,Hepatic Impairment,
B9E-MC-I028,"PHASE I STUDY OF GEMZAR, LEUCOVORIN, AND 5-FLUOROURACIL",
"6978","The risk factors for psychotic inpatients with sudden death,",
H6D-EW-LVEV,LY450190 - Ketoconazole - Ritinovir drug interactions,
"7114",G+Taxol+Herceptin vs. Taxol + Herceptin Breast Cancer,
H3E-MC-S035,Placeholder Trial,
B3D-MC-GHCG,Commercialization trial for label change,
"7183",Placeholder for new Gemzar IITs in 2002,
F1D-SB-O188,Retrospektive Beobachtung d. Aggressivitaet v. Massregelvoll,
"7264",Placeholder 1 for local PTH trial,
"7286",IIT placeholder for Evista,
H6E-EY-S004,Egyptian Observational Study,
B9E-XM-O336,Clinical study of Gemcitabine and 5-Fluorouracil (5FU) in co,
F1D-UT-O023,Olanzapine in Gilles de la Tourette,
"3128",Bioequivalence of Humulin for formulation changes,
F1J-MC-SBBA,Naturalistic Health Outcomes in a Managed Care Setting,
B9E-MC-S115,Ph II Gem + taxol - 1st line Bladder; Jun98SE107,
B1Y-MC-HCJV,Health Economic Study (Tosca),
"3247",Olz in tx of apathy syndrome in pts recvg SSRIs,
H3S-JE-107J,PK: Mutiple dose,
B9E-JE-N12D,JP gem P-II NSCLC w/ TXT,
H4Y-MC-LJBG,Encapsulated sumatriptan comparator,
"3337",Oral Delivery Phase III,
B4G-UT-O007,Pergolide Early de Novo Therapy in PD,
"3385",Smoking Cessation,
B1Y-MC-X019,FLUOXETINE VS PLACEBO FOR CHRONIC HEADACHE PROPHYLAXIS,
B5K-FW-IBEU,Special Conditions Impacting the Bioavailability of PI,
F1D-US-A022,Olanzapine Attenuation of Chronic Haloperidol-Induced Sponta,
"3656",Food Effect Study,
B9E-TW-S140, gemcitabine plus doxorubin in hepatocellular carcinoma,
B9E-BP-O085,"PH II, GEMCITABINE PLUS CARBOPLATIN IN TCC",
F1D-US-X167,Efficacy of Olanzapine for the Tx of Failure to Thrive in a,
H4S-BP-O044,RADIAL-Feasibility of day case angioplasty,
F1J-FP-SBBY,Efficacy & safety of Dulox UI vs placebo,
"7395",Atomoxetine pre-launch experience trial,
B9E-MC-JHEX,GEM + CDDP VS CDDP ALONE IN LOCALLY ADVANCED OR MET. NSCLC,
B9E-US-X373,Ph II rand study Gem + Carb 2 diff dose sch pts w/ rec Ov CA,
"7504","24 Hour Lantus Profile",
B9E-MC-JHFR,PHASE I/II STUDY OF GEMCIT. & VINORELBINE IN ADVAN. BREAST C,
B7A-SB-S002,Pilot study for evaluation of DR staging tool,
"7539",Zyprexa IIT placeholder,
"7584",Guinea Pig Trial No. 1-Resiquimod,
B4Z-CA-LYCS,Open-Label Atomoxetine Trial to Evaluate Academic Outcome,
"7689",PKC Local Trial Placeholder,
B9E-MC-X043,TWICE WEEKLY GEMCITABINE & RADIOTHERAPY IN PANCREATIC CANCER,
"7742",Evista SWEET OS study in Asia (previously called THE),
"7744",Gemzar Observational (ACTION),
F1K-PL-O008,Efficacy and Safety of Xigris in Cardiosurgery pts.,
F1K-PL-O009,Observational study in burned pts with severe sepsis.,
B9E-MC-V206,Using gemzar to test PPAR-gamma agonists,
"7912",Gem/Carbo/Paclitaxel as Neo Adjuvant in NSCLC,
B9E-FP-O088,IIT- PHASE 2B  NSCLC NON RESECTABLE (GIP),
B1Y-MC-X085,THE 5-HT TRANSPORTER:  FUNCTION & EXPRESSION,
H5N-EW-GFFG,Multidose phase 1b for LCS formulation,
B9E-MC-V031,Study of pancreatic cell lines & gemcitabine sensitivity,
H3S-SB-S001,Marketing Surveillance - Observational Trial,
H6Q-LC-JCAC,"Phase I Trial, Multiple Dose in Healthy Subjects",
B1Y-ME-0004,FLUOXETINE: EFFICACY SAFETY TOLERANCE IN MAJOR DEPRESSION,
H4S-SN-O005,REOPRO ASIA PACIFIC OBSERVATIONAL REGISTRY,
B3M-GH-S022,Ceclor vs Velosef in treatment of pharyngotonsillitis,
B9E-UT-O124,Phase II trial of gem and epirubicin in relapsing ovarian ca,
H4S-SB-O006,Pre-Hospital Administration of ReoPro in Pts. with  UA,
B9E-BX-O132,GEMCITABINE + CISPLATINUM IN ADVANCED NSCLC,
B9E-MC-X274,Phase 2 Gemcitabine and Mitoxantrone for Relapsed HD and NHL,
F3Z-VI-IOID,Mimicking a Multiple Injection Regimen with Insulin Lispro M,
A6J-PK-V012,Surveillance of MRSA in Pakistan,
B9R-FP-GDFS,High dosage in prepubertal children with partial GHD,
F1D-US-X195,an open label study of the efficacy of olz in the reduction,
B9E-MC-S192,"1st line-Ph II Gem+Capecitabine - Breast",
"7837","Comparasion Study Duloxetine,Reeboxetine & Sertraline",
B9E-ME-S331,Chemotherapy in bladder transitional cell carcinoma,
B9E-PL-O356,Perioperative sys. chemotherapy in pathologically N+NSCLC pt,
B9E-SP-0025,GEMCITABINE+DOXORUBICIN PHASE II IN ADVANCED BREAST CANCER,
B9E-MC-S351,Ph I/II PVAG 1st line adv HL,
H4S-US-X021,Eff. of ReoPro on Inflm. Markers and EPC in pts undgoing CI,
F1D-CA-O212,Early Psychosis Intervention Programme,
B9E-VI-JHMC,PHASE II: EMCITABINE IN STAGE III & IV NSCLC.,
B9R-CA-C034,HUMATROPE DOSAGE IN PUBERTY: GH DEFICIENCY,
B9E-MC-S339,Ph II Perioperative Chemo Gem + Cis Node Positive NSCLC,
H4S-MC-X022,Pred. of CK-MB Release During Successful Stenting,
B9R-IT-GDDP,HGH AND BONE METABOLISM IN PEDIATRIC GH DEFICIENT PATIENTS,
H6D-EW-LVFS,Ly450190 - ethanol,
F1J-BI-SBCE,Urge Registration study US,
"8296",PPAR Co-agonist IV -Dyslipidemia Proof of Concept Study,
B9E-US-X399,Ph III Cisplatin/Paclitaxel vs Cisplatin/Gem in CA of cervix,
H3S-US-X027,An Observational Trial of HRT Discontinuance,
B9E-MC-S196,Gemzar standard inf + chemo vs fixed dose inf. + chemo(NSCLC,
B9E-MC-S210,Ph II Gem + biotechnology drug -  Pancreas,
F1J-JE-324G,JP dulo P-III elder pts depression Shionogi,
B9E-MC-V081,Study interaction of gem w/mammalian replication enzymes,
B1Y-SZ-IS36,ASSESS EFFICACY AND SAFETY OF FLUOXETINE IN DEPRESSION,
"4850",LY355703 Combination trial,
"4851",LY355703 Combination trial,
B9E-MC-V090,Compare cytotoxicity of gem in anticancer drugs w/anticancer,
B9E-MC-X296,Ph2 of Neoadjuvant chemo.w/gem/paclitaxel in early NSCLC,
"4900",Pio vs. rosi in subjects with type 2 DM & dyslipidemia,
B9E-CO-S178,Study Ph II Gemcitabine +Cisplatin in NSCLC stages IIIB & IV,
"4932",Lower Dose Bioequivalence Study,
B1Y-UA-0001,FLUOXETINE/AMITRIPTYLINE MAJOR DEPRESS DISORDER,
"4958","Humalog Use in Insulin Resistant, Obese Patients (Type 2)",
B1Y-UA-0003,FLUOXETINE V MIAUSERIN IN CARDIAC COMPROMISED,
"5066",Duloxetine Depression,
B1Y-UT-0387,FLUOXETINE EFFECTS GASTRIC ACTIVITY & EMPTYING,
"5105",MGlur2 - Oral Contraceptive Interaction,
H3E-MC-JMGW,"Ph III, ALIMTA + Adriamycin vs FAC in Breast Cancer",
B9R-MC-GDCK,HUMATROPE VERSUS ESTROGEN IN TURNER'S SYNDROME,
H8T-FW-IRAB,Superfine Humulin Insulin (NDP 2 vs NDP 1 vs NPH),
B9R-MC-GDEE,HYPOPITUITARY CONTROL AND COMPLICATIONS STUDY,
F1D-US-X246,Olz in the treatment of child and adolescent stuttering,
B4Z-FP-A002,"Motor activity, impulsivity and attention in the rat",
H4Z-MC-GJAQ, Particle Size (ClinPharm),
H5O-BD-G3AB,"MDSS Isoproterenol test,FFA/Glycerol, Hood Calorimetry",
B9E-MC-S352,"RPh 2, Surgical Resection +/- pre-operative chemo in NSCLC",
B9R-MC-X007,GH-INDUCED CHANGES IN BODY COMPOSITION & LIPOPROTEINS,
"8690",Ruboxistaurin DMC Outcomes Trial,
"8696",Intensive Mixtures Therapy vs glargine-kidney/vascular fcn,
"8766",Ph I/II - ALIMTA + Oxaliplatin + ASAP - CRC,
H3E-MC-X047,"Ph I, 2nd Line ALIMTA + Tarceva in NSCLC",
B9E-IT-O441,GEMCITABINE INTRAVESCICAL IN BLADDER CANCER,
B9R-UT-GDDL,HGH REPLACEMENT IN ADULTS IN REL. TO DIAGN. CRITERIA OF GHDS,
"8867",a-beta ab III Biomarker study #2,
"8896",Placeholder with Humalog - new IITs,
F1D-US-I033,Rapid Dosing of Olz for Stabili. of Psychosis and Agitation,
H4S-US-X009,Angioplasty vs thrombolytic therapy for AMI in the elderly,
B9E-SB-O174,"Gemcitabin, 5FU, Oxaliplatin in gastrointestinal carcinoma",
H3S-SB-GGKI,Prevention of Glucocorticoid Induced Osteoporosis,
B1Y-VI-3001,FLUOXETINE CLINICAL EXPERIENCE PROGRAM IN POLAND,
B9R-SB-O007,Daily height measurements in children with GHD,
B9R-MC-GDGL,Flow Rate Study for Pulmonary hGH,
H3S-US-X018,phytoestrogen and raloxifene effects on endothelial reactivi,
H6N-BD-LEAF,MDSS of LY451395 in volunteers,
"5517","iv proof of concept in Migraine,  LY293558 & pb as controls",
F1D-UT-O112,Sexual Dysfunction in Adolescent Patients with Schizophrenia,
B9E-JE-V233,p53 gene therapy in ovarian carcinoma cell lines,
B3M-SE-1013,CEFACLOR CLINICAL EXPERIENCE EVALUATION STUDY,
H4S-SZ-O023,TAPE 1-Abciximab/reteplase combo in pulm. embolism,
H4S-WF-O022,Emergency room vs Cath-lab. Abciximab in Primary PCI,
H6P-BX-S001,Motor and Cognitive Deficits in Dysthemic Patients,
H7R-LC-GCBA,PPAR-gamma SDSS-MDSS in Healthy Volunteers,
B9E-US-S255,Std Gem vs FDR Gem early/mult relapse plat res. Ovarian Ca,
B9E-BX-JHSR,Phase 1 study combining Gemzar with low dose radiotherapy,
H7T-EW-TAAW,CS-747: Dose proportionality,
F1D-MC-X248,the incidence of new onset diabetes and use of antipsychotic,
B4Z-US-X022,Atomoxetine in Preschoolers with ADHD,
"8995",ALIMTA in Ovary - Pr Marty,
"9002",Placeholder for IITs (US),
H3E-US-X001,Alimta IIT Program/United States,
"9052",Placeholder for Forsteo (OSSO study),
"9063",JP ola Depot P-II,
"9093",Placeholder for Evista trials,
B4Z-EW-LYDF,Initiation of Atomoxetine following treatment with MPH,
H6D-ME-B008,Cialis ICR Regional Observational Study,
B9E-CA-O410,PhII Gem+Docetaxel vs Carbo+Taxol in Ovarian,
"9231",JP Arzoxifene  P-1 MDSS,
B3D-US-X008,Bone Sparing by CA salts w and w/o Extra Phosphorus,
F1D-MC-X260,Atypical Antipsychotic Medication in Anorexia Nervosa,
F1K-MC-S007,Effects Recombinant APC Neutrophil Endolethelial Interaction,
F1D-BP-O181,Patients swtching from typical depot to oral atypicals,
F3Z-SU-O063,Epidemiological Analysis of Type 2 DM Complication - PR,
F3Z-US-X019,Finding the Missing Millions with Unrecognized DM,
H3E-US-X008,Ph II Gemcitabine + Alinmta pts. w/ advanced urothelial CA,
B9E-PK-O418,A Phase II study of Gem+Cis as first line chemotherapyin MBC,
H4S-FP-O059,ABOARD,
H6D-MC-X001,Validation of the Model for Quantifying Myocardial Ischemia,
F1D-MC-HGME,Zyprexa IM Trial in Pediatric Patients,
B4Z-US-X023,Effects of Virtual Reality Driving Performance in ADHD Adult,
B4Z-US-X026,Stratt Tx Adults w/ADHD NOS poor response stimulant THERAP.,
H3E-MC-JMHO,"RPh III, 1st line  ALIMTA/Carbo vs Etop/Carbo in SCLC",
F1D-MC-A004,OLANZAPINE EFFECTS ON FOS-LIKE PROTEINS,
H7L-MC-MDAA,Genotyping for PPAR Platform,
"9762",Placeholder for SBCB local resources,
H6U-MC-X004,Pharmacoproteomics POC,
"9790",Particle Size BE Definitive (placeholder),
F1K-AY-A013,rhAPC for acute lung injury from smoke inhalation in sheep,
H6Q-MC-S003,PK-Pharmacodynamic/Enzastuarin in Localized Breast Carcinoma,
H3S-MC-V009,Effect of raloxifene on ovarian cancer cell line,
H4S-CA-O027,Abciximab on Platelet P-Selectin & Leukocyte Mac-1 Expressio,
H6D-MC-LVED,ED Decision Phase Placeholder,
H6L-LC-LFAF,LY450139 Therapeutic Index Study,
F3Z-PL-O046,Humalog + NPH vs Regular + NPH after oral agent failure,
H6Q-MC-JCAL,Ph I Glioblastoma NCI,
B4Z-MC-LYBN,Adults with Depression,
"6072",Placeholder Olanzapine- Local Plan Spain,
"6084",Gem/Vinorelbine for CDDP-Resistant NPC,
F3Z-US-X011,"Prevalence of type 2 diabetes in youth in Douglas, AZ",
H3E-MC-S008,"ALIMTA + Taxol, 1st Line",
"6169",Miscellaneous IIT- Atomoxetine Spain,
"6260",Effects of Arzoxifene on vertebral fracture incidence i,
H6Q-LC-JCAK,Lilly Clinic Drug Interaction Study,
F1D-AY-O146,Healthy Lifestyle - Antipsychotic meds + Weight management,
"6373",GDEE Placeholder for Business Planning,
"6382",Drug Interaction,
"6462",Ph II - Gemzar + Carbo + Affinitak - Bladder,
B9E-MC-V140,Determine Toxicity of Gem to a dCMP Deam Mouse Colony,
F1D-US-X270,"Potential Tradeoffs between Metabolic Illness, Infecti Disea",
B9E-MC-X344,Ph II Study of Preop Chemo(gem+cis) & gem Chemorad in pancre,
H3S-PL-O022,"Comp. of Ral.,Tam.&ERT in PM Women",
B5Q-EW-E042,NIZATIDINE:TWO DOSES AGAINST RANITIDINE ACUTE OR,
"6617",Placeholder for Evista IITs,
B5V-MC-V007,CEFTAZIDIME RESISTANCE IN KLEBSIELLA PNEUMONIAE,
ZYY-LC-GCBE,Pilot Edema Study,
B3M-GH-O004,Bacterial Resistance Surveillance Study in Shan Dong Provinc,
"6848",Ph III Severe HTN,
B9E-MS-V174,geldanamycin+gemcitabine to enhance cytotoxicity,
B7A-MC-MBDE,Global Phase III for Neuropathy. Bridge to MBDD.,
B9E-MC-V176,Elanco Dog Study,
H4S-BL-O041,Intimal hyperplasia volume in coronary stent implant,
F1D-MC-HGKS,Olanzapine effects on Cognition,
"7056","Phase III, ALIMTA in 2nd line Mesothelioma pts.",
B9E-MC-JHBB,GEMCITABINE PHASE 2 IN HORMONE REFRACTORY PROSTATE CANCER,
"7110",Treatment Resistant Depression Health Outcomes Study,
B9E-MC-S325,Ph II Neoadj. Gem+Adria+Paclitaxel Pharmacogemic Breast,
"7148", IIT placeholder for Gemzar,
F1K-US-X001,Role of Protein C (Activated) in Early ARDS,
B9E-IH-O333,Phase II chemo. GC + carbo NSCLC before surgery,
"7287",IIT placeholder for Gemzar,
B9R-XB-O028,GH/IGF-1 transduction signals in human muscle,
F1D-FP-S043,Zydis vs amisulpride tablet in schizopnrenics in acute phase,
F1K-SB-S005,E/S of rhAPC in Pts w/ sepsis after bone marrow transplant.,
"7422",RAIM - SOHO like design (AO),
F1J-BP-S008,Local Observational Study of Duloxetine (DOHO),
B9E-BL-O341,NEOADJUVANT GEMCITABINE AND CISPLATIN BLADDER CA,
B9E-MC-JHGA,GEM+CISPLATIN VS MVAC IN ADV OR MET BLADDER CA (TCC),
"7592",Untitled IIT for 2003 in China,
"7603",Methods Placeholder,
"7696",gem-carbo-taxol versus carbo-tax in ovarian cancer,
B9E-SB-O350,Gemcitabine in Children with hematologic malign.,
"7740",IIt Forteo 2004,
"7850",Sunnybrook Fellowship,
B9E-PL-O358,Intravesical Gemzar-bladder cancer,
"7866",IIT Mayers,
"7875",IITs Bipolar-2004,
"8002",C14 Metabolism and Excretion Study,
"8004",Pet Scanning Study,
"8008",Canadian Obers Study of Transition from HRT to Evista,
H8O-MC-GWAA,Exendin-4 compared to Glargine in patients with Type 2,
"8117", Ppar-Alpha Pilot Formulation Bridging Study,
H4S-SB-O047,Kuecherer-Evaluation of microperfusion damange due to PCI,
B9E-US-X387,Pilot Study of Exisulind &Gem/Carboplatin Followed bu Exisul,
B9R-EW-GDDQ,THE HYPOPITUITARY CONTROL AND COMPLICATION STUDY (HYPOCCS),
F1D-US-X235,Menopause and Mental Illness,
H6Q-MC-JCAO,Phase II Study of LY317615 in Mantle Cell Lymphoma,
B9E-IT-O383,LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN BREAST CANCER,
H5N-MC-GFFS,Investigator Sponsored Pilot Study V8 GLP-1 in IBD,
"8405",Ph II ALIMTA/Carbo w/ XRT in neoadj NSCLC,
B9R-MC-GDBQ,HUMATROPE HYPOPITUI. CHILDREN NITROGEN RETENTION,
"8425",Ph I/II ALIMTA/Gemzar/Paclitaxel in Breast Cancer,
B4Z-MC-LYCQ,Acute Tourette's study #2 for registration,
"8443",Pilot Alcohol Dependence Study,
B9E-SB-O386,Gem plus CHOP14 as primary therapy for high grade NHL,
H7R-MC-GCCJ,Fat Distribution Study,
H9B-LC-BCDC,MDSS in RA patients,
H9B-MC-BCDD," POC study, RA patients, LY and etanercept, flare reduction",
H4Z-MC-GJAE,Comparison of Arzoxifene and Placebo in Early Postmenopausal,
"8563",MDSS 1B (Including Dosing Regimen Evaluation),
H3S-XM-O118,Analysis action Raloxifene: oxidative stress & prostacyclin,
F1J-MC-HMDP,MDD Pain Enriched,
"8636",RAIM Naturalistic Study,
F3Z-FW-IOOO,Glucose Clamp Methodology Study,
"8666",PET Imaging in Animals/Vasc. Flow,
B9R-MC-X016,EFFECTS OF SEX STEROIDS ON GH/LEUKEMIA-LYMPHOMA,
"8684",AKT-1 Animal Biomarker PET Study,
F1K-BX-B003,Patient Registry for Belgian Authorities,
B9R-MC-X017,USE OF GH IN THE TX OF OSTEOPOROSIS IN WERNERS SYNDROME,
"8713","2004 Preference",
"8747",Ph III 1st line ALIMTA +/- Gem in Leukemia,
B9E-IT-O444,GEMZAR COMBINATION IN OVARY CANCER,
B9E-IT-V238,GEMZAR INTRAVESCICAL IN TCC: PHARMACOGENOMICS STUDY,
"8876",mGlu3 antag II biomarker study #2,
"8887","""BS Replacement"" GAD Phase III BID #2",
"8963",Quality of Life in Breast Cancer,
H7T-EW-TAAT,CS-747: Heparin interaction,
B4Z-US-X011,Atomoxetine vs methylphenidate inhibition in cerebral cortex,
B1Y-CA-C018,FLUOXETINE: VS DOXEPIN IN CARDIAC/NON-CARDIAC MDD PATIENTS,
B1Y-XM-O032,Weekly Fluoxetine. Safety and tolerability.,
"9053",placeholder participation OBSZIM,
"9087",Placeholderstudy for Cymbalta AT 2004/5,
H6N-MC-LEAO,Phase 2b in Moderates,
F1D-MC-X251,Bipolar Disorder Center for Pennsylvanians,
H4S-MC-X023,ReoPro decreases Apoptotice Myocaridal Cell Death,
F1K-US-I002,Act.Protein C vs. Placebo for treatment of Acute Lung Injury,
F1D-EW-E009,HALOPERIDOL BIOAVAIL 5MG CAP (10MG FILL)(LY) V 5MG CAP (LY),
"9353",Egypt local affiliate obs trial Novapen - Humapen,
H3E-PL-S051,Neoadjuvant Alimta an Cisplatin in NSCLC (molecular profile),
"9362",Cialis: Oral dissolve study,
B9E-US-X428,"Ph I/II Gem, Carbo, & radiation stage III NSCLC",
B9E-US-X429,Ph II Gem&Cisplatin pts. w/ Adv. endometrial carcinoma,
F1D-US-A027,Prop. to Invt. the Anticholinergic Prop. of Olanz.,
F1D-PU-O258,Efficacy of typ.vs atypical antipsycho. in acute psycho.symp,
B4Z-US-X018,Pharmacological Treatment of ADHD in Young Children,
F1D-LC-HGAB,LY170053 C14:  DISPOSITION IN MAN,
H3E-US-X012,Ph I/II pemetrexed & oxaliplatin w/ radiation 4 adeno rectum,
"9611",LY451395 fMRI Alcohol Interaction Study,
B4Z-JE-LYDH,Japan study for patient 1501 from study LYBD,
H8A-JE-LZAI,JP A beta AB P-1 SDSS,
B4Z-CA-S014,Atomoxetine in adult patients with ADHD,
"9731",Placeholder for SBBS local headcount,
B9E-FP-O442,IIT-Preclinical Azria B9E-FP-O442 / IGR,
H6Q-LC-JCBC,Enzastaurin HCl Particle Size Study,
H6Q-MC-JCAY,Enzastaurin Interaction With Digoxin In Cancer Patients (Aep,
H6D-MC-O004,Prevention of ED Post Radiotherapy for Prostate Cancer,
F1D-MC-HGAP,FIXED-DOSE OLANZAPINE VS PLACEBO IN SCHIZOPHRENIA,
H6Q-MC-JCBJ,R-Ph 3-Enza vs placebo-pts w/DLBCL in 1st remission-Lymphoma,
F1K-MC-EVDE,PC Profile Study in Early Severe Sepsis,
F1D-US-A035,Defining the Regional Effects of Olanzapine in Brain,
B1Y-CA-C031,FLUOXETINE/PLACEBO IN SEASONAL AFFECTIVE DISORDER,
"9948",Ph2 Alimta and Doxorubicin in 1st line tr-t of breast cancer,
H7L-IS-O003,the realtionship between endotherial and leucoyctes,
B5K-IS-O445,Microvascular Complications and Endothelial Function in T2DM,
H6Q-MC-JCBN,Ph III Enz+XRT+Temozolomide vs Placebo +XRT+temozolomide,
B5K-VI-B005,Observational HumaPen Study,
H3E-UT-O009,Phase I study with Alimta+ Cis concurrent RT in NSCLC,
"10051",Histomorphometric differences in teriparatide & strontium pt,
"10097",RBA,
B9R-IT-O039,Animal models for detection of GH abuse,
B9R-US-X040,ELISA assays,
H3E-CA-JMHU,Ph 1/2 Concurrent Pemetrexed/Cisplatin/Radiation in NSCLC,
H9Y-MC-UTAB,MDSS/Phase1b POC Study,
B4Z-JE-LYFG,JP atomo FG-BE study,
H3E-US-I005,Ph I/II Carboplatin & Alimta for recurrent mullerian malig,
H9P-FW-LNBC,NERI IV: DHPG POC study,
B4Z-UT-S017,ADHD + ASD placebo controlled,
H7U-MC-IDBH,IDAH Extension,
F1J-LC-HMEV,Duloxetine-Alcohol DDI at Steady State In Healthy Subjects,
"10556",Glucagon R Antagonist - SDSS Placeholder,
"10588",SPPARM (MDSS) in Obese Otherwise Healthy,
H7T-FW-TABX,Project Resiliience Phenotype/Genotype for 2C19 Polymorphism,
"10610",Cialis PRN Comparator Study,
H7T-MC-TABM,Switching Study #1 - Chronic Clop w/recent event req PCI,
H7T-MC-TABL,PRas. in comp. to Clop for Inhibition of Platelet Act & Agg.,
"10718",Ph 2 Enz in FOLFOX and Avastin failures in CRC 2nd line,
H3E-MC-S103,Ph 2 Tarceva vs Tarceva/Alimta v Alimta in Asian & Non-Asian,
F1J-US-HMFB,Cymbalta dosing strategy HMDR repeat trial,
F1D-US-X293,Managing Diabetes in Spanish Speaking Latino Chronic Mentall,
F1K-CA-A020,Role of APC in Leukocyte Recruitment in Inflammation,
B9E-MC-V344,Cermide Metabolism in the Chemotherapeutic Tx Pancreatic Ca,
H6Q-OE-V020,in vitro Enzausterin/Alimta in renal cell carcinoma cells,
H7U-MC-IDBL,China registration study (IMCT) for HIIP,
H6Q-MC-S030,Ph 1/2 Tarceva + ENZ in 2nd or 3rd  line NSCLC,
H3E-AY-A003,"Chemoimmunotherapy with cis, Alimta & CD40-murine malig meso",
I1T-EW-MPBA,SDSS (FHD) mGluR2 potentiator/CysLT1antagonistII (LY2421371),
B4Z-EW-LYDX,Thorough QT Study,
"11366",Ph III 1yr Type2 Diabetes Study in Obese Diabetic Population,
H9X-MC-GBDD,Ph III Reg Trial - Add on to Meal-time Insulin,
H8Y-JE-HBBH,Japan contingency,
"11447",FHD for future Compound FC000089,
H8O-FW-GWCB,Korea PK/PD Study,
"11521",GAD Phase III trial #2,
H9X-MC-GBCN,Injection site comparison,
I1V-MC-EIAB,CETP MDSS,
F1D-FR-B035,Zyprexa Effectiveness Naturalistic Schizo and Bipo Study ZEN,
H3E-CR-S111,Alimta w' Standard Supp vs Simplified follate & dex in NSCLC,
B4Z-US-LYEB,ADHD & Dyslexia,
H3E-MC-V102,Bronchioloalveolar and Adenocarcino lung Pem,
F3Z-CA-IOFR,INSULIN LISPRO: FLEXIBLE INSULIN THERAPY EXPERIENCE TRIAL,
H3E-IT-O031,Carboplatin and Alimta vs Gem advanced NSCLC old patients,
F3Z-EW-B003,SWING Patient satisfaction associated with Switching Insulin,
F3Z-JE-301H,PIII CLINICAL TRIAL ON LY275585(COMPARATIVE STUDY),
H3E-GH-O034,China NPC IIT,
F3Z-MC-IOAY,LY275585 VS. HUMULIN R: TWICE-A-DAY INSULIN REGIMEN IN PATIE,
F3Z-CR-IOPF,Lispro mid mix 50 Vs human premix 30/70 (Indian study),
F1D-XM-O309,Subjective predictors of txt compliance in schizophrenia,
F3Z-MC-IOBZ,LISPRO VS. SULFONYLUREA IN TYPE II,
H8C-MC-LQBF,Phase 2 Diabetic Peripheral Neuropathic Pain (DPNP) Study,
B9R-US-X049,Pituitary Evaluation of Patients with Low PSA,
"12077",VTE Treatment #3  (Phase 4),
H6Q-MC-JCCA,Enzastaurin Dose Regime study,
H8O-MC-GWCS,Obesity Phase 3 Study 2,
H9P-MC-LNBS,Heath Outcomes OL NERI vs Seroquel XR augmentation to SSRI,
B9R-IT-O053,GH-IGF1 system in pt after traumatic brain injury and stroke,
F3Z-RC-IODX,OPTIMAL COMBINATION OF INSULIN LISPRO AND BASAL INSULIN,
B4Z-EW-LYFJ,Comparison of Switching Methods from Stimulants to Atomox.,
"12372","1-year obesity in patients with type 2 diabetes",
"12500",Obesity Phase 2,
B9E-US-X469,Ph II Trial of Panitumumab+Gemzar+Carbo in Breast Cancer,
I1D-MC-JIAE,FED_R-Ph Ib/II - p38 Map Kin Inhib + SOC vs SOC Ovarian ,
H7U-MC-IDBO,Long-Term Safety Study of HIIP versus Injectable Insulin,
F3Z-VI-IODA,SAFETY AND EFFICACY OF INSULIN  LISPRO,
H9P-EW-LNCM,Biopharm Hepatic Impairment Study,
H9P-EW-LNCO,Biopharm Elderly Study 75+,
I2K-JE-ZZAW,JP HY10275 P1b PK/PD,
H3E-US-B010,Alimta Obsv Study in 1st Line & Maint Tx for Adv NSCLC,
I1K-MC-GLUG,Phase 1b 4-wk treatment POC,
"12777",Phase II Myostatin – Critical Illness Myopathy,
I3E-BM-MSAB,MAESTRO-01,
I2K-MC-ZZBO,Residual Effects,
H8Y-MC-HBCW,Korea PK Bridging Study,
"12874",R-Ph II - PGx study -Alimta-1st line-NSCLC,
"12890",TDP - Gastric Emptying study (Placeholder),
"12892",GemProdrug - Food Effect,
I2R-EW-BIAF,PK & GD characterisation after multiple SC doses in T2DM,
I1F-MC-RHAV,"Ph 3 RA-2 LYvsPlc MTX IR, 6 mo S&Sx and structure",
B4Z-EW-LYEN,Strattera On-Off Study,
H8K-MC-JZAU,Tasisulam 2C8 DDI,
F3Z-EW-IOPT,Effect of postprandial Hyperglycaemia on vasculature ,
H3E-MC-JMAX,PHASE I TRIAL OF LY231514 AND CPT-11,
H8O-MC-X016,Durability of Initial Comb Therapy vs Conventional,
H7L-PK-O004,Diabetes Survey,
H8O-MC-O015,Glucose uptake in Brain and Heart per PET Scans,
I4F-EW-CCAA,SAD study,
F1D-AY-A160,Investigating the interactions between olanzapine and the ep,
"13379",Role of 5HT-2A/mGLuR2 in mechanism of action of Olz,
H9P-MC-LNDR,Spanish child + adol reading disorder with and without ADHD,
"13402",DDI Study:  Cialis effects on SARM,
H3E-MC-JMIN,Ph III-Alimta vs Tarceva-NSCLC-1st line-NonSq-elderly/PS2,
"13503",Obesity 1-year comparison to sibutramine,
B7A-MC-V011,Rho GTPases in Diabetic Nephropathy,
I3Q-MC-MGCB,LY2491503 mGlu 1 Antagnonist II neuropathic pain PoC study,
"13646",Ph III-Alimta Maintenance-platinum sensitive-Ovary,
H3S-MC-GGHA,RALOXIFENE EFFECTS ON MARKERS OF PROLIFERATION IN UTERUS,
H7T-MC-X007,Medtronic: Endeavor North America DAPT Stent Study ,
H6Q-MC-V059,Pre Clinical - PED PRKCB1 inhibition on Ewing Tumors,
H3S-MC-I001,SKELETAL EFFECT OF ESTROGENS AND ANTIESTROGENS,
H6D-EW-O019,Prospective registry of newly initiated therapies for PH/PAH,
"13874",Real World Trial for RA,
H3W-LC-PPAD,LY300046 HCL: SINGLE DOSE DOSE-ESCALATION STUDY OF SAFETY...,
H8L-MC-IQAR,Artemis vs Luxura Placebo Injection Preference,
I5A-IE-JAEC,CP13-0707: Ph2-A12-mSarcoma-2nd line,
"13957",mPGES Phase 0 Human Whole Blood Assay Methods Study,
"3390",MRI Study of Brain Function in Schizophrenia,
H9X-MC-GBDR,Absolute Bioavailability SC/IV,
"13992",Meal Time Initiation (MTI) Trial ,
"14025",Ph3 Psoriasis OLE,
H4A-MC-A006,LY303366--TREATMENT OF PCP IN IMMUNOSUPPRESSED MICE,
H6O-FW-S007,OPRM1 Antagonism - EET,
"14235",Treadmill Pain Model method study,
H4G-EW-LIAD,LY303870 SINGLE ORAL DOSE IN MIGRAINEURS,
I5E-MC-TSAL,DDS16 - PK PhI to assess Testost. lotion on different sites,
I5V-MC-TGAA,TGFa Epiregulin SAD,
I5A-IE-X006,"8109: Ph I - A12+Temsirolimus - Solid Tumors",
I5A-IE-X020,E1508:PhII -A12+Cis+ Etopo vs GDC-0449+Cis+Etopo-NSCLC,
H4Q-CA-V005,IN VITRO PHARMACODYNAMIC MODELLING OF LY333328: E.FAECIUM,
B3D-IT-B015,BMD in pat. with TD2: glucocorticoid sens. and collagen glyc,
H8O-MC-B015,Byetta pancreatic and thyroid cancer ,
I5U-MC-ANBF,Phase 2 in AAA,
B5K-GH-O448,Expression of intra-encep GLUT in experimental diabetes rats,
I3X-MC-JHTE,JAK2 Inhibitor PPI/Antacid,
I5E-US-TSAW,Switching hypogonadal men from Androgel to Axiron,
I5O-MC-GTCC,Ph 2 - GIP GLP,
F1J-JE-DL02,JP Cymbalta PMS DPNP,
H8O-JE-GWEC,JP exenatide to existing insulin therapy,
B1Y-JE-HCLY,Japan Prozac Thorough QT study,
I1V-MC-EIBB,pH Effects,
I1R-MC-GLBW,GRA + MET +/- SGLT2 vs. MET +/- SGLT2 + PBO,
I6E-AV-TW02,Phase II Taiwan IIT,
B3D-MC-B018,"2012-083Fracture incidence rates,etc in high risk population",
I6B-MC-HZBG,TQT,
B3D-US-X036,"MCP-1 Parathyroid Hormone, Teriparatide, Treatment of Osteop",
H4Y-MS-LJAE,SINGLE ORAL DOSE LY334370 IN MIGRAINE PATIENTS,
"14988",Mix 50/50 Humalog,
I2I-MC-V011,Invest. invitro eff. of LY2603618 in HNSCC cells to chemo,
H8L-MC-IQBL,ePFS Formative Human Factors Study 1,
I6S-MC-ASEA,Single Ascending Dose,
H6D-MC-LVJJ,Tadalafil for Duchenne Muscular Dystrophy,
H3E-US-X045,PhII Pemetrexed in pts with Metastatic Neuroendocrine Tumors,
"10083",Gem Combination with ALIMTA in In vivo  of Col Cancer in Liv,
"10125",PPAR gamma Delta MDSS,
F1D-SZ-B022,Prevention of Bipolar Relapse with mood stabilizers,
"10130",Placeholder for Local Alimta IIT,
"10138",Placeholder for OCT addendum to study B7A-MC-MBDL,
B9E-MC-V261,"Isolated Lung Perfusion with Gem, PK and Survival",
B4G-MC-B001,Observational Study/Pergolide/New Onset Cardiac Valvulopathy,
H6Q-MC-V010,Multiple Myeloma cell lines and enzastaurin,
"10345","Drug-Drug interaction,open label,fixed sequence",
H3E-MC-V064,Effect of ALIMTA in Comb w Gem in  Preclinical invitro,
H3E-MC-V077,Combination effect of pemetrexed disodium with flavonois,
B9R-UT-O043,KLM study,
H8O-JE-GWBF,JP Exenatide P-III active copmarator study (TZD failure),
B9E-BP-O468,Neoadjuvant treatment of advanced ovarian cancer,
H3E-MC-V089,Gemcitabine and Pemetrexed  for testing in cell cultures,
H6Q-MC-S035,Ph II Enzastaurin+Xeloda vs Xeloda in AT Failures - Breast,
F1J-BI-HMES, Severe Major Depressive Disorder Boehringer Ingelheim,
F1D-JE-A132,Expression Level of GABAB Recep. Isoforms related Olanzapine,
I1R-MC-GLDA,GRA I add on to insulin +/- OADs,
I7A-JE-EACB,Single and Multiple Dose in Japanese subjects,
H9B-MC-B001,"2013-334 New US Lupus patient burden survey project (LFA)",
I1R-MC-GLDJ,"1-yr imaging safety study. mPts on MET & SU",
ZYY-FW-O006,Ghrelin EET study,
H3E-MC-V159,sensitivity and reg. of purine synthesis in ALK+ non-small ,
B9E-MC-I024,"Phase I Evaluation - Gemcitabine, Paclitaxel, & Carboplatin",
I4H-MC-A003,Prevention of ER Negative Breast Cancer by Targeting AKT/p70,
"15443",Single ascending dose study with a CYP interaction arm,
I1F-US-RHBO,Early Onset of Psoriasis Ixekizumab Activity,
H9H-MC-A025,Effect of TGFbRII antibody on cancer treatment-induced oral ,
F1D-IT-HGFF,Olanzapine treatment of levadopa-induced dyskinesia in PD,
I7T-MC-RMAE,DDI Study,
H9H-MC-JBAX,Renal Impairment in noncancer patients,
I4C-MC-V003,Primary and hepatic mestasis in gastric cancer,
F1D-TH-HGFG,Efficacy & Safety of Olanzapine in Tretment of Schizophrenic,
"2691",CRO planning for phase 3,
F1D-EW-HGML,Olz+Flx vs Placebo in relapse prevention Bipolar I Disorder,
F1J-ME-HMEX,NDIS design and validation scale IDD for Major Dep,
H3E-MC-S102,Ph 2 Alimta+/- Tarceva in 2nd line nonsquamous NSCLC,
H3E-SO-O017,"Inv. of the combination of Pem. and Gem. in NSCLC, IIIB-IV.",
B4Z-US-X047,Magnetic Resonance Imaging Studies of atomoxetine an dMethlp,
B7A-MC-V015,Can high glucose up-regulation of the human angioten,
"11010",Synergistic Activity of Benzyl Isothiocyanate with Gem,
"11027",Phase I/II MAK Tumor 3,
F1K-FP-O039,IIT - F1K-FP-O039 Hémodynamic effects of Activated Protein C,
"11193",The Therapeutic Treatment of BRCA Deficient Breast & Ovarian,
"11224",Ph 2 enz in recurrent and/or metastatic HNC,
H8O-EW-GWBS,Inhaled Phase I,
"11238",Ph 2 Alimta/Ca+ENZ vs Alimta/Cisplatin+ENZ in ext SCLC,
H3E-US-I016,PhI Alimta & Cisplatin + Radiation for Esophageal Carcinoma,
H9P-MC-LNBE,C14 Study,
"11327",Randomized Confirmatory Phase III,
"11340",RA Phase 3/4 Safety,
F1D-US-X155,Olz. for Reduction of Chorea in Pts. with Huntington's Disea,
"15663",DDI - Oral Hyperglycemic,
"15671",Elderly PK,
"15675",JAPAN Final Formulation PK ,
"15680","URI-Excipient OTHER-Ph1 HV Safety, PK/PD",
I4T-MC-JVDD,Ph IV - Ramucirumab - Post Auth Safety Study,
I5Q-MC-CGAM,Ph 3 Prophylactic Treatment of Chronic Cluster Headache,
"15848",Ph Ib - Olaratumab + Aldoxorubicin - Solid Tumors,
I4E-IE-W820,Protocol CA225-045; An Exploratory Pharmacogenomic Study of ,
I4E-IE-W835,Protocol CP02-9932; Ib/IIa Study of an Anti-Epidermal Growth,
I4E-IE-W841,CA225-245:80405 PhIIIFOLFOX or FOLFIRI+Bev orCetuximab-Colon,
I4E-IE-W859,Protocol CA225-005; I Study of ERBITUX (Cetuximab) in patien,
I4E-IE-W885,Protocol CA225-078; A I-IIA DOSE-RANGING STUDY OF PEMETREXED,
I4E-IE-W919,Protocol CA225-309; MSKCC Protocol (Non-ImClone/ Non-BMS)/ P,
I8B-JE-ITRI,URI-Vasodilator Japan Ph1 Trial,
I7E-AV-_A15,"18F-AV-1451-A15 Urine Collection",
I1F-MC-RHBX,Pivotal Ph3 nr-axSpA Trial in bDMARD Naive,
H5P-LC-BWWM,hepatically impaired,
H9X-MC-GBDE,Ph 3 Trans Launch add on to met Regimen:LY1.5 vs lira,
H6Q-MC-JCCB,Ph II Enz Trial-Lymphoma (CTCL)- T Cell,
"11513",Ph II Alimta + Sorafenib in 2nd line NSCLC,
H6Q-MC-S061, Ph 2 Enzastaurin/Sunitinib in metastatic RCC,
H9X-MC-GBCO,D/D Interaction-Antihypertensive,
H3E-US-X069,PhII Alimta & Gem in Platinum Resistant Stage IV NSCLC,
B7A-LL-A009,PKC Beta:Role in Diabetes and Atherosclerosis,
I2E-MC-BSAA,RA Phase 1 SDSS,
F3Z-MC-I001,LISPRO VS U-5OO PORCINE IN ANTI-INSULIN RESISTANT PATIENT,
"11867",Male SUI,
H8O-MC-A012,Exen in Islet Cell Transplantation in Primate Model,
"11946",CETP Mechanistic Study,
H8Y-MC-HBBM,Acute Schizophrenia - placebo,
H7T-MC-V016,Effect - AM of Pras on plt fxn using PFA-100 & new prototype,
"12076",VTE Treatment #1,
H3E-IH-O038,Ph II Alimta with or without Cisplatin in NPC patient,
"14104",test,
"16222","Phase 3 Efficacy Study #2, Prodromal AD; includes 2-year Ext",
I5T-MC-AACD,MAD PK Dose Escalation Pts,
"16285",DDI Warfarin,
"16306",Step-Down Trial,
I8B-MC-ITRM,URI Vaso/Citrate Phase III T1DM,
H9H-MC-JBEJ,Ph III - Galunisertib - Pancreas PLACEHOLDER ,
I1R-MC-E003,ExIST study role of glucagon in pancreatectomised patients,
I8U-MC-DMBA,SAD study for GPR142 Agonist,
I4L-KL-B005,BIV Korea PMS,
I4X-MC-JFCX,Ph II - Neci + IO - H&N,
I4X-KL-B001,KR_PMS - Ph IV  - Necitumumab - Sq NSCLC,
H9H-MC-E009,Ph I/II - Galunisertib + Chemotherapy - CRC,
I8D-MC-AZFD,Delayed start extension of Amaranth,
ZYY-MC-O008,Evaluating a standardised serial CSF collection methodology,
F1D-US-A152,Acute Effects of Olanzapine on glucose homeostasis,
I1T-MC-MPBD,Phase II in migraine prevention,
B4Z-JE-LYFH,JP atomoxetine P-I FG BE study-2,
I2K-JE-ZZAJ,JP HY10275 SDC/MDS,
F1J-MC-B029,AFFINITY: Assessmt of Funct in Fibro:Longitudinal Study,
"12257",Ph II dose ranging,
I1D-MC-JIAD,"FHD PhI of p38 monotherapy,advanced cancer",
H7T-MC-TACW,Intensified Antiplatelet Therapy in DES pts,
F1K-BL-O047,Risk factors anal. for mortality in  Brazilian septic pts.,
"12344",JP MR Antagonist Phase 1 (MDSS),
I2S-MC-GDHA,Single-Dose Safety Study for LY2515682,
"12378",Chronic Insomnia#2 w/young end elderly 3 months,
I3B-MC-GRAB,Study 2 (MDSS/Phase 2),
F3Z-VI-IOBT,SAFETY & EFFICACY OF LYS-PRO IN PAT. WITH  DIAB. MEL.,
"12487",Exenatide vs Detemir on Beta Cell Function,
H8O-ME-GWDB,Exentide once weekly vs sitagliptin on liver fat content,
H6O-SB-O005,Insulintropic effect of GIP & GLP-1 infusion in pts w/T2DM,
"16624",PsA bDMARD-IR,
F3Z-MC-IOHI,Insulin Lispro LM: Type II pts. with Oral Agent Inadequacy,
F3Z-MC-IOHJ,Insulin Lispro LM use in Oral Agent Inadequacy/Latin America,
I8B-MC-ITRU,T2DM study,
"16654",Child Atopic Dermatitis,
I6E-AV-I050,AV-45-IIT-050: Impact of Disclosing Amyloid Imaging Results ,
I6T-MC-AMAU,Single dose Co-Formulation with PH20/Halozyme ,
B1Y-IT-0005,FLUOXETINE VS AMITRIPTYLINE-DBL-MAJOR DEPRESSIVE,
I3O-MC-JSBK,Ph II - Merestinib + IO Agent TBD - ,
I6A-MC-CBBI,Ph II - Abema+Tamoxifen+PI3 Kinase/mTOR-placebo-MBC,
"16711",Ph II - Ramucirumab - HCC 2L Lenvantinib Sequencing,
I1F-MC-RHCH,Phase 3 rad-axSpA China,
F3Z-MC-IOQT,BRAVO feasibility study,
B3C-MC-JQAE,PH 2 Study of LY309887 with F.A. Supp. in Pts. with H&N canc,
F3Z-MC-IOQU,Pump Safety and Compatability Study,
I8F-MC-GPGF,Phase 2 Titration study,
H7T-DS-TADS,Pras. MD washout estimated by Accumetrics,
H8O-XM-GWDD,Local Extension GWAN study- regulatory requirement,
H9P-MC-LNCD,NERI IV Adjunctive Treatment Comparator study #2,
H6E-AY-O017,Study on the mechanism of the anti-proteinuric effects of pi,
H8C-MC-LQBS,OA pain: One year open label exposure,
H8C-MC-LQBW,DPNP #1 DB LY(2) vs pbo vs Lyrica + 9 mon MOE,
H8C-MC-LQBY,DPNP: open label safety exposure study,
"12759",ECHO Study,
I2K-MC-ZZBM,Oral Contraceptive Interaction,
H7T-FW-TACZ,Multiple Dose Pharmacokinetics and Pharmacodynamics of LY640,
H7T-US-TADL,Bleeding linkage to IPA,
"12912",Biolar and ADHD,
H3E-MC-JMAB,LY231514:  BOLUS INFUSION  WEEKLY,
H8O-MC-GWDI,Pulmonary Outcomes in Diabetic Pts (GPS Obs Study),
H4Z-MC-GJBB,arzoxifene or pla w/ topical estrogen in vaginal atrophy ,
B3D-FR-GHDM,Fosteo- suivi PV de GHCA,
I1F-MC-RHAW,PH 3 RA MTX IR vs Humira vs Plc,
"13071",IIT placeholder for duloxetine study (Guillin),
I8I-MC-JY07,Continued Access LY3023414 from Study CBBA.,
I9M-MI-MIAA,SAD/MAD,
H9X-MC-GBGM,RBA/PK study in Dulaglutide,
I8B-MC-ITSG,Phase IIIb URI vs Fiasp,
H3F-US-X007,The effect of remote monitoring Hypo on bionic pancreas ,
"16945",Ph3-Olara+Dox vs Dox+Placebo-Soft Tissue Sarcoma,
I9W-MC-IFDB,MAD-Titration Study,
"17005",Comparability trial,
H8H-MC-LAIC,China PK HV,
I4V-MC-B023,Post-authorisation Safety Study (PASS),
B1Y-MC-X133,PREDICTION OF OUTCOME DURING FLUOXETINE CONTINUATION,
I7E-AV-E066,"18F-AV-1451-EXIST-066",
I7E-AV-E072,"18F-AV-1451-EXIST-072",
"17349",Ph III - Pegilodecakin + Pembro - 1L NSCLC w/High PDL1,
I8B-MC-ITSW,Ph3b/4 URLi in T2D w/FGM ,
I5Q-JE-CGBB,Japan PMSS ,
B9R-FP-T001,HUMATROPE IN SHORT BOWEL CHILDREN,
"13141",Chart review  to further assess CABG data for safety,
I3W-EW-HHAD,"5 hr Phase Advance",
B5K-US-V015,Study of proinsulin reactive T cells in mouse models of T1DM,
H3E-MC-JMBP,LY231514 IN ANTHRACYCLINE REFRACTORY BREAST CANCER,
F1J-CA-O040,Treatment of postpartum depression with duloxetine,
H3G-LC-BGGC,LY246736:MULT DOSE TRIAL IN SUBJ WITH LOPERAMIDE-IND CONSTIP,
I3X-MC-JHTA,"FHD Trial, Ph 1/2 for JAK-2 Inhibitor",
I3Q-MC-MGCA,LY2491503 mGlu 1 Antagonist II pain study,
H8L-MC-IQAG,Needle depth/injectate volume Magnetic Resonance Imaging ,
H3E-IE-JMIM,DRUG ONLY_R-Ph3-Alimta/Cis+IMC-11F8vsAlim/Cis-NSCLC(nonsq),
I1N-MC-CDBD,RBA mGlu2 Pot/CysLT1 Antag I,
H8O-MC-V009,Anti-Inflamatory effects of exenatide on fat cells,
H6D-MC-LVIL,Cialis BPH Asian Phase III (China Registration Trial),
H6E-AY-O019,Therapeutic regulation of hepatic steatosis and lipid transp,
F1D-US-A161,"5-HT2A/mGluR2 Complex and Olanzapine",
F1J-US-HMGR,MDD and Associated Painful Physical Symptoms,
"5986",Relapse Prevention of Biploar II Disorder,
J2G-OX-Y007,PhI-RET Inhibitor-NSCLC,
J2G-OX-Y012,Ph!-RET Inhibitor+Osimertnib-NSCLC,
J2G-OX-Y028,PhI-RET Inhibitor-MTC,
J2N-OX-JZNH,LOXO-BTK-20014-Ph1-Pirtobrutinib-Pilot Food Effect,
J2A-MC-GZGF,C14 HV,
I3Y-MC-JPEE,EET Taste HV,
B1Y-IT-9102,FLUOXETINE VS AMITRIPTYLINE IN ANXIOUS/AGITATED DEPRESSION,
ZYY-MC-B007,Asymptomatic novel CORonavirus iNfection (ACORN),
J2G-OX-Y184,RET Inhibitor,
J2T-DM-KGAP,Lebri for Adol pts w/ uncontrolled asthma on inhaled cortico,
J2T-DM-KGBA,Evaluation of SC vs IV formulations (ILR4456G),
I7W-MC-UDAB,LY3127804 in pts hospitalized w/pneumonia & COVID-19,
J2G-OX-Y195,RET Inhibitor,
J2G-OX-Y213,RET Inhibitor,
H3E-MC-JMAT,"Phase I & II 1st line NSCLC, ALIMTA + Navelbine",
B9E-MC-V326,Ling perfusion with Gemzar in rat: PK + survival,
B3D-MC-GHDN,Femoral Neck Fx Healing,
"13518",JP OP Depot Ph3 Extension Long Term,
I2I-MC-JMMI,DDI CYP2D6,
"13562",Trial not related to any Lilly sponsored trial,
F1D-AY-O330,Physiological effects of atomox. on additional lapses ADHD,
I1L-MC-GAEF,SAM/Sibutramine: 14C Study,
H3S-MC-GGGE,RALOXIFENE HCL:  EFFECTS ON ADRENAL FUNCTION,
"13597",Schmidt: PK Cbeta: Role in Diabetes and Atherosclerosis,
"13635",JP BIB MDSS,
H8L-MC-IQAI,Humalog KwikPen Color Knob and Coding study,
H6Q-MC-V049,Pre Clinical - Thyroid Cancer,
H9X-MC-GBDX,Ph III Glycemic Efficacy and Safety w T2D w Renal Disease,
B1Y-FP-0710,FLUOXETINE:SEQUEN. EFFIC.-AGITATED&RETARDED DEPN,
I1R-FW-GLBO,Drug Drug Interaction Study,
"13828",DDI Study for LY2899623,
F1J-US-A012,BDNF gene regulations by different type of antidepressants,
H8L-MC-IQAP,Artemis vs Luxura Injection Clinical Trial,
I4T-IE-JVBQ,CP12-0710: Ph2 - 1121B - HCC - 1st line ,
J1O-MC-JZHH,"A phase Ib/II trial to evaluate safety, tolerability and eff",
J3D-MC-FNAC,Controlled Release Formulations,
J2M-MC-GZKD,Ph2a KHKI 12 wk T2DM NAFLD Dose Finding,
F1K-LC-GUAE,LY203638 (rAPC):  Safety Study in End Stage Renal Disease,
I3Y-NS-I036,Combination Dose Escalation CDK4/6 inhibitor + OP-1250,
B3L-MC-LWAF,LY354740 vs Placebo:  Dose Ranging Study for Smoking,
J2N-OX-B007,"2020-9661: MCL:  BRUIN RW Control Comparison",
I3Y-GH-O025,A study of abemaciclib in combination with AI as first line ,
B9E-MC-I100,GEM PLUS HIGH DOSE ARA-C IN RELAPSED OR REFRACTORY LEUKEMIAS,
H9D-MC-B001,KwikPen and Trulicity Post Market Clinical Follow Up,
"18662",Renal Placeholder,
H3Z-MC-JNAR,Phase II Eval. of LY295501 for Treatment of NSCLC,
"1888",Histomorph.-150mg.,
B3N-FW-EUCO,Moxonidine - Investigation of Renal Secretion,
F1D-MC-X078,Biological Correlates,
H5H-MC-DDAH,Neutralization of CDAD Toxins in Healthy C.difficile Carrier,
H5H-MC-DDAF,Open Label Pilot study,
F1D-EW-LOAU,Bioequivalence of amorphous zydis tablets,
B9E-MC-I034,"PHASE 1 STUDY OF GEMCITABINE, PIRITREXIM, AND TAXOL",
H3Z-MC-JNAG,PH. I CLINICAL & PHARMACOKINETIC EVAL. IN METASTATIC CANCER,
I3G-JE-JGCD,JP_p70S6_Phase_1_combo,
"14014",B'pharm DDI with Antihypertensives,
F3Z-GH-O078,A study to evaluate impact of insulin regimen,
"14159",Latent Autoimmune Diabetes in Adults,
F1J-CA-O050, A Telemedicine Neuropathic Pain ,
I2V-MC-CXAB,Phase II trial for LY2510924 in renal cell carcinoma,
I5E-MC-TSAR,MTE12-Ph I interpersonal transfer of testosterone,
H4G-EW-LIAL,LY303870 RADIOLABEL METABOLISIM STUDY IN NORMAL VOLUNTEERS,
B9R-IT-B003,Predictive Factors and Hypopituitarism after stroke,
H8L-MC-IQBA,Device Safety and Tolerability Study,
I5V-MC-TGAB,TGFa Epiregulin MAD,
I5A-IE-X023,E2208: Ph II-A12+Paclitaxel vs Paclitaxel - NSCLC,
I4E-IE-I002,MED P02-08002:R-PhIIb-Cetuximab+Platinum -NSCLC-1st Line,
I1Q-MC-JDDJ,Elderly Fallers,
I3P-MC-GKBN,"3A4 Inhibition DDI",
B5K-MC-IBEP,HumaPen Ergo (Reusable Platform - Atlas II),
B4Z-LC-HFBH,Tomoxetine C-14,
"10066",OpRA III Phase II Trial,
H5P-LC-BWWN,renally impaired,
B1Y-LC-HCFK,DISPOSITION OF FLUOXETINE'S ENANTIOMERS,
F3Z-JE-PV03,JP lispro mixture PMS Antibody test,
B1Y-MC-X142,ESTROGEN REPLACMT THRPY-FLUOX IN POST MENOPAUS MRJ DEPRESSN,
H3E-MC-V050,Efficacy of Alimta on ovarian cancer,
H5P-LC-BWWI,ulcerative colitis (probe),
B9R-US-X019,USE OF HYPOGLYCEMIC CLAMP IN ASSESSMENT OF PITUITARY FUNCTI,
H6R-MC-LSAD,"Phase I PK, Electrophys., and Absorption Study with LY494582",
B1Y-MC-HCJC,Fluoxtine vs Placebo in Panic Disorder,
H7U-JE-IDBC,JP Pulmonary insulin P-II/III (Type 2),
H3Z-MC-JNAK,Phase-I combination study:  LY295501 + Taxol,
F1D-MC-HGEU,OLANZ. VS. PLACEBO IN TRMT. OF PSYCHOSIS ASSO.W/ ALZHEIMERS,
H3E-MC-JMCI,"Phase I, ALIMTA + Adriamycin",
"10342",Single Dose Safety Study (SDSS),
"2242","phase I, Alternate schedule of MTA (possibly Q2W)",
B1Y-MC-HCAH,FLUOXETINE OPEN LABEL,
B9E-AY-O463,EC followed by DG as neoadjuvant chemo for BC,
B3D-EW-GHDW,Ph IV Teriparatide Spine Fractures Superiority Trial Proposa,
I2I-MC-V003,Pre Clinical - CHK1- hem malignacy (Ras/Raf/MEK/ERK),
H8O-MC-GWEH,Regional IMCT,
"14681",Mechanism,
I6K-FW-GLEB,Multiple Ascending Dose Study for LY2922470,
I4J-MC-HHBH,JP_LY2940680 Hedgehog SMO Antagonist_Phase1,
H6Q-MC-V084,Thymidylate Synthase expression levels in Large Cell Carcino,
B3D-CA-O036,Teriparatide as Trmt for Nonunited Type II Odontoid Fracture,
H9P-EW-LNEH,PLACEHOLDER - EDX Definitive QTc Study Part II,
H5M-SB-EIIA,Xipamide vs furosemide in pts. with renal failure,
I1D-MC-JIAJ,Relative Bioavailability in NHV,
J3C-MC-JRAB,PH. 2 DAB389IL-2 IN PREV. UNTREAT. LOW-GRADE NHL,
I5E-US-TSBC,Evalute Axiron in men who have had sub-optimal gel response,
H8L-MC-IQBH,Pythia - LY2963016 KwikPen Summative Human Factors,
B5K-US-V019,Conformational analyses of insulin and its metal adducts ,
H9H-MC-V008,Dev.Animal Models to Test LY2157299 & Enhanced Del. Systems,
"15096",Statin DDI,
H8O-MC-A007,Protective influence of exen on glucolipotoxic dys,
B9E-MC-S059,Ph ll - Gem Post AT- 2nd line - Breast,
F1D-MC-X099,OLAN. ADJUNCTIVE TXT IN PATIENTS WITH NONPSYCHOTIC BIPOLAR D,
B9E-MC-X108,PHASE 1/2 TRIAL OF GEMCITABINE AND TAXOL,
F1D-MC-X031,Cerebral D2 and 5HT2 Receptor Occupany w/ Chronic Olanzapine,
"2340",An Invest. of effects of antipsych. drugs on 5-ht receptors,
B4G-IT-LCCM,Parkinson / Pergolide high dose / Dyskinesia (S2),
"2473",Olan Adjunctive trx in patients with nonpsychotic bipolar di,
B9E-MC-X103,PHASE II STUDY OF GEMCITABINE...ADVANCED BREAST CANCER,
B9E-MC-X020,PHASE II GEMCITABINE ADVANCED SQUAMOUS CANCER OF CERVIX,
B1Y-MC-X175,Trial of Zatosertron in SRI Induced Sexual Dysfunction,
H4A-LC-XBAY,C-14 Study,
B4G-EW-LCDB,Modified Patch in Healthy Volunteers (place holder) CPharm,
B4G-EW-LCDF,Parkinson Patch / Regulatory B (ClinPharm study),
B9E-MC-X066,"Gemcitabine, Cisplatin, and Radiation Therapy in Advanced",
B3D-LC-GHBG,Absolute Bioavailability,
"2617",LY334370 in patients with heart disease and migraine,
F1J-LC-SBAI,Multiple Dose PK - Hepatic Impaired,
F1D-US-X104,"Olanz on platelet function in depressed, schizophrenic pts.",
ZYY-FW-GCAM,serum prolactin response to ascending doses of L-5HTP,
B9E-VI-B007,Pt. Characteristics assoc. to Mono vs. Combi chemo in MBC,
B9E-MC-V293,Dimensional bioreactor model for in vitro cancer screening,
F1D-UT-B025,APROPOS,
B4Z-MC-A007,Effects of ATX in Dopamine D4 Receptor-Deficient Mice,
I1H-MC-JYAA,FHD Ph I Safety/PK LA457 pan-TGFbeta mAb,
F1D-MC-X010,PREPULSE INHIBITION OF STARTLE IN SCHIZOPHRNICS TREATED OLAN,
F1K-MC-EVDK,Research Evaluating Serial Protein C Levels in Severe Sepsis,
H7T-MC-TABN,Switching Study - High-dose Clopidrogel Load plus MD,
"10798","6 month dose ranging study",
H3E-MC-V114,Antimalarial activity of Alimta and its Analogs,
F1J-JE-1003,LY248686 PHASE I REPEATED- DOSE STUDY,
"10997",Cytotoxic effects of pemetrexed in gastric cancer cells,
B9E-MC-V343,LC/MS Assay to determine Gem and Intercellular gem,
I1L-MC-S002,LY377604/Sibutramine Multiple Dose Safety and CV PD Study,
H6Q-MC-JCBS,Ph I Enz in Children & Adolescents w/ Refract. Glioblastoma,
I1Q-MC-JDDB,"FHD, Phase 1 Dose-Escalation Study in Cancer Patients",
H6Q-MC-S046,Ph 2 Gem+Enz vs Gem+Placebo in NSCLC 2nd Line,
I6H-MC-MCBD,C-14 Study,
I6T-MC-AMAB,Ph 2 POC in AxSpA,
I2I-MC-V014,Evaluation of the combination of ionizing radiation in NSCLC,
"1516",Epilepsy Global Registration Trial,
B5K-MC-IBHF,Humulin u500,
I3Y-MC-JPBF,CYP3A4 Inducer DDI study in healthy subjects,
I4O-EW-BACZ,Aricept DDI,
B4G-EW-LCCC,Efficacy of Pergolide in Restless Leg Syndrome (II),
I4T-MC-JVCV,Ph II - Ramucirumab - Gastric 1st Line,
I4M-MC-MRAP,DDI Study,
I4M-MC-MRAQ,RBA Study,
H7L-MC-MDAF,EET Safety and Tolerability Study,
I4V-MC-JAHC,PsA ,
I7Z-EW-FLAL,TQT,
B3M-MC-AJAV,Cefaclor AF vs Clarithromycin in Sinusitis,
F1D-MC-I015,Open trial of Olz./Treatment of patients w/Psychotic Depress,
I6E-AV-I010,AV-45-IIT-010: The 90+ Study,
H9H-MC-A036,comb treatment with LY paclitaxel or 5-FU on a human gastric,
"2667",Advanced Platform I (Odyssey),
"2675",A Phase 2 trial of LY309887 in patients with Hepatoma,
"2715",Pulmonary delivery in asthmatics,
"2721",VOID,
"2764",Bioequivalence Study,
B1Y-MC-HCEM,FLUOX/PHENELZINE DESIPRAMINE RESISTANT PTS MDD,
F1D-US-X117,Olz. vs. Risperidone in Dementia Disturbance in Nursing Home,
F1D-BL-HGHS,Olanzapine in Schizophrenia - healthteconomics,
"2913",COC Interaction Study,
"2923",IIS Baltic Insulin Intervention Trial (BALTINT),
C2N-MC-JXAK,LY355703 in Adv NSCLC 1st line - Ph 2,
B1Y-MC-HCGA,LOVAN:EFFECT ON WT MAINTENANCE AFTER VERY LOW CALORIE DIET,
B1Y-MC-HCHA,LOVAN:EFFECT ON PATIENT ADHERENCE TO A DIET PROGRAM,
B9E-MC-X203,Gemcitabine and Topotecan/Phase 1/Advanced Cancers,
B1Y-MC-HCIB,FLUOX/AMIT IN LATIN AMERICAN PATIENTS WITH MDD & ANXIETY,
B1Y-MC-I001,FLUOXETINE:SEROTONIN REGULATION ANTERIOR PITUIT.,
"3226",Pediatric Drug Interaction,
F3Z-MC-IOMI,"Local registration study in Bulgaria,Slovenia,Croatia,Bosnia",
F3Z-JE-M34H,Long Term,
B9R-US-X023,GH & Leuprolide improve height in 21-hydroxylase Deficient,
H8O-BL-O001,Enteroinsular axis in humans type 2 DM/obesity,
F1D-MC-HGMQ,OLZ in children and adolescente in PDD,
B3D-CA-O011,Teriperatide in Postmenopausal Women with Osteoporosis,
F1K-LC-GUAA,LY203638DOSE-RANG. STUDY WITH SHORT INFUS. TO STEADY STATE,
F1K-UT-A024,APC influence on renal oxygenation+oxygen consumption,
H8O-EW-GWBZ,DDI Study,
H8O-EW-GWCA,Dose Meal Timing Study,
F1J-US-X046,Dulox for Depressed Substance Abusers,
F1D-MC-A138,Pharmacogenomic stdy of antipsych in Caenorhabditis elegans,
F1J-MC-I011,Dulox in prevention episodic migraine - IND Exempt,
F1D-MC-A139,Neuropathology of Dopamine Systems in Schizophrenia,
"11625",Placeholder trial for IITs with Cymbalta in NL,
B9E-US-X463,PhII Biweekly Carboplatin & Gem with Bevacizumab in NSCLC,
H9X-MC-GBDF,Ph III - Switch off Lantus,
"11734",LILL200503: In-vivo Bioluminescence Study with D54 Glioma Ce,
B3D-BL-A002,ExNCR - Forteo in the treatment of dental movement,
F1D-EW-B039,Prospective Obs study - Schizophrenia with depot treatment,
"11817",Phase II ALim/Cis vs 5FU (Head  & Neck),
I4E-IE-W810,"Protocol CA225-022; A II Study of Oxaliplatin (OXAL), 5-Fluo",
I4E-IE-W815,"Protocol Non-BMS/D0432; A II TRIAL OF ERBITUX, RADIOTHERAPY ",
I4E-IE-W862,Protocol CP02-9502; Ib/IIa Study of C225 (Cetuximab) in Pati,
I4E-IE-W863,Protocol CP02-9503; Ib/IIa Study of C225 in Combination with,
I4E-IE-W902,Protocol Non-BMS-0206-0027; A RANDOMIZED STUDY OF CETUXIMAB ,
I8D-MC-AZEJ,Hepatic Impairment,
H7I-EW-S010,Characterize variability of CSF & Qualify Singapore Site,
I7E-AV-_A10,Evaluation of 18F-AV-1451 kinetic modelling in AD & HC,
I6E-AV-I024,AV-45-IIT-024: Super Aging,
I6E-AV-I028,AV-45-IIT-028: IIT-Tablet - Timely Diagnosing of AD in Patie,
I8G-MC-LMDC,Ph2 study in MCI to Moderate AD,
I6E-AV-I041,AV-45-IIT-041: CLEM,
I1F-MC-B004,Patient Preference study,
I1V-MC-EIBR,Lipid 3,
I7E-AV-E044,"18F-AV-1451-EXIST-044",
"16405",Ph II - Gem+Cis +/- Ramucirumab - Neo Adj Bladder,
I8M-MC-BIXB,MAD Study,
I9D-MC-ROAB,Phase 2 Psoriasis,
I5S-MC-EFJP,Heterozygous Familial Hypercholesterolemia,
I8B-MC-ITRZ,Japan Final Formulation PK,
F3Z-MC-IOQX,TANGO Adult Pivotal Study CT4,
"16684",TANGO Post Approval Study,
I5S-JE-EFJU,Japan Ph3 Study 1,
"16903",MAD,
I8B-MC-ITSI,Ph3 URI Pump Safety study,
I6T-MC-AMBM,Psoriasis 2ml Placebo Controlled Study,
I7S-MC-HBEK,Ph3 Alzheimer’s Dementia study,
I6A-MC-E008,"Ph2-PI3Kin/mTOR Dual Inhib+Prexasertib-Ovary Endo, BC",
H9D-MC-ITAT,EET Proposed Pump - Pain/Analgesics HV,
F3Z-MC-IORI,TANGO Peds Late Feasibility ,
B9E-MC-I017,GEMCITABINE AND NAVELBINE IN ADVANCED NSCLC,
J1P-MC-KFAF,Phase 2 Trial in Peanut Allergy,
I7E-AV-E096,"18F-AV-1451-EXIST-096",
I7E-AV-FR01,AV-1451-FR01,
B1Y-BP-HC21,FLUOXETINE VS IMIPRAMINE D.B. PARALLEL STUDY WITH MDD,
"3407",APP Sepsis Mental State using 46090,
H3S-US-GGIX,"A Randomized, double-Blind Controlled Trial of Fluoxetine hy",
"3477",Phase 1b pulmonary (new formulation),
H5P-LC-BWXB,FINAL BIOEQUIVALENCY STUDY WITH MARKETED FORMULATION,
B9E-SN-JHQP,"Phase II, Seq Gemcitabine Followed by Cisplatin,  NSCLC",
B1Y-MC-X050,RAPID TREATMENT OF MAJOR DEPRESSION,
B9E-MC-S138,Ph II Neoadjuvant G vs G+Cis in Pancreas,
B9E-MC-X246,Phase I Study of Gemcitabine and Oral UFT,
B1Y-MC-X066,PRESCRIBING PATTERNS OF ANTIDEPRESSANT MEDIATIONS IN AN HMO,
B1Y-MC-X067,'LUOXETINE IN ELECTIVE MUTISM IN CHILDREN,
B7A-BD-MBCD,Interaction 2D6 desipramine,
B4Z-FW-LYAP,Drug Interaction Methylphenidate,
B3L-MC-LWBA,Ph III LY354740 vs. placebo vs. paroxetine in panic disorder,
"3902",MGlur2 - Renal Impairment,
B1Y-MC-X084,FLUOXETINE & BEHAVIOR THERAPY IN SOCIAL PHOBIA,
"3912",BREAST MILK STUDY,
"6046",Method study 2,
I2G-FW-ALBC,Multiple Dose,
I2O-MC-HAAE,FHD: Single Dose Safety Study,
H3E-US-V144,In Vitro study on the Protein expression level of GARS-AIRS-,
"11886", MDSS,
H8Y-MC-HBCC,QD dosing - POC,
H7T-MC-V012,Pilot study for active metabolite spiking exp.  in TABR,
F3Z-MC-IOCM,PHARMACOKINETICS OF FREE MIXTURES OF LISPRO AND NPD,
F3Z-MC-IODL,LISPRO HM + HUMULIN N VS HUMULIN R + HUMULIN N,
I1F-MC-RHAH,Phase 2 - Crohn's Disease,
F3Z-MC-IOEQ,HUMALOG VERSUS VELOSULIN BR IN PTS W/TYPE1 DIABETES MELLITUS,
I2K-MC-ZZAE,MTD (MDSS),
H3E-MC-S123,Ph II Alimta + Cis + Erbitux in Head and Neck Cancer,
F3Z-MC-IOGI,"INSULIN LISPRO LM,MM,NPL:A COMPARISON W HUMAN NPH TYPE I PAT",
F3Z-US-V008,"ExNCR, Insulin, analogues in insulin sensitive tiss",
F3Z-XM-B007,EDIN :ASSESSMENT OF  EVOLUTION DM2 UNDER  INSULIN TREATMENT,
"12271",LY 2062430 and Hepatic Dysfunction (Placeholder),
"12274",Definitive QTc study (Placeholder),
I8R-MC-B008,"2018-7840 GHO_Characteristics of people w/T2DM on insulin...",
F1D-MC-X048,"RISPERIDONE: DOSE, BLOOD LEVEL, EFFICACY AND ACCUMALATION",
J2G-OX-Y019,PhI-RET Inhibitor-MTC,
J2G-OX-Y046,PhI-RET Inhibitor-NSCLC,
I4X-US-I004,PhI Osi+Neci+Trast in EGFR Mut NSCLC HER2 Res to Osi,
J2G-OX-Y062,RET Inhibitor-MTC,
J2G-OX-Y082,RET Inhibitor-NSCLC,
J2G-OX-Y145,RET Inhibitor,
J2G-OX-Y172,RET Inhibitor,
"18105",ABA HV,
"18127",BE HV,
I7E-AV-E127,AV-1451-EXIST-136: CTE: Using Advanced MRI and PET as Biomar,
H9X-NS-I001,Virtual Prescribing Study,
I8H-MC-BDDA,BIF Ph2 T1DM 12 week titration study,
"18591",PF Patients with severe hypertriglyceridemia,
J1I-MC-GZBQ,Paediatric participant study (6-11 years) w/obesity,
"18626",Atorvastatin administered with LY3502970,
B9E-IN-O095,Gemcitabine and cisplatin in gall bladder cancer,
"3959",Microalbuminuria in diabetic patients,
F3Z-MC-IOMX,HOE once daily vs Mix25 BID,
F3Z-MC-IONF,LM 1x per day +metformin vs. glargine 1x per day +metformin,
H3E-MC-JMEA,MTA + Navelbine i a/t failures,
"4054",Phase II Gem+XRT+ other agent in Head and Neck Cancer,
F1D-MC-HGIN,Olanzapine Study in Children/Adolescents with Psychosis,
B9E-TW-O101,gem for bile duct and periampullary CA,
H4Z-LC-JWXH,pharmacokinetics of LY353381 in cirrhotic patients,
"4129",R-fluoxetine drug interaction study 3,
F1D-MC-HGIS,Olanzapine Depot Phase III Study---Oral olz vs depot olz,
B9E-MC-V026,Evaluation of combination gemcitabine in cancer cells,
A6J-GH-V013,Therapeutic drug monitoring (TDM) of Vancomycin,
B9E-MC-V034,Gemcitabine activity in anaplastic thyroid cancer,
F1D-CA-O055,Actigraphic Monitoring of sleep/wake with Acute Mania,
B1Y-MC-HCKG,JP fluo P-I PK study CLCR,
B9E-GH-O328,Gemzar in treatment of Advanced Nasopharyngeal Carcinoma,
B9E-SB-O133,Gemcitabin + Vindesin in NSCLC second line,
B7A-MC-V012,Role of PKC beta in Fc gamma,
"12334",SGR SDSS,
"12335",SGR Antagonist MDSS,
"12462",patient education program,
"12473",CRH-1 C14 Study,
F3Z-VI-IOCW,PHARMACOKINETICS & GLUCODYNAMICS OF INSULIN LISPRO AFTER IM-,
I3G-MC-JGCB,p70 S6 Kinase Inhibitor Ph1 Combo Study (LY with Erlotinib),
"12570",MR Antagonist II ph1b/POC (LY2580831),
H9P-EW-LNBY,Biopharm Clopidogrel DDI Study,
F1D-CY-O321,ITAREPS: A Prospective Randomized Double-blind Controlled St,
H8O-SB-O009,CNS Effects of Exenatide,
B9E-JE-JHSU,JP Gem P-II Ova,
I2K-MC-ZZAP,"6 Month Efficacy in the EU",
"12687",Ph II- GemPro-2nd/3rd Line-CRC,
H2Q-EW-LZYK,HEALTHY VOLUNTEERS,
F3Z-AY-O070,The Inala Chronic Disease Management Service: a novel model ,
H3E-US-V142,coorelative study to H3e-US-I025,
H8C-MC-LQBX,DPNP #2 DB LY(2) vs pbo vs Lyrica + 9 mon MOE,
F3Z-US-IOHA,INSULIN LISPRO THERAPY IN PERSON OF HISPANIC DESCENT WITH NE,
F3Z-VI-O007,Effect on Insulin Sensitivity & Secretion Capacity in Type 2,
F1D-MC-HGBU,OLANZAPINE/RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,
B1S-MC-EAAO,DOBUTAMINE IN CHF INTRACORONARY RACEMIC,
F3Z-MC-IOHS,COMPARISON OF THE BLOOD GLUCOSE RESPONSE TO A TEST MEAL,
H3E-US-X037,Ph II Alimta & Carboplatin in Extensive Stage SCLC,
B9E-MC-X098,GEM AND DOCETAXOL FOR NSCLC PHASE 2,
"10101",Cohort ATU,
F1D-MC-HGEL,OPEN LABEL STUDY OF OLANZAPINE IN GAD,
"1951",Local registration trial in China,
ZYY-MC-OAAC,OA Biomarkers Following Treatment with Anakinra,
H3U-MC-JPAE,Ph 2 trial/LY300502/metastatic prostate cancer,
F1D-MC-HGCT,LONG-TERM TRIAL OF OLANZAPINE IN CHILDREN,
B1Y-LC-HCEO,FLUOXETINE BIOEQUIVALENCE 60MG TABS V 60MG CAPS,
"10120",Placeholder Xigris local IITs,
F1J-JE-322G,JP dulo P-III elderly pts psychiatry 6wks Shionogi,
F1J-SB-O025,Women suffering from SUI treated acc. to ICI guidelines,
B4Z-LC-HFBI,pEDIATRIC FOOD/FASTED ANTACID,
H6L-LC-LFAC,"Clin Pharm Single Dose  escalation, placebo-controlled",
B1Y-BP-HC32,FLUOXETINE OPEN-LABEL IN MDD,
"4530",Durapac Study in Asia  Pacific,
B9R-BX-O003,hGH treatment after TBI and Bone Marrow Transplantation,
B9E-MC-S187,"Gem + Cis (NSCLC, neoadj/adj)",
B9E-MC-S211,"Ph II Sequential Carbo -->paclitaxel/gem,Ovary stage Ic-IV",
F1D-US-A048,idenification of neurochemical loci of antipsychotic drug ac,
H3S-MC-O007,Raloxifene and Zoladex Research Study,
B9E-SZ-O160,Pancreatic carcinoma Gemzar stop flow adminstration,
B1Y-ME-HCKU,Prozac vs reboxetine; a validation study,
B9E-SN-O161,Phase I/II study of pegylated liposomal doxorubicin and gemc,
B1Y-MC-HCKW,Fluoxetine vs Celexa & Venlafaxine XR Differentiation Trial,
"4853","Phase I, Patient Trial for MRP Modulator",
B9R-US-A002,Mechanisms of GH Regulation During Early Development,
F1D-SB-HGJE,Health Economics of Olanzapine in Treatment of Schizophrenia,
H3S-HL-GGKD,Raloxifene prevention of osteoporosis in postmenopausal wome,
B1Y-UA-0007,EFFICACY OF FLUOX AS ANTI-DEPRESSANT IN ADOLESCENTS,
H6D-MC-LVCU,Preference Starter Study,
H3E-MC-V103,Reversal of ALIMTA resistance invitro and invivo,
"12740",DPNP back up study,
"12765",Observational Study of basal insulin use in T2DM,
I2K-MC-ZZBC,Ketoconazole,
H2Q-MC-LZZE,"LY246708 TARTRATE VS PLACEBO, SAFETY/DOSING TOLERANCE IN AD",
H7T-EW-TADD,Dos Propotionality,
F3Z-US-IOPN,Using Lispro insulin in the pump in pediatric patients,
I2K-JE-ZZAX,"JP_HY10275_P-III_insomnia, open label extension",
F1J-US-HMGL,Duloxetine + NSAIDs (OA Knee Pain),
F1J-MC-HMGJ,Pediatric All-Comers Pain Study,
F1J-MC-A010,Molecular eff of dlx in extinction of conditioned fear,
H6O-EW-GCEH,NMDAR Antagonist Models as Translational fMRI Biomarkers for,
H6D-MC-B013,"Tadalafil, Other PDE-5 Inhibitors, Contraindicated Nitrates ",
"13023",Ph IV Observational Type 2,
H6D-MC-LVIE,PAH long term safety data collection,
I3E-JE-MSAH,JP_Dirucotide Ph1_SPMS and RRMS,
I1R-FW-GLBK,Hepatic Imaging Study,
"13110",Formulation Bridging Study - PK,
F1D-MC-HGCX,PREDICTIVE VALUE OF REM SLEEP LATENCY TO OLANZAPINE IN SCHIZ,
"10179",Synergy gem & clusterin antisense oligonucleotides Bladder,
H3E-MC-V048,Pharmaogenomics Analyses of Pt. Tissue Samples (gem),
F1D-JE-LOBX,JP ola P-I Zydis BE 10mg,
B9E-US-X451,Gem & Paclitaxel for Metastatic Urothelial Cancer,
F1D-US-X279,Double-Blind Placebo-Controlled Olanzapine in the Treatment,
B7A-IT-A015,Effect of PKC b inhibition on VEGF levels in diabetic rats,
H6L-JE-LFAQ,JP A beta lowering P-1 MDSS,
F1D-MC-X002,EFFICACY OF OLANZAPINE IN SCHIZOPHRENIC PTS WITH POOR RESPON,
F1D-BL-S064,Weight gain management,
F1D-MC-X009,COGNITIVE EFFECTS OF OLANZAPINE VS. TYPICALS,
H7U-MC-IDBK,IDBA Extension,
H3E-MC-V079,ALIMTA incomb Endocan and HDAC Lung and meso cells,
B9E-MC-V296,SPAP during BFO for the treatment of pulmonary metastases,
B9E-MC-V277,Effect of Heavy Ion Radiotherapy combination w gemcitabine,
B9E-MC-V286,Sensitivity to Gemcitabine of the Pancreatic Cancer Cell Lin,
H3E-MC-S104,Single arm Ph2 Alimta/Cis + Erbitux in 1st line NSCLC,
ZYY-MC-GOAH,Evaluation of V6 & VLDL as Biomarkers of Metabolic Syndrome,
B9E-MC-X100,GEMCITABINE WITH DOCETAXEL IN BREAST CANCER,
H4Z-MC-JWWH,(JW19)  Phase 2 Endometrial Cancer,
B1Y-MC-C002,FLUOXETINE:  BREAST MILK,
H4Q-BP-V010,LY333328 in various test media against gram postitive bacter,
B1Y-MC-C003,RANDOMIZED TRIAL OF ANTIDEPRESSANT MEDS IN PRIMARY CARE,
H4Z-MC-JWWD,Ph2 Randomized Double Blind Eval 2 dose levels in Breast Ca.,
"2251",Pulmonary delivery in smokers,
"2280",Oral Delivery - Phase II,
"2292",LY333334 use prior to joint replacement,
B1Y-MC-HCCE,FLUOXETINE/ETHANOL INTERACTION-NORMAL SUBJECTS,
B3M-CA-V040,Activity of Cefaclor/Loracarbef to fresh isolates of H.INF.,
B9E-MC-S067,Ph II Alternating Gem+Oxal w/Gem based therapy,
B9E-MC-S071,Gem+Taxol vs. Gem+Taxol / Bladder,
B9E-SB-O013,"Phase II, Gemcitabine In Patients w/ Seminoma Cancer",
B9E-MC-I142,PHASE I DOSE ESCALATION STUDY OF COMB. MODALITY W/GEM + RT,
"2573",Jet Lag,
F1J-LC-SBAD,Digoxin Interaction,
"2649",PED Bronchitis Cefaclor 20mg/kg vs Macrolide,
H6X-LC-GBBA,Single Dose Safety Study,
"5006",Pulmonary hGH: Phase 2/3 in Adult GHD pts,
"5031",Absorption for Line Extension,
"5047",PET / PD study #1,
"5058",Phase II Exercise Asthma Study,
F1D-CA-O095,Olanzapine in Children with Aspergers Disorder,
H3S-XM-GGKE,Compliance and Health Outcomes Osteoporosis,
B9E-MC-X302,Phase I/II Gemcitabine and UART,
F3Z-MC-IONJ,Humalog vs Insulin Aspart:  Test Meal Study in Type 1,
H3S-US-X009,Effects of micronized DHEA on bone turnover,
B9E-SN-JHRR,Ph I-II Inf Gem plus Carbo in chemo naive adv NSCLC,
B9E-BX-O182,Gemcitabine vers cisplatin with gemc. in chemonaive patients,
F1D-JE-RA02,JP ola P-II RAIM DB,
B1Y-VI-A004,FLUCTINE VS LITHIUM IN DEPRESSION PROPHYLAXIS,
H6W-EW-MCAB,A pharmacodynamic study in a model of acute lung injury,
H6D-EW-LVDS,IC351 Interaction with a Angiotensin II Antagonist,
F1D-US-A103,olanzapine interactions w/ nicotine and mecamylamine in rats,
B1Y-BP-O018,Antidepressant Adherence Study,
B9E-MC-V249,LY264368 + topoisomerase 1 Renal Cell Carcinoma,
H8O-MC-O014,Effects of exenatide on pts with T2DM and CAD,
H8O-MC-X018,Effects of Exenatide after Adj Gastric Banding,
H6Q-MC-V047,Enzastaurin in human cancer cell lines,
H9P-MC-LNDS,Persistence of effect in reading disorder,
H8O-IT-B014,EBIRIOS - Observational Study for safety of Byetta in Italy,
I4E-MC-JXBB,CP02-0862: PhII-PK & DDI_Cetuximab-Carboplatin_H&N Squamous,
I2Y-EW-GHFH,BE of synthetic vs recombinant API,
I4G-FW-BIBD,IV/SQ Study,
B7A-MC-V022,Role of Protein Kinase C in VCAM-1 Expression i,
"13634",JP BIB SDSS,
I1F-MC-RHAN,IL17 vs Placebo Efficacy of LY2439821 for Crohn's Disease,
I4J-MC-HHBC,Phase I - LY2940680 topical dose escalation/expansion in BCC,
H3U-MC-V001,LABORATORY MARKER VALIDATION STUDY/5-ALPHA REDUCTASE,
I4T-IE-JVBF,REACH_CP12-0919_R_Ph3_1121B+BSC_vs_Placebo+BSC_HCC_2nd_line,
I5A-IE-JAEG,CP13-0812: PH2 - A12-HCC advance - 1st Line,
H6Q-MC-V077,Pre Clinical - Enz / Ritux anti prol in floo lymph cells,
F1D-VI-HGCK,Olz vs Clozapine in Trtmt Resist/Trtmt Intol Schizohiphrenia,
"10841",FHD trial for future cmpd FC000077,
H3E-US-I012,A PK Study of Alimta in Leptomeningeal Metastases,
F1D-VI-HGDV,OLANZAPINE VERSUS CHLORPROMAZINE IN MOROCCO,
F1D-VI-HGDW,EFFICACY AND SAFETY OF OLANZ IN PAKISTAN,
F1D-VI-HGFJ,MULTICENTER PAN-ARABIC STUDY,
F1J-JE-101G,PHARMACODYNAMIC STUDY ON Dulox (REPEATED DOSE STUDY),
I1R-FW-GLBB,MDSS,
H3E-US-I015,PhI 2-Arm Vinflunine w/ Erlotinib or Alimta in Solid Tumors,
F1D-US-X298,Neuroprotect Effects Antipsycho in Adoles & Young Adult Psyc,
B4Z-SB-LYDV,Effects of Atomoxetine vs Placebo on Cognition Over The Day,
"11150",Test Crystallisation of Gemcitabine,
H4Z-MC-GJAS,Arzoxifene Asian and Russian Registration Strategy,
F1J-LC-HMAB,LY248686 HYDROCHLORIDE: DOSE-RANGING STUDY,
B1Y-EW-E002,FLUOXETINE VS AMITRIPTYLINE-DBL-MAJOR DEPRESSIVE DISORDER,
H6Q-MC-S045,Ph 2 Navelbine + ENZ vs Navelbine + Placebo 2nd Line NSCLC,
H4Q-MC-ARRG,Void,
"2776",PT-Ceclor AF vs Macrolide,
F3Z-US-I013,Metabolic Adaptations to Diabetes,
B5K-MC-IBEY,Bridging study:  commercial inhaler,
H3E-MC-JMCN,PH I MTA + Cisplatin weekly,
B1Y-MC-HCFP,FLUOXETINE VS PLACEBO IN MDD: INFLUENCE OF REM SLEEP LATENCY,
B1Y-MC-HCGB,FLUOXETINE VS PLACEBO: WEIGHT LOSS ON RECHALLENGE,
B9E-MC-X197,"Gemcitabine, Cyclophosphamide, and Cisplatin",
B9E-MC-X201,Gemcitabine and Oral Etoposide Phase 1 Study,
B1Y-MC-HCJW,Fluoxetine versus Placebo in  Child and Adolescent OCD,
F1D-MC-HGIB,Olanzapine SAIM vs control in settings a general hospital,
"3044",Fixed dose oln vs. fixed dose risperidone,
B7A-LC-MBBU,Rifampin drug interaction study,
F1D-MC-HGGY,Placebo-controlled Olanzapine in  Bipolar I Depression,
B9E-MC-X209,Gemcitabine and Docetaxel for Pancreatic Cancer,
H3S-SX-GGJG,EFFECTS AND SAFETY OF RALOXIFENE ON MARKER OF BONE TURNOVER,
F1J-MC-SBBC,Epidemiology of Incontinence Assoc. w/Nursing Home Admission,
B3T-MC-JTAL,LY335979 Short Course IV with CHOP,
"3183",Phase III Colon CA,
F1D-US-A104,The role of Dopamine D25 And D2L receptors in the Mechanisms,
B9E-SB-O210,Gemcitabin + Cisplatin + Herceptin in Mamma CA,
B7A-LC-MBCR,Nitrate Interaction Study,
H3S-US-GGKO,Evista Vs. Alendronate,
F1D-IS-LOBM,SAIM in agitated patients,
H6P-AY-HDAL,Efficacy comparison of OFC in relapse prevention post ECT,
B9R-AY-O009,GH-Deficient Women - comparison of Raloxifene and Oestrogen.,
B9E-MC-X315,Combo Gemzar/cisplatin for advanced gallbladder/biliary trac,
H3S-US-X021,raloxifene therapy and lipoprotein subclass levels,
H6P-MC-X002,Eff of Fluox/Olan in Pts with Borderline Pers. Disorder,
B9E-US-S252,FDR Gem+ Carbo/Platinum sensitive late relapse Ovarian ca,
B9E-US-S257,Ph II Wkly Gem/Epi/Txtr for Locally Adv/Inflam Brst Ca,
F1D-XM-O123,Follow up patients with olanzapine as actual treatment,
B3N-HH-EUAJ,Safety and tolerability in hypertensives with advanced RF,
"5896",FHD,
"5936",Special Population Study,
B3N-PL-EUAO,MOXONIDINE IN LEFT VENTRICULAR HYPERTROPHY,
I1R-FW-GLBP,Thorough QTc Study,
"14168",Pediatric observational study in Japan,
I5O-FW-GTCA,SAD,
I3P-FW-GKBG,Bridging Study Prior to Phase 2,
H4G-EW-LIAQ,LY303870: PET STUDIES,
I5J-MC-NOAB,"Noc-1 Receptor Occupancy, SD, PET, in Healthy Subjects",
I2Y-JE-GHFW,JP Teriparatide Transdermal Phase 2 Study,
I5A-IE-X001,"8147:   Ph I/II-A12+Temsirolimus-Prostate",
I4V-MC-JADT,Psoriasis Phase 3 Randomized Withdrawal Study,
I2M-MC-GSDG,"Sclerostin for Bridging in Men, men w/ primary hypogonadal O",
I5I-IE-JTCA,FHD: PhI - TR 1 - Adv Solid Tumors,
H9H-MC-V001,Pre Clinical - Activity w/ TGF beta in HCC models,
I1R-MC-GLBZ,PK DDI Study - 2C8 & 3A4,
I6G-MC-RBAA,"First-in-human study, combined SAD-MAD",
H9H-MC-A004,Eval eff in gene engineered mouse models of glioblastoma mul,
F1J-MC-B049,"2011_814_Exploratory analysis:costs & resource utilization ",
F1K-US-EVDN,Xigris Surgical Study,
I1T-EW-MPBB,MDSS for mGluR2 potentiator/CysLT1Antagonist II  (LY2421371),
H9P-MC-LNBN,NERI IV Adjunctive Treatment Depression Relapse Prevention,
H7T-FW-TACF,Prasugrel: Asian loading dose study,
H6D-MC-A007,Effects of PDE-5 inhibition (tadalafil) on the lung Na and w,
H4S-FR-O072,CAPTIM DComparison of primary angioplasty and prehospital,
B7A-JE-MBDZ,JP PKC P-III DPN,
H7T-MC-TACI,"Prasugrel effectiveness-ASA intolerance, MPA IPA Accumetrics",
H6Q-MC-S042,Phase II ENZ in MM and Waldenstrom,
"11483",PK/PD Human Experimental Pain in HV,
H6Q-MC-S052,Ph II Bicalutamide + ENZ-Prostate CA (ECOG),
"11500",Ph III ENZ in Prostate,
F1J-MC-B021,Retrospective hepatic  and cardiovascular study,
F1D-US-X301,A Nursing Tool for Insight & Adherence in Psychosis,
H3E-CR-S380,Compare Alimta/Plat vs Taxane/Plat 1st line in NSCLC,
H8O-AY-GWCM,HEALTH OUTCOMES COMPARATOR STUDY,
B9E-MC-S122,Phase 2 Gem + Vinorelbine - 2nd Breast; Jun98SE109,
B1Y-MC-X001,BIOL AND TRTMT STUDIES INPAT ADOLESCENTS AT RISK FOR SUICIDE,
F3Z-JE-M33H,NPL Open,
F3Z-MC-IOIC,LM vs 30/70:  Test Meal Study in Patients w/ Type 1 Diabetes,
"3283",Olanzapine and Fluoxetine in Major Bipolar Depression,
B3N-EW-EUDK,Moxonidine Interaction study with Viagra,
F1D-MC-O024,Olanzapine in the Treatment of Puerperal Psychotic Illness,
B1Y-MC-X010,FLUOXETINE IN DIABETIC NEUROPATHY,
"3356",IPI Hourly Services,
B1Y-MC-X013,FOOD INTAKE/WT. GAIN POST SMOKING CESSATION:FLUOX VS PLACEBO,
"3424",Pilot study of olanzapine/fluoxetine in the treatment of MDD,
F1D-US-X130,Comp. of Effc. & Tol. of Low-dose Olz. vs. Haldol in behav.,
F1D-MC-X144,Open Label Trial of Olanzapine in Anorexia Nervosa,
"3498",support PK in migraine studies,
B9E-XM-JHPZ,"Phase II,Gemcitabine & Vinorelbine, Metastatic Breast Cancer",
B9E-MC-S131,Ph ll - Gem+CPT11 - Colorectal - OCT98SU92,
F1D-MC-O032,Open Study ofOlanzapine in Alzheimer's Dementia,
B4G-BP-LBAH,PERGOLIDE VS BROMOCRIPTIN ON COGNITION & MOTOR CONTROL,
B4G-EW-LBAT,PARKINSON / PERGOLIDE VS PLACEBO AS MONOTHERAPY,
H3E-MC-S011,Placeholder Trial,
F1J-MC-SBBT,Taiwan Local Registration Trial,
"6302","Efficacy, safety anf mood effects vs placebo in PCP",
B9E-GN-O279,Gem+Etoposide in Relapsed Refractory Non-Hodgkin's Lymphoma,
F1D-TW-S024,Olanzapine Observational Study_2001,
H7C-MC-LMBU,LY544344 4 and 16 mg BID Compared with Pbo in GAD,
H6M-BD-LDAO,Fed Fasted/MDSS 108,
B5K-MC-I004,DIABETES PREVENTION TRAIL,
B9E-MC-V153,In vivo Cytotoxic Activity of Gem against Poorly Diff CA,
B9E-MC-V155,"Gem Radiolabelled with Tritium, Cytosine position 5",
"6574",UK Observational Study of Patients with Sepsis,
"6584",Xigris Local IIT's for UK,
H6E-UT-O003,Role of FFA on the activation and expression of PPAR gamma,
B4Z-UT-S002,Adults ADHD and cognitive Dysfunctioning,
B9E-BX-JHSD,Neoadjuvant IIIB NSCLC seq chemo radiation,
H4W-LC-LLAF,MELATONIN:EFFECT ON BODY TEMPERATURE AND PHARMACOKINETICS,
H7L-MC-MDAE,Viscosity Study Support Device,
I1D-MC-JIAM,Ketoconazole/Rifampin DDI in NHV or Patients,
"14969",Alpha-blocker Combo Trial,
H9H-MC-A010,TGFb and focal radiotherapy in glioma in ortho mouse models,
I3G-MC-V002,Contribution of S6 in EGFR-mediated fibrosis,
"15070",Thrombogenesis Study,
I6A-MC-A003,Devel.of PI3KJmTOR for the treatment of soft tissue sarcoma,
H8L-MC-IQBY,BOLT Autoinjector Formative HF1 for Ixekizumab and Tabalumab,
H8L-MC-IQBZ,BIL 60 KwikPen Formative Human Factors 1,
H8L-MC-IQCB,ePFS summative study for Ixekizumab and Tabalumab ,
A3Q-ME-AFBR,Mexico Keflex Bioequivalence Study of Keflex Pediatric,
H9X-MC-GBGE,SGLT2 background therapy,
B1Y-MC-X123,Discontinuation Study of Fluoxetine in PTSD,
I4V-MC-JAHB,H2H trial,
B9Z-SE-9416,DIRTHROMYCIN VS. MIOCAMYCIN IN LOWER RESPIRATORY INFECTION,
H3S-US-GGLM,BrCa Gail vs Modified Gail,
"11731",In vitro interaction between pemetrexed and gemcitabine usi,
F3Z-IL-IOMA,INSULIN LISPRO:F.I.T. EDUCATIONAL TRIAL,
F3Z-MC-IOPE,NPL/Glargine,
F1J-KL-B028,Duloxetine PMS,
H8O-MC-X005,Exen Tx on Hepatic Fat Content w/Type 2 DM,
H3E-MC-V136,Determine contribution of folate receptor to Alimta efficacy,
F1D-US-A146,Pharmaco-Metabolic Phenotyping and Whole-Genome Mapping of,
F1D-XM-O308,Prevalence of subsyndromal symptoms in BP patients under txt,
I2P-MC-GAAC,SDSS/MDSS food effect - FHD MCH-R1,
H9V-JE-GFRC,JP TGFb antibody PhI SDSS,
F3Z-JE-IOPG,JP Lispro MIX50 TID,
"12053",LY2599666 Phase 2 MDSS in Subjects with Alzheimer's disease,
I2R-MC-BIDG,Renal Clinical Study,
"12159",T2DM oral basal combo,
H8O-MC-GWCR,Obesity Phase 3 Study 1,
H9P-MC-LNBR,NERI IV Depression Augmentation #3 NERI +SSRI,
F3Z-JE-M01H,lispro P-I NPH&NPL,
B9E-US-X348,"Ph II Study Eval Efficacy of Gem,Carbo, & Dexameth in Lympho",
"6761",TMS - 108,
"6794","5-HT1F Taste Masking Study",
"6839",Spec Pops Elderly,
B9E-MC-V168,Gemcitabine as a macromolecular drug to enhance tumor direct,
B9E-MC-S303,Ph I/II Gem + 3D XRT after Induc Chemo - nsclc,
ZYL-LC-EOAD,ECG Study in healthy volunteers,
H4S-MC-I016,Defining the Optimal Anticoagulant for Use with Abciximab,
B9E-US-X361,Pilot Trastuzamab & Gem  in Adv NSCLC w/overexpress HER2.,
"7003",Dummy Account IIT Placeholder for CTMat Shared Stock -  USMD,
B9R-MC-GDGF,Safety of Pulm hGH in adult pts with Asthma,
B4Z-MC-LYBW,PET Imaging study in Adults - Atomox vs MPH,
F1D-ME-S039,Schizophrenia Functional and Clinical Outcomes,
B9E-MC-JHCC,GEMCITABINE COMPASSIONATE USE IN PATIENTS W/ OVARIAN CA (OUS,
"7190",Placeholderstudy for Gemzar AT 2003/4/5,
F1D-EW-HGKV,EMBLEM: Euro Obs HO Study of Mania in Bipolar Disorder,
F1D-BX-LOAG,OLANZAPINE IN SCHIZOPHRENIC PATIENTS,
I2L-MC-ALCA,SAD/MAD A beta Antibody Fab PEG,
H3E-BX-T004,Medical Need Program BELGIUM - Alimta,
B4Z-US-B029,"2014-271 Who is the Strattera patient & predictors of choice",
I1V-JE-EIBP,Bioequivalence of 65mg tablet and Japan Food Effect-2,
"15635","DDI  ""Placeholder""",
"15661",DDI - Antibiotics,
I2R-MC-BIDW,T1DM 3 month treatment vs glargine,
H9H-MC-JBEF,"Ph1b/2 - Galunisertib + Nivolumab - NSCLC, HCC",
I2R-EW-BIDX,Absolute Bioavailability study,
H5L-MC-JSAB,Ph 1 Mult. Dose Escalating study of LY320236 Administered PO,
H9X-MC-B009, M-PEM & Network Database Study,
I4E-IE-W817,Protocol CA225-286; CLINICAL STUDY WITH CETUXIMAB/DOCETAXEL/,
I4E-IE-W839,Protocol CA225-224; A I Trial of Cetuximab (C225) and Pemetr,
I4E-IE-W853,Protocol CA225-243; An Exploratory Pharmacogenomic Study of,
I4E-IE-W880,CA225-066:E3303 PhII-CETUXIMAB+Cis+XRT-SCCHN,
B9E-MC-S063,"Ph lll, Gem+Cis vs Cis+Taxol or Carbo+Taxol, Ovarian-1st Lin",
B4Z-US-LYEI,fMRI for ADHD and Dyslexia,
B9R-IT-O052,Pituitary function after cranic trauma,
H8A-MC-LZAS,Special Population - Age/weight ,
I2U-EW-H301,CSF Histamine Methods (no drug),
I3D-MC-GICA,MR Antagonist K+ Challenge Methods Study,
H8O-FR-GWCY,exenatideLAR compared to pioglitazone added to Metformin+SU,
"12345",Biopharm Placeholder for Arzoxifene,
F1D-XM-B040,Time to relapse in schizophrenic pts in risk of non adherenc,
"12364","2yr diabestes durability trial-GLP-PEG 40 montherapy vs met ",
B4Z-IS-O022,The prevelance of ADHD in children with criminal record,
"12440",Phase III 2yr Prevention,
F3Z-VI-IOBQ,SAFETY AND EFFICACY OF LYSPRO.....,
B9E-US-X468,Adjuvant Bev+Dox+Cyclo followed by Tax+Gem in Breast Cancer,
H8O-US-X011,Obese type 2 pts and exenatide,
"12501",PoC/Phase 2 MDD trial w/Obesity (combo therapy),
"12564",Ph II Trial #3 (Tumor Type TBD),
"11192",The role of Pemetrexed in mediating the inhibition of Telome,
I8G-MC-LMDA,SAD,
I1F-MC-RHBU,To evaluate CYP on the metabolism in patients with psoriasis,
I1V-MC-EIBQ,Lipid 2,
B3L-MC-LWAL,LY354740 vrs plac in the reduction of opiate withdrawal sxs,
"16292",Absolute Bioavailability,
"16293",RBA/Definitive Food Effect,
I8K-MC-JPDE,Disposition of [14C]LY3337641 in Healthy Subjects,
I7S-MC-HBEE,C14,
I8C-MC-GSFB,MAD in patients with Sjogren's Syndrome,
I6F-MC-JJCH,PGP DDI,
I8Q-MC-GSEA,SAD/MAD,
H9X-MC-GBGH,Award 12 - Combination w Insulin Glargine,
H8A-JE-B003,GERAS-J Study,
I6T-MC-AMAF,Phase 2 Trial in Psoriasis,
"9117",Efficacy and Safety of Symbyax in bipolar depression,
"7197",Placeholderstudy for Zyprexa AT 2003/4/5,
B9E-XM-O420,PhII OVARY:Paclitaxel+Carbo vs Gem+Carbo -Paclitaxel+Carbo,
B9E-MC-JHCN,GEMCITABINE SAFETY STUDY,
B9E-MC-JHDK,GEMCITABINE IN PATIENTS WITH NSCLC,
H3S-FP-S037,Osteoporosis discovery in Ffench gynecologycal practice,
B9E-US-X364,Ph II for Tx of Recurr or Pers Platinum-Refrac Ovarian.,
B9E-MC-JHDY,GEMCITABINE/VINORELBINE IN METAST. SOLID TUMORS: DOSE FIND.,
"7316",Placeholder for Xigris studies,
F1D-CA-O191,Atypical Antipsychotics After an Acute Manic Episode,
F1D-IT-HGLE,Bipolar weight gain management,
"7409",By up trigger Atomoxetin AT 2004,
B9E-AA-JHSH,Patient Attitude and Lung Cancer Survival - Prospective OS,
F1K-FP-O031,Local effects aPC evaluated by microdialysis - Pr ,
"7485",Placeholder for Alimta IITs- UK,
B3D-FP-A001,transgenic mice,
H6U-MC-A001,mGluR 2/3 Radiotracer Development and Animal Validation,
B7A-MC-MBDJ,McVeigh-Correlation Platelet Activity & Vascular Reactivity,
B9R-IT-V002,Cellulare Damage and Modulation of Gene Expression,
B9E-MC-V049,Intravesical gem for BCG-refract superf carcinoma of bladder,
B9E-UT-O123,Phase II study of GIC in pts with recurrent/relapsed SCLC,
B9E-MC-X264,Phase 2 Gemcitabine and CPT-11 for Metastatic Biliary Cancer,
B9E-MC-X268,Phase II Study of Gemcitabine and Irinotecan,
B1Y-SB-4006,FLUOXETINE 40-60MG/MAPROTILINE UNIPOLOR DEPRES.,
F1D-XM-O066,Evaluation of treatment program with antipsychoti.,
F1D-FP-O072,oculomotricity in schizophrenic patients,
"4584",Definitive formulation of microspheres (LOAX type study),
B9E-UT-V067,Exploration study of Gemcitabine in superficial bladder canc,
F1D-CA-O081,Effects of inducers of cytochrome p450 on metab of Zyp,
F1D-SK-O086,Functional Brain Imaging in Tourette's: Olz versus Haldol,
B7A-JE-104M,JP PKC1 P-I high fat diabetic meal,
H3R-MC-LBBB,migraine study,
F1D-US-X183,an open label trial of olz in children diagnosed with pdd,
B1Y-ME-HCKR,Corelation between changes in cerebral mapping,
F1D-ME-HGJC,Patients with first episode of psychosis,
B1Y-MC-HCKZ,Prozac vs. Reboxetine,
"4820",LY353381 morphine interaction study,
I2O-MC-HAAH,MDSS in schizophrenic patients,
H9P-EW-LNCU,Biopharm Activated Charcoal Study,
H8Y-MC-HBBR,Phase II Open label extension to assess safety ,
I2K-MC-ZZAT,Mid-Term PSG,
I2K-MC-ZZAV,Short Term with Night Impairment,
H8Y-MC-HBBV,Long-Term Open-Label Safety Study of LY2140023(Schizofrenia),
H8Y-MC-HBCT,Formulation: Gastric emptying study,
F3Z-EW-B009,Observational Clinical practice in Arabic country ,
H2Q-LC-LZZC,METABOLISM AND PHARMACOKINETICS OF 14C-LY246708,
I2K-MC-ZZBS,Potential Abuse,
I2K-MC-ZZCH,Formulation Change or Manufacturing Specs,
H7T-EW-TADB,Bioequivalence,
"12883",CRH-1 II Phase 2 Relapse Prevention,
H3E-MC-JMAG,LY231514 (TSI) QX21D IN RECURRENT/METASTATIC BREAST CANCER,
H3E-MC-JMAL,PH II TRIAL OF LY231514 IV Q 21 DAYS IN PTS W/NSCLC,
"13035",spMS Trial,
H3E-MC-JMAO,LY231514 IN COLORECTAL CANCER,
H6Q-MC-A030,Enz and rapamycin in SSCHN,
I8R-MC-IGBI,Intranasal Glucagon PK/PD Study,
B1Y-MC-HCJA,"FLX, PAR, SRT IN THE TREATMENT OF MDD:  SSRI WITHDRAWAL",
I7E-AV-E053,AV-1451-EXIST-053,
I4V-MC-JAIH,Ph3 Ly vs PBO mod to severe UC Mixed Group,
I9H-MC-FFAB,LDI Dermal Flow Study,
I5Q-MC-CGAW,Treatment Resistant Study,
H9X-CA-X001,Dulaglutide&Preservation of Betacell Function in Women w/GDM,
I5T-MC-AACE,Phase III Registration Trial,
F3Z-MC-IOGT,Feasibility of Insulin Lispro MM in MDI,
"16743",PI3 Kinase/mTOR Dual Inhibitor DDI 1,
I6T-MC-AMBL,"2016-5540:Qualitative Research in Adult&Adolescent Pts w/ UC",
H8H-CD-LAHM, IV Lasmiditan in the Acute Treatment of Migraine,
H8H-CD-LAHS,Oral/sublingual solutions (COL MIG-102)randomized,
I7E-AV-E084,AV-1451-EXIST-084,
H3S-KL-S040,Effectiveness of Evista in postmenopausal women with ospeopo,
H3E-US-S058,"Ph II, ALIMTA + Carbo vs Taxotere Carbo in NSCLC",
B9E-MC-JHLT,A PHASE 2 STUDY OF GEMCITABINE IN NSCLC,
"7631",Local Registration,
B9E-AY-O347,Gemcitabine and oxaliplatin in advanced NSCLC,
"7686",IIT / Fellowship / Chair Placeholder for Xigris,
"7741",Atomoxetine vs Methylphenidate in ADHD,
"7750",Fellowship Ctr for Diabetes (Dr. Zinman),
"7768",Obs study: GemDox combination in patients with breast cancer,
"7773",Psychoepidemiological study,
"7790",ICR Regional Observational Study - Cialis,
F1D-AY-O216,Physical co-morbidity study,
B9E-SB-JHMM,GEM IN COMB.WITH 5 FU/LEUC.NONRESECT.PANCR.GALLBLADDE CHOLAN,
H3S-AG-S041,"""SWitch from Evista""",
"7868",PTH compared with Alendronate on spine bone Density in Osteo,
"7909",OS Switching SSRIs to DLX,
H8R-MC-HJAH,Depression Add-on Phase II,
H6D-MC-LVFJ,Cardiovascular Safety - European Regional Study,
"7998","Pre-launch Study at Urologists, GPs, Gynecologists (Sykes)",
"4837","LY293111 in Colon Ca/FAP, Pilot Biomarker",
B9R-US-A003,Biological role of BMP-2 in growth plate chondrogenesis ....,
B7A-MC-MBCX,PKCß-Inhibitor Macular Edema Trial,
"4902",Alzheimer's disease Pk/PD trial,
B9E-BP-O169,"Phase I, Gemcitabine & Treosulfan in Adv. Malignant Melanoma",
H3S-MC-O008,Intensive humulin treatment in early diabetic neuropathy,
"4939",Pivotal Ovulation Induction Trial - II,
B9E-MC-V100,A mechanistic basis to overcome resistance,
H6J-EW-GIAC,rfsh - First Human Dose (Subcutaneous Administration),
B4Z-MC-LYAU,fMRI Imaging study of Tomoxetine,
"5010",Phase 2 schizophrenia,
"5016",LY466700 Interaction Study,
"5033",Olanzapine DI Study,
F1J-MC-HMBS,Fibromyalgia Pain Study (no extension),
B4G-FP-S004,SURVEY ON QOL IN FLUCTUANT PARKINSONIAN PATIENTS,
F3Z-MC-IOIE,Dose Ranging glucose clamp study:  Humalog vs Insulin Aspart,
B9E-SZ-O180,Paclitaxel Gemcitabine and sequential radiotherapy in NSCLC,
"5292",Zyprexa (Bipolar) DBT Confirmatory Study,
F1J-MC-SBBK, Open Label Safety and Exposure to Duloxetine Trial,
"13167",mGlu2 Phase 2 #1 MDD,
"13247",Food Effect Study,
I2M-MC-GSDJ,Global Registration-Active Comparator Fracture Trial,
"13281",QTc trial - CRH-1 Antagonist II LY2371712,
"13344",Ethnic Differences,
B1Y-FP-0071,"FLUOXETINE MAJOR DEPRESSIVE DISORDER, CONCOMITANT OXAZEPAM",
H4Z-MC-GJBC,Arzoxifene Combo PD Study,
B9E-JE-JHSW,JP Gem P-I Ova,
I2Y-EW-GHFG,Application Site ,
H3S-LC-GGHO,RALOXIFENE HCL:GASTROINTESTINAL DRUG INTERACTION STUDY,
I1L-MC-GAEE,SAM:  1-mo T2DM Safety Study,
I4G-FW-BIBB,SAD Study,
"13623",Effect of Sildenafil in genetic rat model of depression.,
H8O-JE-EX01,JP_ EXD_ BID_Special_PMS,
I2I-JE-JMMF,JP_Chk-1_Phase_1b,
H6Q-MC-A038,Pre Clinical - Enz and Oral Cancer,
B1Y-MC-X137,TREATMENT OF BULIMIA NERVOSA IN A PRIMARY CARE SETTING,
I4V-MC-B014,Patient Preference Study to Understand Medical Need in RA,
I8I-MC-JY04,Ph II - Pan Raf Continued Access - MPD,
I9N-MC-FCAB,Phase 2 Atopic Dermatitis LY3375880,
F3Z-MC-IORC,TANGO Feasibility Study 2c,
F3Z-MC-IORD,TANGO Feasibility Study 2d,
I8F-MC-GPHD,Translaunch Trial 2: H2H vs Basal Bolus,
J1R-MC-GZFA,FHD SAD Part A HV and Part B in T2DM Pts,
F3Z-MC-IORL,TANGO T2 U200 Feasibility,
J1L-AM-JZGE,Willow 1 - Ph1 HV - PK of single and multiple doses,
J1L-AM-JZGG,Willow 3 - Ph1 HV -PK crossover prefilled vs vial-syringe,
J1U-MC-JL02,Ph II - Lung Protocol Ram+Doce+TIM3 Post IO/Platinum - NSCLC,
"17346",Ph 1a - Pegilodecakin vs SOC - 1L Uveal Melanoma,
"17348",Ph II - Pegilodecakin + FOLFIRINOX - 1L Pancreatic Cancer,
J1L-MC-JZGM,Ph 1 - Pegilodecakin - 1L RCC (pembro + levatinib),
B7A-CA-S003,Effect of PKC ß Inhibitor on Renal Function,
"8031",PET Study,
"8076",TZD vs. LY2148568 in SU+Met failures (blinded),
H7C-LC-LMCI,Benzodiazepine Interaction Study,
"8091",Repeat dosing of LAR,
B9R-CA-O033,Placebo controlled crossover study in a single GHD patient,
"8115",PPAR Co-Ag 2 Pilot Formulation Bridging Study,
B9E-XB-S338,Ph I study Fxd Dose Rate Solid Tumors,
H3S-US-X025,An Observational Trial of HRT Discontinuance,
B9E-MC-S341,Ph II Neoadj chemo Gem + Cis + Radiotherapy  in Bladder CA,
B9E-MC-V222,Support IIT trial Multicenter Ph II Trial Fixed dose Gem/Cap,
F1D-PL-O230,Peptides in schizophrenia - atypical neuroleptic treatment,
F1D-US-X237,Wt Prevention Program for Mgmt of Wt Gain Mexican-Americans,
"8347",Dulox. open label long term in dysthymia,
"8403","Ph III, ALIMTA + Epirubicin vs FEC in Breast Cancer",
H8Z-MC-A004,Dosimetry in 2nd species,
H6P-MC-HDAV,OFC in the Tx of Pts with Borderline Personality Disorder,
"8572",Type 2 Diabetes Ph 2,
B9E-BP-O192,"Phase I/II, Gemcitabine/Cisplatin, Bladder cancer",
"5318",Phase II dose response in Acute Mania - Japan,
F1D-MC-A102,PFC Transmitter Systems and Cognitive Flexibility,
H6Y-SB-HKAI,"6 Month Observational Trial on Tradon",
B9E-MC-V104,Efficacy of comb of camptothecin derivatives w/gem in lung c,
B9E-MC-V105,HPLC method for analysis of gem & its metabolite,
F1D-GH-HGJY,Efficacy and safety of Olanzapine in schizophrenia patients,
"5469",BIODISPONIBILITY TRIAL FOR BETA ACETILDIGOXIN,
B3D-MC-GHAF,ESTROGENS VS PTH IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS,
"5564",Fellowship,
B9E-MC-X310,PhII Gemzar/Carboplatin/Taxotere 1st line Met NSCL Cancer,
B9E-MC-X318,PII Gemzar/GMCSF/Rituxan for lymphoproliferative disorders,
B9E-ME-O225,Phase II Combining Docetaxel/Gemcitabine in Advanced NSCLC,
"5610",Olanzapine Health Outcomes Study - retrospective,
"5626",GET in Metastatic Breast Cancer,
B3M-SE-1008,CECLOR: EMPIRICAL CLINICAL EXPERIENCE STUDY,
H7F-FP-V002,Effect on Apoptosis of Normal Breast cells,
B3D-MC-X001,Comparison of Histomorphometry and microCT in Bone Biopsies,
H6D-MC-LVJL,Trial(AUT) to demonstrate product usage,
H7T-MC-TAEK,Phase II Adult Sickle Cell Disease,
"14030",Byetta vs glargine in Ramadan,
H4A-MC-A001,LY303366:  INVASIVE PULMONARY ASPERGILLOSIS--RABBIT MODEL,
"14178",Fibrosing Colonoscopy Observational Study,
I4T-IE-JVBY,CP12-1029:PhIb-1121B+Irinotican+Levofolinate+5-Fluor-CRC,
I4F-MC-CCAD,PET Test/Retest and dosimetry,
H7T-FR-B016,French Obs Study (FAST-MI Registry in France),
I5E-MC-TSAH,MTE08 - Phase III OL Titration - Efficacy and Safety,
F1J-SZ-O052,Etude ESPoir-DU (Evaluation de la SMT en pratique ambulatoir,
I1V-MC-EIBL,Lipid Supporting Study 6,
I6I-MC-LMRB,Combined Ph 1b/2 FED Study,
H6D-IT-V012,Effects of tadalafil on aromatase activity in osteoblasts,
"14590",RBA Fixed Dose PK Study w/DPPIV,
I4V-MC-JAGJ,Ketoconazole  and Fluconazole DDI,
H7T-EW-TAEQ,Pediatric bioavail. of commercial peds. formulation,
"14702",Rosiglitazone,
"17534",JP PMS - Ph IV - Abema - ILD Validation Study,
J2M-MC-GZKA,FHD SAD/MAD/DDI HV,
J2G-OX-Y008,PhI-RET Inhibitor-MTC,
J2G-OX-Y031,PhI-RET Inhibitor-NSCLC,
J2G-OX-Y034,PhI-RET Inhibitor-MTC,
J2N-OX-JZNF,LOXO-BTK-20012-Ph1-Pirtobrutinib-Hepatic,
H8H-MC-B002,Lasmiditan Retrospective Pregnancy Database Study,
J2G-OX-Y110,RET Inhibitor-NSCLC,
J2G-OX-Y116,RET Inhibitor-NSCLC,
J2T-DM-KGAQ,Lebri for pts w/mild to moderate asthma,
J2G-OX-Y202,RET Inhibitor,
H3E-MC-JMAW,Phase I  - Renal Impaired,
"18117",China PK Study,
"18132",JP PMS-Ph IV4-Abemaciclib-Breast Cancer,
I8F-MC-GPII,TZP in Underserved Populations,
J3N-OX-JZRF,LOXO-BCL-2x0xx-Ph1-BCL2-Formal Food Effect,
B9R-MC-X001,KERATAN SULFATE: AN INDICATOR OF BONE ELONGATION,
"8600",Karolinska Schizophrenia Genomics Database Project,
F1J-MC-SBCK,Intermittent or PRN Use,
"8645",Exendin-4: Interaction 2,
H6Q-MC-JCAP,Phase Ib Enza w/Alimta in Advanced Metastatic Cancer,
H3E-MC-V004,P-glycoprotein transporter protein in ALIMTA resistance,
"8817",Place HolderIIT Dr Corcos,
"8859",FINDER,
ZYY-LC-B001,Method study,
"8904",ALIMTA CTNR LOCAL SUPPORT WORK,
H7R-LC-GCBN,Renal Impairment Study 1,
H7R-LC-GCBQ,Drug-Drug Interaction Pilot Study,
H7R-MC-GCCE,Efficacy in combination w/metformin & sulfonylurea,
H7T-EW-TAAZ,CS-747: Clopidogrel vs CS-747 LD,
H7T-EW-TAAV,CS-747: Statin interaction,
"9016",Placeholder for Lymphoma,
"9017",Phase II Single Agent Alimta in MBC,
H3E-US-S046,Ph II Adj Gem/Carbo vs Alimta/Carbo vs Alimta/Gem elderly,
B9Z-MC-V016,SUSCEPTIBILITY TESTING OF MYCOPLASMAS TO DIRITHRO AND ERYTHR,
"5111",Glycemic Control No.2,
H9H-MC-A002,Pre Clinical - invivo signal pathways,
H9H-MC-A003,"Sig.. & drug-resist., stem cell phenotype basal-like breast ",
B9R-CY-O057,Search for Genetic Causes of Hypopituitarism by PROP1 Gene,
H9H-MC-V003,Cell Autonomous TGFp receptor sigaaUng In AML stem cells for,
F1D-MC-B043,"2012-037_Use of OLZ-LAI in Sweden",
H4Y-MS-LJAA,"PHASE 1, SINGLE ORAL DOSE IN HEALTHY VOLUNTEERS",
I4J-MC-HHBF,C14 in healthy male subjects,
H4Y-MS-LJAD,LY334370 SINGLE ORAL DOSES IN MIGRAINE PATIENTS,
I6Q-MC-BIFA,Enbrel PK Compariability Study,
I2I-MC-V006,ID of Genes in Drug Resist. or Synergism/Lung Cancer,
I1D-MC-JIAP,Simvastatin DDI in NHV or patients,
"14992","2013-112_Retro cohort stdy inpatient clinical registries/out",
I6L-AV-_D01,"18F-AV-133-D01",
H8L-MC-IQBI,U200 KwikPen Summative Human Factors Study,
F1J-JE-B053,Japan NSOS MDD trial,
"9212",IIT Placeholder - Alimta (Australia),
B9E-XB-S260,"Phase II, gem+docetaxel biweekly, in advanced bladder cancer",
B3N-HH-EUAE,Moxonidine and lipid metabolism vs propranolole,
B9E-MC-V133,Cytotoxic effect of gem-human primary tumor in culture,
"5814",nfmsdnfmdnm,
B9R-EW-GDFZ,Pulm hGH multi dose safety PK and PD,
B7A-MC-MBCU,Vision Loss in Patients with Diabetes Macular Edema,
F1D-US-X212,Treating Refractory Childhood Schizophrenia,
"5917",Phase II ALIMTA + F/A + B12 (patent study) - Solid Tumors,
B9E-XL-S262,Ph II ciclof+epi sec gem+taxol+-hercep neoad in breast ca.,
B9E-MC-S263,Ph III -Metastatic -Rand Docetaxel vs Docetaxel + G -breast,
H3S-XM-O015,Raloxifene in Nitric oxid expresion (platelet agregation),
B3N-SB-EIIA,XIPAMIDE VS. FUROSEMIDE IN HYPERT. PAT. WITH RENAL FAILURE,
B9E-FP-O257,IIT-Bladder B9E-FP-O257 GETUG / VESUNFIT,
B9E-UT-O258,Gemcitabine and Carboplatin followed by Taxol in NSCLC,
H3S-BP-O111,effect oestrogen and ralox on cytokine release in monocytes,
H6N-MC-LEAI,"451395 Cerebrospinal Fluid PK in Healthy Human Subjects",
B4G-BP-0004,SUBTHERAPEUTIC DOSES PERGOLIDE NEED FOR LDOPA IN PD?,
B4Z-MC-LYBK,Treatment of Anxiety,
B3L-MC-LWAG,LY354740 Versus Placebo and Lorazepam in Outpatients w/GAD,
I5T-MC-B002,P-tau Non-Interventional Study,
J4H-NS-I001,SAD/MAD (Non Lilly study in-licensed molecule),
F3Z-BP-O005,Insulin Lispro Injection Timing Study,
B3N-MC-EUBN,"Safety, efficacy, hemodynamic effects/Mox and Beta Blockers",
B1Y-MC-HCJK,Fluoxetine Versus Placebeo in Posttraumatic Stress Disorder,
B1Y-MC-X131,FLUOXETINE IN OUTPATIENTS WITH FIBROMYALGIA,
B9E-MC-I080,"GEMCITABINE, CISPLATIN, AND DOCETAXEL IN REFRACTORY TUMORS.",
B1Y-MC-X128,FLUOXETINE AS QUITE SMOKING AID FOR DEPRESSION-PRONE SMOKERS,
B9E-MC-I105,GEMCITABINE PLUS VINORELBINE IN NON-SMALL CELL LUNG CANCER,
F1D-EW-LOAW,Olanzapine IM Multiple-Dose PK Study in Volunteers,
B1Y-LC-HCCU,FLUOXETINE EFFECT ON EX. VIVO PLATELET FUNCTION,
B9E-MC-JHQG,"Breast-Gemcitabine + Taxol vs Taxol, Phase III",
B9E-MC-S048,Gem + Carbo + Taxol in SCLC,
B9U-MC-V021,LORABID IN VITRO SURVEILLANCE STUDY,
B1Y-MC-X156,PET IMAGING IN IMPULSIVITY: RESPONSE TO PROZAC,
F1D-MC-HGGN,"THE COMPARATIVE EFFICACY OF OLAN, RISPER, HALOP FOR COGNITIO",
I4V-MC-A001,Effect of LN3103801 in Mouse Model of renal disease,
H8L-MC-IQBU,Strattera Dosing Aids Summative Human Factors,
I4O-EW-BADA,Memantine DDI,
H7U-MC-IDAG,"Definitive Dose Response, Pulmonary Insulin",
I6E-AV-_A16,Autopsy follow-up for AV-45 patients in PET trial 18F-AV-A07,
"15253","Role of small molecule therapy, survival renal transplant",
B9E-MC-S266,Ph II(rand) Gem+Cis+XRT +/-Amifostine - NSCLC,
B3D-LC-GHBC,LY333334 Use in Heart Failure Patients,
H9H-MC-A017,AN ORTHOTOPIC MODEL OF HUMAN OVARIAN TUMOR IN NUDE MICE,
F3Z-MC-IOOI,Premeal insulin lispro mixture vs. glargine,
B3D-LC-GHBA,Thiazide Diuretic Interaction Study,
I1F-MC-B001,"2012-466 NPF Psoriasis Cross Sectional Survey Study",
"6155",Bone/Hip (osteo) Oritavancin Study,
"2286",LY333334 Dose Optimization,
H9H-MC-A022,Immunological modulation of ocular tumor metastasaes,
"2291",Use of LY333334 in patient with bone grafts,
H6U-UT-LRAD,MACS,
I7Q-FW-SLAB,Multiple-ascending dose study (MAD),
H4Q-SB-A003,LY333328--Rabbit Meningitis Model (S pneumoniae),
B9E-MC-X240,Adjuvant Gemcitabine and Cisplatin for Stage IB & 2A NSCLC,
B1Y-MC-X041,FLUOXETINE ADJUNCTS IN TREATMENT-REFRACTORY MDD,
H3S-US-A003,Evaluation of the Estrogenic Effects of Raloxifene in the ca,
B9E-BX-O049,"Phase I, Gemcitabine, Ifosfamide, & Cisplatin, In Adv NSCLC",
B9E-MC-S135,Ph 2 Gem + taxotere in 1st line breast cancer-Oct98SE125,
F3Z-SB-O021,"IIT of lispro in type 1, measurement of tissue glucose",
H6D-EW-LVAO,Dipyridamole interaction study,
H3S-US-GGJQ,Study of Raloxifene in PMP with history of migraines,
H6D-EW-LVBX,Dose Strength study with IC351 (LY450190),
"3885",Ph III LY354740 vs. placebo vs. paroxetine in panic disorder,
B9E-MC-X262,Phase I Study of Gemcitabine and Irinotecan,
"3958",PK/PD EVAL OF LY300164 PHOTO-IND PAR EEG ESP PAT EPILEPSY,
F1D-CA-O046,Will Zyprexa be effective in reducing cognitive dysfunction,
B3N-PH-EUDO,Moxonidine in the Treatment of Mild to Moderate Hypertension,
"4175",Open label dose escalation trial,
B9E-MC-V038,Study uptake of gemcitabine in hematologic cells,
"9074",Alimta+Cisplastin in treatment of metastatic gastric cancer,
F1D-LC-HGGX,Pharmacodynamic interaction of Donepezil and Olanzapine in A,
F1D-CA-O015,INVESTIG. OF EFFECTS OF ANTIPSYCH. ON 5-HT2C REC. IN PAT.,
F1D-US-HGGD,Outcomes of Olz. in Schizo. in Usual Clinical Practice,
F1D-MC-HGHJ,Olanzapine vs Ziprasidone in Schizophrenia,
B9E-MC-S070,Ph I/II Gemcitabine in superficial bladder cancer,
B9E-MC-S082,Gem+Tax+Epi vs Gem+Tax / Breast,
B9E-MC-S092,Gem+Tax post anthra/Breast ca,
B9E-MC-S110,"Gem+5FU or Doxorubicin, Ph 2 - Hepatoma",
B1Y-MC-HCJS,Fluoxetine Versus Placebo in Generalized Anxiety Disorder,
B1Y-MC-HCDE,FLUOXETINE/DOXEPIN DEPRESSED GERIATRIC PATIENTS,
B9E-MC-I038,PHASE I DOSE STUDY OF COMB. GEMCITABINE AND TOPOTECAN,
B1Y-MC-X165,PSYCHOTROPIC MED USE IN AN URBAN PRIMARY CARE PRACTICE,
F1D-US-HGHQ,Olanzapine vs. Divalproex in the Treatment of Acute Mania,
"2568",Pharmacodynamic study,
F1J-LC-SBAE,Ethanol Interaction,
B1Y-MC-HCDU,FLUOXETINE ALCOHOL CRAVING EFFECTS NORMAL VOLUN.,
F1D-MC-A002,SPECTROSCOPIC STUD.OLAN. EFFECTS ON BRAIN METABOLISM IN RATS,
H7C-MC-LMCB,GAD Long term efficacy,
B1Y-BP-HC53,FLUOXETINE/COMPARATORS PSYCHOMOTOR PERFORMANCE/ALCOHOL,
B5K-GH-O007,The effect of dury therapy on beta-cell function in type 2,
"6454",CTNR: Gemzar + Cisplatin + Affinitak - NSCLC,
F1D-US-HGKF,Olanzapine add-on in the treatment of bipolar,
F1D-SU-O149,switching study in schizophrenic subjects: From haloperidol,
"6545",Gem-Cis+/- Herceptin in HER2 positive bladder cancer patient,
F1D-BP-O164,Zyprexa IM Case Series,
B9E-CP-O313,A ph II of pegylat liposom doxoru+gem in recurr epi ovar can,
"6627","Olanzapine versus Risperidone, adolescents",
F3Z-US-IOOG,TestMeal Composition,
B9E-UT-O304,Gemcitabine vs taxol in NSCLC in elderly patients,
H7G-MC-PDAD,LY582563 Dose Finding in Chronic HBV Infected Patients,
F1D-US-X221,Cost Effectiveness of Novel Anti-Psychotic Medications Among,
"6812",Bioavailability study,
B9E-MC-V165,Pharmacological - pharmacodynamic study of Gemcitabine durin,
F3Z-US-X014,Effect of Self-Monitoring of BG w/NIDDM Type 2 pts.,
B9E-MC-S298,Ph II-Adj-Gem + Oxaliplatin --> Gem + XRT - Pancreas,
I4V-MC-JAHA,PsA Mixed Population Study (bDMARD Naive & TNF-ir) with OLE,
H9H-MC-A026,Analysis of Anti-Tgfβr2 therapy in KPC mice,
H3E-BX-T005,Medical Need Program - Alimta Thymoma,
H9H-MC-JBAW,CYP3A4 DDI in Healthy Subjects,
H8Y-MC-E001,Biomarker study for adults with PTSD,
I8B-FW-ITRC,URI-Vasodilator Ph1b T2DM PK/PD,
"15670",PKPD study in CSII vs Multiple Daily Injections,
H9H-CR-JBEE,Ph III - TGFb RI Kinase Inhib - MDS,
I4T-MC-JVDE,REACH-2_R-Ph3-Ramucirumab+BSCvsPlacebo+BSC-HCC -2nd L,
I4E-IE-W844,Protocol CA225-100; A RANDOMIZED MULTICENTER II STUDY OF GEM,
I4E-IE-W884,Protocol CA225-077; II Study of Cetuximab in Combination wit,
I4E-IE-W890,"Protocol CA225-091; Cetuximab, Pacitaxel, Carboplatin and ra",
I4E-IE-W924,Protocol CA225-116; BMS: FER-GI-002_OPN 05-020 - A II Study ,
I8D-MC-AZEO,DDI Warfarin,
H3E-MC-B025,Ph IV-Safety Profile-Alimta+Carbo AUC5 & AUC6 - NSCLC,
H3E-IT-JMHK,THERAPEUTIC USE OF ALIMTA AS SECOND LINE TRM NSCLC,
"9235",Davidoff: Diabetic cardiomyopathy: role of insulin resistanc,
F1J-XB-O007,Urinary Incontinence women database maintenance and explota,
H3E-LA-S075,Concurrent therapy with Rx and pemetrexed followed by GC,
F1D-MC-HGLZ,Multiple Oral Dose Study to Assess Potential for Weight Gain,
H4S-US-EWBE,Pre-Hospital Use of ReoPro in Acute Myocaridal Infarction,
"9464",Definitive Bioequivalence/Food Effect,
H3E-US-X011,Ph II 1st line Pemetrexed/Gemcitabine in pts. w/ adv. NSCLC,
H3E-US-X015,Ph II Pemetrexed + Gem 1st line in Extensive stage SCLC,
F1D-AY-I039,Evalluation of Project 300 clients-5 yr F/U.,
"9585",Atomoxetine CSF Study,
H8V-FW-LTBD,ATOMOXETINE CSF STUDY,
B9R-US-X037,Will Testosterone +/- Growth Hormone Improve Bone Structure?,
"9600",Sexual Satisfaction in Pts with ED & their female partners,
"9601",Cialis Daily Dosing to Introduce PRN,
F1K-IT-O027,Use of apc in renal transplantation in nonhuman primates,
B1Y-CA-C029,EFFICACY OF FLUOXETINE IN PSYCHOTHERAPY-RESISTANT BULIMIA,
B5K-US-X012,High dose U500 action/peak effect in severely IR T2D,
H7I-MC-S011,PET test retest,
I1F-MC-RHBV,Pivotal Ph3 AS Trial in bDMARD Naive,
I1F-MC-RHCA,Vaccination response following administration  of Ixekizumab,
I7E-AV-E017,"18F-AV-1451-EXIST-017",
B3L-MC-LWAK,LY354740 vrs plac in fear-potentiated startle paradigm,
I4V-MC-JAHG,Atopic Dermatitis,
"16294",DDI Digoxin,
"16319","Elimination, Safety and Tolerability of BC222 in Healthy Sub",
I3Y-MC-JPCI,Ph II-mBC - Abema+NSAI vs Abema+Fulvestrant,
I4T-MC-JVDM,PLACEHOLDER-Ph III-Gem/Cis+Ram vs Gem/CIS+Placebo-Biliary,
I4X-MC-JFCZ,Ph II - Necitumumab + Abemaciclib - H&N,
I8Y-MC-CRBC,RBA,
I9B-MC-BBEB,S/MAD (1),
"16630",CYP3A Inhibitor and Inducer Study,
I8B-MC-ITRW,Blinded mealtime dosing in T2DM,
H3E-MC-V017,Invitro cytotoxity in the TXT of osteosarcoma,
B9E-MC-V175,interactions btwnGem and bcl-2 and gem and rituximab,
B1Y-KL-S015,Local OS-Prozac weekly- demonstrate compliance/effectiveness,
B9E-MC-V178,Gem in Canine Lymphoma,
H7U-MC-IDAL,"COPD Study, Pulmonary Insulin",
B4Z-BP-LYBS,Broader efficacy of Atomoxetine,
H6D-EW-LVEX,LY450190 - Warfarin,
B9E-MC-JHBH,GEMCITABINE PHASE 2 IN PATIENTS WITH BREAST CANCER,
"7103",Placeholder for NSCLC,
B9E-MC-V189,Evaluation of newly developed in-vitro chemosensitivity test,
F1D-CP-S040,QTC study with antipsychotics,
B9E-FP-O331,IITGem fixe dose rate+radiochemotherapy pancreatic cancer,
F1D-BP-O182,Monitoring Prolactin in a Naturalistic setting,
F1D-BP-O185,How  anti-psychotic prescribing decisions are made,
B9E-XB-S333,gem-cis in second line in bladder,
F1D-US-X220,Retrospective Observational Study in the Texas Department of,
"7297",Gemzar placeholder,
B4Z-EW-S006,ADORE- ADHD Observational Study (no study drug administered),
"7483",ALIMTA+OXALI PHASE I Q2W PLACE HOLDER,
"7498",study with Evista,
F1J-MC-SBAM,Severe SUI Subjects Awaiting Surgery,
H5U-EW-HSAE,Interaction of LY367265 with oral contraceptives,
"2710",LY354740 Alone and Comb. w/Patch vs Placebo - Smoking Cessat,
"2749",RALOX VS PLACEBO IN ELDERLY MEN,
B7A-MC-MBBQ,"PKC Beta Inhibitor, Polyneuropathy - IND #57935",
B1Y-MC-HCEX,FLUOXETINE VS PLACEBO:  LONG-TERM TREATMENT OF MDD,
B7A-MC-MBCC,"Erectile Dysfunction - IND 55,999",
H3E-MC-JMDB,"R- Ph. III 1st Line NSCLC, ALIMTA/Cis vs Gem/Cis",
C2N-MC-JXAN,LY355703 in Metastatic Colorectal CA,
B1Y-MC-HCFQ,FLUOXETINE/DESIPRAMINE/PLACEBO ALTERNATIVE TREATMENT STUDY,
B7A-BD-MBBT,Interaction Study 2D6,
B9E-SB-O031,"Phase II, Gemcitabine & Vindesine, In NSCLC",
"3161",C-14 metabolism in volunteers (liquid),
F3Z-MC-IOIB,Extension study for IOHI and IOHM,
F1J-MC-SBBB,Naturalistic Health Outcomes in the Nursing Home Setting,
F1K-MC-EVAO,Pediatric Pharmacokinetics and Safety in Sepsis,
B4Z-LC-HFBP,Drug Interaction Desipramine,
"3310",Temporal cortex Dysf in neurodevelop.model of schizophrenia,
B9E-IH-O443,BIWEEKLY GC & OXALIPLATIN 1st line in NPC,
H9T-MC-NABG,Multi-dose Safety Study (MDSS),
"9826","Ph II, ALIMTA+Carbo vs Gem+Carbo vs Taxotere+Carbo in NSCLC",
F1J-FR-O013,FR duloxetine UI IIT - Dr Giuliano,
"9899",Place holder - IIT Xigris locale France,
B9E-XV-O472,Study the tendency of carboplatin clearance in elderly pats,
H3E-US-S083,"3 Arm Trial:Alimta/Cis vs. Alimta/Carbo vs. Alimta/Gem-NSCLC",
H9W-BD-GBEB,CB1 Antagonist Multiple-Dose Safety Study (MDSS),
F1J-US-X004,"Depression, Somatic Pain, Health Care Costs",
B9E-ME-O450,Gem + CDDP + Dexa in Diffuse Large Cell Lymphomas (DLCL),
H8O-US-GWAY,TZD Synergy,
B9E-CA-O452,A phase II study of BAY43-9006 + Gem in Epithelial Cx,
"10112",observational Zydis,
F3Z-PL-O065,Functional Therapy with lispro in CSII pediatric patients,
B9R-US-X039,IGf-1 receptor gene mutations/polymorphisms,
F1D-MC-HGDB,OPEN LABEL OLANZAPINE IN PREVIOUS OLANZAPINE CT PATIENTS,
B9E-FP-O458,IIT-MPM B9E-FP-O458 / CHU Nice,
"10183",Placeholder for trial S241,
I8B-MC-ITRY,China PK HV,
"16648",Randomized withdrawal in Atopic Dermatitis,
I8M-MC-BIXE,PII T2DM Trial ,
I9D-MC-ROAE,DDI,
H8H-MC-LAHB,Random Subject and Inv blind Potential abuse of Lasmiditan,
H8H-MC-LAHX,Ph1 Open-label single dosePK in Pediatric Subjects,
B9E-MC-X091,"GEMCITABINE, CISPLATIN, AND AMIFOSTINE IN OVARIAN CANCER",
"16987",Ph IV - Ram Rollover Trial - All Tumors,
H8H-JE-LAIE,Ph1 (Japanese and Caucasion) for Lasmiditan,
B1Y-MC-X132,EFFICACY OF PROZAC IN THE TREATMENT OF POST-STROKE DEPRESSIO,
I8F-MC-GPGW,H2H Trulicity,
"1715",Efficacy in Obesity,
I5Q-MC-B001,Long Term Safety Study (USA database) ,
I8H-MC-BDCQ,Reformulation Safety and Tolerability Study,
"1725",Ly396623-sc infusion,
B3D-GH-O047,teriparatide vs alendronate prevent periprosthetic bone loss,
H4A-MC-XBAG,IV vs Fluconazole in Non-neut. Candidemia and Candidiasis,
"7500",IIT GEMZAR PLACE HOLDER To Be Determined,
"7510",IIT Place Holder New IIT to be determined,
"7530",Placeholder for GDFC for planning purpose,
"7545",Treatment of Subclinical Diabetic Peripheral Neuropathy,
H8I-MC-HQAC,Validation of Daily Telephone Self-Assessment in Pts w/MDD,
"7576",Clinical characteristics of responders to pioglitazone,
H3E-MC-JMHI,R Ph 2 (markers-Pgx) Alimta/TBD vs TBD 2nd line/Adj NSCLC,
H4S-MC-X020,Effect of PTCRA with Adjunctive Coronary Stenting on CFR,
"7694",UK Resiquimod IIT Placeholder for planning,
B1Y-BP-X088,FLUOXETINE VS COGNITIVE THERAPY IN SOCIAL PHOBIA,
B9E-BX-O353,Phase I Gem+RTin Patients with Pancreas Carcinoma,
B9E-MC-X047,GEMCITABINE SALVAGE THER. IN CARCINOMA OF UNKOWN PRIM. SITE,
"7886",Randomized of Gemzar+Cisplatin vs comparator in Ad Gallbladd,
F1D-MC-HGKG,IM Olz + IM Ativan Transition to Oral Olz,
B3D-AG-S002,Forteo in severe osteoporosis vs Alendronato.,
"7939",CTNR: Affinitak + Gem - Hepatoma,
H7I-MC-O001,An Integrative Apprch for Detect. of Methylphenidate Effects,
B9F-LC-I001,C-PEPTIDE COMPARI. UNDER NORMAL & DISEASE STATES,
"3362",Imaging study in humans Pet tracer,
"3364",Ly293558 for postoperative dental pain,
B9E-MC-JHQV,Phase III local registration trial for pancreas cancer,
"3406",Neuroimaging for Concord,
B5K-SF-IBES,Insulin Delivery Using New Lilly 3.0 mL Prefilled Pen Design,
H6K-MC-IIAD,Clamp study in normal subjects,
B5K-FW-IBEV,Insulin glucose clamp study in healthy volunteers,
F1D-MC-X141,Texas Medication Algorithm Project,
B9E-SB-O042,"Phase II, Gemcitabine & Cisplatin In Carcinoma Of Urothelium",
B9E-UT-JHQM,"Phase III, Gemcitabine & BSC  vs  BSC,  Pancreas",
B9E-CA-JHQQ,Gemcitabine and Cisplatin in Patients with bladder Cancer,
B9E-MC-S137,Ph 2 Gemcitabine + Carboplatin in Bladder Cancer- Nov98SU103,
B9E-VI-O058,"Phase III, Gem & Cis vs. Etoposide & Cis,  In Adv NSCLC",
H6D-MC-LVBP,MED vs CVS ***Cancelled***,
B3N-MW-EUDN,CYNT IN HYPERTENSIVE PTHS WITH NIDDM AND INSULIN RESISTANCY,
H6E-US-GLAA,Pioglitazone vs Glyburide in Pt w/ Newly Diagnosed Type II,
B1Y-MC-X071,FLUOXETINE IN MALE ADOLESCENT SEX OFFENDERS,
B1Y-MC-X143,Fluoxetine in ADHD with Co-morbid Mood Disorders,
J1L-MC-JZGL,Peg + Pembro HNSCC & NSCLC,
"1737",LY396623 - Efficacy in obese patients,
I8F-MC-GPHU,Gastric Emptying in Overwt (BMI>27) HV + T2DM Pts,
B1Y-IT-0012,FLUOXETINE AND LIGHT IN SEASONAL DEPRESSION,
J1Y-MC-GZIB,MAD (oral) LY3487929 study in Healthy Subjects,
I3Y-MC-B006,"2018-7481 GHO-Abema-Txt Patterns & Pt Mgmt in BC",
J1I-JE-GZBC,Japan MAD Pts,
J2G-OX-Y033,PhI-RET Inhibitor-NSCLC,
F1D-MC-I009,"Risperidone, Olanzapine, & Clozapine in Chronic Scizophrenia",
I3Y-MC-B010,"2018-7521_GHO_ Abema mCRPC: Adelphi Disease Specific Program",
J2G-OX-Y063,RET Inhibitor-NSCLC,
J2G-OX-Y069,RET Inhibitor-NSCLC,
J2G-OX-Y097,RET Inhibitor-NSCLC,
J2G-OX-Y107,RET Inhibitor-MTC,
J2G-OX-Y134,RET Inhibitor-NSCLC,
J2G-OX-Y144,RET Inhibitor-NSCLC,
"8072",LY2148568 vs. metformin,
B3D-MC-GHCM,Ca effects of PTH in patients pretreated with alendronate,
H3S-MC-GGLF,Long Term Effects of Raloxifene Treatment on Bone Quality: A,
"8171",Dulox HCI in Wmn of Diff. Ethnicities and Co-morbid. w/ SUI,
B9E-MC-V223,Analytical procedure to determine the plasma of GEM,
B9E-CY-O371,phase II Gem Docetaxel Cisplatin first line adv. ovarian ca.,
B9R-FP-0908,GROWTH HORMONE IN CHILDREN WITH I.U.G.R.,
"8335",SBCC - Placeholder for Corporate Business Planning,
B9R-JE-YI10,HUMATROPE:USE IN ACHONDROPLASIA AND DWAIFIZM,
H3S-IS-O131,effects of raloxifene and HRT on insulin sensitivity,
B9E-SB-O394,Primary Breast Cancer Phase I/II GeDoc sequentiell,
F1D-PL-O240,Efficacy and safety of olz. vs typical following previous IM,
H5O-BD-G3AA,"SDSS Isoproterenol Test, FFA/Glycerol",
B4Z-FW-LYCT,pk study in Chinese patients,
"8680",Ph II - 1st Line Gem+Cis-->ALIMTA+Gem - Bladder Cancer (US),
H8L-FW-IQAC,Microneedle Device (Humalog Test Meal),
"8750",Ph II Fixed Dose Gem+Mitoxantrone in 1st relapse Leukemia,
"4209","MRP Modulator, Single Dose",
B1Y-MC-X195,Ephedrine-mediated Inhibition of SSRI-induced Sexual Dysfunc,
B9E-MC-X164,Gemcitabine in Multiple Myeloma,
B1Y-MC-X087,FLUOXETINE IN PSYCHOTHERAPY NON-RESPONDERS,
B9R-US-A001,Leptin serves as a growth-promoting peptide in mice,
F3Z-IN-IOML,Glucose excursion with humalog vs humaninsulin 50/50,
B1Y-MC-X090,THE USE OF PINDOLOL FOR THE TREATMENT OF MAJOR DEPRESSION,
B5Q-HL-O002,Nizatidine: gastric motility and QoL in functional dyspepsia,
F1D-CA-O007,eval. impact of olanz trtmt on v-severely handicapped chroni,
F3Z-MC-IOND,HOE 901 + oral agent vs. Mix 25 + oral agent,
"4065",Cardinal Study,
H5Z-LC-LUAO,Elderly PK,
F1K-MC-EVAS,Compassionate Plea in the treatment of Purpura Fulminans,
"4119",male safety study,
"4152",olanzapine interaction trial with,
F1D-CA-O051,Comparing standard psychiatric clinic care with community,
B9E-MC-V029,Interaction between dFdC and MTA,
B3M-FH-S021,Cefaclor resistance surveillance,
I8F-MC-GPIE,MoA 18FTHA Fasting and MMTT PET MRI Study in T2DM Pts,
J2G-OX-Y158,RET Inhibitor-NSCLC,
J2G-OX-Y164,RET Inhibitor,
J2G-OX-Y177,RET Inhibitor,
B1Y-IT-E041,FLUOX/CLOMIPRAMINE DBL MAJOR DEPRESSIVE DISORDER,
J2G-OX-Y191,RET Inhibitor,
J2G-OX-Y197,RET Inhibitor,
I6T-MC-AMBX,BE for Crohn’s  1mL(Bolt +2mL(Tella) AI ,
J3G-MC-S003,Solution temp and injection site pain study,
B1Y-MC-HCJJ,Fluxetine vs Citalopram in Major Depression,
B1Y-MC-HCJF,FLUOXETINE VS PAROXETINE IN MAJOR DEPRESSION,
"18422",LOXO-BCL-230XX-Ph1-BCL2-BCRP,
"18452",N3PG IV Phase 3 trial,
B9E-MC-I083,"GEMCITABINE, 5FU,RT,&GCSF: PHASE I STUDY IN CANCER PTS.",
J3Q-MC-KJAB,Phase 2 Study Evaluating Efficacy of LY in Adults with MS,
"18636",Post-marketing commitment per the EoP2 interaction,
B9R-SE-9280,HUMATROPE CLINICAL TRIAL:  FOR A PERIOD OF UP TO ONE YEAR,
H3E-MC-V014,Pre-clinical research of ALIMTA,
H3E-MC-V040,Antifolate Sensitivity/Resistance Mutans Generated by SGDP,
B9U-MC-AZCL,LORACARBEF VS CLARITHROMYCIN IN AOME,
"8868",BACE Biomarker Study #1,
"8882",Olanzapine / Xanomeline MDSS,
"8913",Diabetes and depression - stepped care,
"8939",Efficacy in lipid lowering,
"9048",JP 5HT1d P1 MDSS,
B3D-IT-GHCT,OP PTH(1-34) Treat in Multifractured Subjects (OPTIMUS),
H6D-KL-S002,Korean Switch Study,
B4Z-US-A003,Microdialysis Studies of Chronic Atomoxetine in the Rat,
B9R-US-X044,ISS/ Small-for-Gestational Age,
"9352",Egypt affiliate local trial Glustin obs trial combo therapy,
"9377","2-weekly dose dense GT and 3-weekly GT in MBC",
ZYY-LC-MBDN,Ruboxistaurin PBMC Phospho-PKC Substrates Biomarker Study,
H3E-US-S064,Phase II Gem+ Alimta q other week,
H8G-EW-EPBF,Factor Xa: Hepatic Safety Study,
H3E-US-S066,Gem/Cis followed by Gem/Alimta in Bladder Cancer,
F1D-US-X163,Prolactin Levels and Erectile Function in Pts Treated w/Risp,
H3S-SB-S002,Half Year Treatment Marketing Observational Trial,
B1Y-OL-0002,FLUOXETINE V PLACEBO FEMALES WITH BULIMIA,
B1Y-PH-0002,FLUOXETINE: IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDERS,
"4316",Poor Metabolizer Study,
"4377",Ceclor for treatment of LRTI,
H6D-MC-LVCF,"1C351/Viagra Preference Pilot Study",
B7A-JE-103M,PKC1 P-I multi oral dose,
H3S-CA-O003,Evista as adjunct to SSRI treatment for refractory depressio,
F1D-FP-O068,Olanzapine in the treatment of idiopathic dystonia,
B9E-MC-S159,Ph II Gem+Oxalipl. foll. by  Carbo+paclit. in ovarian cancer,
H4S-IT-EWBB,Interventional or conservative treatment in nonST ACS,
B9E-MC-S205,"Ph.II, Tax. + Carbo followed by Gem. + Carbo in ovary",
"4731",Gem Single Agent or Gem/Cis + RT -->Gem+Cis or Carbo(Cervix),
H3S-US-GGKB,RALOX AND SKIN,
B1Y-SP-0002,BIOEQUIVALENCE OF TWO FLUOXETINE ORAL FORMULATIONS (DT VS C),
F1D-CA-O092,Randomized Controlled Trial in Anorexia with Olz Tx.,
B9E-MC-S176,Ph II -  Gem + Oxali - Ovary,
"18712",Baqsimi Post Market Clinical Follow Up,
B1Y-IT-M005,FLUOXETINE VS CLOMIPRAMINE MAJOR DEPRESSIVE DISORDERS,
"1976",Pharmacokinetics in hepaticaly impaired,
"2013",Bioequivalence of SR Forms,
H4Y-MS-LJAJ,Sumatriptan bioequivalent study for LJBG,
B9E-MC-S049,Ph II Gem + Cis+ Etoposide in SCLC,
F1D-MC-X039,OLANZAPINE PLASMA CONCENTRATIONS & CLINICAL EFFECT,
F1D-US-X081,Olz vs Placebo-behavioral disturbances w/vascular dementia,
B9E-MC-S056,Ph lll Carbo/Cis/Ifos vs Carbo/Cis/Gem vs Ifos/Gem in NSCLC,
B1Y-LC-HCIX,SINGLE DOSE SAFETY AND BIOAVAILABILITY/FED-FAST STUDY,
F3Z-UT-O011,NPH once daily vs twice daily with Lispro in IDDM,
"2209",Humalog vs Glibenclamide (early prandial response) followup,
B3D-MC-GHAL,Effects of LY333334 in Women with Rapid Bone Loss,
B9E-MC-I079,PHASE 1 STUDY OF INTRAPERITONEAL GEMCITABINE,
F1D-MC-O019,Dysfunctional saccadic eye movement as biol. mark for schizo,
F1K-LC-EVAK,rhAPC Bolus Injection Study for Sepsis,
F1D-MC-HGHL,Olz vs Plac in Prevention of Relapse in Bipolar I Disorder,
B1Y-MC-HCJN,Intermittent Dosing of Fluoxetine for PMDD - US,
H3E-US-X014,Ph II Pemetrexed for Metastatic Chondrosarcomas,
"9556",PPAR alpha agonist 2nd generation,
"9619",Oral Agent Failure,
F1J-CA-S013,Duloxetine in Primary Care (GP study),
H3E-MC-JMHQ,"RPh II 3rd line, ALIMTA w/ & w/o vit.-relapsed low-grade NHL",
F1D-MC-HGAJ,OLANZAPINE VS HALOPERIDOL IN TREATMENT OF SCHIZOPHRENIA,
F1D-MC-HGAO,OLANZAPINE VS. PLACEBO IN PSYCHOSIS WITH DEMENTIA,
H3E-XM-S092,Alimta-cis farmacogenómica (NSCLC),
H9U-MC-MDBD,Chronic sleep disorder study,
H3E-US-I017,PhI/II Abraxane & Alimta in Solid Tumors for NSCLC/Breast,
"11419",Wittmann-PKC RBX on smoke induc endo dysfunction,
"11420",FHD for AKT inhibitor in healthy volunteers,
B3D-IT-O012,Study of circulating osteoblat.-lineage cells with PTH thera,
H6Q-MC-S051,Phase II Enzastaurin + Aromatase Inhibitor - Breast,
I1Y-MC-JFBB,Phase I Study for Eg5 - LY252335,
F1D-MC-A142,Olz on Electrophysiological Correlates of Cog proc in rats,
H8O-MC-X033,Exen on wt loss/energy/hunger in obese women,
F1D-JE-CMP2,JP ola P-III/IV compassionate,
B1Y-TW-0001,FLUOXETINE VS IMIPRAMINE: CLINICAL EFFICACY & SAFETY,
F1D-SZ-HGJD,Determinations of compliance in schizophrenic patients,
B7A-BD-MBCS,"32mg Desipramine Drug Interaction Study",
"5026",R-Fluoxetine -- Severe/Hospitalized MDD,
H7C-MC-LMBC,mGluR2 Prodrug vs placebo in GAD subjects,
"5059",Single Dose Safety Study,
"5074",V8-Glp Multi-dose Japan/Caucasian study,
B3L-MC-LWBH,Long Term Efficacy for Europe,
H3E-EW-JMEM,"Rand Ph II 1st Line NSCLC, ALIMTA x 6 vs ALIMTA x 2->Gem x 2",
H7S-LC-LHAA,FHD - Combined Single Dose / Multiple Dose Safety Study,
H7C-JE-LMCE,JP mGluR2 P-I MDSS,
B9R-IT-GDFU,High somatropin dosage in early pubertal children with GHD,
"5214",Negative symptoms & response to Olanzapine in Schizophrenia,
F1K-MC-EVBB,Drotrecogin alfa (activated) for use in ARF/CRRT,
F1J-LC-HMBN,Steady state Metabolite Study,
"5262",SDSS,
B9E-BX-O181,A phase I-II study evaluating bimodality therapy for NSCLC,
B4Z-JE-LYBD,JP atom P-II Pilot Safety in children,
F1D-MC-S014,Olz and Ris on Insulin Sensitivity in Schiz,
B9E-EZ-O197,Gemcitabine and Cisplatin in Bilharzia related Bladder Can.,
B9E-MC-V110,Effect of gem on DNA mismatch repair deficient cell,
F1D-US-HGJP,Fixed dose response (10-40mg),
B9E-MC-V113,Effect of Gem on pancreatic carcinoma cells,
"5500",this is a test,
F1K-MC-EVBE,Open Label Study of rhAPC in Patients with Severe Sepsis,
B9E-IS-JHRU,Gem and Cisp treatment in advanced NSCLC,
B3M-SZ-EG63,CECLOR IN THE TTT OF PHARINGITIS TONSILLITIS IN CHILDREN,
"5745",Immediate vs Delayed Second Line Therapy,
B3N-EW-EUBI,MOXONIDINE:PILOT SD STUDY ON EFFECTS OF FOOD/TIME ON SR DOSE,
F1D-EW-S019,OL comp. of EPS and effic. of IM olz with other IM antipsych,
H6X-LC-GBBC,PPAR Co-Agonist MDSS in NIDDM,
"5820",Olz treatment of delirium among HIV-1 seropositive patients,
F1D-FP-O128,ITT-Pharmacogenetic in schz F1D-FP-0128 Pr ,
"5902",Schizophrenia Phase IB Study,
H6L-MC-LFAG,C14 Study (LY450139),
F3Z-XM-O039,INSULIN RESISTANCE SYNDROME PREVALENCE AND ASSOCIATE FACTORS,
"6043",Effect of dulox on human NET and 5HTT occupancy,
F1D-XM-HGKC,Efficacy and safety of second dose of IM OLZ. Pilot study,
B9E-TW-O269,Gem/High Dose 5-Fu for HCC,
H5N-EW-GFFM,GLP-1 analogue - Hypoglycaemia risk,
"6104",GLP-1 analogue - Drug/drug interaction 2,
"6151",Bronchial Alveolary Lavage (BAL) Oritavancin Study,
"6153",Joint Levels (arthritis) Oritavancin Study,
"6172",Ph I/II - ALIMTA in Patients with Relapsed Leukemia,
H3E-MC-S028,Placeholder,
A3Q-FW-AFBM,"125 mg cephalexin bioequivalence study",
H7X-US-JVAK,Phase II Gemzar+Cis + ISIS in platinum sensitive ovarian c,
B9E-MC-V146,Intracellular Phosphorylation of Gem in EBV and KSV Inf Cell,
"6510",ALIMTA + Gemzar + Cisplatin Phase I in solid tumors,
"6538",Rapid Acting Intramuscular Olanzapine with IM Ativan,
F1D-TW-O158,ANS as an index of arrhymogenic effects of Antipsychotics,
B5K-GH-IBFZ,Observational study on the acceptance of HumaPen in diabetic,
B4Z-UT-S003,Atomoxetine for ADHD in children with ASD,
B1Y-BP-HC57,FLUOXETINE VS PLACEBO IN POST NATAL DEPRESSION,
B1Y-GH-O024,"chronic non-organic headache,its psychological status and tr",
H3E-MC-V015,Determine physical compatibility of ALIMTA Y-site &86  drugs,
H5W-BD-LQAA,First human dose,
B1Y-MC-HCDF,FLUOXETINE V DOXEPIN IN DEPRESSED ADULT PATIENTS,
B9E-MC-I070,"GEMCITABINE, 5-FU, & RADIATION THERAPY IN RECTAL CANCER",
B9E-MC-X150,"PHASE II STUDY GEM, 5-FU & LEUCOVORIN PANCREATIC CANCER",
H4Z-LC-LPPB,Aricept Interaction Study,
H4Y-BD-LJBK,Single dose PK - hepatic impaired,
H4Z-LC-JWXA,temporal linearity study,
"2682",Fluoxetine Versus Placebo in Childhood/Adolsecent Depression,
B1Y-MC-HCEH,FLUOX/NORTRIPTYLINE:CARDIAC EFFECTS MDD PATIENTS,
B9R-MC-GDFD,PK/PD in normal adult japanese and caucasian volunteers,
H5X-BD-LTAB,Single oral dose in migraineurs (liquid),
B1Y-MC-HCEN,FLUOXETINE IN TREATMENT OF ATYPICAL DEPRESSION,
B3N-SB-EUCB,Effect on microalbuminuria in patients with IDDM and HTN,
B5K-MC-IBDW,EGDPI,
H3S-MC-GGJC,Retrospective Data Collection in PMW w/Br Ca in Ralox study,
B9E-MC-X152,"Gemcitabine,Cisplatin, and Vinorelbine in NSCLC",
B9E-SB-O032,"Phase II, Gemcitabine  & Carboplatin In Adv NSCLC",
B1Y-MC-I009,TREATMENT OF ANTISOCIAL HEROIN ADDICTS,
B9E-MC-S123,Ph 2 Gem + Cisplatin - Hepatoma,
H7U-MC-IDAI,PI Phase 2 non-inferiority study in Type 1 diabetics,
H6U-BC-LRAG,Latin America depression registry,
B9E-US-S308,Phase II Randomized Trial Gem/Paclitaxel vs. Gem/Docetaxel,
F1K-XM-EVCF,Epidemiologist Study of organ failure on severe sepsis,
F1K-XM-EVCH,Receptor of aPC on the monocyte,
H6D-MC-LVFO,Gastroparesis Open Label Continuation,
B9E-MC-I053,PRE-OPER. RADIOTHERAPY & CHEMOTHERAPY FOR STAGE IIIA NSCLC,
"7050",Stress - Physical Manifestation #2,
"7116",Placeholder Trial,
B9E-MC-V188,Bionalyatical method of gemcitabine and 2-dFdU in biological,
"7228",Placeholder for Gemzar IITs,
B9R-SB-A004,Growth Hormone in Combination with CRH-antagonists,
F1D-US-V015,Olanzapine:  Effects on Cellular Signaling Systems,
H7C-FW-LMBW,AMPT,
F1J-FP-S006,Treatment of patients consulting physical pain and MDD,
"7441",Severe sepsis in burn patients,
"7454",Gem intravescical neoadjuvant therapy,
"7475",Phase II trial SCLC Place Holder,
B9E-US-X374,"Ph II Cis, Bem & Erlotinib in pts w/loc adv NSCLC",
B7A-BD-MBBY,Food effect on different formulation,
B5K-BD-IBED,Humulin Cartridge Treatment with Atlas Pen Device,
B9E-JE-N32D,Phase 3,
B4Z-LC-HFBM,Renal Insufficency,
B9E-VI-O034,"Ph II, Gemcitabine & Ifosfamide,  Adv. Head/Neck Cancer",
"3343","Phase II, MTA + Adriamycin, 2nd line breast",
F1D-JE-G01E,Olanzapine Fine Granule  BE study,
B5K-VI-IBET,Insulin Delivery Using New Lilly 3.0 mL Prefilled Pen Design,
H3S-BP-GGJK,THE DORSET RALOXIFENE STUDY,
B5K-MC-IBFD,"Dose Confirmation, Dose Response",
"3495",opiates interaction,
B9E-MC-S128,Ph IIGem+Oral Etoposide vs Gem+Cisplatin  in adv. NSCLC,
H6C-LC-GKAD,MD Safety/PD dose-ranging in patients with type2 DM,
B1Y-MC-X035,OREXIA NERVOSA:  PREVENTION OF RELAPSE,
B9R-MC-X014,.,
"3577",BRAIN SEROTONIN TRANSPORTER GENE & MAJOR AFFECTIVE DISORDER,
H6D-LC-LVAA,C14 Study  LY450190 (IC 351),
B9E-MC-I144,"Phase 1 Trial of Gemcitabine, Ifosfamide, and Doxorubicin",
B1Y-MC-X191,Fluoxetine for Overtraining Syndrome in Endurance Athletes,
"7571", Retrospective Chart Review,
"7596",Untitled IIT,
B9E-MC-X001,GEMCITABINE IN REFRACTORY GERM CELL TUMORS,
B5K-IN-IBGA,Huminsulin 30/70 in special settings,
F1J-XM-SBCQ,Treatment preference survey to patients,
"7673",TTD,
"7685","IIT for Breast, Sawyers, Latrielle Ovary",
"7701",IIT placehoder : to be defined,
"7738",CTNR bucket,
"7779",Gemcitabine on lymphoma,
B5K-GH-O439,Insulin on restraint of B dysfun-hyperlipidemia in diab rats,
ZYY-LC-LMBY,AMPT Challenged Study,
"7848",Laval Fellowship,
"7862",TRD,
"7911",Locally Adv. and Meta. breast  cancer,
"7914",Zyprexa-epidemiological LOT - Schizo,
B5K-BX-O440,Intensive Insulin Therapy in the Intensive Care Unit,
H6D-FR-B001,Observatory of Mgmt of patients with ED by GPs_B001,
B9F-MC-I021,POSTPRANDIAL INSULIN SECRETION IN OBESE SUBJECTS,
H3S-BX-O001,Study raloxifene in orchidectomized man (IIT),
H6D-EW-LVBA,Ethinic Variability Study,
B9E-VI-O066,"Phase III, Gem & Cisplatin vs. Cisplatin & Etoposide, NSCLC",
H6D-MC-LVBE,Open label safety study,
B9R-JE-COO6,JP hGH P-IV Achondroplasia,
"3906",Benzodiazepam Interaction,
F1D-CA-O037,Reduction of movement disorders benefit at subclinical level,
B9E-MC-JHQT,Randomized Phase II Gem+XRT vs. XRT in NSCLC,
B9E-MC-V017,Measurement of intracellular uptake retention w/ other drugs,
B7A-MC-MBCF,Diabetic Macular Edema Retinal Thickness Analysis,
"4141",Test for SCT Trial,
H4Q-MC-ARRM,LY333328 Dose Escalation. Gram-Positive Bacteremia,
B9E-MC-V035,Gemcitabine +/- XRT in malignant glioma,
"4210",Phase I trial for Cyclin D1/cdk4 Inhibitor,
F1J-LC-HMBJ,Renal Failure study,
F1J-LC-HMBK,Warfarin interaction,
B9E-TW-O114,Weekly gemcitabine plus 5-FU/LCV for Biliary Tract,
F3Z-JE-IOMO,JP lisp P-III/IV Mixture (Extension),
"8097","Ph. II, ALIMTA+Carbo in pts w/ locally adv/met breast cancer",
H8G-MC-EPBB,Phase II post-op VTE Study,
B9E-MC-V219,phorbol ester (TPA) with Gemcitabine HCI in vitro,
H3S-US-X024,Non-hormonal Alternatives for the Control of Hot Flashes,
H4S-CA-O050,EASY:Randomized trial of early discharge after trans-radial,
"8221",QTc Study,
H8O-EW-GWAM,Gastric emptying,
B9R-JE-H01A,LY137998 BIOEQUIVALENCY TEST 36IU VS 18IU,
B9E-US-X401,Two arm Ph II of Gem in pts w/ adv bone sarcomas,
B9R-JE-YI26,HUMATROPE:EVALUATION OF IGFBP-3 WITH GHD,
B9R-LC-GDDC,COMPARISON OF FORM. AND INJ. MODES FOR HUMATROPE IN NORMAL,
B3D-US-GHCQ,FORTEO Observational Clinical Use Study,
B9E-US-X412,Ph II Carboplatin/Gemcitabine/Celecoxib in adv NSCLC,
B9R-MC-I023,AN OPEN-LABEL EVAL. OF GH IN TREATMENT OF SHORT BOWEL SYNDR.,
B9E-AY-O398,Intravesical Gemcitabine in TCC of Bladder,
"8692",US DMC Trial,
H7T-MC-TAAL,CS-747 Phase III PCI Study,
I6T-NS-X003,Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 with Moderate to Severe Crohn’s Disease and Ulcerative Colitis,
F1J-MC-HMAY,Duloxetine vs Paroxetine/Placebo in Treatment of MDD,
B1Y-SB-1016,FLUOXETINE VS. LIGHTTHERAPY IN SAD,
B1Y-SB-2027,FLUOXETINE - PULSE LOADING STUDY,
H4H-MC-LGAP,Long Term Safety of Talampanel in Patients with Partial Seiz,
H6D-MC-LVCH,Untreated Depressed Patients w/ED,
"4418",A-beta Assay in Human Plasma and CSF,
F1J-FW-HMBL,Enzyme Induction study,
"4472",Gemcitabine & RT in Bladder Cancer - Phase I / II,
B3M-BL-S014,Cefaclor Versus Amoxicillin in the Treatment of Acute Pharyn,
B3M-IS-S025,Group A Streptococcal Tonsillopharyngitis Surveillance Study,
B4G-JE-S003,Monotherapy,
"4630",LY354740 in Panic Disorder,
B9E-MC-S163,PhII Gem+Pacli+Cis in chemo naive advanced ovarian cancer,
B4Z-MC-LYAQ,Tomoxetine + fluoxetine for Poor Metabolizer exposures,
F1K-MC-EVAZ,Open Label use of rhAPC for Sepsis,
H3R-BD-LBBC,Treatment of Nitroglycerin-Induced Migraine Headache with LY,
B9E-MC-V084,Inhalation deliv of gem by pressurized metered dose inhaler,
B3M-EZ-AJBK,Ceclor Vs Augmentin in Acute Otitis Media in Children,
H6D-MC-LVFZ,Daily Dosing Study #3,
H9F-LC-GYAB,Multi-dose Safety Study (MDSS),
H9F-MC-GYAE,Obesity Proof-of-Concept (POC),
H9F-MC-GYAF,Dual OpRA I/ OpRA II Phase 2 Efficacy Study,
"8773",Placeholder,
B4Z-XM-LYDM,Efficacy and  Safety of ATX in incident diagnoses of ADHD,
"8850",ALIMTA + GEMZAR FIRST LINE NSCLC,
H7R-MC-GCCA,MonoTherapy;active control;HbA1c endpoint,
F1J-MC-SBCN,QD Dosing,
"9051",placeholder for GH local support,
F3Z-US-IOOP,Humalog 50:50 Mixture Trial,
H6D-FR-S003,Efficacy of Cialis in Paitents with ED and MS,
B3D-IT-GHCU,TUHRS Study - Teriparatide Use in Hip Replaced Subjects,
"9198",Changes in neurotrophic levels in dulox. treated rats,
B9E-MC-V267,Examine Nucleoside Transporters PK and Pharmacodynamics,
B9E-MC-V269,Gemcitabine Pharmacogenomics,
B9E-MC-V271,LY293111 + gem LY188011 in Preclinical Invitro,
H6D-EW-LVGE,Clinical Pharmacology Effects of IC351 on Color Vision,
B9E-US-X425,"Ph II neoadj stage Ib,II,IIIa,IIIb NSCLC",
H6Q-MC-JCAE,Phase I Gem/Cis/LY317615,
H6Q-MC-JCAI,LY317615 in Phase II NHL,
B9E-MC-V091,Efficacy of sequent or simult comb of MTA & Gem,
B9E-US-S177,"Ph2 w/carbo-gem,using 2 different schedules in adv. NSCLC",
B1Y-FP-O012,SURVEY ON THE TAKING IN CHARGE OF DEPRESSIVE PATIENTS,
B1Y-ME-HCLB,COMPARATIVE STUDY WITH FLUOXETINE IN PMDD,
"4948",Mix50 once daily + metformin vs glargine once daily +metform,
H6V-LC-GEBA,Single Dose Safety Study,
B9E-SN-JHRF,"Phase II Gem, Vinorel, Taxel in elderly with NSCLC",
H6D-MC-LVDI,JP IC351 P-II Bridging,
B9E-MC-JHRP,Ph I-II Gem fixed dose rate+ cisplatin in hepatoma,
B9E-MC-X303,Phase 2 Trial of Gemcitabine and Carboplatin - SCLC,
H6D-EW-LVDP,"20 mg IC351 Interaction with Amlodipine",
B9E-XM-S229,PHASE II GEM-TAXOL-HERCEPTIN BREAST ERB2 POSITIVE,
H3E-MC-JMEW,R-Ph III-Alimta+BSC vs BSC alone-Meso,
B2Z-SB-2024,NEOADJUVANT CHEMO-RADIOTHERAPY IN NON RESECTABLE NSCLC,
B9E-MC-S231,Ph II Carbo -->Gem+Paclitaxel/ 1st line adv. ovarian cancer,
B9E-US-S358,PhIII Gem/Carbo vs Gem PS2 Adv. NSCLC,
F1K-UT-O038,aPC and pulmonary microvascular permeability,
F1K-CA-O025,Retrospective Review of Comp. Cohort of Septic Shock,
F1D-JE-P201,LY170053-MULTIPLE DAILY DOSES TO 3 DAYS IN HEALTHY VOLUNTEER,
"9541",Phase III GAD,
F1D-XM-O261,Intramuscular antipsychotic drugs utilization patterns,
B9E-US-X435,"Ph II Doxorubicin, Vinblastine & Gem for Non-Bulky Hodgkin's",
B1Y-CA-C028,ASSESSMENT OF SEROTONIN DYSREGULATION IN OCD,
B9E-BP-O439,"1st line ovarian cancer : carbo ---> gemcitabine + Taxol",
B4Z-MC-LYDK,Dosing study in suboptimal responders (#2),
F1D-MC-A123,Regulation of GSK3B and Signaling Pathways by Olanzapine- Ne,
H6P-MC-A003,In vivo electrophysiological investigation of the chronic an,
H8O-MC-GWBO,Exenatide Re-treatment,
F1D-LC-HGEA,OLANZAPINE IN HUMAN BREAST MILK AFTER SINGLE & MULTI.DOSES,
"9776",Pharmacoproteomics POC Replication Study,
H3E-US-X025,Ph II trial of Alimta in relapsed small cell lung cancer,
B9E-US-X355,Ph 1 Bronchial Artery Inf Gem & Carb in Rec/Prog NSCLC,
"5416",Forteo versus alendronate non vert non traumatic fracture,
B3D-LC-GHBP,Pilot Study Digoxin Echocardiography Validation Trial,
H3S-US-X016,Effect of Raloxifene on Ocular Blood Flow,
"5435",Buccal Insulin - Effect of Liquid Ingestion on Absorption,
H3S-US-I006,Postmenopausal women who have MIs,
"5515",An Open Lable 16Week Clinical Efficiacy Study of the Treatme,
"5518",Rolipram as probe for cAMP 2nd messenger: Acute in vivo,
B9E-MC-X314,PII Gemzar/Docetaxel for stage IV Breast Cancer,
B9E-MC-X331,PhII Gemzar/celecoxib locally adv/met pancreatic cancer,
B1Y-MC-X217,Fluoxetine in Borderline Personality Disorder,
F1D-SB-O115,Effect of olanzapine and quetiapine on cognitive Dysfunction,
"5661",Fellowship for Dr. May Cohen (FEL-055),
B5K-GH-IBFY,Intensive humulin treatment in early diabetic neuropathy,
"5839",Cerebral Spinal Fluid study,
F1J-FW-HMCE,Second Bioequivalence Study,
B3N-MC-EUBD,MOXONIDINE: PILOT PK STUDY DONE AT BIOPHARMA PER JAGO,
"5931",Drug Interaction Study #1,
B4G-EW-LAAX,PERGOLIDE ENDOCRINE COMPASSIONATE USE EUROPE,
B9E-US-S299,Phase II Gem/Carbo/Iressa in NSCLC,
B9E-US-X448,"Ph II Cisplatin, Etoposide, Gem, Solumedrol in Non-Hodgkin's",
H9T-MC-NABH,Multi-Dose PET Study,
F1D-MC-HGBA,OLANZAPINE VS CHLORPROMAZINE IN REFRACTORY SCHIZOPHRENIA,
H3E-US-X027,Ph I/II Carboplatin/Alimta and Bevacizumab in pts. w/ NSCLC,
H3E-US-X028,Ph II Pemetrexed Treatment of Adv. Thyoma & Thymic Carcinoma,
H6P-US-HDAW,OFC vs. Quetiapine vs. Placebo in Bipolar I Depression,
"9885",Ph 2 Gem (continuous infusion) Carbo vs Gem Carbo in NSCLC,
F1K-FP-O032,Observational study on severe sepsis in IC - Pr ,
"9922",Initiation Trial (Daily Dosing to PRN),
"10247",Investigation of Host Inflammatory Factors Affecting Sepsis,
H4S-FP-O062,Evaluation of delayed thrombocyopenia after ReoPro (Nurden),
B9E-FP-O464,IIT-Breast B9E-FP-O464 Gligorov SEGEMOX / GERCOR,
H3E-US-I004,Ph II Alimta & Bevacizumab in recurrent head & neck cancer,
"10428",JP PPAR-alpha/delta P-1 MDSS,
H6D-UT-O007,Tx of complex Regional Pain syndrome type 1 with tadalafil,
H3E-JE-ME02,JP MTA MPM safety confirmation,
B9E-SU-O265,"Neoadjuvant Carboplatin/Gemcitabine IIIA, IIIB NSCLC",
F1D-XM-HGLK,Olanzapine in schizophrenia- Observational Emergency room,
H3E-MC-S002,ALIMTA + GEM + Cis,
H7R-LC-GCBG,PPAR-gamma Japan Bridging Study,
B3D-EW-GHBW,Phase I PK/PD  for Pulmonary PTH Delivery,
B5K-GH-O006,Impact of Insulin Therapy on Insulin Secretion Function,
F1D-SB-S023,Treatment of acute inpatients with Olanzapine in Germany,
B9E-SB-O286,Neoadjuvant Chemotherapy with GET in Breast Cancer,
F1D-US-X213,adjunctive topiramate treatment for overweight patients,
"6604",IIT Placeholder for Xigris,
H8I-EW-HQAD,SDSS,
F1J-UT-S001,"Diagnosis, effectiveness, QoL in GP",
H8A-MC-LZAJ,LY2062430 Abeta Antibody MDSS--Mild to Moderate AD Subjects,
B7A-MS-MBBE,A CROSS-OVER STUDY TO EVALUATE THE EFFECT OF DIFFERENT MEALS,
F1D-GW-S034,Cost-Benefit study comparing Olanzapina versus Haloperidol,
B5Q-KL-NCCQ,Effeectiveness of treatment of GERD with  chronic liver dise,
H8M-MC-HTAB, MDSS in Schizophrenia,
B9E-US-X354,Rand Neoadj Study of Intens Chemo VS Seq Chemorad NSCLC,
"6929",Oral-Labial Safety & Efficacy,
H7D-EW-GNAC,Oral PTH-Gastric regional absorption study,
B9E-IN-S309,"Phase 2 - neoadjuvant, gem + adria and gem + cis in LABC",
"7046",Anxiety with Comorbid Condition (Alcohol Abuse),
B4Z-MC-LYBU,Pilot Augmentation Study,
"7104",Placeholder Trial,
"7118",Ph I/II Alim+Gem+XRT Pancreas,
B7A-LC-MBDI,Potential PKC/Lovastatin Drug Interaction Trial,
B9E-MC-V194,Genetic mechanisms of resistance to gemcitabine in pancreati,
B4Z-SB-O002,Evaluation of the prevalence of ADHD in 5-year old children,
B9E-VI-S326,Gemcitabine plus Cisplatin as First line treatment of MBC,
"7432",Epidemiologic Study,
B9E-MC-JHFC,GEMCITABINE THREE ARM COMPARISON IN NON SMALL CELL LUNG CA,
"7515",Elderly study,
H8N-MC-A001,Micro-PET Animal Studies,
B9E-MC-JHKC,GEMCITABINE PHASE 1&2 IN ACUTE MYELOGENOUS LEUKEMIA,
H8Y-LC-HBBA,SDSS,
"7663",Olanzapine Acute Phase IIT in Pakistan,
"10038",Placeholder for IITs (US),
B3D-BL-B001,Forteo Observational Study,
"7799",IIT Duloxetine SUI,
B9E-MC-V212,gemcitabine + adenovirus dominant negative c-jun gene transf,
"7846",Camos for Evista,
"7871",NSCLC GPI,
H8W-EW-EGEA,Phase I Dose Escalation Study,
"7935",CTNR: Gem  + Carbo seq Gem + Affinitak - NSCLC,
F3Z-MC-O057,Intranasal Humulin R in LADA:  Beta Cell Preservation Study,
"8029",Xigris use in burn patients,
H8O-MC-GWAK,Insulin sparing pilot,
"8119",Japan Bridging MDSS,
H8V-BD-LTBB,MDSS,
B3D-JE-GHCO,Osteoporosis,
B9E-IS-O375,effect Heparin on efficacy of Gem Cis in adv. pancr.ca.,
"8410",Ph II ALIMTA/Cis or Carbo prior to surgery-neoadj St 3 NSCLC,
B9E-SB-O385,"Gem, Cis/Dexa and rituximab in relapsed high-grade NHL",
H8S-MC-LIBA,MeNER Human Radiation Safety Study,
F1K-US-V010,Reg. of of Human Pul. and Coronary Artery Endo. Barrier Func,
H4Z-MC-GJAK,Definitive food effect study (ClinPharm),
B9R-MC-X003,EFFECTS OF HGH AND TPN IN MALNOURISHED ADULTS,
F1J-BI-SBCL,ICR Safety and Efficacy Study,
B9E-US-X414,Wkly Gem/Docetaxel comb. relapsed ovarian & peritoneal CA,
"8628","Ph 2, ALIMTA+Platinum (plat-sensitive) - OUS",
F1D-MC-X244,Effect of Olan w/comb. lithium or divalproex in Bipolar Dis.,
H6D-EW-LVFV,Cialis: Ritonavir study,
"8676","Ph II, Gem + Cis -> ALIMTA + Gem in Pancreas Cancer",
"8677","Ph 3, Gem RTOG Radiation Study (US)",
F1D-MC-X245,Treatment of Bipolar Pts with Comorbid Substance Abuse,
"8715", Prophylaxis for radiation induced ED-Men w/ Prostate Cancer,
F1K-MC-O021,PK in severe DIC,
"8765",Ph I/II - ALIMTA + CPT-11 + novel agents (ASAP) - CRC,
"8772",Placeholder,
B9R-SO-0707,BGH TREATMENT IN ADOPTED GIRLS/PRECOCIOUS OR EARLY PUBERTY,
"8875",mGlu3 antag II biomarker study #1,
H6Q-MC-JCAR,Ph II study of Enzastaurin in metastatic Colorectal Cancer,
"9104",Strattera ICR pre-launch phase IIIB Efficacy & Safety study,
H3E-MC-V029,ALIMTA invitro studies in solid cancers,
H6U-MC-X001,Protein Profiling of Plasma and CSF in Healthy Subjects,
B3D-US-X009,Cross-sectional bone biopsy of postmeno women with osteo,
F1K-XM-EVCZ,Biomarkers in blood and BAL,
F1D-MC-V016,Neuroenhancement by Olanzapine,
H3S-XM-O123,Impact of sanitary education in life quality and compliance,
B9R-MC-O035,Functional relevance of SHOX SNPs,
"9414",Multi.multinational prevalence fracture in asymp. postmenop,
"9424",CS 747 Active Metabolite on Platelet Inhibition,
H3E-US-S065,Phase I/II Alimta/Taxotere in AIPC,
F1D-BL-B014,CGI-SCH Portuguese Translation Valitadion,
H6E-KL-O011,Effects of Pioglitazone on Vascular Endothelial Cells & VSMC,
B1Y-XB-O033,Fluox vs fluoxplus DU125530 in major depressive disorder,
B4Z-US-X020,A Randomized Placebo-Controlled Trial of Atomoxetine for the,
"9515",CVA Study # 2,
"9542",Phase II IBS,
H7U-MC-IDAZ,Glargine comparison study,
F1D-AY-O263,Do mood stabilizers affect neuronal communication processes?,
B9E-US-S373,Ph II - Gem Intravesical w/Gem maintenance - Bladder,
F1D-LC-HGCB,OLANZAPINE-THEOPHYLLINE DRUG INTERACTIONS,
F1D-LC-HGEV,OLANZAPINE:15MG STRENGTH BIOEQUIVALENCE TAB. FORMULATIONS,
"9741",National Collaborative Study of Girls Prenatally Dx w/turner,
H6Q-MC-JCBR,Ph III Enz Trigger Trial-1st Ln NSCLC,
F1K-MC-EVDC,Severe Sepsis Patients with End Stage Renal Disease,
F1D-XM-O271,Obsrvational and retospective study antipsychotic prescripti,
"9847",Gemcitabine in combination with taxanes in MBC,
F1K-HL-O028,IIT- Activated protein C replacement therapy in pancreatitis,
B4Z-FP-S016,Writing disorders: Atomoxetine in pats suffering of ADHD+ WD,
H3E-XM-O019,MPM tissue retrieval,
F3Z-US-IOOT,Lispro Dosing Trial,
"9960",Restless leg syndrome,
B4Z-US-X031,Efficacy of Atomoxetine in Adults with ADHD and Substance Ab,
I1E-LC-ESAB,SDSS,
"10084","Pharmacologic Study gem, 5-fu, leucovorin",
B9R-US-GDGH,Long term growth and skeletal maturation in Turner Syndrome,
"10134",Placeholder Humatrope IIT's in the Netherlands,
F1D-JE-LOBW,JP ola P-I Zydis BE,
H3E-MC-V051,Effect of Alimta + Gemcitabine in colorectal cancer,
I1G-MC-LTDA,FHD (09-Dec-05): iv formulation SDSS,
F1D-OE-O278,Functional Neuroimaging in Olanzapine treated Bipolar Patien,
H6Q-MC-A027,Plasma samples studies with TNF and Enzastaurin,
"10356","18-Mos Open-Label Trial of FORTEO Pts w/Previous Parathyroid",
B4Z-US-X042,Predicting and Measuring response to atomoxetine and methylp,
"10414",Development of Biomarker assays in healthy Obese Volunteers,
F1D-MC-X004,OLANZAPINE:  GLUTAMATERGIC EFFECTS,
B9E-US-X454,Randomized Ph II Carbo/Gem/Dexamethasone for NSCLC,
H6D-EW-LVHL,PAH Clin Pharm Interaction Study #1,
F1K-FP-O036,IIT - ACTIVATED PROTEIN C AND HEPATIC DYSFUNCTION,
F1D-SP-HGDD,OLANZ VS HALOP IN DOPAMINE D2 RECEPTOR BLOCKADE WITH SPECT,
B9E-MC-V315,Cytotoxicity + antitumor activity of Gemzar,
H8O-ME-GWBL,Exenatide at Lunch/Dinner Compared with Breakfast/Dinner,
F1J-BI-SBCX,Mixed Urinary Incontinence (SBCU clone) BI OUS,
H3E-MC-V117,Modulation of Folate Receptor,
F1J-IT-O017,Response to Duloxetine in MDD assessed with MRI,
"11020",Definative QTc Study for Pruvanserin,
F1J-JE-1007,"LY248686 PHSE I SINGLE DOSE ADMINISTRATION,7.5MM TABLETS",
"11050",enz and trastuzimab in lymphoma,
"11142",Association of Gemcitabine to Gluathion S-Transferase,
F1J-MC-I008,cymbalta for smoking cessation: a pilot study,
B9E-IT-V350,Gemzar in superficial carcinoma of the urinary bladder: FK,
B4Z-CA-A008,ExNCR-Atomo vs Methylphenidate -Behavioural Effects in Rats,
F2F-LC-HNAA,LY228729 HIPPURATE:  ORAL DOSE-RANGING STUDY,
"11506",Ph II combo w/ targeted agent based on preclinical studies,
"11510","Ph I ENZ + Erbitux in solid tumors (NSCLC, CRC, HNC)",
"11543",Ph 2 alimta/Ca+Enz v. Alimta/Cis+Enz in ext. SCLC,
"11594",Receptor Occupancy (RO) PET Study,
"11674",LY450139 Asian Phase III Study,
"11700",Gene expression profiling in Human Mesothelioma cell lines t,
H3E-US-I021,Two-Arm Sorafenib w/ Cisplatin/Etoposide or Carbo/Alimta,
B9E-US-I162,"PhII Wkly Gem, Mthly Taxotere & Bi-Wkly Avastin in Breast",
B9R-XS-O048,Insulin resistance and cardiovascular risk factor in obese,
H6D-IT-V009,Characterization of effect of Tadalafil on Adypocites,
F1D-EW-HGMV,Randomized double blind study Olz & lamotrigine in bipolar,
F3Z-XM-O067,Study about Immune and Genetic Metabolic Markers,
I2F-MC-GHEB,Phase ll Teriparatde Inhaled Powder Trail,
F3Z-JE-PV04,JP Humalog N PMS Study,
I1X-MC-BDAB,Phase II Crohn's Disease,
I2A-MC-GABD,Vitamin D Levels in Subjects of Japanese & Western Origins,
I2K-MC-ZZAG,Drug/Drug/Alcohol Interaction,
F3Z-MC-IOEK,USE OF LISPRO IN INS.-RESISTANT NIDDM WITH LIVER DISEASE,
I2Q-FW-GMAI,Safety and QTc Pilot Clamp Study,
H6P-MC-HDAY,Long-term effectiveness and safety of Symbyax in TRD,
I2R-MC-BIAJ,T2DM 12/18mo Insulin Naive v. glargine,
I2R-MC-BIAC,"Type 2 diabetes patients, Phase 2",
I2R-FW-BIAA,SDSS-Glucose Clamp study,
H8O-EW-GWCP,Transdermal Patch (TDP) FHD,
B5K-US-V011,"ExNCR, DeTaeye, Vaughan, insulin, PAI-1 and T2 DM",
"12207",Once Daily Dosing Regulatory Commitment Safety Trial,
F3Z-MC-IOGQ,INSULIN LISPRO LM VS NPH: BID THERAPY IN TYPE II,
"12299",RPh3 Alimta Cis Avastin vs Alimta Cis in 1st line NSCLC,
I2E-JE-BSAD,JP Anti-CD20 Antibody II - CPS,
"12317",Cialis: Placeholder study,
"12377",Chronic Insomnia #1 w/young end elderly-3 months,
H8O-IN-B009,Post Marketing Survelliance Study,
"12439",Phase III 3 yr treatment,
"12447",Hypoglycemia Methods Study,
"12464",Placeholder PRA pharmacy study,
"12479",Placeholder PRA prescription survey on concerta and ritaline,
"12551",Ph II - Patients  w/prostate cancer on anti-androgen therapy,
F1D-MC-A151,Effects of olz on congition in rats,
H3E-EW-S124,PARAMOUNT: Ph3-AlimtaCis x4 with Alimta Maint vs BSC-NSCLC,
H9P-EW-LNCL,Biopharm Methylphenidate study (ADHD),
H9P-EW-LNDC,Biopharm Food Study (with marketed material),
H3S-US-X036,Improving Osteoporosis Care in High-Risk Home Health Pts,
H9P-MC-LNCC,NERI IV Adjunctive Treatment Comparator Study #1,
B1Y-EW-E082,FLUOXETINE: I.V. SALINE INFUSION,
H8Y-MC-HBCJ,Treatment Resistant,
H8O-MC-V004,Effects of GLP1 agonists on vas endo cell function,
H8O-MC-A019,effect of 9 mos ex tx on synaptic mice wtih AD,
I2K-MC-ZZBJ,Driving Impairment,
I2K-MC-ZZBR,SSRI Interaction ,
I2K-MC-ZZBX,BE Study for PEDS Formulation,
"12868",JP QW TZD Phase 3 Study,
"12935",Phase 4 Patient Registry Trial,
"12982",CD-4 wk indiction + 12 month maintenance  + OPel Label Stdy,
I1R-MC-GLBG,Glucagon-Receptor Antagonist 1st Gen Phase 2b,
"13037",ER Beta thorough QTC,
H9B-JE-BCDK,JP LA294 Ph-1b RA,
I1F-JE-RHAL,JP LA426 Ph-1b RA,
F1J-XM-B036,Obs study in PC to evaluate screening tool in MDD patients,
H3E-EW-B012,Alimta in 1st line NSCLC,
I3W-MC-HHAI,CV/PD,
H7T-MC-TADX,PAD Indication,
I4B-MC-GPCD,Phase 2,
H6D-MC-X009,Ultrasound in Evaluation of Orgasmic and Ejaculatory dys,
I1N-EW-CDBC,MDSS  mGlu2 Pot/CysLT1 Antag 1 ,
I4F-MC-CCAF,Def QTc,
I2M-MC-GSDE,Phase 1 Multiple Dose,
H6D-US-LVIQ,Post Nerve-Sparing prostatectomy and ED,
H8Y-MC-HBDA,Taiwan Study Support Asian Registration,
F1D-SB-O331,Clinical efficiency of the newer antipsychotic compounds ,
"13709",Drug Drug interaction study,
H6Q-FR-A032,Pre Clinical study - Enz breast cancer xenographs,
H6Q-MC-V052,Pre Clinical - Human Breast Cancer,
H6Q-MC-A036,Pre-Clinical Xenograft model of human colon cancer,
H3S-MC-GGHW,RANDOMIZED PHASE 3 STUDY OF RALOX IN PATIENTS WITH BREAST CA,
"13795",Phase 2/3 Glioblastoma,
H6O-CY-B001,Epidemiologic report on results of FPG and PPG measurement,
H3U-MC-JPAB,PH 1 MULT ESCALATING DOSE STUDY OF LY300502 ADMIN. ORALLY,
"13962",FED Randomized Phs 2 Stdy for pts w/myloproliferat,
I2R-MC-BIDI,Pragmatic trial,
"13995",CGM,
A6J-MC-X003,Vancomycin  vs. Metronidazole for treatment of CDAD,
"14061",Ph 3 H2H trial in RA,
H3E-MC-JMIS,R-PhII-Alimta+invest agent in ERCC1 positive adv NSq-NSCLC,
I2Z-MC-LAFD,Phase IIA-MDD POC Study,
I4V-JE-JADN,JP_JAK_Ph2_RA,
H4A-MC-V002,"LY303366 VS. OPPORTUNISTIC/ENDEMIC MYCOSES, YEASTS & MOLDS",
I3S-MC-JABB,HRA/MM Phase 2,
B1Y-FP-0721,FLUOXETINE:MULTICENTRIC STY PSYCHIAT.DAILY PRACT,
F1D-JE-CS08,JP_ZYP Depression_Special PMS,
H4S-AY-O083,Physiology of ACS: focus on microvascular dysfunction,
I5Q-MC-CGAA,Phase 1 SAD of LY2951742 in Healthy Volunteers,
A6J-GH-O002,China Infection IIT,
I1Q-JE-JDDH,JP_Myostatin Ab_Ph I_Disuse atrophy,
I1F-MC-RHBD,Ankylosing Spondylitis Phase 3 Biologic Experienced Pts.,
H8O-MC-X030,Changes in Bone Turnover with Exposure to a GLP-1 Receptor A,
I6D-MC-SMRB,MAD,
I5A-IE-X003,"8354: Ph I/II - A12+Everolimus - Neuroendocrine",
I5A-IE-X017,ADVL0821: PhII - A12 - Solid Tumors,
F1D-JE-CS09,Olanzapine RAIM mandatory PMS,
H3E-SB-O070,TS stratified chemo in non-squamous stage IV NSCLC,
"14517",Asian Observational ACS-PCI Trial,
I4M-MC-MRAI,Human C-14 Study,
I4E-IE-JXBH,CP02-0451: Ph II-Cetuximab - Metastatic Colon,
I1R-FH-GLDK,China Study,
I6E-AV-_A12,A study using Florbetapir F18 PET in Parkinson disease,
I4V-MC-JAGM,Absolute Bioavailability,
I1V-MC-EIAS,Pharmacokinetics of Evacetrapib (LY2484595) in Subjects with,
I4J-MC-HHBE,FED_PH Ib/II - LY2940680 Hedgehog/SMO - SCLC,
I4F-MC-CCAI,MTD,
H4S-IN-EWAC,C7E3 FAB IN PATIENTS UNDERGOING HI RSK CORONARY ANGIOPLASTY,
I5E-MC-TSAK,DDS15- PK study to assess 2 formulations of Testosterone ,
"14642",Nerve Density,
I1R-MC-GLBU,Ph3: GRA+MET+SU vs PL+MET+SU vs SGLT2+met+SU (elderly),
I4X-MC-JFCK,Ph II-11F8+ Gem+ Cis -NSCLC-1st line,
H4S-MC-X006,REOPRO READMINISTRATION REGISTRY,
I1R-MC-GLBV,Monotherapy GRA I vs PBO,
"14822",R-Ph III-Evaluate LY2603618 + Gem or SOC - Pancreas,
I6B-MC-HZBE,Antidepressant PK/PD,
H9H-JE-JBAO,Japan_Ph1b combo with Gemzar for pacreatic cancer ,
H4Y-MS-LJAC,SINGLE AND MULTIPLE ORAL DOSE SAFETY AND PK STUDY OFLY334370,
F1J-JE-B058,Cymbalta JP Double Blind Study,
"14968",Combination with Alpha Blockers ,
I4L-MC-ABEO,PK/PD Bioequivalence BIV vs US Glargine,
I4J-MC-HHBJ,JP_L2940680 Hedgehog SMO Antagonist_Phase1 SCLC,
H9H-MC-V006,Dissect. the role of Chk1 in hepatocellular carcinoma invitr,
I4E-MC-JXBI,Ph 4-Assess Immunogenicity Response to Cetuximab-Colon,
I6S-MC-ASEC,POC,
I5T-MC-AACC,SAD/MAD ascending dose,
H9P-MC-LNEJ,POC edivoxetine treatment of MCI with Parkinson's Disease,
I4D-MC-JTJD,Ph1b -Chk-1 Inhib II - Solid Tumors,
I7P-MC-DSAB,Phase 1 MAD Study in Patients,
H9H-MC-JBAT,POC-Ph Ib-TGFb as immunomodulator for cancer,
H9B-MC-BCEI,Tabalumab Autoinjector Trial in Patients with SLE,
I6O-MC-B001,"2012-522_Limited Project Management _DiAlert Study",
I5J-MC-NOAI,TQT study,
H7T-US-B020,US Affiliate Retrospective Observational RWE,
I6O-JE-BHBE,Japan Safety and Efficacy Study-T2DM-LY 900012 vs Glargine,
H9X-MC-B002,Dulaglutide Risk Minimization (REMS) Assessment - 18 months,
F3Z-MC-B016,"2013-066_Lilly vs Novo Insulins",
I7N-MC-BDPB,Phase II POC,
F1J-BP-O055,SPECTROSCOPIC AND CHROMATOGRAPHIC ANALYSIS OF DULOXETINE ,
"15436",LY 2409021 Glucagon-R Antagonist Oral Contraceptive study ,
I5E-MC-TSAQ,"MTE11 Healthy volunteer single-dose,PH1-residual testosteron",
I2Z-MC-E004,POC study of patients with anxiety and anhedonia,
I3Y-MC-V002,Eff.of LYs in pt. derived cell line models of glioblastoma,
B4Z-MC-B028,Adult RMiP Assessment for Effectiveness of DHCPL,
B9E-MC-X089,"Phase I/II Study of Gemcitabine, Navelbine, and Cisplatin",
"15564",MAD PK/PD AD Pts,
"15586",Food Effect in Healthy Subjects,
"15668",Renal Impairment,
"15682",URI-Excipient OTHER-Ph1b T2DM PK/PD,
I8L-MC-IXAJ,T2DM clamp study ,
H9H-CR-JBED,CN_Ph I-TGFb RI Kin Inhib-PK - MDS;HCC;Pancreas;Glioblastoma,
"15795",IMCT-PCSK9,
I3Y-MC-A010,Def. Mech. of Resistance in Castration Resistant Prostrate C,
I6A-JE-CBBH,JP_FHD_Ph I - PI3 Kinase/mTor Dual Inhib-Solid Tumors,
I4E-IE-W832,Protocol CA225-012; A II TRIAL OF CETUXIMAB (C225) AS THERAP,
I4E-IE-W836,Protocol CP02-9816; II Study of Anti-Epidermal Growth Factor,
I4E-IE-W882,Protocol CA225-072; II Selection Design Trial of Concurrent ,
I4E-IE-W898,Protocol MED-PO2-07001; II trial of docetaxel plus oxaliplat,
I4E-IE-W914,Protocol CA225-249; I study of cetuximab/docetaxel/cisplatin,
I4E-IE-W915,Protocol CA225-267; PILOT FEASIBILITY TRIAL OF PREOPERATIVE ,
I6E-AV-I018,AV-45-IIT-018: Return of Amyloid Imaging Results in MCI,
B9E-MC-X017,Phase II Study of Gemcitabine in Recurrent Head & Neck Cance,
F1J-MC-SAAW,Effect of Duloxetine on Genuine Stress Urinary Incontinence,
I8D-AZ-AZEX,Japan SAD-MAD Study (D5010C00003),
"16287",DDI Midazolam,
I8K-MC-JPDF,RBA of Three Formulations of LY3337641 and Effect of Food ,
"1631",LY333013-LC-xxxB Multiple Dose (oral compound),
I8P-MC-OXAA,SAD (FHD) for OXM lll (LY3305677),
I8F-MC-B003,"2015-196-3: Psychometric study validation",
I4E-MC-BSCF,BMS CA225-346: Ph II-Erbitux+Cis+Vinorelbine-NSCLC-1st Line,
I4T-MC-JVDN,Ph II - Ram + Weekly Docetaxel - NSCLC - 2nd line,
I8T-MC-STAB,Ph1b POC Study in T2DM,
F3Z-MC-B023,"2016-203:Study of Glycemia in People w/ T1D",
H3S-MC-GGIQ,Comparison of Raloxifene HCL and ccHRT theraphy in Postmenop,
"1597",Depression Proof of Concept Trial,
I1X-MC-BDAE,IL23 Ab PK/tolerability study utilizing extemperaneous prep,
I8J-MC-JYCC,FRD_Ph II-PD-L1 Antib Monotherapy Registration-Solid Tumors,
I8H-JE-BDCF,BIF Japan SAD in T2DM,
A1L-MC-X001,PREDICTION AND PREVENTION OF RELAPSE AND RECURRENCE IN DEPR.,
"16588",Open Label Extension in UC patients,
I6T-MC-AMAO,Ulcerative Colitis Phase III: Induction trial 2,
"10135", Placeholder for PTH IITs,
"16653",Pediatric OLE in AtD,
"10169",LA307: Phase 2 study in Stage III/IV CKD-Non Diabetic origin,
I4V-MC-JAIF,EUCAN Treat to Target with Bari vs SOC in MTX-IR RA pats,
F1D-MC-HGEB,O-L OLZ IN TRMT OF SCHIZ: IMPACT ON QOL AND COGNITION,
"16722",Diabetes Prospective Observational Study,
H9Y-MC-UTAA,SDSS Phase 1a Study,
H9X-GR-B018,Prospective Observational Study in Greece,
F1D-UT-O280,orally disintegrating olanzapine and weight loss,
I6T-MC-AMBD,China PK HV,
H6Q-MC-V002,Effect of enzastaurin on human colon cancer cell lines,
I9F-MC-SCAB,C14,
"16811",Ph I/II-Chemotherapy or Immunotherapy + Pembro - NSCLC,
I9L-MC-JZCD,Mini-tab RBA/ Food Effect,
H8H-MC-LAHE,MAD safety tolerability/ PK and DDI in Lasmiditan,
B1Y-IT-0007,FLUOXETINE VS CLOMIPTRAMINE IN DEPRESSION SUBGROUPS,
"1690",LY353381 combined with multiple doses of MPA (progestin),
"16907",Dose ranging ph 2B study for Migraine Prevention,
F1J-JE-HMHF,Long term safety of DLX on pediatric MDD,
H4Q-MC-ARRL,LY333328 Multiple Dose--Safety & PK in Skin Infections,
I3Y-JE-B001,PhIV PMSS-Abemaciclib-Metastatic Breast Cancer,
"16952",Ph2/3-Abema +/- Pembro-NSCLC,
B9E-MC-X090,"PHASE 1 STUDY OF GEMCITABINE, CISPLATIN, AND AMIFOSTINE",
I8P-MC-OXAD,MAD in T2DM for OXM III Pts,
H9D-MC-ITAS,URI Analog EET (Pump),
I1F-MC-RHCR,PsO H2H ixe v. guselkumab,
J1K-MC-EZAA,SAD/MAD/POC,
F1D-IS-O285,THE ROLE OF d2 RECEPTOR GENE AND PERSONALITY TRAITS IN ALCOH,
"10361",Trovati- Inf of glucose on nitric oxide in VSMC mod. by PKC,
H3E-US-I002,Ph II gem/alimta followed by chemorad in head and neck,
"10393",Weight Gain Associated w/ Atypical Antipsychotic Treatment:,
"10400","14C Metabolism Study DPP IV Inhibitor",
B9E-MC-V290,"Gem single agent and com w target inhib of AKT meso, panc",
H8Z-MC-JACR,FED Hormone Refractory Prostate Cancer,
B9E-MC-V291,Polymerase cells & epsilon assoc exonucleases in gem cytotox,
F1J-US-X018,Functional Change and Efficacy of Duloxetine in Patients,
H7U-MC-IDBJ,IDAU Extension,
F1K-BP-O034,Long Term outcome- Xigris,
F1D-MC-X012,HALOPERIDOL VS. OLANZAPINE: EFFECTS ON STRIATAL FUNCTION,
H8R-FW-HJAN,Formulation bridging study,
F1J-US-X021,Maintenance Therapies in Late-Life Depression III (MTLD-III),
H7T-EW-TABS,H2 Blocker CoAdmin w/Clopidogrel or Prasugrel,
H6Q-US-S006,Carbo/Alimta/Enz in chemo naive pts with stage IIIB/IV NSCLC,
J2G-OX-Y053,RET Inhibitor-NSCLC,
I1B-MC-NDAB,MDSS / PD Effect,
"10110",Zydis efficacy and compliacnce/ctnr,
F1D-MC-HGCU,A DOSE RANGING STUDY COMPARING OLANZAPINE AND HALOPERIDOL,
H3E-UT-O010,Ph II :Alimta compared to Alimta Carbo in pretreated NSCLC,
"10150",PLACEHOLDER FOR STUDY B9E-MC-S303,
F1J-US-X009,Duloxetine for the Treatment of Major Depression in Postmeno,
F1J-MC-HMEM,DPNP EU Open Label for Maintenance of Efficacy,
H3E-MC-JMHW,Ph II trial Alimta in pediatrics (COG),
H6Q-MC-A010,Efficacies of Enzastaurin on in vitro growth inhibition,
H6Q-MC-A011, Approaches fro repeated analysis of delivery of doses,
B5K-IS-O451,Relationship between leptin and insulin in DKA,
B7A-LL-V002,Effs selective PKC on glomerular perm & VEGF gene ex,
H3E-MC-V062,Effect of Alimta on Lung Cancer and Meso in Skid-Mouse Model,
F1D-US-X282,Efficacy of Olanzapine in Improving Task Engagement in Schiz,
H8O-EW-GWBC,Exenatide Effect on Oral Contraceptives PK,
F1D-XB-O286,IM Olanzapine in treatment of manic or schizophrenic patient,
I1F-MC-RHAB,"MDSS/PoC LY2439821 (RA patients, 3 dose levels) IV  Admin.",
F3Z-MC-IORB,TANGO Feasibility Study 2b,
I4D-MC-JTJP,Ph II - Prexasertib - mBC,
"17280",Atopic Dermatitis Flexibility,
"17354",Ph 2/3 RCC:  3L & 4L (IO naïve and IO exposed) ,
B1Y-US-HCIR,FLX VS. PLB IN GERIATRIC NURSING HOME PATIENTS WITH MDD,
J1X-MC-GZHD,MAD POC 8-week (Intestinal) study in T2DM Pts,
H0P-MC-BP01,Intervention Specific Appendix - CLBP,
J1W-MC-JU01,AMBIANCE - Ph II - MultiCmpd BC ERK+Abema - Post CDK 4/6 mBC,
J2G-OX-Y003,PHI-RET Inhibitor-NSCLC,
J2G-OX-Y015,PhI-RET Inhibiitor-Infantile Myofibroma,
J2G-OX-Y026,PhI-RET Inhibitor-MTC,
J2G-OX-Y029,PhI-RET Inhibitor-PTC,
J2G-OX-Y047,PhI-RET Inhibitor+Crizotinib-NSCLC,
I7E-AV-E106,AV-1451-ExIST-102: Tau Imaging with 18F-AV-1451 in Geriatric,
H4W-LC-LLAJ,LY156735:Effect on Sleep; Comparison to Melatonin,
B3D-CA-O008,Decreasing Incidence of Osteoporotic Fracture -Saskatchewan,
H3E-MC-V094,Preclinical research with ALIMTA,
H9U-BD-MDBI,Relative bioavailability study,
H3E-MC-V100,Invitro study of ALIMTA with doublet screening,
H3E-US-X055,"Ph I/II Bevacizumab, Alimta & Eriotinib in Elderly NSCLC",
H3E-MC-V116,Bifunctional DHFR-TS of the African trypanosome brucei,
B9E-IT-O484,Ph II Gem/Carbo Ovarian Cancer,
H6Q-MC-S027,Ph II Enz+Novel Agent,
B4Z-US-X048,Atomoxetine for Treatment of ADHD and Marijuana Dependence,
H3E-MC-V123,Efffect of Genistein in Potentiating the effect of ALIMTA,
F1J-JE-1006,LY248686:PHASE I MULTIPLE DOSE STUDY(ENTERIC GRANULES),
H8O-MC-A005,Prev of beta cell apopt/dys by exentatide,
H6Q-MC-A022,Enz and breast cancer,
"11083",Incidence of vertebral fractures in women with hip fracture,
B9R-IT-A005,GH and Cardiac Repair,
I1M-BD-PEAA,FHD: SD escalation and Pilot study food effect,
F1J-MC-X027,Pilot Study: Duloxetine & BupropionSR in pts w/depression,
H3E-IT-O024,alimta vs alimta +carbo in NSCLC phase III,
"5126",LY333328 Massbalance Study,
H7U-JE-IDBF,JP Pulmonary insulin P-II/III (Type 2) Study 2,
H7T-MC-TABI,Smoking Study,
F1J-MC-HMER,HMDI extension for post maintenance effect,
"10615",Placeholder for local support Duloxetine,
H3E-SB-O016,AIO Study: Alimta adjuvant in NSCLC,
F1J-US-X017,The Impact of Pharmacy Benefit Coverage for Duloxetine,
H3E-MC-V073,Molecular Parameters of Sensitivity to Pemetrexed in Lung Ca,
F1D-US-X291,Proposal for Analysis of Ghrelin Plasma Samples,
F1D-GW-O290,Metformine Treatment for Olanzapine induced Weight Gain,
H8O-BP-GWBG,Local UK Byetta study into weight maint. & metab. syndrome,
F1K-US-EVDJ,"Double Blind, Placebo controled trial in the ER",
H3E-MC-V095,Efficacy of ALIMTA of Ovarian Cancer,
B1Y-CP-0002,FLUOXETINE IN TREATMENT OF BULIMIA NERVOSA,
B9R-AY-O045,Humatrope - Interaction of testosterone & growth hormone,
"10878",Duloxetine in  MDDpatients with or without MCI,
H9X-MC-GBCC,Definitive QTc study to address some cardiovascular safety,
"10920",Ph 2 Concurrent XRTwith Alimta fu Alimta/Cis,
"11595",Drug-drug interaction (DDI) Study,
J2G-OX-Y060,RET Inhibitor-NSCLC,
J2G-OX-Y122,RET Inhibitor-MTC,
J2G-OX-Y178,RET Inhibitor,
J2G-OX-Y185,RET Inhibitor,
J2G-OX-Y190,RET Inhibitor,
J2T-DM-KGAS,Lebri for pts w/ asthma w/o Inhaled Corticosteroids,
J2G-OX-Y200,RET Inhibitor,
"18098",Reduction of NfL in Patients with Alzheimer's disease,
I8H-MC-BDCS,BIF Ph2 T2DM Insulin Naive Fixed Dose glargine cntrlld study,
"18185","Evaluate pharm, safety, and eff of Bari in peds w/ COVID-19",
B9E-MC-X006,GEMCITABINE AS SECOND-LINE THERAPY IN UROTHELIAL CANCER,
J2X-MC-B002,Prospective Pregnancy Study to assess outcomes,
B7A-MC-MBBK,Phase II/III Macular Edema,
"18415",Oncology Renal Study,
J3N-OX-JZRE,LOXO-BCL-22003-Ph1-BCL2-ADME,
I9Y-MC-JDHN,Ph3-IDH+Gem+Cis vs Pla+Gem+Cis-Cholangiocarcino,
"18711",Lactation Study Post Launch,
I8F-GH-GPIR,Weight regain after withdrawal of TZP: The SURMOUNT-CN trial,
B9E-CA-O485,Gemzar and Bortezomib in Mantle Cell Lymphoma,
F1J-LC-HMAF,LY248686 HCL (DULOXETINE): (14C)-LABELED LY248686 HCL STUDY,
"11226",Phase 2 ENZ+/-Erbitux - 3rd Exposure - CRC,
H8O-MC-V002,GLP-1 and Cytokine Cross-Talk in Beta Cells,
I1T-EW-MPBC,LY2421371 Phase I Biomarker Study,
"11330",Randomized Phase II Monotherapy vs SOC,
"11336","Randomized Phase II/III NSCLC 1st line (3b/4), Combo Therapy",
"11348","Non Pivotal Phase II/III Emerging, Combo Therapy",
H8O-MC-I007,Effects of anti-CD3 & Exen on loss of insulin prod ,
H6D-MC-A011,Prevention or reversal of the development of cardiomyopathy,
H3E-MC-JMIF,Ph II EERC1 adjuvant trial,
"11520",GAD Phase III trial #1,
F1J-MC-B019,Functional Outcomes of Sexual Dysfunction,
F1J-MC-B018,Retrospective CV study,
H9X-MC-GBCS,D/D Interaction-Warfarin,
F1J-MC-HMFW,Potential Glucose Clamp Study,
F1D-MC-X095,"Rotrosen-Olanzapine , valproate and coenzyme Q-10/L-",
F1D-SB-B027,MAX Obs. study on metabolic syndrome in schizophrenic pat.,
H6D-MC-X005,Treatment of hypertensive heart disease w/ LVH,
H3E-MC-V125,Cyclooxygenase-2 inhibitors agonists for cannabinoid Pan ca,
B9E-MC-V342,Invitro Assay,
"11114",Preclinical studies of therapies for malignant pleural meso,
F1J-JE-401G,EARLY PHII STUDY ON URGE INCONTINENCE,
I2N-MC-GPBA,SDSS - FHD study for SARM,
"11239",Ph 2 Topotecan+ENZ vs Topotecan+Placebo SCLC 2nd Line,
"11248",PK/PD of prasugrel & clopidogrel in extensive/poor meta pats,
H7T-EW-TACG,Effect of age on PK/PD of Prasugrel metabolites,
H6Q-MC-S032,RPh 2 Taxotere/Prednisone +/-ENZ f/u ENZ/placebo 1st ln Pros,
"11339","Randomized Phase II/III NSCLC 1st line (3b/4), Combo Therapy",
H9B-MC-BCDN,"Humira H2H, 6moS&Sx,TNF IR",
"11363",PHASE III AD Efficacy for OpRa II,
H9X-MC-GBDA,Ph III Reg Trial - Add on metformin & pioglitazone,
H6D-MC-A003,Effects of the selective phosophodiesterase-5 inhibiitor tad,
H7T-MC-S001,Pts on Pras or Clopid undergoing carotid stenting,
B9E-BP-O493,Ph II R-GCVP in DLBCL not suitable for RCHOP,
F1D-AY-B033,Treatment patterns in SCH patients on depot medication,
H6D-MC-LVHS,Monotherapy Alpha-Blocker Study,
F3Z-US-X029,Basal/bolus ins in transition from ICU to hospital ward,
H6D-IT-O010,Effect of Chronic Tadalafil administration on penile hypoxia,
I2V-MC-CXAA,A Phase 1 FHD Study in Patients with Advanced Cancer,
F3Z-HL-IOGK,LISPRO POSTPRANDIAL TREATMENT IN CHILDREN,
F1D-MC-A143,Drug-induced Neurogenesis,
"11762",PTHrm - Phase 2/Proof of Concept,
I2E-MC-BSAB,RA Phase 2,
"11797",Mammography-Based Risk Assessment for Breast Cancer,
"11820",Phase III Alimta vs Topotecan Ovarian,
I2A-MC-GABB,MDSS LY2148936 in men and PMP women,
H3E-PH-B006,Post Marketing Surveillance Study on Alimta (Pemetrexed),
B9E-XM-X465,Predictive Genetic Biomarkers in intravesical cancer,
B9E-CA-O503,Ph2 GDP for the primary tx of peripheral t cell lymphoma,
F1D-IT-O305,Olanzapine effect on modification of glutammic acid,
H6Q-MC-S044,Ph I/II ENZ + Lapatinib,
F2P-LC-LCAH,(14C)-AMESERGIDE: DISPOSITION AFTER ORAL ADMINISTRATION,
H9X-MC-GBCR,D/D Interaction-Digoxin,
"11580",PET / SPECT -- IMPY as imaging biomarker for amyloid plaques,
H6Q-MC-V037,Enzastaurin in CLL,
"11692",The Anti - neoplastic potential of ceramide Metabolism and A,
B7A-LL-A010,"Ruboxistaruin effects on metabolism, coronary artery",
"11799",Local Resources for External Research for NSD,
F1J-UT-O027,FMRI study workingmechanism of Cymbalta,
H3S-AY-O136,Bone quality asses fragility fract w Antiresorp Rx vs no ARx,
H3E-AY-V138,Study of MTAP deletions in Meso Tissues Samples,
F1K-FR-A025,NIVIERE Activated Protein C,
"11962",Acute Mania-bipolar disorder,
H6D-IT-O011,Possible role of platelet cGMP as an efficacy measure of ED,
B4Z-GH-O018,ADHD in juvenile delinquency,
H8G-MC-EPBL,A-fib Stroke,
H8G-MC-EPBJ,Biopharm DDI NSAID,
F3Z-GH-O069,Prevalence of Diabetes and metabolic syndrome in China,
I2F-MC-GHEC,Phase 3 Teriparatide Inhaled Powder,
H8Y-MC-HBCB,Health Outcomes,
H9X-JE-GBCG,Pan Asian Ph 3 Mono Therapy vs Glimepiride,
H7T-MC-V018,Pras/ReoPro: Comp & Synergistic Inhib of Prothromb Activity,
F3Z-MC-IODI,NPL + LISPRO VS HUMULIN N + HUMULIN R IN DIABETES,
F3Z-MC-IODN,INSULIN LISPRO LM VS. HUMULIN 30/70 BID IN TYPE II DIABETICS,
H8O-EW-GWCZ,Formulation Bridging,
H3E-US-X073,Ph II study of Alimta + Carboplatin in Endometrial Cell Cncr,
B3D-US-X016,Osteoporosis Home Health Intervention,
"12297",Timing of Efficacy - tadalafil vs. sildenafil,
F3Z-SB-IODD,QOL OF DIABETICS (ICT) FOLLOWING 5-OR 12 DAYS EDUCATION PROG,
F3Z-SB-IOEL,PREPRAND ADMINSTR. OF INSULIN LISPRO IN PAT WITH NIDDM,
B4Z-UT-LYEL,atomoxetine in adolescents with ADHD+cannabis abuse,
B4Z-CP-V001,Antidepressant binding of the human serotonin transporter,
B4Z-US-A011,Anti Amyloidogenic effects of Strattera,
F3Z-VI-IOCZ,SAFETY AND EFFICACY OF INSULIN LISPRO VERSUS HUMULIN R ...,
H9P-EW-LNBX,Biopharm CYP3A4 Inhibition - Midazolam as substrate,
I2N-JE-GPBD,JP SARM P1-MDSS,
"13053",IIT Place Holder ZYPREXA (THOMAS),
F3Z-MC-IOES,BIOEQUIVALENCE OF INSULIN LISPRO HM:  CT07804 VS CT07805,
H8O-MC-X035,Postprand Vas Effcts of Exen vs Met in obese pts,
H4S-BP-O078,TRANSPORT AMI,
F3Z-JE-IOPK,JP NPL P-I SDSS,
F1K-US-X007,Implementation of the Surviving Sepsis Guidelines in a Milit,
I2U-MC-H304,Single Dose - PET,
"12361",Restoration of 1st phase insulin trial,
F3Z-SO-IOFT,HUMALOG VS ISUHUMAN INFUSAT IN S.C. DELIVERY,
"12391","11bHSD1 Formulation Bridging Study",
H8O-MC-O006,Mech of action/met effects of exex in obesity,
F1D-MC-X311,Effect of Olz with Riluzole in Tx of Cachexia in Pts. w/ALS,
"12489",PLACEHOLDER (STUDIES 2008),
B3D-IT-O017,Teriparatide in oral implantology,
F3Z-FR-O074,IIT - Obs study,
"12538",Anabolic effects of testosterone w/ and w/out exercise,
"12566",MR Antagonist Phase 2,
H9P-EW-LNDD,Biopharm Dose Proportionality Study,
B4G-EW-LCDD,Parkinson / Final Patch (place holder) CPharm,
F1D-EW-LOAX,Depot Phase 1a - SRI 75:25 Formulation,
B9E-MC-S034,Gem/Nav post CMF in breast-S034,
F1D-US-HGGE,INCIDENCE OF TD IN ELDERLY PATIENTS TREATED WITH OLANZAPINE,
B7A-LC-MBBN,forearm vascular reactivity study,
H4A-EW-XBAV,LY303366 IV Infusion-Oral Absolute Bioavailability,
H4Z-MC-JWWC,Ph2 Randomized Double-Blind of 2 dose levels in Breast Ca,
B1Y-AY-0002,FLUOXETINE: VS PLACEBO + NUTRITIONAL COUNSELLING IN BULIMIA,
B1Y-MC-HCAC,FLUOXETINE VS PLACEBO OUTPATIENT,
"2212",Postprandial control - Pt function/Lifestyle impact,
H3Z-MC-JNAV,Phase-I combination study with LY295501 + CPT-11,
B9E-MC-S061,"Ph lll, Gem+Carbo+Taxol vs. Gem+Taxol vs Gem+Carbo - NSCLC",
"2287",Immobilization (pilot),
"2293",LY333334 effect on patients with osteoarthritis,
F1D-MC-X103,Is Olan superior Cloz. in txt schiz pats. both adult & geria,
B4G-EW-LCCQ,RLS / One year treatment (Open study),
B9E-SB-O015,"Ph II, Dexamethasone For Reducing Side Effects, Gemcitabine",
B9E-MC-I062,PHASE I TRIAL OF GEMCITABINE AND RADIATION THERAPY,
B1Y-BD-HCHO,PROZAC EXPERIENCE PROGRAM IN HUNGARY,
F3Z-BP-IOMD,LISPRO LM VS 30/70 TWICE DAILY IN TYPE II DIABETIC PATIENTS,
H8A-MC-LZAL,Single Dose PK/PD Study in Healthy Subjects ,
"12679",Formulation:BE/Definitive food effect - placeholder,
B5K-GH-O455,insulin intensification therapy in T2DM patients,
H2Q-EW-LZZN,XANOMELINE PATCH:ABSORPTION AND SAFETY IN NORMAL SUBJECTS,
H2Q-EW-LZZU,"TRANSDERMAL XANOMELINE:SAFETY,PK AND PD WITH FORMULATIONS",
F3Z-EW-IOPX,TRIS PK/PD,
F1D-US-A153,Acute and Chronic Effects of olanzapine on arachidonic acid ,
I3M-MC-JJBA,"Ph 1, FHD, Dose Escalation/Tumor Expansion PLK-1",
I3J-MC-LACE,BACE Single Ascending Dose,
"12894",Gem prodrug - Thorough QT study,
H6L-FW-LFBG,China PK study for Registration,
H6D-US-LVIC,Special Population in Adult PAH,
I2Y-MC-GHFC,Teriparatide Transdermal Phase 3 Bridging Study Male,
"12969",CD-4 week induction 12 month maintenance & Open Label Safety,
"12975",MS - Placebo controlled Ph 3 Trial vs LY& Open Label Safety,
H3E-EW-S125,AlimtaCisAvastin induction+Alimta/Avastin Maintenance NSCLC,
B9E-MC-V234,"Phase II study, stage IIIB and IV in NSCLC",
H8Y-MC-HBCG,TQT,
"12681",DDI:Diuretic - placeholder,
F1K-CA-A027,ExNCR: Can Xigris prvt primary graft dysf post lung transplt,
H3E-US-B011,The Psychosocial Impact of Cancer-Rel. Symps. on Lung Ca Pts,
B5K-EW-IBHA,U500 Humulin vs U100 Humulin PK/PD,
I2K-MC-ZZBA,Statin Interaction ,
I2K-MC-ZZBD,Rifampicin,
I1Y-MC-JFBF,"LY2523355, PHII, Adaptive Design-Multi Tumor",
"12861",BACE Definitive QTc Study,
H6U-MC-B002,Characteristics/Outcomes-Hospitaliz Pts Tx IM Antipsych-GPS,
"12980",MS-Placebo controlled Ph 3 trial vs LY+ Open Label Study,
A6J-MC-X002,ASSESSM. OF POINT PREVELANCE OF GASTRO. COLONIZ W/VRE,
F1D-FR-HGMZ,INSIGHT,
F1J-CA-O038,Efficacy Safety Tolerability of Dulox in Dysthymia,
H3F-MC-GFAB,SAFETY AND IMMUNOGENICITY OF RGLUCAGON VS ANIMAL GLUCAGON,
F1K-BP-A028,Effects of RhapC on inflammation & apoptosis in pancreatitis,
I3S-MC-JABC,"Renal, Phase 1/2",
H8K-MC-JZAP,DDI study 3A4 induction ,
F1J-US-X051,Development of Clinical Diagnostic Criteria for Fibromyalgia,
H6D-GH-O017,IIT,
H3E-US-I029,"PhII Preop. Pem/Carbo Ptsw/StageIB,IIB,III NonSquamous NSCLC",
I2R-JE-BIAH,JP BIL MDSS,
I2U-EW-H307,PSG H3 Antagonist ,
H6D-XM-O018,Epidemiological Study for Detection of Sexual Dysfunction,
H8O-MC-A032,Adult and neonatal pig-to-nonhuman xenotransplants,
I2H-MC-JWYB,LY2090314 in AML,
F1J-US-I013,Efficacy of Duloxetine in pts. with painful radiculopathy,
"13396",Adult ADHD OL extension,
H3E-JE-TKB1,JP ALM P2 Head and Neck,
"13521",TDP Dose Regimen,
H7T-SB-O004,BASKET-PROVE II,
H3E-CA-O058,Population-Based Study of Lung Cancer Outcomes,
"13655",Olanzapine Depot dull-needle PK Study,
"13659",iGluR5 Gastric Paresis,
F1D-FP-O013,Olanzapine versus Haloperidol efficacy and cognition,
B1Y-MC-HCDT,FLUOX V PLACEBO MORBID OBESITY: PARALLEL/BLIND,
F1J-LC-SBAP,Eneuresis in Adolescents,
"2753",ACUTE EFFECTS LISPRO TEENAGER IDDM RICH MEAL,
"2834",LM vs. 30/70:  Oxidative Stress-TRAP  in type 2 patients,
H3S-MC-GGIA,Effects of Raloxifene in Elderly Males,
"2894",Lithium interaction,
"2944",Raloxifene in combination with anti-hot flash agents,
"2977",Investigator Initiated block for Gemcitabine Trials,
B9E-MC-X159,"Gemcitabine, 5-FU, and Folinic Acid in Pancreatic Cancer",
B9E-MC-X175,Gemcitabine and Oral Piritrexim in Advanced Solid Tumors,
B9E-MC-X188,Gemcitabine and Interferon in Renal Cell Carcinoma,
B9E-MC-X189,Gemcitabine and Docetaxel in NSCLC Randomized Study,
B1Y-MC-HCKC,Cardinal Study in Persistency,
B1Y-MC-HCHC,FLUOXETINE VS IMIPRAMINE IN ATYPICAL DEPRESSION,
F1D-SN-O021,OLANZAPINE IN THE TREATMENT OF TREMOR OF PARKINSON'S DISEASE,
B9E-MC-I141,Gemcitabine and Intraperitoneal Cisplatin in Ovarian Cancer,
B9E-MC-X215,"Gemcitabine, Paclitaxel, Cisplatin, 5-FU, Surgery in Gastric",
I1F-NS-O018,Rapid Pain control in Ixekizumab targeteD Axial Spondyloarthritis (RAPIDA),
"13223","1- year trial - GLP-PEG 40 monotherapy vs met + 1 oral",
"13297",Phase III Trial,
I1N-MC-CDBE,PhII Migraine Prevention (FED) mGlu2 Pot/CysLT1 Antag I ,
H6E-XM-O020,Differential adhesion of human endothelial progenitor cells ,
F1D-GH-O327,zyprexa or sodium valproate in Bipolar Manic,
I3E-MC-MSAM,Open Label safety exposure study (dependent MA-01),
F1K-MC-EVDH,US EXTEND Trial,
H7T-EW-TAEB,Food Effect Study:  30mg immediate release tablets,
H3S-LC-GGHR,RALOXIFENE HCL:DOSE LINEARITY,
H3E-EW-O012,Ph II ALIMTA+cis in neoadj NSCLC,
"13534",Prasugrel PMS in Korea,
B5K-GH-O449,Effect of insulin on B cells in rat model of type 2 diabetes,
I2R-MC-BIDB,C-Phase 2-3 T2DM,
F1D-MC-HGCN,OLANZAPINE OL IN SCHIZOPHRENIC CHILDREN AND ADOLESCENTS,
H7T-MC-V030,EFFECTS OF P2Y12 RECEPTORS UPON PLATELET REACTIVITIES,
"10114",Placeholder for Yentreve IIT's,
B3D-US-X026,Forteo for Treatment of Jones Fractures,
H6D-EW-LVIT,Efficacy & safety of tadalafil OaD in patients with BPH/LU,
B3D-JE-TP01,JP_Forteo_Osteoporosis_special_PMS,
F1J-XM-B039,"3 years evolution of EARLY study (B023)",
H7O-MC-S005,Methods study to collect samples for hedgehog biomarker,
I1V-MC-EIAI,Pilot Relative Bioavailability study in Healthy Volunteers,
F3Z-US-X033,Translating diet & exercise data to improve R-A dosing,
H9B-MC-BCDV,LY+MTX vs PBO+MTX in TNF-IR population,
I4N-MC-CXBA,A Phase 1 Study in Patients with Advanced Cancer,
H6Q-MC-V050,Pre Clinical - Enzastaurin in pituitary adenoma,
H6Q-MC-A043,Pre Clinical - Indolent Lymphoma and BCL Leukemia,
H3S-MC-JOAA,RANDOM PH.2 STDY (RALOXIFENE IN PTS. W. STG.4 BREAST CANCER),
B3D-US-I005,Early Effects of PTH on the Proximal Femur,
I4V-MC-JADA,Phase 2 trial for RA,
I4T-IE-JVBK,CP12-0712: Ph2-1121B-Advanced Cancer  ,
H9C-MC-BBDL,Phase 2b Study:IL-1 beta antibody II:  Dose Finding in T2DM,
H9V-MC-GFRF,Ph 1b/2 study in Patients with Diabetic Kidney Disease,
F1D-GN-O277,measurement of the efficacy of OLZ by functional component,
B9E-MC-V335,Nucleoside Transporters in PK & Pharmacodynamics,
B9E-MC-V337,PK and momonuclear cell accumulation of gem in dogs,
H3E-MC-V055,Alimta + Gem in Invitro preclinical research,
B9R-US-X041,Anterior Pituitary Function in Patients with hydrocephalus,
H6D-MC-LVGX,Cialis PAH Study #3 Double-Blind,
"10264",SDSS Phase 1a study,
H9Y-MC-UTAC,Phase II Study,
"10284",Hepatic Impairment study,
H6Q-MC-A004,Studies with enzastaurin and human glioma cell lines,
F1D-MC-HGFU,OLAN. ADDED TO MOOD STABILIZERS IN TRMT. BIPOLAR DISORDER,
F1D-MC-HGFW,STRATEGIES FOR SWITCHING FROM CONV. ANTIPSYCHOTICS TO OLANZ.,
H8K-MC-JZAD,Phase II: Soft Tissue Sarcoma,
B9E-MC-V275,Bioadhesive nanoparticles for Oral delivery,
B3D-JE-GHDB,Japan Forteo Phase 3 osteoporosis,
B9E-MC-V281,Cytarabine Triphodphate Using Gem in Leukemia cells,
"10619",Single Dose Study,
J2N-US-I007,GLOFITAMAB-PIRTOBRUTINIB IN R/R MCL,
H3E-US-X084,Ph III Double Blind Evaluating COX-2 Inhibition in NSCLC,
I2Y-EW-GHFO,Skin Irritation and Sensitization Study,
H6Q-MC-V055,Pre-Clinical Enz in acute leukemias,
"13825",JP GPR119 Phase 1 MAD,
"13885",Phase 3 Trial of Teplizumab vs Humira,
"14015",B'pharm DDI Ketoconazole Study,
I4V-MC-JADJ,DDI:  #1,
H3E-CR-JMIT,Alimta/Iressa 1st line NSCLC with activating EGFR mutations,
"14038",JP_ALM_Asian trial_ EGFR(+) + ALM,
"14063",Ph II - Alimta - Pediatric - Juvenile R Arthritis,
H6Q-MC-V073,Pre Clinical - Enz + EGFR Tyrosine Kinase inh. erlotinib,
"14103",Phase 1b - Exploring MTD for Phase 2,
I4T-CR-JVBU,CP12-0921-Ph I - Ramucirumab - Adv Solid Tumors,
F1J-EW-B041,Predictors of early prognosis,
"14177",G-tube placeholder study,
F1J-MC-B040,dulox and NSAIDs GI bleeding evaluation (Reg Comm),
I3W-MC-HHAM,RBA2/Food Effects Study,
"3182",Phase II Leucovorin/5FU/Gemcitabine in Colon CA,
B9E-MC-S113,Ph II Gem + taxol - SCLC; Jun98SU70,
B1Y-BP-E085,FLUOXETINE: OBESITY RELATED HYPOVENTILATION AND SLEEP APNOEA,
"3237",OLANZAPINE IN THE TREATMENT OF BIPOLAR DEPRESSION,
F1J-LC-SBBJ,Absolute Bioavailability (IV formulation),
F3Z-JE-M31H,Comparative,
B9E-MC-X231,Gemcitabine in Thyroid and Adrenal Malignancies,
B9E-MC-X232,Phase 1 Study of Intravesical Gemcitabine,
"3309",Reduction of antioxidant activity (TRAP follow-up),
"3316",INVESTIGATOR INITIATED BLOCK FOR OLANZAPINE TRIALS,
B3L-CA-LWAW,mglur2 in treatment of depression,
B1Y-MC-X020,FLUOXETINE VS PLACEBO FOR MIGRAINE PROPHYLAXIS,
B9E-MC-I146,Gemcitabine and PAclitaxel in Stage IV NSCLC,
B9E-MC-V016,Plasma and CFS pharmacokinetics of Gem. in nonhuman Primates,
B9E-MC-X238,Phase II Trial of Gemcitabine and Vinorelbine in NSCLC,
B5K-MC-IBFJ,Safety of PI delivery in smokers,
B1Y-MC-X029,FLUOX VS PLAC IN POST-TRAUMATIC STRESS DISORDER,
B9E-MC-S130,Ph l/ll - Gem+Oxaliplatin - Colorectal - Oct98SU91,
H6D-EW-LVAG,Oral Contraceptive Interaction Study in Females,
H6D-MC-LVJD,PPHN-safety/PK study,
I2R-MC-BIAZ,C-Phase 2-3 T1DM,
H4H-EW-LGAD,"LY300164 SINGLE DOSE SAFETY PK/PD PATIENTS-EPILEPSY,NORMAL V",
"14423",Liprotamase Compassionate Use Study,
I4J-MC-HHBD,Hedgehog/SMO Phase 1 Pediatric Medulloblastoma/Rhabdomyosar,
H6D-MC-LVJH,BPH - Nocturnal Symptoms PRO Validation,
I3X-MC-JHTC,"JAK-2 Inhibitor, phase I schedule in MF (MPN)",
"14588",PK DDi Study - Digoxin pgp substrate,
H8O-JE-GWEF,JP EX suspension P3 mono,
H8O-FW-GWEI,China PK,
H3E-GH-B015,China PMS in 2nd line NSCLC,
I6E-MC-AVBC,GHO- pragmatic PHIIIB /IV ,
H6D-CA-A018,Effect of PED5 Inhibition-Animal Model-Partial Bladder Obstr,
I6E-AV-ADNI,Ph 2 ADNI-GO,
I2I-MC-A001,Subcutaneous xenograft model system generated from human col,
I4C-MC-V001,c-Met AB & c-Met INH. on Adult T-cell leukemia-lymphoma,
H7C-EW-LMBA,mGluR2 Prodrug FHD,
F1D-MS-HGEE,Study to evaluate sleep influence from morn. vs even dose,
H6Q-MC-S024,Ph 2 Enz  Hrmn Refract 2nd ln & Hrmn rising Andr-Prostate CA,
B3D-US-GHDE,Preos Hypercalcemia,
B9E-MC-V309,Combination Gemzar + Adenoviral Gene Therapy,
B4Z-US-LYDU,Combination Use of Atomoxetine and Concerta,
H3E-MC-V099,ALIMTA + Gemzar in Preclinical invitro research,
F1D-VI-HGDT,OLANZAPINE VERSUS CHLORPROMAZINE IN EGYPT,
H9P-MC-LNBF,NERI IV: Fixed dose vs. PBO and Concerta in pediatric ADHD,
F1J-JE-1002,BIOAVAILABILITY STUDY ON 7.5 MM AND 10 MM TABLETS,
F1K-SB-A022,Effects of APC in severe acute pancreatitis  Alsfasser,
"11104",Sample request,
I1R-FW-GLBF,Phase I Hypoglycemia Safety Study (Clamp) Glucagon-R,
F1J-LC-HMAP,DULOXETINE HCL:ORAL MULTIPLE DOSE STUDY II,
"11335","Randomized Phase II/III, NSCLC stage 3b/4",
H9C-MC-BBDJ,OA Phase II LY2189102 Anti-IL 1 Beta,
H8O-FW-GWBU,Byetta: INR-DDI- Warfarin,
B9E-FR-O492,IIT- Hepato B9E-FR-O492  /Pitie-Salpetriere,
H9P-JE-LNEK,Open-label extension for Japan patients in LNCC and LNCD,
H9P-EW-LNEA,Biopharm Effect of 2D6 genotype on NERI PK Study,
H8K-MC-V001,Pre Clinical - Pancreatic cancer,
"14483",JAK2 C14 - patients - PLACEHOLDER,
I1F-MC-RHBF,PsA Open Label and Randomized Withdrawal Study,
"14528", Axiron application in Russian Subjects,
H9P-MC-LNEE,Health outcomes study in MDD partial responders to SSRIs,
I4E-IE-JXBG,CP02-0555:PH II-Cetuximab+Beva or combo w/Gem-Pancreas-1st L,
I4V-MC-JAGK,Rifampin DDI,
"14655",Ph 3 global,
I5E-MC-TSBA,"2nd Formative Human Factor Study - Gen III Applicator",
"14677",Diuretic DDI,
H6Q-MC-V082,Pre Clinical - Lung adenoccarcinoma cancer cell lines,
I3G-MC-V001,Pre-Clinical role fatty liver formations,
H4S-MC-X003,BALTIMORE CARDIOVASCULAR PATIENT OUTCOME RESEARCH TEAM,
F1J-CA-A016,Impact of Duloxetine upon illness behaviour in diabetic mice,
I2H-MC-V002,Glycogen synthetase kinase 3 beta as a novel molecular targe,
B4G-JE-YI12,EFFECT OF PERMAX TREATMENT WITH SPECT,
"3711",Cognitive effects of olanzapine treatment in schizophrenic p,
H6D-EW-LVCB,Sperm Motility Study,
H5Z-LC-LUAJ,R-fluoxetine/Desipramine drug interaction study,
B9E-JE-C001,JP gem P-IV NSCLC,
B9E-FP-O086,IIT-PHASE 2 GEMZAR IN REFRACTORY/RELAPSED LOW GRADE,
B1Y-MC-X080,FLUOXETINE AS ADJUNCTIVE PHARMACOTHERAPY IN RECOV. ALCOHOLIC,
"3910",Second Asthma study. Bronchial Alveolar Lavage,
B7A-FW-MBCH,Rifampicin induction study,
F1D-CA-A039,Does Olanz. bind loosely to dopamine receptor minimizing EPS,
B1Y-MC-X091,PROPARTNERS PATIENT INTERVENTION PROGRAM EVALUATION PROGRAM,
H6F-LC-PAAC,LY466700 Multiple-Dose Safety Study,
H6D-LC-LVBZ,PET,
"4033",Ramadan Study,
"4036",Ovulatory function study for Concorde,
B1Y-MC-X100,FLUOXETINE EFFECTS ON PHARMACOKINETICS OF MIDAZOLAM,
B9E-MC-JHQU,Gem + Epi + Taxol vs Comparitor,
H6E-MC-GLAG,ACTOS vs. gliclazide (B-cell preservation),
"4145",Dose finding in anovulatory infertile patients,
B5K-MC-IBHD,Comparsion of Human U500 by CSII vs U500 by MDI in Type 2,
I4O-MC-BACN,Warfarin,
F1J-JE-HMHC,JP Cymbalta P-III Long term safety CLBP,
I1D-MC-JIAK,TQT in Cancer Patients,
I4T-MC-JVCO,Ph II - Ramucirumab + Irinotecan - Gastric 2nd line,
B9R-US-X051,Therapeutic effect of rGh on systinosis myopathy&muscle wast,
"15067","Phase 1 Registration, Single Dose Study Glucose Clamp",
"15073",Renal Study,
I6L-AV-PPMI,"Imaging DLB, PD, AD & Healthy Controls with FBP/AV133",
I6E-AV-_739,"18F-AV-739",
I6Z-AV-_657,AV-657 (Binding properties and safety of 18F-AV-657),
I5E-MC-B001,"2012-470 Comparison Costs/Dose Axiron - other topical agents",
H4Y-MC-LJAV,Comparison study LY334370 vs nonencapsulated sumatriptan,
A6J-GH-O003,PK/PD study of vancomycin in MRSA and endocarditis patients,
I7I-EW-XNAB,A PK & ECG Study in Japanese/Non Japanese HV,
F1D-KL-A050,Seizure in Rat using novel antipsycotics,
H9H-MC-A005,Immunomodulatory vs. ani-invasive effects in gliomas,
I6J-MC-PRBD,TQT,
H8L-MC-IQBE,Summative human factor study for IRMA,
B4Z-MC-B022,Atomoxetine Drug Utilization Study Part 2  (B019 repeat),
H4Y-MC-LJAB,COMPARISON OF LY334370 & PLACEBO IN ACUTE MIGRAINE,
B4Z-HU-B023,Prevalence of aADHD in psychiatric settings ,
F1J-US-X064,Dulox for tx of aromatase inh. in early stage breast cancer,
I4T-JE-JVCL,JP-Ph II - Ramucirumab - Gastric Mono,
I6J-JE-PRBE,Japan Phase I Study,
H8L-MC-IQBR,U500 Formative Human Factors #2,
F3Z-MC-B014,TD2 Pts requiring insulin initiation or GLP-1 agonist ,
I7B-MC-DPAA,Single Ascending Dose,
I6I-MC-LMRD,TQT,
I4O-MC-BADC,Particle Size,
B4G-EW-LCCX,Parkinson / Monotherapy / Patch (Patch #3),
I4E-IE-W916,Protocol CA225-271; Study Title: I / Randomized II Study of ,
H6D-MC-A004,Wound healing in the diabetic/hyperglycemic animal model,
H6D-MC-A006,Tadallafil promotes functional recovery after stroke in rats,
F1K-MC-V024, Antiinflammatory and protective roles of APC for cultured c,
H6Q-MC-V035,Enzastaurin and malignant gliomas,
"11444",Japan Phase II FED study,
F1D-UT-O311,effects of Olanz oral and velotab on gut hormones,
H6Q-MC-S047,Ph II Enz Trial in Breast CA (+ tax or + cap/lap),
H6Q-MC-S059,RPh2 Erbitux +/- Enza for 2nd Line HNC,
"11519","Phase 1b,  Proof of Concept #2, SERM Gyn I [LY2066948]",
"11526",Ph I/II Sorafinib+/- ENZ in GI/GU tumors,
H4Z-MC-GJAT,SWITCHING STUDY [ ARZOXIFENE VERSUS EVISTA],
H6Q-MC-V039,ENZ in serially transplanted glio xenografts from pts,
H6Q-MC-V042,Enzastaurin inhibition of PKCa and PKCd may promote chemosen,
B9E-KL-O495,Phase 2 Gemcitabine study for Breast Ca patients,
B4Z-AA-B011,Asia pediatric epidemiology study of ADHD prevalance,
H8Z-MC-JACW,FED PhII with LY2181308 NSCLC Combo,
F3Z-JE-302H,OPEN TRIAL IN PEDIATRIC PATIENTS OF IDDM(PHASE 3),
F3Z-JE-303H,OPEN CLINICAL STUDY ON LY275585 WITH CSII,
B3L-MS-LPAC,LY354740 4-way cross-over using PET (MSG Pharmaco EEG study),
I7O-MC-JOBA,FHD: Ph I- FGFR3-ADC - Solid Tumors,
I7E-AV-_A03,Test-Retest Reproducibility for Brain Imaging of Tau,
I7Y-MC-EBBA,Single Ascending Dose,
"15553",PGP DDI,
"15555",DDI #2,
H8L-MC-IQCR, Formative HumaDapt Human Factor study #1,
H9H-MC-A030,MGMT-Inhib. in Comb. on Preclinical Models of Glioblastoma,
H9B-EW-B002,"2014-028 SLE Utility study for UK to inform Econ model",
I5Q-MC-CGAK,Ph 2/3 treatment of Complex Regional Pain Syndrome,
"15790",Japan Mono,
I5B-MC-JGDL,Ph Ib/II - Gem+Docetaxel +/- Olaratumab -Soft Tissue Sarcoma,
I5B-MC-JGDW,Phase 2 Study in Pediatric and Young Adult Osteosarcoma Pati,
I4E-IE-W807,Protocol CA225-315; A STUDY TO EVALUATE THE RELATIONSHIP BET,
I4E-IE-W813,Protocol CA225-250; RANDOMIZED II TRIAL OF CONCURRENT CHEMOR,
I4E-IE-W819,Protocol CP02-9927; Compassionate Use of Anti-Epidermal Grow,
I4E-IE-W894,Protocol CA225-266; PHASE 2 STUDY OF IRINOTECAN AND CETUXIMA,
B1Y-MC-X129,FLUOXETINE:  TREATMENT OF PREMENSTRUAL SYNDROME,
B9E-SB-O116,Gemcitabine and Topotecan in Patients with Ovarian CA,
B1Y-NZ-0004,FLUOXETINE:  ECONOMIC EVALUATION IN GENERAL PRACTICE,
B1Y-MC-HCKK,One-arm switching study,
B1Y-MC-X201,Combining N of 1 Trials to Access fibromyalgia Therapy,
"4295",Treatment of Anorexia Nervosa,
F1D-US-X166,Pilot Study ..Treatment of Anorexia Nervosa,
"4308",C14 Study of LY300164,
F1J-LC-HMAZ,Desipramine Interaction,
B9E-GH-JHRC,Gemzar + Cis as intensive weekly therapy in NSCLC,
B9E-JE-N11D,gem P-II NSCLC w/ CDDP,
B9E-MC-X270,Phase 2 Gemcitabine and Mitoxantrone for 1st Relapse AML,
B9E-MC-X271,Phase 2 Gemcitabine and Treosulfan in Choroidal Melanoma,
H6M-BD-LDAH,Clinical Pharmacology Study - Pharmaco EEG,
B9E-AY-O188,Phase II Gemcitabine & Navelbine in advanced pancreatic ca.,
"4479",Valproate augmentation in patients treated with Olanzapine,
B9E-MC-S152,Ph I PK study in patients with advanced or metastatic tumors,
B1Y-SB-6038,FLUOXETINE V PLACEBO TREATMENT OF BULIMIA,
H9H-MC-A018,Blockage of other oncogenic pathways/study effects on HCC ,
"15301",Switching study ,
B3D-MC-B023,"2013-207 US DataMart- Forteo vs non Forteo Health care resou",
B3D-MC-A007,PTH Effect on Bone Quality in Sheep Model of OP (Boskey),
I4V-MC-V001,Effect of Baricitinib and Tofacitinib on human dendritic cel,
I1F-MC-RHBN,China PK Study,
I4L-JE-B002,Post Marketing safety study of BIV with Japan DM patients,
I4J-MC-A002,Novel cancer stem cell-targeting strategies for pancreatic ,
I3Y-MC-JPBN,Monarch 1_Ph II - CDK 4/6 Inib - Breast,
B1Y-MC-HCIU,Fluoxetine child and adolescent pharmacokinetic assessment,
I3Y-MC-JPBS,ABA Study in Healthy Subjects,
H9H-MC-JBAZ,ABA in micro-dosing in healthy subjects,
I7X-EW-LLCA,SAD/MAD HV/AD Cohort/RBA Study,
"15594","Food Effect ""placeholder""",
I4T-MC-JVDB,Ph II - Ramucirumab - Gastric - 2nd line,
H7T-SB-O005,ETAMI-Study,
B4Z-JE-LYED,pilot Phase II study for adult ADHD,
B5K-AY-B007,Five year follow-up of Newcastle Empowerment course,
F1J-MC-X045,Brain Morphometric Study in Back Pain Pts in Lilly Dulox Stu,
I2M-MC-GSDB,Phase 2 for Efficacy,
H8Y-MC-HBBP,Acute schizophrenia-low dose,
"11970",The Cytotoxic effect of Pemetrexed on Non-Hodgkins Lymphoma,
"12018",Monotherapy compared to polypahrmacy in tx of DPNP,
F1D-CA-O312,Effective Intervention in Schiz in Underserviced Community,
F1D-SB-O314,BELA program evaluation,
"12138",PET study (placeholder),
I2R-MC-BIAV,Hepatoselectivity Clinical Study,
"12206",Once Daily Dosing Reg. Commitment Trial,
"12227",FD2 MeNER:   Test/Retest,
B9R-US-X046,SHOX IIT,
H8O-US-X008,Exen on post-prandial gluc excur in young adults,
"12331",Comparison of Dulox and Psychoed. Tool vs Dulox in Fibro.,
"5609",Dementia study,
B5K-EW-IBHH,Humulin U500 Steady State S,
I8D-AZ-AZFB,AZD QTc Study (D5010C00008),
"16065",Phase 2B study,
I6E-AV-I035,AV-45-IIT-035: ASAP,
I6E-AV-I015,AV-45-IIT-015: Predicting Alzheimer's from Metabolic Markers,
B1Y-MC-LWAD,Pivotal Efficacy (Initial ID - B1Y-MC-LWAD),
I2R-MC-BIDZ,Long-term liver safety study,
I4E-US-X005,CA225-341 NSABP FC-6 mFOLFOX7+Cetuximab Colorectal Cancer,
I8N-MC-ILAB,Single Ascending Dose study,
"16322",LY3303560 Tau Ab Modulator Efficacy in Mild AD,
I4T-MC-JVDQ,Ph II - Ram + Trastuzumab - GC-1L line-HER2(+) (publication),
J4A-LC-EZZK,Drug Interaction (hepatic),
H3E-TW-O088,NSCLC IIT- Taiwan,
I1F-MC-B005,Assess Maternal & Fetal Outcomes Post Exp to Ixekizumab,
I4X-MC-JFDA,Ph II - Necitumumab+Gem+Carbolplatin-Sq NSCLC-1st line,
I7W-MC-JQBC,R-Ph II - Angiopoietin2 + Ram - HCC,
F1D-SN-S010,QOL in Asian Pats with Schizophrenia - Olanz vs Haloperidol,
F1D-US-X174,preventing wt gain from novel antipsy (feasbility study),
"4570","Erectile Dysfunction - IND 55,999",
B1Y-SX-HCKM,Fluoxetine VS Vitamine B6 in PMDD,
B4G-SB-LCDL,Influence of pergolide on gait initiation in patients with P,
B3L-MC-LWBG,Impact on Psychomotor Performance and Sleep,
B9E-MC-S165,Phase II study of gemcitabine and oxaliplatin in met. breast,
H5N-EW-GFFI,Safety and Tolerabilty of LCS V8-GLP 1 (study 2a),
B9E-MC-S195,Ph II Gem+Tax+Herceptine Breast 1st line Metastatic,
B9E-MC-S204,Ph II (rand) FDR Gem + Cis vs  Gem + Cape - Pancreas,
B1Y-GH-O010,Prozac in treatment of depression find in OB/GYN patients,
B1Y-SP-HCHX,ACTION SPEED OF FLUOXETINE&PINDOLOL VS FLUOX&PLACEBO IN MMD,
F1D-MC-O093,Olanzapine in Borderline disorder,
B9E-MC-X291,Ph1/2 of gemzar/vinorelbine/liposomal dox. in refr. Hodgkins,
H6S-LC-GMAB,Multi Dose Safety Study,
B9R-MC-GDFX,Odessey Pen:  Initial trial,
H5Z-MC-LUAW,Non-Responder Transition,
H5Z-MC-LUAY,R-Fluoxetine Sexual Dysfunction,
I7E-AV-_A04,Follow-Up AV-1451 scan in subjects that have had prior scan,
"15659",DDI - Digoxin,
"15666",JAPAN - Final Formulation PK,
H8L-MC-IQCZ,BIL Supplemental Summative Study ,
I5Q-MC-CGAJ,Ph 3 migraine prevention long-term safety study,
I3Y-MC-JPBY,R-Ph II - NSAI vs NSAI + Abemaciclib - neoadj Breast ,
B3T-MC-JTAA,Ph 1 Dose Escalating Study of IV LY335979 and Doxorubicin,
B4Z-MC-HFBD,Tomoxetine vs Placebo in Pediatric Outpatients with ADHD,
I4E-IE-W803,Protocol CA182-009; A Randomized III Study Of  Alaninate (BM,
"1590",Pediatric ADHD - Safety,
I4E-IE-W883,Protocol CA225-073; II Selection Design Trial of Concurrent ,
I4E-IE-W907,"Protocol CA163-116; A II, OPEN-LABEL TRIAL OF IXABEPILONE PL",
I4E-IE-W917,Protocol CA225-285; I EVALUATION OF CETUXIMAB AND RAD001 IN ,
I8D-MC-AZEC,DDI PgP- Quinidin,
I3Y-MC-JPCC,BE of Abemaciclib in Healthy Subjects,
I7E-AV-E028,"18F-AV-1451-EXIST-028",
I8G-MC-LMDB,Ph3-Enabling Bridging Study,
H4Z-MC-GJAZ,Sensory Evaluation for the Arzox combo with Ca and Vitamin D,
"12390",Phase II Injection Experience with the Aura Device,
F1K-FR-B009,Conditions of use,
"12481",PLACEHOLDER DUMMY TRIAL - Local IITs -- Italy,
"12485",IPO interpersonal Therapy,
"12510",Kappa OpRA Alcohol interaction study,
I2Z-MC-LAFC,Kappa OpRA PET receptor occupancy study,
H8O-MC-A015,Circadian Clock Regulation of Appetite and Ins Sec,
B1Y-EW-E081,FLUOXETINE EFFECTS IN SOLUTE AND WATER CLEARING,
H8C-MC-LQBO,Relative bioavailability Trial (RBA),
H2Q-EW-E003,LY246708 MULTIPLE DOSE:SAFETY/DYNAMICS IN ELDERLY SUBJECT,
"12769",LISPRO VS Humulin,
I3E-MC-MSAA,MINDSET 2 E&S in Relapsing Remitting MS,
I2Q-MC-GMAH,Phase 2 T2DM Study4,
I2K-MC-ZZAZ,Elderly PK,
H9X-JE-GBCZ,JP GLP-1 Analog IV - FC -Phase 2,
B9E-FP-O280,"IIT-Gem-cispl-vinorelbine in patients with NSCLc,stade IIIA",
H8A-MC-B005,Early Alzheimer's patient insight study ,
I5S-MC-EFJR,Statin Intolerant,
I6T-MC-AMAW,Pediatric Ps,
I8B-MC-ITRV,Blinded mealtime dosing study in T1DM,
"16651",Atopic Dermatitis OLE,
H7I-MC-S013,OGA PET test retest study,
I7P-MC-DSAC,Phase 2 POC,
I8L-MC-IXAP,URI-Biochaperone PK/PD Pediatrics,
B9E-MC-X027,GEMCITABINE AND CISPLATIN IN PANCREATIC CANCER,
F1D-MC-X063,Open-Label Olanzapine in the Treatment of Delirium,
I9K-JE-UCAC,Japan Mulptiple dose Ph1 in HVs at non-Japan CRU,
I8B-MC-ITSF,Phase 3 T1DM URI vs Lispro post meal dosing,
B7A-MS-MBBB,CROSS OVER ADMINISTRATION OF TWO FORMULATIONS OF LY333531,
I4V-MC-B010,Survey assessment of risk minimization activities,
H4Z-LC-SDAB,LY353381 HCl:  Multiple Dose in Estrogen-Treated PMP Women,
"5071",LY333013 Versus placebo and active comparator in Crohn's,
F1J-MC-HMBP,Diabetic Neuropathic Pain,
"5093",LY333328 Osteomyelitis Animal Model,
"5118",Weight Gain No. 4 (Ritrodine),
B1Y-UT-0392,FLUOXETINE VS FLUOXETINE + PSYCHOTHERAPY,
"5199",MGlur2 - Prodrug SDSS (2),
B1Y-VI-2000,FLUOXETINE VERSUS MAPROTILIN/TREATMENT OF SEVERE DEPRESSION,
B9E-MC-X304,Ph II Gemcitibine & Navelbine in Metastic Breast Cancer,
"5261",Observe switch & outcomes of zyprexa vs other antipsychotics,
B1Y-VI-4001,FLUOXETINE CLINICAL EXPERIENCE PROGRAM,
B9E-EW-JHRT,Oral Gemcitabine taste study,
X1A-BD-QA01,Quantified EEG study of LY450108 and LY451395,
F1D-SN-HGJR,Schizophrenia Outpatient Health Outcomes for IC Region,
H6M-BD-LDAI,Quantified EEG study of LY450108,
B9E-BP-O208,"Phase II, Gemcitabine and Treosulfan in Adv Ovarian Cancer",
B3M-VI-S028,Ceclor susp vs Augmentin DUO in pediatric otitis media,
F1D-US-HGJU,Olanzapine versus Ziprasidone,
"5613",Raloxifene Health Outcomes Study - retrospective,
B3M-SE-9132,CEFACLOR THERAPY IN ACUTE BRONCHITIS,
F1D-US-A106,Electrophysiological evaluation of the effect of olanzapine,
I4E-US-X008,CA225-312 UPCI08-013 Cetux then Chemoradiation+Cetux HNSCC,
I8O-MC-SBDA,C14,
I1V-MC-EIBX,Simvastatin DDI Study in Chinese Subjects,
"16471",Drug drug interaction study,
I8L-MC-IXAO,Elderly PK study,
I8V-MC-LODD,Phase 2 study,
B3N-MC-EUBK,Dose Response in Class II-IV CHF Patients,
"16620",R-Ph III - Notch II vs BSC - ACC,
I8B-MC-ITRQ,BE (U200),
I8B-MC-ITSA,URI-Vasodilator PK/PD Pediatrics,
I5S-MC-EFJX,Hepatic Impairment Trial,
I6E-AV-_A25,AV-45-A25 (RAMP),
I9N-MC-FCAA,SAD/MAD study in HVs,
B9R-SB-GDDR,Adult Replacement Therapy,
I8B-MC-ITSL,Phase IB URI vs Fiasp,
I4V-MC-B011,EU RA Registry in Nordic countries ,
H9B-MC-BCDZ,MS phase 3 LY1 vs LY2 vs Placebo,
"13020",IC Olz LAI+education program vs other LAIs in Schizophrenia,
H6D-CR-B016,IC Obs study of Tadalafil vs other short acting iPDE5S in ED,
H7T-MC-X006,CORDIS: CYPRESS DAPT Stent Study ,
F1J-US-X053,Dulox-IBS and Comorbid GAD,
I1R-JE-GLBI,JP GRA1 Phase 1,
I3Z-JE-GPDC,JP GPR119 MAD,
I2M-JE-GSDD,JP SOST Ab Phase 2 Osteoporosis,
H8A-FW-LZAQ,Chinese PK Study,
"13345",Abuse Potential,
I4F-EW-CCAB,MAD (MDSS),
"13395",Adult ADHD flex dosing vs. PBO,
I3W-MC-HHAK,Definative QTc study for 5-HT2a,
H9B-JE-BCDL,JP LA294 Phase  1 safety extension,
I2Y-EW-GHFN,Hepatic ,
H6D-US-LVIP,Insufficient responders to short acting PDE5i once daily,
B7A-MC-V010,Regulation of MCP-1 induced PYK2 Tyrosine Phospho,
I9R-MC-BSDE,T2DM Seamless 2/3 ,
I8H-MC-BDCM,Basal Switch 26 Week,
I9Z-MC-OGAA,SAD/MAD,
F3Z-VI-IOHN,Humalog vs Humulin R in Type 1 Pts Fasting During Ramadan,
J1B-MC-FRCD,Pilot study for testing a derm model,
I5Q-MC-CGBA,"2016-5696-GHO-Pragmatic-Carolinas HealthCare:Does Integrated",
J1L-AM-JZGC,Cypress 1 Ph2-Pegliodecakin+Pembrolizumab-NSCLC,
I4V-MC-B016,Assessment of off-label use of baricitinib in peds,
F1D-LC-HGGB,OLANZAPINE-VALRPROIC ACID INTERACTION TRIAL,
I8F-MC-GPHA,Tirzepatide DDI with Lisinopril and Metoprolol in T2DM Pts,
J1U-MC-JZG1,PhII - Lung Protocol Pegilo w/Doce Post IO/Platinum - NSCLC ,
I8F-MC-GPHX,C14 Study - Linker Metabolic Outcome HV,
H0P-MC-OA03,Intervention Specific Appendix - OA,
J1B-MC-FRCG,Ph2b Dose Ranging Atopic Dermatitis Study,
J2G-OX-Y023,PhI-RET Inhibitor-MTC,
I1F-MC-RHCJ,axSpA H2H trial versus adalimumab,
I8H-JE-BDCK,Japan MAD in T2DM Pts,
F1D-MC-X091,Relapse with d/c of antipsychotics in psychotic depression,
I1F-MC-RHCO,hidradenitis suppurativa (HS) randomized withdrawal,
"17053",Sleep Study,
I4V-MC-JAIX,Open Label Extension,
I8R-MC-IGBL,Post-approval PIV Trial ,
I8F-MC-GPGU,MOA Metabolic Chamber Study in Overwt / Obese (non DM) Pts,
H5O-LC-G1AB,Multiple dose safety in obese type 2 patients,
I3Y-MC-B003,"2017-6493  GHO Adelphi DSP Canada",
I1F-MC-RHCS,Ixe Reformulation Safety and Tolerability Study_ ISR,
J1L-AM-JZGA,Ivy Ph1 - Pegilodecakin - Solid Tumors,
I8F-MC-GPGY,Tirzepatide and Atorvastatin Drug Drug Interaction Study,
I9W-MC-IFDD,Proof of concept,
"6340",SDSS in Japan,
I4L-MC-ABEB,T1DM non - inferiority,
H7T-SE-O007,pre & post-PCI P2Y12 inhibition after thienopyridine ,
H3S-MC-GGHI,RALOX: HISTOMORPHOLOGIC EFFECT IN BONE IN PMP WOMEN,
I4P-FW-GPFA,FHD:  SAD GPR 40 Agonist I,
H3E-IE-I032,DRUG ONLY_PhII-1121B+/-Alim/Gem+Carbo vs Carbo+/-Alim/Gem,
H6Q-MC-A042,Pre Clinical - Ly317615 and sorafenib in treatment of HCC,
H6Q-MC-V066,Pre Clinical - Low and High Grade B cell Lymphomas (MOET),
H3X-MC-PPPE,FIAU OCLASSEN STUDY R90-001,
H8L-EW-IQAU,Patient Preference KwikPen vs NGFP,
I4T-IE-JVBG,CP12-0605: Ph 2 - 1121B - RC,
I5A-IE-JAEI,CP13-0502: Ph1 - A12- Adv Solid Tumors - 2nd Line,
B1Y-FP-0713,FLUOXETINE OPEN STUDY MELANCHOLIA (PILOT STUDY),
I2R-MC-BIAU,Exercise,
I2R-MC-BIAT,Three times weekly vs. daily Glargine,
H9P-JE-LNDY,Japan MDD monotherapy OL extension study,
I4O-MC-BACW,Phase 3 Double Blind Study in MCI and Mild to Moderate AD Pa,
J2G-OX-Y040,PhI-RET Inhibitor-NSCLC+Ductal BC+CLL,
J2R-MC-YAAA,Clamp study in HV,
J2G-MC-JZJQ,Food Effect DDI/PPI,
J2N-OX-JZNL,LOXO-BTK-20016-Ph1-Pirtobrutinib-DDI/2C8 (repaglinide),
J2T-DM-KGAB,Lebri mono study in pts with moderate to severe AD (AD1),
I4V-MC-KHAA,Evaluate effect of Bari vs SoC in COVID pts,
J2G-OX-Y056,RET Inhibitor-MTC,
J2G-OX-Y074,RET Inhibitor-PTC,
J2G-OX-Y092,RET Inhibitor-NSCLC,
J2G-OX-Y095,RET Inhibitor-PTC,
J2G-OX-Y112,RET Inhibitor-NSCLC,
I6E-AV-I061,AV-45-IIT-061: Tracking the earliest molecular brain changes,
F1D-MC-X036,EFFECT OF OLN VS ANTIPSYCHOT. ON FAMILY BURDEN,
J2T-DM-KGAM,Evaluation of 1 x 2mL vs 2 x 1mL SC injections (ADO3),
J2G-OX-Y187,RET Inhibitor,
"18007",Exploratory  study of Sintilimab combined with GP regimen,
I7S-MC-HBEN,Phase 3 global registration for LBD,
B9E-FP-O238,IIT-Bladder B9E-FP-O238 Théodore GEMOX / IGR,
B9E-US-S256,"Gemcitabine-Adjuvant Tx, Node Negative Pts - Breast Ca",
B9E-RO-O252,Gemcitabine+Cisplatin in metastatic Bladder Cancer,
B7A-XM-S001,REVISION OF CLINICAL FILES-PATIENT SURVEY,
B9E-MC-V135,Ph I/II Eval of Gem in Dogs with Spontaneous Tumors,
"6016",Placeholder for local Gemcitabine studies,
B1Y-TW-HCLI,Efficacy of Once-Weekly Fluoxetine Hydrochloride,
B9E-MC-S267,"Ph II, Gem+Carbo+targeted agent - NSCLC",
F1J-MC-HMCH,Irritable Bowel Syndrome (second study),
H9D-MC-ITAA,Device Trial for 2003,
"6161",  Deep vein thrombosis in sepsis (with or without heparin),
H3E-MC-S012,Placeholder for Breast,
H7C-LC-LMCD,MGlur prodrug - Absolute bioavailability,
H3E-MC-JMFM,Ph I/II Gem FDR + Alimta Bladder Cancer,
B9E-SU-V136,"Phase II Gemcitabine and Paclitaxel Stage IIIB, IV  NSCLC",
F1D-TW-O140,pressure pain threshold,
B9E-MC-S281,"Ph II - Gem + Trastuzumab (Herceptin), 1st line - Breast",
"6307",rhAPC:  Pharmacokinetic comparison study (Japanese),
H4W-MC-LLAG,Acute Effects on Sleep Latency - Moderate Sleep Disturbances,
J2F-MC-OHAA,FHD SAD HV,
H0P-MC-OA01,Intervention Specific Appendix - OA,
J2L-MC-EZBA,FHD SAD HV,
H0P-MC-NP01,Intervention Specific Appendix - DPNP,
J1X-MC-GZHF,Mini-MAD (Oral/Gastric) HV,
J2G-OX-Y013,PhI-RET Inhibitor-NSCLC,
I5T-MC-AACJ,Open Label N3pG1 for I5T-MC-AACI Placebo Completers ,
J2T-DM-KGAE,"Open label, single arm of Lebri in adol pts w/AD (ADore)",
I3Y-NS-I027,Drug Rediscovery Protocol,
J2U-MC-YBAA,FHD SAD/MAD HV,
J2G-OX-Y115,RET Inhibitor-NSCLC,
J2G-OX-Y117,RET Inhibitor-NSCLC,
J2G-OX-Y131,RET Inhibitor-NSCLC,
J2G-OX-Y163,RET Inhibitor,
B3D-MC-GHDR,Chinese IMCT Phase III Fracture Healing,
I1R-FW-GLBQ,Formulation Bridging and Food Effect Study,
H8O-MC-X029,Effect of Obesity and TCF7L2 Genotype on Insulin Sec,
"14259",Phase 3 Double-Blind Placebo-Controlled Study,
H4G-MC-CBAA,COMPARISON OF EFFECTS OF LY303870 AND MORPHINE,
H7T-US-X014,Study for Access for Enhancing PCI for Women (Safe-PCI),
I5A-IE-X002,"8347: Ph II - A12 - Thymoma",
I4X-MC-JFCH,Ph III - 11F8 - Sq NSCLC,
H3E-MC-V157,Pre Clinical - RNAi-based Screening Mali Mesothelioma,
I5E-MC-TSAV,BE Study #2 for Axiron Gen III Device,
I2I-MC-V001,Pre Clinical - CHK-1 and 2 soft tissue sarcoma,
H9P-MC-LNEG,Pediatric MDD study for PIP/PREA,
I4V-MC-JAGE,Gastric pH,
I1V-MC-EIAV,Effect of moderate CYP3A inhibitor on the Pk of evacetrapib,
H8O-MC-X038,CV effects of Exentaide on exercise adaptation in rats,
H4S-MC-V001,GIIB/IIIA RECEPTOR EXPRESSION IN UNSTABLE ANGINA PATIENTS,
I6E-AV-MAPT,Ph 1 AD preventive trial with multidomain interventions.,
"13964",Japan Phase 1 Study,
F3Z-MC-IORV,OUS Pen Platform Clinical Trial,
B9E-MC-JHBN,JHBN,
"18242",URLi Japan post marketing Validation Study,
J2T-MC-KGBL,Lebri vs placebo in Prurigo Nodularis,
J2N-OX-B002,"2020-10035: Loxo 305-CLL",
H8H-MC-B010,Non-interventional safety study among patients with long-ter,
I4T-JE-B013,Ph4-PMSS of Cryamza in China,
"18644",Bridging Study,
I4V-MC-B036,Pregnancy Database Study,
"18671",Loxo-PIK-22002-Ph1-PI3K-Formulation Comparison,
B9E-MC-I095,GEMCITABINE AND MITOXANTRONE,
H5H-LC-DDAA,Single Dose Safety and Pharmacokinetics,
B9E-MC-S041,Gem/Etoposide in ovarian-S041,
F1J-JE-321G,JP dulo P-III long term/ psychiatry,
B4Z-LC-HFBG,Relative Bioavailability Study,
F1K-LC-EVAG,F1K-LC-EVAG LMW Heparin Interaction,
B1Y-LC-HCIS,FLUOXETINE BIOEQUIVALENCE STUDY:10 AND 20MG TABS VS CAPSULES,
H4Y-MC-LJBB,Open-label extension,
H4Y-MS-LJAQ,Intraveneous single dose escalation in healthy volunteers,
J2G-OX-Y173,RET Inhibitor,
J2W-NS-I002,ACTIV 3,
H3E-MC-JMBQ,Phase II/III NSCLC MTA vs Vinorelbine in Taxane Failures,
J2X-MC-B001,Observational Patient Registry,
H7I-MC-S023,Use of a digital health solution to improve migraine care BW,
I9Y-OX-JDHD,LOXO-IDH-20003-Ph1-IDH1-SAD,
J2N-MC-JZNW,BCRP DDI Trial,
I3Y-NS-O030,"the multicentric, phase II trial FASTENACICLIB",
"18666",DDI Placeholder,
"18668",Hepatic Placeholder,
"18676",Loxo-BCL-23005-Ph1-BCL2-Renal Impairment,
H3Z-MC-JNAM,Phase II Eval. of LY295501 for Treatment of Renal Cancer,
F1J-JE-313G,JP dulo P-III DBS w/ Trazodone,
B9E-MC-S046,Gem/5FU vs 5FU in panc--S046,
B1Y-LC-HCEZ,FLUOXETINE BIOEQUIVALENCE ORAL SOLUTION VS CAPSULES,
H5P-LC-BWWB,H5P-LC-BWWB Multiple Dose,
B7A-MC-MBBS,"Claudication  IND# 56,995",
I1R-MC-GLDH,"3A Induction Study",
B5K-MC-IBDP,VOID,
F1D-US-I035,olanzapine and the treament of alcohol dependence,
B5K-MC-IO10,NURSING INTERVENTION TO IMPLEMENT DCCT IN YOUTH,
"6460",Ph II - 5-FU + LV + CPT + Affinitak - CRC,
H7Y-EW-EYAB,Eflucimibe Phase I Study 110,
H7X-MC-JVAI,Ph I/II-Gem + Cisplatin + Affinitak (7day infusion) - NSCLC,
B9E-MC-V148,Drug Sensitivity Test in Human Panc CA Using Gem,
H7R-LC-GCBC,Formulation Bridging Study,
H6E-UT-S002,IMPact of Actos in Comb Therapy metformine & sulfonylurea,
B9E-LQ-O302,PhII Gem+Xeloda combination in relapsed MBC,
H6N-BD-LEAL,MDSS-PK in Healthy Elderly Males,
H3S-AA-GGKX,Asian Evista CHOOSE OS study,
B3D-SU-S001,Bone marker changes w Teriparatide/Postmenopausal Osteoporos,
F1K-SB-V001,Role of rhAPC in protecting endothelial cells ex-vivo,
"6762",TMS -  395,
B9E-FP-JHLZ,PHASE 1 AND 2 STUDY GEMCITABINE+EPIRUBICIN IN BREAST CANCER,
B9E-IT-JHLL,"COMPASSIONATE USE OF GEMCITABINE IN PATIENTS WITH NSCLC,",
B3D-IT-A003,PTH in Bone Mass Recovery in Osteoporosis and Fract. Healing,
"14896",Therapeutic effect of hGh on cystinosis myopathy/muscle wast,
H6Q-MC-V083,Testing of Lilly Compounds in ISS Cancer Stem Cell Models al,
H4Y-MS-LJAF,DISTRIBUTION STUDY OF C14-LY334370 IN HEALTHY MALE VOLUNTEER,
F1J-CS-A017,Dulox animal models neuropathic and ainflamatory pain,
I4M-MC-MRAG,Hepatic Impairment,
"14953",Phase 2 Lower Limb Disuse Atrophy,
I1D-MC-JIAH,Human C14 in Healthy Volunteers,
I4V-MC-JAGV,Placebo Controlled Efficacy and Safety in patients with DN,
H7T-MC-V037,Examine the reversibility of binding P2Y12 antag & PAR-1,
H7T-US-B019,"2013-109_ Outcomes amng ACS PCI pts treated w Effient vs BRI",
B1Y-FP-0737,PROZAC.EPIDEMIOLOGICAL STUDY IN OBSESSIONAL COMPULSIF DISORD,
I4C-JE-JTBE,JP_Ph II - c-Met Antibody - Gastric,
H9X-MC-GBDZ,Single Use Pen #1,
I6E-AV-_A18,Evaluate effectiveness of florbetapir (18F) in PET imaging ,
H7I-EW-S009,"Tarp Dependent AMPA Antagonist Kinetics, Dosimetry, Test-Ret",
"15150",China IMCT,
"6819",Rand Neoadj Study of Intensive Chemo VS Seq Chemorad NSCLC,
B9E-US-S300,Phase II Gem/Carbo/Iressa in NSCLC,
F1D-US-X262,Olanzapine in the treatment of Migraines,
F1D-GH-O178,"The risk factors for psychotic inpatients with sudden death,",
H7X-MC-JVAN,Ph II - Affinitak+ Docetaxel + Estramustine - Prostate,
H3S-MC-GGKW,Estrogen Therapy in Comb. with  Rlx to Manage Hot Flashes,
ZYY-LC-ECBB,Exploration of Biomarkers in Systemic Lupus Erythematosus,
F1D-BP-O183,Use of Zyprexa velotabs in Acutely disturbed patients,
B9R-FP-GDGD,HGH in peripubertal children with SGA and short stature,
"7254",Placeholder for Xigris trials,
H6E-GR-GLAV,ECLA in Greece,
"7306",Placeholder for Denmark for local studies,
"7317",Xigris non-study related local support work,
B9E-MC-V200,Studying the enzymatic activation of prodrugs,
H3S-FP-S039,"Disease management pathway, implementation",
F1D-XL-O192,The effectiveness of Olanz in treatment refractory schizo,
"7402",Focus on effectiveness of high doses - RIDE,
"7428",Placeholder for olanzapine bipolar observational study (AO),
B9E-MC-X257,Phase I Study of Gemcitabine and Topotecan,
B1Y-MC-X138,ESTROGEN AUGMENTATION OF FLUOX IN PREMEN WOMEN W/MD,
B3M-MC-AJAZ,Cefaclor AF 750mg for treatment of Pharyngitis/Tonsillitis,
F1D-MC-I028,Olan. vs Risp. in treatment resistant schizophrenia,
B5K-MC-IBFO,Efficacy of PI in type 2 pts failing SU therapy,
B9E-MC-S095,Ph II Gem+Taxotere vs. Gem + wkly Tax vs. Gem + Tax / Breast,
B1Y-MC-HCDA,FLUOXETINE VS. PLACEBO IN HEAVY DRINKERS,
H3E-MC-JMDI,MTA vs MTX or Taxol in cis/5-fu faliures,
"2571",Sleep Latency II,
"2606",CYP1A2/SSRI (inhibition),
H4Y-MC-LJBF,Cardiac angiography in compromised blood vessels,
F1D-US-X084,"2yr. Incidence of TD in pts. treated with Olz. vs. Typicals",
F1D-US-A024,Regulation of G Protein After Chronic Treatment with APDs,
F1D-US-X083,Zyprexa Treatment of Post-traumatic Stress Disorder,
B1Y-MC-HCJT,Raloxifene augmentation of fluoxetine for depression,
"2734",(JSA1) Ph 2 trial/LY320236/metastatic prostate cancer,
"2738",(JSA5) Ph 1 combination of LY320236/?? for prostate cancer,
B1Y-MC-X161,OUTCOME OF INFANTS EXPOSED IN UTERO TO FLUOXETINE,
H5W-BD-LQAC,Sumatriptan interaction study,
B7A-MC-MBBP,Peripheral Neuropathy with symptoms patients w/ diabetes I,
B7A-MS-MBBH,"14C Study",
H4Z-MC-JWWK,(J206)  Phase 2 Prostate Cancer Trial -,
F1D-MC-HGHE,Olanzapine vs Placebo in Schizophrenia w/Comorbid Depression,
B5K-EW-IBEI,Atlas (Humapen) Commercialisation Study in type 2 patients,
H3E-MC-JMCA,"Phase I, MTA + DPD Inhibitor (Capecitabine)",
F1D-US-A019,Atypical Antipsychotics and HAL on Rat TD and Working Memory,
B3D-LC-GHAZ,Calcium mechanism of action,
F1D-MC-O018,Is Olan. a substitute for Clozapine?  A computer. registrati,
A3Q-IT-AFBI,BIOEQUIVALENCE STUDY OF TWO FORMULATIONS OF CEPHALEXIN 125,
B9E-MC-S077,Ph II Gem + Doxorubicin neoadjuvant Breast Cancer,
B1Y-MC-HCCP,"FLUOX FIXED DOSE, MILD AND MODERATE DEP.",
B9E-MC-S093,Gem+Taxol vs. Gem+Taxotere / Breast,
B9E-SB-O022,"Phase II,  Gemcitabine In Combination w/ Radiotherapy",
B9E-MC-I072,PHASE II STUDY OF GEMTAX FOR PREVIOUSLY TREATED SCCHN,
"2513",BID Use in Self-Mixed Regimens with NPH/Effect of diet,
"2534",IS FLUOX'S  ANTIDYSPHORIC EFFECT MEDIATED BY NEUROSTEROIDS?,
B4Z-MC-LYAB,Open label pediatric and adolescent safety study,
H6Q-MC-V032,Enz in breast and lung cancer with thyamine depletion,
I6Y-AV-_739,Binding properties and Safety of 18F-AV-739,
I3Y-MC-V001,Thera.Inhib. of cyclin-dependent kinase-4/6 in bladder cance,
H4Y-MC-LJAT,Pilot Mild (3 migraines),
I2M-MC-GSDP,Blosozumab Summative Human Factors Study,
I7G-EW-HLBD,PET RO study,
H3E-MC-A005,Eff. of  Alimta +/-bevacizumab against adult gbm xenografts,
B3D-JE-A008,PTH and Exercise Effects on OP Rat Vertebra (Ohtori),
I4X-CR-JFCO,CP11-1012_R-Ph III-Neci+Gem+Cis vs Gem+Cis-Sq NSCLC-stage IV,
F3Z-MC-B017,"2013-577_Conversion to Small Vial in LTC",
I5Q-MC-CGAD,IC/BPS POC Study,
H9D-MC-ITAP,URI via vasodilation w/lexiscan,
I4M-MC-MRAK,LY2623091 CP Human c14 Study,
A6J-MC-V010,Vancomycin-Resistant subpopulations among MRSA and MSSA Stra,
H6O-US-X001,Cost Barriers and Initiation of Therapy,
I4T-JE-JVCX,JP_Ph Ib - Ramucirumab - Gastric - First Line,
"15560",TQT,
"7446",Gem+Alimta lung (Ceresoli proposal),
F1J-BP-S007,Factorss Influencing Depression UK Study (FINDER),
H8I-MC-HQAH,"5HT1D/SSRI FED - POC Increased Speed of Onset",
B7A-MC-MBDO,RBX improves C-Fiber formation as evindenced by skin Bx-EBF1,
"7615",Use of Vancocin for the treatment of MRSA/MRSE infection,
F1D-PL-O207,Alzheimer related psychosis,
"7834",Breast density & cardiovascular markers with Evista,
"7858",Local proposals,
H8R-MC-HJAI,IBS Biomarker Study,
H6U-MC-LRAI,CSF & Plasma for Alzheimer's Disease Assays (Sulfatide),
F1D-ML-B003,Effectiveness of Olanzapine in Acute Mania in Malaysia,
"8041",Comparison of Humalog Mix 75/25 w/Humulin 70/30,
B9E-PU-JHMV,Gencitabine plus Carboplatin combination in Recurrent or ref,
F1K-US-A002,The role of activated Protein C in acute pancreatitis,
H8O-EW-GWAL,Exendin-4: ECG,
H8O-MC-GWAD,Exenatide vs. twice daily biphasic insulin aspart,
B9R-CA-C036,HUMATROPE DOSAGE IN PUBERTY: GH DEFICIENCY WITH HYPOGONADISM,
"2777",Ceclor Step Down Therapy Trial,
"2795",Streptococcus pneumoniae Surveillance Study,
H4A-MC-XBAH,IV Pediatric Pharmacokinetics and Safety,
B1Y-MC-HCFE,FLUOX VS DESIPRAMINE IN BREAST CANCER PATIENTS WITH MDD,
H3E-MC-JMCY,MTA + low dose 5-FU CI 1st line CRC,
B9E-MC-X185,Gemcitabine and Paclitaxel in Bladder Cancer,
B3N-MC-EUDE,Insulin Sensitivity (Solvay),
F1D-MS-LOAM,"DB,3WAY X-OVER PLAC PHAR COMPARE OLAN. VS RISP YOUNG & ELDER",
H3S-US-GGJF,AN OPEN LABEL STUDY OF RALOXIFENE HYDROCHLORIDE: EFFECTS ON,
B9E-SB-O028,"Ph I/II, Gemcitabine & Radiotherapy In Cervix Cancer",
B1Y-NZ-O001,FLUOXETINE USE IN POST MYOCARDIAL INFARCTION DEPRESSION,
H3Z-MC-JNAY,Registration phase study of LY295501,
"3129",Antibody study for Humulin formulation changes,
F1D-MC-X125,ZYP IN TRTMNT OF APATHY SYNDRME IN PTS RECEIVING SSRI,
B4G-EW-LCDH,Parkinson / Neurogenic Bladder,
F1D-MC-X123,Efficacy/safety of olz & fluoxetine & comb in tx bipolar dep,
B1Y-MC-O003,INFORMATION PROCESSING IN OCD,
B1Y-MC-I010,"FLUOXETINE IN CENTRAL (""HYPOTHALAMIC"") OBESITY",
B1Y-MC-HCDN,FLUOXETINE VS PLACEBO IN BULIMIA: PARALLEL/BLIND,
B9E-MC-I124,PHASE I-II EVALUATION OF GEMCITABINE + TAXOTERE NSCLC,
B9R-SB-IBOK,SOMATROPIN IN CHILDREN WITH HYDROCEPHALUS/SPINA BIFIDA,
"2646",Otitis Media Animal Model - Cefaclor/In Vitro Studies,
B5K-MC-IBFU,"HumaPen Iteration, Primarily of Industrial Design - Mercury",
B3M-MC-S006,Cefaclor vs Augmentin in Acute Otitis Media-CTNR,
"2836","Study 2, Out/in pt overnight  BG efficacy",
"2888",POR Hip Fracture - Japan,
H3E-MC-JMCO,PH I MTA + Epirubicin,
H3E-MC-JMCR,PH II MTA + Oxaliplatin 1st line CRC,
B1Y-BP-E077,"FLUOXETINE VS PLACEBO, MEAL INDUCED THERMOGENSIS",
B9E-MC-X195,Gemcitabine and Docetaxel in NSCLC (Phase 2 Study),
F1D-MC-HGHT,Olanzapine vs. Lithium in Relapse Prevention in Bipolar Diso,
"3048",Olz in trtmt of Psychosis assoc w/Lewy Body disorder,
"3081","Claudication - Ph 3 US IND 56,995",
"3162",Bioavailability of liquid vs tablet in volunteers,
B9E-MC-S111,Tax v Tax+ gem v Gem or Cis in poor KPS-NSCLC; Jun98SU67,
B9E-MC-S127,Phase I study of dose-intensive Cisplatin +Gemcitabine/NSCLC,
H3S-US-X001,Continuation of HRT in Women 65 Years and Older,
I7Z-EW-FLAI,Elderly PK ,
I7Z-EW-FLAK,CYP3A,
H7I-MC-BMOR,b-MOR EET,
I7E-AV-E008,Tau imaging in Neurodegenerative Disorders,
H7T-MC-V042,ELISA VASP/P2Y12 & VerifyNow P2Y12 assays used to assess pla,
I3Y-MC-JPBX,R-Ph II - Abemaciclib vs Docetaxel - Sq NSCLC,
I4C-MC-V004,Treatment gastric cancer by comb. of c-Met/FGFR/TKI w/chemo,
I5B-MC-JGDM,Ph IB-Olaratumab ->Olara+Dox - Soft Tissue Sarcoma-1st line,
I4E-IE-W878,"Protocol CA225-059; A II trial of Cetuximab, cisplatin, and ",
I4E-IE-W918,"Protocol CA225-287; A I BIOLOGICAL, PHARMACODYNAMIC AND RESP",
I4E-IE-W932,CA225-269:R-PhII-PRE-OPERATIVE Chemo RT +/- Cetuximab-Rectal,
I4D-MC-A003,The roles of Chk1/Chk2 in the early stages of erythropoiesis,
I8D-AZ-AZEZ,AZD Relative Bioavailability Study (D5010C00005),
I5Q-MC-CGAQ,Auto-Injector (AI) bridging study,
B3L-MC-LWAJ,LY354740 vrs plac in the reduction of benzod withdrawal sxs,
"3222",Human Imaging study with Ly 426965,
H4A-MC-V019,Antifungal Microdilution Susceptibility Test-Quality Control,
"3370",TO DETERMINE THE EFFECTS OF ADMINISTERING CONTINUOUS COMBINE,
B1Y-MC-X018,FLUOX: PROSPECTIVE ANTIDEPRESSANT OVERDOSE STUDY,
F1D-SF-O030,Olanzapine Versus Chlorpromazine in Kenya,
B9E-XM-JHPX,"Phase II, Gemcitabine, Cisplatin & Taxol,  In Advanced NSCLC",
B9E-MC-S129,"Ph ll -5-FU, Folinic Acid + Gem - Colorectal",
H6D-EW-LVAP,Interaction study with Theophylline,
B9E-VI-O053,"Phase II, Gemcitabine, Cisplatin & Vinorelbine, In NSCLC",
B9E-VI-O057,"Phase II,  Gemcitabine & Cisplatin,  Adv NSCLC",
B1Y-MC-X064,FLUOXETINE VERSUS PLACEBO IN BODY DYSMORPHIC DISORDER,
F1D-US-X148,Effect of Olz. on the Paired Auditory Evoked Potential P50,
F1D-VI-HGIF,Olanzapine in Schizophrenic patients,
H6D-MC-LVBL,Long Term Safety,
F3Z-BX-O024,REGULAR INSULIN VS LISPRO ANALOGUE IN TYPE I DIABETICS-SCII,
H5Z-MC-LUAI,R-fluoxetine vs Placebo in Acute Treatment of GAD,
F1D-US-HGII,Olanzapine vs. Risperidone - Functional Outcome Study,
F1D-AY-O222,Olanzapine treatment of PTSD,
"8183","Effect of PTH dose, 4-MOAC dose and volume on PTH exposure",
B7A-MC-MBDL,PKC beta Inhibitor Macular Edema Trial,
F1D-SB-S053,"Olanzapine ""High-Dose-Study""",
H6U-MC-A004,Development of NET tracer with SPECT,
"8349",Cialis IIT Placeholder for US MPD planning,
B9E-MC-V226,inter-individual variation in gem PK +intra cellular metabol,
"8402",Various Commercialization Studies in Breast Cancer,
H8Z-MC-A001,Thymidine PET biomarker study in mice,
B9E-US-X406,Ph II Gem & Genistein in metastatic breast CA w/biomarker,
B9E-CA-O387,"Peri-Op.Gem. during Pulmonary Resection -Stages I, II NSCLC",
"8534",Single Dose Safety Study in RA Patients,
F1D-MC-O243,Cost-effectiveness of Olz vs Convential Tx for Schizophrenia,
F1D-MC-A120,Comparative Antipsychotic Drug Actions in Brain Neuro,
H6H-EW-JEAN,MEPM Bioequivalence study,
B3D-MW-GHCR,Teriparatide in Postmenopausal Women with Osteoporosis,
"8739",SHS or glargine + Humalog in Type 2 Diabetes,
H3E-MC-V002,Pre-clinical research with combination ALIMTA + Gemzar,
H3E-MC-V034,Alimta In Gastric Cell Lines,
B1Y-IS-B001,Effects of FLX on energy levels,
"16401","Ph II - Ram+Doce, Ram+Nivo v. Nivo -nonSQ, NSCLC - 2nd Line",
I8R-MC-IGBC,Efficacy and Safety of Intranasal Glucagon in Adults ,
F3Z-BP-IOGR,Lispro MM and Lispro LM - Multiple Dose Regimen - Explorator,
I6T-MC-AMAK,Trial II: Randomize Withdrawal Psoriasis phase 3,
I8Y-MC-CRBA,SAD/LDI,
I8Y-JE-CRBD,Japan SAD/MAD ,
B3N-TW-EUBJ,MOXONIDINE VS ATENOLOL IN PATIENTS WITH HYPERTENSION,
"16625",PsA OLE,
"16652",Adolescent Atopic Dermatitis Exposure response trial,
F3Z-MC-B024,"2016-4908: Test Real World Application of Lilly Diabetes Pat",
I7E-AV-E063,AV-1451-EXIST-063,
F1J-MC-B059,Pregnancy Registry Obs/Retro Nordic DB Study (ApEHR),
H8H-MC-LAHD,Assess cardiovascular effects of lasmiditan with propranolol,
I8B-MC-ITSO,Insulin Only Insulet Lyumjev Closed Loop Safety Study,
I4V-MC-JAIS,RA-BRAZEN (monotherapy) Clinical Trial,
"16985",CGRP-CP PET Tracer Validation ,
H6D-MC-LVEB,Preference RR,
"3329",EFFICACY AND SAFETY OF REOPRO IN PATIENTS UNDERGOING HIGH RI,
"3344","Phase II, MTA + Epirubicin, 2nd line breast",
"3352",Phase III S/S rheumatoid arthritis - Europe,
B4G-UT-O002,Pergolide in Nephritic Patients with Restless Legs Syndrome,
B9E-IT-JHPN,GEMCITABINE AND FLUORURACIL IN PANCREATIC CANCER,
"3479",Pulmonary Phase 3 (new formulation),
"3499",bioequivalence (particle size),
F3Z-BP-O019,Prevention of nocturnal hypoglycemia in young children,
H5P-LC-BWWX,Antihistamine/ other drug interaction trial,
B9E-BP-O045,"Ph II, Gemcitabine & Cisplatin,  Adv Esophageal Cancer",
H6K-MC-IIAB,"FED, Safety, Multi-Dose, Accumulation",
B1Y-MC-X049,FLUOXETINE/PLACEBO CONTROLLED CROSSOVER IN TRICHOTILLOMANIA,
B9E-MC-X243,Gemcitabine/Carboplatin/Paclitaxel - Ca unk primary,
H6D-EW-LVAV,Calcium channel antagonist (amlodipine) interaction study,
H6K-MC-IIAA,"FHD Single dose, Safety",
B1Y-MC-X076,TREATMENT OF DYSTHYMIC DISORDER IN THE ELDERLY,
B5K-MC-IBFE,Relationship of PI to meals in type 2 pts,
"3894",LY354740 - Opiate withdrawl,
B9E-MC-I023,GEMCITABINE AND RADIOTHERAPY FOR BREAST CANCER,
"17034",PhII-Ram+Nivo-Mesothelioma,
I9Y-MC-JDHA,FHD Ph I - IDH1 Inhib II - AML,
I8F-JE-GPGO,Tirzepatide Japan Monotherapy,
I1F-MC-RHCQ,PPP OLE,
I8F-MC-GPGR,DDI-OC (EE 35mcg/NGE 0.25mg) in women HV,
B3D-US-B029,Primary Data Collection Site Based Observational Pragmatic S,
I8F-MC-GPGX,Titration Study,
I9X-MC-MTAD,MAD PET HV,
F3Z-MC-IORJ,TANGO Peds Pivotal,
J1P-MC-KFAH,Phase 2 Trial in UC,
I7E-AV-E090,"18F-AV-1451-EXIST-094",
S2C-MC-G2AB,Safety and Multidose Pharmacokinetics of LY396623,
B9E-MC-I085,"PHASE 1/2 STUDY OF GEMCITABINE, CISPLATIN, AND RADIOTHERAPY",
I8B-MC-B002,URLi China PMSS,
B9U-US-AZDG,BIOEQUIVALENCE OF LORABID CHEWABLE IN ADULT VOLUNTEERS,
"3256",Local registration study in Yugoslavia,
"3834",Polymorph human bioequivalence study,
H5P-MC-BWXD,"Phase III RA trial in NA, placebo and Celebrex",
"3911",CIRCADIAN RHYTHM STUDY WITH FINAL FORMULATION,
H6E-MC-GLAC,ACTOS vs. glibenclamide,
"4041",Humalog Premeal + NPH bid vs Humalog Premeal + glargine 1x,
H3E-MC-JMDY,MTA vs capecitabine,
"4084",Cefaclor AF 375 mg for tx of Tonsillopharyngitis,
B9R-SB-GDFQ,Individualized GH-therapy in Dilated Cardiomyopathy,
B9E-SB-O117,Gemcitabine low dose and Radiotherapy in Head and Neck CA,
B9E-MC-V045,Gemcitabine liposome gels for I.V. and I.T. application,
B1Y-BP-HC30,FLUOXETINE/IMIPRAMINE/PLACEBO POST NATAL DEPRESSION,
F1D-US-I032,treating cocaine dependence,
F1D-CA-O061,Prolonged receptor effects of Olanzapine: A PET study,
H4S-SB-EWAZ,Abciximab in Pts. with AMI complicated by Shock,
"4337",Phase 2 Trial of Gemcitabine and CPT-11 in Biliary Cancer,
H3S-US-GGJZ,"Dblbld, plac cont, rand. of Ralox HCl on Vascular Reactivity",
B9E-GH-JHRA,Gem+etoposide vs Gem+Cis in treatment of advanced NSCLC.,
H6N-BD-LEAB,FHD - Single dose escalation+ food effect,
"6603",IIT Placeholder for ALIMTA trials,
B9E-IT-O449,GEMZAR + CARBOPLATIN METASTATIC BREAST CANCER,
"8861",Recurrence Prevention,
"8889","Place Holder ""Local studies with Forsteo""",
B1Y-CA-C017,"FLUOXETINE EFFECTS ON GLUCOSE HOMEOSTASIS, TYPE II DIABETIC",
B9E-US-X417,Ph I/II post-op w/Gem pancreatic adenocarcinoma,
B9E-US-X418,Ph II chemoradiotherapy & stem cell trans. Hodgkins disease,
B5K-GH-O014,Diabetes education on chronic complication in senile DM pats,
H7T-EW-TAAN,CS-747: Hepatic impairment,
"9010",Placeholder to allocate ressources for PURE (SBCB),
B9Z-EW-E011,DIRITHROMYCIN (5 DAYS) V ROXITHROMYCIN (7 DAYS)IN CHRON BRON,
F1J-MC-HMEF,Duloxetine 60/120mg vs Plb in tx of FMS,
F1J-MC-HMEG,Visceral Interstitial Cystitis (IC) Pain,
"9123",Pilot Study in Interstitial Cystitis,
H3E-MC-V026,Alimta to determine structure and activity variants of DHFR,
H9F-MC-GYAH,OPRA I Multi-Dose PET Study,
H9F-MC-GYAG,Combination therapy,
"9243",Cross-Sec Bone Biop Stdy of Postm Wmn w/Osteo prev Evista,
B5K-GH-B004,Insulin on target achievemt w/ HumaPen Luxura,
F1K-MC-A008,Effects of APC on Hepatic Recovery Surgical Model MOD,
F1D-CA-O044,Olanzapine on cerebral activity during memory tasks in MRI,
"4007",yryrytrytrtrtyrytyrtrrryrr,
H6F-LC-PAAB,LY466700--Safety of Single Doses in Healthy Subjects,
"4070",ACTOS vs. Acarbose,
B9E-MC-V020,Assess potential for radiosensitization of prostate CA cells,
B7A-LC-MBCL,Bioavailability,
B9E-FP-O106,IIT-phase II.bladder urothelium carcinoma adv. or met.,
F1D-CA-O050,HE Chart review - Impact of open access to atypicals,
B9E-MC-V032,Gemcitabine entrapment of enkaryotic topoisomerase I,
F1D-GN-O056,Olanzapine with and w/o fluoxetine in Schizophrenia,
F3Z-MC-IONA,Local registration trial in China,
B9E-BP-O130,"Phase I, Gemcitabine, Carboplatin & Paclitaxel, Ovarian canc",
F3Z-MC-IONI,PK High Mix Trial to Support US Registration,
B9E-AY-S168,"Gemcitabine & Cisplatin, RT & 5-FU in Pancreatic Cancer",
B9E-FP-O137,ITT-COMBINATION GEMZAR & RADIOTHER. IN PANCREATIC CANCER,
"4486",Case control study: olanzapine vs resperidone,
B1Y-SB-6006,FLUOXETINE V PLACEBO ALCOHOL DEPEND.PTS.&VOL. DRINKING,
J1B-MC-FRCF,Phase 2 POC in Urticaria,
J2G-OX-Y043,PhI-RET Inhibitor-MTC,
J2F-MC-OHAB,Ph2 RAR Dose-ranging OA trial,
J2T-DM-KGAC,Lebri mono study in pts with moderate to severe AD (AD2),
J2T-DM-KGAG,Lebri for pts w/ persistent mod to severe AD for 1year,
J2G-OX-Y065,RET Inhibitor-NSCLC,
J2G-OX-Y086,RET Inhibitor-NSCLC,
J2G-OX-Y121,RET Inhibitor-NSCLC,
J2G-OX-Y146,RET Inhibitor-NSCLC,
J2T-DM-KGAW,Lebri eosinophilic inflam. in pts w/ uncontrolled asthma,
H4A-MC-XBAF,LY303366 (IV) Pilot Study for Esophageal Candidiasis,
"18125",Safety China PK,
J2N-OX-JZNR,LOXO-BTK-20017 (SAD),
B1Y-IT-E044,FLUOX VS CLOMIPRAMINE MAJOR DEPRESSIVE DISORDERS,
"7115",Placeholder for Breast,
H3S-US-X005,"Study of ralox, estrogen, placebo on Insulin sensitivity",
B9E-AY-O172,Gemcitabine & Navelbine & RT in NSCLC,
B9E-MC-I148,In Vivo Angiostatin Generation in Combination w/ Gemcitabine,
"4497",Cefaclor CE 375mg BID vs Aug. DUO Forte - Acute Bronchitis,
B3M-PK-AJBF,Ceclor in Children with Pharyngotonsillitis.,
B1Y-SB-8076,FLUOXETINE:PATIENTS MAJOR DEPRESSIVE DISORDER,
F3Z-FP-O029,Functional Insulinotherapie in Type I diabetics (FIT),
F1D-KL-S009,Local  QOL of Olanzapine in Schizophrenic patients,
F1D-MC-X176,Utilizing Trancranial Magnetic Stimulation in Olz-Treated Pt,
B1Y-MC-X204,FLUOXETINE EFFECTS ON DEPRESSION & IMMUNE STATUS IN HIV,
H3R-BD-LBBD,Treatment of Nitroglycerin-Induced Migraine Headache with LY,
H6D-MC-LVCQ,Efficacy study at 6 mo.,
B9E-MC-V082,PK of gem+epi in relation to toxicity in pts w/adv nsclc,
B1Y-SZ-GR40,FLUOX IN MAJOR DEPRESSION WITH OR WITHOUT SECONDARY ANXIETY,
B9E-MC-V086,Histoculture drug response assay for Gem in NSCLC,
B9E-MC-V087,Determine value of irrigating surg wounds w/gemcitabine,
B4G-SB-V005,Dopamine agonists in the treatment of Parkinson`s disease an,
"4937",Monotherapy - MPH BID vs LY452504 QD,
H3E-US-X009,Ph II Neoadj w/ Gem & Pemetrexed NSCLC w/ Pharma correlates,
"9454",Placeholder for Alimta in CH,
H3E-US-S071,Ph II - Gem Intravesical w/Gem maintenance - Bladder,
B9E-SO-O430,A phase II study of Gemcitabine + Paclitaxel in MBC.,
H8O-MC-GWAS,Effect of exendin-4 treatment on splanchnic glucose uptake,
"9621",Glargine add-on trial,
F1D-FP-S057,Validation of the MATHYS scale,
"9727",Atomoxetine for the treatment of dysexecutive impairments in,
B9E-SB-O445, Gemzar IITs,
H3E-US-X024,Ph I-IIa Dose-Ranging study of Alimta + Erbitux for NSCLC,
F1D-US-A124,Pharmacology of the neuroprotective actions of olanzapine in,
B1Y-CA-C030,FLUOXETINE VS PLACEBO IN THE TREATMENT OF PANIC DISORDER,
F1K-MC-EVDF,PC Profile Study in Burn Patients,
H3E-FP-S091,NSCLC - Phase I-II Alimta RTH,
H3E-XM-O013,UAM (Resistence to Alimta in cell cultives,
"9914",Ph I/II: Alimta/Cis & RT,
B9E-FP-O447,IIT-Ovary B9E-FP-O447 TOPOGEM / CHU Poitiers,
F1K-SB-O029,Xigris in cardiogenic shock complicating AMI treat. with PCI,
B9E-SB-O139,Gemcitabine + Paclitaxel in Urothelcarcinoma,
H4S-SB-O008,Conservative vs Early Interventional Revascularization in UA,
B1Y-SE-9362,PROZAC: PHYSICIAN EXPERIENCE PROGRAM OPEN LABEL,
"4678",GEP in NSCLC,
B9E-MC-S218,"Gem, alone or combo w/ Cis pts w/ cholangiocarcino - Biliary",
B9E-MC-JHRL,Gem + MTA in Hepatoma,
H6H-MC-JEAJ,"Phase I, LY293111 + Gemcitabine",
B9E-MC-V080,Anti-cancer drugs in pts w/oral squamous cell carcinomas,
B9E-MC-X292,Phase 1 Weekly Cisplatin + Gemzar w/ XRT in Cervical Ca,
B9E-MC-X294,Gemzar/Cisplatin/RT/Surgery - Mesothelioma,
B9E-IT-S222,Gemcitabine in combination with other drugs in colorectal ca,
"5027",R-Fluoxetine -- Insomnia - Dose Response,
"5046",Multiple Dose Safety Study,
"5057",mGluR2 Prodrug2 vs placebo in Panic2 subjects,
"5200",MGlur2 - Prodrug MDSS study,
H4Z-MC-JWXM,SERM III safety protocol for patients post phase 2 protocols,
"7672",Affinitac,
B3D-EW-GHAS,Relative Bioavailability - Pulmonary Route vs Subcutaneous,
I8F-MC-GPIO,High Dose TZP + OC DDI in Postmenopausal Female with T2DM,
F3Z-IT-O009,Postprandial TRAP Activity after Lispro and Regular in IDDM,
B1Y-LC-HCDA,FLUOXETINE VS PLACEBO IN HEAVY DRINKERS,
B9E-MC-O006,"Phase II, Gemcitabine & Cisplatin, In NSCLC",
H5R-MC-V001,LY355090 Against  Clinical Isolates of Filamentous Fungi,
F1D-MC-HGGL,ALLELIC VARIATION IN SCHIZOPHRENIA,
B1Y-MC-HCAF,FLUOXETINE OPEN LABEL,
B3D-EW-GHAT,Nasal Dose Escalation,
H3U-MC-JPAD,LY300502/Biomarker study/Prostate Cancer Pts/Phase 2/NCI,
B1Y-MC-A005,Fluoxetine and Naloxone in Reducing Sucrose Intake in Rats,
B3D-MC-GHAV,"LY3333354/anti-resorptives in OP, PM Women",
B9U-IT-AZDO,BIOEQUIVALENCE STUDY OF TWO FORMULATIONS OF LORACARBEF 100,
B9E-MC-S074,Ph II Gem+Taxol+Epi/Breast,
B9E-MC-S083,Gem+Tax+Dox vs 1st line standard / Breast,
"2565",Pediatric Safety CANCELLED,
B4Z-FW-HFBO,B-Agonist Drug Interaction Study,
"2575",POC Geriatric Replacement,
B9E-MC-V096,Variable Combined Cytotoxi Effects of MTA and Gem,
"5080",Registration Pain,
"5089",Xanomeline Exploratory study / Olanzepine Combination,
H4Q-LC-ARRQ,LY333328 Moderate and Severe Hepatic Failure,
"5131",Clinical pharmacology C14 study,
B3D-FW-GHBO,Effect of PTH on EKG profile in adult subjects,
B9E-UT-O177,Phase 2 study of gem and docetaxel in met. breast cancer,
B9E-BP-O179,"Phase I/II, Gemcitabine combination, Hodgkin's disease",
B9E-MC-V106,Evaluate activity of GemMP[10] in pancreatic cancer,
B9E-GV-O201,Gem+Carbo in IIIa+b NSCLC followed by radiotherapy,
A6J-JE-ASBA,"JP Vanco, Shionogi, Phase 3, open study, PRSP in Pediatrics",
B3M-ME-AJBQ,Ceclor vs. augmentin in AOM in ped. pat.,
B3D-MC-GHAA,LY333334 EFFECTS ON BONE METABOLISM IN POSTMENOPAUSAL WOMEN,
B3L-EW-LPAA,MULTIDOSE PK SAFETY & TOLERANCE STUDY,
B9E-MC-X327,PhII Paclitaxel/carboplatin/etoposide + Gem/Irinotecan CUP,
"5605",Efficacy of Evista in Pakistani patients,
B9E-MC-JHRW,Phase II - Gem/Carbo Ovarian,
"5664",Fellowship for Canadian Psychiatric Research (FEL-058c),
"8223","2-Year Primate Bone Study",
H6W-EW-MCAC,Phase I a PK/PD dose escalation study in normal volunteers,
B3C-MC-JQAA,PHASE I CLINICAL AND PHARMAKOKINETIC EVALUATION,
"5401",Fed/Fasted Study,
"5436",Buccal Insulin - Effect from site of administration,
"5455",Radiochemotherapy for NS,
B9E-MC-X309,"PhII  Gemcitabine,vinorelbine & Trastuzumab in Met. Breast",
B3H-MC-L006,LY320052 VS. STD. TRANSFUSION THERAPY IN ELECTIVE SURGERY,
B9E-MC-X332,PhII Gemzar std infusion vs fixed dose in stage IIB/IV NSCLC,
B9E-IH-O253,Ph II: Induction & Adjuvant Chemo. with Gem+platinol (NSCLC),
"5658",Fellowship for Dr. Brenda Toner (FEL-053),
F3Z-US-IONU,"MM vs Human 30/70, LM,  healthy subject response p test meal",
H6D-MC-LVDU,Internet Trial,
H7I-MC-S001,Assess effects of methylphenidate on QPEEG w/Ritalin,
H6X-LC-GBBB,PPAR Co-Agonist SDSSin Healthy Volunteers,
B9E-MC-S241,Ph II- TAXT -> GEM sequential vs. TAXT -> GEM alternating,
"5767",Bipolar Spectrum Disorder in Urban Primary Care,
H6E-MW-GLAS,Actos observational study,
H7Q-EW-EABA,aPC-II - Phase Ia trial,
H7R-MC-GCBD,Phase 2 Study - Safety and Efficacy in Type 2 Diabetes,
"9963",Placeholder....Phase-Shift effect,
F1D-US-X272,Medication Adherence - Young Adults w/ Schizophrenia Using R,
H9X-MC-GBCT,Elderly Study in T2DM,
H6D-MC-LVHT,Asian Comparator Pilot,
F3Z-CA-IOCC,HUMALOG VS HUMULIN R: BID REGIMEN IN TYPE II DIABETICS,
F3Z-CA-IOCD,HUMALOG THERAPY IN TYPE I DIABETICS: HUMULIN N VS HUMULIN U,
B4Z-XM-O016,Utility of M50 in ADHD diagnoses,
H6L-MC-LFAR,LY450139 Dose Escalation--Safety & Tolerability,
F3Z-MC-IOBN,GLYCEMIC CONTROL IN PATIENTS WHO INJECT BEFORE MEALS,
"11963",Generalized Anxiety Disorder (GAD),
F1J-CR-S016,Depressed Patients with DPNP,
B1Y-GH-O039,antidepressant in patients with stroke,
B9E-US-X467,Ph II Study of Gemcitabine + Oxaliplatin + Tarceva in HCC,
H6D-MC-V010,Effect of Long Term Treatment with tadalafil on PDE5,
F3Z-OL-IOEF,INSULIN LISPRO/HUMULIN NPH V.S CURRENT TREATMENT,
"12283","11bHSD1 Phase 2 Artherosclerosis",
"12343",JP MR Antagonist Phase 1 (SDSS),
B3M-SE-3724,CEFACLOR CLINICAL EXPERIENCE EVALUATION STUDY,
B9E-FP-O236,"ITT-Evaluation of carbo,5FU & Gemzar in patients with NSCLC",
H3S-BX-S003,Raloxifene + Fluor Complement in Postmenopausal Women,
H8D-LC-EMBA,PPAR-alpha SDSS-MDSS in Healthy Volunteers,
"5844",PPAR-alpha Agonist Absolute Bioavailability,
"5847",PPAR-alpha Agonist Drug/Drug Interaction #1,
B3N-LC-EUBU,CLINICAL PHARMACOLOGY,
F3Z-US-IONW,lispro MM pre breakfast & lunch/LM presupper vs glargine qd,
"5904",Schizophrenia Phase II Study,
B4G-TW-LCDO,Observational Study in Taiwan,
B9E-XL-S264,Ph IIb gem+txt vs gem+cis in NSCLC stages IIIb/IV,
F3Z-XM-IONY,"OPTIMIZE INSULIN DOSES *2 TO 3 INJECTIONS""",
B3N-PK-EUAR,EFFICACY AND SAFETY OF ORAL MOXONIDINE,
B3N-SN-EUBL,MOXONIDINE PILOT SINGLE DOSE STUDY OF SUSTAINED RELEASE FORM,
"603",PH 1 DOSE ESCALATING STUDY OF PO LY335979 AND DOXORUBICIN,
F1D-AY-O145,Atypical antipsychotics in the treatment of early psychosis,
B7A-MC-MBCY,Effect of LY333531 on Endothelial Fxn in Patients with DM,
B9R-MC-I026,"Effects of hGH and exercise on growth, density and strenght",
F1D-US-X160,Olz. in Treatment of Psychosis and Agitation in the Elderly,
F1D-US-X105,Olz. Vs. Typicals among Smokers: Smoking Behavior; Cog. Perf,
"2678",TX of Depression in the Medially Ill: A Survey,
B1Y-MC-X160,Compar. of Echocardio in Pts TXd w/Phen-Fenflur v Phen-Fluox,
"2879",ketamine induced psychosis,
H4Q-MC-V015,LY333328 & vanco alone or with gent vs VISA--pharmacodynamic,
F1K-MC-EVAY,Treatment of Disseminated Intravascular Coagulation w/ rhAPC,
"2946",PH II MTA + oxaliplatin 1st line CRC,
B1Y-MC-HCFL,FLUOXETINE IN PATIENTS WITH POST-STROKE DEPRESSION,
B9E-MC-X183,Gemcitabine and Docetaxel in Head and Neck Cancer,
B9E-MC-X207,"Gemcitabine, Cisplatin, 5-FU, and G-CSF in Urothelial Cancer",
"3052",Olanzapine in the treatment of Anxiety,
B9E-MC-X166,Gemcitabine and Docetaxel in Advanced Solid Tumors,
B9E-MC-I067,Gemcitabine and Doxil,
B9E-MC-X138,Gemcitabine and Vinorelbine in Advanced Stage NSCLC,
"3166",Exploratory analgesia #2,
B4Z-LC-HFBL,Drug Interaction SSRI,
"3255",Local registration study in Turkey,
B3N-MW-T001,MOXONIDINE THERAPY IN PTS WITH ARTERIAL HYPERTENSION,
F3Z-XM-O043,REVISION OF INSULINS TREATMENT IN SPECIFIC POPULATION,
B7A-MC-MBCZ,Isoprostane/FMD Study,
H7S-LC-LHAB,Desipramine study - 5-HT6 Antagonist,
H3E-MC-JMFA,"GEM/Cis-> ALIMTA vs GEM/Carbo-> ALIMTA, 1st Line",
H7T-LC-TAAB,C 14 Study,
"6216",Pulm PTH (inhaled) - SD/MD Safety study,
"6227",MGlur prodrug - Relative BA,
H7C-MC-LMBF,mGluR2 - Abuse Potential,
F3Z-MC-IOOE,Premeal Humalog in Obese Oral Agent Failures,
B9E-SB-O274,"Phase III in NSCLC Stage IIIb-IV, 3 arms with Gemcitabine",
H4S-BP-O032,SWEDES-Swedish Early Reperfusion Strategy,
H4S-IT-O033,Impact of abciximab on coronary endothelial function,
F3Z-US-IOOD,Serum glucose resp to test meal w/ type 2 DM tx'd w/ glargin,
"6461",Ph II - Gemzar + Cisplatin + Affinitak - Bladder,
"6465",Evista and Forteo Combination,
B9E-MC-V144,Uptake and Penetration of IV Gem into Normal & Ca Bladder,
B5K-SE-9145,HUMULIN CLINICAL EXPERIENCE EVALUATION: OPEN - LABEL,
"6560",neoadjuvant GAT in breast cancer,
F1D-XM-HGKD,Olanzapine + Anti H2 in Prevention of weight gain,
H6E-UT-O001,Effect of Pioglitazone on Inflammatory parameters,
H3E-MC-S004,"ALIMTA + GEM vs Taxol + Carbo, 1st line",
H7C-MC-LMBK,mGluR2 prodrug vs placebo in GAD at select OUS sites,
F1D-MC-HGKX,Olz vs. Aripiprazole in Schizo./Schizoaffective,
"6262",Phase 3 treatment of OP in postmenopausal women w/out preval,
"6273",Psychotic Depression and OFC,
F1K-LC-EVBK,rhAPC:  Pharmacokinetic comparison of Japanese study,
ZYY-LC-PCAB,Methods Development: Lilly Neuropsychology Test Battery,
"6389",Beta Cell Response to GLP-1 Analog,
"6406",Olz + Lamotrigine Combo in Treatment of Bipolar Depression,
"6434",GLP-1 analogue - Definitive SD/MD dose prop,
F1D-US-A108,influence of olz on expression of BDNF in rats,
B9E-FP-O296,IIT-Gem-epirubicine/cisplatine comb + ZD1839 stomach cancer,
B9E-MC-V142,Gem w/ Oral Celecoxib in pts w/ Pancreatic Cancer,
F1D-TW-O159,Cognitive Function after Olanzapine Treatment,
B9R-EW-GDGB,OPTIMA European Somatropin SGA trial,
"6597",Retrospective analysis of acute patients,
B3D-TW-GHCB,PTH comparison with Calcitonin in post menopausal women,
F1D-PH-LOBT,Olanzapine vs Risperidone - A Retro OS,
"6601",Placeholder for PTH trials,
H6U-EW-LRAF,Methods Validation (NFR) Study,
B7A-MS-MBBA,"SINGLE RISING DOSE,MALE/FEMALE COMPARISON, FED/FASTED",
B3M-GH-O003,Bacterial Resistance Surveillance Study in Nan Jing City,
F1D-KL-S031,CTNR- Control of weight gain,
H8B-MC-EJBB,Ph II HTN Dose Ranging,
"6850",Ph III LY900005 + Thiazide,
H6E-UT-O005,Effects of pioglitazone in familial combined hyperlipidemia,
H3S-HU-S007,"Compliance,  quality of life and safety during raloxifene tr",
H7N-LC-ECBB,Exploration of Biomarkers in Systemic Lupus Erythematosus,
B1Y-KL-S014,The effectiveness of Prozac on restoring energy in MDD,
F1D-CA-HGKN,Health Outcomes: Canadian Naturalistic study,
H6D-MC-LVFL,Preference - EU Switch,
H7U-MC-IDAR,Pulmonary Insulin in Smokers,
F1J-MC-HMDW,Dulox vs comparator vs placebo study + low dose (OUS),
F1D-MC-X126,Olz in Generalized Anxiety Disorder,
F1K-LC-EVAQ,APC/Unfractionated Heparin,
"3324",PH II GEMCIT+IFOSFAMIDE IN LOCAL. ADV. HEAD & NECK,
F1D-MC-O012,Effect of Olz in Schizo w/spec focus of EPS,
"3339","Phase II, MTA monotherapy, ovarian cancer",
B3N-SB-EUDH,Moxonidine on Performance in Flight Simulation Setting,
"3404",Multiple Dose Safety Study for Concord,
B5K-MW-IBEH,"HUMULINS(R, N, MS, M3) VS GLIBENCLAMIDE IN TYPE II DIABETES",
B1Y-MC-X024,FLUOXETINE VS PLACEBO IN BORDERLINE PERSONALITY DISORDER,
B9E-MC-S134,Ph ll - Tax+Epi vs Gem+Epi vs Gem+Taxol (S094),
H3S-US-X002,Evaluation of the effects of raloxifene on the sexuality and,
B9E-MC-X239,Gemcitabine and Hercpetin for Pancreatic Cancers,
"3651",Naturalistic study to assess health economic outcomes of LY,
B9E-UT-O050,"Phase II,  Gemcitabine & Cisplatin,  Malignant Mesothelioma",
"3662",Neuroimaging study,
B9E-SB-V024,Gemcitabine and other in scid-mouses,
B9E-VI-O062,"Phase II, Gemcitabine,  in NSCLC",
B9E-MC-X245,Gemcitabine vs. Gemcitabine + Herceptin for Breast Cancer,
H6D-MC-LVBO,Pivotal on demand therapy vs Viagra,
B3M-GH-V053,National  Bacterial Resistance Surveillance Study,
"6648",LY2062430 Abeta Antibody Single Dose Safety Healthy Subjects,
B9E-SB-S290,GOAL-II: Observational Trial with Gemcitabine,
B3M-GH-S031,Ceclor RTU in Treatment of Acute Bronchitis,
B9E-US-X351,Intrathecal Gem Thpy for Neoplast Meningitis: Ph 1 & PK,
"6811",Phase 1/11 multicenter trial with carboplatin/gem induction,
"6877",PET Study in Healthy Subjects,
H7C-MC-LMBO,Acute Stress Disorder Efficacy Trial,
H7C-MC-LMBP,Human Disorder Model #2 with Imaging,
B9E-US-S302,Phase III Gem/Carbo vs. Carbo/Taxol in Ovarian Cancer,
F1D-CA-HGKO,Open Label with Olanzapine- Safety and Efficacy for Bipolar,
B3D-AA-GHCF,Area PTH study in Asian postmenopausal women (Vs Calcitonin),
"6980",IIT Placeholder for CT Material Shared Stock,
F1K-SB-EVCJ,Sepsis Prevalence Study,
F1J-MC-SBBX,Long Term Safety- Exposure with Bladder Overactivity,
"7014",Cialis - Tesiticular temperature study,
"7041",Health Outcome Observational Trial,
"7080",Olz augmentaton to antidepressants in partial responders,
"7111",Needle Free Injection Trial,
B9E-MC-V182,Measuring Gemcitabine pharmacokinetics,
B9E-MC-V191,Eff of Gem in vitro on growth and proliferation of Plasmodiu,
B9E-SO-O379,Phase II study of Gemzar in comb w Xeloda met breast cancer,
F1D-XB-O190,"20 mg velotab in severe psychomotriz agitation",
"7246",Forteo Efficacy in the Hip,
B9E-MC-JHDQ,GEMCITABINE COMBINED WITH EPIRUBICIN,
"7290",vertebral fracture Impact in GP's,
H3S-FP-S011,Multi Risk assessment in GP's,
B9E-MC-JHDU,PHASE I GEMCITABINE & PACLITAXEL ON REFRACTORY SOLID TUMORS,
"7327",M1 POC CIAS,
F1K-IT-O020,Effect of Hyperglicemia in PAI1 Activity in Severe Sepsis.,
"7435",SERT,
B9R-IT-O040,Small for Gestational Age (ex IUGR),
"7477",UK dulox SUI experience study,
B9E-MC-JHFN,"PH. 2 COMPARISON OF GEMCITABINE INFUSION RATES, PANCREAS CA.",
B9E-MC-JHFO,GEMCITABINE AND RADIATION IN ADVANCED PANCREAS CANCER,
B9E-KL-O342,A PHASE II STUDY OF CHEMOTHERAPY WITH GEMCITABINE AND VINORE,
"7613",MDSS,
H5Z-MC-LUAH,R-fluoxetine in Treatment of Anxiety Disorder,
B9E-MC-X018,Phase II Gemcitabine and Cisplatin in SCLC,
F1D-US-X154,Olanzapine in the Treatment of Stuttering,
B1Y-MC-X144,Fluox & Norfluoxetine in Breast Milk & Nursing Infants,
B4Z-LC-LYAY,Tomoxetine-Fluoxetine Safety and PK Evaluation,
H5P-MC-BWXN,Phase II trial in chronic bronchitis,
B5Q-PH-NCCO,Nizatidine in the Treatment of Post-Prandial Heartburn,
F1J-LC-HMAX,Hepatic Insufficiency Study,
B9E-GH-O126,Navelbine+Gemzar in phase III/IV NSCLC patient,
B1Y-NZ-0002,FLUOXETINE: IN BIPOLAR AFFECTIVE DISORDER,
A3Q-MC-AFBK,Cephalexin vs Amoxicillin in Acute Pharyngotonsillitis,
F1D-MC-O059,Efficacy study of OLZ in alcohol dependence,
H6D-MC-LVCI,Prostatectomy Study,
B9E-MC-X275,Phase 2 IV Gemzar and IP Cisplatin in Ovarian Cancer,
"4487",Olanzapine in the treatment of post ECT psychotic depression,
F1D-US-X177,Olz vs/ cloz in tx refractory schizophrenia,
B9E-MC-S158,Gem+Cis +/- Herceptin in advanced or metastatic pancreas,
B9E-FP-O140,IIT-GemzarCarboplat VS  NavCispl IN STAGE IV NSCLC -PHASE II,
"9144",Dummy trial for Humatrophe (GENESIS),
"7142",Proof of Concept Study,
"7165",Formulation BA #2,
"7276",A beta time course effect and plasma level,
B9E-MC-V203,Effect of gemcitabine on invasive potential and cell mitilit,
"7408",Xigris local by up 2003/2004,
"7423",Effect & safety of raloxifene in Chinese,
"7486",Lispro vs Humulin: A Twice-a-day Insulin Regimen in Diabetic,
B9E-MC-X009,PHASE 2 STUDY OF GEMCITABINE AND CISPLATIN (HEAD & NECK CA),
F1J-XM-SBCP,Development and validation of Diagnostic Questionnaire PCP,
"7653",Post launch open label tx - Dul Cymb,
B9E-MC-X015,GEMCITABINE AS A 150 MINUTE INFUSION IN COLORECTAL CANCER PT,
B9E-MC-X024,GEMCITABINE AND ORAL ETOPOSIDE IN SOLID TUMORS,
"7708",IIT / Fellowship / Chair Placeholder for Reopro,
"7781",Camos for Evista,
"7783",Humatrope Symposium,
B9E-PL-JHLT,PHASE 2 STUDY GEMCITABINE & CISPLATIN IN NSCLC,
"7847",Vanessa Bernstein Gem + Nva + Her,
B9E-SZ-JHLQ,GEMCITABINE IN HORMONE RESISTANT PROSTATE CANCER,
"7940",CTNR: Gem + Alimta + Affinitak + XRT - Pancreas,
"7956",Anxiety Proof of Concept,
"7676",Lung - Observation study,
"7680",Obs study - Assess prescribing diff between PQ & ON,
"7716",Actos/Diabetes Research Fund & Publication,
"7772",placeholder IIT olanzapine,
"7820",Zyprexa,
"7928",Gemzar Breast,
"7929",Place holder for the Pan European Gemzar Lung Study,
"7933",Dalanzapine vs Risperidone in the treatment of schizofrenia,
H6P-MC-HDAS,Safety & Efficacy of OFC in combination with mood stabilizer,
"7973",Adult rapid dose titration,
B4Z-US-LYCD,Pediatric Long term benefit of treatment,
H6P-US-HDAQ,Bipolar study,
F1K-US-A001,Role & Mech. of Xigris in Prevention or Atten. of ALI/ARDS,
H3S-XM-O029,Effect of Estradiol and Calcitriol in renal oteodistrophy,
"8077",adolescent safety and efficacy,
"8094",Placebo controlled crossover study in a single patient,
H8O-FW-GWAC,Exendin-4: Warfarin,
B9R-EW-E005,GROWTH HORMONE REPLACEMENT THERAPY IN ADULTS-CHILDHOOD ONSET,
"8184",Evaluation of food-time effect on peptide exposure levels,
H8R-MC-HJAG,Social Anxiety Disorder POC,
B9E-VI-JHME,PHASE II:  GEMCITABINE IN STAGE III & IV NSCLC.,
F1J-MC-HMCQ,Duloxetine with comparator,
F1D-US-A114,Neuroprotective Actions of Olanzapine vs. Haloperidol in Rat,
H8O-EW-GWAJ,Exendin-4: Dose/meal time,
F1D-AY-O223,Computer based psychopathology/psychopharmacology training,
F1D-GV-O234,Influence of antipsychotic treatment on prolactinaemia.,
H6E-UT-O008,Effect of Pioglitazone on Myocardial Metabolism & Function,
"8429",Adjuvant Trial - ALIMTA + Oxaliplatin in Colorectal Cancer,
"8490",Mexico One-Year Observational Study (DPT 3/10/03),
H8V-LC-LTBC,DHPG/NE Assay and Atomoxetine,
B9E-US-X408,Ph I Dexamethasone w/Carboplatin & Gem in NSCLC,
"8520",Pilot bioequivalence new pediatric formulation,
H9B-LC-BCDB,SDSS in RA & few SLE patients,
B9E-SB-O396,comb.ther.of  colorectal liver metastases in the rat,
H4Z-LC-GJAO,Definitive BE and Food Effect Study for QW dosing,
H4Z-MC-GJAP,Definitive BE and Food Effect Study for   QD Dosing,
F1K-CA-O019,Walley Genomic collaboration,
H8T-FW-IRAA,Superfine Humulin Insulin vs NPH and glargine,
B9E-US-X390,Ph I/II of Xeloda & Gemcitabine in  metastatic colorectal CA,
B9E-CA-S343,Phase 3 comparison of GDP to DHAP in refractory lyphoma,
H3E-BP-S039,Ph. I study of LY231514/Gemzar/Carbo in Adv/Met NSCLC,
F1K-US-EVCU,MERCURY-Retrospec Observ study using Xigris for sev sepsis,
B9E-US-X398,Ph II OSI-774 (Tarceva) & Gem pts w/metastatic breast CA,
F1D-GH-O237,Clinical economics study of first-episode schizoprenia,
H3E-US-JMGP,Ph II - Single Agent Alimta in Platinum-Refractory -Ovarian,
B9E-MC-V227,Analysis of gene expression for anticancer drug pancreas,
B1Y-BX-9101,"PROZAC; QOL IN MDD - AMBULATORY PATIENTS, AGE >60 YEARS",
"8437",LY450190: ANCA study,
H4S-SB-O054,BELOW-Balloonangioplasty or Stents with ReoPro,
F1J-BI-HMDC,Severe MDD Study 1208.2,
F1K-CA-O018,MMPs in the pathgensis of platelet dysfunction in Sepsis,
H9E-FW-S001,PK/PD study comparing Iletin to Diosynth API Insulin,
H7L-SU-O001,Prevalence of Type 2 DM in Adolescents in PR,
B9R-MC-X006,NEUROSECRETORY DISORDER OF GROWTH HORMONE RELEASE,
B9R-MC-X005,NEUROENDOCRINE REGULATION OF GROWTH HORMONE SECRETION,
B5K-GH-O011,Bcell protect & recovery by early intensive insulin in T2 DM,
B3D-US-X007,QCT of the Spine and Hip During Treatment with shPTH(1-34),
H6Q-MC-A001,In vivo analysis of human hematopoietic stem cells-PET,
F3Z-MC-IOOU,Intensive Mixtures Therapy vs glargine in oral agent failure,
"8729",Treatment of Pulmonary Embolus,
B9E-MC-S353,Ph I intravesical gem+ rad transitional cell bladder,
"8830",Health Economics Study Gem + Cis vs TXT+Cis,
B9E-IT-O426,GEMZAR + xeloda in Breast Cancer: ph II,
"8852",alimta + gemzar in metastatic colo-rectal cancer,
H7R-MC-GCCB,Efficacy w/sulfonylurea,
F1J-US-HMDX,Duloxetine and SSRI comparison in 2d6 pathway,
B9U-SE-9631,LORABID VS CEFACLOR; COMPARATIVE STUDY IN ACUTE SINUSITIS,
"9001",Duloxetine in Athletically Active Women with SUI,
"9005","5HT1d/SSRI Dose-Ranging Study",
"9085",Placeholder Gemzar trials (BUY UP),
F1D-EW-E008,HALOPERIDOL BIOAVAIL 5MG TAB (JANSSEN) V 5MG CAP (LILLY),
F1D-EW-HGBC,OLANZAPINE KINETIC INTERACTION WITH CARBAMAZEPINE,
F1J-AY-B008,ICR Cymbalta OBS study,
"8653",Cialis: Haemodynamic study,
B9E-IT-JHSP,phase II of intravescical gemcitabine inpat. with TCC,
"8708",GAD Venlafaxine Comparator #2 (BID no Extension),
"8776",Ph I/II - ALIMTA + novel agents (ASAP) - CRC,
B1Y-BX-9403,TREATMENT OF RECURRENT DEPRESSION IN PSYCHIATRY,
B9R-SP-GDEF,HGH TREATMENT IN SHORT PREPUBERTAL CHILDREN,
"8827",SDSS,
"8870",CRF-1 antag Biomarker Study,
B9E-SZ-O403,Prediction of response in NSCLC  with CHIP analysis,
"8927",Switch Commercialisation,
"8931",Duloxetine compliance SUI,
F1J-LC-HMDQ,Low dose mechanistic study,
A6J-JE-C002,JP vanc pwdr P-IV Enterocolitis by MRSA,
"9058",Stanley-Oxidants increase PA1-1 gene transcription by...,
H4S-US-V006,Effects of GPIIB/IIIa Antagonists on sCD40L (continuation ),
H6L-MC-LFAJ,High Dose Tolerability in AD Subjects,
"9121",Cymbalta Gordon Parker Study in MDD pts,
"9125",E-diary Valiation Study,
"4551",MGluR2 - Absolute bioavailability,
B1Y-SE-9435,PROZAC VS AMITRIPTYLINE A CONTROLLED STUDY IN MDD,
F1D-MC-HGJA,Tolerance and PK of IM olanzapine in chronic schizophrenia,
H6Q-MC-JCAD,"Phase I Trial, Patient Dose Safety",
B9E-US-S191,Breast-GET Neoadj-NSABP,
B9E-MC-S198,Ph II Gem+Taxt vs. Taxt Breast 1st line metastatic,
B9E-MC-S201,"Gemcitabine Single Agent (bladder,intravesical)",
F1D-UT-O087,elderly/ agitation and agression,
H4S-SB-O011,Abciximab in femoral stenting,
B3M-SB-AJBJ,"open, randomised, three-way cross-over bioequivalence study",
"4890",Type 2 - Combination with Orals,
H4S-SB-O013,Prehospital lysis+ ABX with or without PTCA in AMI,
F3Z-FW-IONV,Clamp Study Humalog Mixtures vs Insulin Aspart Mixtures,
"4999",Olanzapine Fluoxetine Combination PK Study I,
B1Y-UT-0191,FLUOXETINE VS PLACEBO IN ABDOMINAL OBESE MEN,
"5050",mGluR2 Prodrug2 vs placebo in GAD1 subjects,
"5061",Duloxetine Depression,
"5064",Duloxetine Depression,
F1D-MC-X259,Pharmacokinetics of Olz After Oral Admin of Standard Tab vs.,
B1Y-GH-B002,Prozac in the treatment of depression co-morbid with anxiety,
"9318",efficacy and compliance,
"9321",Yentreve ICR Pre-Launch OBS study,
"9369",Palatability study - Atomoxetine 3 - LY2124275,
B9E-US-X427,"Ph II Gem, Oxaliplatin combo w/Bevacizumab in hepatocellular",
F1J-US-B004,COSMOS; Cymbalta Observational Study in Managed Care,
H6L-MC-LFAM,LY450139 Inhibits Abeta Formation Determined by 13C Leucine,
H8R-EW-HJAE,Food effects study,
F1D-JE-208E,EXTENSION LONG-TERM STUDY/TREATMENT RESISTANT SCHIZOPHRENIA,
B9R-MC-O034,Prevalence of  SHOX SNPs in normal subjects,
"9415",placeholder atomoxetine,
B9E-US-S365,Gem q 14 day + Taxol vs Gem q 14 day + Weekly Taxotere,
"9461","5-HT2c   Phase 1b  4-Week Safety/PD Study",
H7T-EW-TABF,CS-747: Switching,
F1J-EW-B006,FINDER - EU Health Outcomes,
F1J-XM-HMED,Open label extension phase in patients who completed HMDG,
"5106",MGlur2 - Japan Single Dose,
H4Q-LC-ARRR,LY33328 Drug Interaction Study,
B1Y-UT-0393,FLUOXETINE VS PLACEBO IN POST MYOCARD INFARCTION DEPRESSION,
B9E-MC-JHRN,Phase II Gem+carbo+paclitaxel in NSCLC,
"5198",MGlur2 - prodrug SDSS (1),
B1Y-VI-0029,"FLUOXETINE VS AMITRIPTY. IN HOSP, ENDOGENOUS DEPRESSION",
F1D-XM-O097,Negative symptoms & response to Olanzapine in Schizophrenia,
B1Y-VI-1001,FLUOXETINE EXPERIENCE PROGRAM IN HUNGARY,
"5264",SDSS,
B9E-JE-BT21,JP gem P-II Biliary Tract,
B9R-JE-GDFW,JP hGH PIII SHOX,
F1K-MC-EVBD,Treatment of Purpua Fulminans with rhAPC,
F1J-MC-SBBM,Open Label Safety and Exposure Trial,
F1D-CA-O098,Efficacy of olanzapine in the schizo./substance dependence.,
B9E-SB-V095,Gemcitaine and Cisplatin and Radiotherapie in Bladder cancer,
B9E-MC-S228,Gemcitabine/Carboplatin Surveillance Study,
H3S-MC-A006,Effects of raloxifene on acquisition of spatial memory task,
B9E-JE-P12D,JP gem P-II pancreas w/ 5FU,
F1K-SB-A023,Microcirculation in amodel of gram positive sepsis -Lehmann-,
H6N-MC-LEAP,Phase 2b in Mild study,
F1D-EW-E002,LY170053 - PSYCHOTROPIC/ANTI-DEPRESSANT,
B4Z-US-X019,The Effects of Chronic Administration of Atomoxetine on aggr,
F1K-SB-B004,HISTORY-retrospective study of HSCT patient with sepsis/GvHD,
B4Z-JE-LYDA,JP atomo P-III long-term open-label,
H8D-MC-EMBD,RBA Study,
F1D-MC-HGMB,Olanzapine vs. Placebo for Borderline Maintenance,
H3S-XM-O125,Osteoporosis in postmenopausal women of an area of Madrid,
H8D-LC-EMBI,PPAR alpha C14 Study,
F1D-JE-CMP1,LY170053 COMPASSIONATE USE,
"9486",Graft Patency Follwing CABG in CS747 & ASA,
F1J-LC-SBCR,Duloxetine Interaction With CYP1A2 in Healthy Women,
H6D-MC-LVGI,Phase III Tadalafil in PAH,
H6D-MC-LVGJ,PAH Open Label extension,
H6D-MC-LVGK,Phase 3 EU Comparator Study of Tadalafil in PAH,
H3E-CA-S070,Ph 2 study of Gem and Alimta  in primary Unknown adenoca,
B7A-LC-MBDT,Ruboxistaurin Supratherapeutic ECG Study,
F1J-XM-O008,Somatic symptoms in depression,
"9606",GDGA (Global HypoCCS) Placeholder for local resources,
F1D-LC-HGBY,OLANZAPINE:BIOEQUIVALENCY OF CAPSULE & TABLET FORMULATIONS,
"9703","Ph I, Gemzar+Taxol+Avastin in Breast Cancer",
H9P-EW-LNBA,FHD Atomoxetine IV(10-Oct-05): SDSS/MDSS,
"9714",OCT addendum to MBDL study (PKc beta inh),
H3E-MC-JMHS,Ph II ALIMTA in CLL,
F1D-CA-S061,Olanzapine vs. quetiapine in bipolar depression,
H3E-US-X020,Pilot Ph II Alimta for pts. w/ primary CNS lymphoma,
H3E-US-X022,Ph I Study Intraperitoneal Alimta in Advanced Malignancies,
H3E-US-S081,Phase II Trial of Alimta in second line metastatic TCC,
"9973",Differential Effects of Duloxetine vs Escitalporam on Brain,
"12356",Ph II - 2nd line - NSCLC,
F1J-MC-HMGC,Chronic Lower Back Pain #3,
F1K-US-X010,Define Role of EPCR in Mechanical Stress-Endothelial Injury,
"12466",Placeholder PRA prescription survey of clopidogrel,
"12490",PLACEHOLDER (studies 2008),
B9R-US-V005,"ExNCR - Conway, Humatrope",
I3A-MC-LLBA,SNRI II SDSS (FHD),
"5409",Phase 3 Diabetic Macular Edema Study,
B9E-SX-O205,Ph II- Gemcitabine plus Cisplatin in Advanced Ovarian CA,
"5418",A Macrovascular Outcome Study of Pioglitazone,
B9E-GH-O254,Gemzar+Navelbine vs Gemzar+Cisplatin for advanced NCSLC,
F3Z-IN-IONL,Mix25 vs 30/70 BID in elderly Type 2 (India),
F1D-UT-HGJV,efficacy of oral olanzapine versus oral haloperidol on agita,
F1D-XM-O110,patients subjetive experience discussion,
F1D-US-X202,Traditional Versus Computerized Formats for Initial Diagnost,
H3S-US-GGKM,Hot Flash,
B1Y-MC-X218,Fluox on ventilatory drive & obesity hypoventilation,
H7G-FW-PDAB,LY582564 & Lamivudine in Lamivudine-Resistant HBV,
H6K-MC-O001,Clamp Study in Normal Volunteers,
F1D-ME-O120,Olanzapine in children and adolescent with schizophrenia,
H3S-BX-S004,Assessing Bone Resorption or Bone Density in Patients,
"5746","The relationship among insulin resistance, obesity and ADRB3",
H4S-SN-O028,AP Acute Myocardial Infarction Trial(APAMIT)-extended phase,
F3Z-MC-X010,BARI 2D: ByPass Angioplasty Revascularization Investigation,
H6N-MC-LEAH,Phase II MDS in Patients with MCI with Ampa II,
H9N-MC-LTCB,LY451395 FDG PET biomarker,
H7U-MC-IDAX,Compliance protocol #2,
B9E-JE-OV21,Jp gem P-I/II Ovarian,
B4Z-US-X030,Atomoxetine Treatment of Cognitive Impairments in Women 40-5,
H8O-US-GWAW,"24 Hour Glucose Comparator",
H8O-FW-GWBD,PK trial for support of AO IMCT - China,
B4Z-US-X029,Atomoxetine for the treatment of dysexecutive impairments -,
H6Q-MC-S012,Ph I Enz + Carbo Brain (NCI),
ZYY-MC-OAAA,Exploration of Biomarkers in Subjects with Osteoarthritis,
"9947",Init of Atmx following treatment with Dex in ADHD children.,
F1D-MC-HGBQ,OLANZAP. VS HALOPERIDOL IN PARTIAL RESPONDER SCHIZOPHRENICS,
B9R-MC-GDGM,Pediatric GHD Dose Response Study for Pulmonary hGH,
H8C-MC-LQBC,"Multi-dose Safety, Tolerability and PK Study with LY545694",
"10554",Research Evaluating Serial Protein C Level in Severe Sepsis,
H3E-MC-V067,Quantitative Analysis of ALIMTA polyglutamates in the Biolog,
H3E-MC-V071,Effects of Pemetrexed and target-based drugs on meso,
H3E-MC-V074,Bcl-2 and Bcl-X in Chemoresistance in Lung Cancer Cell Lines,
H3E-MC-V090,Alimta and Gemzar for preclinical studies,
"2541",MTA Q2W,
H3S-MC-GGKS,PTH and raloxifene HCl,
H3S-XM-O014,BMD evolution during 5 years in THS vs other treatments,
"6047",Monoamine - blink reflex study,
F1J-MC-HMDT,Dulox Once Daily vs Placebo in the treatment of GAD,
"6099",GLP-1 analogue - Renal,
F3Z-MC-IOOB,Humalog Pump Ready Formulation vs Humalog vs Aspart in CSII,
H3E-MC-S010,"Ph I/II 1st Line NSCLC, ALIMTA/Carbo dose escalation",
F1J-MC-HMCJ,Fibromyalgia Registration Trial,
H3E-MC-JMFN,"Ph II, First Line G + Alimta + Carbo Ovary",
B3D-MC-GHBV,Forteo Efficacy in the Hip,
"6317",Compare Pioglitazone & Once Daily to Type 2 Pts,
B9E-FP-O282,IIT-Gemcitabine chronopharmacoly in Mice study,
B9E-FP-O283,IIT-Gemzar aerosol administration in animals,
"6368",Factor Xa - food effect,
H8X-MC-JGBA,Dose escal trial low dose oral gem in pts w/ refract malign,
"6435",GLP-1 analogue - Injection timing,
B9E-MC-V159,Intracell Cell Death Signal Mech in Panc AdenoCA Cells,
B4G-XL-O010,Metanalysis of therapeutic options in Parkinson illness,
B9E-UT-O298,Pre-Operative Chemotherapy in pt with resectable NSCLC,
"6556",gem-taxol vs cis etoposido in first line,
"6614",Placeholder for Zyprexa IITs,
F1D-XM-O169,Anhedonia validation scale,
B4G-SB-V006,Neuroprotect. potential of pergolide f. dopaminergic neurons,
"6798",Cognitive Battery Pilot Study in Patients with Alzheimer's,
B9E-IT-JHLQ,"GEMCITABINE,CISPLATIN,VINORELBINE IN NSCLC",
"6857",Placeholder trial for Olanzapine Local trials,
B9E-MC-V171,Gem and pre-treatment with dexamethosone,
B7A-SB-O004,New Device to capture neuropathy in diabetic patients,
"7063",NGHDSS Japan Registration,
F1J-MC-HMDV,GAD EU relapse prevention study,
"7121",G+5FU+LV vs. G+5FU+LV+CDDP in Pancreas,
B9E-MC-JHCK,COMPASS. USE OF GEMCITABINE FOR PTS WITH ADV. PANCREATIC CAN,
"7243",IIT placeholder for raloxifene,
ZYY-LC-PCAD,HIV methods study,
B9E-MC-JHEM,PH1 GEMCIT. PREOP. & POSTOPER. IN LOCAL. RESECT. PANCREA. CA,
"7396",Atomoxetine IIT Placeholders,
F1J-MC-HMCN,Treatment of pts previously treated with duloxetine,
"7448",Dulox in UI: Experience Study Second Level,
"7484",Phase 2 Iressa/Alimta in meso,
B4G-FP-O011,PERGOLIDEvsROPINIROLE: watchfullness § sleepiness assessment,
"7538",NL CTNR with pioglitazone,
"7698",vMRI study in Alzheimer Patients,
"7719",Xigris in Meningococcemia,
"7785",IIT - 2004 (6) - Cymbalta,
"7872",A naturalistic study of olz in bipolar disorder,
B5K-AG-S005,Treatment schemes for early insulin use in T2 diabetes,
F1D-BP-O210,Velotab in ICU: Does it decrease the use of IM agents?,
"7923",Phase I Renal Impairment Study,
"7945",Ph II - Affinitak Compassionate Use IND/US - NSCLC,
H5N-MC-GFFR, Antibody Follow up Study for Patients Participated in GFFH,
F1D-MC-X232,Effects of Olz vs Placebo on Ghrelin Plasma Levels & Eating,
B9F-MC-I020,INCRETIN EFFECT IN DIABETIC PKT PATIENTS,
B1Y-BX-8701,PROZAC-OPEN EVALUATION FOLLOWING LIEGE SCH. STAR MDD,
H8O-EW-GWAX,Exendin-4: Statin SS,
F1K-PU-EVCT,multiple organ disfunsion in patient with sepsis,
H6U-MC-A003,[11C] Doxepin and H1 Receptor Blockade by Olanzapine,
"9711",Ph III ALIMTA+Carbo vs Gem+Carbo or Taxol+Carbo - Ovarian,
"8233",Grana-Role of PKCß in PMA-medicated upregulation pf P-TEFb..,
"8235",Berkowitz-Association of LY333531 with retinal perfusion...,
"8245",ALIMTA in Gastric Cell Lines,
B9R-HL-GDDV,EFFECT OF HGH ON THE CLINICAL COURSE OF PRADER-WILLI SYNDROM,
H6Q-LC-JCAN,Relative Bio-Availability,
H8E-MC-KBAG,Phase IIa Dosing,
"8273",Fellowship Funding: Neuroprotective Effects of Prozac & Olz,
"8352",Endotoxin Induced Pulmonary Inflammatory Response,
"8359",Lilly Clinic: PK Comparison of Feed State vs. Fasted State,
H7T-EW-TAAK,CS-747: Ketaconazole study,
B4Z-MC-LYCN,clinical study in pts with oral liquid formulation,
"8430","Ph II, 1st Line, ALILMTA + Oxaliplatin in H&N Cancer",
F1D-US-X241,Retrospective Antipsychotc Agents in the Developmentally dis,
B9R-SB-V001,Placental markers with relevance for IUGR,
B9E-US-X410,Rand. Ph III Carbo/Gem vs Gem single agent adv NSCLC,
"8565","5-HT2c  Phase 2B (Obese w/ Co-morbidities)",
F1J-CA-B002,"Community Psych study, depression-free days (DFD)",
F1J-BI-HMDJ,Major Depressive Disorder (MDD),
H9I-EW-S001,FD2 MeNER Human Radiation Dosimetry Study,
"8614",FD2 MeNER: Human Dosimetry Test/Retest,
"8668",Rat Sleep EEG Study for M1 Agonist,
"8758",Ph II- GDP- good perform pts not eliga autologous - Lymphoma,
H6O-LC-GCAQ,OpRA  Pilot Biomarker Study,
"8893",Placeholder with PKC (Spanish local support),
"8900",Comparison to Seroquel in Bipolar Disorder,
"8974",CS-747: switching,
H7T-EW-TAAY,CS-747: Def BE (Ph 3 v comm),
B4Z-US-X010,Atomox vs Placebo for Cognitive Effects in Childhood Cancers,
H6D-MC-O001,Treatment of ED after Radiotherapy for Prostate Cancer,
B9U-US-AZDD,LORABID IN ACUTE OTITIS MEDIA: 10 DAY VS. 5-DAY THERAPY,
B9U-US-AZDE,LORABID IN ACUTE OTITIS MEDIA: 10 DAY VS. 5-DAY THERAPY,
"9078",Treatment for symptomatic peripheral neuropathy in diabetes,
H6D-XM-B005,ED Observational in Non-Urologic Setting,
H6D-MC-LVGA,Daily Dosing 1-year Open Label Safety Study,
H3E-MC-V027,Alimta & Gem evaluation of TK inhibitors on Lung and Breast,
B9E-MC-V348,Test Crystallization of Gemcitabine,
B9E-OE-O413,"Gem/Cis in correlation to p53 genotype, NSCLC",
B3D-US-I002,Impact of PTH on osseous regeneration in the oral cavity,
B7A-SB-O006,Regulation of Protein Kinase C beta by hyperglycemia in huma,
H3E-US-X003,Ph 1 biweekly Alimta combo Taxotere in adv solid tumor pts,
H6R-MC-LSAC,"Single and divided oral dose: Safety, tolerability, and PK",
H3E-US-S056,Phase II Alimta+Carboplatin+RT in Esophageal Cancer,
"9429",IIT Bucket for 2005 - Local Support,
H3E-US-S061,Ph II Alimta+Gemzar q 14d vs Alimta+Gemzar q 21d in NSCLC,
H3E-US-S063,Phase II Alimta + Doxil,
"9442",LY2059346 Proof-of-Concept for Depression,
B9E-US-X432,Gem & R115777 Combo Therapy for Metastatic Breast CA,
B9E-US-X433,Ph II pilot of bortezomib & Gem for pts. w/ Hodgkin Lymphoma,
F1D-JE-P100,"LY170053 SINGLE DOSE, DOSE-RANGING IN HEALTHY VOLUNTEERS",
"9490","300/600mg Clopidogrel vs. 60mg CS747 Loading Dose in PCI Pat",
F1K-US-A012,Mod. of HepaticEndothelial Dys. By APC after Trauma & Sepsis,
F1D-US-I040,Control of body weight and improved cognition in olanz treat,
H6Q-MC-V022,Enz and trastuzimab breast cancer,
H3E-MC-S106,Ph 2 Adjuvant NSCLC,
"9724",Place Holder IIT-In vitro B9E-FP-O284,
F1D-MC-A005,ATYPICAL PROPERTIES OF OLANZAPINE IN RATS,
"9767",Definitive BE Biopharm Study,
H6D-AU-X003,Preference for Tadalafil or Sildenafil - Partner Perspective,
H3E-US-X021,Neoadjuvant Chemo with Cisplatin and Alimta in NSCLC,
F1D-SB-O270,Olanzapine in treatment-resistant anorexia nervosa,
"9789","Placeholder for H3E-SB-JMFT, -S020 and -S041",
"9791",BE (Ph3 v Comm) II (placeholder),
H3E-MC-JMHM,Ph I ALIMTA +/- NSAID solid tumors-PK eff. long-acting NSAID,
B9E-MC-JHST,"R Ph II, Gemzar + Taxol in Breast Cancer (China)",
"9822",Ph II ALIMTA in 2nd line metastatic TCC,
F1D-MC-HGAR,OLANZ:  PET STUDY OF 5-HT2 & D2 DOPAMINE RECEPTOR OCCUPANCY,
"9844",GEMCITABINE COMBINATION IN NHL,
H3E-US-X029,Ph I/II Alimta given w/ Ressa in pts. w/ NSCLC,
F1D-SB-O274,Potency to improve facial expression of emotion of schizo,
H6O-FW-GCAV,Beta-cell mass method in Type 2 Diabetics,
B9R-US-X043,GH and GnRHa Adolesc. Patients with Acquired Hypothyroidism,
B4Z-MC-X039,Functional & Pharmclgic MRI of Atomox and Placebo in ADHD,
H6Q-MC-A009,Enzastaurin and irradiation for glioma xenografts,
H6Q-MC-V006,Multiple Myeloma cell lines,
"10365",Gnegy-PKC Amphetamine-med dopamine releas,
H7T-MC-TABE,HRVD,
B1Y-CA-P004,FLUOXETINE/AMITRIPTYLINE MAJOR DEPRES. DISORDER,
F1D-MC-X005,OLANZAPINE VS CLOZAPINE OUTCOMES ANALYSIS LONG-TERM TREATMEN,
B4Z-MC-A005,Study of time-dependent behavioral effects of a,
H3E-BX-O014,A Randomized multicenter phase II trial of pem and Cisplatin,
H7U-JE-IDBG,JP Pulmonary insulin Extension,
"10558",Pulmonary hGH: Phase III Pediatric Turner/SHOX,
B1Y-CA-P006,FLUOXETINE: COMPASSIONATE USE IN BULIMIA NERVOSA,
B9E-MC-V299, Potentiation of activity of gem by HKH40A,
F1K-BP-A017,APC on experimental acute pancreatitis,
H3E-MC-V084,Pem and oxal interaction in bladder ca cells:drug activity,
H3E-MC-JMIA,RPh2 Alimta w/AUC dosing in solid tumor pts,
H6Q-MC-S026,Ph II ENZ for pts headed to resection GBM (NCI),
H8O-CR-GWBH,Exenatide at Lunch/Dinner Compared with Breakfast/Dinner,
B9E-MC-V307,Combination of Gemzar + Adenoviral Gene Therapy,
B9E-MC-V313,Gemzar and dFdU detection in bio fluids by HPLC-ESI-MS/MS,
B9E-MC-V324,Effects of Gemzar on human pancreatic cancer cells,
H3E-MC-V098,Effect of ALIMTA on Cell Lines,
H3E-MC-V101,MTA + chemotherapeutic drugs in human gastric tumor cells,
F1D-CA-O291,Outcome of Bipolar Disorder in Community Treated Sample,
"10919","Ph2 Alimta/Plat with Tarceva, 2nd Line non-smoker",
"10922",Ph2 randomized Gem/Cis vs Gem/Carbo 1st Line NSCLC,
F3Z-MC-IOOX,Mix 50 BID vs Glargine Once Daily in Type 2 Diabetes,
F1D-VI-HGFK,OLANZAPINE IN SCHIZOPHRENIC PATIENTS IN LITHUANIA,
F1D-IT-B029,H. E.  study on  psycothic pts. in an Italian SERT,
F1D-IT-B030,H.E. evaluation of switch from  Typical to Atypical AP,
H4S-CA-O069,ExNCR - Structure and Function of Hantavirus Glycoproteins,
B9E-MC-V341,Effect of Gemcitabine on Pynpase Activity Urinary Bladber,
B9R-US-X045,Estrogen Replacement in Girls with Turner Syndrome: Pilot,
H6U-MC-LRAJ,CNS Protein Production & Clearance Rates--Isotope Labeling,
I1L-MC-S001, Drug/Drug interaction SAM Classic/Sibutramine combo,
B5K-IT-O452,ExNCR,
H3E-EW-B002,SELECTTION: Choice of Treatments in observed NSCLC,
I1R-MC-GLBH,Glucagon-R C14 study,
H3E-US-X062,PhII Alimta & Carboplatin in Esophageal Cancer,
H3E-US-X063,PhII Alimta + Gemzar for Metastatic Head & Neck Cancer,
B9E-US-X458,PhI Gemcitabine & Bevacizumab in Pancreatic Cancer,
F1D-US-X296,LONG EFX of APS on HC Shape & Volume in 1st EP. Psychosis,
"11204",AKT Inhibitor Phase I trial in Cancer Patients,
F1J-LC-HMAJ,DULOXETINE-TEMAZEPAM DRUG INTERACTION STUDY,
H9X-MC-GBDC,GBDC - Monotherapy (Fc or placebo + Met),
H6Q-MC-S034,RPh II Alimta+carbo+Avastin+/-ENZ in NSCLC,
F1K-LC-GUAC,LY203638: DOSE-RANGING STUDY-6 AND 24 HOUR INFUSIONS,
H6L-MC-LFBD,JP Abeta lowering P-II Asian study,
H6Q-MC-S058,Ph II targeted pop based on potential molecular biomarker,
F1J-MC-B020,Fibromyalgia polypharmacy and resource utilization,
B9E-IT-V354,Characterization of new mechanisms of resitance to Gemcitabi,
I1U-MC-S001,LY333334 effect on bone biomarkers in postmenopausal women,
H8O-EW-GWCC,Byetta: Very Elderly PK,
F3Z-US-IOPB,ILPS vs glargine added to exenatide in type 2 diabetes,
F1J-MC-HMFN,Duloxetine pediatric depression (pharmacokinetic trial),
H6D-MC-LVHR,Efficacy in BPH/ED Co-morbid population,
H3E-CR-S119,Alimta/Cis vs Vinorelbine/Cis as adjuvant therapy in NSCLC,
H6D-MC-X007,Tadalafil for the Treatment of Seconday Reynaud's Phenomenon,
I2D-FW-GIBB,MDSS for healthy subjects,
B7A-LL-A011,Impact of PKC-b on glomerular and tubular function,
I1M-BD-PEAB,MDSS,
H3E-FR-O036,IIT-Alimta mésotheliome H3E-FR-O036,
H8O-MC-GWCG,EU BID TZD,
I1C-MC-JLBF,Ph 1 LY2334737 + Radiotherapy,
H7T-MC-B004,ALKKA Registry (Critical Care Europe),
H7T-MC-X003,German STEMI Registry ( IIT),
F1J-MC-HMFV,"Receptor Occupancy of Duloxetine Using FD2MeNER ""Pet Study""",
H9P-JE-LNBG,JP NERI-IV PhI SDSS/MDSS,
F1D-MC-V020,Prediction of in-vivo Anticholinergic Activity by in-vitro,
B9R-XC-O050,Cardiovascular risk biomarkers in obese children,
F1D-CA-O313,Prevention of Postpartum Mood Episodes in Bipolar II Women,
H8O-PH-B006,Byetta Post Marketing Surveillance Study,
H6E-AY-O015,Risks & benefits of Actos in pts with abdo aortic aneurysms,
I2R-MC-BIAM,T2DM 6mo Basal Bolus v. Glargine ,
F1D-CY-O315,ITAREPS: IT Aided Relapse Prevention Validation Study,
H8O-EW-GWCQ,"LAR Dose Ranging: 3 arm, 40 pts/arm, PBO, 2mg, 3 mg",
F3Z-MC-IOPV,Humalog 6 days vs. Aspart 6 days in Pump use,
H6D-JE-B012,JP Cialis PMS ED,
F3Z-ME-IOCO,LISPRO VS HUMULIN R IN ADOLESCENTS W/TYPE I DIABETES,
"12262",PH2 OBESITY FOR GLP-PEG 80 kDA,
H6O-MC-S001,PET dosimetry/kinetics of [18F]FMPEP-d2,
"12357",R-Ph III-Tasi+/-Temozolomide-1st line-Malignant Melanoma,
F1D-US-X310,Improving Awareness cognitive dysfunction in schizophrenia,
F3Z-VI-GVAG,SAFETY ¢ EFFICACY OF HUMALOG VER.REGULAR IN PATIENTS FASTING,
H3E-FR-O041,IIT-Alimta  meta cérébrale,
"12460",placeholder PRA retailed prescription,
"12467",Placeholder PRA dose distribution in hospitals,
I1L-MC-GAEC,SAM treadmill PD study,
H7I-MC-S007,PET dosimetry/kinetics for Kappa OpRA,
"12688",PH II-GemPro-2nd Line - T-cell Lymphoma,
H8R-MC-HJAP,LY686017 ethanol interaction study,
ZYY-BP-O004,United Kingdom Asian Diabetes Study (UKADS),
"12752",Radicular Pain Pbo Controlled #2,
H6D-JE-LVIA,Phase 2 Japan Tadalafil BPH Dose Finding Study,
I2K-MC-ZZBL,Hepatic,
I2K-MC-ZZCB,PET 5HT2a study,
I2K-MC-ZZCD,Digoxin,
I2Q-MC-GMAK,C14 study for LY2599506,
H3E-SB-O047,NSCLC Bevacizumab in combi with pem or pem+carbo,
H7T-EW-TADP,Relative Bio Availability w/Extemporaneous Formulation,
H3E-KL-O049,Alimta IIT (Alimta + Cisplatin in Advanced Urothelial Ca) ,
"13079",Placeholder (ITAREPS like study for France),
H3E-MC-JMAQ,PH I TRIAL LY231514 & GEMCITABINE Q21 DAYS/LOCAL/ADVANCED/CA,
H6D-EW-LVIJ,Once daily tadalafil vs sildenafil in ED treatment naive pts,
"13088",Use of Memoir pen in young patients,
H8O-FR-B013,observational study in diabetes T2 pat initiating byetta tt,
I3Z-MC-GPDA,GPR119 SAD (Phase 1),
"13123",Direct Costs of 3 basal insulin analogues DM2 real practice,
H7T-US-TADU,Chart review to further assess CABG data from TRITON,
H8O-MC-A021,Insulin secretion and B-cell mass in Baboons,
"13177",Glucose metabolism in brain and heart,
"13234",IIT Placeholder for Strattera Studies,
H3Q-EW-LHHC,LY297802 SAFETY AND PHARMACOKINETICS IN ELDERLY VOLUNTEERS,
H3R-LC-ERRA,"LY293558: DOSE-RANGING, SAFETY AND PRELIMINARY PHARMACOKINET",
H8Y-MC-HBCO,POC Add-On ,
I3E-BM-MSAJ,Compassionate Use CPMS,
H6N-MC-LEAS,A Placebo controlled study of the Electrophysiological,
H6N-MC-LEAW,Warfarin Interaction,
H7T-EW-TAEA,BE Study without PPI:  30 mg immediate release tablets,
I2Y-EW-GHFI,Dose Proportionality ,
I2Y-EW-GHFJ,Special Population (Race) – Pop PK ,
H3S-LC-GGHK,RALOXIFENE HCL: 60MG BIOEQUIVALENCE STUDY,
"13474",Non-union Sites Study 1,
"13501",Patients with Recurrent or Metastatic Nasopharyngeal Cancer,
B7A-MC-V008,Maccrophage signaling mechanisms that induce A,
H3S-MC-GGGG,RALOXIFENE VS PLACEBO IN PREVENTION OF OSTEOPOROSIS,
H3E-EW-JMIQ,Alimta Cis Erbitux > Cis + XRT in Loc Adv SCCHN,
F1J-MC-HMGV,China DPNP Second Registration Study,
"13652",iGluR5 Hepatic Impaired Population,
"13688",Methods study to collect samples for hedgehog biomarker,
I4O-MC-BACA,SAD (FHD) BACE Inhibitor II,
H6Q-MC-A033,Pre Clinical - Pancreatic human tumor cells and xenograft,
I1F-MC-RHAQ,Safety and Efficacy in patients with Palmoplantor Psoriasis ,
H3Z-BP-JNAD,LY295501 - A CLINICAL + PHARMACOKINETIC EVALUATION,
I4Y-IE-JCDA,CP14-0501: Ph1 - 18F1 - Adv Solid Tumors - 2nd Line,
I4Y-IE-JCDC,CP20-0902: Ph2 - 18F1 - mUrinary Tract - 2nd Line,
I2Y-MC-GHFS,China International Multicenter Clinical Trial (IMCT),
I5A-MC-JAEM,CP13-0915:R-PhII-A12+Alim+Cis vs Alim+Cis-NonSq-NSCLC-1st Ln,
I1F-MC-RHBI,Phase 3 RA for China,
"14012",B'pharm DDI Lorazepam OR Temazepam,
"14144",R-Ph III-Capecitabine+/-18F1 - Breast,
I2V-MC-CXAC,Phase 2 Study of LY2510924 in small cell lung cancer,
I5E-MC-TSAP,Phase I antisp./deod. appln. impact on PK of testosterone,
I5W-EW-LBCA,SAD Study,
I2R-MC-BIDE,Missed dose Trial,
I5A-IE-X013,"8199: Ph II - A12+Mitotane vs Mitotane",
I5A-IE-X024,S0925:PhII-A12+Androgen Depriva vs Androgen Depriva-Prostate,
I3P-MC-GKBM,TQT,
B4Z-JE-LYEP,Taste testing study of child friendly formulation in Japan,
I1V-MC-EIBJ,Lipid Supporting Study 4,
H3E-US-JMIU,Ph II - Alimta + Cis + XRT --> Alimta - Locally Adv NonSq ,
I1R-MC-GLDL,Single Dose Pilot PK Study,
H4S-BD-EEAC,REOPRO IN PATIENTS UNDERGOING HIGH RISK CORONARY ANGIOPLASTY,
I4T-JE-JVCJ,JP - Ph Ib-Ramucirumab - NSCLC - 1st line,
I6B-MC-HZBB,Single Dose PET Study for LY3006072,
I6E-AV-AVBB,Japan Ph2/3,
"14756", Microvascular and Macrovasular Outcomes in Type 2 diabetesd,
I6L-AV-_B04,A ph II/III AV 133 PET to identify subjects with ,
I5J-MC-NOAD,Phase 2a Signal Detection trial for ADD,
H7T-MC-TAER,Paediatric Cardiac Conditions Requiring Long Term Antiplate,
I6M-JE-SSAA,Japan Phase 1 Study,
"14843",Phase 2 Dose Finding Study,
H9H-MC-A006,Pilot experiment using Alk5 inhibitor L Y2109761,
H6D-EW-LVGT,Cialis Alpha Blocker Interaction Study with Doxazosin,
H6D-IT-V014,Tadalafil relaxes human urinary bladder through H2S in vitro,
I3Y-MC-A001,ADPKD - Lilly CDK4/6 inh Collab with the PKD Fdn.,
"10069",aPC as protective strategy against ischemia/reperfusion pigs,
I1D-MC-JIAR,Definitive Bioequivalence in NHV,
H8L-MC-IQBG,Summative Human Factors (usability validation) Study for Hum,
"10098",Methods Study,
B3D-US-B020,"2013-197 Japan Adherence stdy for Forteo 2yrs follw-up presc",
H3E-SZ-O006,Neoadjuvant chemotherapy in MPM,
"14987",Mix 50/50 Humalog,
B9E-MC-V257,Role of Nucleoside  Transporters,
H8L-MC-IQBM,KwikPen HD Summative Human Factors Study,
B9E-BX-O461,Novel approach: escalating RT concomitant to chemotherapy,
H9P-MC-LNEI,POC edivoxetine for monotherapy treatment of PTSD,
F1D-MC-HGEF,EFFECTS OF OLANZAPINE ON COGNITIVE FUNCTION AND RCBF,
B4Z-MC-B024,Physician Survey to Assess Effectiveness of Strattera DHCPL,
F1D-UT-O281,Geestkracht Studie,
H6Q-MC-A025,Studies to evaluate dosing regimen of enzastaurin,
F1D-MC-HGFV,OLAN VS PLACEBO FOR TMT-ASSOC. PSYCHOSIS IN PTS W/PARKINSON,
F1D-MC-A129,GABA Receptor Modulation by Flavonoids,
B9E-MC-V274,Gemcitabine /dFdU:Plasma levels validated analytical assay,
H3S-MC-X032,Sex Hormones and their Correlation to the Gail Risk Model f,
B9E-MC-V295,"Regional PK of Gem in Canine: Liver, Gastor, Lung",
H6Q-US-S002,Ph II Randomized Trial - Gemzar+/-Enza in Adv Pancreatic CA,
H3E-MC-V082, Non-Small Cell Lung Cancer Therapy Alimta and Erbitux,
H6Q-MC-S018,R-Ph II - 2nd Exposure - CPT-11/Erbitux +/- ENZ  - CRC,
B9E-US-I155,"PhII Study of Oxaliplatin, Gem & Bevacizumab for Carcinoma",
H6Q-MC-S020,Ph II Whole Brain XRT Therapy vs. Therapy + Main.-Brain Met.,
B9E-MC-V319,hENT1 Gene Expression + Gemzar Sensitivity in Lung Cancer,
H3E-EW-S098,Alimta Carbo vs. Gem Vinorelbine in advanced BC,
I1P-MC-JJAA,FHD trial for compound LY2401401 (AML),
H3E-MC-V111,BCRP-mediated Transport of Pemetrexed,
H9T-MC-NAHJ,Biopharm Neurohormone,
I4E-IE-W935,CA225-314:Ph II-Cetuximab+Cisplatin w/IMRT- SCCHN,
I8D-MC-AZEE,DDI Dabigatran,
I8D-MC-AZEF,DDI Donepazil,
B3D-MC-B027,"2014-110 Comparative effectiveness of Forteo vs Prolia",
I8D-MC-AZET,Phase 3 mild dementia of Alzheimer's type,
B1Y-MC-LWAB,Long-term exposure (initial ID of B1Y-MC-LWAB),
I6I-MC-LMRI,Exploratory study on HFF at 12 weeks,
I1F-EW-RHBZ,PS Ph3b - Ixe vs Fumaderm vs MTX 24 weeks,
F1J-MC-B056,Retro Obs Study for GPS,
I4E-US-B001,CA225-503 Single institute exp w/Cetuximab in SCCHN Retrospe,
"1630",LY333013-LC-xxxA Single Dose (oral compound),
I3Y-MC-JPCH,Ph II - Abemaciclib - Gastric/GEJ - Her2+,
I8O-MC-SBDE,"LY3323795 - SAD, DDI",
"16389",Renal Impairment in HV,
B1Y-IT-0002,FLUOXETINE VS CLOMIPRAMINE IN MDD,
I6T-MC-AMAL,IL-23 Ab PK/tolerability study utilizing extemp. prep.,
B9E-MC-V346,Regulation of de novo ceramide generation by gemcitabine,
"11013",Placeholder Study for Enzastaurin DDI with ketoconazole,
H3S-US-X033,Raloxifene in Women with AD: Randomized Controlled Trial,
F1J-JE-103G,BIOEQUIVALENCY STUDY:  S10 VS L10,
H3E-EW-S107,Phase I/II study of cisplatin-pemetrexed and RT in SCLC,
F1D-US-X297,A Comparison of the Effects of Modafil on Olanzapine Associa,
F1D-US-X294,Improving Management of Cardiovascular Disease and Metabolic,
H8O-MC-GWBP,"Effect of Exenatide on Weight in Non-DM IGT, IFG, NGT (POC)",
B9E-US-I160,"PhII Gem, Vinorelbine & Doxorubicin for Hodgkin Lymphoma",
H3E-BL-O027,Phase III Alimta versus the combination of Alimta and Carbo.,
"11345",Randomized Phase II/III Pancreatic Cancer,
H9B-MC-BCDM,"Structure: 6 mo S&Sx, 1 & 2 yr structure",
"11361",Phase IIb Alcohol Dependence Dose Ranging Efficacy,
F1J-MC-SAAL,DULOX V. PLACEBO/OXYBUTYNIN IN URINARY URGENCY/FREQUENCY,
F1J-IT-O022,Evaluation on Duloxetine effects on BDNF,
B9E-FR-O489,IIT-PHASE II TRIAL-GEM/PACLITAXEL IN META BREATH CANCER,
H6D-MC-V006,The endothelium in health and disease: vascular homeostasis,
I5S-MC-EFJT,Open Label Extension for Ph3 studies,
I8F-MC-GPGE,Formulation PK Study,
I8Z-MC-APCB,Artificial Pancreas Feasibility Study,
I6T-MC-AMBH,Ulcerative Colitis Peds PK E-R (Phase II),
H9X-MC-GBGL,Dulaglutide,
I7E-AV-E085,AV-1451-EXIST-085,
B9E-MC-X014,"PHASE 2 STUDY OF GEMCITABINE, CISPLATIN, AND DEXAMETHASONE",
J1A-MC-KDAB,SAD,
I1F-US-I004,"A pilot study of a single, easily measurable outcome for PsO",
F1D-MC-O002,comp. on ganglia size & cerebral blood flow using MRI,
H5M-SB-EIID,Xipamide i.v. infusion vs xipamide oral,
I3Y-MC-JPCR,Abema Tissue Collection - Biomarker in Breast Cancer,
F1D-MC-HGGW,"Olanzapine vs Placebo in Bipolar I Disorder, Manic or Mixed",
H7T-MC-V010,In Vitro Cone and Platelet Device,
H7T-EW-TACJ,End-Stage Renal Disease,
F2F-LC-HNAB,LY228729 HIPPURATE:  ORAL MULTIPLE-DOSE STUDY,
H9X-MC-GBCV,D/D Interaction-Antidepressant,
H9X-MC-GBCQ,D/D Interaction-Oral Contraceptives,
"11581",Placeholder IITs  Insulins,
B1Y-EW-E066,FLUOXETINE VS PLACEBO TO TREAT BULIMIA,
F1D-US-HGMU,Zydis Vs Oral Olanzapine in weight and metabolic changes,
"11693",Pharmacogenetic and pharmacokinetic study with gemcitabine,
H6O-FW-GCEE,Method study on optimum rate of glucagon infusion,
H8O-MC-X004,Retro rev of exen use in routine clinical practice,
F3Z-XM-O068,Analyses of the Diabetic Mellitus Type MODY characteristics,
H8O-IT-GWCF,Compassionate Use of Byetta in Italy,
H8Y-EW-HBBW,C-14 Study,
B5K-AY-A001,Type 1 DM in baboons:Effect of Inhibiting glycation,
H8A-MC-LZAO,LY2062430 Extension of Phase III Trials,
H8O-EW-GWCI,QT BID,
H7T-MC-B003,Registry to assess thrombotic risk w/DES,
B3N-MC-GRRG,Efficacy of Moxonidine SR in the treatment of type 2 DM,
I3Y-MC-JPCV,Ph II - ABema vs SOC - MCL,
I7E-AV-E083,"18F-AV-1451-EXIST-083",
I7E-AV-E103,AV-1451-EXIST-070,
F3Z-MC-GZKC,Tango Peds Late Feasibility,
F3Z-MC-IORP,Tango T2 Late Phase Feasibility,
"17589",Ph IV-PMSS-Ram+Paclitaxel-Adv Gastric or GEJ Adenocarinoma,
H0P-MC-BP03,Intervention Specific Appendix - CLBP,
I4E-MC-B004,Ph IV-PMS-Cetuximab-NI Obs CRC,
H8L-MC-IQDF,Exploratory:Study the Wear-Ability of Various Test Articles,
J2G-OX-Y071,RET Inhibitor-NSCLC,
J2G-OX-Y078,RET Inhibitor-NSCLC,
J2G-OX-Y148,RET Inhibitor-NSCLC,
J2G-OX-Y156,RET Inhibitor-NSCLC,
I4V-MC-B029,BARI RA Observational Retrospective Chart Review Study,
J2G-OX-Y167,RET Inhibitor,
J2T-DM-KGAX,Prev. Of Allergen-Induced Airway Obs. In Pts w/ Mild Asthma,
H3E-MC-JMBV,Phase I MTA + Oxaliplatin,
H7T-FW-TACQ,Stand Alone Reg. study for Korea,
B9E-US-X466,Ph II Study of Gem + Cape + Bev in Sarcomatoid Renal Cell,
I2K-MC-ZZAB,Relative Bioavailability Study #1,
B9R-US-V004,Rational design of ligand-mediated protein delivery systems,
H4Z-MC-GJAV,Phase II Arzoxifene Bridging Study for Korea,
I1N-MC-CDBB,"Single dose, safety, tolerability and efficacy (PoC)",
H8K-MC-JZAL,Phase 2 Eval of LY573636 in patients w/breast cancer,
H8A-MC-LZAU,Formulation Support Study ,
H8Y-EW-HBBX,Urinary pH,
F3Z-SB-IOEO,HYPOGLYC.COUNTERREGUL.AFTER LISPROTHERAPY WITH TYP1 DIAB.PT.,
"12354",Obesity Biopharm study-placeholder for study 1,
"12379",Chronic Insomnia TBD,
H8O-BP-O005,Tubular disf in Diabetes on Erythroeoetin/ Mineral met GFR,
F1J-UT-O033, dulox +coll trm vs dulox alone trm pain and depr.,
H7T-EW-B006,APTOR II,
H9P-EW-LNBV,Biopharm SSRI Augmentation Study - Paxil std,
"18103",Rifampin DDI,
J2X-NS-I002,Pragmatic Study of Anti-COVID-19 mAb (LY3819253),
H7I-MC-S024,Use of a digital health sol to improve migraine care IU,
I3Y-MC-B012,"2019-9051: Danish National BC Registry: RWE BC Outcomes",
"18305",Restore RI Uptake by Selp in RI Refrac RET Pap Thyroid Cance,
F1D-MC-HGGA,"OLANZAPINE, FLUOXETINE VS. PLACEBO IN MDD WITH PSYCHOSIS",
"18424",LOXO-BCL-22002-Ph1-BCL2-Pilot FE w/ possible PPI,
J3U-MC-EZGA,FHD study patients with high triglycerides,
J2N-OX-B006,"2020-9695: MCL:JP/EU M5-Treatmeant Patterns ",
B1Y-IT-E046,FLUOXETINE V CLOMIPRAMINE DBL BLIND MAJOR DEPRES,
"18512",Investigate the safety/tolerability of GGG versus PBO,
B1Y-IT-E061,FLUOXETINE/CLOMIPRAMINE DBL MAJOR DEPRESSIVE DISORDER,
"18601",Small intestine transit time,
"18680",Loxo-FG3-23003-Ph1-FGFR3-ADME,
B9E-MC-S042,Ph III S->5FU->5FU/XRT->5FU vs S->G->5FU/XRT-G,
"2012",Pilot Evaluation of SR Forms,
B9E-MC-S055,Gem + Vindesine + Carbo in SCLC,
H9P-EW-LNCE,Biopharm CYP1A2 DDI - Theophylline as substrate,
H2G-LC-BZAD,LY213829 ORAL DOSE ESCALATION STUDY.  PHARMACOKINETICS AND,
H9P-EW-LNBZ,Biopharm SSRI Augmentation Study -Celexa (citalopram),
H9X-JE-GBCL,JP GLP-1 Analog IV-FC-MDSS,
H8Y-MC-HBCI,China IMCT trial,
H9D-EW-ITAF,PK/PD Device needle length/Obesity study,
H7T-MC-TADK,PPI,
B9E-CA-O509,Genzar and Clofarabine in Solid Tumours and Lymphoma,
"12995",OpRa II Thorough QTC Study,
H7T-EW-TADQ,Relative Bio Availability w/Pediatric Commercial Formulation,
H8O-EW-GWDL,"""D3"" Once weekly exenatide vs detemir ",
F1J-US-X052,Impact of Cymbalta on Pain in Perioperative Spine Patients,
I4B-FW-GPCA,SADS (Single Ascending Dose Study),
"13176",Metabolic Fingerprint Study,
H8O-MC-X019,Effects of Exen on Thermogenesis and Weight Loss ,
B4Z-LC-HFBJ,Single /Multiple Dose Escalation  in Adults of Known CYP2D6,
F3Z-US-X005,EFFECT OF POSTPRANDIAL HYPERGLYCEMIA ON ALPHA-DICARBONYLS,
H5P-MC-BWWF,PHASE III S/S rheumatoid arthritis North America,
H3Z-MC-JNAW,Phase-I combination study with LY295501 + carboplatinum,
H3E-MC-JMCD,"ALIMTA + Gemcitabine in 1st line NSCLC, PH II",
B3D-MC-GHBH,Hip Imaging LY333334 on hip strength -post menopausal women,
"2313",LOW DOSE ZYPREXA IN GENERALIZED ANXIETY DISORDER,
B4G-MC-X002,Menstrual Migraine (S6),
H4H-UT-LGAJ,INTEGRATED PHARMACOKIN/DYNAMIC EVALUATION OF LY300164,
B9E-MC-S091,Gem+Dox post Taxanes / Breast,
B9E-MC-S094,Gem+Tax post anthra / Breast,
B1Y-MC-HCCX,FLUOXETINE VS. PLACEBO FIXED DOSE IN OBESITY,
B9R-MC-X012,Effects of provocative GH testing on linear growth,
B9R-MC-X011,Growth Failure in the CHARGE Association,
"2574","Geriatric Replacement, Ph 2",
"2608",Telemetry in ischemic heart disease,
B4Z-MC-LYAG,Variable discontinuation study #1,
F1D-US-X106,Olz for Psychosis in pts. with Neuroleptic Induced Akathesia,
F1D-US-X142,Effects of Olz. and Risperidone on Smoking Behavior,
B1Y-EW-8888,FLUOXETINE VS CITALOPRAM,
H8O-MC-X025,Effects of Exenatide on Brain Glucose Uptake,
I2M-JE-GSDC,JP SOST Ph1,
"13309",Dedicated Ambulatory Blood Pressure Study in Healthy Subj,
"13317",ADME Placeholder Study #2: Drug Interaction,
H3S-JE-104J,PHASE 1 CLINICAL STUDY OF RALOXIFENE HCL(PK STUDY),
I4K-MC-GPEA,SARM 1 (LY2452473) RBA Study,
H7T-MC-A001,Japanese Pig Stent Study ,
"13375",Ph2-OA pain,
"13385",Type 2 Diabetes,
H4Z-MC-GJBE,Alendronate to Arzoxifene Sequential Trial,
I2R-JE-BIAQ,JP BIL PhIII T2DM,
H6D-MC-LVIN,Peyronie's Disease #1,
F3Z-SO-O076,Memoir vs Luxura in Adolescent T1DM Patients,
H7T-CR-TAEH,platelet inhibition afterRELOADing with Prasugrel And clopid,
B4Z-CA-O030,Retrospective Chart Rev-Impact of NRI on Memory & Cognitive ,
H9P-MC-LNDV,ADHD pediatric ADHD study in patients ages 4 - <6 yrs,
"11188",DPP IV Phase 2 efficacy study,
F1D-JE-CS06,JP_ZYP_Acute_PMS_NSOS,
I4G-MC-ABDC,T2DM non - inferiority,
I1F-MC-RHAX,Ph 3 OLE trial,
"13720",Cis/Pem/Cetux f/b Pem/Cetux vs Pem/Cetux in 1st line NSCLC,
I4O-MC-BACD,BACE Inhibitor II 14C study,
H8O-EW-GWDP,Revised Exenatide Gall Bladder Study,
H6Q-GE-V058,Pre Clinical - Akt activity in human breast cancer cells,
H6Q-MC-V062,Pre Clinical- Chronic Lymphocytic Leukemia B cells,
H6Q-MC-A040,Pre Clinical - Encephalomyelitis and animal model of MS,
H6Q-MC-V067,Pre Clinical - Adult T-Cell Leukemia/Lymphoma,
H8O-EW-GWDR,PK Confirmatory,
I1Y-MC-JFBG,Eg5 Inhibitor C14,
"13826",DDI Study for LY2899623,
H7N-EW-ECBC,NDIS - Sickle Cell Patients,
I4T-IE-JVBC,ROSE_CP12-0606:R-Ph3-1121B+DocetxVsPlcbo+Docetx-Breast-1st L,
"13955",Japan Phase 1 Study,
"14018",B'pharm Activated Charcoal Study,
B9R-MC-GDFL,Humatrope in Pediatric Pts with Idiopathic Short Stature,
B1Y-MC-HCEF,FLUOX V PLAC: ANALGESIC EFFECT DIABET.NEUROPATHY,
B3N-EW-EUCU,Multiple dose pk of the final SR dosage form,
H4A-MC-XBAM,Oral vs TMP/SMX in PCP - seconday prophylaxis,
B1Y-BP-0003,FLUOXETINE OBESE PTS. PRIOR TO GASTROPLEXY,
"3117","Gemcitabine, Cisplatin, and Methotrexate in Bladder Cancer",
B9E-MC-S117,Phase 2 Gem + Taxol + Herceptin - 1st breast; JUN98SU65,
F3Z-MC-IOMJ,"Local reg. in Morocco, Algeria, Egypt, Saudi Arabia, Kuwait",
B1Y-MC-X002,FLUOXETINE ADJUNCTIVE THERAPY IN SCHIZOPHRENIA,
"3358",LY293558 for post operative Dental pain,
F1D-SE-9831,EFFICACY & SAFETY OF OLANZAPINE IN SCHIZOPHRENIA,
"3380",Animal Study - Ginsberg Exp. Head Trauma,
B1Y-MC-X017,FLUOXETINE IN SMOKING CESSATION AND MAJOR DEPRESSION,
F1D-MC-A031,Olanzapine and Dopamine/Serotonin Receptors in Rat Brain,
F1D-MC-X131,Treatment of Refractory Panic Disorder with Olanzapine,
B5Q-SI-O001,Nizatidine in Combination with Amox/Clari for H. pylori,
B9E-BP-O039,"Phase IB/II, Gemcitabine & RT, Cervical Cancer",
H6Q-MC-V074,Pre Clinical - B-Cell Lymphoma signaling ritux and enz,
H4A-MC-A003,LY303366 IN AN EXPERIMENTAL MODEL OF INVASIVE ASPERGILLOSIS,
H4A-MC-A005,LY303366--TREATMENT OF HISTOPLASMOSIS IN A MURINE MODEL,
F3Z-MC-IOQH,T2 pump study,
B9E-MC-V357,Pre Clinical - Gemcitabine ribonucleotide reductase R1,
H4G-EW-LIAB,LY303870 MULTIPLE ORAL DOSE SAFETY KINETICS & DYNAMICS,
I5E-MC-TSAG,"MTE07-A Phase II, randomized, four-way crossover study ",
"14338",FRD ph 3 SCLC,
H4G-MC-CBAC,LY303870 ANALGESIC EFFECT IN DIABETIC NEUROPATHY PAIN,
"14362",Proof of Concept MDD Monotherapy ,
I5A-IE-X010,"8131:  Ph I/II - A12+Doxorubicin - Soft Tissue Sarcoma",
B4G-MC-B002,Pergolide Usage Survey ,
I5A-IE-X015,ADVL0712: Ph I - A12 - Solid Tumors,
I4T-IE-JVCA,CP12-1032: Ph II - 1121B + Paclitaxel - Solid Tumors DDI,
I4T-IE-JVCB,CP12-1033: Ph II - 1121B + FOLFIRI - Solid Tumors DDI,
H4Q-FP-A005,LY333328 IN THE RABBIT ENDOCARDITIS MODEL,
B9E-MC-X155,Gemcitabine and Doxil in Recurrent Ovarian Cancer,
F1D-MC-HGIE,Fluox. & Olan. Combo Therapy: Dose Study,
B9E-MC-I106,Gemcitbine and Topotecan for Ovarian Cancer,
H5P-LC-BWXC,LY333013: Second Multiple Dose Study in healthy Subjects,
B9E-SB-O084,Gemcitabine and Docetaxel in Pancreatic Cancer,
B1Y-MC-X072,FLUOXETINE TREATMENT FOR INPATIENTS WITH ANOREXIA NERVOSA,
H4Q-JE-101N,glyP P-I single dose PK,
B9E-FP-O087,IIT- CISP/NAV/GEM/ IN NON RESECTABLE NSCLC,
B9E-XC-O092,PHASE II NEOADJUV TAXOL-ADRYAM-GEMC;FORTNIGHTLY;BREAST CANCE,
B1Y-MC-X200,Treatment of Childhood/Adolescent Autism,
B9E-MC-X119,Phase II Trial of Gemcitabine in Hodgkin's Disease,
A3H-MC-IAAM,SODIUM INSULIN:  COMPASSIONATE USE,
F1D-CA-O008,are schiz clin sympts & cog defts better corr by olanz vs ha,
H3E-MC-JMDV,Ph I/II - ALIMTA + Cyclo - Breast,
H3E-MC-JMEF,MTA + Gem neoadjuvant OUS,
H6E-VI-GLAF,ACTOS+insulin vs. SU + insulin,
B1Y-MC-X109,FLUOXETINE VS PLACEBO IN DEPERSONALIZATION DISORDER,
"10016",SDSS,
B4Z-MC-A004,Study Drug Only,
"10065",OpRA-III PET (SPECT) Study,
F1J-XM-B016,Observational study about residual symptoms,
B4Z-PL-B005,Local HO and cost study in patients with ADHD.,
B9E-MC-V250,T Cell assay for oral gem,
F1D-US-X278,Examination of the Association between Psychological and Fun,
F1D-US-X277,Recovery of Metabolic Function in First Episode Psychosis Fo,
B9E-MC-V242,Single-nucleotide polymorphisms of Cytidine Deaninase gene,
"10239",CV Safety Study,
"10271","Drug-Drug Interation Study,  CYP3A4",
F1K-US-V016,aPC Promotes Cell Migration in an Anti-infllam. Process,
"10282",-,
"10413",Place holder - IIT Pr Teboul,
H8Z-MC-JACS,PH I/II FED: LY2181308 Hepatocellular Carcinoma,
"10486",Placeholder for Strattera IIT's,
F3Z-SB-IOOW, Comparison of ICT with Bedtime NPL Insulin and Prandial Ins,
B9E-MC-V280,Analytical Research:  LRL Discovery Chemistry Res-Technologi,
H6D-MC-LVJI,Switching from Sildenafil to Tadalafil ,
I4M-MC-MRAH,Thorough QTc Study,
"14556",China local PK study,
"14591",RBA Fixed Dose PK Study w/Metformin,
H8O-JE-GWEG,JP EX suspension P3 combo,
I4T-CR-JVCI,CN - R-Ph III - Ramucirumab vs Sorafenib - HCC - 1st Line,
B4Z-XM-O035,Neural Functioning in ADHD,
H7T-MC-X017,Prasugrel Pre-Hospital Versus at the Time of Primary PCI in ,
I4V-GH-JAGR,China PK Study,
I5J-MC-NOAH,Human c14,
H4S-TW-EWAF,C7E3 FAB IN PATIENTS UNDERGOING HIGH RISK CORONARY ANGIOPLST,
H9D-MC-ITAH,T2DM clamp,
I6F-MC-V001,Effect of Notch inhibitors on patient-derived models of glio,
H7T-US-X018,Platelet Reactivity in Patients w/ Systolic Heart Failure,
H6O-XM-B004,Early Diagnosis of Abnormalities in CH Metabolism in Diabete,
H9B-MC-BCEG,Autoinjector Human Factors Summative Study,
I1Q-MC-JDDL,Phase 3 Trial to evaluate Myostatin Ab in Elderly Fallers,
F1K-MC-EVAT,Aquired PC deficiency with evidence of infection,
B9E-MC-V021,Influence of chemo on angiogenesis of endothelial cells,
"4195",RA PROBE STUDY,
H5Z-MC-LUAM,R-fluoxetine vs. Placebo and Venlafaxine in Treatment of GAD,
F1D-US-X164,Olz. in Treating Behavior Disturbances in Adolescents w/MR,
B9E-MC-V056,Gemcitabine andtemozolomide in human glioblastoma cells,
B1Y-SB-1015,FLUOX. VS. TRIMIPR. IN GERIATRIC DEPRESSED PATIENTS,
H6L-MC-LFAE,AD Bridging Study,
F1D-US-X170,An Open Lbl Study of Olz in the tx of beha lewy body dementi,
B1Y-SB-5009,FLUOXETINE40MG/NOMIFENSINE D.B. PAR. REACT.DEPR.,
H6D-MC-LVCO,Pivotal Study in Taiwan,
B9E-MC-S157,Ph III GET vs anthracycline -based therapy in breast cancer,
F3Z-SB-O028,Comparison of CT vs. ICT in patients with Type 2 diabetes,
F1D-PU-LOBB,Olanzapine in first psychotic epysode,
B1Y-CO-S007,treatment of premenstrual dysphoric disorder,
B1Y-BP-HC34,FLUOXETINE DEPRESSION WITH BIOLOGICAL MARKERS,
B9E-MC-S213,Ph II ALIMTA+Carbo->Cis+Gem->Taxol Consolidation in Ovarian,
"10629",Placeholder for local support Gemzar,
B9E-MC-V297,Gemcitabine resistance in gastrointestinal tumors,
B1Y-CA-P007,FLUOXETINE-COMPASSIONATE USE (OBSESSIVE COMPULSIVE DISORDER),
H6Q-MC-A016,Enz as a radiosensitizer,
H6D-US-LVHF,"Comparator - Efficacy of tadalafil, sildenafil, & vardenafil",
"10799",Placeholder...Abuse Liability Study,
F1J-US-HMEZ,"Gaba Non-Responder Switch to Dulox, Dulox Add on, or Pregab",
F1D-US-HGMO,Acute Study of Olanzapine in Mixed Bipolar Patients,
"10840",FHD trial for future cmpd FC000076,
B9E-MC-V332,Sensitivity to Gem centration changes of cellular (dCK),
F1D-VI-HGDQ,OLANZAPINE VERSUS CHLORPROMAZINE IN THE U.A.E.,
H3E-MC-V112,Evaluation therapy of meso for pem and anti-IGF,
H6Q-MC-A017,In vivo studies of enzastaurin in colon cancer model,
H6D-MC-LVHJ,Cialis Phase 3 BPH LUTS Study,
B9E-US-I157,PhI Study Gem in Bronchial Artery for NSCLC,
I1P-MC-JJAB,Phase I MAK (Solid Tumors),
H3E-SB-O021,pemetrexed in anthracycline/fosfamide-refract. pat.,
H8O-MC-A004,Exen as growth prom and anit-apop-IV/IV islet cells,
I4J-MC-A001,PTEN and PJ-3 kinase in the cancer stem cell com. of medullo,
H8L-MC-IQBN,BIV 80 KwikPen Formative #1,
B5K-US-V020,Qualification of ELISA assay specific for human insulin(bhi),
"15072",QTc Study,
"15077","Imaging DLB, PD, AD & Healthy Controls with FBP/AV133",
I5S-MC-EFJI,ASCVD/Diabetes,
I4D-MC-JTJC,Ph1b/II - Chk-1 Inhib II - relapsed AML,
"15123",Human C14,
F1J-MC-B052,Signal detection-SAEs in pts taking dulox and/or analgesics,
I3Y-MC-JPBG,CDK4/6 Dual Inh Food Effects in Healthy Subjects,
H6D-US-X013,PITCH 40 mg Tadalafil Adcirca,
H4Y-MC-LJAU,Moderate to severe - consistency of response - 4 migraines,
H8L-MC-IQCA,Auto-Injector Summative study for Ixekizumab and Tabalumab,
I4D-EW-JTJE,DDI study,
B9E-US-X460,PhII Gem+Oxaliplatin & Cetuximab/Gem/Oxa in Pancreatic Head,
I4W-FW-HMJD,SAD MAD CSF Ph I,
F1D-MC-HGMP,Japan Bipolar Depression,
B9E-MC-S216,"dFdCTP levels in tumor biops vs PMNCs, stand vs dose rate",
B1Y-SO-E067,FLUOXETINE CONTINUOUS THERAPY,
B1Y-BP-HC36,FLUOXETINE NEW ANTIDEPRESSANT IN PANIC STATES,
"4936",Monotherapy - HOE vs LY452504,
"4986",Multi-dose Safety Study (PK/PD),
B3N-VI-S001,Moxonidine in combination treatment of postmenopausal HTN,
"5036",Definitive Bioequivalence for Oral Liquid,
"5049",Japan FHD study,
F1D-MC-S013,Effect of Antipsychotic Therapy on Insulin Sensitivity,
B1Y-UT-0487,FLUOXETINE EFFECTS BODY WEIGHT & DIET COMPOSITION,
B3M-FW-AJBO,comparative PD study between cefaclor and augmentin,
H6E-MC-GLAQ,met+pio vs met + SU,
F1D-SB-O099,Potency of Olanzapine vs. Typical NL to improve facial expre,
B9E-MC-V102,Invest Gem pharmacokinetics in rat brain,
"5399",Affiliate Commercialization Trial,
"5411", Phase II Efficacy Trial for Type 2 Diabetes,
I7J-EW-BCGA,SAD HV,
H7T-MC-TACH,Intra-subject variablility of prasugrel v clopidogrel,
B9E-MC-S232,Ph II Gem+Taxol+Epi/Breast,
I4C-MC-A001,Eval. the comb. of LY2875358 and erlotinib in lung cancer,
"15248",Renal study - PK study in subs with degree of renal impair,
I7H-MC-JNBA,FHD-Ph1-Met/EGFR Bispec Antib-dose escalation-Solid Tumors ,
H3S-MC-A011,SERM treatment in animal model of Alzheimer's Dis (Ferguson),
I5E-MC-B004,"2013-136 Differentiation of Axiron vs. other TTAs ",
I2R-MC-BIDV,BIL and Glargine Clamp-Meal Tolerance Type II DM,
H9H-MC-A024,New targets/immune mod. to enhance vaccine induced antitumor,
I7S-EW-HBEA,Single Ascending Dose,
I4L-MC-ABER,T2DM Ph3 BIV vs. Lantus,
"15673",Counter Regulatory Response to Hypoglycemia,
F3Z-JE-ITCE,URI-Citrate Japan Ph1 Trial,
I6E-AV-I002,AV-45-IIT-002: PET imaging evaluation of amyloid deposition,
H7T-MC-V040,Aggeguide will detect effect of Prasugrel on platelets ,
I4E-IE-W854,"Protocol CA225-008; A II Study of Paclitaxel, Carboplatin an",
I4E-IE-W921,Protocol CA225-103; BMS: #05033 - A II Study of a Combinatio,
H8O-MC-A006,Study of exendin-4 + glybenclamide on insulin secretion,
B3D-JE-A009,PTH Raloxifene Collagen CrossLinks in OVX Rabbit (Saito),
H9H-MC-A021,Disease progression in the SOD 1 G93A mouse model,
I6F-MC-A003,Effects of NOTCH pathway inhibitors in renal cell cancer,
I4D-MC-A001,Comb. EGFR and Chk 1 with/without irradiation in head & neck,
I4D-MC-A002,Antagonists / Ras/Aaf/MEKIERK pathway in hematologic malig.,
I7D-MC-SGAG,RBA-Relative Bioavailability Study ,
I3Y-MC-JPBW,Renal imp in NonCa,
I4D-MC-JTJO,DDI #1,
"15587",Drug Abuse Liability Study,
"15596",RBA ,
H8L-MC-IQCQ,U200 KwikPen Summative HF Study #2,
B9U-SE-9416,Lorabid vs. Cefaclor; Comparative Study in Acute,
"15658",DDI - DDP IV,
I4T-MC-JVDC,RANGE-Ph3-Ram+Docetaxel vs Placebo+Docetax-Bladder-2nd Ln,
I7Z-MC-FLAC,Phase 2 Dose Finding,
I7Z-JE-FLAD,Ph2 Japan,
I2V-MC-A003,Perivascular macrophages in modulating on on tumour regrowth,
H8L-MC-IQDB,Axiron Gen III Summative HF study,
H6L-MC-LFAY,Digoxin Interaction,
H9P-MC-LNBM,Depression Augmentation #1 NERI + SSRI,
"11320",D/D Interaction Study,
H9P-MC-LNDH,ADHD Open Label extension up to 5 years treatment,
F1J-MC-SAAI,DULOXETINE VS. PLACEBO IN PATIENTS WITH IRRITATIVE BPH,
H6Q-MC-S033,Ph II ENZ+Avastin in GBM,
H6D-MC-V002,Binding of radiolabeled cialis to PDE5,
B9E-KL-O491,A phase II study of Gemcitabine in advance stage MZL,
F1D-SR-B032,Greek lifestyle program Solutions for Wellness,
F1J-MC-X033,Effects of Duloxetine on Fear Conditioning in PTSD,
B9E-US-I161,Ph III Neo-adj brst AC f/b Gem or Cape +/- Avastin,
H8C-BD-LQBE,iGluR5: RBA + MDSS,
F1J-MC-X035,Dulox for central pain in MS,
"11570","GLP-FC restoration of 1st phase insulin, glucagon",
F3Z-BP-GVAD,INSULIN  LISPRO - INCIDENT OF SEVERE HYPOGLYCAEMIA,
F3Z-BP-GVAF,INSULIN LISPRO - BASAL INSULIN REQUIREMENTS,
F1D-MC-HGCP,COMPARISON OF D2 AND S2 RECEPTORS - OLANZAPINE VS CLOZAPINE,
B9E-MC-V248,Gem and Adenoviral Gene Therapy,
H3E-MC-V056,"Eval Pem Growth Inhibitory activity  w cis, doxu, gastric",
"10290",Arzoxifene BIoequivalence Study,
H7U-FW-IDBD,"10U Dose Equivalance",
F1J-MC-X012,Predicting Remission/Relief Painful Sysmptoms Depres Brain,
H6Q-MC-V005,Endothelial progenitor cells increased in cancer patients,
H6Q-MC-V007,"PKC biochemistry, structure studies",
H6Q-MC-V011,CLL and enzastaurin,
I1A-MC-BPAD,Multiple-Dose Safety Study in BPH Patients,
B4Z-US-X044,A Prospective Evaluation of the Effects of Atomoxetine,
F1D-BL-A130,"Eval of neuro parameters olz, cloz, arip, hald, ofc in rats",
"10427",JP PPAR-alpha/delta P-1 SDSS,
H9X-JE-GBCB,JP GLP-Fc P-I (SDSS),
B9R-JE-GDGJ,JP Pul HGH P-1 SDS/MDS,
H4S-BP-O068,Randomised Control Trial to compare theeffects of G-CSF,
B3D-MC-GHDF,Clinical Study of Colter Pen,
H7T-MC-V003,OnPar 1 Inactivation InVitro EX pts.,
I4R-MC-V002,FGFR inhibition in Biliary Tract Cancer,
H7T-MC-V039,Investigate discrepancy between ticagrelor&platelet inhibito,
I4E-IE-W801,Protocol CA206-001; A PHASE 1/2 STUDY OF BMS-908662 (XL281) ,
I4E-IE-W896,Protocol Med-PO2-06005; BiWeekly Cetuximab at Either 500 or ,
I1F-MC-RHBP,PS - PH3: Q2 Week Maintenance Therapy,
I5E-MC-B005,Seven-Year REMS Assessment ,
I4T-MC-B003,"2013-612:Treatment patterns/costs-Ramucirumab-Gastric-2nd Ln",
"16078",Hepatic,
I7E-AV-E018,"18F-AV-1451-EXIST-018",
H3E-MC-B021,"2014-787-3:PhysDecisionMaking&Attitudes-NSCLC-Maint-PtInterv",
"16221","Phase 3 Efficacy Study #1, Mild AD;  includes 2-yr Extension",
"16408",Ph II - Ram + Chemo - Gastric (mSC EC),
"16414",Ph III - Ramucirumab beyond progression - Gastric,
I8R-MC-IGBD,"Safety, PK/PD in Healthy Volunteers",
F1J-JE-DL05,Post-mark safe study Dulox f/long term use Japan pts Osteoa ,
I9D-MC-ROAA,SAD,
I5S-MC-EFJQ,Primary Prevention ,
"11695",Placeholder for olanzapine regional trials,
B7A-XB-O008,Teleophtalmology in Spain,
H4S-CA-O075,EASY MI-Rescue Study,
B5K-US-X030,Primary Oral Insulin Trial (POINT),
B3D-KL-B012,Forsteo PMS (Post Marketing Surveillace) in Korea,
H3E-US-I023,Ph 3 Trial of Pem vs Carbo/Pem in pts w/ adv NSCLC & PS 2,
"11791",Phase I/II CCRT wit Aliimta/Cis in UCC,
F1D-US-I041,A New Pharmacotherapy for Alcohol Dependence,
"11827",Simultaneous RCTx followed by 6 cycles Alimta/Cisplatin,
F1J-US-HMFU,Duloxetine in the Treatment of Chronic Daily Headache,
H8Y-EW-HBBJ,MTD Safety and Tolerability Study - Phase 1,
H6O-MC-S006,PET --Test/Retest of [11C]ABP-688 for mGlu5 target,
B3D-US-I003,Teriparatide in accelerating the healing of pelvic fractures,
"12073",VTE Prophylaxsis #3 (Knee),
F1J-MC-HMFZ,Pts w/MDD & Pain Symptoms Shown No Response to SSRI or SNRI,
I3V-MC-GLCA,SAD GLP-PEG 80 kDA,
B3D-CA-GHCP,PTH Pre launch CTNR,
"5999",Ph 3 Safety & Efficacy in Acute Ischemic Stroke,
H8I-EW-HQAA,"5-Ht1d/ssri - PET validation study",
H7U-MC-IDAB,"Dose Ranging Clamp, Pulmonary Insulin",
H3E-US-JMFC,Phase 1 ALIMTA - Pediatric Recurrent Solid Tumors,
H3E-MC-S009,"Phase 2 ALIMTA + Oxaliplatin, Second Line CRC",
B4G-JE-YI03,COMPARISON OF PMX+L-DOPA VS L-DOPA(INTENSIVE) IN PD,
B4G-JE-YI04,CLINICAL UTILITY OF PERMAX AND L-DOPA COMPAIRED WITH L-DOPA,
F1J-MC-SBBP,Patient Registry,
"6198",Pivotal trial for ART - I,
H7T-LC-TAAC,Effect of increasing gastric pH on absorption of CS-747 base,
H7C-LC-LMCG,MGlur prodrug - Renal,
B4G-PH-0001,PERGOLIDE IN THE TREATMENT OF PARKINSON'S DISEASE,
H7X-MC-JVAD,Ph II - Affinitak + Gemzar+ Carboplatin - NSCLC,
F1D-US-HGKE,Olanzapine IM to oral transition,
H6E-CA-O002,Triple Therapy with Actos,
F1D-UT-O153,Zyprexa Intra Muscular - outpatients,
B9E-MC-S288,Ph II - Gem+Docetaxel+Cis - 1st line - Ovary,
B5Q-LC-NBBK,NIZATIDINE: INVEST. OF POSS. DRUG INTERACTION WITH PIROXICAM,
F1J-US-X019,Open-label Dulox tx trial of dysthymic disorder in elderly,
H3E-MC-V119,Pem and oxal interaction in colon cancer cells:drug activity,
B9E-MC-V303,Breast cancer cell lines invitro resistant to Gemzar,
B9E-MC-V338,Exploratory study of Gemcitabine,
"10839",FHD for (Opra MU) future cmpd FC000075,
ZYY-MC-GCCN,Type 2 Diabetes Questionaire Study - Lilly Clinic,
H3E-SN-O018,Ph II Alimta as salvage ther for met NPC,
"10889",epidemiology of care of DR W/WO MO,
H3E-SE-O020,ALIMTA plus MTHF (Modufolin) - companion IIT to H3E-MC-S077,
H7T-MC-X001,Plavix and Simvastatin (Accumetrix Bates),
H3E-US-I013,PhI Topotecan with Alimta for Advanced Malignancies,
B9E-KL-O482,Randomized Trial of Neoadjuvant+Surgery vs Surgery+Adjuvant,
"11138",Enzastaurin in treatment of brain metastases from lung cance,
B4Z-US-X050,Long-term Tolerab/Safety of Atomox in Kids w/Fetal Alcohol,
H8O-MC-I004,Effects of Exen on Hyperlipidemia and Inflamation,
H8O-MC-I005,Strategies to Improve Long Term Islet Grft Surv.,
F1J-MC-I009,Effects of Dulox on Fear Conditioning in PTSD,
"8485","Ph II, ALIMTA + Taxane in Breast Cancer",
B5K-MC-IBHI,FR_TempAuthroizForUse(ATU)_Humulin U500,
I6E-AV-I049,AV-45-IIT-049: Detection of Disease-Related Changes in Choli,
I1F-MC-RHCF,Head to Head - ixekizumab vs adalimumab,
I8L-MC-IXAQ,URI-Biochaperone Ph3 Pediatrics,
I5S-MC-EFJY,Device Bridging  ,
I7E-AV-E036,AV-1451-EXIST-036,
I8B-MC-ITSH,Dose proportionality (LY vs. Humalog),
H8H-CD-LAHP,"QTc Study  (COL MIG-105) A randomized, double-blind, placebo",
B9E-MC-I076,HIGH DOSE CHEMOTHERAPY PLUS ASC TRANSPLANT W/ GEMCITABINE,
I9V-MC-IFBA,"SAD-Random,Double-blind,Placebo-Controlled,Single Ascending ",
"17032",AV-1451-EXIST-080,
F1J-MC-B060,Takotsubo Cardiomyopathy-Serotonin (NE) and (SNRI),
I4V-MC-JAIY,Global Combo Study to support JP registration,
J1D-MC-GZAA,FHD SAD/MAD HV,
H8K-MC-JZAK,"Phase 1b of LY573636 in ""Complete Phase 1"" combo study",
H8O-JE-GWCX,JP Exenatide TDP J-Phase 2,
I3D-MC-GICB, MR Antagonist SDSS (FHD),
H8Y-EW-HBBY,Gastric pH,
H8O-EW-GWDN,Optimisation study for TDP,
"12373","1-year obesity sibutramine add-on",
H9P-MC-LNDM,Peds reading disorder NERI-IV flex dosing vs. PBO (study #2),
H4S-SB-O079,Abciximab i.v. versus i.c. in STEMI trial (Abciximab-STEMI),
F1D-US-X312,Glucocorticoid Dysregulation & Metabolic in pts with Schiz.,
H9X-MC-GBCK,Phase 2 dose finding mono-therapy,
H4S-SB-O081,Doppler HITS Study,
H9P-EW-LNBU,CYP2C19 Study - Omeprazole as substrate,
H9P-EW-LNCG,Biopharm DDI Lorazepam,
B9E-IT-O508,"Ph II study, Adjuvant chemotherapy Cispaltin + Vinorelbine",
F3Z-CA-O071,Markers of Insulin Resistance in Women following Gest Diab,
"6606",Placeholder Zyprexa IIT,
B9E-UT-O299,Gemcitabine cisplatin followed by gemcitabine + XRT,
H8A-LC-LZAH,LY2062430 A Beta Antibody SIngle Dose Safety in AD Subjects,
B1Y-BP-HC58,FLOUXETINE V PLACEBO ON THE PROGNOSIS OF MUSC/SKELETAL PAIN,
B9E-KL-O308,Proteome change with Gemcitabine in Refractory Breast Cancer,
B9E-KL-O310,Changes of gene expression of breast cancer cell with Gem,
"6840",Spec Pops Renal impairment,
"6847",Ph III CHF,
F1J-LC-HMCG,QTc Study,
H6E-ME-S003,Zahos trial,
B9E-KL-S305,Pancreatic  Gemzar OS,
"6932",Roll-over Study 1452-RESI,
F3Z-FP-O056,Insulinotherapy in inaugural cetosis of Insulin dep. DM,
F1D-BP-O184,"Self Monitoring, Cognition and Social Functioning-Schizophre",
"7181",Ph II 5-FU/FA/Gem vs Gem/Cape in Met Colorectal Ca,
B9E-EW-S345,Gemcitabina and platinum with or without Vitamin supplements,
H3E-US-JMGC,Ph I/II Dose Escalating Bi-Wkly Gem/Alimta in Adv Cancer,
H6D-EW-LVFC,Pan European Observational Study on ED,
H6L-MC-LFAV,Donepezil Drug Interaction,
B1Y-EW-E004,FLUOXETINE/FLUOXETINE DIFFERING DOSAGE REGIMENS IN MDD,
"11350","Non Pivotal Phase II/III Emerging, Combo Therapy",
B9E-FR-O488,IIT-NSCLC B9E-FR-O488 (no drug administered),
H6D-MC-A009,Acute and chronic effects of tadalafil on bladder function,
H3E-MC-JMIE,RPh II Alimta +/- ZD6474 (Zectima) in 2nd line NSCLC,
F2X-LC-HIAB,LY210448:  ORAL MULTIPLE DOSE RANGING STUDY,
H6Q-MC-S062,Ph II Enz Imaging Trial,
I1F-MC-RHAF,"2 Part SDSS/MDSS of LY2439821 in patients with RA",
"11642",SDSS in Japanese Subjects,
F3Z-CA-IOBI,CONTINUOUS SUBCUTANEOUS INSULIN: LY275585 VS. HUM. R,
F1D-MC-A144,Effects of Atypical Antipsychotic Drugs on Hypothalamic Cont,
I2A-MC-GABC,POC/Phase 2 - LY2148936 in PMP Women,
I2C-MC-BABA,Single Dose Safety Study for LY2328382,
B3D-XB-GHDI,Pharmacokinetics of Teriparatide in severe renal dysfunction,
"11902",PET -- Kinetics/Dosimetry of [11C]GR103545 for OpRA Kappa,
H8A-MC-LZAN,LY2062430 Alzheimer's Disease Progression Study (II)),
"8497",GED-aPC Phase I ASA Interaction,
H8H-MC-LAIK,DDI - Lasmiditan/Metformin ,
"17273",Actemra RWE Study,
J1V-MC-RHMA,Appendix 2 of Master Protocol for Ixe,
I7E-AV-E074,"18F-AV-1451-EXIST-074",
J1L-MC-JZGI,Reduced PK Renal Impairment,
"1736",LY396623 - Efficacy in obese type 2 DM patients,
J2A-MC-GZGA,FHD SAD MAD HV,
B9U-US-AZDI,LORABID MIDDLE EAR FLUID CONCENTRATIONS,
J2G-OX-JZJD,LOXO-292 Hepatic Impairment Trial ,
J1X-MC-GZHC,MAD (SC) study in T2DM Pts,
H4S-MC-EWAD,"A PHASE II RANDOMIZED, OPEN LABEL ANGIOGRAPHIC TRIAL EVALUAT",
I1F-MC-RHCY,Open-label Extension Trial of Ixekizumab for patients with J,
J2G-OX-Y030,PhI-RET Inibitor+Osimertinib-NSCLC,
J2G-OX-Y038,PhI-RET Inhibitor-MTC,
F1J-BI-SBCG,High Study Conducted at BI,
H8C-EW-LQBN,iGluR5 Formulation Optimization,
I3H-MC-GAFA,POC-evaluate Gastrin once daily w/LY2428757 given once wkly,
"12767",ILPS vs. Glargine  Initiating step wise basa/bolus therapy ,
I2K-MC-ZZCF,Ambien Interaction,
"12830",Place Holder for Photosensitivity,
"13007",Naturalistic Trial,
H3E-MC-JMAK,PH II TRIAL OF LY231514 IV Q 21 DAYS IN PTS W/BLADDER CANCER,
"13024",IC Atomoxetine study in female vs male adolescents with ADHD,
B3D-US-GHDL,Skeletal Histomorphometry in Pts on Teriparatide/Zoledronate,
H7T-MC-TADO,Phase 3 Pediatric Indication,
I1V-JE-EIAD,JP CETP Inhibitor Phase 1,
H8K-MC-JZAO,SUMMIT-1 - PhIII - Tasisulam vs Paclitaxel 2nd-line Melanoma,
"13102",Ph III - ASAP + -2nd Line - Ovary,
B3D-XM-GHDP,Vertebral fracture prevalence patients with glucocorticoids ,
"13158",PoC/Ph2 fracture healing in Tibia,
H3M-LC-EQAD,LY294468: INTRAVENOUS BOLUS DOSE STUDY,
"7230",Placeholder trial Growth Hormone,
B5K-GH-O437,Impt transient intensive insulin on 1 phase resp to glu&arg,
B5K-GH-O438,Relat bet glu toler & 1 phase insu secret in 1deg relatives,
B9E-MC-V202,Effect of PTEN on sensitivity of LY188011 to pancreas cancer,
"7330",Cialis CTNR Placeholder,
F1D-AY-O196,Neuropsych function in patients treated with olanzapine,
B9E-US-X370,Ph II Cap + Gem for metastatic renal cell carcinoma,
"7404",Duloxetine vs Sertralina,
"7420",Duloxetine in Severe SUI - trial at urogynecologists,
"7487",Duloxetine vs Venaflaxine,
"7563",Gem-carbo in first line- (Algeciras),
"7572",Zyprexa RAIM (Area),
"7611",Methods Placeholder,
B3M-GH-V056,"Susceptibility test of H.flu, Step.pneu,M.cat to Cefaclor an",
"7623",Gemar in Ovary cancer,
F1D-PL-O205,Bipolar Mania Observational Study,
B9E-PL-O354,Gemcitabine plus Docetaxel in NSCLC Stage IIIb and IV,
F1D-MC-X228,"Rand., placebo-controlled, flex dose study of Olz in PTSD",
"7822",pth replacement in women with hypoparathyroidism,
H3S-ME-GGLC,CHOOSE Mexico,
I2K-MC-ZZAA,Single-Dose 5-hour Phase-Advance PSG in HV,
F3Z-MC-IOEY,IV ADMINISTRATION OF LISPRO VS REGULAR IN TYPE I DIABETES,
F3Z-FW-IOPL,U200 Bioequivalence,
B4Z-US-A010,Modeling a Putative Role for Oligodendrocytes in the Pathoph,
"12355",Obesity Biopharm study-placeholder for study 2,
"12365","2 yr diabetes add-on w/metformin & SU/LY vs Liragl & placebo",
"12366","2-year monotherapy with GLP-PEG 40",
F3Z-US-X031,Use of Mix 50/50 in gestational diabetes,
F1J-FR-B030,duloxetine prescription survey,
H8R-MC-HJAQ,Double-blind prevention in alcohol dependence Ph2,
F1J-US-X048,Combination Analgesic in HIV Assoc Painful Peripheral Neurop,
I3C-FW-BLAB,MDSS CRH-1 Effort 3,
F1J-SZ-O035,a combined fMRI/MRS and EEG study in major depression,
I2K-MC-ZZBU,PPI DDI,
I2K-MC-ZZBZ,Antidote,
I2K-MC-ZZCE,NSAID Interaction,
H2Q-MC-LZZX,XANOMELINE TTS VS PLACEBO:BEHAVIORAL EFFECTS IN ALZHEIMERS,
I4V-EW-B027,Nordic Obs Study for Olumiant in Rheumatoid Arthritis (NORA),
I1F-EW-B014,GPORWE Psoriasis UK Retrospective Obs study,
I3Y-MC-JPED,Ph4-Abemaciclib-mBC Active Symptom Monitoring,
J2G-OX-Y114,RET Inhibitor-NSCLC,
I6E-AV-I063,AV-45-IIT-063: Validation of bolus and constant infusion of ,
J2G-OX-Y174,RET Inhibitor,
J2G-OX-Y175,RET Inhibitor,
B1S-MC-EAAI,DOBUTAMINE:EFFECT VASCULAR RESISTANCE & COMPLIANCE,
J2G-OX-Y196,RET Inhibitor,
I7E-AV-E121,AV-1451-EXIST-121,
J3D-MC-FNAB,"Dose Finding of IL-17 SMI/PBO to eval efficacy, safety, PK ",
"18401",Placeholder MAD study,
"18402",RBA/ FE study,
H9X-MC-B022,"2020-9286: Clinical outcomes among elderly T2D patients on d",
B9E-MC-X278,EFFECTS OF DIURNAL HORMONAL RHYTHMS ON COLLAGEN,
F3Z-BP-O004,Timing of Administration & Frequency of Hypoglycemia in IDDM,
"1978",Drug Interaction,
B9R-AY-V006,"Can histidine-containing dipeptides, like carnosine, block",
I1R-JE-GLBJ,JP GRA1 Ph 2,
I2K-MC-ZZCI,Protactin Study,
H3S-JE-201J,EARLY PHASE II CLINICAL STUDY OF LY139481 HCL,
H3S-LC-GGGA,RALOXIFENE HCL: MULTIPLE DOSES UP TO 600 MG,
"13411",Food Effect #2,
I4E-US-S003,"REGISTRY Trial-""LOHRAN""-ERBITUX multi-center -H&N Carcinoma",
H3S-LC-GGHH,ABSOLUTE BIOAVAILABILITY OF RALOXIFENE HCL,
"13472",Lumbar Vertebra Study 1,
"13499",Multiple Myeloma Phase II/III,
H8Y-JE-HBDC,JP_mGlu2/3PDII_P-II monotherapy,
B7A-MC-V018,Protein Kinase C beta and eNOS Activation in Isolated,
B4Z-XM-B016,Cross-sectional study of patients participating in LYDM ,
"13708",Human 14C study,
H9B-MC-BCDW,Phase III/ Ankyolosing Spondylitis,
I4P-FW-GPFB,MAD GPR 40 Agonist 1,
H6D-MC-LVIV,A UT/Lilly Alliance IIT ambersentan and tadalafil in PAH,
"12937",ExNCR with human insulin,
F1D-MC-X315,Olz/Exenatide in Obese Adults w Bipolar,
H8V-MC-B002,Atomoxetine-Cardiovascular & Cerebrovascular Outcomes-(GPS),
F1D-AY-O332,Pharmacogenetics in First Episode Psychosis,
H3E-UT-O044,phase I stereostatic RT cis/pemetrexed,
B9E-US-X472,PhII Gemzar in tx of recurrent/persistent endometrial carcer,
F1D-JE-CSOS,JP Olanzapine PMS Study,
H3E-BP-JMIK,L-Ph2 - TS expression in NSCLC pts treated with pem/cis,
F1D-US-A158,Effects of Olanzapine in the Adolescent Rat Brain,
H8O-MC-X017,Eval of 4 peripheral paths for reduction of food  ,
B3D-US-X022,Bone Strength Assessment using CT Colonography Scan,
F1D-US-X319,Efficacy of Olz in Attenuating Weight Loss in Panreatic Canc,
"13162",Survey,
I4B-FW-GPCC,DDI Study,
H8O-MC-A024,ID key receptor populations for actions of Ex-4,
H7T-PH-B009,Effient (Prasugrel) Post-Marketing Surveillance Study,
B9E-SB-O016,"Phase I, Gemcitabine &  5-FU, Cholangiocellar Cancer",
"7841",Progression of microvascular diabetic complications DIMITRI,
"7864",Invitro - preclinical investigation on MTA,
"7874",IITs Bipolar-2003,
B9E-AG-O362,Gemcitabine intravesical in bladder CA,
F1D-TW-B017,Effectiveness and Safety of olanzapine in acute mania,
B9E-FP-S332,Therapeutic managt with RT of stade III & IV NSCLC patients,
"8025",IIT Placeholder for Korea,
B9F-MC-I010,PULSATILE INSULIN RELEASE IN PANCREAS/RENAL TRANSPLANT,
H7C-LC-LMCH,Definitive Food Effect Study,
"8126",CV Hypertension Study,
"8150",Zyprexa Use in High Doses,
B3D-MC-GHCN,Fracture Healing - Colles fracture,
B9E-US-X394,Ph II Gem Cisplatin & dexamethazone in Hodgkin Lymphoma,
F1J-MC-HMCX,Lilly's Emotional and Physical Symptoms of Depression,
"8307",Phase II Study NSCLC,
F1K-US-X002,Eff. of Xigris on exp. profile of monnuclear cells in sepsis,
H3E-US-S053,Phase 1 Alimta plus Oxaliplatin Dose Finding Study,
B9E-MC-S022,Gemcitabine + Piritrexim on Carbo/Tax - refractor Bladder Ca,
A1L-MC-X002,COMPARISON OF AVENTYL AND PLACEBO IN CHILDREN WITH ADHD,
B9E-MC-S050,Ph II Gem + Oxaliplatin in SCLC,
H4Y-MC-LJAY,Mild - 2 Migraine,
H4H-MC-I001,Theodore NIH monotherapy study,
H3Z-MC-JNAJ,Phase-I Combination Study:  LY295501 + Gemcitabine,
"2275",Oral Delivery Phase I - FHD,
F1D-MC-X064,"OLANZAPINE, RISPERIDONE AND BRAIN PHYSIOLOGY",
H4A-MC-XBAX,Oral Pilot Vaginal Candidiasis Study,
B9E-MC-X044,PHASE 1 STUDY OF GEMCITABINE AND CPT-11,
B9U-MC-AZDK,BIOEQUIVALENCE OF LORABID CHEWABLE TABLET TO SUSPENSION,
B9E-VI-JHMN,A Phase 2 Study of Gemcitabine in Biliary Cancer,
B9E-GH-O392,Phase II Study Gemzar & Cisplatin Treat Esophageal Carcinoma,
B4G-EW-LCCE,Parkinson / Neurogenic Bladder (Pilot Study),
B9E-US-X409,Ph II Gem/Irinotecan in metastatic renal cell carcinoma,
B4G-US-I003,Tourette (S7),
H3S-BX-O117,Recognition of vertebral fracture on chest radiography,
B9E-MC-S100,Gem+Carbo+Tax vs. Carbo / Ovarian,
F1K-LC-EVAM,rhAPC Bolus Infusion:  Dose-Range,
H3S-MC-GGII,"RALOXIFENE HCL VS PLACEBO EFFECTS ON BMD, BM, LIPIDS",
I3W-JE-HHAG,JP(FHD) 5HT2a antagonist P-1  ,
F1J-US-V002,Duloxetine-induced movement of Gsalpha from lipid rafts,
H6Q-MC-V071,Pre Clinical - Anti-Tumor activity of Enz in NSCLC,
H8L-MC-IQAM,Humalog KwikPen Color Knob and Coding study,
H8O-MC-GWDQ,Exenatide Study of Cardiovascular Event Lowering Trial,
I4I-MC-SNAB,Phase 1 MDSS of LY2878735 ,
I6X-MC-JBDA,FHD B-Raf Inhibitor,
"13886",Phase 2b Extension,
I5A-IE-JAEB,CP13-0706: Ph2-A12-HeadNeck-2nd Line,
B9R-JE-GDGP,Humatorope-Achondro,
I4Z-IE-JDEA,CP22-0901: Ph I/Ib - 20D7S - Malignant Melanoma - 2nd Line,
I4V-MC-JADH,Relative Bioavailability/Pilot Food Effect,
"14032",Alimta 1st line in pts unsuitable for platinum combination,
"14129",R-PhIII-Tarceva +/-A12 - NSCLC - 2nd Line,
H4S-MC-EWAU,Epilog Stent,
H6D-MC-LVII,Alpha-Blocker Switching Study,
H3M-MC-EQAK,TO COMPARE THE EFFICACY OF EFEGATRAN SULFATE TO HEPARIN,
H3R-MC-I001,LY293558: PAIN PERCEPTION IN NORMAL VOLUNTEERS-SAFETY/EFFIC,
H3S-JE-101J,PHASE 1 CLINICAL STUDY OF RALOXIFENE(SINGLE DOSE STUDY),
I4K-MC-GPEB,A Mechanistic study of effects of LY2452473 HDL-C Metabolism,
"13458",Dose Ranging Study rrMS,
B7A-MC-V006,Role of PKC-beta in the expression of ACE in vascu,
H3E-MC-V146,Phospoproteins in cytologic samples,
H8O-MC-O019,Extrapancreatic effects of exenatide: ,
B5K-US-X010,U500 Insulin Bolus Kinetics,
F1D-GH-O241,"A long term comparison study on efficacy,safety,compliance a",
"13647",JP mGlu2 Potentiator P-I,
B9E-MC-I126,GEMCITABINE/CISPLATIN IN  ESOPHAGEAL CANCER,
I5B-IE-JGDG,CP15-0806: Ph Ib/II - 3G3 - Adv Soft Tissue Sarcoma,
B9E-MC-I020,PHASE I STUDY OF GEMCITABINE AND CLADRIBINE IN HEMATOLOGIC,
F1J-MC-HMDE,G2 - EU Duloxetine vs Duloxetine Plus Non-Pharmacological,
H3S-MC-GGGN,RALOXIFENE & PLACEBO IN TREATMENT OF OSTEOPOROSIS/ASSESS BMD,
B3M-GH-V049,Ceclor for treatment of AECB,
F3Z-MC-IONM,Hyperglycemia effects post MI on CV outcomes with Type 2 D,
A6J-GH-ASCG,Vancomycin for MRSA infection,
F1K-LC-EVBH,Plasma and serum samples for LY203638-related antibodies,
B9E-FP-O226,ITT- activity of Gemcitabine-Cisplatine in stage IV NSCLC,
B1Y-MC-X215,Neuronal Dysfunct. in Premenstrual Dysphoric Disorder,
"5665",Fellowship for Dr. Kellie Ledrew (FEL-058d),
F3Z-US-IONT,Retro Obs.study with LM; physician perception & utilization,
B4Z-US-LYBG,Early Morning Study,
"5680",Raloxifene efficacy in Females,
H4S-FP-O021,Abciximab in renal stenting,
B9E-FP-O239,IIT-ass Gem/Cispl and Docetaxel (sec line) in NSCLC cancer,
B9R-SB-O014,rhGH abuse in athletes: evaluation of an assay,
H6P-MC-X003,PET scan study of pregenual cingulate matabloism of OFC,
H4Z-LC-JWXO,Arzoxifene Japan Bridge,
B3N-MC-EUAM,SYSTEMIC AND CORONARY NE KINETICS IN CHF,
B9E-SB-O251,Gemcitabine & 5-FU & Irinotecan in pancreatic cancer,
B9R-XM-O023,INTRATUTRINE GROWTH RETARDATION-1,
"5981",Random ph II  trial gem-oxali in NSCLC,
B1Y-MC-HCDJ,FLUOXETINE VS. PLACEBO IN DEPRESSED PATIENTS,
B4Z-MC-LYAF,Relapse Prevention trial - Global,
"2562",Adult Open Label,
B1Y-MC-X145,EFFECTS OF ESTROGEN ON DEPRESSIVE RELAPSE,
"2684",Elderly Discontinuation of Fluoxetine Hydrochloride,
"2707",Smoking Cessation - Study #2,
"2748",RALOX VS PLACEBO IN ELDERLY MEN,
B5K-BP-IBEE,INSULIN DELIVERY USING A NEW LILLY 3.0ML PREFILLED PEN DEVIC,
B3M-MC-S004,Cefaclor AF vs Augmentin BID Sinusitis CTNR,
H4Z-MC-JWWM,(J205) Ph 2 Surrogate Endpoint BioMarker in Newly Diag Br Ca,
"2822","Study 1Dose Equiv, PK, PD vs. NPH",
H4A-MC-XBAD,Oral vs. Fluconazole in Oral Thrush,
B1Y-MC-HCES,FLUOXETINE + CLOMIDINE TREATME.SMOKING WITHDRAW.,
"2865",VOID,
B1Y-MC-HCFC,FLUOXETINE VS PLACEBO IN DIALYSIS OUTPATIENTS WITH MDD,
"2911",Single Dose,
"2915",Exploratory - Panic Provocation,
H3E-MC-JMCK,Leuk/Lymph PK/PD Study,
"2954",Ralox- PET Scan (regional blood flow),
I4O-MC-BACT,Phase 3 Double Blind Study in MCI and Mild AD Pts,
I5L-MC-TCAJ,Ped study  (>2 yrs old to <7 yrs old),
H9H-MC-JBAK,FED_Ph II- TGFb or TGFb combo-HCC-1st/2nd Line,
I5O-FW-GTCB,MAD,
"13722",Maintenance Pem Following Induction treatment with Pem-CDDP,
I6C-FW-FRCA,SAD,
H3E-NI-I031,DRUG ONLY_R-PH II-ASA404+Alimta+Cis_non-sq NSCLC,
H8Y-MC-HBDE,Double-Blind Safety Exposure Study,
H6Q-MC-V044,"Pre Clincial Research NSCLC, SCLC and Malignant Meso",
H7L-MC-TRED,Treadmill Pain Model Method Study,
H6Q-MC-V046,Enz affects EGFR signaling in lung cancer cell lines,
I5X-MC-PFAA,"Single Ascending Dose Safety, Tolerability, and PK Study of ",
H7T-MC-V034,Frelinger: Pediatric Non-clinical,
I5A-IE-X019,ARST08P1:PhII-A12+multi-agts vs Temzolomide+Multi Agts-Rhabd,
H6U-EW-S008,Development of a Translational EEG Pharmacological Marker,
I3P-GH-GKBL,China Phase 2 for GKA II (LY2608204),
I1F-MC-RHAY,Phase 3 RA trial - Monotherapy,
H4A-BP-V008,LY303366 AGAINST ASPERGILLUS & FLUCONAZIDE RESISTENT CANDIDA,
"14047",Triple versus double therapy in ACS patients undegoing PCI,
B1Y-FP-0714,FLUOXETINE:  CHRONOPHARMACOLOGY,
H8O-CR-GWDV,EMBU: Byetta compared to NovoMix30,
"14143",R-PhIII-5FU/FA+Oxali+/-18F1-CRC-2nd Line,
H8O-UT-O026,The eft of GLP-1 rec activation on cen reward and satiety ,
H6D-MC-LVJB,Tadalafil OAD + Testosterone - Global,
F3Z-EW-O080,Efficacy and mechanisms of a short course of intensified ins,
H6D-IT-O020,MR imaging on monitoring Tadalafil effect on OOP PH pts,
H3E-MC-V154,Pre-Clinical -TS IHC in NSCLC,
I5U-MC-ANBC,MAD,
H4G-MC-LIAF,DOSE COMPARISON OF LY303870IN TREATMENT OF ACUTE MIGRAINE,
H7T-FR-O016,ORBI,
F1D-SB-O336,Reduce Noncompliance in Schizophrenia Treatment,
H6Q-MC-A049,Pre Clinical - Enz transformed cells w/ wt and mutant eIF6,
F1J-JE-HMGY,JP Cymbalta P-III CLBP,
"14431","FHD, ALK Inhibitor",
I1V-MC-EIAL,SAD/MAD/Keto,
I2Z-MC-LAFF,Thorough QTc Study,
B4Z-EW-B020,ADHD Prevalence in Adult Psychiatric Practice,
H4Q-MC-V004,LY333328 MICS IN 200 GLOBAL PNEUMOCOCCI & TIME-KILL ANALYSES,
I2I-MC-V002,Pre Clinical - CHK 1/2 with Cytarabine in AML,
I4V-MC-JAGB,Elderly PK,
I1V-MC-EIAQ,Effect of Evacetrapib on the Pharmacokinetics of Digoxin in ,
I5J-MC-NOAF,Drug-Drug Interaction Study + SNRI,
I6J-FW-PRBB,Multiple Ascending Dose Study for GPR40 Agonist II,
I1D-MC-A002,Attempt to id add or parallel target genes/pathways - breast,
I5S-MC-EFJG,PCSK9 Ph 2 DM Dyslipidemia,
"14880",DIAMONDS Digital Assisted MONtoring for Diabetes ,
F3Z-IT-O081,DIAMONDS Digital Assited Monitoring for Diabetes,
I1D-MC-JIAQ,Absolute Bioavailability in NHV,
F3Z-GH-O083,A comparative study of Humalog Mix25 versus Humalog Mix50,
H7T-US-X019,Prasugrel-associated Thrombocytopenic Purpura,
B5K-US-X011,Durability of Glycemic Control & Outcomes in LT use U-500,
B9E-MC-X213,Phase 2 Study of Gemcitabine and Docetaxel,
H5N-MC-GFFD,LY307161: Multiple dose study in Type II diabetic patients,
B9E-MC-X225,Phase 2 Trial of Gemcitabine and Docetaxel in SCLC,
B1Y-MC-I011,FLUOXETINE TREATMENT OF NOCTURNAL ENURESIS,
F1D-US-HGHC,Prev. of Hyperprolactinemia in Schizo. PTS with conv. APD,
B9E-MC-X228,"Gemcitabine, Carboplatin, and Interleukin 11 in NSCLC",
B9E-JE-P22D,LY188011 GEMCITABINE PHASE 1 STUDY (PANCREAS),
"3290",BUSINESS PLANNING FOR POTENTIAL ALLIANCE FOR CNS,
B9E-MC-X124,Phase 2 Study of Gemcitabine/Previously Treated Breast Ca,
"3360",Ligand development study with WAY 100635,
B3L-MC-LWAT,A comparative OMEI PET image analysis of LY354740,
"3400",Fluoxetine Phase III Local Registration (PMS) - China,
H5Z-MC-LUAB,R-fluoxetine vs. Placebo in the Treatment of MDD,
B9E-SB-O036,"Phase II, Gemcitabine &  Cisplatin, In Pancreatic Cancer",
"3440",rhAPC/Aspirin Interaction II,
B1Y-MC-X026,FLUOXETINE VERSUS PLACEBO IN DYSTHYMIA,
"3527",Vanco vs. Metronidazole in Development of VRE colonization,
F1D-SU-HGMA,Bipolar Depression Assessment Study on Treatment Response,
B9E-UT-O417,Phase 2 of 2-weekly dose dense GT and 3-weekly GT in MBC,
H6L-FW-LFAO,PK Bridging Study,
H7T-MC-V011,AntiPlatelet effects of CS747 vs. Cangrelor & AZD6140,
"9492","300/600mg Clopidogrel vs 60mg CS747 Loading Dose in ACS",
B9E-BX-O424,Phase 1/2 study caelyx/gemzar in ovarian falopean tube,
F1J-EW-B005,EU Health Outcomes Compliance Study,
F1J-MC-HMEU,Assessment of duloxetine an SNRI at 60 mg QD,
B9E-SB-O428,NSCLC 1st line project on quality management,
H9N-EW-LTCA,LY451395 fMRI Biomarker,
"9644",Comparison of LY458202 in patients with ST elevation,
F1D-LC-HGBE,OLANZAPINE:INTERACTION STUDY WITH WARFARIN,
H3E-MC-JMHT,Ph II ALIMTA in ALL,
H6D-MC-A001,Effects of Tadalafil on Myocardial ischemia/Infarction,
H6E-RO-B003,TO DO Study,
"9852",placeholder : participation in a future European study,
F1D-MC-HGBG,OLANZAPINE VS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA,
"9910","Ph1, single agent Alimta, MBC after anthracyc. or taxane",
I1F-MC-RHBJ,Phase 3 CHINA AS,
I4T-MC-JVCF,Ph III - 1121B - NSCLC - 1st line,
H4Q-LC-ARRK,SAFETY AND PK OF SINGLE IV DOSES OF LY333328 IN HEALTHY VOL,
H8O-GH-O030,Efficacy of Exenatide therapy on metabolic syndrome patients,
H4Q-SP-A006,LY333328 VS 3RD GENERATION CEPHS AGAINST PRSP--IN VIVO/VITRO,
I4V-MC-JAGF,pH Omeprazole,
B4Z-MC-B019,Atomoxetine Drug Utilization Study,
I4T-JE-JVCG,JP - R-PhII-Ramucirumab-NSCLC-2nd line,
"14680",Blood Pressure Con-Meds,
I6H-MC-MCBA,SAD,
F1J-MC-B047,"2012-202_RETROSPECTIVE -PH 2-CYMBALTA EMR IN OA",
I5J-MC-NOAG,Drug-Drug-Interaction Study + SSRI,
I2H-MC-V003,Therapeutic implications of combinatorial inhibition of Chkl,
I2R-MC-BIDN,Lipid Kinetics Study,
I4T-MC-JVCP,EXPANDED ACCESS - Ph III - 1121B - Gastric - 2nd Line,
H9H-MC-A012,"14-3-31; overexpression enhances TGFb's tumor promoter funct",
B3L-MC-LWAV,LY354740 in Ketamine Induced Psychosis,
I6U-MC-GHRA,SAD/MAD,
I7I-MC-XNAA,Phase 2 (FED) Study,
H6O-UT-O008,"In control, The effects of real-time continuous glucose ",
I2I-MC-V013,Enhancing Chk1 inhibitor lethality by inhibition of PARPI,
I2R-MC-BIDS,T1DM Pediatric Safety/Efficacy Study,
I7G-EW-HLBA,SAD,
I5E-EW-TSBE,Evaluate Residual Testosterone on Clothing after Axiron Use,
B9E-MC-I048,Phase I/II    Study of Gemcitabine and Carboplatin (NSCLC),
I3G-MC-V007,In vitro Investigation in DLCL and MCL,
I2R-MC-BIDT,T1DM 6 month treatment vs Glargine ,
B3D-MC-B024,Forteo Risk Minimization (REMS) Assessment - 7 year,
B1Y-FP-0780,FLUOXETINE: CONTROLLED PILOT STUDY IN BULIMIA,
I3O-MC-V002,Eval. c-Met Pathway Inhibs. Using Energy Pair Score Methods,
I4X-MC-JFCS,Ph Ib Necicumumab+ERBB3 - NSCLC - 2nd line,
"15598","QTC  ""Placeholder""",
H3F-CA-O003,Efficacy in single and dual hormone overnight in Children,
B1Y-HL-0002,FLUOXETINE POSTMARKETING SURVEILLANCE,
B3N-MC-EUDL,Moxonidine vs Active Comparator -BP primary measurement (#5),
F1D-MC-X143,Early Intervention Strategy in Schizophrenia Spectrum,
H5P-LC-BWXA,FED/FASTED STUDY WITH MARKET FORMULATION,
F1D-US-HGIC,Treatment of Olanzapine in Patients with mild to moderate AD,
H6K-MC-IIAC,Product Decision Study  Safety & Efficacy in Type 2,
B1Y-GN-O006,Fluox in Pts with Congestive Heart Failure and Depression,
H6D-EW-LVAJ,Renal Impairment Study,
B1Y-MC-X060,A NATURALISTIC STUDY OF PROZAC IN CLINICAL PRACTICE,
B1Y-MC-X063,"FLUOXETINE, NORTRIPTYLINE & PLACEBO IN MIGRAINE PROPHYLAXIS",
H6D-MC-LVBU,Mulitple dose PK (Glaxo study),
H6D-MC-LVBJ,Onset and Duration of Response to IC351,
F3Z-FP-O025,INTENSIFIED INSULINOTHERAPY IN NIDDM WITH CORONARY EVENTS,
B1Y-MC-X070,FLUOXETINE IN SELF INJURIOUS BEHAVIOR,
B5K-MC-IBFB,Long term safety of PI in subgroup,
B5K-MC-IBFC,Lung CT scans on normal volunteers,
H5P-MC-BWXK,Phase II Asthma Trial,
H5Z-LC-LUAK,R-fluoxetine sleep study,
H9X-MC-GBGA,Single Use Pen #2,
I6W-MC-TNAA,"FHD/TNFa/IL-17 Bispecific, Ph1",
H8A-MC-LZAX,Effect of Passive Immunization on the Progression of Mild AD,
H8L-MC-IQBS,U500 Summative Human Factors,
"1515",North America Epilepsy Registration Trial,
I6E-MC-AVBF,Drug Utilization,
"1519",Global ALS Trial,
I7J-MC-BCGD,Safety AD Patients (phase 2),
"15357",Comb. between primary and hepatic metastasis in gastric canc,
I2R-MC-B001,"2013-524_Diabetes Utility Validity via EQ-5D and NICE doc",
I7R-EW-HPBB,Single Dose Proof Of Concept,
F1J-MC-B054,VAMPSS Pregnancy Surveillance for Duloxetine,
H9H-MC-A023,Eff./neutralizing on tumor lntlatlng stem-like cancer cells,
I7T-MC-RMAG,DDI Study w/ 3A4 Inhibitor,
I3Y-MC-V003,Assess. anti-proliferative effects/medullary thyroid cancer,
I3Y-CR-JPBR,CH_PH1_CDK46_All Comer Solid Tumor Patients,
H8L-MC-IQCX,autonomy titration application Summative HF study,
H6D-MC-LVDZ,Pan-Asian Trial,
F1D-MC-HGFT,Fluoxetine + Olanzapine in Schizophrenia/Schizoaffective,
H9H-MC-A035,Inhibitory pathways to improve radiation-induced vaccination,
"15789",POC in DPNP,
"15794",Head to Head Comparison,
F1D-MC-X041,"Smoking, schizophrenia, and atypical antipsychotics",
B3D-MC-B025,"2014-214 EU database analysis (Italy) - defining the patient",
I4E-IE-W829,Protocol CA225-081; A II TRIAL OF CARBOPLATIN PLUS CETUXIMAB,
B1Y-HL-E030,FLUOXETINE/DOXEPIN PATIENTS WITH UNIPOLAR MAJOR DEPRESSION,
I4E-IE-W856,Protocol CP02-9710; Study of Anti-Epidermal Growth Factor Re,
I4E-IE-W891,Protocol CA225-092; A II STUDY OF EVALUATION OF CETUXIMAB (E,
I4E-IE-W901,Protocol Non-BMS/UPC-06-006; A PHASE 2 STUDY OF IRINOTECAN A,
"1596",Obesity Proof of Concept Trial,
I7U-MC-GAHB,Glucagon Analog AgonistMultiple Dose Study,
I8D-MC-AZER,DDI Midazolam,
I8D-AZ-AZEV,AZD MAD Study (D5010C00002) ,
J2G-OX-Y059,RET Inhibitor-MTC,
B1Y-IH-0001,FLUOXETINE PLAN D STUDY,
B1Y-MC-X099,FLUOXETINE IN THE TREATMENT OF CHRONIC PELVIC PAIN,
B4Z-LC-LYAE,Tolerance and QTc Interval Correlation Study,
B4G-SB-LCDK,Parkinson / Parkinson Experience Program (Dose increase),
"4154",Multiple dose safety study,
"4177",Lispro vs Humulin,
"4196",Exploratory study,
"4300",GEMCITABINE-CISPLATIN-5FU IN GASTRO-INTESTINAL CANCER,
B9E-XV-S147,Gem-cis-taxol vs. observ. as adjuvant treatmen bladder cance,
H4H-MC-LGAO,Epilepsy Monotherapy Trial,
B9E-FP-O129,ITT-LOCALIZED NSCLC GEMZAR & CHRONOMODULATED 5FU & CISPLATIN,
H6D-MC-LVCK,Time to Onset,
B9E-MC-X273,Gemcitabine and Radioterhapy for Bladder Cancer (RTOG 99-06),
F1D-XL-O070,Olanzapine for the treatment of alcohol dependence,
H6M-BD-LDAG,Multiple Dose Escalation,
B1Y-SB-6012,FLUOXETINE FIXED DOSE STUDY,
B3M-PG-AJBH,Cefaclor Versus Amoxicillin/Clavulanate in AECB,
B4G-EW-S002,Bioequivalency/Pergolide comparing manufacturing processes,
B9E-XB-S167,Phase I Gem  + Radiotherapie in bladder cancer,
H8E-MC-KBAA,"1466-RESI (1410 Roll-over Study)",
I3Y-MC-JPBV,Hepatic imp in NonCa,
"15600",ABA ,
I6F-MC-A005,Effects of NOTCH pathway inhibitors in renal cell cancer,
H9H-MC-E004,Ph I - TGFb RI - Melanoma,
"15654",Hepatic Impairment,
 ,URI-Excipient OTHER-Ph1b T1DM Pump PK/PD Variability,
H9X-MC-B016,Prospective Observational Study - OUS,
I3Y-MC-A007,Targeting APC and PIK3CA Mutant Colorectal Cancer,
I3O-EW-JSBD,LY2801653 RBA with food effect,
H9H-MC-JBEG,Ph Ib Galunisertib+MEDI4736 in Pancreas,
"15792",Statin Bank,
I4E-IE-W874,Protocol CA225-051; II Evaluation of Cetuximab (C225) Combin,
I1F-MC-RHBR,CV PET Scan Study,
B5K-MC-B011,"2014-303 Clin and econ outcomes of U500 vs. High Dose U100",
I7E-AV-_A13,"18F-AV-1451-A13 High Resolution Autopsy",
I6E-AV-I027,AV-45-IIT-027: ADNI Depression,
I6E-AV-I046,AV-45-IIT-046: AMPLE,
I8D-AZ-AZFA,AZD Mass Balance Study (D5010C00007),
I8E-MC-APBA,SAD-Sleep,
I6E-AV-I040,AV-45-IIT-040: MEMENTO,
I8L-MC-IXAA,URI Biochaperone phase 3 T2D,
I7E-AV-E043,"18F-AV-1451-EXIST-043",
"16402",Ph II - Ramucirumab - High Risk Adj Gastric,
I4V-MC-B002,Assess Maternal & Fetal Outcomes Post Exp to Baricitinib,
"1650",LY354740 addictive potential,
I9B-MC-BBEA,SAD (1),
H9X-MC-GBGJ,Dulaglutide High Dose ,
ZYY-MC-O007,Hyperglycemia clamp in healthy volunteers,
I4V-MC-JAHL,Ph3 LY vs PBO in moderate to severe AtD Adults,
I4V-MC-JAHZ,Ph3 SLE Registriaiton Trial,
I8B-MC-ITSB,URI-Vasodilator Ph3 Pediatrics,
I5S-MC-EFJW,Absolute Bioavailability,
B1Y-BP-HC35,FLUOXETINE VS PLACEBO IN SUICIDAL PATIENTS,
B9E-MC-S175,Ph III - Gem + 5-FU w/Folinic acid vs Gem - Pancreas,
B9E-XL-V093,In vitro study effect of drug secuenciation in NSCLC cells,
H4S-IN-EWBC,Reopro-Indian patients experience registry,
B1Y-MC-X210,STEPPED CARE VS BEST AVAILABLE CARE FOR BULIMIA NERVOSA,
B3M-MC-AJBN,CTNR Acute Exacerbations of Chronic Bronchitis,
H5Z-LC-LUAR,Multiple dose Sepracor Study 41-003,
"4960",detection of osteop pts and evaluation of Evista treatment,
H6D-MC-LVCX,Geriatric Experience with General Practitioners,
H6D-MC-LVCY,"Cialis 20mg vs. Sildenafil 100 mg, 50 mg",
"4991",GHS Interaction study 1,
"4995","ORAL PTH (LY900002), FOOD EFFECTS STUDY",
B4Z-MC-LYAW,School Outcomes Study,
H6D-MC-LVDF,Phase III S & E Open Label Extension Trial FSAD,
H5Z-MC-LUAX,R-Fluoxetine -- Transition from BZD,
B4Z-LC-LYAZ,Definitive Bioequivalence/Adult Fed/Fasted 60 mg,
"5062",Duloxetine Depression,
H3E-US-JMEO,Phase II ALIMTA/Gemzar in MBC with prior Taxane Therapy,
I1F-MC-RHCI,Phase 3 nonrad-axSpA China,
I8Z-MC-APCC,Phase 2 Adult Glucagon Analog Agonist III Study,
I8I-MC-JY03,JAK2 Inhibitor - CONTINUED ACCESS - Lymphoma,
I7E-AV-E056,AV-1451-EXIST-056,
I7E-AV-E065,AV-1451-EXIST-065,
I9O-MC-AABB,Single dose c-formulation with PH20/Halozyme,
H8H-CD-LAHN,Renal (COL MIG - 113)    ,
I9R-JE-BSDF,LY3374849 J MAD,
I3Y-MC-E018,PhII-Abemaciclib-GEP NET,
I8R-JE-IGBK,Japan Use-ability Study -EET,
I1F-MC-RHCK,Bolt New Device Safety and Tolerability Study ,
I8F-MC-GPGK,GIP/GLP-1 Monotherapy,
I8F-MC-GPGG,Study of GIP/GLP-1 Coagonist Peptide II in Renal,
H8H-MC-LAIF,Assessing Effects of Lasmiditan on Simulated Driving perform,
I9Z-MC-OGAB,SD-PET,
I9V-MC-IFBF,FED POC Ph2 Study,
I7E-AV-E033,"18F-AV-1451-EXIST-033",
I5Q-MC-S001,LDI Capsaicin Biomarker study,
"16305",Muscle Trial,
I6E-AV-I047,AV-45-IIT-047: AD and MCI in African Americans,
I8L-MC-IXAS,China PK Study,
F3Z-GH-O085,Analyze the relationship between BG and HbA1c in T2D patient,
I8R-MC-IGBG,"4-Period Study to evaluate the Pharmocokentics",
I3Y-MC-JPCK,Effect of Abemaciclib on Renal Transporters Glomerular Filtr,
H6D-US-SANA,Tadalafil OTC Conversion,
"16650",IL-23 in combination with topical corticosteroids in AtD,
"16668",Ph II - Necitumumab+Gemcitabine+Carboplatin-Sq NSCLC,
I4V-MC-JAIA,Ph3 SLE Registration Trial,
I1F-MC-RHCE,Early onset of action (Time Point),
I6T-MC-AMAV,MOA,
H4Q-LC-ARRB,SAFETY AND PK OF MULTIPLE IV DOSES OF LY333328 DIPHOSPHATE,
J2G-OX-Y100,RET Inhibitor-NSCLC,
"1712",Efficacy in obese patients with type 2 diabetes mellitus,
B9R-US-X029,"""Psycho-social Development and Parental Stress in Girls ...""",
"5275","2yr BMD Study with All Type DXA Instruments with Chugai",
B4Z-JE-LYBC,JP atomo P-II/III,
B9R-UT-O013,hGH in young adults who survived acute lymphatic leukemia,
"5299",Bioequivalence (powder to capsule) LY459477,
B9E-BP-O194,"Ph1, Gemcitabine plus RT, Brain mets",
B7A-FW-MBCP,PKC-Beta inhibitor Warfarin interaction study,
F1D-US-X200,Olanz and Fluox in young children w/ high function'g autism,
B9R-US-X031,Pituitary Tumor Database Prospective Study,
"5434",Dose-Response of Buccal Insulin and Bioequivalence to SC,
B3D-LC-GHAB,"LY333334:SINGLE-DOSE DOSE-RANGING,PK/PHARMACODYNAMICS PROPER",
F1D-XM-O109,sexual disfuntion disturbances due to the use of neuroleptic,
B9E-XM-S237,Phase 2 trial gemcitabine + docetaxol in breast cancer,
B3L-MC-LWAD,LY354740 VS PLACEBO & LORAZEPAM IN GENERALIZED ANXIETY DISOR,
F3Z-PK-S010,Observ. of pts. transferred from Hum R to Lispro,
B3M-MC-AJAI,CEFACLOR AF VS. CEFUROXIME/AXETIL AND CLARITROMYCIN IN ASOC,
H3S-MC-GGKR,Switching from HRT to Raloxifene,
"5453",Gemzar+Cisplatin for bladder cancer,
I4V-MC-JAIZ,Phase 3b study for Baricitinib AD,
H9X-MC-B021,Dulaglutide / Semaglutide Pen Preference Study,
I9S-MC-BTAB,MAD SLE Pts,
I8F-MC-GPHF,Diabetes regression,
J1Q-MC-JZIA,FHD Ph 1 - CD226 Agonist Antibody - Solid Tumor,
"17385",Janus Kinase Inhibitor (Baricitinib) for Aicardi Goutières S,
I7E-AV-E098,"18F-AV-1451-EXIST-098",
I8B-MC-ITSX,Ph 3 URLi Plus Basal vs. Basal in T2D w/Connected Pen,
H8H-MC-LAIM,Effects of Daily Lasmiditan on Simulated Driving Performance,
H0P-MC-NP03,Intervention Specific Appendix - DPNP,
H0P-MC-NP04,Intervention Specific Appendix - DPNP,
F1K-MC-EVAD,PROWESS: Recombinant Human Activated Protein C Worldwide Eff,
"16810",Ph Ib/II - Cetuximab+Hu5F9-G4 - Solid Tumors/CRC (47INC),
I4T-US-I010,PHII Cis+Pemetrexed+/-Ramucirumab Mesothelioma,
I4V-MC-JAIM,Ph3 SLE 3-yr Long Term Extension Trial,
I6T-MC-AMBK,Autoinjector in patients,
I5Q-MC-CGAV,"2017-5809:PRO Usability&Debriefing Study for MSQ2.1 & eDiary",
I8B-MC-ITSJ,Ph3b URI vs Lispro pediatric pump,
I8B-MC-ITSP,Lyumjev Feasibility Algorithm Trial,
I4V-MC-JAIQ,LTE for AtD Peds Program,
I8B-MC-ITSZ,Ph2 URLi Dose Optimization Study,
I8F-MC-GPGJ,GIP/GLP-1 add onto Orals,
I1F-MC-RHCM,hidradenitis suppurativa study 1 ixekizumab vs placebo ,
J2P-MC-LXBA,MAD (plus DDI) HV,
I4V-MC-B015,Risk Tolerance Among Patients Seeking Treatment for AA,
J2N-OX-JZNI,LOXO-BTK-20011-Ph1-Pirtobrutinib-CQT,
B9E-US-S249,Phase 2 Gemcitabine/5-FU/LV - Colorectal Cancer,
F1D-XM-O124,PET in psychiatrist disturbances,
B1Y-GH-O020,Treating depression associate to diabetes mellitus with Proz,
"5843",PPAR Co-Agonist Absolute Bioavailability,
H6P-MC-HDAM,Bipolar Depression Health Outcomes Trial,
B7A-MC-MBCV,Validation of End Points Measurement Study.,
H6M-MC-LDAK,Phase II MDS in Patients with MCI with Ampa I,
H6L-JE-LFAL,JP A beta lowering P-1 SDSS,
H3S-XM-O020,Expression&regulation CYP19 in human osteoblast,
B9E-XV-S265,Ph II secuential montheraphy in NSCLC (GECP),
J1K-MC-GZCA,SAD/MAD,
B1Y-MC-X220,Relapse Prevention of Bipolar II Disorder,
I4V-MC-JAJG,RA BeMono,
"6019",JP hGH P-IV Child GHD,
J2G-OX-Y109,RET Inhibitor-MTC,
"6060",ReoPro Stroke Phase III (Trial #2),
J2G-OX-Y132,RET Inhibitor-NSCLC,
H6D-EW-LVGL,Cialis: alpha blocker interaction study (1),
"8657",Cymbalta IIT Program,
H9C-LC-BBDF,Relative Bioavailability/Bridging Study,
B9R-SB-1018,SOMATROPIN: ULLRICH-TURNER SYNDROME DRUG MONITORING,
"8767",Ph I/II - ALIMTA + Oxaliplatin + C225 - CRC,
B9R-SB-GDEK,NVSS2 - FOLLOW-UP TO FINAL HEIGHT,
H3E-MC-V005,Resistance of cisplatin selected leukimai cells of ALIMTA,
H3E-MC-V038,Translational Regulation of Dihydrofolate Reductase,
H3E-IT-S079,ALIMTA PLUS CISPLATIN NEOADJUVANT THERAPY IN MESOTHELIOMA,
"8866",a-beta ab III Biomarker study #1,
B9R-XM-B002,hGH Epidemioligical study,
B9E-US-X419,Ph I Pharm biwk Gem 24hrIV + Ironotecan 24hr IV in Adults,
B9U-SE-9434,LORABID VS ERYTHROMYCIN CONTROLLED STUDY IN URI,
"9064",JP ola  Bipolar P-III,
F1D-AY-S055,Rapid Initial Dose Escalation,
"9162",Bipolar Disorder Center for Pennsylvanians,
B9E-CA-O409,PhII Gem+Capecitabine in Adv Adenocarcinoma of Biliary Tree,
"9320",zydis efficacy and compliance,
H3E-PL-S049,Alimta first line NSCLC molecular study,
J2G-OX-Y149,RET Inhibitor-NSCLC,
J2G-OX-Y159,RET Inhibitor-NSCLC,
J2G-OX-Y193,RET Inhibitor,
J2G-OX-Y204,RET Inhibitor,
J2X-MC-PYAD,Prevention of SARS-CoV2 in nursing home patients,
J3G-MC-FSAA,Nocturnal Scratching Atopic Dermatis ,
B9E-MC-JHBI,JHBI,
J2A-MC-GZGJ,Food Effect Pharmacokinetic Component HV,
J2N-NS-I001,Ph2-LOXO-305+VEN+OBIN-naïve CLL (Jain/Wierda),
I5T-MC-B001,P-tau Non-Interventional Study,
I9Y-OX-JDHK,LOXO-IDH-22010-Ph1-IDH1- Formal Food Effect,
"18393",DDI Placeholder,
"18398",Placeholder DDI Repaglinide study,
"18405",DDI Placeholder #1,
J3N-OX-JZRD,LOXO-BCL-2x0xx-Ph1-BCL2-DDI TBC,
B9E-MC-X077,"Phase II, Gemcitabine, For Resistant Or Relapsed Lymphoma",
B9E-MC-X070,PHASE II STUDY OF GEMCITABINE IN PLATINUM TREATED NSCLC,
H6Q-MC-JCAM,Ph II Enzastaurin in Colorectal Cancer,
H7U-MC-IDAF,"Dose Confirmation, Pulmonary Insulin",
H3E-MC-S015,Placeholder for Breast,
H3E-MC-S027,Placeholder for NSCLC,
F1D-XB-O137,Neurocognitive activity in psychotic patients,
"6314",Cialis in Depressed patients treated with ISRS,
B9E-BP-O276,"Phase I, Intravesical Gemcitabine, Bladder cancer",
H3S-ME-GGKU,"FIXED DOSE OPEN STUDY IN LIPIDS, HOMOCISTEINE, ETC.",
H6N-LC-LEAN,C-14 Study LY451395,
H8G-EW-EPBC,Factor Xa - Single dose bioequivalence,
B4Z-MC-LYBO,Substance abuse,
H7X-MC-JVAC,Ph I - Gemzar+Carbo+Affinitak (7day infusion),
H7Y-MC-EYAD,Eflucimibe Phase II Study 202 (Eflucimibe + Statin),
B9E-BX-O292,Gemcitabine and Cisplatin in Urothelial Cancer,
B5K-MC-X006,EFFECTIVENESS OF HUMULIN VS.PORK INSULIN IN PREPUBERTAL IDDM,
B9E-MC-V147,Meas Effect of Gem on Cells of Primary Lung CA by CD-DST,
F1K-UT-O004,colitis ulcerosa,
B1Y-KL-O022,The Effect Fluoxetine on neurogenesis,
F1D-UT-S033,Olazapine and theoretical liquor levels,
B9E-MC-S291,Ph II- neoadjuv - Gem + Paclitaxel - Breast pharmacogenomic,
B9E-GH-S293,Gemzar 3 week regimen for NSCLC patients,
"6757",SPECT Imaging,
"6795","5-HT1F Phase lb (FHD sl/po)",
B9E-IT-JHPI,PHASE 1/2  STUDY OF GEM & EPI & PACLITAXEL IN BREAST CANCER,
B9E-MC-V177,Gemcitabine in dogs,
B1Y-GH-O026,The effect of Prozac for depression of patients with breast,
B9E-BP-O324,G-STEP: Randomised Phase II Gemzar doublets in erlderly SCLC,
F1D-MC-HGKP,Olanzapine in the Treatment of Bipolar I Depression,
"6998","1D/SSRI PET: 5HT1a ligand displacement",
H7T-EW-TAAI,CS-747: Expanded gastric pH study,
F1D-CA-HGKU,Observational Trial: Patient Outcomes with Antiphsychotics,
B4Z-MC-LYBZ,MeNER Strattera RO Study,
H6D-EW-LVES,LY450190 - Visual,
H6D-EW-LVFA,LY450190 - Renal blood flow,
J2X-MC-PYAI,combination 2800mg 555 + CB6,
"18390",Zagotenemab Phase 3 trial,
"18425",LOXO-IDH-22013-Ph1-IDH1-Cocktail in Pts,
B9E-MC-I035,PHASE I/II STUDY OF GEMCITABINE AND LOW DOSE 5 FLUOROURACIL,
F3Z-MC-B031,HumaPen PMCF study,
J2X-MC-B003,Realworld utilization & effectiveness Bebtelovimab in US EUA,
"18667",China PK Placeholder,
F1D-MC-X096,Woods-Atypical Antipsychotic Meds:  outcomes and costs,
F1D-MC-X080,Olanzapine vs. Haloperidol in Children with PDD,
B9E-MC-S014,Ph III Gem+Cis+Paclitaxel vs Gem+Cis,
F1K-LC-GUAF,F1K-LC-GUAF Aspirin Drug Interaction,
H4Z-MC-JWWI,Ph2 Endometrial Cancer: Megace Failures,
F1D-MC-HGHM,Eff. and Saf of Olanz. in tx of schizo patient in India,
F1D-MC-X082,A db olan-hal comp on clinical & neurocog measures in childr,
"2215",Comparative efficacy (HbA1c) - Modif. of physical activity,
B9E-MC-S064,"Ph ll, Gem in soft tissue sarcoma, Sarcoma",
F3Z-SB-S001,POSTPRANDIAL ADMINISTRATION  OF INSULIN LISPRO FIXED MIXTURE,
F1D-MC-X093,D2 Receptor Occupancy with Olanzapine vs. Risperidone,
B4G-EW-LCCS,Parkinson / Oral vs Patch,
"7098",Phase III GAD Placeholder for Base Case Timeline,
"7119",R Ph II G/XRT vs. Alim/XRT vs. Alim+G+XRT- Pancreas,
H3S-SB-S009,Raloxifene Obs. Trial Germany,
H8F-MC-LGCD,M1 Agonist Single & Multiple Dose Safety Study (DAT Pts),
"7269",IIT placeholder for Zyprexa tardiv,
"7300",Finland placeholder for local trials,
H8F-MC-LGCF,M1 FED DAT,
F1K-FP-EVCO,Xigris 4 days vs 7 days infusion severe sepsis,
F1D-FP-S042,Study on weight gain and metabolic issue with olanzapine,
"7362","Reimbursement Study for Italy, Spain and France",
"7416"," Duloxetine IIT Placeholder ""PAIN""",
B9E-MC-JHEU,PH.I TRIAL OF GEMCITABINE & HYDROXYUREA IN REFR. SOLID TUMOR,
"7425",Olanzapine Retrospective Study in Health Outcomes (AO),
"7439",Steroides in septic shock,
B9E-MC-JHFF,PHASE 2 TRIAL OF GEMCITABINE IN METASTATIC ESOPHAGEAL CANCER,
"7507",Observational trial to promote insulin initiation by PCPS,
"7582","Ph III Rand. APVG vs. ABVD in 1st line HD, >60 yrs. Lymphoma",
B3M-GH-S033,Ceclor in treatment of Sinusitis,
B9E-MC-JHPE,A STUDY OF GEMCITABINE IN STAGE IIIB & IV NSCLC,
"18778",GGG Kwikpen vs PBO,
F3Z-MC-IOHQ,Comparison on Humalog vs. Regular IV in Diabetics,
F1D-MC-HGHB,Olanzapine Short-Acting IM Versus Haloperidol IM,
F1D-MC-X124,Olz in the txt of children/adol. w/ bipolar,
F1D-MC-X128,Olz augmentation of fluoxetine in BDD,
B9R-MC-GDEJ,Humatrope:Dose Ranging in pediatric patients with burns,
B9E-MC-S037,Ph ll Gem+5FU CI vs. 5FU CI or other anti-folate in breast,
B9E-MC-X023,PHASE 2 STUDY OF GEMCITABINE AND CARBOPLATIN IN NSCLC,
B9E-MC-S005,Ph III Gem+Cis vs Gem+Taxol vs Taxol + Cis/NSCLC,
B9E-MC-S016,Taxol+Cis or Carbo+Tax vs. Gem+Carbo+Tax - 1st bladder cance,
B3N-ME-EUBZ,"MOXONIDINE FOR HYPERTENSION, COMPARATIVE VERSUS ENALAPRIL",
B1Y-LC-HCIL,FLUOXETINE:INTERACTION STUDY WITH TERFENADINE,
H3S-BP-GGJA,A PILOT CROSSOVER RALOX HCL VS PLACEBO ON UTERINE PLUSITILIT,
F1D-LC-LOAV,Olanzapine IM: Lorazepam IM Interaction Trial,
"2282",Alternate Delivery Phase III: BMD #2,
F1D-US-A016,Neuroprotective Actions of Olanzapine in Rat,
B9E-MC-X063,PHASE I STUDY OF GEMCITABINE PLUS CARBOPLATIN AND PACLITAXEL,
B9E-BX-O008,PI PHARMACOL. STUDY OF GEMCITABINE + VINORELBINE + CISPLATIN,
B9E-SB-O011,"Phase III Gemcitabine Adjuvany vs Control, Pancreatic Cancer",
F1D-MC-O020,Eff of Olan in 10 Puerto Rican Pat. with Chronic Tic Disorde,
B9E-MC-X101,PHASE II STUDY OF GEMCITABINE IN SOFT TISSUE SARCOMAS,
H3E-MC-JMDF,MTA in Cervix Cancer,
H4Y-BD-LJBI,Valproic acid interaction,
"2611",Alcohol interaction,
F1J-LC-SBAR,PK Study with Final Formulation,
F1D-US-X100,Olanz. vs. Halop. for Psycho-Stimulant Dependent Schizo Pts.,
"2656",Clinical and Pharmacokinetic evaluation of LY309887 administ,
"2676",A Phase 2 trial of LY309887 in Patients with NSCLC,
"2705",Corporately-funded Investigator Initiated Studies,
H4Z-MC-JWWU,(JW24)  Phase 3 Breast Secondary Prevention,
"2796",Sinusitis: Cefaclor AF 750 mg vs Cefuroxime 500 mg,
"2800",Safety and efficacy of oral moxonidine mile to moderate esse,
B1Y-MC-HCEV,FLUOXETINE VS PLACEBO IN SMOKING CESSATION,
H2Q-MC-I002,Efficacy in schzophrenia and schizo-affective disorder,
"2895",Abuse potential,
"2902","GHS:  Strength and Endurance, Phase 3",
H3E-MC-JMCL,Phase I MTA + 5-FU Bolus,
B9E-MC-X206,"Gemcitabine, 5-FU, and Leucovorin in Solid Tumors",
F1K-BL-O007,rhApc LPS binding monocytes in vitro,
B4Z-CA-B001,Atomoxetine Observational Child Study,
"7717",Duloxetine Local Registry Study,
"7746",Fellowship - Quebec Chair,
"7748",Fellowship for Dr. Cohen,
F1D-PL-O198,Prevalence of Hyperprolactynemia in atipical vs classic,
F1D-PL-O200,Efficacy of oral olanzapine in agitated pts.,
"7861",Olanzapine extension M&D,
"7870",Breast GCH,
F1J-SU-HMCW,Level of Recognition MDD with Pain in PR - SAPRID,
F1K-US-EVCR,XEUS - An Obs. Study Assessing Use of Xigris in Adults,
"7966",Characterization of EEG on Freely Behaving Rats,
"8043",Somatic Scales Validation symptoms,
"8058",Effect of Pioglitazone on Myocardial Metabolism & Function,
B9E-BX-O369,Stage IIIb NSCLC,
F1D-AY-O228,Psychosocial treatments for people with psychosis,
B4Z-US-A001,Effects of Atomoxetine on Locomotor Hyperactivities in Neona,
F1D-MC-A116, Effects of Olanzapine on Alterations in Sensory Gaiting,
"2391",GEMC.+CISPL. VS TAXOL+CARBOPL. VS NAVELBINE+CISPL. IN NSCLC,
B9E-MC-S072,Ph II Gem+Oxaliplatin,
B9E-MC-S104,"Gem+Carboplatin vs. Gem+Cisplatin, Ph 3 - Ovarian Cancer",
B9E-MC-S108,"Ph I/II High ds XRT and concomittant 5FU, f/b adj G Pancreas",
B9E-SB-O019,"Phase II, Gemcitabine,  Carboplatin  &  Vindesin In SCLC",
B9E-MC-I086,USE OF GEMCITABINE AS 2ND LINE THERAPY FOR ADVAN. NSCLC,
B9E-MC-I089,PHASE II OF GEMCITABINE + TAXOTERE ADV. CARCIONOMA OF BLADDE,
B9Z-MC-V023,In Vitro Suseptibility of Pneumococci to Dirithromycin,
B9U-US-AZDN,"Acute Sinusitis, Short Course (5day) vs 10day",
F1J-MC-SBAF,Biofeedback/Pelvic Floor Exercises,
F1J-LC-SBAL,Interaction - Calcium Channel Blockers,
B4Z-MC-LYAT,QD Dosing,
B1Y-MC-HCEI,FLUOXETINE VS PLACEBO: TREATMENT OF OBESE NIDDM,
F1K-MC-EVAF,rhAPC in acute ischemic Stroke,
H5X-BD-LTAC,"Single dose i.v. PK, PD in volunteers",
B1Y-MC-X164,"Fluox: on Conduct Disorder, Drug Abuse & Depression in Delin",
B3M-MC-AJBM,Acute Otitis Media Efficacy Study with Tympanocentesis,
B3N-PH-EUAX,A dose ranging study on moxonidine for mild to moderate hype,
B9E-MC-X208,Gemcitabine and Docetaxel/Phase 2/Urothelial Cancer,
"8329",Ph I Dose Find and Ph II MTA + Oxal in Colorectal,
B9E-SB-O020,"Phase II, Gemcitabine & Dexamethasone In Hodgkin's Disease",
F1D-MC-HGHZ,Combo of Olanz & Fluox in TX resist. dep. w/o pysch features,
F1D-MC-X118,Tx of weight gain with fluox in olanz-treated schizophrenics,
B9E-MC-X226,Phase 1/2 Study of Gemcitabine and Docetaxel in Pancreatic C,
B3M-BP-V043,PD Investigation of Cefaclor's Action on H. flu and S. pneum,
F1D-US-A026,Effect of Olanzapine on prefrontal and parietal cortex neuro,
"3158",SAIM-12.5mg  PK,
B3N-MC-EUDG,Exercise Tolerance in Congestive Heart Failure,
H3S-JE-106J,JP ralo P-I PK-BE; SDSS,
H5P-LC-BWWW,pediatric PK- POLYARTICULAR JRA.,
F1J-BD-HMAR,"Single Dose pK, pD Study of 20, 40, 60 and 80mg bid",
H6C-LC-GKAB,"SD, dose escalation in healthy volunt.with MD component",
B4Z-MC-LYAC,Dosimetry study,
H4Q-FP-A007,LY333328+ GENTAMYCIN IN ENDOCARDITIS RABBIT MODEL,
"3478",Pulmonary absolute bioavailability,
B9E-XM-JHPS,"Phase II, Gemcitabine, Adriamycin & Taxol, Breast Cancer",
H4S-SB-EWAW,Primary Stent vs Accelerated t-PA Lysis in Pts. with AMI,
B1Y-MC-X187,Antidepressant on Smoking Cessation & APA Axis Function,
"8295",PPAR Co-agonist IV -Safety and efficacy in type 2 diabetics,
F1K-MC-I001,Endotoxin Induced Pulmonary Inflammatory Response,
"8416",Ph I/II ALIMTA + Carbo + Trastuzmab in Breast Cancer,
B9E-US-X405,Ph II Cisplatin & Gemcitabine in ovarian cancer,
B9R-MC-I008,EFFECT OF SEX STEROIDS IN GH TREATED TURNER SYNDROME,
F1D-CA-O242,"Antipsychotics, Wt Gain, Diabetes and Tardive Dyskinesia",
B9R-MC-X008,EFFECTS OF RHGH THERAPY IN PATIENTS W/ CROHNS DISEASE,
"8658",Strattera IIT Program,
F1D-SB-O246,Functional magnetic resonance imaging (fMRI) study,
"8778","Ph II, ALIMTA+Carbo or Cis, Adjuvant (genomic based) NSCLC",
H6U-US-X002,PRECISE (pb responder evaluation using EEG),
B9R-SP-0002,RECOMBINANT HUMAN GROWTH HORMONE ON MAJOR BURNED PATIENTS,
"8811",Placeholer  --  [F19}MRI Validation Study  for A3,
"8816",IITs Zyprexa: Dr Millet/Dr Henry,
H3S-FP-GGLL,proportion of women with OP performing a BMD for 1st time,
H7R-MC-GCBZ,Efficacy as Mono therapy;Placebo control,
H7R-MC-GCCG,Efficacy in combination with exenatide,
B3N-BL-EUCH,Moxonidine in the treatment of arterial hypertension-mild,
H4Z-MC-JWWN,(JW22)  Ph 1/2 Trial Premenopausal Breast Canc Gene Carriers,
B1Y-MC-HCER,FLUOX V PLACEBO II:INTERMITTENT DOSING OBESE PTS,
"2835",HM/MM/HM+ Bedtime NPH vs. Premeal Regular + NPH in Type 1,
"2873",Phase 3 Pivotal 1 yr. Met Trial Extension,
H5N-MC-GFFP,Efficacy in Patients with Late Stage Type 2 Diabetes,
H4Z-MC-JWWW,(JW21)  Phase 3  Prostate Cancer Trial,
"2907",Investigator Initiated Block for Humalog - 1999,
C2N-MC-JXAL,LY355703 in Adv Ovarian CA,
B9E-MC-X178,"Gemcitabine, Ara-C, and Fludarabine in AML",
B9E-MC-X187,Low Dose Gemcitabine  Drug Incorporation,
B9E-MC-X216,Phase 1 Study of Gemcitabine and CPT-11,
"3124",Phase 1 Gemcitabine in Pediatric Leukemia,
F1D-SB-O017,Effects of Olanzapine on the Electrical Brain Activity,
H3S-US-GGJI,LIPID ALTERING EFFECTS OF EVISTA AND STATINS,
B9E-MC-X234,PHASE I TRIAL OF GEMCITABINE IN COMBINATION WITH DOCETAXEL A,
H4S-MC-V002,Evaluate new point of care coagulation tests with ReoPro,
B9E-SE-S146,GEMZAR PLUS CISPLATIN VS ETOPOSIDE PLUS CISPLATIN IN NSCLC,
F1D-MC-O025,Neuroendocrine Aspects of Olz Tx in Women w/schizophrenia,
H3S-MC-A002,Primate Study with Raloxifene and SERMIII,
B1Y-MC-X040,EFFICACY OF FLUOXETINE FOR TRICHOTILLOMANIA,
H5U-MC-HSAH,Sleep study,
B9E-MC-X249,Triple Doublet Therapy in Mullerian Cancer,
B9E-SB-O081,Gemcitabine + Vindesin in Breast Cancer,
F1D-US-X153,Data and Diagnosis:  How Real-Time Interviews Correspond wit,
"3817",Erectile Dysfunction-Comb Drug Trial w/cyclic gmp pde inhib,
F1D-MC-O034,Depot Neuroleptic Replacement with Oral Olanzapine,
B1Y-MC-X198,Treatment of Depression in Head and Neck Cancer Pts.,
B3L-MC-LWBK,Global Comparator Study,
H5P-MC-BWXH,Phase II Osteoarthritis Trial,
F1D-MC-HGIM,Effect of Antipsychotic Therapy on Glycemic Control Paramete,
F1D-MC-HGIP,Open Label safety of combination (olz & flx) therapy,
"4155",Fed Fasted Study,
B9E-MC-V025,Determine apoptotic pathways of gem in cancer cells,
B9E-VI-O109,Phase II Gemcitabine+Cis in adv. and metast. cervical cancer,
B9E-SB-O118,Gemcitabine and Vindesin in Melanoma,
"8955",Duloxetine v Duloxetine + augmentation,
B9E-US-X420,"Ph II Gem/Docetaxel recurrent Ewing's sarcoma,chondrosarcoma",
"9013",Placeholder Atomoxetine Local Plan Spain,
H8R-JE-HJAM,JP NK-1 P1 MDSS,
H6D-HL-LVGD,LiSat-Finland,
B9E-SU-I151,Phase 2 GROC in relapsed or refractory NonHodgkins Lymphoma,
"9136",US affiliate IITs,
F1J-LC-HMDS,Pilot Inhibitor study,
H3E-MC-V021,Alimta activity in Pancreatic lines,
H3E-MC-V022,Invitro ALIMTA chemosensitivity test using lung cancer cells,
B3D-BL-B004,FORTEO - HEALTH OUTCOMES,
H4S-MC-I018,Stroke Prevention with Abciximab in Carotid Endarterectomy,
F1D-JE-CS04,JP ola P-IV  Schizophrenia Health Outcome,
B9E-SB-O414,Qualitätssicherungsprojekt Gyn. Onkologie,
"9337",ZYDIS STUDY,
F1D-JE-207E,LY170053 BIOEQUIVALENCY BETWEEN 5MG TABLET AND GRANULES,
B4Z-MC-X017,"Efficacy of Atomox in Treating Inattention, Impulsivity, hyp",
B1Y-CA-C027,LOVAN VS. PLACEBO:LONG TERM TREATMENT OF OBESE NIDD,
"3367",EFFICACY & SAFETY OF OLANZAPINE IN SCHIZOPHRENIA,
B9E-MC-X149,Gemcitabine and Taxotere in Advanced Untreated NSCLC,
B1Y-MC-HCJZ,COUPLING ANYLATE CYCLASE USING 46090,
B9E-MC-V015,To Determine the chem. shift of Gemc. Metabolite (500mg),
B9E-MC-X146,Gemcitabine & Cisplatin for Adenocarcinoma of Unknown Primar,
F1D-US-X140,Olanzapine in the Treatment of Depression in the Elderly,
H4S-SN-I008,ASIA-PACIFIC ACUTE MYOCARDIAL INFARCTION TRIAL(APAMIT),
F1D-MC-X145,Effects of Olz on Neurocognitive Performance In Schizophreni,
B3D-MC-GHBJ,PTH Withdrawal Follow-up Study,
B1Y-LC-HCJX,"40mg bioequivalent study",
H3E-MC-JMDS,Pharmacogenomics in Breast Cancer,
B9E-VI-O056,"Phase II,  Gem & Cisplatin,  Adv Bilharzial Bladder Cancer",
B9E-VI-O071,"Phase II, Gemcitabine & Doxorubicin, In Adv Breast Cancer",
B5K-JE-HN03,PATIENT EXPERIENCE PROGRAM,
F1D-MC-O033,Artificial Neural Network measuring cognition w/ Olanzapine,
B1Y-MC-X078,THE ROLE OF SEROTONIN IN ANTIDEPRESSANT ACTION,
F1D-MC-A037,Effect of Olz on Behavior of OB Rat Model of Depression,
"3895",LY354740 in PMS,
H4W-MC-LLAR,Sleep Maintenance Insomnia,
B9E-MC-X265,Gemcitabine and Radiotherapy for Advanced Breast Cancer,
H6D-MC-LVCG,Preference Switch Study,
B1Y-SB-4007,FLUOXETINE/PLACEBO PARALL DBL MAJOR DEPRESSIVE,
F1D-MC-HGIW,OLZ VS ACTIVE COMP VS PBO IN BEHAVIORAL DIST/PCP DEMENTIA,
F1D-FP-O071,Reevaluation at 2 years of 145 schizophrenics cohorte,
F1D-FP-O073,olanzapine effects on attention and social adaptation,
H6M-BD-LDAF,FHD - Single Dose Escalation + food effect,
F1D-AY-O236,Schizophrenia cohort olanzapine & resperidone in the elderly,
B1Y-SB-5056,FLUOXETINE VS. AMITRIPTYLINE INPATIENT STUDY,
B9E-SB-O138,Gem + Cisplatin + Radiotherapie in NSCLC,
B4Z-MC-LYAO,Adult ADHD trial #2,
B9E-FP-O168,ITT-FEASIBILITY STUDY OF GEMZAR-CISPLATINE AS ADJUVANT THERA,
B9E-FP-O153,ITT-TREATMENT OF ADENOCARCINOMA OF UNKNOWN PRIMARY WITH CISP,
B9E-MC-S193,"GCT vs GemCarbo --> Tax vs GemCarbo (NSCLC, 1st line)",
B1Y-ME-HCKS,Use of HRT to potentiate the antidepressant efect,
B4Z-MC-LYAS,Tic/Movement Disorder,
B1Y-TW-0004,FLUXETINE VS. IMIPRAMINE IN MAJOR DEPRESSION DISORDER,
"6815",Concomitant Use of Teriparatide and Raloxifene,
"9539",Drug interaction study,
B4Z-US-X025,Pilot Stratt Tx kids w/ADHD poor response stimulant THERAP.,
F1D-JE-BMAC,JP ola P-III Bipolar DB,
F1D-LC-HGDC,OLANZAPINE/FLUVOXAMINE INTERACTION TRIAL,
H8O-MC-GWBA,Exenatide IMCT in Type 2 DM treated with Met (alone or SU),
H8O-MC-GWBJ,Monotherapy,
F1J-MC-SBCU,Mixed Urinary Incontinence study,
"9778",Ketamine,
F1D-US-X267,Awareness of Cognitive Dysfunction in Schizophrenia,
H6D-FR-LVGR,Cialis French Preference Study (Taldalafil vs Sildenafil),
B1Y-GH-O034,mechanism of cytochrome P-450(CYP)gene's influence,
B4Z-US-LYDR,Pediatric ADHD with comorbid Anxiety,
B9E-US-X442,Ph II Rituximab & Gem in pts. w/ Large B-Cell Lymphoma,
H7R-MC-GCCK,Phase 2: naveglitazar 0.75 mg vs rosi 4mg BID,
F1J-US-X001,Duloxetine for Chronic Depression: A Double-Blind Study,
B3D-US-GHCV,Forteo use in Osteoporosis evaluated by Nuclear Scintigraphy,
"9946",OLZ vs Quetiapine vs Plcb in Bipolar Depression.,
H5P-MC-BWXF,Phase III Juvenile Rheumatoid Arthritis Trial,
B9E-UT-O090,Gemcitabine and cisplatin in patients with resistant SCLC,
"3938",Effects of Classical and Atypical Neuroleptics to Anhedonia,
B9R-XM-O020,INTRAUTERINE GROWTH RETARDATION.ARAGON,
F1D-CA-O042,Olanzapine's effect on the QOL in urban homeless,
F1D-CA-O006,"a 6-month, open-label study of olanz in pts w/schizophrenia",
H3E-MC-JMED,MTA + Oxaliplatin,
B1Y-MC-X146,Serum Concentratn & Placental Passage of Fluox in Preg. Wom.,
F1J-MC-HMAT,Fixed Dose Study,
B1Y-MC-X106,FLUOXETINE SETOTONERGIC STUDY AND TREATMENT OF SPOUSAL ABUSE,
"4112",Acute Septicemic Melioidosis,
B1Y-MC-X108,FLUOXETINE: DEPRESSION AND GLYCEMIC CONTROL IN DIABETES,
H3E-MC-JMEH,MTA + adriamycin PH II,
B9E-MC-V033,Measurement of gemcitabine concentration in cancer cell line,
"4230",VOID,
B9E-BL-O110,PHASE I STUDY OF THE COMBINATION OF GEMCITABINE AND VINBLAST,
B4G-GH-O009,Dosage selection and titration study on Pergolide,
H4H-EW-LGAM,Drug Interaction Study,
B9E-MC-V098,Interaction between Gemcitabine and Vinorelbine,
B4Z-LC-LYBF,Pilot Bioequivalence #1 for Line Extension,
"6492",MDSS 1 (healthy volunteers),
"5040",Craving POC study,
F1J-MC-HMBO,Duloxetine Fibromyalgia and MDD,
"5108",MGlur2 - Prospective Cross-Racial Study,
F1D-MC-HGJG,IM Olz Depot:  Switching Study,
"5136",FHD - Single Dose Escalation,
H3S-US-X008,Effect of raloxifene on aortic elasticity in PM women,
F3Z-GN-O034,Use of CSII in severely insulin resistant patients,
B3M-SN-AJBP,Ceclor prohost effects vs Augmentin in Patients with AECB,
B9E-MC-X307,Ph Ib/II thoracic RT concurrent Gemcitabine in Limited SCLC,
B9E-JE-FACS,JP gem P-III NSCLC,
ZYY-LC-GEAB,Methods development study related to PPARalpha development,
"5320",PK comparison study - SAIM Japan,
B9E-MC-V103,Phosphorylating gem in tumor cells overexpr deoxyc kinase en,
B9E-MC-V111,Sub-cloning of human pancreatic canc cell lines,
F1D-BP-O102,"Naturalistic, Retrospective Evaluation of the Use of Zyprexa",
B3D-LC-GHAD,THE EFFECT OF LY333334 ON CALC.HOMEOSTASIS IN HEALTHY PMP FE,
H9U-BD-MDBA,Food/Ketoconazole Interaction study,
"6547",Pharmacogenomic study on solid tumor (De Braud),
H3E-US-X034,Ph II Cisplatin/Alimta & RT followed by Docetaxel in NSCLC,
B4Z-US-X032,Study of Concurrent Validation of Adult ADHD Self-Report,
H4S-BP-O014,PTCA with stenting + abciximab vs CABG in diabetes pts.,
B9E-US-S235,Ph II Gem + Paclitaxel vs Gem +Carboplatin neoadjuvant NSCLC,
H3S-EW-GGKL,CHOOSE 2:1 Evista : bisphosphonate ratio,
F1D-US-HGJT,Olanzapine vs Risperidone in the treatment of acute mania,
H3S-US-GGKN,Blood Pressure Ambulatory Monitoring,
B9E-FP-O229,ITT- Pancreas B9E-FP-O229 GEMTAX / RIO,
X1A-MC-QA04,CSF study of LY450108 and LY451395,
"5669",A COMPARISON OF VARIOUS PROVOCATIVE TESTS AND INDICES,
B9E-US-V126,gem PK for intra arterial admin for unresect. panc cancer,
H4S-SO-O020,SWEDES-Abciximab/reteplase Prehospital in AMI,
B9E-MC-V131,Cytotoxic effects of Gem on ovar clear cell carcinoma,
"5134",Central Penetration Study,
H6D-EW-LVDV,IC351 Clinical Pharmacology study in Hypertensive Patients,
"5166",Multi dose PK/PD in postmenopausal women,
B9E-SB-V057,Gemcitabine and Paclitaxel in Urothelium cancer cell lines,
B1Y-SB-0008,FLUOXETINE: DRUG MONITORING,
B1Y-ME-HCKH,FLUOXETINE VS PAROXETINE IN MD : SAFETY AND QUALITY OF LIFE,
B5K-GH-IBFG,Switch animal insulin to Humulin,
B9E-VI-O131,Phase II Gem + Cis in Stage III and IV NSCLC,
"4555",Olanzapine SAIM - paediatric study,
B9E-VI-O146,Ph II Gem+Docetaxel in MBC,
F1D-SB-O080,Efficacy of olanzapine compared to amisupride on negative s,
F1D-CA-O090,Relationship pf menstrual status to use of antipsychotics,
B9E-MC-V079,Refractory Transitional Cell Carcinoma treat w/IV Gem,
F3Z-HU-S007,Humalog Treatment of Type 2 Patients with Obesity,
B3L-BD-LWBC,Fear-Potentiated Startle Paradigm Europe:LY354740 vs Placebo,
B1Y-SZ-SZ34,FLUOXETINE: IN DEPRESSION AND OCD (COMPASSIONATE USE),
F1D-HL-HGJF,evaluate safety of olanzapine over conventional neuroleptics,
"5005",Pulm hGH: Dose Ranging in Adult GHD pts,
B1Y-UT-0194,EFFECT OF FLUOXETINE IN MEN WITH ED/PE DISORDERS,
B1Y-UT-0289,FLUOXETINE: MAINTENANCE STUDY,
F1J-MC-HMBM,"MDD Duloxetine vs Placebo, Once Daily Dosing",
B4G-EW-LBAZ,PARKINSON / PERGOLIDE MULTIPLE DOSE PK STUDY (CLINPHARM),
J1L-MC-JZGN,Ph 1/II - Pegilodeckain + Pembro + Lenv in 1L HCC,
I8F-MC-GPHS,Ph3/4 Registration w Biopsy and Liver Outcome Extension,
J1W-MC-JFFF,AMBIANCE - Ph II - MultiCmpd BC Master - Post CDK4/6 mBC,
B1Y-MC-HCIZ,Weekly dosage of enteric coated fluoxetine,
H8H-MC-LAIL,Safety of Lasmi given daily for the tx of episodic migraines,
I8H-MC-BDCR,Preservative PK HV,
F3Z-FP-IOGE,USE OF INSULIN LISPRO IN SUBCUTANEOUS PUMP,
J2G-OX-Y010,PhI-RET Inhibitor-MTC,
I7E-AV-E108,AV-1451-EXIST-105: Dallas Lifespan Brain Study - Wave 3,
J2T-DM-KGAD,Lebri w/corticosteriod in pts w/mod to severe AD (ADhere),
J2T-DM-KGAF,Lebri for pts w/ mod to severe AD,
H7I-MC-S018,UC Health feas stdy to integrate VEGA HCP report n2 workflow,
"1788","MTA for patients on a ""named patient"" basis",
"17975",Exercise capacity in patients with obesity-related HFpEF,
B1Y-IT-E042,FLUOXETINE VS AMITRIPTYLINE-DBL-MAJOR DEPRESSIVE DISORDER,
B1Y-MC-HCLC,DuraPac Seeding,
H3S-SB-GGKH,Renal insufficiency,
H4S-US-X010,Use of Abciximab during Percutaneous Coronary Intervention,
"5322",Cross over study comparing SAIM and oral - Japan,
F1D-US-X197,Olanz w or w/o Fluoxetine in treatment of  Anorexia Nervosa,
F1D-US-HGJQ,Elderly cognition trial,
F1D-US-X198,Weight Loss Program for overweight patients treated w/ APD's,
F1D-SB-O101,Gait and motor performance in schizophrenic patients under t,
B1Y-MC-X213,IIT Placeholder for CT Material Shared Stock,
F1D-SO-HGJS,Pilot Study of Zyprexa IM vs Ziprasidone IM in agitated pts.,
"5452",Gemzar+Cisplatin for NCSLC adjuvant,
B9E-MC-V114,Gem as radiosensitizer of human squamous cell carcinoma,
"5493",Ceclor MR vs Augmentin DUO in sinusitis,
F1K-MC-EVBG,Open Label Study of rhAPC in Patients with Severe Sepsis,
B3D-LC-GHBR,PTH/ Digoxin Drug Interaction Trial Part II,
F1D-IS-LOBL,Olanzapine versus Lithium in acute mania,
B9E-MC-X317,PhII Gemzar/cisplatin in unresectable pancreatic cancer,
B9E-MC-X320,PhI/II UART/Gemzar in locally adv/met pancreatic cancer,
B9E-MC-X337,Ph II wkly Gem in Children with relasped Leukemia,
"6608",iiii,
B3N-MC-EUAA,"LY326869 VS PLACEBO IN CHF:  A PHASE 2, DOSE-FINDING STUDY",
H3S-BL-I007,Randomized comparative study ralox/low dose percutaneous 17b,
H6D-MC-LVEN,Global Continuance Trial,
F3Z-XM-S015,TYPE 2 DIABETE- INSULINS REGIMEN POPULATION,
B9R-XM-S004,EFFECT OF GH IN SHORT IUGR CHILDREN,
F1D-MC-HGKA,Olanzapine Monohydrate Depot vs. Oral Olanzapine,
"6010",Prevention of Organ Dysfunction in Sepsis,
H7C-MC-LMBI,mGluR2 Prodrug vs Placebo in Mixed Anxiety/Depression,
H3E-MC-JMEY,"Phase II, Single-agent Pharmacogenomics in Colorectal Cancer",
"6048",Comparison of dulox and specific NE and 5HT transporter,
F1D-AY-O144,Nutrition group therapy to reduce weight gain in pts on Olz,
B4G-FP-LAAV,PERGOLIDE PARKINSON COMPASSIONATE USE EUROPE,
H7Z-LC-BHAA, FHD in RA patients,
B4G-JE-YI10,GAIT MONITOR,
B9E-TW-JHSB,Observational Study of Gemzar for Advanced NSCLC,
H6D-MC-LVEO,BPH,
"7495",IIT PLACE HOLDER BREAST NEOADJ LEVY,
B9E-MC-V139,Determine PK of gem in pts w/adv bladder CA,
B5Q-LC-NBBM,NIZATIDINE: EVALUATION OF POSS. DURG INTERATION/NAPROXEN,
H3S-PL-O112,"Ralox Modifies Symptoms, Joint Structures of Oseoarthritis",
B3N-CY-O001,ramipril-moxonidine vs. ramipril-HCHT in renal hypertension,
B7A-MC-A005,LONG TERM STUDY IN ALLOXAN DIABETIC RATS,
F3Z-US-X012,Comparison of Humalog Mix 75/25 with Humulin 70/30,
"6777",Multiple Course Shedding Study,
"6802",Phase 1b: Tolerability in mild Parkinson's patients,
"6841",Spec Pops Hepatic impairment,
"6851",Ph III LY900005 vs Valsartan,
"6860",Placeholder trial for IITs with Alimta in NL,
F1D-KL-S038,The efficacy and safety of IM Zyprexa,
B9E-MC-I040,"PHASEL/X STUDY OF GEM PLUS CISPLATIN,G-FU, AND LEU. IN GICA",
B9R-MC-GDGK,Adult GHD Pivotal Safety Study for Pulmonary hGH,
B9E-SB-V179,Pharmacogemonics-Project,
H7C-MC-LMCC,GAD Phase III QD Dosing,
B9E-BX-O227,PhaseII neoadjuvant chemotherapy in NSCL Cancer,
B9E-FP-O232,ITT-Gem-Ox in 1st line metastatic ovarian cancer-phase II,
F1D-US-X205,bupropion SR treatment pf overweight and obese pts,
B9R-XM-O021,GENETIC ANALYSIS OF AUTOIMMUNE THYROID DISEASE,
B9E-XM-O440,Gem-hidroxiurea,
F1D-MC-HGJZ,Olanzapine Pamoate Depot,
B9E-FP-O259,IIT-Breast B9E-FP-O259 GNOM,
H7C-LC-LMBE,Food Interaction Study - ProDrug,
B9E-FP-O262,IIT-Eval of Gemzar in patients with multiple myeloma,
F1D-US-X225,Treatment and Outcomes of Early-Onset Bipolar Disorder,
F1J-MC-HMBU,Duloxetine with comparator,
"6101",GLP-1 analogue - Geriatric,
H3E-MC-S007,"ALIMTA + GEM + cisplatin, 1st Line",
H3E-MC-S026,Placeholder for NSCLC,
F1J-MC-HMBW,Neuropathic Pain or Diabetic Neuropathic Pain #1,
H7C-MC-LMBQ,Human Disorder Model (Treier Stress Model),
B9E-MC-I074,PHASE II TRIAL OF CISPLATIN PLUS GEMCITABINE IN BREAST,
H3E-MC-S080,R-Ph II AC-->Txt vs AA-->Txt: Breast neoadjuvant,
"7120","Ph I, ALIMTA + XRT -> Gem + Cis",
H3E-MC-S036,"Phase  2 ALIMTA x 3 + GEM x 3 + ALIMTA x 3, 1st Line NSCLC",
B7A-MC-MBDF,Open Label Study for Diabetic Retinopathy and Macular Edema,
"7149",IIT placeholder,
B4Z-LC-LYCO,Definitive Bioequivalence 80 mg,
B9E-SB-S317,NSCLC patient Registry (no study drug administered),
F1K-BL-O006,BrAzilian Sepsis Epidemiologic Study - BASES,
H3E-XM-S040,PhI : Alimta-Taxotere in locally advanced/metastatic cancer,
B9E-MC-V193,Maxia pharmaceutical study,
"7249",Placeholder (Zyprexa as adjuvant therapy in ECT),
F1K-MC-EVCK,Adult patients with severe sepsis and lower risk of death 2,
B9E-MC-X073,Ph I/II study comb Gem & Rad Thpy in Tx of Panc or Biliary.,
"7363",Pre-launch observational trial,
"7419",Non-interventional Observational Pilot Trial,
"7447",Dulox in UI: Experience Study First level,
"7460",LY231514-Cis as 1st-line in advanced Gastric Ca,
"7488",ELPING,
B9E-SN-O287,PhII gem plus cisplatinum on inoperable or advanced HCC,
H7X-MC-JVAM,Ph II - Docetaxel + Affinitak - Prostate,
F1J-US-HMBZ,Open-Label Treatment with Duloxetine QD for final dose - MDD,
B1Y-BP-HC54,FLUOXETINE VS NOMIFENSINE/SLEEP AND PERFORMANCE,
"6548",Neoadiuvant Gem+RT in locally advanced bladder cancer,
F1D-UT-O157,Olanzapine bloodlevels,
F1D-AA-HGKM,Olanzapine Observational Study in Asia,
"6662",Development of Korean SCAN (K-SCAN),
"6683",Placeholder for Xigris study,
"6718",placeholder IIT Zyprexa,
F1D-BL-S035,Schizophrenia Functional and Clinical Outcomes,
"6735",Differentiating unipolar depression from bipolar depression,
B9E-US-X349,Ph II Study Gem & Carbo in Tx of Met or Recur Gallbladder,
H4S-US-X017,Safety & Efficacy of bivalirudin compared to UFH or Lovenox,
B3D-MC-GHCD,Concomitant Use of Teriparatide and Raloxifene,
B9E-MC-I013,PHASE I GEMCITABINE AND VINORELBINE IN NSCLC AND SCLC,
B9E-US-X357,Phase I Study w/CP-461 in Combination with Gemcitabine,
B9E-IN-S310,Observational - gem in urinary bladder CA,
"7597",Untitled IIT,
"7612",SDSS,
"7616",continuation treatment with Duropac in antidepressant respon,
"7647",Obs trial of Rx with Olan starts Q1 02 & ends Q2 04,
H6E-XM-B001,Observational study: Metabolic sindrome,
"7654",Psych Study efficacy of Dul in Major Dep Disorder,
"7660",Gemzar in MBC IIT # 1,
F1D-TW-O194,An open-lable study of olanzapine,
B9E-IN-O349,Gemcitabine in Breast Cancer,
"7730",Neoadjuvant use of Gemzar in Breast Cancer,
B9E-MC-V214,gem effect on panc cancer cell lines,
F1D-AY-O217,Bipolar scale,
"7830","Gemzar in Lung, Pancreas, Bladder cc.",
"7857",Fellowship for ENDO,
B9E-VI-JHDI,PHASE 2 STUDY OF GEMCITABINE IN PATIENTS WITH NSCLC,
F1D-CA-O211,Neuropsychological Change Post 6 Mth Trtmt of Schiz,
B3M-GH-V055,National Networks for the Surveillance of Antimicrobial Resi,
F1D-AY-O220,Role of D1 receptor in cognitive improvement by Olanzapine,
F1D-US-A115,Olz and Hal effects on MA drug discrimination,
H6D-MC-LVFE,Sperm Assessment Study 20 mg,
H7C-MC-LMCQ,Stress Physical Manif #1 - Cardiac Ischemic Events,
B9E-MC-V192,The research objective is to devise a quantitation method wi,
"7294",Drug Interaction - Alcohol,
B1Y-BP-HCHT,FLUOXETINE VS DOTHIEPIN COMPLIANCE STUDY IN GENERAL PRACTICE,
B1Y-BP-HCHV,FLUOXETINE TREATMENT OF DEPRESSION/ANXIETY IN THE ELDERLY,
B9E-US-X371,Immune cell func of Pan CA pts & effects of tx w/ Gem,
B3D-FR-O006,IIT -B3D-FR-O006 Pr ALEXANDRE,
"7474",Pan european NSCLC ph III trial Gem Cis +/- Vit place holder,
B7A-MC-MBDQ,Treatment of Neuropathy in Combination w/Palliative Oral Med,
B5K-GH-B001,Convenience and QoL in HumaPen Users,
B9E-PK-O345,Phase II study of Gem+ Cis as first line MBC,
"7639",IIT/ Fellowship / Chair Placeholder for Zyprexa,
B9E-US-X377,Ph II wkly Docetaxel in comb w/ Gem in Ovarian CA,
"7677",Ovarian Cancer,
"7710",IIT / Fellowship / Chair Placeholder for MTA (Alimta),
B9E-US-X382,Ph II Neoadj Thpy w/ Carbo & Gem w/ Thalidomide NSCLC.,
"7733",IIT Gemzar 2004,
"7838",Olz extension M,
"8238",Bhagat-Use of oral LY333531 in treatment of choroidal neo...,
F1K-OL-A004,Cardiopulmonary effects of aPC on lung injury in sheep,
F1D-TW-O232,The Effectiveness of weight reducing group therapy for schiz,
B9E-US-X395,Ph II Oxaliplatin & protracted infusion of Gem met. colon CA,
F1D-MC-O233,"Effect of Alcohol, Drugs & Stimulants on Course, Outcome",
"8297",Gyn Safety Core-Registration,
B1Y-BX-9001,PROZAC: EFFICACY-SAFETY IN DEPRESSED PATIENTS,
"8320",Pediatric PK Study,
H3E-US-JMGR,Single Agent Alimta in Gestational Trophoblastic Disease,
ZYY-LC-S002,Methods: Biomarker study p38 MAP Kinase,
B9E-BP-O382,Ph I Gemcitabine/concurrent RT in Cholangiocarcinoma,
"8468","Ph. II, ALIMTA + Iressa",
H8R-EW-HJAD,MDSS/PET,
"8501",Other Anxiety Disorder Commercialization Trial #2,
B9E-US-X411,Rand. PhII Gem/Trastuzumab vs Gem/Cisp/Trastuzumab breast CA,
"8579",Once Weekly Bridging study for Arzoxifene,
F1J-MC-HMDI,Recurrence Prevention,
H8G-EW-EPBD,Factor Xa: PM dosing study,
H6U-MC-X003,Continuous Performance Test (CPT) Validation Study,
H6D-SI-B003,Saudi Men - Effectiveness and Sexual Encounter Attributes,
"8752",Ph I/II - Gem + PKC-beta inhib in pts w/relpased/refrac-NHL,
H3E-US-S059,Ph II - ALIMTA /C225 vs. Alimta.>C225 - 2nd line - NSCLC,
F1D-XM-O248,Experimental study of cognitine functions,
H3E-MC-V016,Preclin Research w ALIMTA & Tritum ALIMTA in Meso Cell lines,
"8883", Local SHOX trial in France,
"8891",Placeholder with EVISTA (Specialists) (IITS+CTNR),
B9U-MC-AZCX,LORACARBEF IN ACUTE MAXILLARY SINUSITIS,
H7R-LC-GCBP,Hepatic Impairment Study,
"8926",Painful Physical Symptoms and MDD,
F1D-SB-O250,Olanzapine augmentation therapy in treatment-resistent depre,
H8D-LC-EMBC,Drug Drug Interaction PPAR Study,
B9E-SX-O427,Ph II Gem+Carbo as neoadjuvant in locally advanced Breast CA,
F1J-FW-HMEE,Cymbalta PK study for local registation,
"9089",Placeholder Nordisk studie Cialis,
"9122",Australia Open-label study,
H4S-SZ-O057,Meta Analysis,
"7842",PTH vs Alendronate in glucocorticoid induced osteoporosis,
"7851",CHUM Fellowship,
"7938",CTNR: Affinitak + Gemzar - Biliary,
B4Z-MC-LYCG,Cognition in Alzheimer's Patients,
F1D-MC-A112,Olz and neurosteroids in rodent hippocampus and olfactory,
B1Y-BX-8601,PROZAC VS TCA OPEN EVALUATION (SAFETY-EFFICACY),
"8001",Duloxetine IIT Placeholder,
F1D-US-X230,Team Solutions as a Treatment for Schizophrenia:  Testing of,
F1K-UT-O011,Activated Protein C in severe Dengue fever; DSS,
H7C-LC-LMCK,Diuretic-Probenecid Interaction Study,
F1J-JE-HMCU,LY248686 60mg multiple dose study managed by Shinogi,
B9E-XM-S336,Ph II combo Doc + Dox alternating w Gem + Cape Breast,
F1D-MC-X234,Retrospective Chart Review Study in Eldery Residential Care,
"8203",IIT Placeholder for CT Material Shared Stock,
F1J-US-A002,Chronic Admin of Dulox to Rats fro SERT and NET,
"8210",Fellowship: Olz vs Trazodone for Agitation in Dementia,
"8225",BMD BRIDGING STUDY Q-Weekly,
"9131",Olanzapine Study Drug Needs,
H6U-MC-HGLM,Olanzapine Augmentation POC,
H4S-CA-O051,The WEST study,
"8428",R2 ALIMTA+Dox vs ALIMTA+Cyclo vs Cyclo Dox Neo-Adj - Breast,
B4Z-US-X004,Atomox vs. Fluoxetine in depressed females,
"8488",Placental markers with relevance for IUGR,
H4S-SB-O055,SAM Study,
B4Z-SO-LYDC,OL treatment in adults with ADHD,
B9R-MC-I024,GHD ADULTS: EFFECT OF RHGH ON ENDURANCE AND CARDIOPULMONARY,
H7G-MC-PDAJ,Evaluation on effect ofLY582563 on Human sperm concentration,
"8577",LY450108--Rat Sleep EEG,
"8703",Daily Dosing Long-term Open Label study,
"8712","GAD Registration for China,Korea,India",
"8812",Drug Interaction Study with Duloxetine,
"8855",IIT Neurogeriatria,
B4Z-IT-LYCY,Italian Efficacy study,
B9U-MC-AZCR,LORACARBEF IN PEDIATRIC PATIENTS WITH SKELETAL INFECTIONS,
"8871",GlyT 1 inhib II Biomarker Study,
ZYY-MC-BPAA,ERbeta Ejaculate Method Study,
"9137",Evaluation of elderly patients with GHD,
"9213",IIT Placeholder - Alimta (Argentina),
B4Z-US-X028,Atomoxetine for Freezing of Gait in Parkinson's Disease,
H6D-EW-LVFW,Cialis: effect of Cialis 20mg on colour vision,
B9E-BP-V237,Molecular markers in TCC Bladder,
F1D-US-X112,Olz. on Self Injurious Behavior in Mentally Retarted/DDD Pts,
F1J-JE-HMEB,JP Dulo P-I  BE comparative study by Shionogi,
F1D-JE-202E,LY170053 LATE PHASE 2 DOSE-FINDING STUDY,
F1D-JE-301E,OLANZAPINE DOUBLE-BLIND TRIAL VERSUS HALOPERIDOL,
F1D-JE-A100,LY170053-DEPENDENCY STUDY,
B9R-BP-O036,GH in postmenopausal women and elderly men with reduced BMD,
H6D-MC-LVGH,Global Daily Dosing,
"9503",Gemcitabine & Cisplatine treatment in patients with relapsed,
"9558",PPAR alpha agonist 2nd generation,
F1D-MC-HGMG,Adolescent Safety and Tolerabilty Study,
B4Z-US-X024,Treatment related functional outcomes for Adults with ADHD,
F1D-JE-DP03,JP ola Depot DB,
"9646",LY450108 Biomarker Placeholder,
B9R-JE-GTSS,JP hGH P-II/III ISS,
"9689",MC4R Agonist -- Proof-of-Concept (POC),
"8878",SARI biomarker study #1,
"8879",SARI biomarker study #2,
"9023",JP mGluR2 P-1 new  MDSS,
"9076",Gem-platinum OS (smoking vs outcome) for 1st-line NSCLC,
"9142",Duloxetine Effectiveness for MDD+Somatic Complaints/Pain Pts,
B9E-LA-S360,Rand Ph II 1st line MBC post anthracycline GemPac vs GemCis,
B4Z-MC-X013,Atomoxetine Treatment for Cocaine Abuse & Adult ADHD,
"9326",effectiveness of olanzapine on cognitive symptoms of schizop,
H7T-MC-TAAM,Inhibition of Platelet P2 Y12 Receptor,
H8F-MC-LGCG,"Scopalamine reversal study, Double blind, pbo controlled,",
F1D-MC-A122,Regulation of GSK3B & Singaling Pathways by Olz,
H8G-MC-EPBG,Phase 2b VTE Treatment Study,
H9X-MC-GBCA,SDSS GLP-1 Analog IV-FC,
B9E-BX-O429,Ph III rand. comparing 3 combin CT in chemonaive adv. NSCLC,
"9604",Placeholder for HMDI Local Headcount,
"9620",Glargine comparison study,
H9Q-EW-LHBB,Atomoxetine V: MDSS/PET,
H3E-SB-T003,Phase I/II ALIMTA in Androgen-Indep. Metastatic Prostate-Ca.,
H6U-US-O007,Portfolio Project Triage Tool - Phase 1,
F1D-US-HGMJ,Olanzapine vs. Atypical Antpsychotics in Schizophrenia/affec,
H3E-US-X030,"PhII Cisplatin & Alimta in metastatic, squamous cell carcino",
"9940",Duloxetine in stage I and II according to Ingelman-Sundberg,
H3E-US-X031,Ph I Dose-Escalating Gem/Alimta in Adv. Pancreatic Cancer,
H3E-OL-O005,"1st line Alimta /Carboplatin vs. X",
"9938",IIT Placeholder for CT Material Shared Stock,
"10831",FHD trial for future cmpd FC000067,
I1R-FW-GLBA,SDSS,
H3E-MC-V113,Synergism between pemetrexed and PXD-101,
"10886",Zyprexa Zydis in non-compliant out-patients,
H8O-CA-GWBK,Byetta versus SU in Type II Diabetes,
H3E-AA-S110,"Alimta/Plat. w/Iressa vs Alimta/Plat. in NSCLC, non-smokers",
"10932",Ph II randomized Alimta/Carbo vs Alimta 2° line NSCLC,
H3E-IT-S105,Alimta schedule finding pilot study for Gemzar combination,
F1J-VI-B017,TRESOR: TREatment of Sub-Optimal Responders to escitalopram,
B4Z-IT-LYDS,Efficacy of Atomoxetine Hydrochloride on Quality of life,
F1J-FR-B010,Placeholder for French SBBS addendum,
B9E-FP-O446,IIT-NSCLC adjuvant B9E-FP-O446 / CH Marseille,
H3E-US-S084,Alimta/Carbo vs. Taxotere/Carbo in NSCLC,
H6N-MC-LEAR,LY451395 RBA/Food Effect,
H9P-EW-LNCZ,Biopharm CYP3A4 study - Ketoconazole and Rifampicin,
I2O-MC-HAAG,MD/PET Study,
H8Y-EW-HBCD,Formulation study:Regional Absorption Gastric (RAG),
H8Y-MC-HBDK,China PK bridging study ,
H9B-MC-BCDJ,Phase 2 placebo controlled dose ranging study in rrMS,
"11061",PET,
F1J-US-X026,Duloxetine for Perimenopausal Depression,
"12844",C14  mGluR5 Antagonist I,
"12898",Gem prodrug - Renal placeholder,
"12939",R-Ph III - GemPro vs Standard of Care-NSCLC stage 3b/4,
"12979",MS-LY vs placebo vs active Comparator + Open Label Study,
H7N-MC-FDAA,Utility of FDG-PET for development of vascular wall targets,
"13006",Non-compliance Trial ,
I3W-EW-HHAC,MAD,
I3R-EW-HMIB,mGlu2 DDI  (CYP2C9),
H8O-MC-O016,Exenatide and Cardiac Energetis in T2DM,
H3S-CA-GGGZ,RALOXIFENE VS. PREMARIN/PROVERA EFFECTS ON THE UTERUS,
H8O-MC-X002,GLP-1/GIP Levels in Pregnant Women W/ & W/O GDM,
B9E-IT-V244,In vitro study with Gemzar in various cancer types,
B9E-CA-O451,Genetic Polymorphisms and Gem/Carbo therapy for NSCLC,
F1D-IS-S062,"Zydis efficacy and compliance trial, ctnr",
H3S-JE-203J,LATE PHASE II FOR POSTMENOPAUSAL OSTEOPOROSIS,
"10149",PLACEHOLDER FOR STUDY  H3E-FP-S057,
"13401",DDI Study:  SARM Effect on Cialis,
H3S-LC-GGHL,RALOXIFENE HCL: 150MG BIOEQUIVALENCE STUDY,
H3S-LC-GGHM,RALOXIFENE HCL: 30MG BIOEQUIVALENCE STUDY,
I1K-MC-GLUF,"Phase 2 Combination Study LP10152 + TZD, SU, or DPP-IV",
"13497",Obesity 2-year treatment and maintenance,
H6D-CR-LVIW,Tadalfl in combo with 5-alpha reductase inhibitors - BPH,
H3S-MC-GGGC,RALOXIFENE VS PLACEBO IN POSTMENOPAUSAL WOMEN,
B7A-MC-V014,Assess whether Ruboxistaurin prevents or attenuates,
I4E-MC-JXBD,EXTREME - Ph II-Erbitux Safety Comparability-H&N,
H6Q-MC-V008,Enzastaurin and Alimta combinations on tumor growth,
F1J-US-X055,The Experience of Chronic Pain: A Focus Group Approach,
"13667",sTM SAD,
H6Q-MC-A034,"Pre Clinical - Lymphangiogenesis, Angiogenesis and Validatio",
I4B-JE-GPCE,JP GRAII Phase I MAD,
H3U-MC-JPAA,PH 1 CLIN/PHARM EVAL. OF LY300502 ORALLY IN PROSTATE CA. PTS,
I2Y-EW-GHFQ,Drug / Skin Interaction,
I3O-JE-JSBB,JP_c-met_Phase_1,
I4S-EW-HHCC,Biomarker-fMRI/Biopharm Sudy,
B3D-US-I006,Evaluation of PTH in Vertebral Insufficiency Fractures,
I4Y-IE-JCDD,CP20-0903: R- Ph2 -18F1 or 1121B + cape vs cape - adv or mBC,
"10165", Safety QTc Int,
B9E-MC-V258,Plueral Effusion of Carcinomatosa cancer cells,
"10226",iv Proof of Concept Migraine,
F1D-US-A127,The Effects of Adulthood Olanzapine on Behavior and Genetic,
H6Q-MC-JCBP,Hepatic Impairment Study in Cancer Patients,
"10385",AMPA IV csf study,
H6D-IT-O008,Expression and activity of PDE5 in vas deferens,
F1J-US-X024,Open-Label Duloxetine Monotherapy in the Treatment of Post t,
H6Q-MC-S015,Enzastaurin (single-agent) in AT Failures - Breast Cancer,
"10551",Acute Renal Failure,
B9E-MC-V278,p38 MARK Pathway in Gem-induced Human Pancreatic Cancer Cell,
B9E-MC-V289,Gemcitabine with Immunotherapy in Murine Tumor Model,
B9E-MC-V287,Analyze (HPLC) Triphosphorylated Metobolite of Gemcitabine,
H9W-MC-GBEC,CB1 Phase 2 Efficacy Study,
F1D-MC-HGCR,OLANZAPINE VS HALOPERIDOL IN CHILDHOOD ONSET SCHIZOPHRENIA,
"10595",Xigris in Acute Renal Failure,
F1D-IS-B021,observational zydis,
H7T-MC-V007,Prasugrel Active Metabolite on Plt Leuk Interaction,
H3E-OL-O007,"SCLC, second line, relapse after PV",
B9E-BP-O453,ABC-02 Gemzar vs Gemzar/Cisplatin in Cholangiocarcinoma,
I1K-MC-GLUE,"3 Month Phase 2 Safety and Efficacy Study",
B9E-OE-V241,E2Fregulation of GEM Resistance in Ovarian Cancer Cell Lines,
F1D-MC-HGEH,OLAN. VS. PLACEBO IN TREATMENT OF MANIA ASSOC. W/BIPOLAR I,
H6Q-MC-S007,Phase I trial Enzastaurin + temozolamide,
F1D-MC-HGFR,STUDY OF OLAN IN TREATMENT-RESISTANT MAJ.DEP W/O PSYCOTIC FE,
"10346",Relative bioavailibilty (RBA),
F1D-IS-O282,investigation of BDNF gene  poplymorphism in schizophrenia p,
B3D-US-X012, An 18 Months Open-Label Trial of Forteo in Patients with Pr,
F1D-MC-I004,Olanzapine vs. Haloperidol in Schiz.: A Health Econ Study,
H4S-BP-O066,Leeds Clopidogrel Resistance Registry,
A3Q-ME-O002,One cycle cephalexine treatment prior to amygdalectomy,
H3E-MC-V088,Chemotherapy of Pemetrexed and Gem against Nuroblastoma,
B4Z-UT-O010,Cognition IIT Buitelaar,
H6D-MC-LVHC,JP Cialis PAH Phase 1 MDS,
"10497",Drago-PKC inhib on Ocular VAS VEGF levels,
F1D-MC-X028,FIXED-DOSE VS. DOSE ESCALATION SCHEDULE FOR ORAL OLANZAPINE,
"10694",Placeholder - Partial Sleep Deprivation Study,
"10704",PH 2 Gem+Taxotere in pediatrics (w/sarcoma),
H6Q-US-S005,PII Alimta/Carbo with concurrent RT followed by Alim +/- Enz,
B9E-MC-V302,gemTP,
F1D-CA-O289,Retrospective Case Reports on Pts Using ZIM Off Label,
B9E-MC-X221,Randomized NSCLC Study,
I1J-FW-O001,Characterisation of DMET Genotypes in human subpopulations,
H6Q-MC-V017,human urothelial transitional carcinoma,
F1D-BL-S066,RAIM Olz vs haloperidol IM for acute mania rand trial,
B1Y-CP-0003,THE VALUE OF PROPHYLACTIC TREATMENT WITH FLUOXETIN AFTER ECT,
"11088",Comparation of Detemir MET versus NPL MET,
"11094",Glucagon-R Fasting/Exercise Study,
F1J-JE-106G,PHASE I STUDY ; 40MG X 1WEEK,
F1J-SB-S015,Cymbalta for Diabetic Pain +/- Depression,
B7A-EW-B002,DRIVE: Obs study of patients with diabetic retinopathy,
"11220",Ph 3 Enz vs Placebo in 2nd line meso,
H8O-MC-GWBQ,Efficacy of Exen in adolescent patients with Type 2 Diabetes,
F1J-IT-HMFQ,Cymbalta CTNR on depression in PD patients,
"11131",Comp.Ins.lispro/regular ins.in elderly pts. with Type2 Diab,
F1J-LC-HMAA,LY248686 HYDROCHLORIDE:  DOSE-RANGING STUDY,
B9E-IT-V351,Measurament of Gemcitabine in plasma and white blood cells,
H6Q-MC-V028,Enz and gemzar effect on pancreatic cancer cells,
"11210",FHD for future Compound FC000081,
H3S-US-GGLI,Estradiol Combination Therapy - 1 month treatment period,
H7T-MC-TACA,Response to antiplatelet therapy in multiple high risk pts.,
H6O-FW-GCAZ,Robustness of Beta Cell Mass Biomarker tool (Exercise),
B5K-US-X027,Oral Insulin in Relatives at Risk of Type 1 Diabetes Mellitu,
F1J-MC-SAAD,DULOXETINE FOR UI DOSE TITRATION EFFICACY/SAFETY STUDY,
H9P-MC-LNBK,NERI IV Fixed dose Monotherapy Depression placebo controlled,
F1K-SZ-O040,"Variation in Determining time ""0"" in Sepsis Care Bundles",
F1J-MC-SAAN,Effect of Duloxetine on the Serotonin/Norepinephrine Uptake,
H6Q-MC-S038,RPh II Taxol+Avastin +/- ENZ in metastatic breast cancer,
I1Z-MC-JRBA,FHD for AKT inhibitor in cancer patients,
"13946",Characterization of proinsulin specific T-cell responses in ,
B9R-IT-O042,rhGH replacement in patients with pseudohypoparathyroidism,
F1K-US-V020,"Venous Thrombosis: Genes, risks, and Management",
B9E-MC-V300,Investigate Effect of Gemzar on Pancreatic Cells,
H6U-ME-S002,Validation of a psychiatric tool IDD for Major Dep,
H6O-FW-GCAW,Exploratory study on affects of ginseng on metabolism of AZT,
"10758",Cialis Phase II PAD Proof of Concept Study,
B9E-MC-V312,Gemzar PGx,
F1J-US-HMFA,Cymbalta Vs Placebo in Long-Term Treatment Late-Life MDD,
B9E-BL-O474,Molecular markers in breast cancer.,
F1J-AA-B015,Depression Registry in Asia,
F1D-VI-HGDR,EFFICACY AND SAFETY OF OLANZAPINE VERSUS HALOPRIDOL,
F1D-VI-HGDZ,OLANZAPINE (SCHIZOPHRENIC & SCHIZOAFFECTIVE PATIENTS)RUSSIA,
B4Z-US-X052,Atomoxetine and the treatment of Adolescents with ADHD and C,
F1J-MC-I007,"Dulox double-blind, placebo pts w/ chronic fatigue syndrome",
F1D-US-X295,Oral Disintegrate vs Regular Olanz Tabs: Effects on Weight,
"11057",Acute Coronary Syndrome Subjects who are Medically Managed,
H9X-MC-GBCF,GLP-Fc in Type 2 Diabetes Mellitus with Metformin Therapy,
H3E-AG-B005,QoL in patients w/ pretreated NSCLC- Pemetrexed or other,
"11502",Ph II  ENZ Imaging Study in PET (+) pts or post chemo (NHL),
F1J-JE-HMFM,GAD Asian Ph3,
F3Z-CR-IOPH,Paragiam 1-2-3 Trial,
"11567",IIT-NSCLC H3E-FR-       Moro Sibilot/CHU Grenoble,
"11579",Placeholder IITs with PKC,
H8Z-MC-JACU,Acute myeloid leukemia,
F3Z-BP-IOFM,INSULIN LSIPRO & HUMULIN S IN ADOLESCENT PATIENT WITH IDDM,
B9E-US-S379,Ph II Gem + Avastin in MBC,
I1Q-MC-JDDC,Myostatin Ab Methods Study in Cachetic Patients,
F1J-CP-O026,"Pain, anxiety and depression Duloxetine IIT",
H6O-MC-GCEF,Pilot study for evaluationg SIDMAP for measuring Lipid flux,
I1M-MC-PEAC,Phase 1b MDSS in Parkinson's patients,
F1J-UT-O028,Added value social worker  in Tx of depr pat with Cymb,
H7U-MC-IDBM,Additional PK Study - Human Insulin Inhalation Powder,
I4V-MC-JADB,Phase I JAK vs MTX Open Label in RA done by Incyte 103,
I5T-MC-AACA,Phase 2 Efficacy study in AD patients,
B3D-US-X027,The Denosumab and Teriparatide Administration Study,
H4A-MC-V006,LY303366 STANDARD IN VITRO TESTING-CANDIDA/NEOFORMANS/KRUSEI,
H9X-MC-GBGB,Pediatric Study 1,
H8O-JE-GWDX,JP EXD QW Special PMS,
I1Y-MC-JFBI,Eg5 Inhibitor:  Hepatic Impairment ,
H9X-MC-GBDW,DPP IV Inhibitor Drug Drug Interaction Trial,
B1Y-FP-0725,PROZAC: VALIDATION OF U.S. DEPRESSION QUESTIONNAIRE,
H8Y-MC-HBDG,"Peds OL safety, tol, PK ages 12-17",
I4V-MC-JADS,Psoriasis Phase IIb PBO Controlled Efficacy and Safety Study,
"14527",C14 in oncology patients,
I6F-MC-JJCA,FHD: Ph I- ST Trial - Solid Tumors,
I1V-MC-EIAZ,Rifampin Drug Interaction Study,
H4S-MC-EWAL,CADILLAC-C7E3 AND ACS STENT TO LOWER LATE PTCA COMPLICATIONS,
"14723",Diabetes treatments targeting,
B4Z-UT-O034,"ADHD in older adults, psychiatric and physical co morbidity",
H9P-MC-LNDQ,ADHD Pediatric Relapse Prevention,
"11342",OA phase III Hip (Structural Signs & Symptoms) LY2189102,
"11364",Phase III AD Health Outcomes for OpRA III,
B9E-ME-O490,Ph II Breast cancer Gem-Car Gem-Doc Biological Markers,
H4S-FR-O073,ReoPro In Prehospital treatment Of ST Elevation (RIPOSTE),
"11516",Ph II Alimta single agent in Kras mutations 2nd line NSCLC,
"11525",Ph 3  Enzastaurin Placeholder for Planning #4,
B1Y-GH-O037,a clinical study of fluoxetine in primary depression patient,
"11593",Human 14C Study,
F3Z-BP-GVAH,INSULIN LISPRO - BASAL INSULIN REQUIREMENTS,
"11789",China Local IIT Placeholder,
F3Z-JE-305H,OPEN CLINICAL STUDY ON LY275589 BY MULTIPLE INJECTION (PRPD),
B9E-KL-O502,"Phase III, Maintenance Gemcitabine and Paclitaxel,Breast Ca.",
"11860",Placeholder for Alimta IIT,
B5K-AY-V007,Characterisation of recombinant human insulin-degrading enzy,
H8O-MC-GWCH,QW Mono,
I2D-JE-GIBD,JP 11bHSD1 PhI MDSS,
H7T-MC-V013,Effects genetic polymorph CYP286-metab clop and ticl,
B9R-GB-O046,HGH on circadian rythms in patients with low BMD and AGHD,
F1J-LC-HMAD,LY248686 HCL: MULTIPLE DOSE DOSE-RANGING STUDY. SAFETY AND,
H7T-MC-TACB,Timing of Elective CABG and admin. of prasugrel LD,
H6L-MC-LFAT,Definitive Food Effect & Administration time,
F1J-MC-SAAB,DULOXETINE FOR UI MULTIPLE DOSE EFFICACY/SAFETY STUDY,
"11300",Plan 708 was cancelled so this trial mapped to Plan 396,
"11307",UK Retrospective Audit,
"11465",Effects of Strattera and Behavior Therapy on the School and,
H3E-CA-O029,Pemetrexed/Cisplatin then Surg/Rad in Pleural Mesothelioma,
F2X-LC-HIAF,DAPOXETINE HCL (LY210448 HCL):  MULTIPLE DOSE REGIMEN AND,
B9E-IT-O505,"Ph III trial of Gem vs Gem+Cispl in NSCLC, pt with PS2",
F3Z-CA-I0CC,HUMALOG VS HUMULIN THERAPY IN NIDDM,
H9X-MC-GBCU,Drug-drug interaction with antibiotics,
B1Y-MC-HCLU,Sexual Maturation in Children wtih Depression,
F3Z-FP-IOFU,HUMALOG/HUMULIN ZINC VERSUS ACTRAPID/ULTRATARD,
"11788",China local IIT Placeholder,
H3S-US-X035,Mommagraphy-Based Risk Assessment for Breast Cancer,
I2O-MC-HAAF,Multiple Dose Safety Study,
H3E-MC-V137,Determine role of MTHFR in Alimta efficacy,
F1D-AY-B037,Inv. of Eff Combo Olan and Lith vs. Chlorpro and Lith Manic,
F3Z-MC-IOBJ,INSULIN LISPRO VS HUMULIN R IN ADOLESCENT PATIENTS,
B4Z-MC-A009,Catecholamines in the animal model of MS,
H8G-MC-EPBH,BioPharm Food Effect (EPBH),
F3Z-PH-B006,Humalog Mix 25 Post Marketing Surveillance Study,
H8Z-JE-JACX,Survivin J-PhIb,
I2K-MC-ZZAI,Relative Bioavailability #2,
I2R-MC-BIAL,T2DM 6mo Algorithm Selection Insulin Naïve ,
"12154",Miscibility Clamp Study,
F1J-JE-HMGA,JP Dulo MDD P-III Open-Label Study Managed by Shionogi,
H9R-MC-JKAH,FED TRIAL OF LY2275296 IN NSCLC PTS,
F3Z-MC-IOGV,INSULIN LISPRO LM BID+LISPRO AT LUNCH VS. HUMULIN 30/70 BID,
F4A-SB-A001,immunogenecity of pro-insulin-derived peptides,
H8O-US-GWCV,Byetta vs. Januvia (DPP-IV): 24-hour glucose profiles,
F3Z-PG-IOFN,INSULIN LISPRO IN INTENSIVE INSULIN TREATMENT:EFFECT OF PREP,
H6U-MC-X007,IVRS ASEX Validation Study,
"11802",Local Resources for External Research for WH,
F3Z-EW-S020,Progressively Upgraded Insulin Therapy Regimens,
F1K-SZ-O044,Effects of a Sepsis Management Care Package,
F1J-US-X044,Dulox Tx-Older Adults w/Comorbid Depress/Chronic Back Pain,
I1L-MC-GAEB,Phase 2 Efficacy Trial,
F4A-JE-INBA,External non-clinical research of proinsulin,
"12035",Effect of exen on intimal hyperplasia after balloon catheter,
"12066",Phase 1 study for CXCR4 peptide LY2510924,
B4Z-MC-LYEG,Atomoxetine Asia Pilot Phase2-Korea,
F1D-MC-HGMX,Long-term safety in adolescents w/ schizophrenia or bipolar,
F3Z-MC-IOFX,INSULIN LISPRO LM VS HUM 30/70: TEST MEAL STUDY IN TYPE I,
F3Z-MC-IOPW,Humalog 6 day vs. Aspart 6 day in Pump use,
"12180",Ph III Enz China Reg Trial,
H9P-MC-LNBQ,NERI-IV Depression Augmentation #2 Flex dose NERI + SSRI,
H7T-EW-TACR,Prasugrel formulation study,
"12046",polymorphism at val66met and COMT genes,
B4Z-US-X056,Evaluation of Atomoxetine for Cocaine Dependence,
I2K-MC-ZZAC,C14 Study,
H9X-MC-GBCJ,Phase 2 GLP-Fc,
F1D-US-X157,Olz. for the TX of Chorea in Huntington's Disease,
I2K-MC-ZZAH,dQTC,
H7T-EW-TACS,Prasugrel: Tablet Age on rel bio of 60mg in Healthy subs(PPI,
"12269",ABeta Antibody Renal Impairment (Placeholder),
"12279","11bHSD1 Human C14 Study",
H3E-US-S121,Phase I/II Alimta/Sutent/Carbo in NSCLC IIIB/IV,
H7T-EW-TACU,Prasugrel Particle size study (placeholder),
B4Z-US-LYEJ,ADHD and Anxiety,
I1C-JE-JLBG,JP Gemcitabine Prodrug Phase 1b,
I2U-EW-H302,SDSS,
"12326",Ph 2 Alimta-cis vs cis with Concurrent XRT in Head & Neck,
F1J-EW-HMGD,"Optimal time for switching to DLX, MDD pts SSRI non-respoder",
"12333",CGMS pilot study for algorithm,
"12336", LTB4 SDSS (FHD),
I3G-MC-A001,Novel Treatment for Pulmonary Fibrosis,
B3D-MC-B017,"2012-108_Impact on Forteo persistence on fracture outcomes",
I3S-MC-V001,High-throughput identification of biotherapeutics with minim,
I2R-MC-BIDO,"Diurnal Glucose, Lipid Metabolism Study",
I3Y-MC-JPBD,CDK4/6 C14 in Healthy Patients,
B3D-CA-O037,OPTIMUS II:Osteoporosis & Peripheral Fractures,
F3Z-CA-O082,Metabolic impact of sm intestinal nutrient sensing in humans,
I3F-MC-A001,Xenograft models of human (ACC) in immune-deficient mice,
I7D-FW-SGAA,Single ascending dose (SAD) study,
I7C-MC-FEAB,Multiple Ascending Dose Study,
H9H-MC-JBAU,Food Effect in Healthy Subjects with Standard High Fat Meal,
H9H-MC-JBAV,FED:Ph II/III LY2157299-very low to intermed risk pts w/MDS ,
I4H-MC-A002,Effects of Akt2 inhibition on human cell lines carrying Akt2,
H8L-MC-IQCF,Summative Human Factors for U-500 Syringe,
H8L-MC-IQCI,Bmab 2nd Formative HFS with PFS,
H8L-MC-IQDA,Axiron-GenIII-Formative HF study,
"12286","11bHSD1 Phase 2 Diabetes",
I3D-MC-GICC,MR Antagonist MDSS,
"12374","2-year obesity with active comparator",
"12376",MDSS/POC for LY2515682,
F1K-US-X009,Effects of Sepsis and Hemorrhage on the Lung,
F3Z-VI-IOCX,SAFETY AND EFFICACY OF INSUL. LISPRO VS. REGULAR,
H6O-SB-O004,Restoration of bcell responsiveness to GIP in patients w/T2D,
H9P-EW-LNCF,Biopharm CYP2C9 DDI - Warfarin as substrate,
H8K-JE-JZAM,JP ASAP PH 1,
H8Y-MC-HBBS,Augmentation,
H8Y-MC-HBBZ,Fail first transition to LY2140023,
H8C-MC-LQBV,OA Pain: LY545694 vs. Standard of Care (HO study),
"12754",iGluR5 Migraine Phase II,
I2K-MC-ZZBP,Antipsychotic DDI,
I2K-MC-ZZBQ,Activated Charcoal,
I3J-MC-LACF,BACE Multiple Ascending Dose (MAD),
H8K-MC-JZAN,Ph 1b-LY573636+Doxil Solid Tumor: Dose confirmation:Ovary ,
"15359",Post launch Ph 4 trial for US affiliate,
"15370",CED Registry,
I3O-MC-A001,Therapeutic agent in Malignant Pleural Mesothelioma,
I2Z-MC-E005,Impact on neuroendocrine status during cocaine dependence,
I4V-MC-JAGZ,Interferonopathies Compassionate Use,
"15492",SAD/MAD  A beta Antibody Fab PEG Japan,
I7U-MC-GAHA,Glucagon Analog Agonist II/III SAD (LY3143753 & LY3185643),
I3Y-MC-JPBP,EET Taste Study,
I7S-EW-HBEC,Multiple Ascending Dose,
H3S-US-GGIJ,Effects of Transfer from HRT to Raloxifene on QOL in postmen,
H8L-MC-IQCP,"Dulaglutide HF summative SUP, PFS (Differentiation)",
"15597","Blood Pressure  ""Placeholder""",
H3F-US-X004,Summer Camp Study 2,
I7E-AV-_A07,Tau and Amyloid Imaging in Subjects with Brain Trauma,
"15689",Japan Ph1 Trial,
I6A-EW-CBBC,C14 study,
F1D-MC-V004,Proposal to Study the Neuroprotective Effects of Olanzapine,
B3T-MC-V001,Lab study of drug resistance in leukemia/myeloma pt samples,
I5B-MC-JGDN,Ph I - Olaratumab -Pediatric Safety ,
I4E-IE-W865,Protocol CP02-9605; I Study of C225 in Combination with Pacl,
I4E-IE-W881,"Protocol CA225-071; II STUDY OF CETUXIMAB PLUS CISPLATIN, IR",
I4E-IE-W887,Protocol CA225-083; II TRIAL: CONCURRENT CHEMORADIOTHERAPY W,
I4E-IE-W938,Protocol CP02-9922; Compassionate use of anti-epidermal grow,
I4E-IE-W939,"Protocol CA225-003; A PHASE II MULTI-CENTER, OPEN-LABEL STUD",
F1J-JE-DL03,PMSS long term Fibro patients,
I7E-AV-E016,AV-1451-EXIST-016,
I6E-AV-I033,AV-45-IIT-033: NIMAD,
I2R-MC-BIDY,Short-term reversibility liver study ,
B1Y-MC-LWAG,Pindolol alone (Initial ID B1Y MC LWAG),
H3E-MC-B022,"2013-258_Alimta TKI Tx Patterns - NSCLC",
I7S-MC-HBEF,DDI CYP3A4 Inhibitor,
B4Z-EW-B013,Strattera post launch observational study (AUTOR),
B7A-MC-A022,Hypercholesterlemia incr contribution of PKC beta,
H6D-MC-A016,Treatment of Chronic HF following MI with Tadalafil,
"12371","1-year in morbidly obese patients",
"13288",OpRA Kappa - Hepatic Impairment,
B4Z-JE-LYEK,Japan Adult ADHD long-term extension,
"12424",Phase III PTHrm,
"12426",The prevelance of ADHD in children with criminal record,
H8Y-MC-HBBN,Acute Schizophrenia-placebo,
F3Z-VI-IOBU,SAFETY & EFFICACY OF PAT. WITH DIAB. MEL.,
H6D-UT-O013,Tadalafil on erectile dysf. with schizophr on antipsych med,
F1J-MC-O034,dulox in trmt of post prostatectomy urinary incontinence,
I2T-MC-LADA,Pilot CV Safety Trial,
I2T-MC-LADB,Pilot DDI trial,
"12546",Phase 2-Visceral Pain,
I3C-FW-BLAA,SDSS (FHD) CRH-1 Effort 3,
F4B-EW-E004,SEPROXETINE SAFETY AND EFFICACY PILOT IN MDD,
H2Q-EW-E002,LY246708 MULTIPLE ORAL DOSE SAFETY AND DYNAMICS,
"12347",Elderly Study,
H7T-MC-B005,ADAPT-DES Study,
H3E-BP-O040, ACCURATE: Pem-based concurrent chemoRT in ES SCLC,
"12402",Tadalafil Vs Viagra,
H8O-US-GWDW,EQW vs Lira - US,
F1J-US-X049,Duloxetine for Chemotherapy-induced peripheral neuropathy,
F3Z-XM-B008,ECOBIM: Economic impact of BMI on cost associated DMII,
F3Z-VI-IOCY,SAFETY AND EFFICACY OF INSULIN LISPRO VS REGULAR,
F1J-US-X050,Pharmacodynamics and Pharmacokinetics of dulox,
H9P-EW-LNDB,Biopharm Venlafaxin DDI Study,
H8Y-MC-HBCA,Early Episode,
I3E-BM-MSAC,MAESTRO-02,
H8O-MC-A018,Effects of DPP-4/Ex on insulin sec/card comps,
I3C-MC-BLAC,CRH-1 II Alcohol Interaction Study,
F3Z-US-IOPO,Education Study for Humalog,
H8O-EW-GWDY,QW TQT Study - BACKUP 10 week treatment,
"12895",Gem prodrug - Proton Pump Inhibitor (PPI),
"12899",Gem prodrug - Digoxin placeholder,
"12913",Dirucotide Open Label Extension - SPMS,
H8C-MC-LQBU,OA Pain Naproxen Adjunctive study #2,
"12770",Aura 3 11717,
I2K-MC-ZZAY,Anticholinergic Effects,
H2Q-MC-LZZJ,MECHANISMS OF XANOMELINE-RELATED SYNCOPE IN PTS W/ ALZ DIS,
H3E-CR-S131,R-PhIII-IC st. Alimta+Cis w/Gefitinib-Adv NonSq NSCLC-1st Ln,
F3Z-EW-S021,Randomised-controlled to assess impact of Conv.Maps on 2DM,
H3E-EW-S128,Ph2 AlimtaCis XRT in Loc Adv NonSq NSCLC,
H6D-MC-LVIF,PAH Pediatric Formulation Relative BA/BE,
F1D-US-A156,"Effect olanz hyperactivity, low self-groom, maternal neglect",
"13174",Bioavailability to compare IV and Subcutaneous dosing,
H9X-MC-GBDI,Ph IIIb Trans launch add on to basal insulin,
I3L-MC-LABB,A Multiple-Dose Study of LY2165766 in Healthy Subjects,
F1J-SB-O041,Duloxetin Pain,
F1D-GH-O324,MRS for cognition function evaluation in schizophrenes,
B4Z-JE-ST01,JP_STR_ADHD_Child_Special_PMS,
B9R-MC-GDGR,Bioequivalence of Humatrope liquid formulation,
H6D-MC-LVIG,PAH Peds - PK trial that  leads in to LVHV,
H3E-MC-JMAJ,LY231514 EVERY 21 DAYS IN LOC. ADV. OR MET. HEAD/NECK CANCER,
"13111",Ph II - Met Breast,
H6O-PL-O006,Invest. of molecular basis of MODY DM in Polish population,
H3E-CA-O053,Diagnosing lung cancer in 2008,
I2N-MC-GPBG,DDI Study: SARM + Statins,
H6N-MC-LEAX,Hepatic Impairment,
B5K-US-V016,"50 mg. human pro insulin",
F1D-US-A162,Mouse strain differences in suscept to olz-induced wt gain,
H3S-LC-GGAA,RALOXIFENE HCL TABLETS:PILOT FORMULATION EQUIVALENCE STUDY,
H9X-MC-GBDJ,Cardiovascular Study,
H6N-JE-LEBA,Japan Phase 2 Alzheimer's Disease,
"13500",LA294 Oncology phase 2/3 Multiple Myeloma study,
"13509",SAM:RBA Study,
"13617",JP TRIS PK/PD,
H3S-MC-GGGY,"COMP OF RALOX, HRT & PLACEBO IN PMPS, ASSESS LIPIDS & COAG",
H8O-MC-X024,Effect of Exenatide Treatment on Myocardial Fat Cont,
"12891",TDP - PK bridging study (Placeholder),
"12897",Gem prodrug - Hepatic placeholder,
H6U-MC-B001,DM & Dyslipidemia-Adolescents w Bipolar DO or Schizoph-(GPS),
F1J-US-I012,Dulox for tx AI-associated arthralgias in breast cancer pts.,
H8K-MC-JZAQ,Tasisulam DDI -  CYP2C19 ,
"13100",CV risk factors associated to degrees of obesity in TM2,
I3U-MC-GRCA,SDSS for Safety and Tolerability,
H3E-MC-JMBN,"COLORECTAL, PRIOR CPT-11, DOSE SCHEDULE",
I3R-EW-HMIA,mGlu2 C14,
H6D-MC-B015,Dispensing of Phosphodiesterase5 (PDE-5) Inhibitors in Men ,
I4J-MC-HHBB,FHD/FED LY2940680 in Advanced Cancer/BCC,
H7T-CA-O001,The Macstrack Project,
F1D-AY-O323,Differential treatment effectiveness in patients with the me,
H3E-US-X082,Ph I Trial Ixabepilone/Pemetrexed in Adv Solid Tumors,
H3E-US-S130,PRONOUNCE:PhIII-Pem/Carbo-->Pem vs Pac/Carbo/Bev-->Bev-NSCLC,
H6Q-MC-V070,Pre Clinical - B-cell Chronic Lymphocytic Leukemia,
H9B-MC-BCDP,LA294 Phase IIIb RA Open Label Extension,
"13504",Managing hyperglycemia in hospitals,
I4G-MC-BIBA,End Stage Renal Disease,
H3E-EW-JMIP,Single Arm Ph II NeoAd Nsq NSCLC expl. role relevant Markers,
"13627",China Byetta study,
H7T-MC-A002,Kaikita:  Effects of Pras on MI Reperfusion Injury in Mice ,
"13664",GPR119 SAD,
I4L-MC-ABEA,PK / PD Bioquivalence in Healthy Subjects,
I4L-MC-ABEC,T2DM non - inferiority,
H6Q-MC-V057,Pre Clinical - PRKCQ and KIT oncogenic in GIST,
H6Q-MC-A039,Pre Clinical - Squamous cell carcinoma of head and neck,
H6Q-MC-A041,Pre Clinical - Qdot/phosphoprotein human tissue,
I2I-MC-JMMG,Ph Ib/R PhII - LY2603618 + Pemetrexed + Cisplatin - NSCLC ,
H7T-MC-X008,Abbott: XIENCE V EECSS USA DAPT Stent Study ,
F1J-IT-O048,Ability of dlx to counteract depression-associated defects ,
"3291",BUS. PLANNING FOR POTENTIAL ALLIANCE FOR ENDOCRINE,
I3E-BM-MSAL,Repeated IV use of MBP8298 for Chronic Progressive MS Ph 2,
H8Y-EW-HBCP,PK Study to Support Add-on Indication,
"13289",OpRA Kappa - Definitive QTc,
H8A-MC-LZAP,China IMCT,
H7L-MC-MDAB,Study of FolateScan in Patients with Osteoarthritis,
H6D-MC-LVIM,"16 Wk. Unblinded Lt. Wt. Suspension PH.III OLE Pedi PAH",
F1D-FW-HGNA,China PK Trial,
"13475",Non-union Sites Study 2,
H8L-MC-IQAL,"KwikPen ""hold time"" study",
H6U-XM-S007,Effectiveness of program for high risk patients with MDD,
I3E-MC-MSAN,Progression in MS,
F3Z-CR-IOQE,Comparison Mix 25 BID vs glargine QD+Lispro ,
"13495",Alimta as 2nd line NSCLC in pts who had 1st line with Alimta,
I5Z-MC-JKBA,"FHD p38 MAP Kinase Inhibitor II, ph 1",
"13522",TDP Phase 3 with commercial device,
I4R-MC-FGAA,Phase I Study of LY287445 in Patients with Advanced Cancer,
H8L-MC-IQAO,NovoPen-3 User Study,
H7T-US-X009,Switch 600/60,
H3Z-MC-JNAA,PHASE I CLINICAL AND PHARMACOKINETIC EVALUATION LY295501,
I5E-MC-TSAF,Testosterone- Sex Dys/Energy ,
"13997",IgluR5 B'pharm Metformin DDI study,
I4V-MC-JADK,DDI:  #2,
H7T-MC-TAEM,Comparison of PD in CAD pts treated w/pras & ticagrelor ,
I4V-MC-JADY,Ph 3 Extension for all Ph 3 trials to feed into,
I4T-CR-JVBV,CP12-0924-Ph III-Ramucirumab - 2nd Line HCC,
H4A-MC-V003,LY303366 VS 400 CLINIC ISOLATES OF CANDIDA SPP & T GLABRATA,
I4I-MC-SNAC,PoC study - LY2878735,
I4L-JE-ABEK,Japan Phase 3 study with Basal Insulin Analog V,
H8O-MC-X028,Exenatide in Extreme Pediatric Obesity,
I4X-GH-JFCN,CP11-1011: CN_Ph 1B - Necitumumab (11F8) - Adv Solid Tumors,
I5L-MC-TCAA,"TC-2A Phase II, Double Blind, Safety & Efficacy Study",
B1Y-FP-0722,FLUOXETINE IN DEPRESSIVE STATES OF CANCER PATIENT,
H8O-GH-O024,"Comparison of exenatide, insulin, oral hypo agent on gly",
H3Z-SB-JNAH,PHASE1 CLIN/PHARM EVAL OF LY295501 ORAL/DAILY 5DAYS ADV/META,
"14001",Phase 2/3 with PK for CHINA,
F1D-MC-X034,Olz. vs. Hal. in Primary Negative Symptoms in Schizophrenia,
H4A-EW-XBAE,"LY303366:INTRAVENOUS SINGLE DOSE ESCALATION,SAFETY AND PK",
B9R-CA-V007,rinsulin analogues & human growth hormone in doping control ,
H3E-MC-V150,Pre Clinical - TS and Alimta Lung Cancer Therapy,
F1J-US-I014,Created in error,
"14324",Pre-Clinical TS expression in lung biopsies,
"14331",Study of the origin of irreversible endotherm:hGH&human insu,
H4H-EW-LGAA,"LY300164 SINGLE DOSE SAFETY,KINETICS AND DYNAMICS IN HEALTHY",
H4H-EW-LGAE,LY300164:SD AND MD PK IN CHRONIC EPILEPSY PATIENTS,
I5A-IE-X025,"8124: Ph II - A12 - Hepatocellular",
I5A-IE-X026,N0733: Ph II- A12+ Capec+Lapatinab vs Capec+Lapatinab-Breast,
I1F-MC-RHBH,Phase 3 CHINA Psoriasis,
F1J-US-X062,Eval Dulox’s Analgesic Effectiveness in Chronic Pelvic Pain,
I1V-MC-EIAM,Chinese PK study,
"16162",Ph2b study in Dialysis pts with Iron Restricted Anemia,
I1V-MC-EIBT,Rosuvastatin DDI,
I1F-MC-RHCD,Ixekizumab Pediatric Psoriasis Efficacy Safety Study  ,
I4X-MC-JFCW,Ph III - Necitumumab  + Pembro - NSCLC,
"16514",PK During Migraine,
I8Y-MC-CRBB,MAD/DDI,
H3F-CA-O006,"An open-label, randomized, five-way, cross-over study to com",
I7E-AV-E045,AV-1451-EXIST-045,
B1Y-IT-0004,FLUOX VS IMIPRAMINE DBL MAJOR DEPRESSIVE DIS.,
I3Y-MC-JPCO,Ph IV - Abema+Fulvestrant After Abema+AI Failure,
I8K-MC-JPDK,TQT Study,
I7E-AV-E050,AV-1451-EXIST-050,
H8H-CD-LAHF,Hepatic(COL MIG-114) ,
H8H-CD-LAHL,GLADIATOR Long Term Safety trial Lasmiditan,
H8H-CD-LAHQ,RBA liquid and tablet andStudy (COL MIG 103),
"16904",EP-RBA,
"18672",Loxo-PIK-23005-Ph1-PI3K-AME,
H7T-MC-TAED,Switching between thienopyridines ,
B7A-MC-V009,Mech and role of PKCß splicing in adipose cell,
H8O-MC-X023,Impact of Exenatide on CV Exercise Perform in T2DM,
I1A-JE-BPAG,JP ERB P-1 BPH,
"13648",iGluR5 Warfarin DDI,
F3Z-US-IOPZ,Hospital Hyperglycemia Study,
H9B-MC-BCDR,Mechanistic Study in ESRD patients ,
I1F-MC-RHAP,"Ph3: PsA in bDMARD Naive Pts 24-wk endpoint, 2 LY doses",
I4O-MC-BACF,BACE Inhibitor II tQTc,
H6Q-MC-V045,Ovarian Cancer in vitro cell cultures,
H7T-MC-V033,Teitel: Eval pras AM response in ThromboGuide platelet Agg ,
"13766",Phase III Psoriatic Arthritis,
I1F-JE-RHAR,Japan Phase 2 Study for RA,
I4W-FW-HMJB,Multiple-Ascending Dose,
H3V-MC-ETAB,LY297141 IN UNSTABLE ANGINA: DOSE RANGING AND PHASE II,
I4T-IE-JVBL,CP12-0917:R-Ph2-1121B + Platin Based Chemo-NSCLC - 1st Line,
H8H-CD-LAHR,Food Effect Study  (COL MIG-104),
I8W-MC-PDBC,MAD in HV,
H3E-MC-B028,Ph IV-PMS NI Obs Pem+IO - NSCLC,
H5N-EW-GFFA,Safety and PK of single SC and IV doses in healthy volunteer,
H7I-MC-S015,PET tracer Clinical Valid study (Test/re-Test),
"17207",Tirzepatide Risk Minimization (REMS) Assessment - 18 months,
I7E-AV-E088,"18F-AV-1451-EXIST-088",
I7E-AV-E101,"18F-AV-1451-EXIST-101",
I9R-MC-BSDG,Basal Insulin Acylated T2DM,
J1P-MC-KFAI,Japan SAD HV,
I3Y-MC-B005,"2017-6461 GHO Supportive Care Cost of Key AEs Clinical Pract",
F1D-MC-X023,Antiparkisonian Drug use during Risperidone Therapy,
J2G-OX-Y025,PhI-RET Inhibitor+Osimertinib-NSCLC,
"1783","Multiple Dose Study in Healthy, Estrogen-Treated Postmenopau",
J2G-OX-Y161,RET Inhibitor-Cholangiocellular Carcinoma,
H8O-ES-O029,EXENATIDE SAFETY & EFFICACY IN DAILY CLINICAL PRACTICE,
"13979",Humalog Mixtures Patient Driven Algorithms,
"13994",T1DM Glucose Counter Reg.,
H4A-CA-V009,LY303366 SUSCEPTIBILITY STUDY,
H7T-IT-O012,PRINA Study,
F1J-CA-O049,PERSISTANCE,
H4A-MC-V001,LY303366 AGAINST CLINICAL ISOLATES OF FILAMENTOUS FUNGI,
I2R-MC-BIAX,Any Time of Day Dosing,
I3P-MC-GKBJ,Bridging Study,
H4A-MC-XBAC,LY303366 DOSE-RANGING EFFICACY & SAFETY IN ORAL CANDIDIASIS,
"14258",Phase 3 Double-Blind Placebo-Controlled Study,
"14266",PET dosimetry/kinetics for PDE 10 Pet Tracer,
I5E-MC-TSAM,MTE04-Rand. 4-way crossover-steady state PK of testosterone,
I5L-MC-TCAG,TC-1C Open label Safety & Tolerability,
H7T-US-X013,Prevalence/association with outcomes of genetic variation,
"14322",Male Hypogonadal Osteoporosis,
I4M-MC-MRAC,PoC in Chronic Kidney Disease,
I1V-MC-EIBK,Lipid Supporting Study 5,
"14555",China IMCT single arm mono hypogonadism,
J2Z-MC-PGAA,FHD SAD SOLO COVID19 prophylaxis HV,
H7I-MC-S019,Vega Telehealth Study,
"18121",Safety MAD with healthy volunteers study,
B1Y-IT-E043,FLUOX VS IMIPRAMINE DBL MAJOR DEPRESSIVE DIS.,
F3Z-SB-IOHD,INSULIN LISPRO VS. GLIBENCLAMID/REGULAR INSULIN,
J3P-MC-FTAB,RBA of Two Formulations,
B9R-MC-B006,HumatroPen Post Market Clinical Followup,
F1D-MC-HGFM,EFFICACY & SAFETY OF OLAN. IN TX OF SCHIZO. PATIENTS IN CHIN,
H8H-MC-B009,"Single country, prospective, non-interventional, 1 arm study",
I7E-AV-E128,AV-1451-EXIST-150: KEEPS 002,
"18665",Male Fertility Placeholder,
F1D-MC-X043,Anticholinergic Effects of Olanzapine compared to Clozapine,
F3Z-US-IOHW,Type 2: Premeal Humalog as Addition to Oral Therapy,
B1Y-LC-HCCS,FLUOXETINE-DETERMINATION OF METABOLIC FATE,
B1Y-LC-HCCT,FLUOXETINE INTERACTION WITH SECOBARBITOL,
F1D-EW-HGHI,Olanzapine Transdermal Patch Pilot PK Study,
"2011",GI Absorption Study,
B9E-IT-JHQA,Ph III Gem + Cis vs Carbo + Taxol Vs Nav + Cis /NSCLC (S007),
"14589",PK DDI Study - Warfarin,
I4T-JE-JVCM,JP - R-PhII-Ramucirumab-Met Breast-1st Line,
I4T-JE-JVCN,JP - Ph Ib - Ramuricumab - Met Breast - 1st line,
I2K-MC-ZZCL,"5HT2a PET RO with HY10275",
I5E-MC-TSAZ,First Formative Human Factor Study - Gen III Applicator,
B7A-MC-V027,Sohn-levobupivacaine-induced contraction of rat aorta,
I4L-MC-ABEN,PK/PD Glargine Bridging Study,
B1Y-FP-0735,FLUOXETINE EFFICACY IN DYSTHYMIC PATIENTS,
I6B-MC-HZBD,C14,
I6H-MC-MCBC,mPges-1Inhibitor 2 Dental  Pain Study,
I1H-MC-V001,Long term cellular responses to a pulse ofTGF-beta in vitro,
I3Y-MC-A002,Preclinical testing of novel therapeutics for treating GBM,
"14963",NSTE-ACS Registry,
H9B-JE-BCEH,Autoinjector Human Factors Summative Study Japan,
H7T-MC-V036,Binding characteristics of ticag & its active metabolites,
A6J-PG-ASCC,VANCOMYCIN LEVELS DETERMINATION AT ACETATEFREE BIOFILTRATION,
I4V-MC-JAGW,Phase III multidose trial,
B1Y-HL-XO76,FLUOXETINE IN SOCIAL PHOBIA,
B9E-MC-S052,Ph lll Gem + Carbo vs Gem in NSCLC,
F1K-LC-EVAI,F1K-LC-EVAI Dialysis Filters (In Vitro),
"2110",Ph1 Randomized Multiple Dose Safety and Biomarker modulation,
B1Y-MC-HCAB,FLUOXETINE SINGLE BLIND,
H3E-MC-JMCE,"Phase II, MTA + Gemcitabine 1st line NSCLC",
H3E-MC-JMBW,"Phase II, MTA monotherapy, ovarian cancer",
B3D-MC-GHAP,Buccal delivery phase IB (GHAP),
B4G-EW-LCCT,Parkinson / Parkinson Experience Program (Dose increase),
B9E-SB-O024,"Phase I, Gemcitabine & 5-FU, Pancreatic Cancer",
B9E-SB-O025,"Phase II, Gemcitabine ,  in Adv, Inoper Cholangiocellular",
B1Y-MC-HCJR,Adherence trial comparing weekly vs daily fluoxetine,
B9E-MC-I098,PHASE 1/2 STUDY OF PROLONGED INFUSION GEMCITABINE,
B3L-BD-LWAS,LY354740 on EEGand Auditory Evoked Related Potential Brain,
B9E-MC-X055,PHASE II GEMCITABINE AS 2ND LINE THERAPY FOR SCLC,
B1Y-MC-X166,SWITCHING SSRI NONRESPOND VS CONTINUED TX  WITH SAME SSRI,
F1D-US-I026,Clozapine Vs. Olanzapine: An Effectiveness Study,
B1Y-MC-HCDY,FLUOXETINE/PLACEBO:ALCOHOL WITHDRAWAL-RELAPSE PR,
H9B-MC-BCEE,UCSD Biopsy/ MOA Study,
H7I-MC-MGDB,PET study in depressed patients for OpRA Kappa,
B5Q-KL-NCCP,GERD with LPR,
I5A-IE-X008,"8124: Ph II - A12 - Hepatocellular",
H7T-US-X015,Impact of self-reported race/ethnicity,
I4T-IE-JVCC,CP12-0713:  Ph II - 1121B + Docetaxel - Solid Tumors DDI,
I2H-MC-JWYD,Ph I/II-GSK3 Inhibitor+Chemotherapy-Untreated Met Pancreas,
H8O-SZ-O028,Tx of IR obese pt with T2DM: exenatide vs U-500,
I5E-MC-TSAU,BE Study #1 for Axiron Gen III Device,
"14538",Study of non-LY marketed compounds by Neuropsych/fMRI,
H7T-CA-O019,BADCOP: Antiplatelet effect with Clopidogrel or Prasugrel,
I1R-MC-GLDD,"DDI Study - Beta Blocker (Metoprolol, CYP2D6 inhibition) - ",
I4V-MC-JAGL,Digoxin DDI,
H7T-US-X016,TRIAGE Study,
I1F-MC-RHBK,RA Phase 2 study,
I6E-AV-_A07,Ph III correlation btw F18-AV-45 PET Imag & Amyloid Patholog,
H9S-MC-JDCJ,Phase 1 China PK study in MM patients,
I4X-IE-JFCJ,CP11-1115:PhI-11F8+Gem+Cis-Adv Solid Tumors-DDI,
I4M-MC-MRAM,Food Effect Study,
I6I-MC-LMRA,SAD,
F1J-MC-B044,Retrospective claims  for SAEs in dulox + analgesics,
"14535",Phase 1 study with Japanese HV,
H4R-LC-IPAB,LY309132:DOSE RANGING AND COMPARISON WITH HUMULIN N (II),
H7T-EW-TAEP,Oral Sensory Eval of Intermediate Peds. formulation,
I6E-AV-_010,"Ph II,Florbetapir study to eval FTD, AD and healthy controls",
H8L-MC-IQBF,Prefilled Syringe Summative Study,
H9D-MC-ITAL,Safety & Effectiveness of Aura in Type 2 Initiating Mealtime,
I4M-MC-MRAE,Drug-Drug Interaction with Keto,
H3E-MC-A004,Formyl Polyglutamate Syntase as a Predictor,
I1D-MC-JIAS,PPI/Definitive Food Effect in Healthy Subjects,
P1A-LC-Z013,METHACHOLINE AEROSOL CHALLENGE,
H7N-MC-ECBD,Viscosity Study support Device,
I5E-MC-TSBD,PK study-assess effect of shaving/deod on Axiron absorption,
I2M-MC-GSDO,Blosozumab BOLT L Formative Human Factors Study #1,
I4H-MC-V001,Effects of LYS6KAKT1 in Ephithelial versus Mesenchymal Tumor,
H3E-KL-O074,alimta IIT comparing pem and pem+cis after TKI,
H9X-MC-GBGD,Cognitive Interviews to Evaluate the MDDA Questionnaire ,
"15182",Dental Pain,
I7B-MC-DPAB,Multiple Ascending Dose ,
I6O-MC-B002,"2012-165_An Investigation of EQ-5D-5L ",
"15220",High Risk Vascular Disease,
I4L-MC-B001,Costs and health quality of life outcomes for T1 in Spain,
I7E-AV-T807,"Exploratory and Safety Study of [F-18] T807, Phase 0",
I4T-FR-JVCS,FR_TempAuthorizForUse(ATU)-PhIII-Ramuciruma-Gastric 2nd Ln,
I4T-CR-JVCT,CN_R-PhIII-RAM+Docetaxel vs Docetaxel+Placebo,
B3D-US-A004,hPTH Effect on OP Spine: Rabbit Spine Fusion Model (Nassr),
H9X-MC-B008,GHO Pragmatic Study,
I2Z-MC-E003,RAPID ExIST Trial for LY2456302 (OpRa KappaI),
F3Z-EW-IOQM,Comparison of PK and GD Profiles of U200 and U100 Humalog,
I3Y-MC-JPCB,DDI + ABPM in Pts,
I4X-MC-JFCL,Ph II-11F8+ Pac+ Carbo vs Pac+Carbo-NSCLC-1st line,
I6B-MC-HZBC,Multiple Dose Escalation study in Healthy subjects and POC ,
H4W-AY-LLAE,DOES 1 MG ORAL MELATONIN ADMINISTRATION INDUCE SLEEPINESS,
H6D-IT-A019,Effect.Tadalafil on prostrate inflammation in animal model  ,
I5H-IE-JKCA,Phase I Study of IMC-D11 in pts with Advanced Solid Tumors,
B3D-US-B021,"2013-199 ACE-Sequential OP treatments and outcomes",
J4A-LC-EZZE,PHARMACOKINETIC/DYNAMIC STUDY IN PATIENTS WITH SEVERE SEPSIS,
"15017",Conformational analyses of insulin and its metal adducts,
I4O-EW-BACX,High dose SD/MD PK study in NHV and Alz pts ,
F1D-JE-CS11,PMSS of olanzapine treatment as extension of F1D-JE-CS09,
H8L-MC-IQBT,Strattera Dosing Aids Formative Human Factors,
I6H-JE-MCBE,SD MAD,
I7D-MC-SGAE,Thorough QTc Study,
I6I-MC-LMRE,Renal Impairment,
B1Y-FP-0742,SYMPTOM INVENTORY AFTER ANTIDEPRESSIVE TREATMENT DISCONTINUA,
I7F-AV-T808,"Exploratory and Safety Study of [F-18] T808, Phase 0",
I3Y-MC-JPBJ,Ph Ib-CDK 4/6+Alimta or Gem or Ram or PI3K or Pembro - NSCLC,
I6F-MC-A002,Invitro and in vivo models of cholangiocarcinoma,
I7L-MC-ECCA,SAD/MAD,
A3Q-ME-AFBP,Mexico Keflex Bioequivalence Study of Keflex Capsules,
I1C-MC-V001,Inter-individual Variability in the Activation of LY2334737,
H9H-MC-A027,Modulation of immune responses to cancer vaccines ,
I7T-MC-RMAI,MRA III/Tadalafil Phase 2b in Resistant Hypertension,
F1D-SE-HGFH,Olanzapi Haloperidol treatment of Patient with Schizophrenia,
I6E-AV-I013,AV-45-IIT-013: Beta Amyloid in the Corital Executive Network,
"15846",Ph I-US PMC Placeholder -Olaratumab+Dox-Soft Tissue Sarcoma,
I4E-IE-W821,Protocol CA225-085; I STUDY OF ERBITUX (CETUXIMAB) IN PEDIAT,
I4E-IE-W846,CA225-112: Irino+Cis+Cetuximab-->Surg+Chemo RT-Gastric,
I4E-IE-W860,Protocol CA225-010; A I/II Study of C225 In Combination with,
I4E-IE-W868,Protocol CP02-9709; Ib/IIa Pharmacokinetics/Pharmacodynamics,
I4E-IE-W912,Protocol CA180-098; A I STUDY OF THE COMBINATIONS OF GEMCITA,
I7J-MC-BCGE,C14 Study,
I4R-MC-A001,Anti-tumor effects of LY in FGFR2-amplified gastric cancer,
I7X-EW-LLCB,MAD HV,
I6E-AV-I001,AV-45-IIT-001: Florbetapir Imaging of Patients with Dementia,
I6E-AV-I003,AV-45-IIT-003: Neuroimaging in Head Injury and MCI,
I3Y-MC-A009,CDK4/6 Inhibition in Melanoma,
F3Z-MC-B022,"2014-300 Cost Savings & Envirmtl Impact of U200 vs U100",
I4E-IE-W808,Protocol CA163-139; RANDOMIZED II OF IXABEPILONE ALONE AND I,
I4E-IE-W831,Protocol CP02-0144; A II Multicenter Study of Cetuximab in M,
I4E-IE-W851,Protocol CA225-236; II STUDY OF NEOADJUVANT GEMCITABINE/OXAL,
I4E-IE-W852,Protocol CA225-239; A II STUDY OF CETUXIMAB IN COMBINATION W,
"1592",Adult ADHD,
I8D-MC-AZEI,Formulation BE,
I4T-MC-JVDH,CRC Ph II-Ramucirumab 8mg vs 12mg 2nd line post-anti-EGFR,
A3Q-ME-AFBS,Mexico Keflex Bioequivalence Study of Keflex Liquid,
I8B-FW-ITRF,URI-Citrate+Remodulin Ph1b T1DM Pump PK/PD Variability,
I8B-FW-ITRJ,URI-Citrate+Remodulin (multi-formulation) Ph1 HV Clamp,
B1Y-MC-LWAE,Discontinuation (Initial ID B1Y-MC-LWAE),
J4A-LC-EZZG,Pilot Efficacy Rheumatoid Arthritis,
I4V-MC-B004,GPS RA EMR Claims Retropsective Obs Study,
"16511",Ph2 Abortive sumatriptan differentiation study,
I8H-MC-BDCD,"24W Phase 2 Study",
I3Y-MC-JPCN,Ph II - Abemaciclib - Mantle Cell Lymphoma,
I9K-MC-UCAA,SAD/MAD for Urocortin-2 Long Acting (LY3322207),
H3F-CA-O007,"A single-blind, randomized, cross-over study ",
B1Y-IT-HCIN,A DOUBLE BLIND PLACEBO CONTROLLED STUDY OF FLUOXETINE,
I8B-MC-ITSQ,Late Feasibility Pump Trial,
"16955",Ph2-Abema NeoAdj to Adj +/- NSAI (TRIO)-mBC,
"16956",Ph2-Ram Biomarker Sampling-CRC,
I8B-JE-B001,URI Japan Post Marketing Safety Study,
I8K-MC-JPDN,EET - Receptor Occupancy,
I9Z-MC-OFBA,SAD/MAD,
I9W-MC-IFDC,FED POC Ph2 Study,
H2Q-MC-LZYJ,Safety in mild to moderate Alzheimers (S2),
I4S-MC-HHCH,PK of LY2979165 in subjects with impaired renal function,
I6E-AV-I031,AV-45-IIT-031: PHAO,
I4C-MC-JTBH,Ph II - c-Met Antibody - NSCLC - 3rd Line,
I6F-MC-JJCD,Ph I - Notch Inhib II Combination - Solid Tumor,
H3E-MC-B024,"2013-257:Alimta-Treat to progression-Cost&CE-NSq NSCLC-1stLn",
"16318",Evaluation of the BE of Two Formulations of Mid Mix in HV,
I4T-JE-B005,JP_PMS-Ph IV - Ramucirumab + Docetaxel - NSCLC,
I7E-AV-E042,"18F-AV-1451-EXIST-042",
B9E-MC-I069,Phase I/II Trial treatment of ovarian can. with gem and doxo,
I4E-MC-JXBJ,Ph Ib - Erbitux + Pembro - SCCHN,
J4A-LC-EZZJ,C14 Metabolism,
H5H-LC-DDAB,Multiple Dose Safety and Tolerance,
I6T-MC-AMAS,Adaptive Phase 2a/2b for Atopic Dermatitis,
F3Z-MC-X039,BIGFOOT BIOMEDICAL CLINICAL RESEARCH CENTER (CRC) TRIAL,
I8K-MC-JPDI,Phase 2 POC in Pemphigus,
"3241",INVESTIGATOR INITATED TRIAL BLOCK - RALOXIFENE,
"2702",Humatrope in Pediatric Pts with Genetic Short Stature,
B9E-MC-V232,Role of Membrane transport in Gem cytotoxicity in hem malign,
"2732",Alternate delivery mechanism of action,
"2736",(JSA4) Ph 2 LY320236 for prostate cancer after surg or XRT,
H4Q-MC-ARRI,LY333328 vs Vancomycin in Complicated Skin Infections,
B3M-MC-V047,Haemophilus influenzae/Moraxella catarrhalis Surveillance,
B3M-MC-S003,Cefaclor vs Augmentin in AOME-CTNR,
B3N-AB-EUCS,Effect on hypertension in combination with SU,
B1Y-MC-HCEP,FLUOXETINE VS PLACEBO IN OBSESSIVE COMPULSIVE,
H4A-MC-XBAQ,IV vs AmB in Systemic Mould,
"2867",VOID,
"2868",VOID,
B1Y-MC-HCHP,FLUOXETINE VERSUS PLACEBO IN SOCIAL PHOBIA,
"3086",ReoPro in PVD (DUDA Study),
H4S-SB-EWAO,ReoPro as Adjunct Therapy in Peripheral Artery Thrombosis,
B9E-MC-X220,Intraperitoneal Gemcitabine and Cisplatin,
B9E-MC-X139,Gemcitabine with Continuous G-CSF,
B9E-MC-S118,Ph l/ll Gem + Capecitabine - 2nd Breast; JUl 98SU65,
B7A-BD-MBBX,Hepatic insufficiency,
B1Y-MC-I012,EXOGENOUS MELATONIN AS A HYPNOTIC AND ADJUNCT TO SSRI TREAT.,
J2G-OX-Y037,PhI-RET Inhibitor-Infantile Myofibroma,
I1F-MC-RHCU,BE PK HV,
I8F-MC-GPGZ,Tirzepatide DDI Study with Digoxin in Healthy Subjects,
I9X-MC-MTAB,SAD PET HV,
J1P-MC-KFAB,MAD in SLE (Lupus),
I6Q-MC-BIFE,Pain and Tolerability of Large Volume Delivery,
J1L-AM-JZGF,Willow 2 - Ph1 HV - PK crossover dose levels/formulations,
I6T-MC-AMBR,Miri Reformulation Pain and Tolerability Study,
"17352",Ph II - Pegilodeca+Chemoradiation+Pembro - Neoadjuvant NSCLC,
C2N-MC-JXAA,"Ph1 Dose Esc. of LY355703 IV Days 1, 4, 8, & 11 Q21 days",
F1D-MC-X045,OLANZAPINE(ZYPREXA)FOR DEVELOPMENTAL STUTTERING,
I4T-NS-I019,PhII-Ram-Nivolumab-Docetaxel-NSCLC,
J1W-MC-JE01,AMBIANCE - PhII - MultiCmpd BC TGFb+Pembro - Post CDK4/6 mBC,
H0P-MC-NP02,Intervention Specific Appendix - DPNP,
I5Q-CA-O004,tolerability of CGRP mAbs in a real-world setting,
I5B-MC-B001,Ph IV - Olaratumab - Soft Tissue Sarcoma,
H3S-MS-GGIP,PK INTERACTION - RALOXIFENE MD/METHYLPREDNISOLONE SD,
I7E-AV-E078,AV-1451-EXIST-078,
"1691","Efficacy, dose ranging in patients with uterine fibroids",
I5B-JE-B003,PMSS for Japan-Olaratumab-Soft Tissue Sarcoma,
I1F-MC-RHCL,Ph3 PPP registration trial 1,
"17029",Ph III - Ram Combo - 1L PeriOp Gastric Cancer,
J1Z-MC-HUAA,FHD SAD/MAD/DDI HV,
H8H-MC-LAIJ,Consistency Trial- ME2 China,
I9X-MC-MTAA,Single-ascending dose of LY3372689,
I4D-MC-E009,Ph2 - Prexasertib+PI3K/mTOR Inh - Ovary and Endo,
I4L-IN-ABEX,India Basaglar Ph IV Post Approval Commitment Study,
F3Z-MC-IORE,TANGO PK Study,
J1O-MC-JZHA,"Ph I/II - AurA Kinase Inhib - SCLS, Breast Cancer",
I8F-MC-GPHQ,Pediatric (Age 7-11),
J2G-OX-Y041,PhI-RET Inhibitor-NSCLC,
H9X-MC-GBGO,China Trulicity Add On Insulin Phase 3,
F1D-MC-X037,Olanzapine in Elderly Psychotic Patients with Dementia,
I4T-MC-JVDT,SAD PK sc/ISR study in HV,
J2G-OX-Y057,RET Inhibitor-NSCLC,
J2G-OX-Y067,RET Inhibitor-MTC,
J2G-OX-Y123,RET Inhibitor-MTC,
J2G-OX-Y137,RET Inhibitor-MTC,
I4V-MC-K001,NIH Bari Trial,
F1D-MC-X035,EFFECT OF OLN. VS ANTIPSYCHS ON COGNITIVE & ADAPTIV FUNCTION,
J2G-OX-Y182,RET Inhibitor,
"1800",LY303366 (IV) Pilot Study for Esophageal Candidiasis,
"1804",Phase I Trial of MTA and CPT-11,
H7I-MC-S020,Detecting Facial Changes During a Migraine Attack ,
I7E-AV-E124,AV-1451-EXIST-119: Comparison of Two Next Generation Tau Rad,
B1Y-MC-X007,FLUOXETINE IN TOURETTES SYNDROME,
F1K-MC-EVAP,The Use of rhACP in Acute Respiratory Distress Syndrome,
"3425",olanzapine and fluoxetine in the treatment of MDD,
F1D-US-X152,"Safety, Dose & Effectiveness of Olanzapine for the Treatment",
"3456",PHASE II GEM+CIS IN BREAST CANCER,
B3M-PH-S001,Open Label Efficacy & Tolerability Study,
B5K-MC-IBFK,Lung deposition study for pulmonary insulin,
B3M-IT-O001,Pharyngotonsillitis -Ceclor for 5 day vs Amoxicillin 10 day,
F1D-MC-X135,Prospective Study of Tardive Dyskinesia Development,
H4S-SB-EWAP,ReoPro in Prehospital Pts. with AMI (REOMOBILE),
B9E-MC-JHQK,Phase 4 study of the pharmacokinetics between gem + cisplati,
B1Y-MC-X036,FLUOXETINE/HALOPERIDOL IN THE TREATMENT OF SCHIZOPHRENIA,
H3S-MC-I004,Raloxifene Cardiovascular to assess arterial physiology,
B9E-UT-JHQN,"Phase  , Gem & Epirubicin, Second Line Breast Cancer",
B1Y-MC-X042,FOLLOW-UP OF MEDICATION-TREATED DYSTHYMIA PATIENTS,
B5K-MC-IBEZ,The effect of COPD on pulmonary insulin delivery,
B1Y-US-HC I,Fluoxetine Versus Placebo in Geriatric Nursing Home Patients,
I3O-MC-V003,Therapeutic targeting of Mnk kinases,
J2G-OX-Y004,Ph1-RET Inhibitor-MTC,
J2G-OX-Y048,PhI-RET Inihibitor-NSCLC,
J2G-OX-Y081,RET Inhibitor-NSCLC,
J2G-OX-Y126,RET Inhibitor-NSCLC,
J2G-OX-Y128,RET Inhibitor-NSCLC,
I8S-MC-E007,Phase I/Ib study with the combination of RMC-4630 (SHP2 inhi,
J2G-OX-Y155,RET Inhibitor-MTC,
J2G-OX-Y160,RET Inhibitor-NSCLC,
J2G-OX-Y176,RET Inhibitor,
J2T-DM-KGAY,BE Study of Vial/Needle vs Pre-filled Syringe (GB29651),
J2T-DM-KGBC,Lebri in Pts with Chronic Obstructive Pulmonary Disease,
I7E-AV-E122,AV-1451-EXIST-122,
J2N-MC-B001,"2020-9983: BTK-Mantle Cell Lymphoma",
F1D-MC-X079,OLANZAPINE FOR DA INDUCED HALLUCINATIONS IN PD W/O DEMENTIA,
B3D-EW-GHAN,Relative Bioavailability - Buccal Route vs Subcutaneous Rout,
I3Y-NS-O032,Abema combined with endocrine therapy for breast cancer,
B9E-MC-I010,Phase 1 Study of Gemcitabine and Docetaxel in NSCLC,
"15595",Renal PK ,
"15638",Second Phase 3 Trial,
I8B-FW-ITRB,URI-Vasodilator Ph1b T1DM PK/PD,
I8B-FW-ITRD,URI-Vasodilator Ph1b T1DM Pump PK/PD Variability,
I5B-EW-JGDI,LY3012207 DDI study with Doxorubicin,
F1J-JE-HMHE,JP- Cymbalta- MDD- Driving study,
H9H-MC-V016,Inhibition of DNA repair in aggressive B-cell lymphoma,
I6E-AV-I016,AV-45-IIT-016: Parkinson's Disease and Movement Disorders Cl,
H6O-JE-O010,Identification/characterization of early predictors of OP,
I4E-IE-W869,"Protocol CP02-9925; Ib, IIa Study of Anti-Epidermal Growth F",
I4E-IE-W888,"Protocol CA225-087; A II TRIAL OF ERBITUX, RADIOTHERAPY AND ",
I8D-MC-AZEM,DDI PPI,
I4D-MC-V006,LY eliminates tumor cells with oncogene-mediated DNA damage.,
I6E-AV-I019,AV-45-IIT-019: White Matter Involvement in Preclinical AD,
B4Z-US-X063,ExNCR - Atomoxetine and Phasic Dopamine Signaling,
B9E-MC-I134,"PHASE I STUDY OF GEMCITABINE, DOCETAXEL, AND CARBOPLATIN",
B9E-MC-I092,GEMCITABINE AND TOPOTECAN IN ADVANCED MALIGNANCIES,
J2N-OX-B003,"2021-10188: Loxo 305: CLL Concert Adm Claims Study",
J1S-MC-JV04,Ph2-Abema+TMZ+IRN vs TMZ+IRN-Ewings Sarcoma,
H5H-MC-DDAE,Gamma Scintigraphy - Oral Delivery of Single Dose Placebo,
"18400","PF , AIIMIN-Autoimmune, Immunomodulators & Inflammatory",
I8R-MC-B009,"2021-10667: National Trends in US Hospital Admissions for Hy",
J2A-MC-GZGR,CWM in high-risk CVD,
"18590",Patients with mixed hyperlipidemia on background stat,
"18618",DDI - Study 1 (perpetrator) - PGP and BCRP,
"18623",RBA Definitive Food Effect - Capsule formulation,
H3S-MC-GGIO,RALOXIFENE USE IN THE HEART (RUTH),
"18813",OFG CWM Peds Ph3 adolescents,
"1945",Hypoglycemia unawareness,
F3Z-FP-O014,PP Dosing: Pt function/lifestyle by age (school children),
B9E-MC-S033,Gem/Nav vs CMF in breast-S033,
B9E-MC-S017,XRT followed by Gem in bladder ca,
B9E-MC-S020,Gem+Taxetere in MVAC resistant Bladder Ca,
H4Y-MS-LJAP,"PK comparison of 2 solid formulations vs liquid, single dose",
I1F-US-B003,Determining Generalizability of Pts Enrolled in RCT for Ixe ,
I8M-MC-BIXA,SAD Study,
B3L-MC-LWAM,LY354740 effects in model of performance anxiety,
I7S-MC-HBEH,PRESENCE: Phase II in PDD,
"16316",Phase 4 placebo-controlled Vaccine Titer Trial,
H8A-MC-LZBE,Safety and Efficacy of Solanezumab in Prodromal Alzheimer's,
I1R-MC-E002,ExIST study role of glucagon signalling ,
I6T-MC-AMAH,LTE for Psoriasis,
I8H-MC-BDCJ,PK bridging HV,
I4V-MC-JAHI,NIH Natural History Study-Outcome Autoinflammatory Diseases,
I3Y-MC-JPCL,Ph Ib/II - Abemaciclib - HER2+ Neoadj Breast,
I5T-MC-AACF,Phase III Registration,
I5S-MC-EFJZ,Japan Statin Intolerant Study,
I4V-MC-B008,"2016-4942 Mixed Methods Study to Explore Experience of Pts ",
F1D-UT-HGEW,OLANZAPINE SCHIZOPHRENIA,
B9E-MC-X191,Gemcitabine & Concurrent Intracavitary Implant Radiotherapy,
J1A-MC-KDAG,Explor OL Biomarker Study for RA Pts Receiving Peresolimab,
B9E-MC-X097,GEMCITABINE AND LIPOSOMAL DOXORUBICIN IN BREAST CANCER,
B9E-MC-X110,GEMCITABINE AND PACLITAXEL IN ADVANCED NSCLC,
B9E-MC-S035,Ph II Gem/Cis post AT/ Breast ca-S035,
B9E-MC-S038,Gem/Carbo/Tax in ovarian- S038,
H4A-MC-A007,LY303366 in murine aspergillosis resistant to itraconazole,
B9E-MC-S004,Ph III Gem+Nav vs Gem+Cis / NSCLC,
"2059",LY333328 Etest development,
"2071",F1K-LC-GUAF  Aspirin Drug Interaction,
B1Y-MC-HCJB,Fluoxetine vs Placebo in Panic Disorder,
B1Y-MC-X148,"DEPRESSION, SSRI TREATMENT AND WOMEN'S SEXUAL FUNCTIONING",
F1D-MC-X061,Olanzapine on Probes of Frontal Lobe Functioning in Schizo.,
H4Z-MC-JWWS,(JW12)  Phase 2 Prostate Trial,
H4Q-IT-V016,"Resistant induction, isogenic pairs & intracellular activity",
"2217",Blinded study in type A1C-D,
H3E-MC-JMBE,"phase II, Hepatoma, this trial will be conducted by ILEX",
B3M-MC-V042,Streptococcus pneumoniae in vitro Global Surveillance Study,
H3S-BP-GGIV,MRI MEASUREMENT OF BREAST AND UTERUS USING RALOXIFENE,
B9E-MC-I122,GEMCITABINE/CAROPLATIN FOLLOWED BY PACLITAXEL IN NSCLC,
B9E-MC-X153,"PHASE I/2 STUDY OF GEMCITABINE, CISPLATIN, AND RADIOTHERAPY",
B9E-MC-I118,PHASE I/II TRIAL DOXORUBICIN/GEMCITABINE AND IFOSFAMIDE...,
H4A-MC-V017,E-test strip development for LY303366,
F1D-BL-HGHP,Open study olanzapine in Alzheimer,
B9R-MC-GDEZ,Humatrope:efficacy in elderly patients with burns,
"2564",Pediatric C,
B9E-MC-X169,"PHASE I/II TRIAL OF GEMCITABINE, CARBOPLATIN AND PACLITAXEL",
"2655",Phase 1 Clinical and Pharmakokinetic evaluation,
H5U-EW-HSAD,Effect of LY on sleep parameters using EEG,
B3T-MC-JTAH,LY335979/Daunorubicin/Ph 2/Acute Myeloid Leuk,
B1Y-MC-HCEJ,FLUOX V PLACEBO I: INTERMITTENT DOSING OBESE PTS,
B3N-ME-EUCA,Moxonidine for the treatment of hypertension. Adequate calcu,
H4A-MC-XBAK,IV vs AmB in febrile neutropenia,
C2N-MC-JXAC,Variable Infusion Rate of LY355703 in Solid Tumors,
H3S-MC-GGIY,Raloxi & Tamoxifen in PMW @ high risk of breast cancer,
H4A-FP-XBBA,Oral - Drug interaction,
"2905",Investigator Initiated Block for Humalog 1998,
B9E-MC-X031,Gemcitabine and CIsplatin/Phase 2 Study/Head and Neck Cancer,
B9E-MC-I147,Gemcitabine and Carboplatin/Phase 1/AML,
H4Z-MC-JWWZ,(JW10)  Phase 2 Breast Biomarker,
B1Y-MC-X134,FLUOXETINE TREATMENT OF SKIN PICKING,
F3Z-IT-O013,Lispro alone or w/NPH in IDDM teenager after CHO rich meal,
H3E-MC-JMAV,Ph I: ALIMTA+ Carbo + Radiation,
"2297",Evaluation of LY333334 response by ultrasound,
B1Y-MC-HCCD,FLUOXETINE COMPASSIONATE USE,
B1Y-MC-HCCF,FLUOXETINE/PLACEBO NO CODE BREAK,
B1Y-MC-HCCG,"FLUOXETINE AM VS PM (BREMNER #54, GROSSER #55)",
F1J-LC-SAAY,Multiple Dose PK - Elderly,
B4G-EW-LCCF,RLS / Patch (PLWA),
B4G-EW-LCCU,Parkinson / Adjunct / Pergolide vs Ropinirole,
B9E-MC-S069,Ph II Gem+Carbo vs. Gem+Cis in NSCLC,
B9E-MC-S078,Ph II Gem+Tax / Adv. Breast Cancer,
B9E-MC-X126,PHASE II TRIAL GEMCITABINE 150 MIN. INFUSION WEEKLY X 3,
"2505",DIFFERENTIATING PHENOTYPES FOR SMOKING,
B1Y-MC-HCDI,FLUOXETINE/PLACEBO FIXED DOSE SMOKING WITHDRAWAL,
B9E-MC-I130,PHASE I GEMCITABINE AND CARBOPLATIN IN ADVANCED NSCLC,
B1Y-MC-X170,POSTPARTUM WOMEN WHO BREASTFEED ON FLUOXETINE,
B9R-MC-GDGG,Pulm hGH; Dose Ranging in Ped GHD pts,
B1Y-BD-HCIP,SAFETY AND EFFICACY OF FLUOXETINE TREATMENT IN OLD PATIENTS,
F1J-MC-SBAQ,Urinary Incontinence in Multiple Sclerosis Patients,
F1D-US-X101,Outcome of Treatment of Psychoses by Zyprexa Vs. Haloperidol,
B1Y-MC-HCEB,FLUOXETINE PHARMACOKINETICS IN OBESE SUBJECTS,
"2719",LY354740 vs Zyban vs Placebo; Smoking Cessation,
B9R-CA-GDEL,hGH use in pts with cardiovascular disorders,
H3S-MC-GGJB,"Raloxifene vs Placebo, Effect of Markers of Bone Meta",
F1D-US-X114,Olz. in the Treatment of Secondary Symptoms in AD,
H4Z-MC-GJAA,LY353381HCl vs Placebo and Evista in Postmenopausal Women,
B3N-SB-EUBR,Effect on peripheral perfusion in NIDDM and hypertension,
"2816",Multiple Dose,
B3N-MC-GRRD,Efficacy vs Comparator,
H4A-LC-XBAN,Oral - New Capsule (cup) vs. Old Capsule (pen),
F3Z-VI-O017,IIS Lispro for Initiation of Treatment in Type 2 (Howorka),
H3E-MC-JMCV,PH II MTA + Carboplatin 1st line NSCLC,
H3E-MC-JMCX,PH II MTA + Navelbine 2nd line NSCLC,
B9E-MC-I097,Gemcitabine and Radiation Therapy for Pancreatic Cancer,
F1D-MC-HGGF,Delaying or Preventing Psychosis Onset: Olanzapine,
B5K-BD-IBEM,HUMAN INSULIN TREATMENT WITH HUMAJECT,
H8H-MC-LAHU,Evaluate Lasmiditan when Coadministered with Sumatriptan,
I9T-MC-ILAC,HV SAD/MAD w/ Pso Pt MD cohort(s),
I5B-GH-B004,CN_Ph IV PMSS-Olara+Dox-Soft Tissue Sarcoma,
I8B-MC-ITSS,U200 BE,
J1L-AM-JZGD,Cypress 2 Ph2-Pegilo+Nivolumab-NSCLC,
I8H-MC-BDCP,T1DM Tolerability Study,
I7S-MC-HBEM,PET Northwestern ClinPharm cognition fMRI study HV,
I4E-MC-B003,Ph IV - Cetuximab - Obs Retro CRC,
J2E-MC-GZJB,MAD Study for LY3374849 in Patients with T2DM,
J1L-MC-JZGK,Dose Proportionality/Injection Site Location PK study,
I6E-AV-I055,AV-45-IIT-055: ARIC-PET,
J2G-OX-Y017,PhI-RET Inhibitor+Crizotinib-NSCLC,
J2G-OX-Y027,PhI-RET Inhibitor-NSCLC,
"3073",LVH Regression,
J2G-OX-JZJS,"2 C8 Probe",
J2G-MC-JZJU,BA HV,
J2G-OX-Y066,RET Inhibitor-NSCLC,
J2G-OX-Y073,RET Inhibitor-NSCLC,
J2G-OX-Y091,RET Inhibitor-NSCLC,
J2G-OX-Y096,RET Inhibitor-NSCLC,
J2G-OX-Y113,RET Inhibitor-NSCLC,
J2X-MC-PYAC,SARS-CoV-2 Neutralizing Antibody Prophylaxis Study,
J2G-OX-Y168,RET Inhibitor,
J2G-MC-B001,"2020-9319: Clinical outcomes of RET fusion positive NSCLC ",
"18101",Dabigatran DDI HV,
J2T-MC-KGBH,Lebri vs. Dupi in moderate to severe AD,
J2T-MC-KGBK,Lebri vs placebo in Prurigo Nodularis,
I8B-MC-ITTC,Infusion Pain Pts,
J3Y-MC-LXCA,"FHD, SAD/MAD HV",
B9E-MC-X107,PHASE 2 STUDY OF GEMCITABINE AND VINORELBINE,
B9E-AY-S169,A Randomised Phase II Gemcitabine/Carboplatin in NSCLC,
F1D-MC-HGHV,SAIM Dose RESPONSE study in schizophrenia trxt of acute agit,
B9E-MC-X222,"Phase 2 Study of Gemcitabine, Cisplatin, & Ifosfamide",
B9E-SB-O033,"Phase I/II, Paclitaxel & Gemcitabine In Adv Head/Neck",
B9E-MC-X230,"Gemcitabine, Cisplatin, and Herceptin in NSCLC",
B1Y-UT-O005,Effects of Fluox in Patients with Irritable Bowel Syndrome,
B9R-US-X022,Serum Leptin Concentrations and Body Composition in GHD,
F1D-MC-X127,Olz vs Haldol in Treatment of Psychotic symptoms/PTSD,
B9E-MC-X235,Gemcitabine and Taxol in Metastatic Bladder Cancer,
"3349",Treatment of Acute Ischemic Stroke with rhAPC --Phase II/III,
"3368",EFFICACY & SAFETY OF OLANZAPINE IN SCHIZOPHRENIA,
B4G-UT-O003,Pergolide versus L-Dopa or Clonazepam in Restless Legs,
B4G-UT-O006,Pergolide Efficacy in Urine Incontinence in PD,
"3392","This is a ""block trial"" for 14 IITs for 1999.",
F1J-BD-O001,Duloxetine-tyramine pressor test,
"3430",Eneuresis in adolescents,
B4G-MW-LBAW,AN OPEN NON-COMP CS OF EFFICACY AND SAFETY OF PERGOLIDE TREA,
B1Y-MC-HCIE,FLUOXETINE VS. PLACEBO IN BULIMIA RELAPSE PREVENTION,
B9E-MC-I078,Gemcitabine and Radiation Therapy for Pancreatic Cancer,
"3181",Phase III Gem vs Topotecan in Early Relapsed Ovarian CA,
B9E-MC-S126,Ph II Gem + Taxol +Cis - 1st line Bladder cancer,
B1Y-MC-X006,TREATMENT OF HIV ASSOCIATED DEPRESSION,
B9E-SB-JHML,"Phase I/II, Gemcitabine & 5-FU, In Pancreatic Cancer",
"3328",EFFICACY AND SAFETY OF HUMALOG IN KOREAN DIABETIC PATIENTS,
B5K-MC-IBFS,Efficacy of PI in patients on metformin,
B1Y-MC-X028,FLUOXETINE:PLACEBO CONTROLLED TRIAL IN ANOREXIA NERVOSA,
"3519",SAFETY STUDIES FOR CONCORD ANIMAL STUDIES,
B7A-JE-102M,PKC1 P-I single oral  FED,
B9E-MC-S136,Ph 2 Gem+5FU/Leucovorin in 2nd line CRCancer-Oct98SU90,
H6D-EW-LVAQ,Warfarin Interaction study,
B9E-VI-O064,"Phase II, Gemcitabine & Vinkristin,  Study in NSCLC",
H6D-EW-LVBW,LY450190 study in the Elderly,
H5Z-MC-LUAF,R-fluoxetine PET study,
B1Y-MC-X074,OBSTRUCTIVE SLEEP APNEA,
B9E-XM-JHPH,"Phase I/II, Gemcitabine, Cisplatin & Taxol,  Bladder Cancer",
B1Y-MC-X032,FLUOXETINE VS PLACEBO IN BULIMIA NERVOSA,
H6D-LC-LVAB,Short-acting Nitrates Interaction Study,
H3E-MC-JMDR,A Phase II Trial of MTA in Patients with Pleural Mesotheliom,
H6D-EW-LVAX,Thiazide interaction study,
B9E-VI-O072,"Phase II, Gemcitabine & Doxorubicin, In Adv Breast Cancer",
B3N-SB-EUDM,Mox. vs Enalapril in the Treatment of HTN in Depressive Pts,
H6D-MC-LVBN,Pivotal on demand therapy,
B9E-BX-O080,"PH. II OF CARBOPT, TAXOL, GEMZAR IN UNTREATED OVARIAN CANCER",
B9E-XV-S141,PHASE II; GEMCITAB. & 5-fu 48 h C.I; ADVANCED PANCRE. CANCER,
B1Y-MC-X194,Treatment for Adolescent Depression Study,
B4Z-LC-LYAJ,Drug Interaction Midazolam,
"3905",Alcohol Interaction,
B9E-MC-X252,Phase I Study of Gemcitabine and Bryostatin,
"3960",Pioglitazone Interaction,
H3S-IT-V005,Raloxifene and  modulation of vascular wall  through NO,
H3E-MC-JMDZ,MTA in taxol herceptin failures,
"4122",Warfarin Interaction,
F1J-MC-HMBH,Duloxetine Depression - Once Daily Dose,
B5Q-JE-YI27,CLINICAL TRIAL OF NIZATIDINE FOR THE TREATMENT OF GASTRITIS,
B1Y-BP-HC26,FLUOXETINE/AMITRIPTYLINE IN MDD ECG & EGG EFFECTS,
H5P-MC-BWXG,Phase Ib Arthroscopy Trial,
F1D-SB-LOAO,Cognitive Effects of Olanzapine Treatment in Schizophrenic P,
B1Y-BP-HC27,FLUOXETINE VS IMIPRAMINE IN MDD,
F1D-CA-O009,effectiveness of Calgary early psychosis trtmt & prev prog,
H3E-MC-JMEE,MTA + Gem neoadjuvant,
B9E-TW-O002,Feasibility of Gem/Cis before Loc treat in NSCLC,
B1Y-MC-X101,FLUOXETINE TREATMENT OF ADOLESCENTS WITH MAJOR DEPRESSION,
B9E-SB-O097,Gemcitabine + Cisplatin in Mamma-CA,
B1Y-MC-X102,ADJUNCTIVE FLUOXETINE IN NEGATIVE SYNDROME OF SCHIZOPHRENIA,
"4130",R-fluoxetine Platelet Effect,
"4156",Ovulation Study,
B9E-GH-O125,New adjuvant therapy of Gemzar in phase III NSCLC patient,
"4203",Single dose; dose escalation,
B9E-MC-V053,Radiosensitizing properties of gem in brain tumors,
B1Y-NZ-0003,FLUOXETINE:  PREDICTORS OF OUTCOME IN DEPRESSIVE DISORDERS,
B5K-MC-IBFA,Effect of RA disease on pulmonary insulin delivery,
F3Z-MW-O022,POSTMEAL VS PREMEAL HUMALOG IN CHILDREN WITH IDDM,
B9E-VI-O059,"Phase II,  Gemcitabine,  Adv. Bilharzial Bladder Cancer",
B9E-VI-O065,"Phase II, Gemcitabine & Cisplatin,  In NSCLC",
H6D-MC-LVBS,First Human dose (Glaxo study),
B9E-PK-O077,"Phase II, Gemcitabine & Cisplatin, in Adv Gallbladder",
B9E-PK-O078,Phase I Gemcitabine & Ifosfamide in Metastatic Breast Cancer,
F1D-US-A036,Neuroleptic Effects on Glutamatergic Transmission,
H3S-BP-GGJU,EASTELL - BONE MARKER  MONITORING STUDY,
F1D-SB-HGFZ,German Drug Utilisation Observation Study Olanzapine,
H4Z-MC-JWXD,Phase III Metastatic Breast - SERM vs Tamoxifen -,
"3887",Ph II LY354740 vs. placebo vs. paroxetine in panic disorder,
"3908",MGlur2 - Antihypertensive Interaction,
"3914",Phase II efficacy/safety trial of concorde in depression,
B9E-MC-X256,Gemcitabine/XRT/Amifostine in NSCLC,
B7A-BD-MBCG,Food effect/timing,
B9E-MC-X260,Phase 2 Trial of Gemcitabine and Paclitaxel in Breast Cancer,
B7A-FW-MBCO,"32mg Bioequivalence",
F1D-CA-O029,Service delivery patterns of schizophrenics,
"4142",Single dose safety study Japan,
F3Z-US-IOMN,Comparison of LM + metformin vs NPH + metformin,
F1D-CA-O053,Relation btw nutrition and weight gain with Zyprexa,
F3Z-IN-S004,Effect of Insulin Lispro in various ethnic groups in India,
B1Y-OL-E049,FLUOXETINE/AMITRIPTYLINE MAJOR DEPRES. DISORDER,
B9E-MC-V063,Effect of Tax on Gem incoporation into RNA and DNA,
B9E-GH-JHRB,Weekly schedule of Texotere+Gem in NSCLC,
B1Y-GH-O015,Prozac in treatment of depression in cancer patients,
B9E-BX-O134,GEMCITABINE/CISPLATIN IN PATIENTS WITH NSCLC STAGE IV,
F1K-LC-EVAW,LY203638: ESRD (III)--rhAPC during hemodialysis,
"4461",Test,
B3M-PU-S019,Ceclor vs. Augmentin in Acute Otitis Media,
"4554",Olanzapine SAIM - site of injection study,
H4H-MC-LGAQ,AMPA Receptor blockade in Parkinson's Dis.,
"4652","GHS: Physical Performance Score, Phase 3",
B9E-BP-A005,Tumour uptake and metabolism of gemcitabine in solid tumours,
H4S-SB-O012,t-PA+Abciximab vs. stenting +Abciximab in AMI,
F1D-US-A049,"effect of olz, ris, & halo, administered to rats during dopa",
"4811",Phase I/II study of pegylated liposomal doxorubicin and gemc,
B1Y-SB-1012,FLUOXETINE DRUG MONITORING II,
F3Z-IT-O027,Lispro and NPL vs Regular and NPH in NIDDM,
B9E-MC-S148,Phase III Gem vs Gem+5-FU in Pancreatic Cancer,
B9E-SB-O135,Gem/Vinorelbin/Taxol vs Gem/Vinoralbin/Cis vs Taxol/Cis,
H6N-BD-LEAC,Multiple Dose Escalation,
H6N-BD-LEAD,Clinical Pharmacology Study - Pharmaco EEG,
F1D-US-X172,An Olz model for relieving anxiety in schizo pts/compliance,
"4545",AP Regional Humulin/Humalog Switch Study,
"4632",LY354740 vs. Placebo in Panic Disorder,
B1Y-SO-0001,FLUOXETINE:  NAMED PATIENT,
H6O-FW-GCAJ,Ehnicity on CYP 3A metabolism & induction by rifampicin,
B9E-MC-S217,Gem vs Gem + 5FU,
H6R-BD-LXAB,"PHASE 1,SINGLE I.V., DOSE KINETICS,SAFETY,DYNAMICS",
H6Q-MC-JCAH,Phase I  Cap/LY317615,
B9E-MC-X287,Ph2 with Exisulind & Gemzar in Pt w/ Recurrent NSCLC,
B9E-MC-X298,"Ph2 study of gem,5fu,rad therapy in nonmet. pancreatic Aden.",
B3M-IN-AJBL,Cefaclor vs amoxycillin clavulinic acid in otitis media,
H6D-EW-LVCT,IC351 Multiple Dose Study in Japanese Subjects,
"4950",Clin Pharm Drug Interaction Study #2,
"5494",Phase 1 Single Dose Study,
H3E-MC-JMDX,R Ph III ALIMTA + Gem vs Gem + Taxol - Breast,
"4073",Gem plus Ifosfamide as second-line for SCLC,
F1D-CA-O047,Does the use of zyprexa reduce incidence of polypharmacy,
"4086",Cardinal study,
"4132",R-fluoxetine 14C study,
B1Y-BX-S005,Assessing Compliance of Pts. w/Fluox. 20mg vs Parox. 20mg,
B9E-MC-V028,Determine combination effects of gem+MTA or vindesine,
B9E-MC-V039,Biokinetic and metabolite analysis of radiolabeled gem,
H6E-MC-GLAH,Use of Actos in patients with secondary failure on SU,
H6Q-LC-JCAB,"Phase I Trial, FHD Single Dose",
"4212","MRP Modulator, Multiple Dose",
B9E-MC-V040,Gem uptake in head and neck cancer cells,
B9E-MC-V051,Regulation of nucleoside transporters activity in gemcitabin,
B9E-TW-O120,Standard Chemotherapy Regimens for NSCLC,
H4S-FP-O007,arterial thrombosis in UA and GPIIB-IIIA numbers,
F1J-MC-HMBC,Relapse Prevention Study,
B9E-MC-S161,Ph III gem+vinorelbine vs cis containing chemo in NSCLC,
B9E-FP-O148,ITT-Gemzar-Oxaliplatine in pancreatic cancer locally advance,
I9Y-MC-JDHO,Ph1-IDH-China PK Study,
B1Y-IT-HCIA,FLUOXETINE VS PLACEBO IN PROPHYLAXIS OF MIGRAINE,
I8R-MC-B010,Baqsimi Medical Device Post Market Clinical Follow Up,
"18729","PF, DDI - OC ",
B3N-MC-EUDC,Moxonidine SR Vs. Active Comparators,
"1977",C-14 study,
H3U-MC-JPAC,Ph 2 trial of LY300502 for prostate cancer after surg or XRT,
B3L-MC-LWAQ,LY354740 vs placebo vs paroxetine in OUS panic patients,
H4Z-MC-JWWJ,(JW13)  Phase 2 Ovarian Cancer - Refractory Population,
B1Y-MC-HCJP,Single dosing of Fluoxetine in the Treatment of PMDD,
F1D-CA-HGHF,Olanzapine in Schizophrenia and Related,
B1Y-FP-S001,FLUOXETINE VS PAROXETINE: MDD IN ANXIOUS PATIENTS,
F1D-MC-X033,OLANZAPINE POTENTIATION OF FLUOXETIME TX IN OCD,
F1D-BP-X100,OLANZAPINE IN LEVODOPA-INDUCED DYSKINESIAS,
B3D-LC-GHBB,Effects of LY333334 on Cardiovascular System,
B1Y-MC-HCCW,"FLUOX. V AMITRIPTYLINE, PLACEBO-PSYCHOMOTOR FUNC",
F1D-FP-S002,Olanzapine vs risperidone in post-psychotic depression,
B9E-SB-O009,"Phase II, Gemcitabine vs Docetaxel In NSCLC",
B3L-LC-LWBE,Cerebrospinal Fluid Penetr. and Renal Clrnce of LY354740,
B9E-MC-X135,PHASE II TRIAL WEEKLY COMBINATION GEMCITABINE+VINORELBINE,
B9E-MC-I138,"PHASE I STUDY W/GEMCITABINE, PACLITAXEL AND 5-FU",
B1Y-MC-X172,Fluoxetine in Adolescents with AUD plus MDD,
B9E-MC-X281,Phase I Stufy of Fludarabine and Gemcitabine,
B1Y-MC-HCDL,FLUOXETINE DOSE ESCALATION STUDY IN MDD,
"2610",Metaclopromide interaction,
F1J-FW-SBAG,SSRI Drug Interaction,
"2673",Phase 2 Trial of LY309887 in Patients with Colorectal Cancer,
H4H-MC-LGAL,Long Term Safety of LY300164 in Pts w partial seizures,
H5U-EW-HSAB,Multiple dose - safety and PK in healthy subjects,
"2714",Humatrope Depot Formulation in Adult Pts with GHD,
"2717",Humatrope Depot Formulation in Japanese Adult Pts with GHD,
H5W-BD-LQAB,Multiple doses safety study,
"2775",PT-Ceclor Susp  vs Augmentin,
H4A-MC-XBAJ,Oral vs. Fluconazole in Candida Esophagitis,
"2844",CTNR Grant:  Humalog Mixtures Support,
B9R-MC-GDFJ,POR Hip Fracture,
"2932",Efficacy Trial I - Depression,
"2952",Raloxifene - Cardiovascular Carotid Artery IMT,
F3Z-SB-IONR,Humalog vs NovoRapid in CSII,
F1D-IT-HGFD,OLN IN MGMT OF SCHIZO.:CLINICAL AND PHARMECONOMIC IMPACT,
B1Y-MC-HCKA,Cardinal Switching Study,
"4841",Olanzapine in Borderline personality disorder,
F1D-MC-HGHW,SAIM oln in trxt of agitation in bipolar mania patients,
B5K-OL-IBEF,Insulin Delivery Using a New Lilly 3.0mL Disposable Pen Desi,
B9E-MC-S114,Gem + taxol - adj bladder; Jun98SU79,
B7A-LC-MBCB,Ketoconazole Drug Interaction Study,
"3240",INVESTIGATOR INITIATED TRIAL BLOCK - SOMATROPIN,
F3Z-JE-M04H,Pharmacokinetic bridging study in ~30 Japanese Patients,
B1Y-MC-V001,IN VITRO STUDY OF FLUOX ADSORPTION BY ACTIVATED CHARCOALS,
"3330",Pharmcacokinetics of Humalog Mixtures in Healthy Subjects,
"3336",Oral delivery: Fed-Fast,
B9E-SB-O035,"Phase I/II, Gemcitabine &  Mitomycin,  In  Adv NSCLC",
B4G-UT-O004,Pergolide in Early Morning Dystonia/Akinesia in PD,
B1Y-MW-HCJM,"FLU, VS AMITR. IN THE TREATMENT OF MAJOR DEPR. IN THE ELDERL",
B3N-MC-EUDJ,Moxonidine vs Active Comparator-BP primary measurement (#4),
F1D-MC-X136,Olanzapine in Refractory Bipolar and Schizoaffective mania,
H6D-CA-LVAC,"""On-Demand"" Male Erectile Dysfunction",
"4140",PD Study,
B9E-MC-S170,Ph II - Gemcitabine - NSCLC,
B9E-MC-X299,"ph2 of adjuvant carbo/gem,surg. stage1b/IIA NSCLC",
"4930",Lower Dose R-Fluoxetine/Omeprazole Interaction study,
"4931",Lower Dose Sleep Study,
F3Z-MC-IOOC,Effects of Lispro Low Mix Vs Glargine on Perceived Mood Symp,
"4980","PMS Compliance, safety and treatment satisfaction of Evista",
"5090",LY333328 NCCLS Quality Control (In Vitro),
H3E-MC-JMEQ,"Ph 3, 1st line ALIMTA/Oxali/Avastin vs FOLFOX4/Avastin - CRC",
"5196","20 mg IC351 Safety Study with Nitrates",
"5203",mGlur2 Prodrug Safety and PK in healthy subjects - SDSS,
F1D-JE-HGJM,JP ola P-I IM SDSS,
"5226",Epidemiology of Metabolic and CV Complications in Type 1,
H3E-JE-1001,JP MTA  P-I FA+B12,
B9R-JE-PQSS,JP hGH PMS QOL,
F1D-SU-S015,Switching Patient From Haloperidol to Olanzapine,
H7B-BD-LXAB,"PHASE 1, Single I.V., DOSE KINETICS, SAFETY, DYNAMICS",
B9E-MC-V116,Determ concentration of gem sufficient to inhibit lymphocyte,
B3D-MC-GHAJ,EFFECTS OF LY333334 IN THE TREATMENT OF MEN WITH OSTEOPOROSI,
H3F-US-X001,Preservation of Residual Insulin Secretion in Children,
B9E-BX-O156,Phase III trial of sequential VS stand. chemo in NSCLC,
F1D-US-X187,a double blind trial of olz in pts with borderline personali,
B9E-MC-X288,Gemzar for Metastatic Carcinoid and islet cell cancers,
B9E-MC-X289,"Ph1 w/gem,carbo,paclitaxel,radiation in favorable prog.NSCLC",
"5015",LY466700 Bioequivalency Study,
"5028",R-Fluoxetine -- Insomnia - Flexible Dose/Comparator,
B1Y-UT-0290,EXP.WITH FLUOXETINE IN DEPRESSION IN GENERAL PRACTICE,
"5067",Multi-dose Dose Ranging,
"5070",Phase II Concomitant Steroids w/ Steroid Sparing in Asthma,
"5081",Registration Pain,
H3E-MC-JMET,Phase I/II Study of ALIMTA in Patients with Relapsed AML,
F1D-XL-O096,Olanzapine-ETC combination for resistant depression,
B1Y-VI-0034,FLUOX20MG V FLUOX40MG V CLOMIP75MG OUT PT. MAJ. DEPRESSION,
B9E-SB-O175,"Gemcitabine,Paclitaxel,Cisplatin in Patients with germinoma",
"5432",Ph II Gem+Oxali-> Tax Ovary 1st line (S208),
H3S-US-X017,Augmentation Therapy for Trtmt Refractory Depression,
B9R-US-X030,Is Stress a Possible Cause for Transient Childhood Idiopathi,
"4959",Observational Health Outcome Study/Analysis Support,
B9E-MC-V099,Determine chemosensitivity of ovarian carcinomas in gem,
B9E-MC-V101,Study cytotoxic and apoptotic effects on breast carcinomas,
"6310",Placeholder for Xigris studies,
H6D-MC-LVDC,Gastroparesis,
B1Y-UT-0294,RELAPSE RATE OF OCD AFTER STOPPING FLUOXETINE,
H6D-MC-LVDH,Pivitol #2 - Phase III Safety and Efficacy FSAD,
H3E-MC-JMEJ,Ph 1 MTA + gemcitabine + carboplatin,
H6D-EW-LVDL,Relative Bioavailability (20mg),
"5154",Definitive Bioequivalence,
H3S-US-GGKJ,Effects of raloxifene on symptoms of genital atrophy in PMW,
H3E-JE-ME01,JP MTA P-I/II Mesothelioma,
"5279",NSCLC combination with CDDP,
F1D-JE-RA01,JP ola P-IB/II RAIM Pilot,
F1J-MC-SBBL,Urge Incontinence Proof of Concept,
B9E-FP-O204,Gemzar in 1st line treatment for pt >70 years old,
B1Y-GH-S011,Fluoxetine in treatment of involutional depression in women,
B3D-MC-GHBQ,Forteo/Evista Sequential and Combination Trial,
H3E-MC-S016,Placeholder for Breast,
B9E-XB-S240,Gem+oxali in 1st line NSCLC,
H3S-US-X020,Effect of ralox on insulin sensitivity in PM women,
"5672",LY582563:  Vertically and Horizontally Acquired  HBV Phase 2,
B3N-SB-S002,Drug surveillance of Moxonidine in essential hypertension,
B3N-BD-EUAH,MOXONIDIN EFFICACY AND  SAFETY TRIAL,
F1D-MC-X208,Bipolar Spectrum Disorder in Urban Care Practice,
B3N-HH-EUAF,Drug surveillance study of moxonidine 0.2; 0.3; 0.4 mg,
B9E-KL-O248,Animal Study,
H5N-JE-GFFL,JP&EW v8gl P-I MDSS,
F1D-KL-O126,Korean version of the diagnostic interview for genetic studi,
B1Y-KL-S010,The Effect of Fluoxetine on the Energy level in MDD patients,
B9E-XB-V134,Molecular basis of Gem.sensitivity in hum pancreatic tumors,
"5953",HYPERGLYCEMIA AND ITS CORRECTION AFTER ISLETS TRANSPLANTATIO,
F3Z-XB-O042,PREDICTION FACTORS OF INSULIN THERAPY AND MARKERS,
F3Z-XB-O045,"DIABETES TYPE 1 IN CATALUNA.METABOLIC CONTROL, CRONIC COMPL",
"6026",Placeholder for local Alimta studies,
B9E-MC-S275,Intravesical - PhII Gem in recurrent superficial TCC-Bladder,
B9E-MC-S276,Ph II - Randomized ABVG vs. ABVD,
B5K-GH-O002,Multi-endpoint clinical observation of insulin treatment in,
B9E-SN-O211,Ph II Gem + Paclitaxel + Carboplatin in Nasopharyngeal CA,
B3L-MC-LWAB,MGLUR2 AGONIST VS PLACEBO IN NICOTINE WITHDRAWAL,
B9R-US-X032,estrogen replacement in hypogonadal girls tx with GH:diffe..,
B9E-MC-X325,PhII Gemzar/Radiation for localized unresectable pancreatic,
"5639",Fellowship Dr. Ashok Malla (FEL-058b),
B9E-FP-O233,ITT-gem+oxa in patients with early relapse of adeno phase II,
"5662",Fellowship for Dr. Donna Stewart (FEL-049),
"5684",LY582563 6 month dosing study in WT pts,
B9R-CA-O010,GH effect on premature infants previously treated with Dex,
F1D-FP-LOBN,olanzapine (two doses) versus comparator,
F1D-JE-CS02,JP ola P-IV Schizophrenia,
B9E-US-S259,Breast-Ph 2 Gem+Navelbine+Herceptin -Winer,
H3S-UT-O011,"eff ralox vs tibolon,placebo on musclestrength, balance, BMD",
H6D-MC-LVDW,Korea Local Registration Trial,
H6D-MC-LVEJ,EU Regional Trial #2,
H3S-XM-O013,"17-estradiol vs SERM in human osteoblast and osteoclast",
H6M-MC-LDAM,LY450108 Cerebrospinal Fluid PK in Healthy Human Subjects,
B3M-MC-V048,Follow-up in vitro testing by MacKenzie/Gould,
B1Y-BP-HC43,FLUOXETINE VS DOTHIEPIN IN MDD,
B9E-MC-S238,PhI Immediate Intraoperative&Post Instill of Gem in bladder,
F1D-PK-S017,Olanzapine in Schizophrenia in Pakistani patients,
"5657",Fellowship for Dr. Bill Evans (FEL-054),
B4Z-US-LYBH,Enuresis,
B9E-US-V128,Use of gem on pancreatic cancer cell lines,
B3N-HH-EUAC,Moxonidine in dialysis,
H6P-MC-O001,IIT of Olanzapine on sleep EEG of trd patients,
"5862",SERM V  Phase 2 Safety and Efficacy,
H6D-MC-LVDX,India Local Registration Trial,
F1D-US-X209,Differential effects of Olz and Risp in pts. using fMRI,
"5935",Renal Failure Study,
B3N-PL-EUAG,MOXONIDINE EFFIC/SAFETY IN PTS-MILD & MODERATE HYPERTENSION,
B9R-XM-O025,hgh treatment in local population/clinical files revision,
H7B-MC-LXAE,Compar.466195 & 293558 on visual function in h-volunteers,
"6042",Effect of atomoxetine on NET occupancy,
"6105",GLP-1 analogue - Drug/drug interaction 3,
F3Z-US-X013,Switching Type 2 diabeteics from Humulin U-100 to U-500 Reg,
H5N-EW-GFFQ,GLP-1 analogue - Injection time/sites,
"6254",GI Motility Study,
"6277",Olz vs Pbo in the Treatment of Post-Traumatic Stress Disorde,
F1D-IH-LOBP,Comparative study with haloperidol in first episode patients,
B9E-SB-S282,Observational Trial in NSCLC and Pancreatic cancer,
"6365",Vistaril vs pamoate,
B9E-MC-V137,Ph I Gemcitabine for Dogs with Spontaneous Malignancies,
H7Y-MC-EYAC,Eflucimibe Phase II Study 201 (Eflucimibe Alone),
B3D-US-GHBZ,Glucocorticoid Induced Osteoporosis,
B9E-MC-V143,Phase I Study of Dose-Intensive Cisplatin +Gem in NSCLC,
B3D-SO-B011,European Forsteo Observational Study (ExFOS)(former ScanFos),
B9E-UT-O300,"Gemcitabine and taxol inpts with resistant SCLC, phase 2.",
B5Q-SE-9131,NIZATIDINE CLINICAL EVALUATION IN THE PEPTIC ULCER DISEASE,
H3S-PL-O023,"Effect Ralox. on Bone Turnover, Surrogate Atherosclerosis",
B9R-BP-O027,Cardiac and muscle changes following GH therapy,
B1Y-BL-HCLN,Prozac Durapac Outpatients Health Outcomes,
F1D-GH-S036,Olanzapine in acute schizophrenia a comparison with a typica,
B9E-CA-JHLX,PHASE II STUDY OF GEMCITABINE IN GLIOMA,
"6229","will be decided on Jul 20, 2001",
"6256","1 yr. Diet/Exercise (Study A)",
B1Y-XM-HCLO,Prozac weekl naturalistic- Primary care,
"6312",aPC- Observational study. Spain,
H7C-MC-LMBS,Global Phase III GAD Trial with Pivotal CT,
B9E-MC-S283,"Ph I - Gem + CHOP, 21 day - Lymphoma",
B5K-MC-I009,TRAIL OF ORAL & PARENTERAL INS.THERAPY DURING REM.PHASE IDDM,
H7X-MC-JVAO,Ph I/II - Gem + Affinitak +/- Herceptin - Breast,
"6458",Phase II Gemzar + ISIS in plat.-resistant ovarian cancer,
B9E-MC-V154,Gemcitabine Chronopharmacology in Mice,
B9E-MC-V161,Role of DCK and CDD in the Sens of Blad CA Cells to Gem,
F3Z-SB-O050,Lispro vs. regular insulin in CSII children w/ type 1 DM,
H4S-SB-O035,"BRAVE II-An international, Multicentre, Randomised Trial",
B3D-US-X002,Investigator Initiated Trials,
"6564",Intravesical + Rdt,
"6600",Placeholder for Raloxefene trials,
F3Z-FW-IOOF,PK/PD comparison of lispro injected by device vs sc inject,
H7U-MC-IDAC,"IFR Training, Pulmonary Insulin",
H3E-MC-S005,"ALIMTA + GEM vs GEM + Cis (or GEM/Carbo), 1st Line",
H3E-MC-JMFI,"Phase  2 ALIMTA x 3 + GEM x 3 + ALIMTA x 3, 1st Line NSCLC",
"6197",Multiple dose study in women,
F1D-US-X147,An eval. of the Effic. and Safety of Olz. in treating Risp.-,
B9E-SB-O275,"Phase II in Pancreatic cancer, 3 arms with Gem+radiotherapy",
"6351",Effect of moxonidine in overweight patients with hypertonia,
"6366",Factor Xa - multiple dose,
F1D-CA-O151,Bipolar Disorder and Diabetes Mellitus,
B5Q-JE-YI06,NIZATIDINE: EARLY SYMPTOMATIC IMPROVEMENT & PREVENTION/RECUR,
F1D-CP-O176,Control of appetite,
F1J-UT-S002,Comparison with TVT,
F1D-KL-O167,Development of Korean SCAN (K-SCAN),
"6681",Placeholder for Zyprexa trials,
"6707",Placeholder for PTH trial Iceland,
"6719",placeholder for IIT Gemzar,
H8F-EW-LGCB,Multiple Dose Safety Study - MDSS,
B9E-AY-O305,Ph II Thalidomide alone & with Gem/Cis in Malignant Meso,
H4S-CA-O039,Transradial coronary Angioplasty for Acute MI: Pilot Study,
"6775",Nucleoside Supression vs. Resiquimod,
H8I-EW-HQAE,MDSS,
F1D-BP-O177,Antipsychotic use in Bipolar Disorder,
B4Z-UT-S004,Broader efficacy trial,
B9E-US-X353,Ph II Study of Wkly Docetaxel & Gem in Platin Resis Ovary CA,
B5V-MC-V006,EFFECT OF SERUM PROTEIN BINDING ON ANTIMICROBIAL ACTIVITY...,
F1K-MC-EVCM,Adult Patients with Early Stage Severe Sepsis,
F1D-BL-HGKI,H2-antagonist in the weight gain control with olanzapine,
H8R-EW-HJAC,SDSS,
"6789",ACAT inhibitor 111,
"6832",Drug Interaction - Digoxin,
H7G-MC-PDAF,China Open Label Extension Phase Study,
H7Y-EW-EYAE,Eflucimibe Phase I Study 111,
B7A-XM-O002,ROLE OF PROTEIN KINASE C bII ISOFORM IN CARDIAC AND VASCULAR,
H7T-EW-TAAG,CS-747: Clopidogrel encapsulation study,
H6D-MC-LVFM,US Titration,
H6D-MC-LVFP,Cialis Daily Dosing #2,
H7C-MC-LMBV,Evaluation of LY544344 in Patients with OCD,
B9E-MC-I060,STUDY COMPARING TWO DOSES OF GEMCITABINE IN METASTATIC NSCLC,
B9E-MC-V183,Measure uptake kinetics of gem in gentically modified tumors,
H4Z-MC-JWXP,Tamoxifen safety protocol for patients post phase 3 protocol,
H8E-MC-KBAD,Nucleoside (Episodic) Synergy / Time to Heal Study,
H3E-MC-S052,Ph I/II FDR Gemzar + Alimta in Pancreas & Biliary Cancer,
"6904",Placeholder trial for Xigris IITs,
F1D-EW-LOBU,PK/Toler. Study of Higher Doses Oral Olz/Stable Schiz./BPDis,
H8I-EW-HQAB,SPECT ligand validation/method study,
"7022",Safety of Pulm hGH in Elderly GHD compared to Subcutaneous,
B9E-US-S320,Ph II Gem/Cape in Metastatic colorectal Ca,
"7100",Lung Placeholder,
"7102",Placeholder for NSCLC,
"7156",Blink Reflex Method Validation Study,
B9E-US-S318,Rand PhII Gem/RTInduction or cons Gem/Carbo in IIIb/IV NSCLC,
"7329",Cialis IIT Placeholder,
H3S-FP-S013,"disease management pathway, pilot study",
F1K-SB-S004,E/S of rhAPC in Pts. w/ prolonged Severe Sepsis (4 vs 7 day),
"7440",severe sepsis in transplanted pts,
ZYY-FW-GCBH,augmentation by L-5HTP added to 5mg iv citalopram,
B1Y-BP-HCIM,FLUOXETINE/DOTHIEPIN/PLACEBO EFFECT IN HEALTHY VOLUNTEERS,
H8Z-MC-JACP,Phase I FHD trial of Survivin ASO in solid tumors,
"6836",Drug Interaction - TBD from ADME data,
"6846",Ph III HTN Diabetics,
"6854",Placeholder trial for IITs with Gemzar in NL,
B9E-SB-O315,Gem/Cis + Amifostine in Adjuvant Bladder Cancer,
B9R-EW-GDGC,Flow rates and volumes in ped pts w/ GHD or Turner,
B9E-MC-V190,Gem + MAP4,
F1D-US-X219,Risk of Diabetes Mellitus After Use of Anti-psychotic Drugs,
F1K-SB-O005,IIT - Placeholder (in-vitro),
"7009",Premature Ejaculation Pivital Registration Trial,
H3E-MC-JMFQ,"Ph III, 2nd Line ALIMTA + CPT-11 vs. CPT-11 in CRC",
B9E-GH-O329,Gemzar plus Ifosfamide as Treatment for Patients with NSCLC,
H6P-BL-HDAP,"Identif., Resource Utilization and Dir Costs of TRD",
B9E-MC-JHCG,GEMCITABINE IN PATIENTS WITH REFRACTORY PANCREAS CANCER,
"7193",weight gain management,
"7204",IIT placeholder for Alimta,
H3E-US-JMFY,Ph II Single Arm Gem/Alimta in 1st line NSCLC,
"7250",Placeholder for Atomoxitin trials (BUY-UP),
B9E-MC-JHDN,GEMCITABINE + BEST SUPPOR. CARE VS BEST SUP. CARE IN NSCLC,
B9E-MC-V196,Gemcitabine- A  study to analyse Gemcitabine genotoxicity,
B9E-SB-O046,"Phase II, Gemcitabine & Carboplatin, In NSCLC",
B1Y-MC-X190,Computerizing the Texas Medication Algorithm Project,
B9E-MC-X244,"Gemcitabine, Oral 5-FU, and GW776C85",
H6D-EW-LVAU,Multiple Dose Study,
H6D-EW-LVAY,LY450190 interaction study with Vasomax,
H6D-EW-LVBB,LY450190 in Breast Milk,
ZYY-LC-JUAA,Tamoxifen bioequivalence study,
B9E-PK-O079,"Phase II,Gemcitabine & Cisplatin, Epithelial Ovarian Cancer",
"3824",Evaluation of Gemzar in Multiple Myeloma,
"3866",ReoPro with low dose lytic in Acute MI,
B5K-MC-IBFF,Flow rate training,
H5P-MC-BWXI,Phase II Pain Study,
B1Y-MC-X086,FLUOXETINE IN CHILD/ADOLESCENTS,
B9E-MC-X254,Adjuvant Gemcitabine and Radiation for Pancreatic Cancer,
B9E-MC-JHQS,"Rand Ph III Gem+Cis+XRT-->Gem+Cis vs Cis+XRT, cervix",
F1D-CA-O005,switching outpts w/schiz on long-act inj antipsychs to olanz,
B1Y-BP-HC28,FLUOXETINE/MIANSERINE MAJOR DEPRESSIVE DISORDER,
H6H-MC-EBAG,Phase Ic/IIa to assess the safety and efficacy,
F1D-OE-O186,Prevention of Zyprexa induced weight gain by non-drug interv,
F1D-SB-O189,Effect of weight management program to prevent weight gain,
"7205",Gemcitabina-navelbine (farmacogenómico),
"7257",Placeholder for ALIMTA trials (triggers),
B5K-GH-O436,Signi. of determine true & proinsulin for estimate fun Bcell,
B9E-US-S324,Phase II Gem/Carbo with or without Herceptin in MBC,
B1Y-FP-O029,IIT- smoking cessation CHU Montpellier,
"7444",Duloxetine study on depression in Asia,
"7533",Gemzar Breast phase III,
"7588",MOA in Humans,
B9E-MC-X117,"STABILITY OF GEMZAR IN VIALS, SYRINGES, AND AS INFUSION",
H3S-EY-B001,Efficacy ofRaloxifen in osteoporotic postmenopausal EG women,
"7819",Diabetes file review,
"7829",Advisory lung group,
"7901",Quality of Life in Postmenopausal Women,
B9E-SP-JHPB,PHASE II GEM+CDDP RECURRENT/METASTATIC HEAD-NECK CARCINOMA,
F1D-BL-HGLA,Antagonist H2 + olz  in weight gain,
"7997",Duloxetine in Mixed UI at Urologists,
H8Y-FW-HBBC,Methods/Biomarker Development,
H9M-BD-LGEA,Single-dose safety study in healthy male subjects,
B9E-MC-X012,PHASE 2 TRIAL OF CISPLATIN PLUS GEMCITABINE IN OVARIAN CANCE,
B4Z-BL-O001,"ADHD predom.inattent type: candidate genes, environ. factors",
"7729",IIT OFC 2004,
"7734",RAIM - IM Olz vs IM Haloperidol Bipolar,
F1D-PL-O206,Efficacy and safety of initiation and cont. from oral RAIM,
"7778",Postmenpausal ostoeprosis,
B9E-ME-JHGB,PH II GEMCIT. IN PTS. WITH LOC. ADV./METASTATIC CERVICAL CA.,
"7793",IIT bucket,
B1Y-BP-X089,FLUOXETINE VS PLACEBO IN L-DOPA INDUCED DYSKYNESIAS IN PD,
"7930",Gemzar CTNR related local support work,
"7944",Ph II - Affinitak Compassionate Use/OUS - NSCLC,
B9E-MC-V216,preclini eval tyrosine kinase inhibitors with cytotoxics,
B4Z-MC-LYCI,Treatment optimization- switching study,
B7A-LC-MBDK,PKC ß Inhibitor 14C Study,
B9F-LC-IEAJ,C-PEPTIDE:DETERMINE IF SUPPRESSES INSULIN SECRET,
H3E-FR-T002,ALIMTA - ATU de Cohorte (compassionate use),
B1Y-MC-X117,SEROTONIN AND IMPULSIVE AGGRESSION: TREATMENT CORRELATES,
"4213",Phase I trial for Cyclin D1/cdk 4 Inhibitor,
"4221",Digoxin interaction study,
F1D-US-X161,Effect of Olanzpaine on Delta Wave Sleep Deficits in Schizo.,
F1D-US-X162,Olanzapine vs. placebo in Childhood and Adolescent Autism,
B9E-SZ-O121,radiotherapy and gemcitabine for rectal cancer,
H6D-MC-LVCL,Diabetic Study,
F1J-LC-HMBG,Duloxetine bioequivalence study,
F1D-SX-O069,SWITCHING FROM PREVIOUS ANTIPSYCHOTICS TO OLANZAPINE,
F1D-US-A044,Olanzapine Modulation of Brain Allopregnanolone Levels,
B1Y-SB-7023,FLUOXETINE/PLACEBO OBESE PT PRETREATED WITH BEHAVIOR THERAPY,
B9E-MC-S160,GET vs ET in 1st line metastatic breast cancer,
"4543",post marketing survelliance of an FDA approved drug,
B9E-VI-O145,Rand.comp. Gem+Cis followed XRT vs. stand. XRT,
B9E-BL-O186,Combination of Gemzar and Carboplatin in NSCLC,
F1D-US-X178,"comparative effects of olz, other atypical antipsychotics/co",
F3Z-IN-IOMZ,Huminsulin R/N/L cartridges used in HumaPen,
B9E-MC-S180,Ph II - Gem+Cis+Iressa - Urothelium,
B9E-GH-O367,A phase II Study of neoadjuvant Gemcitabine/Carboplatin,
H3E-IT-S043,Alimta-Oxaliplatino in II line gastric cancer,
F1J-MC-HMCS,Norepi transport blockade by dulox: PETstudy,
H7C-MC-LMCF,NIDA Cocaine Abuse Study,
B9E-XM-I152,Viability of clinical trial with Gemcitabine + Carboplatin,
B9R-FP-0909,GROWTH HORMONE IN CHILDREN WITH RENAL FAILURE,
H3S-IT-GGLH,LOOP - Lipidic Outcome in Osteoporotic Patients,
B9E-MC-JHSN,Ph II Gem intravesical in superficial bladder cancer,
F1K-CA-B001,Addendum to Trial Number 6858,
"8369",Duloxetine vs. Lexapro (Onset of Action) with HMCR,
"8414","Ph II Maint. 1st Line, Taxane->Plat x4->ALIMTA vs. BSC NSCLC",
"8418","Ph I/II, ALIMTA + Oxaliplatin + Trastuzmab in Breast Cancer",
B4Z-MC-LYCR,Relapse prevention study with Tourette's,
B9R-MC-I011,GH IN TX OF SHORT STATURE SECONDARY TO JRA,
"8556","Phase 1b Study [200,400 and 600 mg]",
"8597",Placeholder Trial for ReoPro IIT (CARESS: H4S-IT-O038),
H4S-SZ-O056,Wake Up Stroke,
"8626","Ph 2, ALIMTA+ (Platinum) (plat-sensitive) - AGO",
B9F-MC-I011,INSULIN RESPONSES TO HYPERGLYCEMIA IN FIRST DEGREE RELATIVES,
H8O-MC-GWAO,Single oral failure pts:  exenatide vs lantus crossover,
F1J-MC-HMCT,MeNER Duloxetine vs Venlafaxine RO Study,
H3S-PU-GGLD,Switching from hormonal replacement therapy to Evista,
B9F-MC-I025,EFFECT OF C-PEPTIDE ON RENAL AND SYMPATHETIC FUNCTION,
"8118",Relative Bioavailability and Food Effects Study,
F1D-CA-O231,Internet Health Care Support Intervention for Caregivers,
"8222",Bioequivalence for Phase 3 Comparator study (encapsulation),
F1D-SB-S052,Impulse: German obs. study Aggression control,
F1J-GW-HMDA,Safety & Tolerability of Duloxetine 60mg in LA pts with MDD,
B9R-JE-YI51,HUMATROPE:R-HGH THERAPY FOR SENILE OSTEOPOROSIS,
"8409","Ph II, ALIMTA + Gemzar (q2w schedule) in Breast Cancer",
B9R-MC-GDCI,SOMATROPIN&LOW-DOSE ESTROG./TURNER'S SYNDR.CHILD,
H3S-MC-X030,Raloxifene use among women with a history of breast cancer,
B4Z-US-X006,"Atomox treatment of Inattention, Hyperactivity + Impulsivity",
H8I-EW-HQAG,SPET with LY628535,
H9A-BD-GSBB,GLP-1 Analog II- Phase 1 (MDSS),
H7C-MC-LMBX,CCK-challenge Pilot Study,
"7364",Uptake Patients Study,
B9E-AU-O337,Ph2 GemVin followed by Vin RT in NSCLC,
F1J-FP-SBCA,duloxetine versus TVT in patients with severe UI,
"7407",Uptake study,
"7462","Single Agent LY231514 1st-line in adv Gastric Ca, unfit pt",
B9E-MC-JHFM,GEMCITABINE FOR MALIGNANT MESOTHELIOMA: A PHASE 2 STUDY,
"7522",ACTION; Assessment of costs of CT in obs study NSCLC,
"7570",Switching Atypical to Zyprexa,
"7600",Place holder for local IIT,
"7625",Gemzar/Carbo in NSCLC,
"7683",Evista switch obs (COMFOHRT),
F1J-MC-I002,Voiding Patterns in Asymptomatic Women,
"7735",Regional Post Hip Fracture Study: teriparatide X alendronate,
B9E-MC-X116,THE PHYSICAL COMPATIBILITY OF GEMZAR WITH OTHER DRUGS,
"7792",Alimta Compassionate Use,
"7824",Psychosocial treatment of schizophrenia,
B9E-SB-V002,Gemcitabine &  Hypertonic In Vitro Investigation,
"7881",Keflex Health Economics,
H3S-SU-GGLA,Latin America Vertebral Osteoporosis Study (LAVOS) - No Drug,
H5Z-FW-LUAT,PK study on Asian population,
F1D-UT-O088,improvement of quality of life in first onset schizophrenia,
F3Z-US-IONH,Mix50/50 BID + Metformin vs Humulin 70/30 BID + Metformin,
B1Y-ME-HCKP,Hemodynamic cerebral characterization in patients with MDD,
H6H-MC-JEAL,"Rand. Ph II, LY293111+Gem vs Gem+Placebo in Pancreatic Ca",
B1Y-GH-HCLA,Fluoxetine in treatment of depression in general hospital,
H7D-EW-GNAB,"ORAL PTH (LY900002) SDSS, PROOF OF CONCEPT",
F1J-MC-HMCI,Addiction Potential,
B1Y-BP-HC38,FLUOXETINE VS CLOMIPRAMINE TREATMENT OF OBSESSIONAL FEATURES,
B9R-IT-GDFT,Genetics and Neuroendocrinology in GHD children,
"5204",mGluR2 Prodrug Safety and PK in Healthy subjects - SDSS,
B1Y-VI-4000,FLUOXETINE: TREATMENT OF SEVERE DEPRESSION REGISTRATION TRIA,
H4S-US-X011,Occluded Artery Trial (OAT),
B1Y-BP-HC40,"FLUOXETINE V AMITRIPTYLINE, ELDERLY DEPRESSED PSYCHOMETRICS",
H3S-SB-GGKP,Pain Study,
B9E-UT-O219,phase II study of seq/alt gem and paclitaxel in NSCLC,
"5646","Add on OLA on typical neuroletics, safety and effectiveness",
"5647",combining treatment of pergolide in Parkinson's patients,
B9E-ME-O231,Ph II Study Carboplatin/Gemcitabine in Bladder Cancer,
H6P-US-HDAR,OFC Observational Study,
F1D-JE-CS03,JP PMS Glucose Safety Study,
B9E-JE-BL21,JP Gemcitabine Bladder cancer,
B9E-VI-JHMJ,PHASE 2: GEMCITABINE IN STAGE III AND IV NSCLC,
F1K-UT-O010,Safety and Efficacy of RAPC for Moderate to Severe Ulcerativ,
B9F-MC-I024,EFFECT OF C-PEPTIDE ON DIABETIC MICROANGIOPATHY,
H3S-CA-GGLB,Canadian Obser Study of Transition from HRT to Evista,
H6D-MC-LVFQ,Prescription Event Monitoring,
B9E-MC-JHSL,Phase IIa Hepatoma Study,
"8143",Gemzar Cis versus Alimt in NSCLC Ph II (Scagliotti proposal),
B4Z-US-X001,Atomoxetine as an Adjunct to Novel Antipsychotic Medication,
"8220",Repeat SDSS/MSDD for Japan bridging,
"8239",LeWinter/Ruch-Effect of PKC on myofilament func.-Rat model,
H3E-MC-V033,Drug Sensitivity pesence and absense of TS using Cell lines,
B5K-GH-O442,Establish hyperglycemic clamp technique in assess of insulin,
"8399",PET Study,
"8413","Rand Ph I/II Seq. ALIMTA (d1) & Docetaxel (d8) Q 21d, Breast",
H3S-IS-O129,effectts of raloxifene on serum levels,
B9R-MC-I019,PROMOTING INTESTINAL ADAPTATION IN THE SHORT BOWEL PATIENT,
B9R-MC-I022,EFFECT OF GH THERAPY ON CARDIAC ABNORMALITIES            I,
"8569",PK Bridging Study,
"8682",PK/PD:  LY22109967 (AO:K) vs LY211419 (TriArg) vs Glargine,
"8890",PLC Local activities (Evista),
F1D-US-HGLS,olanz v aripiprazole acute agitation in schizophrenia,
H7T-EW-TAAS,CS-747: CYP3A4 inducer,
"9008",Effects of PTH on bone turnover in patients with PBC or PSC,
H3E-MC-JMHC,"Ph III,1st line - ALIMTA/Gem vs Gem/Carbo - NSCLC",
B9Z-MC-AQBP,DIRITHROMYCIN: TERFENADINE DRUG INTERACTION STUDY,
"9124",Biomarker Feasibility Study,
"9138",Forteo Dummy IIT Trial for CT-material planning,
H8Y-LC-HBBB,MDSS/CSF,
B9E-US-X422,"PhII combined modality,chemo+RT w/Iressa stg IIIA/IIIB NSCLC",
"9211",IIT Placeholder - Xigris (Australia),
B9E-MC-V266,The combination of Gemcitabine and Adenoviral Therapy,
B9E-XB-V239,EVALUTION OF THE ANTIANGIOGENIC ACTIVITY OF GEMZARGEMCITABIN,
"9338",BIPOLAR II EPIDEMIOLOGY STUDY,
H3E-US-X004,Single Agent Alimta in poor performance status NSCLC,
F1D-MC-HGJX,X-sectional study of glucose abnormalities in schizophrenics,
F1D-CA-O119,Shifting to a Novel Antipsychotic: Survey and Pt Outcomes,
B3M-MC-V052,invitro,
H4S-BP-O019,CARDia-PCI + Abciximab vs CABG in Diabetic,
H7R-LC-GCBB,PPAR-gamma MDSS in NIDDM,
"5805",JP PKC-II P-I MDSS,
F1D-SB-O125,Risk assessment of tardive dyskinesia: Evaluation of oxidat,
H4S-BL-O026,Comparison of Intra-stent Intimal Hyperplasia Volumes in Dia,
B3N-HH-EUAP,Effects of moxonidine on early atherogenic lesions (MEAL),
B9E-AY-O263,Pharmacokinetics of Gemcitabine & Intratumoural Gemcitabine,
B5K-GH-O005,"The relationship among insulin resistance, obesity and ADRB3",
B9R-XM-O024,POST-CHEMEOTHERPIC INTESTINAL LESION REDUCTION WITH hGH,
F3Z-XM-O041,POSTPRANDIAL KETONURIA ON CHILD.WITH INSULIN DEPENDENT DIAB.,
H3S-XM-O019,Body composition in childs with DEXA (auxologic&endocrine),
F1D-TW-O132,A pilot IIT for risperidon-refractory TD,
B9E-TW-O260,"Phase II, Gem+Carbo/Gem+Tax for NSCLC",
"6000",Purpura fulminans 4 vs 7 day therapy,
"6007",Benzodiazepine Transition Study,
"7081",Bipolar in the Elderly,
H3E-MC-JMHR,"Rand Dbl-blind Ph III, ALIMTA + Cis vs Cis in H&N Cancer",
B4Z-MC-LYCP,Acute Tourette's study for registration,
H3E-MC-V060,Alimta Efficacy in Prostate Cancer Cells,
F1K-MC-O016,Acute Coronary Syndrome,
"8448",Formulation Bridging Study,
F1D-XM-O239,effectiveness of olanzapine with velotab,
B9E-US-X413,Ph II molecular analyses-based chemo  w/stage IV/IIIB NSCLC,
H4Z-LC-GJAL,rel BA Risedronate -blinded placebo (ClinPharm),
B5K-GH-O012,Prevent and treat of DN with Humilin N and JinQi,
H6Q-MC-JCAQ,Phase II Enzastaurin in 2nd/3rd line treatment NSCLC,
"8711",Pregabalin-Comparator Trial,
B4Z-EW-LYDB,Initiation of atomoxetine following treatment with stimulant,
"8725",Human Intravital Microscopy,
"8754",Rand Ph I/II - ALIMTA +/- vitamins pts w/relapsed ALL/AML,
"8757",Ph II - Gem (bi-weekly) - relapsed pts - NHL,
H3E-MC-V008,Effect of ALIMTA in Binary Comb. w/ oxal/top I/topo II inhib,
"8930",Pelvic floor exercise vs. Yentreve,
H7R-MC-GCCF,Efficacy in combination w/insulin,
B3D-BX-O005,Forsteo as osteoporosis treatment after hearttransplantation,
H3E-US-X005,PhII Alimta & Irinotecan unresectable adenocarcinoma stomach,
H9G-MC-GXAD,PET Safety Dosimetry Study (5HT2c),
"9441",Ly2059346 Proof-of-Concept for CIAS,
F1D-MC-HGMF,Zyprexa Pediatric PK Study,
H8G-EW-EPBE,SDSS/MDSS in Japanese Subjects,
F1J-EW-SBCS,PK STUDY IN HEALTHY POST-PARTUM WOMEN,
"9540",Phase III SAD,
F1D-JE-RA03,JP ola P-III RAIM,
"9642",CS-747: Particle size BE pilot (placeholder),
F1D-AY-O264,White matter pathology in schizophrenia sufferers,
"9669",Severe Sepsis pts. at low risk of death with PC deficieny,
"9720",Place Holder French Addendum B9R-MC-GDFN (SHOX),
B9E-US-X438,Ph II Bi-Weekly Gem & Weekly Taxol for Metastatic Breast CA,
H6Q-LC-JCAV,DDI-MIDAZOLAMCYP-3A4 Biopharm Study in Cancer Patients,
"9804",addendum  GHBQ(4) trabecular bone microarchitecture,
B9E-IT-S376,Gemcitabine+Tax vs Gemcitabine + TxT in MBC,
F1J-US-SBCW,Dulox HCl in Women Who Failed Detrol Therapy,
F1K-MC-EVBJ, Sepsis Patient Registry (no study drug administered),
F1D-KL-S021,A combination of short & long term OS of Olanzapine therapy,
B9E-MC-S269,"1st Line-Ph II-Gem+Txt+Herceptin - Breast",
H3E-MC-S001,ALIMTA +Carbo +Tax,
H3E-MC-S006,"Ph II, 2nd Line, Single Agent ALIMTA (Calvert) Ovarian",
B9E-MC-S277,Gem FDR + Cis vs Dox - Hepatoma,
H3E-KL-JMFK,Phase 2 study of LY231514 + Cisplatin in Gastric Cancer,
"6160",Sepsis induced thrombocytopenia,
H3E-MC-S022,Placeholder for NSCLC,
F1J-MC-HMBX,Fibromyalgia Pain,
H3E-MC-S034,Placeholder for NSCLC,
"6276",Olz vs. pbo in the treatment of Post-Traumatic Stress Disord,
H7G-FW-PDAH,LY582563 Phase 1 in China,
H4S-SB-O031,Assess Value of Mechanical Reperfusion in AMI>12 hrs Onset,
B1Y-BP-HC52,FLUOXETINE/AMITRIPTYLINE CARDIAC & ANTICHOLINERGIC EFFECTS,
ZYY-LC-BFAA,Method study to investigate the biomarkers for anti IL 1beta,
F1D-XM-O147,AntiH2 efectiveness in weigth gane,
"6418",Study in the Surgical Patient,
"6436",Triple reuptake inhibitor - MDSS,
B9U-SO-AZCK,LORACARBEF STEP DOWN THERAPY IN COMMUNITY ACQUIRED PNEUMONIA,
H3E-US-S048,Phase I/II Stage IIIa/b NSCLC Alimta/Cis/XRT,
B4Z-US-LYCU,continuous symptom relief in adult population,
"9062",JP ola P-IV Treatment Resistant,
B9E-JE-MB22,Jp gem P-II Breast (B),
B9R-MC-B001,Follow-up of B9R-EW-E001 patients,
F1D-AY-O251,Discharge Planning from a Carer Perspective,
"9203",Treating Institutionalized People W Severe Dvlpmntl Disab W/,
F1D-EW-HGCF,OLANZAPINE VS CLOZAPINE IN REFRACTORY SCHIZOPHRENIC PATIENTS,
B1Y-CA-C024,FLUOXETINE: ON METABOLIC RATE DURING WEIGHT REDUCTION,
F1D-EW-LOAJ,OLANZAPINE 5MG BIOEVIV OF TABLET FORMULATIONS IN VOLS,
F1D-EW-LOAL,Zydis 20mg in HEALTHY VOLUNTEERS,
B9E-XM-O434,DTIC VS GEM+ DTIC IN SARCOMA,
"9375","Development, accessment and application of clinical-sepcific",
"9426",LY451395 Alcohol Interaction Study,
B4Z-BL-B003,ADHD and Substance Use: study of its association,
H9T-BD-NABF,FHD(30-Aug-05):Single-and Multi dose safety study(SDSS/MDSS),
"9409",Functional relevence of SHOX SNPs (in vitro),
F1D-MC-HGBL,"DOUBLE-BLIND, OLANZAPINE VERSUS FLUPENTIXOL IN THE TREATMEMT",
H3E-US-X033,Ph II Alimta & Gem q 2 wks. in Stages IIIB/IV NSCLC,
F1D-MC-HGBR,EFFICACY OF OLANZAPINE IN PATIENTS WITH SCHIZOPHRENIA,
F1D-US-X271,Characteristics of Bipolar Disorder in Primary Care,
I1E-LC-ESAD,Study in Subjects with Renal Impairment,
F1D-MC-HGCA,OPEN LABEL EXPERIENCE WITH OLANZAPINE,
B9R-XB-O038,Longitudinal and transvesal studies of growth in the populat,
F1D-MC-HGCO,OLANZAPINE OL IN RISPERIDONE NON-RESPONDERS,
F1J-IS-S014,open label fixed dose duloxetine trial,
H3E-MC-V047,Alimta and Radiotherapy,
I1C-MC-JLBA,"FHD, Ph I, escalation, gemcitabine prodrug alone & comb",
F3Z-US-X022,Prevention of T2 DM and CV Complications in African American,
F1J-MC-X011,Positron Emission Tomographic (PET) Imaging Brain Metabol,
H6D-MC-LVGY,Phase III Cialis in PAH (5-arm study),
F1D-MC-HGET,OPEN LABEL OLANZAPINE,
H6Q-MC-V009,Enzastaurin effects on lung cancer cells,
B4Z-AY-O008,"Atmx in children with ADHD, a CT and fMRI study",
B9E-MC-V152,Pre-Clin Studies Intravesical Gem to Reduce Blad CA Reimplan,
B9E-FP-O295, IIT-Gem-Oxali in inoperable liver cancer,
B9E-MC-V151,Measure Gem and its Primary Metabolite dFdU in Clin Plasma,
B9E-XM-O306,Incidence/evolution  of mesothelioma cancer in Madrid area.,
F1K-UT-EVBO,evaluation of efficacy and safety in septic children,
H6U-UT-O002,progressive structural brain abnormalities in schizophrenia,
H6E-BX-GLAU,Effect Pioglitazone on cardiovascular risk factors,
H3S-PL-O113,"Influ. of Ralox on Pain, Quality of Life and BMD in  Women",
F3Z-BP-O052,Normalisation of post-prandial metabolism in type 2 diabetes,
"6827",Phase I 14C Study,
"6831",Cancelled trial,
"6856",ADHD and Conduct Disorder,
B9E-SB-O316,Phase II Breast Cancer GemCis vs. GemVino vs. GemXel,
F1D-VI-S046,Obs. study - transition from Olanz. IM to Olanz. PO,
B9E-BP-O322,Gemzar/Carbo vs Gemzar/Cis (Fractionated) in adv/met NSCLC,
B9E-MC-I039,"PHASE I/II STUDY OF GEMCITABINE, DOCETAXEL, & CISPLATIN",
H7C-MC-LMBT,Evaluation of LY544344 in Schizophrenia,
B9E-AY-O399,Phase II salvage tx in relapsed refractory lymphoma,
H9C-MC-BBDE,anti-IL 1 MDSS in RA Patients,
"8719",Needlefree PK/PD Mix 75/25,
"8760","Ph I/II, 2nd Line  ALIMTA + cox Inhibitor 2 in NSCLC",
H3E-IT-S093,ALIMTA + GEMZAR FIRST LINE NSCLC,
"8872",mGlu1 antag II Biomarker Study #1,
B9U-MC-AZCU,LORABID VERSES AUGMENTIN:  SINUS TISSUE PENETRATION,
H3E-UT-O003,Mesothelioma: Alimta/Carbo(JMFL) -> thalidomide if PR/CR,
B5K-GH-O016,Effect of amylin on insulin stimulated glucose uptake of,
H7T-EW-TAAU,CS-747: Aspirin interaction,
H7T-EW-TABA,CS-747: Def BE - LD formulation,
F1D-SB-O249,Olanzapine and anterior cingulate cortex activation,
H3E-US-S045,Phase II Single Alimta in MBC,
F1J-MC-HMEH,Fibromyalgia Safety and Tolerability,
B9E-XB-O406,INTRAVESICAL GEM AFTER BCG FAILURE,
B9E-XB-V236,Estudio de sinergismo entre gemzar y paclitaxel in vitro,
B9E-MC-V268,PK and Mononuclear Cell Accumulation fo GEM in Dogs,
F1K-MC-S008,Sensitive Assay for Calcitonin Precursors/Children w Sepsis,
B9E-XM-O466,Fase II study with Gemzar in Unknown Primary tumors (TOD),
H7U-MC-IDAS,HIIP in patients who have asthma and/or have COPD,
B9E-US-S375,Randomized PhIII Trial-Neoadj. Chemo Stage II/IIIa Breast Ca,
H3E-FP-S099,Pemetrexed+Carboplatin_NSCLC_Elderly patients,
F1J-MC-HMEK,Differential Effects of Duloxetine vs Escitalporam on Brain,
"9994",Definitive Drug Interaction Study - Phase 1,
H8Y-FW-HBBF,Assessment of CSF Metabonomic and Proteomic Changes After LY,
F1K-US-X004,Pilot study w/ Xigris in treatment of burn patients,
B4Z-UT-O011,IIT Korebrits Conduct disorder,
H6Q-MC-S064,Ph II - 5FU/LV/Bev +/- ENZ-CRC,
H6Q-MC-S014,Ph II - 2nd line - Alimta +/- Enz in 2ndline NSCLC,
F1J-LC-HMEW,Duloxetine PK In Mild to Moderate Hepatic Impaired Patients,
B3D-MC-GHDG,Teriparatide in treat of Chinese Osteoporotic Men & PM Women,
H7T-MC-V002,Effects of Pras Active Metabolites on deagg in Baboon model,
F1D-MC-X019,PET STUDIES OF AKATHISIA AND OLANZAPINE,
H3E-MC-V080,Effects of carboxypeptidase G2 pemetrexed inactivation,
H6D-MC-X004,Effect of tadalafil on erectile function following BNSRP,
F1K-SU-EVCS,Demographic and Severity Characteristics in Severe Sepsis,
H3E-US-JMFU,Phase 2 Trial of Gemzar + Alimta in 2nd line ovarian cancer,
B9E-MC-JHBY,PHASE 2 STUDY OF GEMCITABINE/CISPLATIN IN CANCER/UROTHELIUM,
B9E-MC-V198,Effect of Gem loaded novel cationic liposomes that bind pref,
H6N-MC-A001,Hypnion Rat Sleep EEG Study,
H8E-MC-KBAE,Low Frequency Occurrence of Gen. Herpes with Use of Resiquim,
"7430",MDD - registry study (AO),
"7471",Phase 1 Gem/Carbo/Alimta,
"7496",IIT ACUP PS02 FIZAZI,
"7506","Hyperglycemia and Perceived Symptoms: mood, cogn., physical",
F1J-SB-S009,Local SUI Placeholder,
F1K-FR-O026,Multicenter open label : A ,
"7535",UK Compassionate Use Study for PTH,
F1J-MC-SBCB,Prospective Urinary Incontinence Research In Europe (PURE),
F1D-IS-B001,olanzapine observational study,
"7702",Prof Vansteenkiste : phase II of GIP as neoadj in NSCLC,
F1D-PL-O197,Prevalence of Hyperprolactynemia in Diff. Groups - retrosp.,
"7806",Dulox SUI Epidemiological Studies,
H3E-MC-V091,Evaluation of Gem Modulation of Cisplatin Drug Resistance,
"9519",Cialis: aspirin interaction study,
H3E-US-X010,Ph I Pemetrexed+Hemithoracic radiation for mal pleural meso,
H6O-LC-GCAS,Obesity Biomarker - MD Sibutramine Effect on Lipid Profile,
F3Z-XM-O061,Insulin resistance in refractory hypertension,
F1D-LC-HGAV,OLAN: PILOT BIOEQUIVALENCY OF CAPSULE & TABLET FORMULATIONS,
"9660",Ped OL ext for pts in combo stimulant+Strattera studies,
F1D-MC-O268,"Comparison of Lithium, Olanzapine, Fluoxetine, and Olanzapin",
"9719",French F1J-EW-SBCC addendum,
"9780",Schizophrenia Augmentation POC,
H6Q-MC-S008,Ph I/II Enz+ temozolomide + XRT in GBM,
"9849",Alimta in Prev. treated patients with GET in MBC,
ZYY-MC-OAAB,Collection of Joint Replacement Specimens for OA Research,
H3E-XM-V042,Searching of paramethers of drug resistence in LC (LVIV),
F1D-MC-HGBI,OPEN LABEL OLANZAPINE,
H6D-US-B010,Observational Study,
"9926","1 year follow-up after acute treatment has finalized",
"9952","placeholder study, not to be included in business planning",
H3E-US-X032,Ph I/II Cisplatin & Alimta in pts. w/ Stage III NSCLC,
"7906",Liabilities Management,
F1K-IN-S002,Observational study in adult patients with severe sepsis,
B4Z-MC-LYCK,ADHD and comorbid dyslexia: DYSTRACT,
"7977",mGlu2 Prodrug-induced Protein Expression,
"7981",Geriatric depression,
"8013",Eval. of effectiveness of Solutions for Wellness program,
F1D-XL-O215,"Cognitive schizophrenia endophenotype, genetic",
H8O-EW-GWAG,Exendin-4: Statin PK,
"8111",Exendin-4: Gastroparesis,
H3S-MC-GGLE,Raloxifene and placebo on carotid artery intima media thickn,
B4Z-TW-S010,Safety and Efficacy of QD dosing Atomoxetine in ADHD in TW,
F1J-AY-HMCZ,Efficacy of Duloxetine in MDD,
F1D-IT-S049,A 5-months obs cross sectional study into italian SPDC,
F1D-US-I038,Effects of olz on 5-HT1a receptor: a PET study,
"8257",Fuller-LY379196-PKCß Inhibits AS1C1 function,
H7R-LC-GCBV,Drug-Drug Interaction Study (Zantac),
"8956",SSRI switching study,
F1J-MC-X007,A Single-Blind Placebo Run-In Trial of Duloxetine Pain,
"10229",Migraine Prevention POC  (placeholder study),
I1B-MC-NDAC,Multi-dose PET Study,
"10696",Placeholder - Multiple Dose PET Study,
"10709",Ph 2 ENZ vs OBs in former smokers-in situ NSCLC (Bepler),
F1J-MC-X022,Predictors of Antidepressant Tx response: Emory CIDAR,
"10903",Placeholder for future Humalog IIT,
F1D-MC-X287,Study of LT Effects of Atypical Antipsychotics in Older Pts,
"10982",Placeb-Controlled trial of aripiprazole added to obese Olanz,
F1K-EW-S009,Septic Patients after Stem Cell Transplantation,
H3E-US-I014,PhI Cis/Gem w/ Pemetrexed for NSCLC,
F1D-MC-A135,Dev Minipump Del Model to Study Antipsychotics-IWG in M Rats,
H6Q-MC-A019,Enz in combo in colorectal xenografts,
H8O-MC-I003,Exex as Adj Therapy in Islet Cell Transplant,
H8O-SB-GWBN,Effect of Exenatide plus Metf.vs premixed Hum.Ins.plus Metf.,
B3D-XM-O010,Valoration of vertebral and peripherical fractures in women,
B4Z-SB-LYDW,Atomoxetine vs Placebo in Patients with ADHD & comorbid ODD,
H9F-MC-GYAK,MDSS caloric intake study w/ Opra I and Sibutramine,
H3S-SB-B002,Observational Study with Raloxifen,
H8O-MC-GWAN,Long term Extension for GWAA and GWAD,
H7C-LC-LMCO,ECG-QTc Study,
B9E-FP-O378,IIT-B-cell Lymphoma B9E-FP-O378 R-GEMOX / GELA,
H8O-JE-GWAQ,JP Exenatide P-I MDSS,
B1Y-FP-O031,Efficacy of maintenance of treatment on recurrence in depres,
H4Z-MC-GJAF,QTc trial (ClinPharm),
F1J-MC-HMDD,G1 - EU Duloxetine vs. Duloxetine Plus Non-Pharmacological,
F1K-BX-S006,open-label LY203638 pediatric purpura fulminans,
"8678","Ph II, Gem + ALIMTA, Pharmacogenomics in Bladder Cancer",
F1K-MC-O022,Human Intravital Microscopy Belgium,
H3E-MC-V011,ALIMTA/GARFT w/ mutant forms of reduced folate carrier,
"8806",Immunocytometric protein profiling of LFAE CSF/plasma,
F1J-FR-A004,comparison of dulox & venlafax on serotonin and NE in mice,
"8838",Multiple Risk assessment in OP women without prevalent Fx,
"8846",GEMZAR OBSERVATIONAL TRIAL IN BREAST CANCER,
H3S-FP-B003,raloxifene prescription survey (transpar. request) (VISION),
"8906",Ph II ALIMTA Single Agent-Hormone Refractory Prostate Cancer,
B9E-US-X421,PhI bi-wkly Gem 24 hr IV fol by Irinotecan 24 hr IV adult CA,
F1D-EW-E003,LY170053 VS HALOPERIDOL IN THE TREATMENT OF SCHIZOPHRENIA,
H3E-MC-V024,Antitumor activity determining the effects of ALIMTA,
"9272",Neoadjuvant therapy for locally advanced breast cancer,
F1K-MC-A007,Mechanisms of APC Function in Sepsis,
F1J-BI-B003,Registry study,
"9348",Haemodynamic effects of treatment with aPC in severe sepsis,
B1Y-CA-C026,FLUOXETINE: EVALUATE OBESE TYPE II DIABETIC SUBJECTS/EFFECT,
B9E-US-S367,Ph III Gem+Cis vs. Taxol+Cis vs. combo in adv cervical ca.,
H3E-US-X016,Ph II study of Pemetrexed & Gem in elderly pts. w/ NSCLC,
B9E-GH-O433,Phase II study of Kanglaite plus Cisplatin and Gem in NSCLC,
B7A-JE-O007,Japan/Takeda Ph II ME Trial,
H6Q-JE-ST11,JP Enzastaurin P-I,
"9647",Duloxetine in Primary Care (GP study),
F1D-MC-X264,Olanz & Fluox Tx of Bipolar Disorder w/concurrent OCD sympt,
F1D-LC-HGEX,OLANZAPINE 20MG STRENGTH BIOEQUIVA. OF TABLET FORMULATIONS,
"9757",Multiple Dose  Study,
H6Q-LC-JCAU,DDI-KETOCONAZOLE-CYP3A4 Biopharm Study,
H6D-MC-LVHH,Cialis Phase III BPH/LUTS Study #2,
B4Z-US-LYDQ,Adult ADHD & Anxiety,
F1K-SB-A014,The effects of rhAPC in cardiac arrest model in rats,
F1J-MC-HMFL,Korea MDD post approval  committment study,
F1D-MC-HGBH,OLANZAPINE VS AMISULPRIDE OR PLACEBO IN NEG SCHIZOPHRENIA,
F1J-FR-SBCV,MAPI: Dev & validation of SUI questionnaires,
"9906",Gem-oxali + rituximab in linfome,
"9954",the realtionship between endothelial and leukocyte adhesion,
"9958",PSG (polysomnogram) Acute Single Dose POC study,
H8Q-MC-GQAG,"Phase 2, 4 month dosing in fibroid patients",
F1J-PL-B012,Efficacy of dulox in females awaiting SUI surgery.,
B4Z-MC-X034,A PET Study of Dopamine Transporter Binding Using C-11 Altro,
"10067",Anti-imfammatory effect of aPC in sepsis patients : ex vivo,
"10092",Trace Level gem and metabolite in human urine,
F1D-XM-S069,Pilot study to improve hygienic-dietetic habits in schizophr,
B4Z-MC-X035,Pharmacological Treatment of ADHD in Young Children,
"10124",PPAR gamma Delta SDSS,
"10131",Placeholder for local support Alimta in Breast Ph I & II CH,
B9R-US-X042,"GH Replacement on reactive oxygen, vasc. compl.",
F1J-PH-B013,Local Post Marketing Surveillance study on MDD,
"10383", GLP-I AnalogV  PEG (Phase II),
F1D-MC-A131,Body Weight in Rats given OLZ by Infusion,
F1J-MC-HMEO,Chronic lower back pain pivotal #2 fixed dose,
H3E-US-X035,Ph II Aimta and Vinorelbine in Leiomyosarcomas,
B9E-IT-V243,In vitro study with Gemcitabine in pat.with renal disease,
"10096",Drug-Drug Interaction,
B4Z-MC-X036,Pharmacological Treatment of ADHD in Young Children,
F1D-MC-HGCV,OLANZ IN SCHIZOPHRENICS INTOLERANT OR RESISTANT TO CLOZAPINE,
F1K-SI-A016,"Coagulation Response in heat stroke, Baboon model",
"10180",Mechanisms of resistance to gem in cancer cells,
"10227",PO SDSS/MDSS,
"10241",Phase2  Efficacy Study,
F1D-MC-HGEJ,Switching Psy  Pat from Halop to Olan Open lab Effic/Safety,
F1D-MC-X280,olz inhibit insulin secretory response to insulin resistance,
H3E-MC-A001,"Intravesical pemetrexed (Alimta), a dose finding animal stud",
H6U-MC-X005,Blink reflex Study,
B4Z-MC-A006,PET imaging:  cortical and striatal dopamine levels with ATX,
B1Y-GH-O036,Orbital Frontal Cortex Volumes Changes and Functional disabi,
"10039",IIT Placeholder (US),
F1D-MC-X276,Demonstration of Drug-Effect on the Morphology of Subcortica,
F1J-MC-HMEP,Osteoarthritis knee pain fixed dose,
B3D-MC-GHDC,Pulmonary (Alkermes) Phase II Trial,
B9E-MC-V334,Cytotoxicity and antitumor activity of gem,
B9E-US-X455,"Ph II Treatment of Uterine Cancer, Gem/Docetaxel/Doxorubicin",
B9E-CP-O455,Phase I/II of docetaxel & gemcitabine in horm. refr prostate,
H6O-FW-GCAU, Beta-cell mass method in healthy volunteers,
"10559",Pulmonary hGH: Phase III Pediatric SGA,
H3E-MC-V045,Antifolate sensitiv/resistance of mutants generated by SGDP,
F1J-MC-HMEQ,Chinese Cymbalta DPNP Registration Study,
ZYY-FW-GCCL,Methodology study  (platelet aggregation),
F1D-MS-E001,PHARMACOKINETIC INTERACTION BETWEEN OLANZAPINE AND LITHIUM,
"10695",Placeholder - Non-restorative sleep,
H3E-US-X056,PhII Biweekly Alimta & Gem in Head and Neck Cancer,
"10760",Lispro Mix 75/25 pump usage and complications,
H8O-US-GWBM,Diet and Exercise study,
"10767",FHD trial for Future cmpd FC000066,
B4Z-US-LYDZ,Functional Outcomes in Young Adults,
I1O-BD-MGAA,SDSS + food effect,
H9T-MC-NAHI,Drug-Drug Interaction with Food Effect,
F3Z-MC-IOOY,NPL vs detemir in type 2 insulin starters,
F1D-US-X290,Placebo controlled trial of aripiprizole added to obese Olan,
B3D-FP-B009,forsteo conditions of use (transparency request),
F3Z-US-X025,Dx people w/ Unrecognized Diabet,
"11030",Characterization of Neutrophils in sepsis,
F1J-JE-1008,EARLY PHASE II FOR DEPRESSION AND DEPRESSIVE STATE,
H4S-CY-O070,PRAGUE 7,
F1D-JE-A136,Effect of ola on neural network regeneration,
F1D-MC-X024,CLIN. PREDICTORS OF ACUTE OLAN. RESP. IN SCHIZOPHRENIA,
F1D-MC-X027,DEPOT ANTIPSYCHOTICS VERSUS ORAL OLANZAPINE,
ZYY-MC-GOAG,Optimizing Scan conditions for qNMR Body Composition Tech,
"10727",Cerebral Morphometric Correlates Schizophrenia & Diabetes Me,
H3E-US-S097,R - Ph III Alimta/Carbo vs Alimta in elderly met NSCLC,
X1C-MC-QC01,OpRa II Phase II Efficacy Study,
H3S-US-GGLJ,Estradiol Combination Therapy - 1 year treatment period,
H8O-US-B004,Observational,
"10762",ISS Dose Optimization Study,
H3E-MC-V092,Preclinical studies with ALIMTA,
F1D-UT-HGFO,"SUBJECTIVE EXPERIENCE OF PAT.ON OLANZAPINE, OPENLABEL PILOT",
F1J-MC-I004,fMRI neural correlates of  efficacy in pt w/ chronice back,
"10907",Actos In Label CTNR,
F3Z-VI-S019,Comparison of Treatment Algorithms with Insulin Lispro Mixtu,
H3E-US-I011,PhII Alimta & Oxaliplatin for Head & Neck Carcinoma,
F1D-EW-LOBZ,OP Depot PK Study with Material from Commercial Facility,
F1D-SB-O294,Bipolar disorder: new program of computer based charting,
F1K-BP-B007,Effects on short & long term outcomes of severe sepsis w APC,
I1A-MC-BPAC,FHD: Single Dose Safety Study in Healthy Volunteers,
H6Q-MC-A012,Enzastaurin and lung cancer,
B1Y-CA-CO37,FLUOXETINE EXCRETION INTO BREASTMILK,
B9E-SB-O462,Gemcitabine-Docetaxel adjuvant and ext. Bisphosphonate trial,
F1D-MC-X001,OLANZAPINE TREATMENT IN OCD PTS WITH TICS OR TOURETTES,
"10438",Definitive drug-drug interaction - Phase 1- rosuvastatin,
F1D-SB-S065,Olanzapine in bipolar depression (local study),
B9E-MC-V330,PK Study of Gemcitabine 100 mg/m2 at FDR infusion,
F1K-US-V019,Effects of Xigris on human endothelial progenitor cells,
B9E-MC-V298,Effect of comb. Gem & Radiation on Panc Stem Cells,
"10686",Bridging Study - LY517717 difumarate and LY517717 D-tartrate,
H3E-US-I009,PhII Eloxatin & Alimta w/ Bevacizumab in Advanced NSCLC,
H3E-MC-S101,Ph 2 Alimta Std Vitamins vs Day 1 Vitamins in Solid Tumors,
B9E-MC-V316,Preclincial research with Gemzar,
F1D-UT-HGFP,EFF. OF OLANZAPINE IN CHILDEREN WITH PERVASIVE DEVEL.DISORD.,
H9F-MC-GYAJ,OpRa I Biopharm/Neurohormone study,
"10921",Ph2 Alimta/Plat in NSCLC (Alimta/Cis vs Alimta/Carbo),
H3E-MC-V122,Cytotoxic effects of pemetrexed in gastric cancer cells,
F1K-SO-V022,Effects of rhAPC on whole blood coagulation Engstrom,
F1J-JE-301G,EARLY PHII STUDY ON STRESS URINARY INCONTINENCE,
H9P-MC-LNBD,Adult depression,
H7T-MC-TABY,Acute Coronary Syndrome subjects who are medically managed,
H6Q-MC-V026,Enz and Avastin in colorectal cancer and endothelial cells,
B9E-US-I158,"PhII Gemzar, Taxol & Avastin for Metastatic Breast Cancer",
"11099",Anti tumor efficacy of IGF-1R antagonist vs. Pancreatic canc,
B7A-AA-MBDX,IMCT: Clinical Significant Macular Edema assessed by OCT,
B5K-JE-V006,ExNCR,
H8K-MC-JZAE,Phase Ib: Combination with Alimta in solid tumors,
B9E-US-I159,PhII Bevacizumab w/ Gemcitabine & Carboplatin for NSCLC,
H3E-BX-B003,Alimta Registry,
H3E-US-X066,PhII Cisplatin+Alimta+Bevacizumab for Advanced NSCLC,
H9P-MC-LNBO,NERI-IV Open Label Exposure in Augmentation for Depression,
"11357",Phase 2 LY vs SOC,
F3Z-BP-B002, UK Incidence of Insulin Initiation in Primary Care,
H8O-MC-I006,Effects of exen in women with PCOS,
"11450",ombination Treatment with Gemzar & SzpC-DOPS for Xenograft,
H3E-MC-JMBX,"Phase I, MTA + CPT-11 Weekly",
H9D-FW-ITAD,Pilot Study to evaluate PK/PD with the prototype Aura device,
F1J-MC-SAAA,DULOXETINE VS PBO IN URINARY INCONTINENCE,
H6Q-MC-A028,Radiation sensitization of lung cancer with enzastaurin,
H9P-MC-LNBI,NERI IV flexible dose vs. PBO in MDD,
H6D-MC-A008,Effect of chronic tadalafil administration on penile hypoxia,
H6Q-MC-S055,Ph II ENZ Safety Extension Trial for Long Term Patients,
"11528", fMRI biomarker,
H8O-IT-O002,Transdifferent. of LCC into Bcells with Exenatide,
H3E-JE-AK01,JP Alimta PMS all patients surveillance,
"11653",Definitive Bioequivalence trial,
F1K-US-EVDO,Endothelial Cell Study,
"11730",Possible anti-Cancer activitiy of LY231514 against ATLL,
H3S-US-X034,Primary Care Based Breast Cancer Risk Assessment and Mang,
H8O-CA-GWCE,Visceral fat distribution with exenatide as assessed by MRI,
F1J-EW-B026,Prospective observational study MDD,
H7T-MC-B002,TRIUMPH Registry Expansion,
H6Q-MC-S054,Phase II Alimta /- ENZ in PR patients - Ovarian,
H3E-MC-JMIH,R-Ph II-PGx -Alimta -1st line -NSCLC,
H9H-MC-JBAI,Ph1b/IIa - TGFb RI Kin+ Radiation Therapy - Glioblastoma ,
H3E-IT-O011,Alimta in combination with cisplatin in NSCLC,
H3E-US-X038,"Ph I/II Bortezomib & Pemetrexed in Adv. solid tumors, NSCLC",
F1D-MC-X302,Melatonin: Lvls and metabol efx in Olz Trt Pt,
B4Z-MC-B006,PEMS study in the UK,
H3E-US-X068,PhII Study of 2nd-Line Pemetrexed in Pancreatic Cancer,
I2J-MC-GTBA,PTHm Receptor Modulator - SDSS/MDSS,
H6D-AU-O005,Effects on Men's Partners of ED,
H8O-EW-GWBE,Long-term glycemic control - EUREXA-Trial,
"10144",Placeholder for local support of B9E-MC-S273,
"11900",PK Study comparing African American vs Caucasian,
B9E-SB-O457,Thyroid cancer GemPac Phase I/II,
H3E-MC-V120,Cytotoxic Effects of Pemetrexed in Gastric Cells,
"10178",Generate Gemcitabine Resistant Breast Cell Lines,
F1D-MC-HGDY,ST OF OLANZ IN SCHIZOPHRENIC PTS. DISCONTINUING CLOZAPINE,
H8D-JE-EMBK,JP PPAR-alpha P-1b PK/PD study,
H8W-MC-EGEB,Phase I - Dose Escallation in Stoke Patients,
F1D-MC-I001,Long-Term Olanz Tx in Chronic Psychosis w/Tardive Dyskinesia,
H6D-MC-LVHD,JP Cialis PAH Phase II,
F1D-MC-X008,ZYPREXA IN DECREASING CAREGIVER BURDEN/ALZHEIMER'S DISEASE,
"10706",Ph2 Tarceva v Tarceva/Alim v Alim never/nonsmokers NCSLC 2nd,
F1D-US-X286,Retrospective Review of Olanzapine Levels in a State Hospita,
"10744",Effects of Duloxetine over anxiety on depressed patients,
F1D-SB-HGEQ,SWITCHING PSYCHOTIC OUTPATIENTS TO OLANZAPINE: A.O-L.N.P.S.,
F1D-UT-HGER,EFFECTS OF OLANZAPINE ON NEUROTRANSMITTERS IN PT WITH SCHIZO,
F1J-FR-HMFC,Duloxetine for patients with or without PPS,
H3E-MC-X057,Ph 2 Velcade+Alimta vs. Alimta vs. Velcade in 2nd line NSCLC,
"10941",Stepped Care for Affective Disorders and Musculoskeletal Pai,
H8O-MC-X006,Effects exen on liver biochem/hist/lipid metab,
F3Z-MC-IOCE,INSULIN LISPRO TREATMENT AFTER ORAL AGENT FAILURE,
F3Z-MC-IOCP,INSULIN LISPRO IN PATIENTS WITH FAILURE OF REGULAR INSULIN,
H3E-US-X071,Ph II Cisplatin + Vinorelbine or Alimta as Adj tmt for NSCLC,
H8O-MC-V006,Effects exen on red Cyt-indu Inflam Human Fat Tissue,
I1F-MC-RHAK,Rheumatoid Arthritis - Phase 2,
I2K-MC-ZZAF,Cognition Impairment Comparator Study in HV,
"12078",VTE Treatment Prevention,
B1Y-EW-E074,FLUOXETINE V PLACEBO MODERATELY HYPERTENSION PLUS OBESITY,
I1I-MC-GECD,Phase 2 Diabetes,
I2R-MC-BIAK,T2DM Insulin Naive - 26 wk treatment BIL (3 PEGs) vs. NPH,
F3Z-MC-IOFZ,INSULIN LISPRO VS HM VS HUM R:  TEST MEAL STUDY IN TYPE I,
B9E-MC-V355,High dose Pem and Gem combo treatment for NSC carcinoma myel,
F3Z-ME-IOBF,LYSPRO: GLUCOTOXICITY REVERSAL IN NIDDM,
I2N-JE-GPBB,JP SARM Phase I SDSS/MDSS,
F1J-CR-S022,Switch to Dulox in MDD from inadequate response to SSRI/SNRI,
B1Y-CP-E068,FLUOXETINE VS. IMIPRAMINE TO TREAT MDD,
H8O-MC-X031,Metformin/Exenatide/Insulin (MEXELIN) Type 2 ,
H6Q-OE-V025,in vitro Enzausterin -BCLL,
H3E-SB-S109,Alimta/Cis or Alimta/Carbo in metastatic NSCLC,
H4S-MC-X026,The interactions of platelets with biomaterial surfaces coat,
"11133",ExNCR in Belgium,
F1D-XM-O297,Clinical Sociodemographic and Therapeutics Characteristics,
"11184",Sequence-dependent Anti-Tumor Effects of Erlotinib and Pemet,
H6Q-MC-S066, Ph II enza +/- sorafenib in hepatoma,
I1G-MC-LTDB,LY2359171 IV POC Efficacy Trial in Migraineurs,
F1J-MC-SAAC,DULOXETINE FOR UI DOSE TITRATION EFFICACY/SAFETY STUDY,
"11301",Plan 708 was cancelled so trial was mapped to Plan 396,
F1J-MC-SAAG,DULOXETINE DOSE TITRATION FOR EFFICACY AND SAFETY IN URGE,
"11365",Phase III 2yr Safety/obesity Efficacy Study OpRa II,
H6D-BP-O009,"Coronary artery disease, metabolic syndrome in men with ED",
H3E-MC-JMIG,PROCLAIM:PhIII A/Cis/XRT->A consol vs Etop/Cis/XRT-local Adv,
H8O-EW-GWBY,LAR - Site of Injection Study,
H9Z-JE-O002,LY2429577 Taisho MDSS in Healthy in Type 2 Diabetic Subjects,
F1D-JE-CS05,Zyprexa PMS Acute phase,
F1J-MC-I006,Dulox fMRI efficacy in chronic lower back pain - IND Exempt,
H3E-MC-V126,Antifolate sensitivity/resistance genterated by (SGDP),
A6J-MC-V009,PROSPECTIVE IN VITRO GLOBAL SURVEILLANCE STUDY,
H3E-US-X060,PhII Alimta/Tarceva vs. Alimta for Progressive NSCLC,
I1R-MC-GLBM,Glucagon-R formulation/bridging study,
"11163",Adult depression,
"11177",Gemcitabine metabolism in the brainstem of non human primate,
H6Q-MC-S029,Ph I Safety Eval. Oral Enz + Avastin- Adv. Metastatic CA,
"11213",Levels of cEPCR in Plasma of Healthy Children,
F1K-MC-EVDM,Acute Kidney Injury,
I1X-MC-BDAA,SDSS in Mild Psoriasis LY2525623 - FHD,
H7T-MC-TACC,Comparison of graph patency in CABG pts. w/pras. v clop.,
H6Q-MC-V030,Role of PKCB in TRAIL-induced apoptosis in CLL,
H8O-MC-A008,Enhancement of Glucose Tolerance by Exen & GLP-1,
H9T-MC-NABJ,OpRA II Phase 2 AD Product Decision Study,
B7A-JE-MBDY,Japan/Takeda Ph III DME Trial,
H3E-EW-S120,Phase I Alim/Erbitux/rad SCCHN,
F1J-XM-B024,Prevalence of PPS in GAD with  or withouth MDD,
"11830",Phase II trial with Alimta in UOT,
F1J-PH-B025,Post Marketing Surveillance Study on Cymbalta (Duloxetine),
F3Z-MC-IOAK,LONG TERM MONITORING SFTY IN PTS CURR TRTD WITH LY275585,
F1D-IT-B038,nutritional & behavioural approch in psych.pts'weight gain,
I1V-MC-EIAK,CETP Inhibitor - Through QT - interval (TQT),
H8Y-MC-HBBQ,Relapse Prevention,
H7T-MC-V019,ADP P2Y12 Binding in Propagating PAR-1 and PAR-4 Activation ,
H7T-MC-V023,Platelet inhibition by Pras AM using ELISA to monistor VASP,
F1D-US-A148,Microdialysis delivery of the atypical antipsychotic olanzai,
"12121",Human Experimental Pain Model POC,
"12187",BE Study - In-vivo Performance of Capsule Formulation,
B5K-US-V012,"ExNCR, Insulin, mechanisms of insulin resistance",
H6D-MC-LVHX,EuU OaD Label changes for men naive to PDE5 Inhibitors,
B3D-IT-V001,Molecular  mechanism of teriparatide on bone remodelling,
"11474",Alimta-cis-Avastin vs Alimta-Carbo-Avastin,
F2P-LC-LCAF,LY237733: ORAL MULTIPLE-DOSE STUDY II,
I1V-EW-EIAC,CETP Inhibitor: MDSS in Japanese Subjects,
F3Z-CA-IODF,RESPONSE TO EXERCISE IN PATIENTS WITH TYPE I DIABETES,
H3E-MC-V134,Role of breast cancer resistant protein in Alimta resistance,
"11777",OA Phase3/4 Safety,
"11786",China Local IIT Placeholder,
"11790",Alimta/Irresa in 1st line NSCLC,
"11800",Local Resources for External Research for ONC,
F1D-EW-B036,Observational study in bipolar with residual symptoms,
H3E-KL-O035,"2nd line Alimta study in NSCLC",
H4S-CA-O076,POSTCONDITIONING IN PCI FOR ACUTE ST ELEVATION MI,
F3Z-CA-O066,Revisiting insulin pharmacokinetics in obese subjects w/T2,
F1J-IT-O031,Neuroplastic changes produced by antidepressant,
F1K-FR-V026,GIBOT Activated Protein C,
I2D-JE-GIBC,JP 11bHSD1 PhI SDSS,
H7T-MC-V001,Crystallization P2Y12 receptor-complex w/Prasugrel,
H3E-UT-O037,Ind. chemo Alimta/Cis foll. by pleurectomy or BSC in MPM,
H8G-MC-EPBK,VTE Treatment Phase 2b,
H6Q-JE-GB21,JP ENZ P-II GBM,
H6Q-MC-JCBY,Ph II ENZ in CLL--pivotal reg trial,
B4Z-CA-O014,Longterm effect of atomox on neuropsychological function,
F1D-CR-S070,Zydis vs Quetiapine in Schizophrenia Maintenance Treatment,
F1D-MC-HGMT,Oral Olanzapine vs long acting injection,
"11699",Regulation of nuclear localization of the ATBF1,
B3D-EW-GHDH,Effect of Teriparatide/Risedronate on vBMD in GIOP in men,
H7T-MC-TACL,Coronary Stent Registry (CSR),
F3Z-MC-IOPD,NPL PK/PD 2,
I4K-MC-GPEC,Phase II -Erectile Dysfunction,
H8O-MC-A011,Red of cellular stress/incr of prolif signals on beta,
B3D-US-GHDJ,Effects of Forteo on Bone Microarchitecture,
"12049",LY2599666 A Beta Antibody Single Dose Safety in Healthy,
H3E-US-I026,Ph II Study of RT+Cetuximab+Pemetrexed +/- Avastin in H&N,
H8O-MC-B007,LAR 106,
H8O-CR-GWDK,IC study of Exenatide and Sitagliptin in patients DM2 ,
F1D-MC-X137,Olanzapine in Major Psychotic Illness,
H8O-EW-GWDG,TDP MDSS - post FHD,
"12413",Placeholder Insulin Trial Germany,
"12539",Human C14 Study,
H8O-US-X012,Exenatide IIT: Exenatide and Diabetic Neuropathy,
H9P-EW-LNCJ,Biopharm DDI Beta II agonist (inhaled),
H3E-US-X076,Ph II Study of Pem + Cisplatin + RT in Mesothelioma,
H3E-JE-JMII,JP-ALM-Maintenance,
"12672",PhII-GemPro-2nd/3rd Line Breast,
"12730",iGluR5 DDI,
H8C-MC-LQCB,DPNP: LY545694 vs Standard of Care (SOC),
I2K-MC-ZZBG,Autonomic Response,
I2K-MC-ZZBY,Anti-Hypertensive Interaction #1,
"12846",Phase 2 (Depression) #2 mGluR5 Antagonist I,
H3E-FR-O045,IIT-Elderly selection on geratric Index Assessment,
"12901",Gemprodug - DDI placeholder,
"12926",Cialis ED comparison of tadalafil and sildenafil,
B5K-IT-B008,Prevalence and predictivity for c.v.disease in type 2 diabet,
H7O-MC-S004,Method to determine Hepcidin levels in multiple myeloma,
F1J-US-X047,Cymbalta for Depression as a Complication of Bereavement,
H4S-IT-O077,FABOLUS_synchroFacilitation through Abciximab By drOpping In,
"12226",Research of polymorphism in psychiatric patients,
H6D-MC-A012,Effect of tadalafil in Preserving Smooth Muscle Function,
I2W-MC-DMAA,SDSS for LY2590443 w/ketoconazole challenge,
"12300",RPh2 Alimta Cis Avastin vs Alimta Cis in MPM,
H8O-MC-X009,New Tx strategy for Exen + insulin for T2D & NAFLD,
I2M-MC-GSDF,Ph 3 Placebo-controlled Fracture Trial (3-yr tx 3 arms),
H6N-MC-LEAQ,LY451395 vs Placebo-Aggression/Agitation in AD,
I2D-FW-GIBE,Single Dose Study to Evaluate PK and PD of LY2508913,
I2P-MC-GAAE,MCHR-1 RBA Study,
H8O-MC-X013,IV Exen. for tx of Perioperative Hyperglycemia,
H6D-SO-O016,"The effect of tadalafil on capillary recruitment, glucose up",
H2Q-MC-LZZB,A TRACER PET-STUDY OF THE M1-AGONIST (BASE OF LY246708),
B4Z-TW-O025,Attention-Deficit Hyperactivity Disorder in Adulthood,
B9E-US-X471,PhII Albumin-Bound Paclitaxel in combinatio w Gem/Bev in MBC,
H9T-MC-NABO,Hepatic Impairment ,
H3S-US-GGLN,Bone on Alendronate and Raloxifene Therapy,
H3E-MC-JMAI,PH II TRIAL OF LY231514 ADMIN Q 21 DAYS IN MET RENAL CANCER,
B1Y-EW-HCCR,FLUOX. (40/60)/AMI: UK ADULT DEPR DOSE RANGING,
H3E-MC-JMAS,Ph I LY231514:Folic Acid in Locally Adv or Metastatic Cancer,
I3R-EW-HMIC,mGlu2 MDSS,
F1K-XM-V028,Study of mechanical and inflammatory changes in alveolar epi,
H9X-MC-GBDH,Ph 3 Trans Launch(LY1.5+met+sita)or(LY1.5+met)vs(pl+met+Sita,
H6O-PL-O007,Pathogenesis in one-year-old patients with DM in Poland,
I3T-MC-PRAA,Trial for Progesterone Receptor Modulator,
F1D-AY-V026,How does developmental vitamin D deficiency alter dopaminerg,
F1J-US-A011,Establishment of the DLX-principle in persistent pain models,
H3S-JE-103J,PHASE 1 CLINICAL STUDY OF RALOXIFENE(MULTIPLE STUDY),
H4Z-MC-GJBD,Arzoxifene Lasofoxifene Comparator Trial,
I4E-MC-JXBC,"CP02-0452: ""SELECT""R-PH3-DocetaxorPemetrex+/-Cetuximab-NSCLC",
I4E-US-S002,R-PhII-Cetux+Carbo+Pac vs Gem or Alimta+Cis or Carbo_NSCLC,
B4Z-JE-LYEE,JP Atomoxetine Adult Phase2/3 - Asian,
H4Z-MC-GJAY,Comp. of Arzox and BP Comparator on Bone Quality Assessments,
F1J-JE-HMFY,JP Dulo DPNP P-III Open-Label Study Managed by Shionogi,
"12282","11bHSD1 Biopharm QTc",
H3E-US-X074,Ph II Study of Alimta in Patients with CTCL,
F3Z-SB-IOCI,INSULIN LISPRO:BLOOD GLUC LEV AFTER MEALS OF DIFF COMPOSITIO,
F1D-FR-HGMY,"Extension study for patient previously in HGLQ, HGMT",
F3Z-SB-IOFS,HUMALOG BOLUS THERAPY AND DIABETES MELLITUS TYPE II,
"12367","2-year diabetes add-on to SU - LY as Liraglutide",
F3Z-TS-IOGL,INSULIN LISPRO IN INTENSIVE INSULIN TREATMENT,
I2U-MC-H306,POC Excessive Sleepiness Study in HV,
"12471",CRH-1 Alcohol Interaction Study,
H6Q-EW-V040,Enz biomarkers and potential for resistance In Vitro,
B3D-IT-O021,Use of PTH to prevent collapse in osteonecrosis of fem.head,
"12563",Ph II trial #2 (Tumor Type TBD),
H8C-FW-LQBH,Drug-Drug Interaction Study in Asian Population (3A4),
H9P-EW-LNCH,Biopharm DDI Fluoxetine Study,
I2R-JE-BIAB,JP BIL P-I SDSS,
"12358",Ph III - Single Agent - 3rd line - Ovary,
"12369",Hypoglycemia recovery trial,
B1Y-EW-E080,FLUOXETINE VS PLACEBO/BEHAVORIAL MOD AND LOW CALORIE DIET,
F3Z-VI-IODQ,LISPRO VS HUMULIN AT DIFF. MEAL RELATED TIMES,
F1D-KL-V023,Non-clinical Olanzapine IIT,
H3E-US-V141,Genetic determinations of Pemetrexed responsiveness NSCLC,
H6D-US-LVHZ,Tadalafil OaD Compared to Pbo in Day of Onset of Efficacy,
H8C-MC-LQBZ,DPNP:  Noninferiority vs Pregabalin (#1 of 2),
I2K-MC-ZZBH,Metabolism/Transporter #1,
I2K-MC-ZZBT,Abuse #2,
H8Y-MC-HBCY,Particle Size Study,
"12888",The Inala Chronic Disease Management Service : A novel model,
H2Q-SP-LKAD,XANOMELINE-TTS & HALOPERIDOL INTERACTION STUDY,
I1F-MC-RHAI,rrMS,
H3E-MC-JMAH,PH II TRIAL OF LY231514 IV Q 21 DAYS IN PTS W/ESOPHAGUS CA,
I1C-MC-JLBI,Ph II - GemPro - T-Cell Lymphoma,
I3N-MC-ABCB,Multiple Dose Study of LY2562175,
H8L-MC-IQAJ,Luxura HD vs. NovoPen Jr study,
H3S-LC-GGHN,RALOXIFENE HCL:FED/FASTED AND AMPICILLIN INTERACTION,
"13569",IIT-Place Holder FORSTEO,
B5K-IT-V018,Effect of Increase proins/ins ratio inRPE cell line ARPE- 19,
F3Z-JE-PV06,JP_Insulin_Ph4_Non Safety and Observational study (INSIGHTS),
"13639",(CT-3) PK/PD Study,
H7T-MC-TAEJ,PK/PD Study in Patients with Sicle Cell Disease,
H6Q-MC-V056,Pre Clinical - T-cell leukemia/lymphoma and ATLL cells,
F1J-US-X057,Dulox for Fibromyalgia: An Open-Label Pilot Study,
I4W-FW-HMJC,sleep EEG study,
I4T-IE-JVBJ,CP12-0708:Ph2-1121B+Paclitaxel+Carbo-IIIB/IV NSCLC-1st Line,
I4T-IE-JVBM,CP12-0401: Ph1-1121B- Advanced Solid Tumors - 2nd line,
I4M-MC-MRAA,SDSS dose escalation - FHD,
"13965",Phase 2a Clinical Trial - for RA done at Incyte,
I2R-MC-BIDQ,Pediatric T1DM 1-5 years,
H3E-JE-O062,JP_Ph III-Alimta+Platinum+BEV->Alimta+Bev - NSCLC,
I3E-BM-MSAD,MAESTRO-03,
I2K-MC-ZZCA,Night time impairment,
H9P-MC-LNDK,MDD Pilot Augmentation Study,
B4Z-XM-O024,Parent-Psychoeducational Program. Adherence to txt ,
H3E-MC-JMAF,LY231514 EVERY 21 DAYS IN LOCALLY ADV.OR MET. GASTRIC CANCER,
"12981",CD-4 week Induction 12 month maintenance+open label safety,
B3D-IT-O024,Eval. of Bone Healing in pts. treated with PTH,
F1J-CR-HMGM,IC Duloxetine Study in MDD & residual or SSRI-induced apathy,
B5K-US-V014,The effects of slow-release or long-acting insulin on plasma,
"13036",ER Beta Renal Insufficiency Study,
F1J-EW-HMGQ,Dulox and PGB monotherapy in DPNP,
"13132",Relative Bioavailabiltiy of LY2456302 (OpRa Kappa),
H7T-DS-TADV,Estimation of number of platelets needed to reverse the IPA ,
H8O-MC-V005,Characteristics of molecular pathways,
H8O-MC-A023,Effect of exen on ins graule exocytosis/mito ,
H3E-EW-O052,Avastin+/-Alimta maintenance in non-squamous NSCLC,
H8K-MC-JZAT,Tasisulam QT study,
"13093",OpRA KAPPA C14 ,
"13104",Ph III - Met Breast,
I3W-MC-HHAF,"14-C Metabalism",
H8O-MC-V008,Further studies of exenatide in vitro on endo cell,
H8O-MC-A029,Identifying key receptors for exanatide actions,
B3D-US-X025,Forteo in Patients with Diaphyseal Fracture,
H8L-MC-IQAH,Device assessment/Humalog KwikPen vs. Next Gen FlexPen,
"13507","Chk-1 Inhibitor Effort 1, ph 1",
I6A-MC-CBBA,FHD PI3 Kinase/mTOR Dual Inhibitor ,
"13628",TDP Usability and Relative BA study (Placeholder),
H6P-GH-HDAZ,O+F TRD Trial for China Registration ,
H3S-MC-GGHF,"RALOX,HRT & PLACEBO: HISTOMORPHOLOGIC EFFECT IN PMP WOMEN",
H7T-MC-V032,Levy: Therapeutic Approaches for In Vitro Reversal of Pras,
I4S-EW-HHCB,MAD,
I4L-MC-ABEF,BIV China PK/PD Study,
F1D-JE-CS10,Zyprexa Japan bipolar NSOS,
H9P-EW-LNCN,Biopharm Rel BA Study for Child Formulation (Healthy Adults),
H2G-LC-BZAB,LY213829: SINGLE ORAL DOSE SAFETY AND PHARMACOKINETICS,
H2Q-EW-E001,LY246708 SINGLE ESCALATING ORAL DOSE - SAFETY & DYNAMICS,
F1D-MC-O334,Eval of Histalean in attenuating Olz-assoc wt gain in female,
H9X-MC-GBCY,Exploratory method study for insulin restoration,
I3F-MC-JSRA,FHD Study for Notch-1,
H8Y-MC-HBCL,QD dosing - Phase III,
H8O-MC-X014,Coronary ICU Hyperglycemia,
"12745",iGluR5 OA Pain 8  (PhIII),
H8C-MC-LQCA,DPNP: Noninferiority vs. Pregabalin (#2 of 2),
"12776",PoC – Unilateral Leg Suspension (Myostatin Ab),
H2Q-MC-LZZA,LY246708 TARTRATE VS PLACEBO IN MILD TO MOD. ALZHEIMER'S,
H8O-MC-V003,The role of exenatide in the human overy,
H8O-MC-GWDF,"2nd Gen. Pen Patient Usability/Acceptability",
H8Y-MC-HBCZ,DDI: Charcoal Interaction,
F3Z-MC-IOPP,China NPL Registration Study,
H2Q-MC-LZZY,XANOMELINE TTS SAFETY/EFFICACY IN MILD-MOD ALZHEIMER'S,
F1D-MC-A032,Olanzapine and Microdialysis in Rhesus Monkeys,
H8L-MC-IQAW,Safety & Effectiveness of Aura in Type 2 initiating mealtime,
H6Q-MC-V076,Pre Clinical - PKC b inflammation response in airway cells,
I4X-IE-JFCE,CP11-0401: Ph1 - 11F8 - Solid Tumor,
I2Z-MC-LAFE,Phase IIA-AUD POC Study,
H6O-EW-S012,Apelin Infusion - EET,
I4F-EW-CCAC,PoC Study - LY2828360,
I4S-JE-HHCD,JP mGlu2 Agonist Prodrug II P-I,
I5N-MC-MGLA,PET Ligand Validation Study,
I4O-MC-BACI,French Brain Imaging Initiative Treatment Study,
I5E-MC-TSAJ,DDS08-Rand. 2-way PK comparison crossover study-test.,
I1Q-JE-JDDI,JP Myostatin for Disuse Atrophy,
I5A-IE-X012,"8155: Ph I - A12+Sorafenib - Hepatocellular Carcinoma",
H8L-MC-IQBB,Volume Study in Healthy Volunteers to Support Device Dev,
I1V-JE-EIBG,Japan Statin Add-On Hypercholesterolemia Study,
"14507",The Needs for ADHD Patients Beyond School,
"15664",Bioequivalence Study,
H7T-IT-O002,PROVE study,
F3Z-CA-O075,Piloting a Standardized Order Sheet - Chart Review,
B9E-IE-JHSV,DRUG ONLY_R-Ph3-Gem-Cis+IMC-11F8vsGem-Cis_NSCLC(squamous),
"13332",DDI for 5-HT2A antagonist,
B4Z-XM-O029,Relation: Cognitive-attentional and social abilities in ADHD,
F1J-US-X054,Effect of Roux-en-Y Bariatric Surg. on Blood Levels of Dulox,
"13369",C14,
B3D-US-X024,Forteo in Pts with Secondary Hyperparathyroidism Vit D Defic,
F1D-UT-O329,ROCKSAN Random. olanz. clozap. key study schizophr. &addict.,
H4Z-MC-GJBH,Combo Oral Irritation study (Chewable formulation only),
H3S-LC-GGHE,RALOXIFENE:PHARMACOKINETICS AFTER MULTIPLE DOSING,
"13443",Definitive BE with PPI #2:  PLACEHOLDER,
H8O-FR-O023,"GLP-1R agonsts cardiac funct., EAT vol & myocard TG in obese",
B7A-MC-A025,The role of vasoactive peptide in the development of d,
I3U-JE-GRCB,JP DKK Ph1 MDSS,
"13651",iGluR5 Digoxin DDi,
H8O-CA-O031,Exenatide for Myocardial Protection during Reperfusion Study,
I4M-MC-MRAF, RBA Study,
H7T-MC-TADF,Pre-Treatment,
H3E-BP-0001,A PHASE 1 STUDY OF LY231514 USING A DAILY X 5 Q 21 SCHEDULE,
F1J-MC-HMGI,Pediatric General Anxiety Disorder Study,
H9B-MC-BCDY,MS Ph 3 LY1 vs LY2 vs Avonex Relapsing Forms,
"12965",Treatment Flexibility,
I3N-MC-ABCA,LY2562175 First in Human Dose Escalation,
H7K-SB-B001,Observational evaluation of resources and costs (Munich),
H8C-JE-LQBJ,JP iGluR5 P-I,
"13065",JP iGluR5 Antagonist Ph2  Pain,
"13094",Phase 2 dose ranging OpRA Kappa,
I1R-MC-GLBN,Definitive QTc Study,
H3E-MC-JMBM,PHASE II TRIAL OF LY231514 IN REFRACTORY PATIENTS,
H9X-MC-GBDG,Phase 3b translaunch add on to SU regm:LY1.5 vs placbeo,
H3M-LC-EQAH,EFEGATRAN SULFATE:  EFFECT OF RENAL DYSFUNCTION ON THE PHARM,
F1J-MC-HMGP,OA Pain Fixed Dose,
H3M-LC-EQAI,EFEGATRAN SULFATE: EFFECT OF RENAL DYSFUNC.ON PHARMA.OF EFEG,
I4T-IE-JVBE,RAINBOW CP12-0922:R-Ph 3-1121B+- Paclitaxel-Gastric-2nd line,
I4T-IE-JVBI,CP12-0816: JP_Ph 1 - 1121B- Advanced Solid Tumors,
I4X-IE-JFCB,CP11-0805:INSPIRE-R-Ph3-11F8+Alimta-Non-Sq-NSCLC ,
I4T-IE-JVBP,CP12-0605: Ph2-1121B-Renal Cell CA,
"13982",Placeholder-POC Ph2 Sleep Hypothesis,
I4M-MC-MRAB,LY262309 MDSS PoP ,
B3D-US-X029,Teriparatide for Osteo and RA Erosions in PM Women,
F1J-XM-B042,Treatment outcomes in depression,
I3P-MC-GKBH,Simvastatin DDI,
H6D-MC-LVJA,Tadalafil PRN + Testosterone Solution,
H8L-EW-IQAZ,EQW Device Usability Simulation Study in Pts w/type 2 Diabet,
H3E-MC-V151,Pre Clinical - Epigenetic Regulation in NSCLC,
I5W-MC-LBCC,Phase 2 Osteoarthritis,
I5W-EW-LBCD,C-14 Study,
H8A-FW-LZAV,China Multiple Dose PK Study,
"9018",Randomized Ph II Adjuvant Gem/Cis vs Alimt/Cis in NSCLC,
H8O-MC-B018,EU Thyroid Neoplasm and Pancreatic Cancer database study,
I4V-MC-JAGN,Definitive Food Effects,
I4F-MC-CCAH,Abuse Potential Liability,
I1Q-MC-JDDK,Phase IIb / III - Evaluate Myostatin Ab in Elderly Fallers,
H8O-MC-X037,Impact of GLP-1 on intrinsic Brain Activity ,
F3Z-MC-IOQJ,Title Assessment of Hypoglycemic Events among Type 2 Diabete,
F1J-MC-B046,"2012-202_Cymbalta EMR Study in CLBP_Phase II ",
F1J-MC-B045,"2011-376_Post pain launch Cymbalta CLBP/OA  Patient profile",
F1D-AY-O338,The anti-cancer effects of cholesterol trafficking and synth,
H6D-PH-B018,CIALIS 5MG ONCE A DAY PH PMS,
B5K-US-V021,Qualification of ELISA assay specific for human insulin(zf),
H3E-MC-V158,Antineoplastic Drug Exposure/Health Care Workers/Ambulatory ,
I5S-MC-EFJK,Statin Intolerant ,
H9H-MC-A013,Investigation in Murine Melanoma Models,
B1Y-FP-0739,FLUOXETINE VS TIANEPTINE IN DEPRESSION IN ELDERLY PATIENTS,
"15214",Phase 2 Study #2,
I4O-MC-BADB,China PK/PD,
"14373",JP_Ph3-Necitumumab+Gem/Cis - Biliary,
H4M-LC-NRRB,LY307640: PK/PD IN IN PATIENT W/H.PYLORI,
H9S-MC-JDCH,CN FRD: Ph III - LA294 + Bortezomib - Multiple Myeloma,
I4V-MC-JADO,TQt Study,
B7A-MC-V026,Aloneazi Renoprotection Rat Diabetic Nephropathy Model,
B4Z-MC-LYFK,CFF Stabillity Taste Study,
I1V-JE-EIBI,Japan Hypercholesterolemia Study - mono therapy,
"14537","PDE1b Kinetics, Dosimetry, Test-Retest",
H3E-GH-JMIV,Alimta/CDDP 2nd line NSCLC with activating EGFR mutations,
I4V-MC-JAGI,Statin DDI,
I1V-MC-EIAT,Absolute Bioavailabiity/Intravenous tracer Method,
"14647","Taiwan, Korea PK Study",
I6E-AV-AVBA,Japan Dosimetory Ph1,
"14704",Hypoglycemia Recovery Study ,
B5K-OE-O457,Insulin Therapy for the Prevention of NODAT,
H4S-MC-EWAG,Dose-finding trial of ReoPro in acute ischemic stroke,
"15319",Axiron study in hypogonadal men with diabetes,
B3D-MC-A006,Genome Analysis PTH BMP Synergy Spine Fusion Rabbit (Witham),
H3S-MC-A012,Preventing skeletal fragility in Type 2 diabetic rats (Burr),
I1V-MC-EIBM,Terminal Elimination PK Study,
I4V-JE-JAGX,Japan Open Label Phase 3 Psoriasis Trial,
I4R-MC-V001,Platelet factors and HCC growth,
H6D-GH-B022,Phase IV Post-Marketing Study in China,
I7Q-FW-SLAC,Contingency: O-glycoside risk study,
I6K-JE-GLEF,Japan Phase I Study,
"15528",Placeholder MR Antagonist III plus Tadalafil Phase 1 Japan,
"15559",Hepatic Impairment,
I5Q-AR-ART1,"Randomized, DB, PBO-Controlled Study in migraine patients",
F1D-MC-I010,A double-blind study of Olanzapine vs. Cloz/Parks Patients,
H6D-MC-B023,"2014-243 QOL and treatment preference in BPH and ED patients",
B9E-TH-X005,"Phase II, Gemcitabine & Cisplatin,  In NSCLC",
"13657",iGluR5 Addictive Potential,
"13671",Maintenance effect of tadalafil OAD on pts naïve to PDE5i,
H3E-MC-V148,Gene-Environment Interactions in Lung Cell Growth,
H3S-MC-GGHP,RALOXIFENE VS. ESTROGEN/PROGESTOGEN TX IN POSTMENOPAUS WOMEN,
H3S-MC-GGHV,COMP. OF RALOX AND ALENDRONATE IN TREATMENT OF POSTMENOP. OP,
H6Q-MC-V051,Pre Clinical - Impact of Enz on CLL B cells,
"13848",MDSS CGRP Neutralising AB I,
H3Z-MC-JNAB,PHASE I CLINICAL AND PHARMACOKINETIC EVALUATION LY295501,
I5A-IE-JAEK,CP13-0604: Ph2 - A12 - Breast - 2nd Line,
H4A-CA-V005,SUSCEPTIBILITY & STOOL STUDIES WITH ANTIFUNGAL LY303366,
"14013",B'pharm Hemodynamics Study,
"14027",EQW combination therapy in patients failing OAM,
I4V-MC-JADF,Ph I JAK Plc - single dose healthy volunteer Incyte 101,
"14111",Phase IIB-MDD dose-ranging,
"14127",R-PhIII-A12 vs BSC-Soft Tissue Sarcoma-2nd Line,
I4S-MC-HHCF,Phase 2A signal Detection-Bipolar depression,
H3E-RE-I035,DRUG ONLY-R-PhIII-Nanoplatin+Alimta vs Cis+Alimta-NSq-NSCLC,
I5S-MC-EFJM,Safety and Tolerability study,
H8L-MC-IQCY,Autonomy titration app second Formative HF study,
I7E-AV-_A09,"18F-AV-1451 Injection for Tau in Subjects with PSP",
H3E-GH-O079,Pemetrexed and cisplatin for lung adenocarcinoma ,
B9R-MC-GDEX,Humatrope: safety and efficacy in Pediatric Burns Patients,
"15793",Statin Rechallenge,
I5Q-JE-CGAN,Japan 2b Migraine Prevention Dose Ranging,
I6A-MC-CBBF,FRD_Ph III-Letrozole+Abema+PI3K/mTor-mBC ,
I4C-MC-A002,Devel. of systemic treatments for metastatic uveal melanoma,
I1D-MC-V001,p38 MAPK inhibitor in CRC-targeted theapy,
I5B-MC-JGDP,Ph Ib/II - Gemcitabine+Nab-paclitaxel +/- Olara - Pancreas,
I4E-IE-W800,Protocol CA191-006; A I/II TRIAL OF BMS-754807 IN COMBINATIO,
I4E-IE-W857,Protocol CPO2-9813; IMCL-9813; II Study of C225  in Combinat,
I4E-IE-W934,"Protocol CA225-302; II STUDY OF CETUXIMAB, 5-FU AND RADIATIO",
H3F-MC-E001,ExIST Trial to Examine the effect of GRA 1 on GIGD Incretin,
I6E-AV-I034,AV-45-IIT-034: COGHIC,
I6E-AV-I036,AV-45-IIT-036: IMAP/IMAP+,
H6D-US-V013,ATP Release from Human RBCs: Role of UT-15C and Tadalafil,
I5S-MC-EFJN,Formulation Bridging Study,
H9X-MC-GBDT,PK of Pre-filled Syringe versus Auto Injector,
"14156",Subcutaneous 5 day regimen,
H7T-US-X012,RELOAD,
F1J-US-X061,Brain morphometric study in knee osteo pts tx'd w/dulox,
H6D-US-X012,Daily Cialis and Gastric Empt Time in Diab Gastroparesis,
I5A-IE-X021,E3508:PhII-A12+Pac+Carbo+Bev vs Pac+Carbo+Bev-Nsq NSCLC,
I4V-MC-JADQ,Placebo-Controlled Study Of Efficacy & Safety for Psoriasis,
B3D-US-GHDU,Treatment of osteo in postmeno women at risk high fracture,
H4R-LC-IPAA,LY309132: DOSE-RANGING AND COMPARISON WITH HUMULIN N,
I4V-MC-JAGC,Hepatic Impairment,
I4V-MC-JAGG,Probenecid DDI,
B9E-GH-O512,Gem+Cis VS 5-Fu+Cis in treatment of recur and metastatic NPC,
I6H-MC-MCBB,MAD,
I6E-AV-A011,A05 extension study,
H3E-UT-O071,Novel Predictive parameters for pemetrexed-based therapy ,
F1J-XM-O054,Clinical Staging In Depressive Disorders,
F3Z-MC-B013,VISION Verifying Insulin Strategy and initial Health Outcome,
H7O-MC-B001,Impact of palliative care on BDMC & disease bio in Gliomas,
"14769",Humulin U500 in CSII with Device X vs Basal Bolus Standard ,
F3Z-MC-B011,"2011-780_Small vials vs pens in hospitals economics & safety",
I2Z-MC-LAFI,RBA Bridging Formulation Study,
"14897",Theurapeutic effect of rgh on cystinosis myopathy_muscle was,
I4J-MC-HHBI,FRD - Ph 2 - Hedgehog - PLACEHOLDER,
I4O-MC-BACO,Digoxin,
I4O-MC-BACP,Abuse liability,
I1D-MC-JIAO,Digoxin DDI in NHV or patients,
I2I-MC-V008,Validation of chid as a therapeutic target in osteosarcoma,
I4L-MC-ABEQ,PK/PD BIV versus Glargine (Vial),
"15005",P70 S6 Kinase as a critlcal node in cancer cell slgnaling,
H9H-MC-A011,Study - Receptor I kinase inhibitor in hepatocarcinoma model,
S2B-LC-LSSA,LY368975: ORAL DOSE-RANGING STUDY,
T4V-LC-ERAA,CARDIOVASCULAR ACTIVITY AND SAFETY OF RACTOPAMINE HCL,
H9H-MC-A014,Tumor progression of pancreatic cancer,
H4Y-MC-LJAW,Adolescents with migraine,
"13254",Enzastaurin and Cyclin D1 in Squamous Cell Carcinoma ,
"13293",Ph 2a Indication exploration Study other/population 2,
"13301",U200 Humalog Clinical Trial,
H6N-MC-LEAU, Drug Interaction Study CYP3A,
"13404",This is a test,
I4E-MC-JXBA,CP02-0861: PhII-PK & DI_Cetuximab-Cisplatin_H&N Squamous,
I5R-FW-CIAA,"c-Met Inhibitor Effort 2,ph 1",
H6D-CR-B017,Obs study in treatment persistence within MENA countries,
B7A-MC-V007,The Role of PKCb in Dopamine Transporter Traffick,
H3S-MC-GGBB,BREAST CANCER CASES-RALOXIFENE,
B7A-MC-A023,PKCß1 mediates high glucose-induced Akt ,
I2I-JE-JMME,JP_Chk-1_Phase_1,
B3D-IT-O025,Glucocorticoid Induced Osteoporosis Tool,
H3S-MC-GGGF,RALOXIFENE VS PLACEBO IN PREVENTION OF OSTEOPOROSIS,
H3S-MC-GGGP,COMPARISON OF RALOX AND PLACEBO IN TX OF OSTEOPENIA,
"13661",IGluR5 Pivotal IV/IVC (Placeholder),
H3E-XM-O059,CUANTIFICATION OF ENDOTHELIAL CIRCULATING CELLS AS PREDICTIV,
I8B-MC-ITRN,URI Vaso/Citrate Phase III T2DM ,
I8J-JE-JYCB,JP_FHD Ph I - PD-L1 Antibody - Solid Tumors,
I9F-MC-SCAA,"D-LY3323795 - SAD, DDI",
I8X-MC-JECC,CYP3A4 DDI in Healthy Subjects,
I8P-MC-OXAB,MAD for OXM III (LY3305677),
I8K-MC-JPDG,Phase 2b in Rheumatoid Arthritis ,
I9I-MC-LGDB,LA Glucagon/Dulaglutide Combo (LY900019) Adaptive Multi-fact,
H9X-JE-GBGK,Japan MMTT,
I9D-MC-ROAC,MAD LLY3310756 ROR Gamma Inhibitor (LY3310756),
I9L-MC-JZCA,FHD - Ph I - ID01 Inhib - Solid Tumors,
H3S-US-GGIK,"A RANDOMIZED, PARALLEL TREATMENT STUDY OF DOUBLE-BLIND RALOX",
I5S-MC-EFKB,Drug Drug Interaction ,
B1Y-MC-X130,LITHUANIAN TRANSLATION OF ZUNG SELF-RATING DEPRESION SCALE,
I9R-MC-BSDA,FHD SAD HV,
I9R-MC-BSDD,T1DM Seamless P2/3 ,
F1K-XM-O050,Propspective Observational Study,
H3S-JE-A010,Central control of bone metabolism by mice,
I4S-EW-HHCA,SAD,
I4V-MC-JADC,Phase 2A Study in RA done by Incyte 201,
I5E-MC-TSAD,Cialis OaD + Testosterone- Global,
B9R-JE-GDGQ,JP Humatrope Phase1 Liquid,
F3Z-MC-B010,A Multinational Observational Study Assessing Insulin use.,
I4S-MC-HHCE,Phase 2A Signal detection-Bipolar mania,
H3E-US-X085,PhI Preop Carb/Cis+Pem w ThoracicRx fb lobectomy inSIIINSCLC,
I2R-MC-BIDA,Hepatic Impairment Study,
"14231",Cardiovascular Effects of Apelin Infusion,
I5U-MC-ANBD,C14,
I4X-IE-JFCI,CP11-1114-PhII-Evaluate 11F8+QT Interval Chng-Solid Tumors,
I4V-MC-JADU,Psoriasis Phase 3 Comparator Study,
B1Y-FP-0729,FLUOXETINE VS PLACEBO IN MDD WITH GASTRIC COMPLAINTS,
H4Q-MC-V003,"LY333328, AMPI, VANCO, TEICO, RP59500, & GENTAMICIN VS VRE",
I4C-MC-JTBF,PH Ib/II - c-Met Antibody + Ramucirumab - Adv Solid Tumors ,
I5J-MC-NOAK,DDI With Midazolam Study,
B4Z-MC-B025,Atomoxetine Drug Utilization Study Part 3,
H8L-MC-IQCM,PCSK9 in PFS Formative Human Factors,
I6O-MC-BHBD,Phase III BID Trial vs Novo 70/30 in T2DM Patients,
H9H-MC-A019,CONTROL OF TGFb FUNCTIONS IN THE HEMATOPOIETIC SYSTEM BY ESL,
B1Y-FP-0770,FLUOXETINE VS PLACEBO IN DEPENDANT ALCOHOLICS,
I5F-MC-JSCB,Ph I - CS4 - investigate immune MoA - Prostate and Breast,
I7X-MC-LLCE,RBA/Food Effect Study,
"15588",PK DDI study with 2B6		,
I7E-AV-_A06,"Evaluate 18F-AV-1451 PET in AD, MCI, Non-AD compared to HC",
H8L-MC-IQCS,Summative HumaDapt Human Factor study ,
H8L-MC-IQCU,Diabetes Medical App Formative 1,
"15656",DDI - Statin,
F3Z-MC-IOGU,Comparison of Insulin LisPro LM and Humulin 30/70,
H9X-MC-B007,"2014-624_Patient Preference Study",
H9H-MC-A031,Novel therap. interven. for Cerebral Cavernous Malformations,
H8H-MC-LAID,Consistency Trial- ME2 China,
H8H-MC-LAIA,BE Oral Disintegrating Tablet HV,
I6Q-MC-BIFC,Matrix Study,
F3Z-MC-B026,"2016-5432 Identify Reasons Insulin Disc from Unstruc EHRdata",
F3Z-MC-B027,Tango Feasibility Study 3 (a)  ,
I8F-MC-GPHO,IMCT H2H glargine,
F1D-MC-X059,A DOUBLE BLIND STUDY OF Olz. VS CLOZ IN PARKINSONS DISEASE,
"17254",Ixekizumab in the treatment of Lichen Planus,
I7E-AV-E054,"18F-AV-1451-EXIST-054",
J1A-MC-KDAD,Phase 2 POC in Rheumatoid Arthritis,
J1X-MC-GZHA,FHD SAD HV,
I6E-AV-I056,AV-45-IIT-057: KEEPS,
F3Z-MC-GZKB,Tango T2 Late Feasibility ,
I5Q-MC-CGBC,GI Motility study,
J2G-OX-Y024,PhI-RET Inhibitor-NSCLC,
J2N-OX-JZNB,LOXO-BTK-20007-Ph1-Pirtobrutinib-ADME (C14),
H7T-SB-O018,TATORT-NSTEMI,
B4Z-JE-ST02,JP_STR_ADHD_Adult_Special_PMS,
"14645",Cyclosporine Drug Interaction Study,
I4L-MC-ABEM,BIV - 2 Dose Study,
I1F-MC-RHBL,Phase 3 - Autoinjector Trial,
H7T-MC-TAES,Pediatric Sickle Cell in 1 -2 Year Old Patients,
H4W-LC-LLAD,LY156735:ORAL DOSE-RANGING STUDY,
F3Z-MC-IOQL,Treatment Strategies in Elderly Patients with Type2 Diabetes,
I1D-MC-JIAI,Renal Impairment in Cancer or Non-Cancer Patients,
H8L-MC-IQBK,HumaPen® Savvio™ Summative Human Factors Study ,
I6J-MC-PRBF,GPR40 Agonist II Phase II Study,
H9H-MC-V009,RADIOTHERAPY/CHEMOTHERAPY-PROSTATE TUMOR CELL BONE METATISIZ,
B5K-MC-IBHE,Parellel Comparison of Humulin U-500R,
H4Y-MC-LJAK,Pilot Aura (3 migraines),
"15213",Phase 2 Study #1,
I7B-MC-DPAC,VEGFR1 Phase 2 in CKD,
J2N-OX-JZNE,LOXO-BTK-20010-Ph1-Pirtobrutinib-DDI Cocktail,
F3Z-MC-B021,U200 Risk Minimization Assessment Study - US #2,
B3T-MC-JTAB,Ph 1 Dose Escalating Study of PO LY335979 and Doxorubicin,
I4E-IE-W802,Protocol CA225-106; II STUDY OF CAPECITABINE PLUS IRINOTECAN,
I4E-IE-W834,"Protocol CA225-014; A III Study of Cetuximab, Oxaliplatin, 5",
I4E-IE-W845,Protocol CA225-107; II TRIAL OF CETUXIMAB IN PATIENTS WITH M,
I4E-IE-W926,Protocol CA225-121; II TRIAL OF CETUXIMAB PLUS CISPLATIN AND,
I4T-MC-JVDG,Ph II - Ramucirumab+Docetaxel - NSCLC - 2nd Line,
"16073",C14,
I7E-AV-E025,"18F-AV-1451-EXIST-025",
I5Q-JE-CGAP,Japan migraine prevention open-label extension study,
I6E-AV-I029,AV-45-IIT-029: Tracking Myelin Changes In Vivo with 18F-Flor,
I6E-MC-AVBH,Phase 1 Dosimetry,
I4E-US-X015,CA225-503 CHRV0020 Retro CHRV of Pts w H/N tx w/Cetuximab,
I4V-MC-JAHY,Pediatric Uveitis Open Label Extension,
I4E-US-X016,CA225-040 R0234 Surgery followed by ChemoRT+Erbitux SCCHN,
I4E-US-I006,CA225-320 R0617 High Dose RT Carb/Pac/+-Cetuximab NSCLC,
I4E-IE-W840,"Protocol CA225-237; PILOT STUDY OF GEMCITABINE, OXALIPLATIN,",
I4H-MC-A001,Assess.of the Dual 70S6K/AKT Inhibitor in cancer xenographs,
I1R-MC-GLBY,Renal Impairment Study,
B1Y-FP-0736,"COMPARATIVE STUDY ON FLUOXETINE,PAROXETINE, AMITRIPTYLINE",
I2I-MC-V005,Chk1/Chk2 Inhibitor LY2606368 in B-Acute Lymphoblastic Leuke,
H9H-MC-V004,TGFb Inhibition in Acute Myelogenous Leukemia,
J4A-LC-EZZD,LY315920:PK STUDY IN PATIENTS WITH END STAGE RENAL DISEASE,
B5K-US-V022,Charcterizing the spreading of autoactive T cell responses ,
I3G-MC-V005,The role of S6 kinase in SREBP regulation,
H7T-US-X020,Inhibition of ADP mediated platelet aggregation,
I2I-MC-A002,Eval. of CRC case that carries a mutation in Chk1,
I7D-FW-SGAB,Multiple ascending dose (MAD) study,
I6H-EW-MCBF,A randomised crossover study to assess pain intensity in sub,
B5K-MC-B010,"2012-552 U500 Study - MarketScan data to provide cost Info",
I5M-MC-FABC,MAD-POC PH I/II,
I1A-MC-BPAK,EXIST: Efficacy and Safety of LY for neg symp and cog impair,
I7G-EW-HLBB,MAD,
H8L-MC-IQCH,Luxura /BIV Summative Human Factor study ,
I4T-CR-JVCR,R-PhIII- Paclitaxel +/- Ramucirumab -Met Gastric-2nd line,
I7G-EW-HLBC,Single dose POC,
I2M-MC-GSDQ,China PK,
"15430",Thorough QTc Study,
I5Q-MC-CGAC,OA Pain POC Study,
B9E-MC-X057,Gemcitabine and Paclitaxel Combination Chemotherapy,
H8L-MC-IQCO,Humulin Kwikpen Summative Human Factor,
I6Q-MC-BIFB,BE study ,
H9H-MC-V014,Role of TGF beta in uterine carcinosarcoma,
"15665",Food Effect,
ZYY-MC-B005,"2013-581_SHIRLOC understanding of insulin pump use among pat",
I6I-JE-LMRH,Japan Ph2,
I7Z-JE-FLAE,Japan Mono study Ph3,
H6D-JE-LVJK,Post-Mktg Tadalafil Treatment for BPH in Japan ,
I3Y-MC-A008,Screening of test agents,
H8L-MC-IQDC,U500 syringe summative HF study 00709,
"15783",JP Phase 2 Dose Ranging ,
J2N-OX-JZNG,LOXO-BTK-20013-Ph1-Pirtobrutinib-Renal,
H7I-MC-S016,Migraine headache identification using passive data,
J2Q-MC-JZOA,A Phase 1 Study of RAS mRNA G12D Vaccine,
J2N-MC-JZNK,LOXO-BTK-20009-Ph1-Pirtobrutinib-Food Effect,
J3E-MC-EZDA,FHD SAD MAD HV,
C2N-MC-JXAB,"Phase 1 Dose Esc. of LY355703 IV Days 1, 8, & 15 Q28 days",
J2W-MC-PYAA,FHD COVID-19 Antibody Study Pts,
J2G-OX-Y058,RET Inhibitor-NSCLC,
H3E-MC-JMBY,"MTA to be given on a ""named patient"" basis",
J2G-OX-Y106,RET Inhibitor-NSCLC,
J2G-OX-Y129,RET Inhibitor-MTC,
J2G-OX-Y139,RET Inhibitor-NSCLC,
F3Z-SP-O003,Economics of Severe Hypoglycemia in IDDM Patients,
J2T-DM-KGBD,Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis,
J2G-OX-Y211,RET Inhibitor,
H3E-MC-JMBU,Phase I ALIMTA + Taxotere,
I7J-MC-BCGF,Relative Bioavailability Study,
H8L-MC-IQCN,ePFS Glucagon Formative Human Factors,
B7A-MS-MBBI,Multiple oral dose study in the elderly,
I1D-MC-E002,R-Ph II- LY2228820 + Tamoxifen - Breast,
I2M-MC-GSDS,Device Bridging Study,
"15446",Multiple ascending dose study with a combo dosing arm,
"15488",Japan Phase I Study,
F1D-IT-HGDL,Olanzapine vs Haloperidol in the treatment of tardive diski,
H9H-MC-JBEA,TQT in healthy subjects,
"15599",Thrombogenesis ,
F1J-JE-HMHD,JP Cymbalta P-III Long term safety OA pain,
"15655",DDI - Antihypertensive,
I4E-IE-W805,"Protocol CA182-025; A BLINDED, RANDOMIZED, I/II STUDY OF  AL",
"1587",Pediatric ADHD - A,
B3D-MC-A011,Study of PTH (1-34) and BMP-2 on spincal fusion in rabbits ,
"16061",Ph III - c-Met Antibody - NSCLC-2nd Line,
I8B-FW-ITRH,URI-Citrate+Remodulin Ph1b T2DM PK/PD,
H3S-CA-GGIF,Raloxifene HCl vs Transdermal HRT,
I4E-IE-W858,Protocol CA225-004; I STUDY OF ERBITUX (CETUXIMAB) IN PATIEN,
I4E-IE-W867,Protocol P02-9608; Toxicity and tumor Saturation I Study of ,
I4E-IE-W870,Protocol CA225-042; A III randomized open label study compar,
I4E-IE-W889,"Protocol CA225-089; A II TRIAL OF DOCETAXEL, CETUXIMAB (C225",
I4E-IE-W923,Protocol CA225-110; RANDOMIZED II TRIAL OF CETUXIMAB WITH AN,
B5K-EW-IBHG,Humulin U500 PK/PD Bolus via Syringe vs Continuous Infusion ,
I6T-JE-AMAD,Japan Phase 1 Study,
B3L-MC-LWAE,LY354740 effects on regional cerebral glu. metabolism by PET,
I7X-MC-LLCF,Phase 2 Tau Tracer Study,
I8L-MC-IXAB,URI Biochaperone Phase III T1D,
F3Z-MC-ITCH,URI Citrate Phase III T2DM,
"16317",Evaluation of the BE of Two Formulations of Low Mix in HV ,
I8O-MC-SBDB,RBA/Food Effect,
I5Q-MC-CGAR,Cluster headache long-term open-label safety study,
I7E-AV-E012,"18F-AV-1451-EXIST-012",
I8O-MC-SBDC,"SAD, DDI for LY3314605",
I5F-MC-JSCC,Ph 1a/b - CS4 + PD-L1 or CTLA-4 - Solid Tumors,
I8F-MC-B002,"2015-196-2: Cognitive Interviews w T2 diabetes patients",
I8F-JE-GPGC,Japan MAD Trial in T2DM patients,
I8T-MC-STAA,Combined SAD and MAD trial in healthy volunteers,
"16469",Definitive PK/PD clamp study,
"16478",EU Ph 3 registration study,
I5Q-MC-CGAU,persistent post-traumatic headache,
"16530",Japan Capsule Food Effect,
I8H-JE-BDCG,BIF_Dula Japan MAD,
I7E-AV-E035,AV-1451-EXIST-035,
"16572",FHD_Ph I - PD-1 antibody Inhibitor - Solid Tumors,
I6T-MC-AMBB,Ulcerative Colitis pediatric Maintenance/Long Term Extension,
I4L-MC-B007,Pragmatic Trial to Evaluate Patient Perception of Tools ,
"16776",Ph I - Neci + Afatinib - EGFR Positive NSCLC  (NCCN),
I6E-AV-I051,AV-45-IIT-051: Impact of Amyloid Imaging on Diagnosis and Ma,
I7E-AV-E031,"18F-AV-1451-EXIST-031",
H3S-MC-LRAA,Effect on cognition in mild to moderate Alzheimer's Disease.,
B1Y-MC-LWAC,Pivotal Efficacy (initial ID B1Y-MC-LWAC),
H8A-MC-LZBC,Effect of Passive Immunization on the Progression of Mild AD,
"16289",Particle Size,
I1V-MC-EIBV,RBA,
I8V-MC-LODB,PET Ligand,
B4Z-MC-B031,The Risk of Dystonia among Pediatrics and Adolescents,
I4D-MC-JTJL,Ph Ib - Chk1 Inhib II + P38 Map Kin - Solid Tumors,
I3O-MC-JSBH,Food Effect Study in Healthy Subjects,
I7W-JE-JQBB,JP_FHD Ph I - Angiopoietin2 - Solid Tumors,
I8G-MC-LMDD,MAD,
"16512",Ph2 Prevention Dose ranging study,
"16513",C14 ,
H9H-MC-JBEK,Prospective-Assess TGF-B1 blood samples_Pancreas-HCC-GBM,
I8B-MC-ITRR,Elderly PK study,
J2G-MC-B004,"2020-9353: Anaylsis of RET mut on CO in pts with med thyroid",
J2Y-MC-B001,"2021-10106: SINT 1L NSCLC: US Outcomes Sim of ORIENT-11",
B9E-MC-I084,"GEMCITABINE, CISPLATIN, AND METHOTREXATE IN BLADDER CANCER",
"1883",Prevention of Breast Cancer,
"1886",Transdermal Patch Development,
H3S-MC-GGJO,TREATMENT OF VASOMOTOR SYMPTOMS DURING RALOX HCL USE,
H4S-MC-UAIN,Interventional Study in ReoPro,
F3Z-MC-IOGG,Pharmacokinetics of Lispro in Obese Patients,
"1947",Postprandial dosing: Improved compliance (dose adjust/var),
B1Y-JE-2001,FLUOXETINE PHASE I CLINICAL STUDY - MULTIPLE DOSE,
B9E-MC-S024,Ph II Gem+Taxol  in Breast,
B9E-MC-S019,Gem+ Cis vs Taxol +Carbo Vs MVAC in Bladder Ca,
B9E-MC-I087,GEMCITABINE PLUS RADIOTHERAPY IN NSCLC,
B1Y-MC-X139,NUTRITIONL SUPPLEMENT TO INC. EFFICACY OF FLUOX FOR ANOREXIA,
H5P-LC-BWWE,drug interaction  with NSAID,
H5P-LC-BWWK,bronchitis (probe),
H5P-MC-BWWH,PHASE II/III STRUCTURAL DAMAGE RA,
F3Z-MC-IOHT,Test Meal study in Type II pts:  LM vs 30/70 Excercise Study,
"16409",Ph III - Ram + Pembro - Gastric 1st Line,
J4A-MC-EZZI,Sepsis Phase IIb,
I4T-JE-B006,JP_PMS_Ph IV - Ram+Irinotecan+Levofolinate+5FU - Colon,
I5B-MC-JGDR,Ph Ib - Olaratumab + Dox/Ifos - Solid tumors,
B5K-RC-IBEB,Atlas Road Test,
F3Z-GH-IOQR,CN_ph4_Humalog MIX50 pragmatic; Diabetes,
I8B-MC-ITRS,Definitive PK/PD clamp study,
I5B-MC-JGDS,LY3012207 Bridging study,
I4D-MC-JTJN,Ph II Prexasertib Ovarian,
"16742",PI3 Kinase/mTOR Dual Inhibitor - ABA,
I4T-MC-JVDR,Ph II - Ramucirumab PEDIATRIC Trial - Solid Tumors,
I6E-AV-I048,AV-45-IIT-048: A Mechanistic Study of Florbetapir-Fibril Bin,
I6T-MC-AMBI,Ulcerative Colitis Phase III Active Comparator,
"16845",Dulaglutide IIT,
I7E-AV-E075,AV-1451-EXIST-075,
"16913",C14,
I6T-MC-AMAT,PH20/Halozyme-Single Dose  and Impact of Dose level,
F3Z-MC-IOHM,Use of Lispro Low Mixture in elderly type II patients,
F3Z-US-IOGW,INSULIN LISPRO THERAPY IN AFRICAN AMERICANS WITH NEW ONSET,
I8Q-MC-GSEB,MAD,
I8L-MC-IXAT,BC3-CT014 T2DM_MDI Safety/Efficacy,
I9K-MC-UCAB,POC in HFrEF Urocortin-2 Long Acting (LY3322207),
I7E-AV-E071,AV-1451-EXIST-071,
H8H-CD-LAHH,C14(Drug Metabolism)(COL-MIG-110),
B9E-MC-I015,PHASE 1 STUDY OF GEMCITABINE AND VINORELBINE,
I3Y-MC-E019,PhII-Abemaciclib-Multiple Myeloma,
"16986",PsO Observational Study,
"1699",Lorabid Middle Ear Fluid Concentrations,
H9X-IN-GBGN,Trulicity Phase IV - Post Marketing Study for India,
H8H-MC-LAHZ,"Safety, Tolerability, and P of Subcu Lasmiditan",
I8H-MC-BDCO,Fixed Dose Regimen Study 12 Weeks,
I7E-AV-I7E-,"18F-AV-1451-A24: LMDC Pre-Screener",
J2G-OX-Y141,RET Inhibitor-NSCLC,
H8H-MC-LAHT,DDI - Lasmiditan/Topiramate,
J2G-OX-Y068,RET Inhibitor-NSCLC,
I8R-JE-IGBJ,Japan Registration T1DM Cross-Over Study ,
I9V-MC-IFBB,"MAD-Double-blind,placebo-controlled,randomized, multi-dose",
I7E-AV-_A23,"18F-AV-1451-A23: AACG Pre-Screener",
"17052",MAD,
I5Q-MC-CGAX,China IMCT,
"1706",Phase 2 trial of gemcitabine HCl in Grade III and IV NSCLC.,
H8H-MC-LAIG,"PK, Safety,Tolerability of Lasmiditan in Elderly Healthy sub",
H9X-MC-B019,Scope of Bileduct/gallbladder disease in pt on anti-Diab med,
H5N-MC-GFFE,Efficacy of premeal SC injections vs insulin in type 2,
I8S-MC-JUAC,PPI and Food Effect,
"17208",Tirzepatide Risk Minimzation (REMS) assessment 3 yrs,
J2D-MC-CVAB,LDI -Dermal,
J1W-MC-JP01,AMBIANCE-PhII - MultiCmpd BC  Abema+Pembro - Post CDK4/6 mBC,
J2O-MC-EKBA,SAD/MAD/POC,
H4Z-MC-JWWQ,(JW14)  Phase 2 Ovarian - Refractory Population,
J2G-OX-Y088,RET Inhibitor-NSCLC,
I6T-CR-AMBN,Active controlled psoriasis phase 3 China IMCT,
J1F-MC-JZFA,Ph1 - CDK7 - SCLC and TNBC,
J1L-AM-JZGB,SEQUOIA Ph3-Pegilodecakin + FOLFOX-Pancreatic Cancer,
I4V-MC-JAJB,RA Structure Study,
J1N-MC-KEAA,"Ph 1 - mRNA Vaccine - NSCLC, CRC, Pancrease",
I5B-MC-B005,"2017-6505 GHO: OLAaSTS - Post Launch Chart Review in Italy",
J1O-MC-JZHF,C14 AK-01 in Healthy Volunteers,
H8H-MC-LAIO,DDI with Dabigatran & Rosuvastatin HV,
J2G-OX-JZJL,PPI/H2 blocker in healthy volunteers,
J1W-MC-JFF1,Ph II-MutliCmpd Control ERK+Abema+Aura-Post CDK4/6 mBC,
J2G-OX-JZJO,EET Taste HV,
F1D-MC-X051,"5-HT RECEPTTOR FOR PREDICTING CLINICAL RESP TO OLZ",
F1D-MC-V005,Difference in bone marrow toxicity of clozapine & olanzapine,
I8B-KL-B004,URLi Korea PMS,
I4T-MC-B010,"2018-7440_GHO_RAM 1L NSCLC:(US&IBU5) Adelphi DSP_EGFR+Cyramz",
J2G-OX-Y089,RET Inhibitor-MTC,
J2G-OX-Y119,RET Inhibitor-NSCLC,
B3T-MC-JTAE,Ph 1 Study: LY335979/Vinorelbine in Refractory Solid Tumors,
J2G-OX-Y170,RET Inhibitor,
I4V-NS-O028,AMMURAVID,
J2T-DM-KGAU,Lebri for pts w/ uncontrolled asthma on inhaled corticostero,
J2G-OX-Y207,RET Inhibitor,
H8H-MC-B008,Assess safety & Drug patterns for migraine patients tx Lasmi,
"18224",PF DIAB-Diabetes,
B3D-LC-GHAE,SAFETY OF LY333334 IN HYPERTENSIVE WOMEN,
"18411",DDI Placeholder  (PGP inhibitor),
I8F-MC-GPIK,Multi Metabolic Outcomes Trial,
J3L-MC-EZEC,Phase 2 Open Label Study,
"18682",Loxo-FG3-23005-Ph1-FGFR3-Renal Impairment,
H4A-MC-XBAI,Oropharyngeal Candidiasis in Immunocomprimised Patients,
J2G-OX-Y039,PhI-RET Inhibitor-Lipofibromatosis,
J2G-OX-JZJR,DDI/Midazolam study,
F1D-MC-V006,Olanzapine's action on dopamine receptors,
F1D-MC-X066,EEG Sleep Correlates of Treatment Response to Olanzpine,
J2T-DM-KGAH,"Pts w/ persistent moderate to severe AD, inad cont. by TCS",
J2G-OX-Y118,RET Inhibitor-NSCLC,
J2G-OX-Y125,RET Inhibitor-NSCLC,
J2G-OX-Y127,RET Inhibitor-MTC,
J2G-OX-Y138,RET Inhibitor-MTC,
I7E-AV-E112,AV-1451-EXIST-112: A Phase IIa Study to Evaluate the Safety ,
I7E-AV-E113,AV-1451-EXIST-113: SILK,
J2W-NS-PYAE,ACTIV 3,
I5V-JE-TGAC,Japan Ph1 SAD and BA study,
I5T-MC-AACL,BE HV,
I4E-CA-O001,Molecular Residual Disease Advanced High Risk HPV+ and HPV– ,
J2Y-JE-JZSC,Japan ph1 Sintilimab-advanced solid tumor,
H4Y-MC-LJAX,Aura - 2,
"2216",Comparative efficacy (HbA1c) - Modific. of dietary intake,
B3M-MC-AJBA,Cefaclor 40mg/kg vs cefuroxime in OME,
"2289",Osteoporosis and pain,
"2290",Fracture Healing,
H4Z-LC-JWWG,carbon-14 and relative bioavailability study,
B9E-MC-I045,"PHASE 1 STUDY OF GEMCITABINE, 5-FU, AND RADIATION THERAPY",
F1D-TW-S001,Olanzapine Refractory Trial,
F1D-MC-X016,Clozapine to Olanzapine Cross Titration Protocol,
B9E-MC-S068,Gem+Cis vs. Gem+Carbo in NSCLC,
B9E-MC-S073,Ph II Gem+Cis vs. Gem+Carbo Bladder,
B9E-MC-S087,Gem+Carbo post CMF / Breast,
B9R-MC-GDFA,Humatrope in Elderly Burned Patients,
"2579",Pulmonary hGH; Phase 2/3 Pediatric,
B1Y-MC-X176,A Therapy Outcome Study in Women w/Childhood Abuse Experienc,
H4Z-LC-JWXC,definitive food effect study,
"2671",Phase 1 combination study with LY309887,
F1J-MC-SBAT,Single Dose vs. Placebo,
B1Y-MC-HCEC,FLUOXETINE VS PLACEBO MAINTENANCE OF WEIGHT LOSS,
B9E-MC-S032,Ph llI Gem+Epirubicin+Taxol vs 5FU+Epi+Cytoxan,
B9E-MC-S002,"Phase II Gemcitabine, single agent in Elderly NSCLC patients",
B9E-MC-S011,Ph III Gem+Carbo vs. Mito+Ifos+Cisplatin in NSCLC,
H4Y-MS-LJAR,Intraveneous single dose during migraine,
F3Z-FW-IOHX,P Glucose Clamp Study in Asian Subj with LisPro/Reg. Insuli,
H4Q-BX-V013,Cellular PK & subcellular localization: phagocytic & nonphag,
B5K-MC-IBEN,Safety Using PI at mealtimes in type 2 pts,
F3Z-MC-IOMQ,Double-blind Humalog vs Humulin R in Type 1 Pts,
B9E-MC-S085,Gem vs Gem+Cisplatin / Breast,
B9E-MC-X115,"PHASE 2 STUDY OF GEMCITABINE, 5-FU, & LEUCOVORIN IN BREAST C",
B1Y-MC-HCDM,FLUOX. V PLACEBO:CARBOHYDRATE CRAVING IN OBESITY,
F1J-MC-SBAB,Biomechanics of the Urethra,
F1D-US-X119,Olz. vs. Valproic Acid in treating Agitation in Alzheimer's,
B3N-EW-EUCP,Centrally active drug interaction study,
"2794",Haemophilus influenzae/Morexella catarrhalis Surveillance,
B7A-MC-EKAB,Decision phase II trial,
H4A-UT-V018,In Vitro-De Pauw,
J1I-MC-GZBB,MAD 12-week in T2DM Pts,
I4V-MC-B017,Atopic Dermatitis Patient Risk Tolerance B-R Trade-Off Surve,
"17290",AD Observational Trial,
I4V-JE-B020,Database study of baricitinib with RA in Japan (Malignancy),
I7E-AV-E093,"18F-AV-1451-EXIST-093",
I7E-AV-E095,"18F-AV-1451-EXIST-095",
I8R-MC-B006,"2018-7061_GHO_Incidence,Prevalence,HCRU & Costs of T2DM... ",
I1F-GH-B013,A Prospective Observational Study to Assess Safety of Ixekiz,
I6M-NS-E001,EXIST - Sjogren's,
"17608",Ph II/III-Peg+Pembro+Axi or Lev- in 1L RCC,
J2G-OX-Y022,PhI-RET Inhibitor+Imatinib-MTC+CML,
J2G-OX-Y042,PhI-RET Inhibitor-MTC,
J2A-MC-GZGC,MAD POC 12-week with Dose Titration Pts,
J2I-MC-JZMB,SAD/DDI in Healthy Volunteers,
I9Y-OX-JDHJ,LOXO-IDH-22009-Ph1-IDH1- Transporter Cocktail,
J2T-MC-KGBN,MOA Biomarker Trial ,
I6E-AV-PT01,AV-45-PT01,
B4Z-MC-HFBE,Open Label Discontinuation,
F3Z-MC-IOHR,Early Intervention in Type 2 Diabetes,
B5K-JE-HN01,HUMAPEN ROAD TEST,
B1Y-MC-HCJL,Fluoxetine Versus Placebo in Posttraumatic Stress Disorder,
H4S-MC-EWAS,Stroke Registration,
B9E-MC-X036,"PHASE 1 STUDY OF GEMITABINE, CARBOPLATIN, AND TAXOL",
B9E-MC-S028,Gem+Dox vs FAC in Breast- S028,
B1Y-LC-HCEY,FLUOXETINE:ASSESS.INTERACT.FLUOX.&TRICYC.ANTIDEP,
B3N-LC-EUCQ,Moxonidine/Ethanol drug interaction trial,
H5P-LC-BWWQ,drug interactioin (warfarin),
F1D-MC-X030,VOLUMETRIC AND FUNCTIONAL MRI SCANNING IN SCHIZO PAT. B/4 AN,
H4Z-MC-JWWB,Ph1Randomized MultiDose Safety/Biomarker Trial of LY353381HC,
B3D-MC-GHAM,Assessment of renal function in pts treated with LY333334,
F1D-US-X087,Outcomes Evaluation of Olanzapine Therapy: Pilot Study,
"2699",pulm hgh in peds with asthma,
B1Y-BP-0001,FLUOXETINE: OBESE DIABETICS WITH HYPERTRIGLYCERIDAEMIA,
H4S-FH-EWAT,Registration Support Trial,
"2737",(JSA2) LY320236/Biomarker study/Prostate Cancer/Phase 2/NCI,
"2820",Mechanism of action study 2,
H3E-MC-JMF5,PH II MTA + 5-FU Bolus 1st line CRC,
"2948",Raloxifene - Cardiovascular Regression,
B9E-MC-X171,"Gemcitabine, 5-FU, and Leucovorin in Advanced NSCLC",
B9E-MC-X193,Gemcitabine Intrahepatic Infusion (Animal Study),
B9E-MC-X210,Gemcitabine and Cisplatin/Phase 2/Breast Cancer,
B9E-MC-X223,Phase 2 Study of Gemcitabine and Cisplatin (HPBC),
B3T-MC-JTAK,LY335979-CHOP/Ph 1/2 study-Non-Hodgkin's Lymphoma,
B1Y-MC-X180,TRX .W/FLUOX ON DEVELOPMT OF BREASTFED INFANTS,
F1J-MC-SBBF,Collaborate on the MAOUS Project,
B9E-JE-N22D,phase 1 NSCLC,
B3D-MC-GHAR,Steroid-induced osteoporosis (B3D-MC-GHAR),
"3399",Olanzapine Phase III Local Registration Trial - China,
"3408",'A BETA' COMPOUND NEARING CANDIDATE SELECTION,
"3437",Neuropathy / 4 treatment arms,
J2G-OX-Y147,RET Inhibitor-NSCLC,
J2G-OX-Y186,RET Inhibitor,
I8I-MC-JYAB,Continued Access of LY3023414,
J2T-DM-KGAN,Lebri for pts w/ uncontrolled asthma on inhaled corticostero,
J2X-NS-I001,PYAB ACTIV2,
"18128",BE HV,
J2X-MC-Y001,Expanded access program for LLY3819253 Anti-COVID-19 mAb,
I8B-MC-I8B,PF Infusion Pain,
"1844",Effect of SERM III on Alzheimer's Disease in Women,
F3Z-US-IOMB,COMPARISON OF INSULIN LISPRO AND 70/30 HUMAN INSULIN IN THE,
"18679",Loxo-FG3-23002-Ph1-FGFR3-DDI CYP 384 Inhibitor/Inducer,
"18696",FHD (Dicerna),
H5H-MC-DDAG,Radiotelemetry for pH profile in CDAD Patients,
H4Q-MC-V011,LY333328 Etest development,
B9R-EW-T002,compare the safety profiles of 2 different hGH dosages regim,
B1Y-MC-X159,"FLUOX TX OF SUBSYNDROMAL DEPRESSION, PRIMARY CARE ELDERLY",
"2101",LY354740 vs placebo vs paroxetine in outpatients with panic,
F1D-MC-X076,LOW DOSE ZYPREXA IN GENERALIZED ANXIETY DISORDER,
"3497","Pet Scan (Cardiac, PD",
B9R-MC-I025,GH and Leuprolide to Improve Final height in pts with CAH,
B9E-MC-S075,Ph II Gem+Docetaxel/Adv. or Met. Breast Cancer,
F1D-US-X077,Olz. on Substance Use and Self Medication for Schizophrenics,
B9E-SB-O017,"Phase II, Palliative Treatment Gemcitabine,  Bladder Cancer",
F1J-MC-SBAV,Single Dose vs. Placebo,
B9R-MC-GDFN,Humatrope use in pts with SHOX gene defect,
"2762",Drug Interaction,
B1Y-MC-HCEL,FLUOXETINE VS DESIPRAMINE IN PATIENTS WITH MDD,
B3M-MC-V046,Streptococcus pnemoniae Surveillance Study,
B3N-BC-EUAQ,Moxonidine open trial for efficacy in hypertension,
B3N-AB-EUCT,Effect of moxonidine on BetaARK in CHF,
C2N-MC-JXAJ,(J111) LY355703 in Pts with Hormone Refractory Prostate CA,
"2899",beta blocker interaction,
C2N-MC-JXAM,LY355703 in Extensive Stage SCLC,
B9E-MC-X176,Gemcitabine and Radiation Therapy for Pancreatic Cancer,
B9E-SB-O029,"Phase II, Gemcitabine In Patients w/ Glioblastom",
B1Y-MC-I003,FLUOXETINE V PLACEBO PATIENTS WITH FIBROMYALGIA,
"3169",First efficacy dose LY397584,
H4S-MC-EWAV,Phase II/III ReoPro Stroke Dose Confirmation Study-Extension,
B1Y-MC-X048,FLUOX VS PLAC IN POST TRAUMATIC STRESS DISORDER,
B1Y-MC-X053,FLUOX VS DESP IN FEMALE HIV SEROPOSITIVE PATIENTS WITH MDD,
B9E-VI-O061,"Phase II, Gemcitabine,  Transitional Cell Carcinoma",
H3S-BP-GGJT,"MCKAY HART, MEGACE + RALOXIFENE SYMPTOMS STUDY",
F3Z-IT-IOMK,Acute effects of Mix25 vs 30/70 on BG in overweight NIDDM,
B1Y-MC-X082,COMBINED MEDICATION AND GROUP PSYCHOTHERAPY OF DYSTYMIA,
"3907",Antipsychotic Interaction,
"3917",Human imaging (WAY ligand),
H4Q-MC-ARRF,LY333328 single dose in skin/skin-structure infections,
B9E-MC-X251,"Phase I/II Study of Gemcitabine, Cisplatin and 5-FU",
H3S-MW-GGJX,Comparison  of previous Raloxifene/Placebo  effect on BMD,
F1D-CA-O043,Bipolar registry to evaluate treatment,
F1D-CA-O045,Relationship btw trmt response and family history,
B1Y-MC-X096,PROZAC AND REGIONAL METABOLIC ACTIVITY IN AUTISM,
H5P-LC-BWWA,H5P-LC-BWWA FHD,
H5P-LC-BWWG,C14 metabolism,
B3D-LC-GHAY,LY333334 & Digoxin Interaction Study,
H4Z-MC-JWWT,"(JW08)  Phase 3 -Breast Cancer, Prev and Adjuvant Therapy",
"2168",Pan-Arabic Multicenter Study of Olan. in tx of Schizophrenic,
H4Q-SZ-A007,In vivo model of foreign body infection--MRSA,
B3D-MC-GHAI,Raloxifene and LY333334,
F1D-MC-X057,Olz. treatment of Attentional Deficits in Schizophrenia,
B9R-US-X021,rGH in the treatment of dilated cardiomyopathy in children,
B4G-EW-LCCR,Parkinson / Neuroprotection,
B9E-MC-S080,"Ph II Gem+Epi, Neoadjuvant Breast Cancer",
B9E-MC-X144,PHASE II STUDY UTILIZING GEMCITABINE AND CISPLATINUM,
F1D-US-X110,Olz. Treatment for Tourette's in Children and Adolescents,
B9E-CA-O010,"PHASE II, GEMCITABINE & VINORELBINE, ADVANCED NSCLC",
"2620",Food and Diurnal Affects of Duloxetine,
F1J-LC-SBAJ,Multiple Dose PK - Ischemic Heart Disease,
B1Y-MC-HCDV,FLUOXETINE VS. PLACEBO:  ALCOHOL CRAVING EFFECTS,
F1D-US-HGHR,Olanzapine in the Treatment of TD,
B1Y-MC-X152,Flouxetine vs Placebo in Advanced Cancer Outpatients,
B9E-TW-O102,Monochemotherapy with Gemcitabine for metastatic NPC,
B9E-MC-V327,MEPM + Gemzar in Preclinical Invitro Studies,
B9E-MC-V019,Determination of CSF penetration of gemcitabine,
F1D-MC-HGIQ,Combination Therapy (olz & flx) in MDD,
H4Z-LC-JWXF,warfarin drug interaction study,
H4S-SB-O004,Med. and Intervent. Ther. of ACS during GP IIb/IIIa Blockade,
B9E-MC-I128,Gemcitabine and Radiotherapy - Cervical Cancer,
F1D-PH-HGIT,Olanzapine in the treatment of Schizophrenic Filipino,
"4217",Hypertension study,
F1J-BD-HMBD,Benzodiazepine interaction,
B9E-BX-O127,GEMCITABINE-CISPLATIN-5FU IN GASTRO-INTESTINAL CANCER,
B9E-MC-S149,Gemcitabine+Cisplatin in advanced metastatic bladder cancer,
B3M-IS-S016,Group A Streptococcal Tonsillopharyngitis Surveillance Study,
F1D-FP-S007,Survey on treatment of acute states in shizophrenia,
F1D-US-X181,Influence of the HIV protease inhibitor Ritonavir on the pha,
B9E-SB-O151,Radio-Chemotherapy with Gemcitabine in urothel CA,
B9E-MC-V073,Gem as a radiosensitizer,
B9E-MC-V074,Test combination chemo w/gem & perillyl alcohol,
B1Y-SO-0702,FLUOXETINE VS PLACEBO TREATMENT IN MDD,
B9E-MC-JHQZ,Gemzar Clinical Benefit program for patients with NSCLC,
B9E-MC-S203,Ph II Gem+Carbo->Tax Ovarian 1st line,
B1Y-SO-E050,FLUOXETINE VS MAPROTILINE-SLEEP STUDY,
B9E-MC-S221,Phase II Gem + cis in Advanced Gallbladder cancer,
B9E-MC-V078,Standard for chromatographic detection of dFdCTP in cells,
F1D-KL-O091,"Social Function , familly burden in Schizophrenia",
B9E-MC-X283,Phase 2 Trial of Gemcitabine & Vinorelbine/Breast Cancer,
X1B-MC-QB01,MEPM+Gem/Cis or PKC2+Gem/Cis vs Gem/Cis in met NSCLC,
H6D-MC-LVDA,Spinal Cord Injury,
"4992",GHS interaction study 2,
"5039",PET / PD study #2,
"5072",LY333013 Phase II in Patients with Ulcerative Colitis,
"5086",Support depression,
F1D-MC-HGJI,Olanzapine + Mazindol/Placebo in weight gain prevention,
F1D-MC-HGJH,Dose finding study of olz in tx of bipolar depression,
B9E-SB-V094,Chemosentivitytest in Lungperfusionmodell,
F1K-MC-EVBA,Phase IB study of human model of endotoxemia,
H5W-BD-LQAE,Electrophysiological effect,
"2884",forearm nitroprusside sensitivity study,
"2896",MGlur2 - Neuroleptic Interaction,
"2916",Safety/Efficacy,
F3Z-RO-O015,IIS Lispro in Mild to Moderate DKA (Cheta),
"2953",Raloxifene - Cardiovascular Electron Beam CT,
B1Y-MC-X167,"Phase III Dbl-Blind, Placebo ContrldTrial Mgmt of Hot Flashe",
B9R-MC-GDFH,Humatrope use in hip fractures,
"3080",OLAN + PROZAC IN UNIPOLAR DEPRESS. EVALUATING ONSET OF ACTIO,
B1Y-MC-HZAA,FLUOXETINE\PINDOLOL SUSTAINED RELEASED DOSE FINDING,
"3146",Olanzapine and Valproic Acid Treatment of Agitation and CSF-,
B1Y-MC-X135,MOOD EFF. OF TESTOSTERONE. VS FLUOX. IN HIV ILLNESS,
B9E-MC-X167,Phase 2 Trial of Gemcitabine and Vinorelbine,
B1Y-MC-I008,FLUOXETINE AS ADJUNCTIVE PHARMACOTHERAPY IN RECO. ALCOHOLICS,
"3190",long term safety study,
B9E-MC-S121,Phase 2 Gem + Capecitabine - 1 st breast,
B1Y-MC-X005,PROZAC TRTMT OCD ASSOC WITH TOURETTES SYNDROME,
B9E-MC-X148,Phase 2 Trial of Gemcitabine and UFT,
H3E-MC-JMDQ,"Phase II, MTA + Cis, single arm, H&N",
"3391",IIT Block Trial,
H5Z-MC-LUAC,R-fluoxetine PET study,
F1D-MC-A018,Prot. Effects of Olz in Phencyclidine-Induced Apop Cell Deth,
B3T-MC-JTAJ,LY335979/Docetaxel/randomized Ph 2/met. breast cancer,
H5P-LC-BWWV,Relative bioavailability (phase 2 vs. phase 3 forumlations),
B9E-MC-I114,Gemcitabine and Paclitaxel in Bladder Cancer,
B7A-BD-MBCA,Concomitant medications - digoxin,
B9E-MC-X233,Phase 2 Study of Gemcitabine and Docetaxel in Pancreatic Ca,
"3315","5HT1F early phase II",
B1Y-MC-X181,DEPRESSIVE DISORDERS IN COLLEGE STUDENTS IN INDIA & US,
F1J-MC-HMAQ,Duloxetine Versus Fluoxetine Plus Placebo: Major Depression,
B9E-MC-I116,"Gemcitabine, 5-FU, Mitomycin,C, and Interferon",
B1Y-MC-X011,FLUOX TMT AGGRESSIVE BEHAVIOR IN PERSONALITY DISORDER PATS,
B1Y-MC-X182,FLUOX IN HYPERTENSIVE PTS W/DEPRESSIVE SYMPTOMS,
F1D-MC-O027,Olanzapine in Adults with ADHD,
F1D-MC-X129,Sibutramine for Olanzapine induced weight gain,
"3490",Male/female comparison,
"3492",pizotifene interaction,
"3507",PHASE IV; GEMCITABINE&VINORELBINE;ADVANCED NSCLC,
B1Y-MC-X038,FLUOXETINE IN THE TREATMENT OF MDD OR AGRESSION/IMPULSIVITY,
B9R-HL-GDFO,HGH to children with JRA,
F1J-MC-I001,Efficacy of Duloxetine in Patients with Diabetic Neuropathy,
H5P-LC-BWWZ,DOSE PROPOTIONALITY STUDY,
B9R-MW-O001,GH THERAPY IN ADULTS WITH CO OF HYPOPIT AND GHD,
B1Y-MC-X051,FLUOXETINE IN MED/SURG PATIENTS WITH DEPRESSIVE SYMPTOMS,
H6D-EW-LVAW,Beta blocker interaction study with metoprolol,
B4G-SB-O008,Neuromodulation of D1 versus D2 Receptors on working memory,
"3736",Efficacy safety population PK,
H3S-US-GGJS,Safety of Raloxifene in postmenopausal women with primary hy,
B3L-MC-LWAY,"LY354740 vs. placebo and Lorazepam in GAD, OUS",
"3896",LY354740 in Social Phobia,
H5P-MC-BWXJ,Phase II Pain Study-Premenstrual,
"3963","64mg Bioequivalence",
B9E-MC-X120,Gemcitabine Hyperthermia Study,
B9E-SB-O096,GEM +  VNR vs. GEM + VNR + P in NSCLC,
B9E-BP-O193,"Phase II, Gem. vs Methotrexate/Vinblastine, Bladder cancer",
B1Y-MC-X030,"EFFECTS OF PROZAC ON MOOD, COGNITION AND BRAIN GLUCOSE METAB",
"3524",Oral Delivery Phase I - FHD,
F3Z-MC-IOMH,local registration trial Taiwan,
B9E-SN-JHQO,"Phase II, Gemcitabine, In Metastatic Nasopharyngeal",
"3740",First human dose,
B9R-US-X027,"A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SOMATROPIN FOR S",
H6D-MC-LVBH,Multiple dose PK elderly,
B1Y-MC-X065,CHILDHOOD DEPRESSION - BIOLOGICAL CORRELATES,
B9E-MC-X248,Phase II Trial of Gemcitabine in Adv Neuroendocrine Tumors,
"3797",Wild-vs-re-encapsulated sumatriptan BE,
B1Y-MC-X193,Predictors of Response to Fluoxetine and Serotonin Transport,
"3855","Insulin dosing in pump users with high CHO, high fat meals",
B1Y-MC-X199,Treatment Outcomes of Fluoxetine vs. EMDR in PTSD,
H6C-MC-GKAE,Efficacy and safety of LY368842 for treatment of type 2 DM,
B1Y-MC-X079,EFFECTS OF FLUOXETINE ON BEHAVIORAL CONCOMMITTANTS OF HOSTIL,
H6C-MC-GKAF,Efficacy and safety of LY368842 for treatment of Obesity,
F1K-SB-EVCI,Sepsis - Registry,
"5332",Bioequivalence study (powder to capsule LY459477),
F1D-BX-O100,Study Effect of Amantadine on Weight Gain induced by  Olanz.,
B9E-BP-O203,"Phase II, Gemcitabine/Retinoic acid in Pancreatic cancer",
B3D-MC-GHAH,LY333334 VS. ALENDRONATE IN TREATMENT OF POSTMENOPAUSAL OP,
"5491",Lispro intensive therapy pump study,
F3Z-CA-O037,Impact of Type 1 attendance on School Attendance,
B1Y-CA-O019,Sarafem in the Treatment of PMDD,
B9E-MC-X313,PhI/II ABVG for advanced and localized Hodgkin's disease,
B9E-BX-O220,Phase II Paclitaxel-Gemcit-Carbo as neoadjuvant with NSCLC,
B9E-MC-X328,PhII Docetaxel/Gemzar in 1stline small cell lung cancer,
F1D-AY-O117,Olanzapine use in relapse depression of pts on medication,
"5660",Fellowship for Dr. Ann Cranney (FEL-052a),
B9E-AL-O235,PhII Gem+Cis for adv. or metast. Cholangiocarcinoma (gall b),
B4G-UT-LCDN,Func Improvem of Parkinsonian Pat by Optimalizing Pergolide,
"5800",Phase II Rand. Ovarian/LY317615,
"5895",PET Study,
H4A-EW-XBAZ,HF Capsule-Metaclopramide Study,
B9E-MC-I046,GEMCITABINE AND DOCETAXEL IN PTS. WITH ADVANCED MALIGNANCIES,
H4Z-MC-JWWP,(JW09)  Phase 3 European Strategy Breast Cancer Trial,
"2955",Raloxifene Marketing Support Studies,
H3E-MC-JMCT,PH II MTA + Taxotere 2nd line NSCLC,
B9E-MC-X198,Gemcitabine 24 Hour Infusion for Colorectal Cancer,
B1Y-MC-X178,Fluoxetine Plus Olanzapine in the Treatment of OCD,
H3S-MC-GGJE,Comparison of Raloxifene & Placebo (Asia Pacific Reg Trial),
B9E-MC-X211,Phase 1 Study of Gemcitabine and Paclitaxel,
B1Y-MC-X179,Fluox vs Placebo in Relapse-Preventioin of Type II MD,
F1D-US-X120,Olz. vs. Haldol in the Management of Patients with Intensive,
B9E-MC-I121,Phase 1 Study of Gemcitabine in Relapsed AML/ALL,
B9E-MC-S120,Gem + taxotere - 1st breast; Jul98SE121,
B9E-MC-S125,Ph 1 Gem - refractory solid and CNS in children; Jun98SE118,
F1J-MC-SBBE,Development of a Duloxetine Epidemiological Model,
"3238",Investigator Initiated Block for Fluoxetine Trials,
"3239",INVESTIGATOR INITIATED BLOCK - PERGOLIDE TRIALS,
B1Y-MC-S002,SUICIDE IDEATION SCALE VALIDATION IN DEPRESSED INPATIENTS,
"3248","Non-comparator study in ~150 Japanese Patients:  LM, MM, NPL",
H3E-MC-JMDP,"Phase II, MTA + Gem, CRC",
F3Z-MC-I015,ADARF:  Humalog CSII vs MDI therapy in older type 2 patients,
B3N-PG-EUAN,MOXONIDINE THERAPY IN PATIENTS WITH MILD TO MODERATE HYPERTE,
X1A-MC-QA05, Pk CSF Phase 1a Study for LY450108 (and Ly451395),
H7C-MC-LMBR,Open-Label Extention for Previous Study Completers,
F1D-AY-O143,Olanz and Li vs chlorpromazine and Li in 1st manic episode,
F1D-EW-LOBR,Olanzapine - Placeholder for LOAZ,
"6294",PPAR Co-agonist Japan Bridging Phase 1,
B4G-SE-9435,PERGOLIDE IN PARKINSON'S PAT FAILING BROMCRIPTINE/LISURIDE,
"6311",Biomarkers in blood and BAL,
B3N-HU-S003,Effect of moxonidine in overweight patients with hypertonia,
"6391",Japan-MDSS,
B4Z-US-LYBP,Atomoxetine in the treatment of anxiety in pediatric patient,
B5K-RC-IBDY,INSULIN DELIVERY IN A NEW LILLY 3.0ML DISPOSABLE PEN,
F1D-US-A111,Mechanisms of Olanzapine Induced Weight Gain: Activation of,
F1D-IT-O031,Treatment of acute patients in SPDC,
"6550",Intravescical GEM vs BCG in superficial bladder cancer,
"6570",Gemzar IITs in Germany,
H6U-UT-O001,diff bipolar symptoms,
F1J-JE-HMCD, JP dulo P-III/IV 321G compassionate,
"9086",Placeholder OASIS  (BUY UP),
"3393",Antifungal Phase III Local Registration - China,
"3395",Glycopeptide Phase II Local Registration Trial,
B5K-MC-IBFR,Efficacy of PI in pts. failing combination therapy,
B1Y-MC-X027,FLUOX VS PLAC IN ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,
B3N-MC-EUDI,Moxonidine vs Active Comparator -BP primary measurement (#3),
"3518",SAFETY STUDIES FOR ORAL AMPA,
H3S-US-A001,Financial Support to accelerate publication of colaborative,
H4Z-EW-V001,In Vitro activity of LY353381 in Ovarian cell lines,
B9E-VI-O055,"Ph II, Gem & Cis v ICE, NeoadjuvTherapy NSCLC",
"3816",Erectile Dysfunction in Non-Diabetic Males,
F3Z-US-X007,Effect of lispro insulin on leptin concentrations,
H3E-MC-JMDT,MTA+GEM+CPT-11,
"3864",Registration Phase ReoPro with low dose lytic,
"3904",Antidepressant Interaction,
F3Z-FW-IONE,PK/PD Comparison of Lispro and Insulin Aspart,
F1D-US-X159,Dev of the Scale for the Repeated Assessment of Neurocogniti,
"4125",Omeprazole drug interaction study,
B9E-BX-O107,COMBINATION GEMCITABINE AND RADIOTHERAPY IN HEAD AND NECK,
"4181",Empirical use of Vanvomycin for Neutropenic patients,
"4243",Block grant for Takeda partnership,
F1D-XM-O170,Incidence of sexual dysfuction.Comparative study,
"6700",Gemcitabine +Cisplatin in Metastatic Breast Cancer,
B9E-US-X347,"Ph II Study of Gem, Cis, & Celecoxib in Tx of Pancreatic Ca",
B9E-MC-V166,Evaluate the growth inhibitory effects of gem in vitro,
"6844",Ph III HTN US ACE,
B9E-MC-V173,Potentiation of gem cytotoxicity by nucleotidase inhibition,
B9E-CP-O317,Primary inoperable and locally advanced breastcancer,
B1Y-BP-HC59,FLUOXETINE V PLACEBO IN CHRONIC FATIGUE SYNDROME,
B7A-XM-O003,STUDY OF THE INVOLVEMENT OF PKC beta IN LIPID-ASSOCIATED HUM,
H7U-MC-IDAK,"Asthma Study, Pulmonary Insulin",
B1Y-BP-HC60,FLUOXETINE V DOTHIEPIN ON COGNITIVE FUNCTION AND SLEEP,
H6D-EW-LVET,Cialis Ethanol Interaction,
F1D-MC-HGKQ,Mild to Moderate Mania assoc with Bipolar I Disorder,
H6D-EW-LVEY,LY450190 - Aspirin,
"7101",Placeholder for NSCLC,
F1J-MC-HMDU,Dulox vs Venlafax in GAD - US study,
B9E-MC-V185,Determine the plasma concentrations of gemcitabine in patien,
H6H-MC-JEAI,"LY293111 Phase I, Single Agent",
B9E-MC-V054,Anticancer effect of gem with CD-DST method in lung cancer,
F1D-US-A042,Amelioration of VCMs by olz in a rodent model of TD,
F1D-CA-O060,Evaluation of anti-aggressive effects of Olanz in psychotics,
F3Z-SB-IOMT,Use of snacks in patients treated with Lispro LM or 30/70.,
B9E-SB-V064,Preclinical evaluation of Gemcitabine-Liposome-Gel,
B1Y-MC-X202,Fluox in Depressed Adolescents w/Substance Related Disorders,
F1D-US-X171,Sht Term Eff of Stim and Olz Aug in tx of Aggre. ADHD chi/ad,
F1D-XL-O074,Pharmacogenetic study to predict the Olanzapine answer,
F3Z-XM-IOMW,Insulin Lispro LM Twice Daily vs NPH Twice Daily (Spain),
B3M-PK-AJBG,Cefaclor Vs Clarithromycin in Bronchitis,
F1D-XB-O077,Schizophrenia and Serotonin: Therapeutic Implications,
B3M-FW-AJBI,Bioequivalence of Cefaclor CD 500mg & Reference Formulation,
F1D-XL-O082,Study about patients with first psychotic episodes,
F3Z-CA-O033,Effect of Carbohydrate Source on Postprandial Blood Glucose,
B1Y-MC-X206,CHILDHOOD DEPRESSION:  REMISSION AND RELAPSE,
B9E-MC-S185,Ph III Gem/Plat(or Taxane/Plat)-->Surg vs Surg alone-NSCLC,
B1Y-SO-E048,FLUOXETINE VS PLACEBO TREATMENT IN MDD,
B9E-MC-S214,Gem/RT vs Cisplatin +RT (Cervix),
F1J-MC-HMAU,Open-Label Exposure Trial,
B9E-ME-O105,A PHASE II OF NEOADJ. CIS/GEMCITABINE IN LOCALLY CERVICAL CA,
B9E-XB-S144,CLINICAL EFFICACY/SAFETY,
H6H-MC-EBAF,Phase Ib Study to assess the safety and efficacy,
"4110",GHS - MultipleDosing,
B3M-VI-S010,Pharyngotonsillitis (Cefaclor Suspension vs Augmentin),
B1Y-MC-HCKL,Sexual Dysfunction Trial,
H6D-LC-LVCC,IC351 Visual Study in Diabetic Patients,
F1D-BP-O063,Weight gain and use of Orlistat in Schizophrenic pts,
F1D-XM-O064,Follow-Up Study of Patients with first schizophrenic episode,
F3Z-SB-S006,Observ. trial of humalog in combination with oral antidiabet,
F1K-LC-EVAU,LY203638 (rhAPC):  Pharmacokinetic comparison of products,
H6D-EW-LVCM,Interaction between IC351 and a nitrate in the Elderly,
H3S-US-X004,Comp. of Prempro and Evista on triglycerides and lipoprotein,
"4488",Olanzapine in the treatment of dementia,
B9E-MC-S162,Ph II Gem + Oxaliplatin in recurrent or metastatic breast c.,
F1D-US-V011,differential effects of typical vs. atypical neuroleptics on,
H3S-VI-O005,Education as strategy to improve patient's compl.with ralox,
H6R-BD-LSAA,Ph1a healthy volunteers p.o SDSS,
B9E-MC-V085,Assay concentrations of metabolites in pts treated w/gem,
B9E-MC-S174,Gem + Cis + Palliative Therapy Radiation,
"4904",Alzheimer's disease PK/PD trial,
"4905",Schizophrenia PK/PD trial,
B1Y-UT-0288,FLUOXETINE:THERAPY-REFRACTORY DEPRESSED PATIENTS,
"5048",PET /PD #2,
H7V-BD-GPAA,SDSS - Food and Gender Effect in Overweight Healthy Subjects,
B1Y-UT-0389,"TREATMENT OF PREMENSTRUAL SYNDROME WITH FLUXETINE,OPEN STUDY",
H3E-MC-JMEL,"Rand. Ph II 1st Line NSCLC, 3 dosing schedules of ALIMTA/Gem",
"5144",Pamoate Phase II (Post LOBE),
B9E-MC-S226,Phase II Gem + Taxol Vs Gem + Weekly Taxol in NSCLC,
B4Z-MC-LYBA,Pilot Study School Outcomes,
H4Z-MC-JWXL,Neo-adjuvant trial in women with newly diagnosed breast ca.,
H3S-UT-GGKG,PMS raloxifene: compliance and treatment satisfaction,
B4G-GH-LCDM,Celance in the treatment of Parkinson's disease,
"6053",Investigation of novel method for studying nicotinic pharmac,
B9E-VI-S314,Phase II Gem Cis neoadjuvant NSCLC,
F3Z-JE-IOOK,JP lisp P-III post meal,
H3E-US-JMFW,Rand Ph II Alimta/Cis vs Alimta/Carbo extensive stage SCLC,
"7275",A beta time course effect and plasma level,
B9E-US-X366,Ph II Txmt w/ Cisplatin/Gem foll by Radiation & 5FU Adv Pan,
"7350",Placeholder for Gemzar,
F1J-FP-S005,Screening MDD in patients consulting for physical pain symp,
"7405",Olanzapine Placeholder IITs,
"7464",Xigris OS - Single Arm study for 2nd tier,
ZYY-FW-GCAO,intra-subject variability: zolmitriptan-hGH study,
B9E-MC-S349,Ph III GDP vs DHAP Lymphoma FB Maint Ritusimab vs Obs,
"7679",Addendum Alimta trials,
H3E-US-S067,"Ph. I 2nd Line NSCLC, ALIMTA/Iressa",
"7745",Fellowship - McMaster Chair,
F1D-PL-O199,Prevalence of hyperprolactynemia in atipicals,
"7780",Camos for Forteo,
H6E-CA-GLAW,ACCESS - Actos Canadian Effectiveness and Safety Surveillanc,
"7821",Xigris SAP Program,
B9E-BP-O178,"Phase I, RT and Gemcitabine, Bladder cancer",
H6D-EW-LVDQ,"20 mg IC351 Food Effect Study",
B1Y-CA-O017,Light Therapy vs. Antidepressants in SAD,
F1D-US-V013,Olanzapine Effects on Nerve Tissue Susceptibility to Excito,
H3E-MC-JMEX,Ph 2 Pharmacogenomics with ALIMTA in 2nd line MBC,
"5454",Gemzar+Cisplatin+5Fu for Hepatoma,
B9E-MC-V115,Gem+Carbo to determine pharmacokinetics of gem,
H6N-BD-LEAE,Quantified EEG study of LY451395,
H6M-BD-LDAJ,MDSS of 450108 in volunteers,
H3S-EW-GGKK,Compliance and Health Outcomes Osteoporosis Study of EVISTA,
H4S-UT-O017,VIAMI-Viablility-guided Angioplasty after AM,
B9E-CP-O323,rand ph III cmp. of Tax+Gem+Cis vs Nav+Cis inope NSCLC,
B5K-PK-S002,Observational study of Humulin in Pakistani patients,
B9E-MC-X334,PhII Gem/5FU/Leucovorin Met biliary tract/gallbladder cancer,
F1D-GH-O116,The effects OLA AddingTherapy on Partial Respond Schizophren,
B9E-US-V127,gemcitabine mechanism of action,
F3Z-US-X009,sc LP vs continuous IV Regular for hyperglycemic crisis,
"5730",Eartly Intervention to Diabetic Neuropathy,
H3S-US-X022,effect of ralox on heart rate variability,
F1J-MC-HMET,PD- Low Dose Escalation Study,
B9E-US-S182,R - Ph II - Cis/VP16/RT--> Gem vs G/Taxotere - NSCLC,
B1Y-ME-HCKT,Neurophysiological and neuropsychological changes,
B9E-MC-V088,Using H3 Gem intend to define intracellular dist of the drug,
"4933",Fed-Fasted Study with Capsule,
B3D-MC-GHBL,Phase 4 Commercialization Trial  of PTH Followed By Evista,
H6D-MC-LVDE,Pivitol Phase III Safety and Efficacy Active Comparator FSAD,
H6E-MC-GLAL,B-cell preservation trial (GLAG extension),
"5079",Registration Pain,
H6E-MC-GLAM,Metformin + pioglitazone vs. metformin + placebo,
"5130",LY333328 VS Linezolid in VRE Infections,
B9E-SB-O176,Chemotherapy followed by simultaneous Chemo-/Radiotherapy,
H4S-US-X012,CCF Registry of Abciximab use for Coronary Indications,
B9E-BX-O183,Tomudex (raltitrexed) in combination with Gemzar,
B9E-VI-O184,Gem+Doxo in Pat. with advanced epith. ovarian carcinoma,
B9E-MC-S230,"Ph I/II  altered BAGCOPP regime, adv hodgkin lymphoma",
B2S-IN-AHBV,CEFAMANDOLE VERSUS IN SURG PROPHYLAXIS OF BILLARY TRAC SURG,
"5402",MDSS - Multiple Dose Escalation,
F1D-SO-O108,Zyprexa vs Ziprasidone,
"6100",GLP-1 analogue - Hepatic,
B9E-PL-O357,Neoadj. therapy + surgery + Gemzar in pancreatic cancer,
"7869",Ovarian GPI,
B9E-SB-V005,Resistance Mechanism Against Gemcitabine,
B9R-AY-O030,Requirements for a robust test for GH doping (WADA study),
B9F-LC-I002,HUMAN C-PEPTIDE EFFECTS WGT REDUCTION INS SECRET,
B4Z-US-S009,Phase IV Observation study of Strattera in child/adolescents,
H7C-LC-LMCN,hPepT1 Substrate Study,
H8O-EW-GWAE,Exendin-4: ACE Inhibitor,
H4S-BP-O046,MOHAN-Evaluation of microperfusion damage done due to PC,
H3S-SN-GGLG,Observation of Transition from HRT to Evista,
F1D-UT-O229,Efffect of olanzapine on Tardive Dyskinesia,
B9E-US-X389,Ph II Gem w/5-fluorouracil & leucovorin w/CP-461 in esoph CA,
"8294",PPAR Co-agonist IV Dose Ranging,
"8314",PET Study,
B9E-TW-O373,GP/NP vs GP/NP+thalidomide for NSCLC,
"8348",Dulox. vs. comp. in Fibromyalgia,
B9R-JE-YI41,TO EVALUATE EFFICACY OF FINAL HIGHT,
H3E-MC-JMHZ,Ph III Confirmatory Trial for ALIMTA  in Ovarian Cancer,
"4953",Clin Pharm Drug Interaction Study #4,
B9E-MC-S142,Ph 2 Gemcitabine +Cisplatin +/- Gem Maintenance - NSCLC,
B9E-MC-X081,Phase 2 Gemcitabine and Taxol/Mesothelioma,
"3965",Particle Size,
B3M-FW-AJBC,BE study comparing 2 formulations of cefaclorCD375 mg,
F3Z-MC-IOMS,Humalog Mix25 versus NPH BID:  Asia Pacific,
B1Y-MC-X104,FLUOXETINE TREATMENT OF DEPRESSION ON PARKINSON'S DISEASE,
"4104",Single-dose study in hepatically-impaired patients,
B7A-BD-MBCN,Sulfonylureas drug interaction study,
H6D-EW-LVCA,IC351 Formulation particle size study,
A6J-GH-V014,Antimocrobial resistance monitoring,
F1D-GH-LOBA,Olanzapine in treatment of different kinds of Schizophrenia,
"4313",LY333328 Multiple Dose,
B9E-MC-V062,Determin importance of NER and/or MMR in gem cytotoxicity,
F1D-US-X169,"Comparative effectiveness of Olanzapine, Risperidone, and Pe",
F1D-XL-O065,Retrospective study of the OLZ effectiveness in demencia.,
B1Y-GH-O013,Prozac in treatment of depression in chronic pain patients,
B1Y-GH-S008,Prozac in treatment of depression in people suffer high stre,
"4397",R-fluoxetine,
F1K-LC-EVAV,LY203638 (rhAPC): End-stage Renal Disease II,
F1D-SU-HGLV,Switching from Seroquel,
B9E-MC-V119,Implications for chemotherapeutic efficacy of gem,
F1D-MC-X194,Assessing the Neurochemistry of Adolescent Mania,
B9E-MC-X311,Ph II Gemzar/Carboplatin/Taxotere in 1st line Met NSCL Cance,
B9E-MC-X312,PhII Triple doublet for new  cancer of millerian origin,
B9E-MC-S239,EC -->T vs EC --> GT,
F1D-MC-V014,The Antidepressant Effects of Olanzapine,
F1D-US-X211,Functional and Structural Effects of Typical and Atypical -,
H4Z-LC-JWXN,LY353381 Formulation #4 Pilot Bioequivalence Study,
H7G-FW-PDAA,Multiple-Dose Safety in Healthy Volunteers & HBV Patients,
H3S-SN-GGKQ,"OS-Side Effects,Compliance,Satisfaction of use of Evista",
H6P-MC-X001,Use of Flx + Olz in Elderly Agitated Depressed Patients,
B9E-FP-O244,IIT-Gem-Cisp+concom cerebral radioth in NSCLC,
B9E-US-S254,Gem vs. Doxil vs. Gem/Doxil platinum resistant Ovarian Ca,
B9E-SU-O249,"Phase II Study in Advance Cervix, Stage IIA, IIB, IIIA, IIIB",
B7A-MC-MBCT,US Optical Coherence Tomography,
H6D-MC-LVEM,Safety & Efficacy Trial,
B1Y-BP-HC47,PROZAC:  MONITORED RELEASE IN MDD,
B9R-MC-GDCH,SOMATROPIN:NON-GH DEFICIENT CHILD. SHORT STATURE,
"8434",Placeholder,
H8Z-MC-JACQ,"Biomarker Method Trial, 50 NHL Patients",
F1J-IT-SBCI,Duloxetine vs Currently Available Therapy for SUI,
"8632",Fellowship Funding:  Dementia Patient Database,
F1D-CA-B011,Mixed bipolar symptoms in a community setting,
H8O-MC-GWBI,CV outcomes,
B9R-OL-0002,SOMATROPIN IN TURNER'S SYNDROME,
H3E-MC-V012,Non-Clinical Pharmacological study of drug uptake in CNS,
H8Q-LC-GQAD,SERM GYN 1/LY2066948  Drug-Drug Interaction,
"8865",MEX Biomarker Placeholder,
"8886",Placeholder for Forsteo IITs Netherlands,
B3D-XM-B003,Recognition of vertebral fractures with chest radiography,
"8905",Gemzar + Novel Agent in Breast Cancer,
"8953",Cognition,
"9029",Relative Bioavailability Study,
H8Q-MC-GQAE,SERM GYN 1st Generation / LY2066948 Phase 1b - 5 day Dosing,
B4Z-MW-LYCZ,"Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine",
B4Z-MC-X003,Atomoxetine for weight reduction in obese patients,
B9E-MC-S268,Neoadjuvant - Ph II - Gem+Cis+Iressa - NSCLC,
B4G-JE-C001,PERMAX PMS IN PARKINSON'S DISEASE,
B4G-JE-YI02,COMPARISON OF PMX+L-DOPA VS L-DOPA INTENSIVE TREATMENT IN PD,
H3E-MC-S021,"Ph 1 ALIMTA + GEM + Cisplatin, 1st Line NSCLC",
F1J-MC-SBBS,QOL Post  Launch,
"6265",Pulmonary Insulin Phase 3,
B9E-TW-O273,Gem/Cis/IFO for TCC,
"6315",Spinal cord,
B9E-KL-O277,Gemcitabine and cisplatin in TCC,
B3D-MC-GHB7,Sequential Use of Forteo and Evista ECG Addendum,
F3Z-MC-IOOJ,Premeal mixtures  (HM/HM/LM) vs 30/70 bid in type 2 diabetes,
F1D-TW-S025,LOCAL REGISTRATION TRIAL FOR RAIM,
B9E-GM-O290,Gemzar in Metastatic and/or Recurrent Nasopharingeal Cancer,
"6459",Ph I - Gemzar + Alimta + Affinitak - Solid Tumors,
H8C-BD-LQBA,SDSS,
"6513",ROLE OF PROTEIN KINASE C bII ISOFORM IN CARDIAC AND VASCULAR,
B9E-MC-V160,Act Phosphatidylinositol on Gem-induced Cell Death/Panc,
F1D-UT-O154,Zyprexa Intra Muscular inpatients,
H3E-MC-V023,Invitro Test w Alimta in Drug Sensitivity Testing,
H3S-US-X006,Effect of Raloxifene and placebo on cognitive function,
B3M-BL-S015,Cefacl BD Vs Amoxic/Clavu in the Tx of Acute Sinusitis,
"4521",LY466700 Multiple-Dose Safety Study--IFN Optimization,
"4536","Olanzapine pamoate, 'HGIL like study', multiple dose",
"4561",Relapse Prevention Study,
B9E-SB-V066,In vitro Chemosensitivity tests in human cell lines,
B1Y-SE-9281,CLINICAL EXPERIENCE EVALUATION OF PROZAC,
B1Y-SE-9304,PROZAC CLINICAL EXPERIENCE EVALUATION: OPEN-LABEL,
B9E-KL-O154,GEP In NSCLC,
H3E-MC-JMEV,Ph II Gem+ALIMTA Bladder 1st line,
F1D-US-HGJB,olanzapine vs. seroquel in the treatment of schizophrenia,
B9E-MW-O159,Ph II Gem/Paclitaxel/Cis 2nd line Gem cell testicular cancer,
H6D-MC-LVCR,U.S. Experience Study,
B9E-MC-S173, Phase II Gem+Carbo vs Gem+Vinorelbine -NSCLC,
B5K-GM-IBFI,Transfer of U-40 to U-100 Humulin 30/70 at Indonesia,
"4938",Pivotal Study in Ovulation Induction - I,
B3D-MC-GHBK,Treatment of Steroid Induced Osteoporosis,
B1Y-MC-X211,FLOUX-INDUCED CHAGES IN TACTILE THRESHOLD & SEXUAL FUNCTNG,
B9E-RO-S261,Ph IV Gem+Nav -> Gem+Ifosfa. vs. Gem+Cis in III and IV NSCLC,
B9R-XM-O016,HUMAN PUBERTAL DEVELOPMENT,
A3Q-ME-AFBG,CEPHALEXINE AND BROMHEXINE IN ACUTE BRONCHITIS,
B9E-SU-O266,Phase II Gemcitabine/Docetaxel in Metastatic Breast Cancer,
F3Z-FP-IONZ,Lispro MM vs NPH @ bedtime in combination with oral agents,
H6M-MC-LDAN,Screening Patients for Probable AD/MCI,
F1J-MC-HMBV,Major Depressive Disorder,
F1D-EW-LOBS,Olanzapine depot - Marketed pamoate formulation,
H3E-SB-S020,"PH 1, 1st Line ALIMTA + Carbo + XRT in NSCLC",
H3E-MC-JMFG,Ph 1 ALIMTA + Platinum or GEMZAR + Cytostatic 1st Line NSCLC,
B4G-JE-YI05,PERMAX SPECIAL INV. II:COMPARISON OF PMX+L-DOPA VS L-DOPA,
H3E-MC-JMFL,"Ph 2, ALIMTA Global Mesothelioma Compassionate Use",
H4S-BP-O030,ReoPro Therapy in Acute Myocardial Insufficiency Syndromes,
B4G-UT-LBAV,PERGOLIDE VS LEVODOPA AS MONOTHERAPY IN PARKINSON'S DISEASE,
"6355",Regional Biomicroscopy Trial,
"6379",Japan-SDSS,
B9E-MC-X214,Gemcitabine and Weekly Paclitaxel in NSCLC,
B9E-XM-O363,"Ph II study of gem in long infusion, ovarian ca.",
"6580",new Oncology IITs,
B1Y-GH-L001,Fluoxetine in tired unmotivated depression,
H8F-EW-LGCC,M1: F-18 Micro-dose PET Study,
"6758",PET Study II,
"6833",Drug Interaction - Warfarin,
"6845",Ph III HTN OUS CCB,
B9E-MC-I009,RAD. & GEMCIT. IN LOC. ADV. NON-MET. ADENOCAR. OF PANCREAS,
F3Z-KL-O055,Insulin Resistance and Metabolic syndrome in Korean Adults,
"7007",Dummy Account for Amy Kuntz - USMD,
"7088",Pulmonary Insulin in COPD,
B9E-MC-JHBP,PHASE 2 STUDY OF GEMCITABINE IN PRETREATED HODGKINS,
B9E-MC-V186,Bioanalytical method of gemcitabine and 2-dFdU in biological,
F1K-BX-S001,open label RAPC adults sepsis and 2 or more organ dysfunctio,
H3E-US-S069,Single Arm Ph II Alimta in second line SCLC,
F1K-MC-EVCL,Adult patients with early stage severe sepsis,
"7261",Olanzapine placeholder,
H6E-CA-O006,Insulin sensitivity and metabolic control in adolescents,
"7326", Edema Study,
B1Y-UT-0188,FLUOXETINE V PLACEBO POST GASTRIC BALLOON PER.6MOS,
"5017",LY466700 Renal Study,
"5085",Support Pain,
"5109",MGlur2 - Pediatric PK,
H3E-MC-JMEK,"Randomized Ph. II 1st Line NSCLC, ALIMTA/Carbo or ALIMTA/Ox",
"5135",PET Neuroimaging Study in Healthy Volunteers,
B3T-MC-JTAM,Oral LY335979+dox and LY335979+dox+cyclophosphamide,
"5150",IV short course LY335979 plus anthracycline +/- taxane,
B1Y-UT-0989,FLUOXETINE IN BULIMIA N. WITH OR WITHOUT BORDERLINE PERSON.,
"5167",Dose interval (single vs. multiple daily doses),
B1Y-MC-X212,Fluox. in Patients Ungerdoing Coronary Artery Bypass Surgery,
H3S-US-X011,Effect of Evista on Peripheral Blood Flow Velocity,
F3Z-UT-S008,Clinical Experience with Humalog Mix25 in the Netherlands,
"5272",JP lisp P-II post meal,
"5323",Weight Control of patients treated with olanzapine,
B9E-SO-O199,gemcitabine and epirubicine in ovarian cancer,
B9E-MC-X308,PhI/II Zyprexa for prevention of delayed emesis in chemo pts,
B5K-MC-IBFT,"Dose Confirmation, Dose Response",
B9E-US-X360,Ph II Gem & Etoposide Locally Adv or Met Pancreatic CA,
F1D-MC-HGLQ,Olan Pamoate Depot vs Oral Olan in Schizo Open Label Study,
"6396",MDSS 395,
B9E-SU-O289,A phase II study of docetaxel in combination with gemcitabin,
B9R-MC-GDGA,Global Hypopituiary Control and Complication Study - HypoCCs,
"6514", STUDY OF THE INVOLVEMENT OF PKC beta IN LIPID-ASSOCIATED H,
B9E-MC-V157,Gem in Treat of Blad CA in situ Refract to BCG,
F1D-IT-O161,Treatment of the weight gain associated to Olanzapine,
F1K-UT-EVBN,prolonged administration 4 vs 7 days,
B4Z-SO-LY15,Broader Efficacy STudy in ADHD Children - Strattera,
B3D-KL-GHCC,Forsteo versus Calcitonin in Osteoporotic Women,
B4Z-SB-S008,"Non-medication study, epidemiology, cost of illness",
"6796","5-HT1F CSF Study",
H6K-FW-IIAF,Clamp Study in Normal Volunteers,
B9E-MC-I002,PH. I GEMCIT. IN CHILDREN WITH LEUK. & NON-HODGKINS LYMPHOM.,
"6887",Xigris IIT - place holder,
B9E-MC-I029,PHASE I STUDY OF INTRA PLEURAL GEMCITABINE,
H3S-XM-O024,"17betaestradiol & raloxifene action at the human apoptosis",
"6255",Hypoglycemia Study,
F1D-FP-S044,olanzapine vs lithium in manic patients,
"7526",Immunocompromised Host SAFETY Study,
B7A-EW-MBDH,DIMITRI Treatm.of Clin. Diabetic Microvascular Complications,
"7542",ID of Biomarker to Assess PKC Beta Inhibitor,
B9E-MC-JHFY,GEMCITABINE COMBO WITH CISPLATIN IN UROTHELIAL CANCER,
"7574",Dummy trial for MPD,
F1D-GH-B002,"switching to olanzapine,the effectiveness and safety study",
"7626",Gemzar untitle IIT,
F1D-AY-S047,Efficacy of Zyprexa in tbt & wafer in schizophrenia,
F1D-CA-HGLJ,"Acute Tx of Agitation in Schiz, Schizaff disorder & bipolar",
B9E-GN-O374,Gemcitabine in intravesical bladder cancer,
"7662",Olanzapine switching IIT in Pakistan,
F1D-TW-O195,"An open labeled,randomized,flexible dose comparison follow-u",
"7709",Post Launch NOC Trial vs Stimulants (Child),
"7727",Atomoxetine in Learning Disorders,
"7736",Forteo versus risedronate,
H3E-MW-JMGJ,Alimta plus Carbo first-line in patients with breast cancer,
"7774",Gemcitabine in refractory and relapsing lymphoma,
B4Z-MC-LYDG,sensory study with liquid formulation prototypes (taste),
"9331",Dose Frequency study,
"9374","Development, accessment and application of clinical-sepcific",
"9386",UK Local headcount placeholder F1J-MC-HMCN,
F1D-BP-O256,Schizophrenia and the Metabolic Syndrome,
B9E-OE-B006,Treatment Evaluation of Gemzar in Breast Cancer - OS Austria,
H7T-MC-TABR,PK and PD comparison in subjects w/ stable atherosclerosis,
B4Z-US-X021,An Open-Label Safety and Efficacy Study of Atomoxetine in th,
"9554",A Multiple-Dose Study to Evaluate the Safety of LY570977,
"9570",A Pilot study of Strattera Treatment in Adolescents with Att,
B5K-GH-O444,Contd glu spectrum of diabetic gastroparesis pt after insuli,
H3S-US-A008,Are Reloxifene Effects on VEGF and TSP - 1 mediated via the,
H3E-XM-S094,Alimta-Cis + Radiotherapy in NSCLC patients,
"9708",French Addendum for H3S-MC-GGIO,
H6E-XM-B002,Epidemiological Study about Metablic Syndrome,
H6Q-MC-JCAX,DDI Warfarin-CYP2C9 Biopharm Study in Cancer Patients,
H6D-MC-LVGQ,Phase 3 Daily Dosing in a General Pattient Population,
B9E-MC-S233,Ph II Gem+Cis+Dexamethazone - Mantel Cell Lymphoma,
B9E-US-S236,Ph II Gem + Cisplatin vs Gem + Carbo neoadjuvant NSCLC,
B5K-GH-IBFV,Efficacy and safety of Humulin,
B5K-GH-IBFX,Transient intensive insulin tx in newly diagnosed type 2 DM,
F3Z-SU-S011,Observ. trial comparing Mix25 (LM) to NPH BID,
H4S-UT-O016,ICTUS-Invasive vs conservative treatment in ACS,
B9E-MC-V121,Pharmacokinetic study:fixed dose rate of gem,
B3L-EW-LPAB,LY354740 PILOT BIOAVAILABILITY STUDY CAPS VS SOLUTION,
B9E-SB-O217,Gemcitabine FDR with platinum in Bladder-CA,
B3L-MC-LWAC,MGLUR2 AGONIST VS PLACEBO IN PANIC PROVOCATION MODEL,
B1Y-DI-O227,Does Fluoxetine Tx Prevent or Attenuate PTSD?,
B9E-CY-O242,Vinorelbine+Gem in III and IV NSCLC,
B3N-GE-GRRA,LY326869:  EFFICACY IN NIDDM,
F1K-MC-EVBI,Post-acute follow-up of PROWESS Day 28 Survivors,
B9E-US-S243,Ph I/II in SCLC-Gem+Carbo+Irinotecan,
B9E-MC-O246,Neoadjuvant Gem-Cis in Advanced Cervix Carcinoma (IB-IIIB),
"7514",Pergolide vs cabergolina and ropinirolo,
H6D-MC-LVFK,Preference - US,
"7018",Capsule Bioequivalence Study for Pulmonary hGH,
"7044",ASD Phase III #1,
H4S-UT-O042,HIS-Holland Infarction Study,
"7147",Formulation bridging study,
"7172",Zyprexa in Dual Diagnosis Patients:  A Chart Review Study,
H3E-US-JMGA,Neoadjuvant Multimodality Mesothelioma,
B9E-US-S321,Phase II Gem/Trastuzumab/Docetaxel in HER2 FISH Positive MBC,
"7255",Placeholder for DULOXETINE trials (BUY-UP),
"7256",Placeholder for GEMZAR trials,
H3S-FP-O027,plasticity and cerebral neuroprotection,
"7382",placeholder IIT Zyprexa (bipolar),
B7A-FP-MBDG, future eventual local study (sympt neuropathy or DIMITRI),
B9E-MC-JHFB,GEMCITABINE PLUS PACLITAXEL COMBO IN REFRACTORY SOLID TUMOR,
B9E-AA-S355,R-Ph II-Gem+Pacli vs Gem+Carbo vs Gem+Cis-MBC,
"7480",Place holder IIT France Dr Rascle,
"7489",GSEN,
"7511",Placeholder for local support of H3E-EW-JMEM,
"10496",Corporate Placeholder for H3E-SB-S089,
"7814",Loading dose of olanzapine in acute agitation,
"7817",Zyprexa - chart review of safety in doses over 20mg,
H3E-PL-O002,Alimta - compassionate use,
"7860","PKC in Neurophaty, changes in the Analog Visual scale",
H6D-VI-LVFH,Switching from Sildenafil to Tadalafil in Treatment of ED,
"7937",CTNR: Affinitak - Biliary,
B4Z-MC-LYCJ,Alternate titrations,
"8000",Observational study at all Key Players,
B9E-US-X383,"Feasbility Gem post Plat/Paclitaxel in St III-C, IV Ovarian",
B9E-MC-S344,"Ph II, rand. Gem vs. Mitomycin-C in superficial Bladder CA",
H6D-CA-B007,Canada TED local obs study,
B9R-BX-8702,"SOMATROPIN:IN NVSS, MORNING V EVENING ADMINISTR.",
B1Y-AY-O030,A population based study of post menopausal depression,
F1K-US-V005,Coag. Effects on Neutrophil-Endothelial Cell Interactions,
H4S-CA-O049,Abciximab s effect on coronary microvascular endothelial dys,
H8U-BD-HEAC,Multi-Dose Safety Study,
"8253",test for US country code.,
H6D-MC-I001,Scleroderma in Females with FSD,
"5840",Cerebral Spinal Fluid Study,
"5842",PPAR-gamma bridging study; solution to solid dosage form,
"5846",PPAR Coagonist Drug/Drug Interaction #1,
"5853",Pilot Bioequivalence for Oral Liquid,
H6D-MC-LVEH,Brazil Regional Trial,
B3N-MC-EUAS,DOSE RANGING STUDY SR&IR FORMUL OF LY326869 IN HYPERTENSION,
"5901",Alzheimers Phase IB Study,
F1D-XB-O136,Neurological diagnosis of deficitary syndroms,
H3S-MC-A007,Continued Evaluation of CV Effects of Raloxifene in Sheep,
"6006",Depressive Symptoms in GAD,
B4Z-MC-LYBM,ADHD Partial and Full Responders-adult,
"6102",GLP-1 analogue - Hypoglycaemia symptom recognition,
H3E-MC-JMFH,"Ph 2 GEM/Cis+ ALIMTA vs GEM/Carbo + ALIMTA, 1st Line NSCLC",
H3E-MC-S031,Placeholder for Breast,
F1D-KL-O141,Striatal Dopamine transporter in Schizophrenia patients,
"6357",Mechanism of Action Blood Flow Study,
"6381",Drug-drug interaction study with 395,
"6404",Olanzapine in the Treatment of Bipolar II Depression,
H6O-FW-GCAL,Glucose Tolerance Test on Beta-Cell Function Study,
F1J-MC-SBCF,Urge Open Label US study,
H8Q-LC-GQAC,LY2066948 SERM GYN 1st Gen MDSS,
H4S-PL-O052,Efficacy of Abciximab for Coronary Intervention in Diabetics,
B9E-MC-V225,HPLC method for analysis Gem + 2-dFdU,
H8Z-MC-A002,FDG - PET biomarker preclinical study in mice,
H3S-US-X029,Enhancing Cardiovascular Health After Menopause:  Raloxifene,
H9C-LC-BBDD,Single Dose Safety Study in RA Patients,
"8593",Switch Study from other ADHD meds to Strattera,
F1J-MC-HMDL,GAD,
"8674","R Ph II, ALIMTA+Gem (D1,D8) vs ALIMTA+Gem (D1,D15)  Pancreas",
H8O-US-B002,Observational- US,
"8753","Ph II, 2nd line ALIMTA+Gem in platinum resistant ovarian",
"8755",Ph I - intrathecal ALIMTA - pts w/ - ALL,
"8851",ALIMTA + GEMZAR IN METASTATIC BREAST CANCER,
B9U-MC-AZCT,LORACARBEF CONC IN SINUS SECRETIONS/MUCOSA IN CHILDREN,
B4Z-XB-O004,ADHD neuropsychological and behavioural phenotypes,
F3Z-US-X015,Multifactorial Intervention Before Vascular Surgery in T2 DM,
"8946",PLACEHOLDER local trials with dulox (BE),
B4Z-US-X005,Acute & 1-month effects of atomox in cerebral cortex,
"7523",Phase 2 Gem/carbo followed by Alimta sequential NSCLC,
B7A-MC-MBDM,Correlation of Microvascular Damage w/Nerve Integrity,
B1Y-GH-HCLQ,Effectiveness of Fluoxetine in depression pts in general hos,
F1D-US-X227,Olz on auditory gating deficit in pts with schizophrenia,
ZYY-LC-GBBE,Cardiac enzyme method study,
"7720",ADHD Observational Study,
B9E-US-X380,"Ph II Eval Combo of Carbo, Gem & Cap pts w/ CA.",
"7816","Reason for discontinuation, switching study olz/quetiapine",
"7893",Placeholder for IITs,
B9E-SP-JHLH,GEMCITABINE + CDDP IN NSCLC WITH PROLONGED INFUSION,
"7903",Zyprexa in Dual Diagnosis Patients:  A Chart Review STudy,
B9F-MC-I007,USE OF C-PEPTIDE TO DETERMINE INSULIN SECRETION RATES,
"8114",LY517717 C 14 Metabolism,
B9E-US-X385,Ph I Eval Gem/Fluarabine/Mitoxantrone for Hematologic Malign,
H4S-KU-O048,Glycoprotein receptor blockade avoid peripheral restenosis,
"8178",Exendin-4: Placeholder - Elderly,
B3L-UT-A001,Role Glutamate receptors (GLU2/3),
B9E-SB-S347,Breast cancer treatment. Obs. study,
F1J-US-X002,Duloxetine for the Treatment of Dysthymia ,
H8O-US-B001,IIT,
F1D-AY-A126,Effect of Olanzapine on Dendritic Spines in Rats,
F1D-GI-O275,Comparative Clinical Efficacy of typical versus atypical ant,
B1Y-CA-P001,FLUOXETINE OBSESSIVE COMPULSIVE DISORDER,
"10137",Alimta in first line NSCLC,
B4Z-US-X037,A Pilot Study of Atomoxetine for Aggression Measures in Boys,
B9E-MC-V262,LY29311 + LY188011 invitro,
"10228",PO Phase II Acute Migraine Study,
"10233",RUTH Observation Study,
F1D-MC-HGED,OLANZAPINE VS. THIORIDAZINE/LATE ONSET PSYCHOTIC DISORDERS,
H3E-US-S087,Ph II-Bi-weekly ALIMTA & FDR Gem in Adv Panc&Biliary Tract,
B1Y-CA-P003,FLUOXETINE VS DOXEPIN MAJOR DEPRESSIVE DISORDER,
H8K-MC-JZAI,Phase 1b of LY573636 w/Sutent in patients w/renal cellcancer,
ZYY-LC-GOAF,Development of biomarker assays in obese volunteers,
B9E-US-X453,"Ph I/II Combo of Docetaxel, Gem, & Bevacizumab soft tissue",
B9E-CA-O471,Phase II Trial of Cap/Gem for Tx of Metastatic Breast Cx,
F1J-MC-HMEN,Chronic lower back pain,
H7X-US-JVAJ,"Phase I/II Gemzar, Carboplatin, Taxol + ISIS ovarian trial",
B9E-BX-O291,Gemcitabine and Carboplatin in Urothelial Cancer,
F1D-US-A109,effect of Olz immobility in the forced swim test,
B9E-FP-O294,IIT-ZD1839 and Gem/5FU in renal cancer,
B9E-XM-O301,Ph II neoadj. gem-cis in post-cystectomy bladder cancer,
"6622",continuous renal replacement therapy,
B9E-MC-V163,Gemzar for the Treatment of Canine Cancer,
F1K-CA-O002,VETEC STUDY,
F1D-ME-HGKW,RAIM IM three arms of therapy vs haloperidol and zuclopentix,
"6717",Bipolar QOL,
"6740",IIT-combination Gem-taxol in weekly chemotherapy in NSCLC,
H4S-CA-O040,Stent Restenosis and Metabolism-STREAM,
B9E-KL-O307,A Phase II Study of Induction Gemcitabine and Vinorelbine,
H8M-LC-HTAA,SDSS,
"6835",Drug Interaction - Statins,
"6901",Ph III HTN active comparator dose titration,
H3S-US-GGKV,study of pmw transitiong from HRT to ralox,
F1D-MC-HGKR,Olz + Cbz versus Placebo + Cbz in Bipolar Mania,
"9007",CS 747 ECG study,
B9Z-PH-0008,IN-VITRO EVALUATION OF DIRITHROMYCIN IN MALAYSIA,
B4Z-EW-B002,ADORE-II,
"9092",PLACEHOLDER BE for switching study rilat/atomox,
H6L-MC-LFAI,High Dose SDSS in HV,
H6D-MC-LVFX,Phase 4 Efficacy & Saefty in Different Dosing Scenarios,
"9119",Placeholder HypoCCS(B9R-MC-GDGA),
F1D-CA-HGDF,"OPEN LABEL-INVIVO5-HT2, D2 RECEPTOR OCCUPANCY OF OLANZAPINE",
"9135",IIT Placeholder for Insulins,
"9153",ICR observational study,
B9E-MC-V235,Selective COX-2 Inhibi enhance efficacy of gem Breast/Lung ?,
F1D-MC-X255,"Prospective Study of Glucose Tolerance, Insulin Secretion, &",
B9E-BP-O412,Phase III Neoadjuvant breast study: (EC--->GT Vs EC---->T),
F1K-MC-A006,Effects of DAA on Pulmonary Vascular Permeability,
"9316",EFFICACY IN PHYSICAL SYPTOMS,
H6P-IS-O003,effects of flx olz or combo on expression of brain of Rats,
F1D-BP-O257,SORTS IIT,
F3Z-SU-O062,Utilization services of DM pts. in a Disease Mgmt Prog in PR,
"9367",Placeholder GeNeSIS and HypoCCS,
H8Y-FW-HBBE,Formulation Bridging Study,
B9E-BP-O381,Phase II Gemcitabine/concurrent RT in Bladder Cancer,
B9E-US-X404,Ph II molecular & genetic changes in pts w/resectable NSCLC,
"8455",Raloxifene use among women with a history of breast cancer,
B9R-MC-I010,SHORT TERM GH THERAPY ON POST-OP RECOVERY JOINT ARTHROPLASTY,
F1D-XB-O245,neuropsychological assesment in manic episodes,
"8643",Exendin-4: antibiotics,
H9F-LC-GYAA,Single-dose Safety Study (SDSS),
"8781","R Ph III, ALIMTA/Cis vs VP16/Cis in SCLC",
H3E-MC-V007,"Pre-clinical research with ALIMTA, derivative of LY338913",
"8809",Placeholder  -  CB-1 Tracer Development,
H3S-XM-O121,Raloxifene Treatment monitoring through bone markers measure,
B9E-IT-O425,GEMZAR + PLATINUM COMPOUND IN OVARIAN CANCER,
"8881",placeholder MEX,
H7R-MC-GCCC,Mono therapy;active control;Lipids endpoint,
"8944",PK/PD of Insulin Basal Analog in Patients with Type 1,
B4Z-US-X014,Atomoxetine Pilot Feasibility Study for ADHD Symptoms in Au,
"8951",AIM Study,
H8K-MC-JZAB,"Phase I Dose Escalation Study of LY573636, 24hr-IV,28d Cycle",
B4Z-MC-LYBX,Comorbid ODD in Peds,
"7096",Micro Needle Injection PK/PD Pilot,
B9E-MC-JHBQ,GEMCITABINE AND CISPLATIN IN TREAT. OF ADV. OR MET. PANC. CA,
F1D-XL-O180,prodromal phase with olanzapine,
B9E-VI-S316,Egyptian Gem Cis in Loc Adv. Metast. BC,
B3M-GH-V054,Invetigation of pathogen of CAP in Chinese Urban Area,
"7171",Local trials with FORTEO PMS,
"7180",Placeholder for PKCi IITs,
"7199",Placeholder for Actos IIT's & not yet appr oth local studyNL,
"7207",Ac-T vs AC-TG neoadyuvancia est II/III,
H3E-US-JMFZ,PhII Single Arm Gem/Alimta in Malignant Pleural Mesothelioma,
F1D-US-X222,sexual dysfucntion in bipolar and schizo pts,
"7270",IIT placeholder for Alimta,
H6L-LC-LFAH,A beta time course effect and plasma level,
H8Q-LC-GQAA,LY2066948 SERM GYN 1st Gen SDSS,
F1D-SO-HGLY,Olanzap vs Conventionals in the treatment of mania in Sweden,
F3Z-US-X016,Multifactorial Intervention before Vascular Surgery in T2 DM,
F1D-MC-HGMD,IM Olz Depot: Backup study US Registration- schizophrenia,
F1D-JE-303E,LY170053 PHASE 3 LONG-TERM STUDY INCLUDING THE ELDERLY,
F1D-JE-M01E,CLINICAL PHARMACOLOGY OF LY170053,
"9528",Zyprexa Switch in stable schizophrenic patients,
B1Y-MC-HCLT,Fluoxetine vs placebo effect on growth in children with MDD,
F1D-LC-HGAI,THE DISPOSITION OF 14C-LY170053 IN MAN (SINGLE DOSE),
H6Q-LC-JCAS,Second Relative Bio-Availability/Particle Size,
B9E-US-S370,PK Com. to Ph. III FDR Gem+Oxal vs FDR Gem vs Gem in Pan Cnr,
H7U-MC-IDAU,Insulin treated type 2,
F1D-JE-BMEX,JP ola P-III Bipolar Ex,
"9662",Second study- ped comorbid ADHD + anxiety,
F1D-CA-HGMH,Olanzapine monotherapy in bipolar I and II depression,
B9E-US-X437,"Ph II dose dense Neo. Gem, Epirubicin, AGI-007 in breast CA",
F1D-MC-HGAG,LY170053 VS PLACEBO IN SCHIZOPHRENIA,
H6D-MC-LVHG,"Cialis Phase II-III BPH/LUTS Study #2 5-Group, Multinational",
"9132",Placeholder Trial for 2004 CT-Material Estimate,
F1D-MC-X250,Metabolic Effects of Olanzapine Versus Typical Medications,
B9E-MC-V272,Antitumor Effects on Interferons on Pancreatic Cancer,
B4Z-US-X043,Open Label Study of Strattera in a Correctional Setting,
H3E-CA-S050,Ph II-Alimta+Gem-Breast,
F1K-US-A009,Meas. of Eff. of Xigris on Cytokine Act. & Down Reg. apoptos,
"9333",Evista switch from bisphosphonates,
"9358",Ph II -  2nd line - ALIMTA - Superficial Bladder (US),
F1D-JE-206E,QUANTITATIVE EEG STUDY OF LY170053 (OLANZAPINE),
B4Z-IS-S015,post launch CTNR,
F1J-VI-S012,Duloxetine in the treatment of MDD in CEE-AMEA,
F1D-BL-B013,Schizophrenia Outpatient Health Outcomes,
B9E-US-X431,Ph II Gem plus Docetaxel in pts. w/ AIPC,
B9E-SB-O437,MBC Anthra pretreated Phase I/II GemPac 1st/2nd line,
F3Z-MC-IOOR,LRT in China Humalog Mix 50,
H8K-MC-JZAC,Phase II: Non-Small Cell Lung Cancer,
B1Y-JE-HCZZ,JP Prozac P-II placebo controlled study,
B9E-XB-O338,phase II in NSCLC of gem/cis follwed by weekly paclitaxel,
"7380",Gem-Oxaliplatino in II line gastric cancer,
B4Z-EW-LYCA,European Broader Efficacy Study with Atomoxetine,
F1D-SB-S050,Olanzapine vs. comparator in psychotic depression,
B9E-MC-JHER,GEM/CISP. PH.2 EFFIC. IN ADVANC. EPITHIAL OVAR. C. 1ST LINE,
"7426",Retrospective study in patient response for olanzapine (AO),
"7456",Compliance Register in Teraparatide Therapy,
"7531",Void,
"7553",Foot Ulcer,
B7A-MC-MBDS,Stehouwer-Endoneurial Blood Flow Study,
"7560",IIT placeholder,
"7580","Ph III, 1st Line Gem/ALIMTA 15d vs Gem/ALIMTA 21d in NSCLC",
"7609",SDSS,
B9E-PK-O346,Effi & safe of Gem in combi with Cis inABC,
"7661",Gemzar in MBC IIT# 2,
B9E-IN-O348,Gemcitabine in Gallbladder Cancer,
"7706",IIT / Fellowship / Chair Placeholder for Forteo,
B9E-AY-O351,Gemcitabine & Cisplatin in Gall Bladder Cancer,
F1D-PL-O202,Weight Gain Management,
H4S-UT-O061,Ongoing Thrombolysis or 2b/3a inhibition In Myocardial infar,
F1D-LC-HGAH,LY170053:DOSE PROPORTIONALITY/EFFECT FEEDING ON BIOAVAILABIT,
B9E-GH-O432,Phase II study of Gemzar plus Cisplatin in Cervical Cancer,
H3E-MC-JMHE,R Ph II ALIMTA+dox vs ALIMTA+Cis in Hepatoma,
H3E-MC-S077,Ph II ALIMTA + Folic Acid  - Pharmacogenomics - Rectal,
F1J-SB-B007,DUROSA Obs. study Germany SUI-Satety,
H3E-MC-JMHL,Ph I-ALIMTA + Cis-MPM/NSCLC,
"9769",Placeholder for local resources in HMCN,
"9779",Exploratory Craving,
B4Z-US-X051,Open Label Study of Adjunctive Atom in the Trx ADHD Ped Bip,
F1D-MC-HGBD,VOID,
F1D-MC-HGBT,OLANZAPINE IN DOPAMINOMIMETIC IND. PSYCHOSIS IN PARKINSON D.,
B9E-MC-V284,Radiosensitizing of dFdU in 2nd cell line with wild-type p53,
H7T-MC-V004,Genotype Banked Samples of Low/Non/Responders (GANR),
F1D-MC-X020,Open-label Olanzapine Extension,
F1K-US-V018,A puntative mechanism for Activated Protein C clearance,
"10664",OpRA III (NS) C-14 Study,
B3D-BP-O004,Bone metabolism and blood flow in women treated with PTH,
B4Z-IT-O006,Cognitive functions in rat model of ADHD,
F1K-SB-O030,Addendum Antiinflammatory & Profibrinolytic Mech. of rhAPC,
"9987",Randomised Phase II Gem/Txtr/Cape in 1st & 2nd line MBC,
"9993",IIT Bucket (Alimta),
H3E-MC-V083,"Effect of Alimta, Lometroxel, GarftII on MTHFS",
F1D-US-X283,Retrospective: Clin Outcomes for OR Medicaid Clients,
H3E-MC-JMIB,ph 1 Alimta in renal compromised pts w/solid tumors,
H6Q-MC-S021,Ph II Alim/Cis+/-Enz in 1st line NSCLC-BID,
B9E-MC-V310,Gemzar + Topoisomerase I to test human renal cell carcinoma,
B9E-MC-V317,Intracellular assay for phosphorylated metabolites of Gemzar,
B9E-MC-V323,Sensitivity of pleuritis carcinomatosa pts. to Gemzar,
"10898",Prevalence and characteristics of PPS in MDD patients,
H3E-IT-O023,Ph I alimta/Cisplatin + RT IIIB N2 NSCLC,
F1J-SB-O018,A fMRI study in MDD,
H6Q-MC-A018,Enzastaurin in CLL,
B4Z-SB-B007,Obs. study Atomoxetine and adolescents,
H9H-MC-JBAG,Biomarker Method Study 50 Pts,
F1D-PL-O204,Efficacy of oral Olanzapine in first episode schizophrenia,
B9E-EY-S372,Phase II trial Gem+Navelbin as 1st line chemotherapy for MBC,
B9E-PL-O355,Neoadjuvant therapy of advanced bladder cancer,
H6U-MC-V001,Kallakrein 6 Levels in Human CSF and Plasma (In Vitro),
H6P-MC-HDAT,OFC for maintenance of effect in bipolar depressed pts,
B4Z-US-LYCF,Autism,
"8024",Patient Registry (switching from zyprexa to other atipicals),
H4S-SB-O045,DECHEND-Abcixmb diabetes mellitus in PCI,
B9E-XB-V220,EGFR expression in  NSCLC patients,
F1D-SZ-O225,Effect of antipsychotic medication on psychopathology,
B9E-MC-S340,Ph II Intravesical Gem for Superficial Bladder CA,
B9R-EW-GDDZ,SAFETY AND EFFICACY OF SOMATROPIN IN ELDERLY WITH HIP FRACT.,
B9E-US-X391,Ph II Gem + Irinotecan + Celecoxib in pts w/Hepatobiliary CA,
"8293",PPAR Co-agonist IV Pilot Formulation Bridging Study,
"8306",Phase II Study Indolent Hematological Malignancies,
"8309",Krum-Effect of PKC on collagen prod. in cardiac fibroblasts,
B9R-JE-CMP1,LY137998 COMPASSIONATE USE,
F1K-MC-O014,rhAPC in patients with submassive pulmonary embolus,
"8371",Pioglitazone in the treatment of type 2 DM: observational,
B9E-MC-V230,PK study in Gemcitabine,
F1K-US-V009,Determin.of the Charge Valence of Drotrecogin Alfa (Act.),
F1D-US-A117,Neuroprotective Effects of Olz in Developing Mammalian CNS,
"8421","Ph I, ALIMTA + Gem (FDR) in Colorectal Cancer",
F1D-US-X240,"Retrospective Olz, Clozapine + Risperidol in schizophrenia",
B4Z-LC-LYDN,Definitive bioequivalence new pediatric formulation,
B9R-MC-I017,USE OF GH IN COUNTERACTING THE CATABOLISM OF CROHN'S DISEASE,
"8546","McVeigh (ex-vivo) ""Effect of PKC inhibition on platelet..""",
F1D-MC-A119,PFC Transmitter Systems & Cognitive Flexibility,
"8595",Post-launch observational study Forsteo,
F1D-TW-O244,"efficacy, safety of Olanzapine for TD, neuropsychological fu",
"8627","Ph 2, ALIMTA+Platinum (plat-sensitive) - OUS",
"8642",Exendin-4: Oral contraceptives,
"8650",M1 agonist: EEG,
B9R-MC-X009,IDENTIFICATION OF CHILDREN WITH BIOINACTIVE GH SYNDROME,
H6Q-MC-S011,Ph II ENZ in follicular lymphoma--pgx,
H3E-MC-V115,Meso Cell Growth by Alimta in Combination w COX-2 inhibitor,
H6D-MC-LVGF,Peri-prostatectomy,
B9E-US-S364,Ph III - ATC vs AC ->Taxol  vs AC ->Gem+Taxol - Breast,
"8769","R Ph II, 1st Line ALIMTA HD/Ca vs ALIMTA 500/Ca - NSCLC",
H3E-MC-V013,Non-Clinical Pharmacological Study of Drug Uptake in CNS,
F1J-XM-B001, Epidemilogical study of prevalence and symptoms of depressi,
F1D-FP-B009,B009 Follow-up study of French EMBLEM cohorte during 3 years,
H7R-MC-GCCH,Atherosclerotic Regression,
B9E-BX-JHSQ,Phase II Trial with gemcitabine and RT in NSCLC,
"9027",GH in obeses patients,
"9059",Torp-Pedersen--Importance of diabetes and diabetic act...,
"9099",ICR open-label Cymbalta,
H6D-EW-LVGG,Oral Dissolve Relative Bioavailability,
H9G-LC-GXAE,Caloric Intake (Biomarker),
B9E-BP-O408,Gemcitabine & split dose Cisplatin in NSCLC,
H3E-MC-V019,Transfer of 200mg ALIMTA,
F1K-IT-A003,APC in Pig Model of Lung Injury (dose finding study),
H3S-CA-O122,FORCE Study,
B9E-GV-B002,Gem.+ Carboplat. Prosp. Obs. Study in Relapsing Ovarian Ca,
B4Z-US-S011,Strattera Real-Time Observational Pilot (RTOP) Study,
F1D-US-X258,Increasing specificity of neurocog improvement,
B3D-AG-B006,PTH in severe osteoporosis,
B9E-XM-O421,GEM-CIS FOLLOWED BY CARBO-PACLITAXEL IN OVARIAN CA,
B9E-US-S363,Ph III 6-arm trial of multiple agts in recurrent ovarian CA,
H3E-US-S060,Alimta/Gem Biweekly H&N 1st line,
"9462",Xigris IIT Australia 2004,
H9X-MC-GBCD,MDSS (proof of concept) GLP1-Analog IV-FC,
F1D-LC-HGAF,INTERACTION OF LY170053 AND BENZTROPINE MESYALTE,
"9559",PPAR alpha agonist 2nd generation,
F1D-LC-HGAM,ORAL OLANZAPINE: SAFETY AND PK STUDY IN THE ELDERLY,
B9E-XM-O436, Gem+txt bisemanal vs standar (Across-Arco),
F1D-LC-HGAT,"OLANZAPINE: BIOAVAIL. WITH CIMETIDINE, ANTACID AND CHARCOAL",
H7U-MC-IDAY,Oral Agent Failure,
H7U-MC-IDBA,Glargine Add-on Trial,
H9H-MC-A001,Animal Profiling Study,
F1J-JE-105G,BIOEQUIVALENCY STUDY:  L5*2 VS L10,
B4Z-US-X038,rCBF Correlates of Cognitive Treatments in Schizophrenia,
H3E-MC-JMHD,POINTBREAK_Ph III A/Plat/Avas - 1st line NSCLC,
H3E-MC-JMHF,R Ph II ALIMTA 500 vs 900 in plat-resistant pts in Ovarian,
F1D-SB-B018,PROTECT Obs. study Phasenprophylaxe,
H6Q-LC-JCAW,PPI Biopharm Study (fed and fasted state),
"9809",Multi-Dose Caloric Intake Study,
H6Q-MC-JCBE,"Ph II, Single Agent Enzastaurin in recurrent glioblastoma",
B9E-IT-O454,Gemcitabine in combination in Lymphoma,
"9859",Atomoxetine effect on cognition in children with ADHD,
H3E-US-X026,Ph II Feasibility Cisplatin/ALIMTA in Malignant Pleural Meso,
B4Z-FW-LYDP, Strattera/inhaled Salbutamil drug interaction study,
"9931",Product Team Dummy Account for Business Purposes (IITs),
H9U-LC-MDBC,C-14 study,
B5K-GH-O447,"Intensive Insulin on homocysteine, folic acid & Vb12 in diab",
H3E-US-X046,Ph I/II Pemetrexed & Erlotinib in Advanced Solid Tumors,
F1D-CA-O276,Effects of Olz & Lithium on Brain Activation in BP Dep`d Pts,
B9E-BL-O456,PH 2 Neoadj (AC) followed by (GP) in Local advanced BC,
B9E-MC-V254,(hENT1) Gene Expression and Gem Lung Cancer,
H9Z-MC-RKAB,DPP-IV Inhibitor Analog I Phase 2 study,
H6D-MC-O006,Tadalafil co-administered with Testosterone,
H4S-MC-X024, Coronary Revascularization in Diabetic Patients - FREEDOM,
B9E-MC-V247,Gemcitabine Pharmocogenics,
B9E-MC-V256,T Cell Giomarker for oral gem FHD study,
H3E-MC-V059,Evaluation of in vitro assays w ICOS chk-1 inhibitor,
F1J-US-X010,Investigation of Duloxetine for the Treatment of Depression,
F1D-MC-HGEC,OLANZAPINE VS OTHER ANTIPSYCHOTICS IN PSYCH REHAB SETTING,
H8Q-MC-GQAH,Carbon-14 ADME Study LY2066948,
H3E-US-X050,Feasability of adjuvant chemo w/ Carboplatin & Alimta NSCLC,
ZYY-FW-GCCM,Exploratory biomarker study,
"10315",Placeholder for trial H8O-MC-B003 - no. 10028,
H6Q-MC-A005,Effect of enzastaurin on lung cancer in mice,
"10368",Dalanza;ine local trial,
B9E-US-X452,Ph I Biweekly Gem & Paclitaxel & Radiation Head/Neck Cancer,
F3Z-PT-IOEH,DIABETES TYPE 1,
F1D-US-X281,Study to Establish Population Norms for the Brief Assessmen,
B9E-US-X446,Ph II Combo Bortezomib & Gem for Non-Hodgkin's Lymphoma,
"10010",Phase II trial Alimta in breast cancer (Spain),
H3S-CA-O132,Identify Gene for Hereditary Form of Osteoporosis in Family,
H3S-IT-O133,Raloxifene on human osteoarthritic condrocytes  (IIT study),
F1D-SB-B020,Early retirement in pts. with schizophrenia; HO,
F1D-XM-B024,Epidemilogical study,
B9E-MC-V336,Gem TP,
H6D-MC-LVGV,Cialis PAH Study #1,
B9E-US-X449,Ph II Weekly nab-Paclitaxel combo Gem in Breast Cancer,
B9E-JE-BT22,JP gem P-II BTC,
H3E-MC-V043,Intra-Plueral Adminis of Pem for Malignant Plueral Effusion,
H6Q-MC-V001,Inhibition of sarcoma cell lines by enzastaurin,
H3E-US-X051,"Ph. I/II Docetaxel,Alimta with Neulasta Breast&Solid Tumor",
F1D-MC-I003,Olanzapine in Tx Resistant Schizophrenic Outpatients,
B7A-LL-A008,Smirnova-cardiac complications in diabetes,
H6Q-MC-A007,Enzastaurin efficacy in multiple myeloma cells,
H3E-MC-V087,Intravesical pemetrerxed alone/in combination w bladder canc,
"10344",Phase 2 FED Dose-ranging Study,
B7A-LL-A013,Prevention of CV Dysf in D-Mellitus,
H4S-PL-O067,EURO TRANSFER -Transfer for pPCI-registry,
B3D-LC-GHCZ,TIP Pulmonary Flow Rate Trial without trial drugs,
H3E-MC-V078,Characterize binding of Anti &Folates BrushBorder Kidney,
B9E-BP-O469,Gem/Carbo dose dense in advanced breast cancer,
B9E-FP-O470,IIT-Biliiary tract tumours B9E-FP-O470 /FFCD,
"10616",Placeholder for local support Olanzapine,
H7T-EW-TABO,CYP3A4 Probe Study Clopidogrel Active,
F1J-US-A005,SUI: Est of Basic Science Model for Eval of Pharmacotherapy,
"10701",NESDA,
"10713",Ph II Alimta/Carbo in AT Failures In MBC,
H3E-US-B001,Evaluating Choice of Txt in Observed NSCLC (Observational),
H6Q-MC-S023,RPhII Enz vs Faslodex vs Fas + Enz in Er + Al Failuares-Brst,
F1D-SP-HGEY,OLANZAPINE VS. HALOPERIDOL STUDY,
I1V-MC-EIAA,CETP SDSS,
B9E-AY-O476,Phase II study of dose-dense chemotherapy in early Br ca,
F1D-MC-X006,OLAN. SAFETY & EFF. IN PTS W/BORDERLINE PERSONALITY DISORDER,
B1Y-ME-I015,Influence of Serotonergic and Noradrenergic Systems in MDD,
H3E-US-X040,Ph I/II Alimta + Bortezomib in malignant effusion or NSCLC,
"10078",CB-1 C14 study,
"10126",PPAR gamma Delta Phase 2 study in Type 2 Diabetes,
B9E-MC-V251,HPLC Method for Analysis of Gemcitabine,
F1D-UT-O279,Staisfaction of bipolar patients with their treatment,
B7A-LL-A012,LY on SREBP-1c in mice,
I1I-EW-GECB,MDSS GLP-I AnalogV  PEG,
"10386",MDSS (14 day),
H8Z-JE-JACT,JP Survivin ASO P-I,
H3E-US-X052,"PhII Alimta/Carbo Ovarian, Peritoneal, Fallopian Tube Cancer",
"10535",Ph II - 1st line - Folfox/Enz - CRC,
B9E-MC-V283,An LC/MS method for the determination of dFdCTP,
I1A-MC-BPAF,ERbeta 14C Study,
H3E-MC-V081,Modulation of prostate tumour cell function/behav after pem,
"10685",Food Effect on the bioav of LY517717 D-tartrate,
F1D-MS-HGCD,PHARMACOKINETICS OF OLANZAPINE AND METABOLITES,
F1D-UT-HGES,OLANZAPINE IN REFRACTORY BIPOLAR/SCHIZOAFFECTIVE DISORDER,
"10892",Local placeholder for B3D-US-GHCV,
H7T-EW-TABV,CS747 Hepatic Impairment,
"10913",CTNR on depression in Parkinson,
F1J-SB-O019,A pilot study with fMRI,
F1D-CP-B028,Eval. of effectiveness of Solutions for Wellness program,
H3E-MC-V118, Effect of Alimta /vinorelbine against NSCL Cancer cells,
H6Q-MC-JCBU,Enzastaurin DDI w/Antacid,
F1J-US-X025,Prevention of Depression and Enhancement of Cognitive Recove,
H6Q-MC-S040,"Open label, Ph 1 safety enza+ bortezemib in multiple myeloma",
B5K-CY-B006,Non-Interventional Eval. of Educ. Program Diapartner (NEED),
"11178",Treatment of human pancreatic carcimona in nude mice,
F1J-LC-HMAO,PILOT BIOEQUIVALENCY STUDY: DULOXETINE HCL ENTERIC COATED,
H6U-MC-S004,LTD4-induced Wheal Biomarker Study,
H8O-MC-A009,Circadian Clock Reg of Appetite/Insulin Secretion ,
F1J-MC-SAAE,'ULOXETINE FOR URGE UI MULTIPLE DOSE SAFETY/EFFICACY STUDY,
F1J-JE-HMFH,"JP Dulo P-III DB Study Managed by Shionogi Company, Ltd.",
"11432",RBA Intravenous vs subcutaneous in NHV for LY2525623,
H3E-MW-S108,Efficacy and  safety of Alimta/Cis in gastric cancer,
"10891",Local placeholder for B3D-US-GHCV,
H3S-XM-O135,Study extension:Raloxifene at the osteoclastogenesis,
"11060",MDSS + Pain model,
F1J-MC-I010,Open label pilot of dulox in prevention of episodic migraine,
I1K-MC-GLUC,"Safety, Tolerability, PD and PK of LY2405319",
F1J-LC-HMAE,LY248686 HCL (DULOXETINE): INFLUENCE ON MOOD OF NORMAL VOLUN,
H6Q-MC-A024,enzastaurin efficacy in TCC with gemcitbine,
H7T-EW-B001,obs study of anti-platelet therapy post-PCI in ACS patients,
I1N-MC-CDBA,"Phase 1, Safety, Tolerability and PK study of LY2300559",
"11234",Drug Interaction Study: Sulfonylureas (glyburide),
H6L-MC-LFAX,Warfarin drug interaction,
"11349","Non Pivotal Phase II/III Emerging, Combo Therapy",
"11360",Ph III/IV Safety Study,
H9X-MC-GBCI,"GLP-FC restoration of 1st phase insulin, glucagon",
F3Z-GH-IOPA,humalog low mixture in insulin-requiring diabetic patients,
H8K-MC-JZAG,"Phase II: Ovarian Cancer, Advanced / Metastatic",
"10516",Local Placeholder for H3E-SB-S089,
F1D-XM-B026,Epidemiological study in Bipolar Patients,
F1D-MC-X014,OPEN-LABEL OLAN. IN SCHIZOTYPAL/BORDERLINE PERS. DISORDER,
H3E-MC-V072,"Folate Antagonist, Pemetrexed, against Carcinoma Cell lines",
F1J-MC-I003,Dulox to Tx OCD (obsessive compulsive disorder) - IND Exempt,
F1D-MC-X025,EFFECT OF OLANZAPINE VS RISPERIDONE ON COGNITIVE FUNCTION,
B9E-US-I156,PhI/II IMOxine w/ Gem & Carbo in Patients w/ NSCLC,
H3E-MC-JMIC,Ph 4 Alimta 2nd Line NSCLC (post commitment Taiwan),
B9E-MC-V314,Sensitivity of Human renal cell carcinoma to Gemzar,
B9E-MC-V320,Gemzar loaded novel cationic liposomes on adenocarcinoma,
H3E-MC-V097,Interplueral admin. of ALIMTA for malignant plueral effusion,
B9E-FP-O479,IIT-Breast - Gem+Paclitaxel  B9E-FP-O479 Namer /OSMO,
H6D-MC-X006,Tadalafil long-term therapy to alleviate recurrent priapism,
F1J-BL-O020,correlation between depression and cerebral apotosis,
H6Q-MC-V019,Enzastaurin with alimta in various cell lines,
F1J-MC-B022,Son of DUROSA trial,
B9E-US-X457,PhII Gem & Doxil for Metastatic Renal Cell Carcinoma,
H9P-MC-A001,Monkey trial for NERI IV,
H8O-MC-X001,Effects of Exen vs Lantus on Vas Function,
H3E-IT-V130,Pemetrexed and gemcitabine interaction in bladder cancer cel,
B9E-US-X459,PhII Intravesical Gem in Superficial Bladder Cancer,
H6Q-MC-V029,Enz and gemzar effects on pancreatic cancer cells,
"11325",Randomized Phase III Monotherapy vs SOC for STS,
"11358",RA- PhIII/IV - LY+MTX vs MTX (TNF INR on stable MTX;S&Sx),
F1K-LC-GUAD,LY203638(RAPC):DOSE-RANGING STUDY-6 AND 24HR INFUSIONS (II),
"11446","PhI, FHD for LY2447782 (Tumor Type TBD)",
"11493",Ph II Enzastaurin 2007 CRC Trial #1,
H6Q-MC-S056,Ph II Rituxan-based Therapy in DLBCL,
F1K-TW-O042,Clinical Effectiveness of Xigris in Combination with ECMO,
I1W-EW-GBFB,Multi dose safety /PET Study  (MDSS/PET),
H6D-MC-LVHP,Ocular Blood Flow,
"11696",Placeholder for exenatide regional trials,
F1J-MC-A008,Dulox on Substance P Release in the Spinal Cord,
"11704",Planning for LC000082 AKT-1 Inhibitor,
"10495", Local placeholder for B9E-SB-O422,
H7U-MC-IDBI,IDAS Extension,
H7T-MC-V005,Effects of Pras on PLT Pro-coag InVitro/ExVivo,
H7T-MC-V006,P2Y12 Evaluation,
H6D-EW-LVHM,PAH Clin Pharm Interaction Study #2,
H3E-MC-V108,Reversal of Alimta resistance colon cancer cell lines,
"10711",Ph II Alimta in High Risk Superficial Bladder Cancer,
"10773",US microalbumin and retinopathy concept,
B9E-MC-V305,PK + Mononuclear Cell Accumulation of Gemzar in Dogs,
"10836",FHD trial for furture cmpd FC000072,
H9T-MC-NABK,OpRa II C14 Metabolism study,
H9T-MC-NABM,Relative Bio-availability and Food Effect,
F1J-EW-E001,DULOXETINE A PILOT STUDY IN MAJOR DEPRESSIVE DISORDER,
H6Q-MC-V023,Enz and mantle cell lymphoma,
H3E-MC-A002,Repeated intrapleural chemo for MPM using mouse model,
I1L-MC-GAEA,SAM Classic/sibutramine combo Wt Loss Proof-of-Concept,
H6O-FW-O003,Pilot study - cell based bioassay for steroid hormones,
"11093",Glucagon -R Phase 1b/POC,
F1J-US-X028,The Efficacy and Tolerability of Duloxetine for the Treatmen,
"11111",Olanzapine obs study of pharmacological treatments,
"2389",Olz treatment of Children with Severe Emotional Disturbance,
F1J-JE-221G,EARLY PHASE II STUDY IN PSYCHOSOMATIC FIELD,
"11205",FHD for future Compound FC000083,
F1J-MC-HMAH,DULOXETINE 20/30 MG VS PLACEBO IN MAJOR DEPRESSION,
"11270",Mexican PK Study (Placeholder),
H6U-MC-X006,CYP2C19 Screening Protocol,
H6D-EW-LVHN,Elderly BPH Pharmacokinetics Study,
F1K-LC-GUAB,LY203638:DOSE-RANG.STUDY WITH SHORT INFUS. TO STEADY STATE,
F1K-MC-EVAA,RECOMBINANT ACTIVATED PROTEIN C (R APC) IN SEVERE SEPSIS,
I1F-MC-RHAE,Phase 2 - Efficacy of LY2439821 in RR Multiple Sclerosis,
H8Y-JE-HBBG,JP mGlu2/3pro II SD/MDSS,
"11487",Ph II ENZ (+Xeloda) Open-Label PGx Trial,
H6Q-MC-S049,Ph I/II Enz Pgx Trial in Pancreatic Cancer (Mayo) SPORE Gran,
I1X-MC-BDAC,"Phase 2, LY2525623 (LA328) Efficacy in RRMS",
F2X-LC-HIAC,DAPOXETINE HYDROCHLORIDE: ADME OF 14 C LABELED DOSE,
H4S-AY-X028,ReoPro Ambulatory Study,
H8R-MC-S002,PTSD Phase 1b POC study,
F1D-MC-A140,Stdy Effects of Chronic Antipsychotic Trtmt on Rat Adipocyte,
F1D-MC-A141,Antipsych Drug Reg of Neural SC & Neurogenesis Mamm Brain,
F1J-US-X042,A Placebo Controlled D-blind of Dulox for Small Fiber Neurop,
H8O-US-GWCO,Add exenatide to existing insulin therapy,
F3Z-FP-IOEB,LISPRO VERSUS ACTRAPID FOR EXTERNAL PUMPS IN DIABETICS TYPEI,
B9E-US-X464,PhI Bortezomib & Gem in Elderly Patients w/ Solid Tumors,
H9B-MC-BCDI,RA Open Label - safety follow up,
"11779",RA- PhIII/IV-LY+MTXvsMTX (MTX INR on Stable MTX;S&Sx,
"11785",China Local IIT Placeholder,
B1Y-EW-E071,FLOUXETINE TREATMENT OF BULIMIA,
H3E-US-I024,"Ph II Pem/Gem plus Avastin1st line chemo for elderly, NSCLC",
F3Z-MC-I005,INSULIN LISPRO IN A WOMAN WITH SEVERE INSULIN RESISTANCE,
H6E-AY-O014,Anti-inflam effect of Actos-acute stroke:double blind placeb,
"11919",DDI- Antibiotics,
"11945",CETP Combination Study,
F3Z-MC-IOBY,OPTIMIZATION OF INSULIN LISPRO ANALOG IN MAN,
H7T-MC-X002,Accu. in ASA resistant on Clopidin pts with CAD (DANART),
"11477",Efct of RBX in Pts w/Vision Loss <1 Month OD duration w/DME,
H4S-US-X029,non-randomized data collection on pts with acute MI (IIT),
F1D-MC-X300,Effect of Betahistine on weight gain due to olanzapine tx.,
H4S-BP-O074,Acute Intervention for ST-Elevation Myocardial Infarction: P,
H3E-US-I020,PhI Sutent & Alimta for Ovarian & Breast Cancer,
I1Q-MC-JDDE,Phase II Myostatin - hip replacement surgery,
"11717",Non-inferiority A1c Basal / NGS see commnets,
F3Z-EW-B004,TREAT Treatment Parameters for Optimal Glycemic Cntrl Type 2,
F3Z-IT-IOEC,OPTIMIZATION OF INS.THERAPY IN TYPE I WITH LYSPRO+HUMULIN I,
"11809",NPL PK/PD 1,
F1D-EW-HGMW,Zyprexa Adhera study in schizophrenia,
I2G-FW-ALBB,Single Dose Safety & Alcohol Interaction Study,
"11887",Phase1b POC,
B4Z-US-X055,Efficacy & safety of Atomoxetine & parent behavior training,
H3E-JE-SC01,JP Alimta ph1 SCLC,
H6D-EW-LVCS,ICOS Japanese EW study 1,
H3E-BP-V132,Lab study of genetic/receptor markers in MPM,
"11733",Combines Chemoimmunotherapy  with Dendritic/tumor fusion cel,
H7T-EW-TACK,BE Study-Assess in vivo performance of APIs of various size,
F1J-IT-O029,IIT Observational study on QoL in GP Patients,
B4Z-SB-O015,Driving Performance in ADHD Patients Treated with Atomoxetin,
F1D-KL-O304,Penn Alcohol Craving Scale (PACS-K) in Korean Alcoholics,
"11873",Multiple Dose PET Study,
F1D-FH-O307,olanzapine in bipolar disorder,
H7T-MC-V020,Clop AM analysis for rifampicin/Clopidogrel DDI study,
F3Z-CR-IOPI,Diabetes Nurse Educator study,
F3Z-MC-IODJ,PHARMACOKINETICS OF INSULIN LISPRO FIXED MIXTURES,
"12072",VTE Prophylaxsis #2 (Knee),
I2Q-MC-GMAF,MDSS in HV and T2D subjects,
B3D-AY-O015,PTH sensitivity testing for the diag of psuedo-hypoparathyro,
H8O-MC-GWCT,GWBR Extension (LAR vs Lantus),
B4Z-AY-O020,ADHD Controlled Trial Investigation Of a Non-stimulant,
F1J-MC-V001,Therapeutic Drug Monitoring of Duloxetine,
H8Y-MC-HBBO,"long term, open label",
H8O-MC-A016,Preservation of insulin gene exp by exen tx IV,
H8O-EW-GWCJ,Gall Bladder (BID),
F3Z-MC-IOCF,INSULIN LISPRO IN PREPUBERTAL PATIENTS WITH TYPE I DIABETES,
H9V-JE-GFRD,JP TGFb antibody P-II,
H7T-MC-TACM,Prasugrel Loading Dose washout estimated by Accumetrics,
"12036","A Double-Blind, Randomized, Placebo-Controlled Trial of Rimo",
F3Z-MC-IOFC,INSULIN LISPRO LOW MIXTURE:  LONG TERM MONITORING OF SAFETY,
F1D-MC-X307,Eval. risks of arrythmia & sudden death assoc w/anti-psych,
H4Z-MC-GJAU,Definitive Bioequivalence for Arzoxifene,
F1D-US-A149,Modeling a Putative Role for Oligodendrocytes in Pathophysic,
H4Z-MC-GJAW,Effects of Aroxifene and BP Comparator on Bone Turnover,
B4Z-TW-O021,Effect of Atomoxetine on Neuropsychological tests and fMRI,
H6D-MC-A013,Effect of tadalafil at a clinical dose on chloride secretion,
B9R-IT-O051,GH secretion in ps with or without HIV-related lipodistrophy,
"12275",Labelled LY2062430 ADME Study (Placeholder,
B7A-MC-V019,Mech. of Glucose-induced s-oxide production by rat,
B4Z-CR-B015,Ph IV Obs Study of Tx Patterns & Functional Outcomes in ADHD,
B5K-KL-O454,the effect of high fat diet in insulin pathway,
I1V-MC-EIAF,CETP Phase 2 Monotherapy/Statin Combo,
"12486",IIT Humalog - PLACE HOLDER,
B3D-HL-O020,The effectiveness of teriparatide in clinical practice,
F3Z-FR-O073,IIT - inter sans pdt,
F3Z-FR-V009,IIT - Dr Mallone - Ex NCR,
F3Z-VI-IODC,SAFETY AND EFFICAY OF LISPRO,
"12577",MCHR-1 C14 Study,
"12580",SPECT CRH-1 effort 3 receprtor Occupancy,
H9V-MC-GFRE,FHD Phase I Dose Escalation Study of LY2382770 - Metastatic,
H3E-BP-O042,LLCG ET study - ERCC1 directed in adv/met NSCLC,
I2K-MC-ZZAR,"8 Week Mid-Term Non-Elderly (1)",
H2Q-EW-LKAE,XANOMELINE TTS ADHESION AND PK OF PEPT PATCHESVSWOVEN TEXT,
H8C-MC-LQBT,OA pain Naproxen Adjunctive study #1,
F1J-MC-HMGE,Duloxetine Adolescent (13-17yrs) Fibromyalgia,
"12872",Dirucotide Open Label Extension - RRMS,
"11573",placeholder study for relative bioavailability 250mg tablet,
I1Y-MC-JFBA,FHD Study for Eg5 - LY2523355,
H6Q-JE-NS12,JP ENZ PhI comb w/ Alimta in NSCLC,
"11718",Non inferiority A1C BBT/ NGS - see comments,
"11746",preclinical evaluation of pemetrexed against cell lines,
"11787",China local IIT Placeholder,
B3D-XM-O013,THE ADMINISTRATION OF A BONE ANABOLIC AGENT ON THE ARTICULAR,
H3S-MC-I008,Raloxifene VS Letrozole  NSABP P4,
H7O-MC-S002,Collection of Blood Samples from Subjects with PCV,
"11882",Role of uptake transporters expressed in the kidney to the,
"11889",Bone & Muscle Biomarkers - Testosterone & Aromatase Inhibitr,
I2M-MC-GSDA,Phase 1 SDSS/POC Safety and Tolerability,
H7T-MC-V024,Effects of pras AM on Acc P2Y12 base channel formulation,
F1J-MC-B027,Retrospective psychobehavioral study,
H3E-US-I025,Ph I Alimta + Cisplatin & Paclitaxel given IP in Ovarian Cnr,
I1R-FW-GLBD,LY2409021 drug-drug interaction study,
H8G-MC-EPBN,Definitive BA/BE,
H7T-MC-TACN,Pras. vs Clop in Pts. of African Descent,
B9E-US-I163,Phase III Immed. post-TURBT Gem vs. Saline in Bladder Cancer,
"18686",ABA Placeholder,
"12041",Seamless Study,
B4Z-SB-B012,COMPLY Obs. Study Strattera Adherence + Compliance,
F1D-XM-O317,Validation of a cost benefit model,
"12101",MDSS in Patients with T2DM,
I2R-MC-BIAD,"Type 1 diabetes patients, Phase 2",
F1J-IT-O032,Safety and tollerability of Dlx. in elderly pts. with MDD,
"12259",Adhera Drug Needs for Marketing Demos,
H6D-US-LVHY,Sexual Health Counseling,
F1D-IS-O318,Genet'c chracteristics of schizophrenia mood and obsessive c,
I2X-MC-JBBB,Dose escalation in solid tumors w/MAK Inhibitor II/DDI/combo,
H3E-TW-B008,To identify use of EGFR TKLs or C/T in 2nd line NSCLC,
B9E-US-X470,Ph II Neoadjuvant Abrax + Gem + Dox + Cyclo in Breast Cancer,
"12545",Phase 2 Neuropathic Pain ,
H7I-MC-S008,Kinetic/Dos/Test/Retest H3 PET Ligand,
H3E-MC-V070,Alimta + Iressa in Lung Cancer,
"12574",CRF SPECT Ligand Dosimetry and Kinetics study (for CRH-1),
B3D-US-X019,Effect of PTH Combined with Weight-Bearing on Bone Density,
H9P-EW-LNBW,Bio-equivalence Study (Final commercial tablets),
H9P-EW-LNDA,Biopharm Ritonavir Study,
H8G-JE-EPBR,JP Factor Xa Inhibitor P-1b Prev CVA,
"12659",Evaluation of Memoirpen versus conventional injection pen,
B5K-GH-O456,insulin secretion in Ketosis-Prone Diabetes patients,
H2Q-LC-LZZG,"LY246708: PK SURVEY FOOD, DIURNAL & DOSE LEVEL EFFECTS",
"12761",Landmark Insulin Trail,
B1Y-EW-E083,FLUOXETINE: EFFECT ON WATER BALANCE IN DEPRESSED PATIENTS,
I2K-MC-ZZCC,Diabetes Drug Interaction,
"12862",BACE Renal Impairment Study,
H8O-MC-I013,Effect of Exenatide on Gatric Transit Time,
F1J-MC-HMGF,Elderly GAD registration study,
I3E-MC-MSAI,MINDSET-3: Dirucotide in RRMS,
"12880",R-Ph III-GemPro+/-(SOC) vs (SOC)-CRC,
B1Y-EW-E087,FLUOXETINE:EFFECT ON WATER BALANCE IN DEPRESSED PATIENTS,
B3D-US-X021,Role of PTH in Low Bone Mass in Anorexia Nervosa,
F1J-US-HMGK,OA pain vs NSAIDs,
H6D-MC-LVID,Cialis BPH EU Ph3 registration trial with Tamsulosin,
I2R-FW-BIAG,IV Adminstration of LY2605541,
H6D-EW-LVIK,Effect of Tadalafil administered OaD/PRN after prostatectomy,
I4H-MC-JWAA,"FHD p70 S6 Kinase/AKT Dual Inhibitor, ph1",
F1J-CA-O039,Early Detection of Antidepressant Efficacy Using Imaging,
H3G-LC-BGGA,DOSE-ESCALATION STUDY,
H8O-MC-A025,Bcell regen in IGT: Study of A1 Antitrypsin and Exen.,
I2Q-MC-GMAM,DDI #1,
"13218",DDI #2 - Placeholder,
I3Z-MC-GPDB,GPR119 MAD (Phase 1),
I3L-MC-LABC, LY2165766 POC in healthy subjects,
F1J-MC-O042,Success in Neuropathic Pain Patients,
"13282",PK Study to support add-on Indication,
H7T-BP-O003,Antiplatelet treatment in patients with diabetes mellitus,
"13310",BACE RelBioav ,
B4Z-US-X058,Atomox for the Treatment of Attention Disorders with TBI,
F1D-IT-O316,AD and Antipsychotics: a pragmatic RCT,
"12572",MCHR-1 Ph II,
H8G-JE-EPBM,JP fXa P-I SD/MD combine,
H8O-IT-B008,Exenatide use in real setting - Italian Obs Study,
B4Z-MC-B014,Claims database review of Atx and Cerebrovascular outcomes,
"12418", Phase 3 - LY2148936 3-yr Treatment Study (Placeholder),
F3Z-US-IOEZ,"COMP OF COMB T'PY GLYBURIDE / W LISPRO, METFORMIN OR NPH HS",
F3Z-VI-IOBP,SAFETY AND EFFICACY OF LYSPRO IN PAT WITH DIAB. MEL.,
"12480",PLACEHOLDER DUMMY TRIAL - Local Italy IITs,
"12483",PLACEHOLDER DUMMY TRIAL - Local ITALY IITs,
"12544",MDSS,
H7T-US-B007,Post Launch Observational Study,
H9P-EW-LNCK,Biopharm PGP study (Digoxine),
I2K-MC-ZZAN,"4 Week Efficacy",
I2K-MC-ZZAQ,Mid-Term PSG,
"12671",R-Ph III - GemPro +/- (S)C) vs (SOC) -3rd line-Breast,
"12685",DDI: Psychometric (antipsychotic) Assessment - placeholder,
"12902",Non Intervential prospective study of 5 parallel cohorts,
H7T-MC-TADG,Nominative ATU,
"1507",THIS TRIAL IS VOID!!            REFER TO TRIAL #1647,
H3E-CA-O043,Phase 3 2nd Line Therapy in NSCLC Alimta vs Erlotinib,
H3E-MC-JMAC,PH II TRIAL LY231514 IV Q 21 DAYS IN MET COLORECTAL CANCER,
I3P-FW-GKBA,Single Ascending Dose Study (SADS) w/DDI Arm for LY2608204,
H3E-MC-JMAN,LY231514 IN NON-SMALL CELL LUNG CANCER,
H8O-EW-GWDM,"""4B"" Add exen to Pts not achieving tgt on B/Ins or Glargine",
H3F-LC-GFAA,"COMPARISON OF PK PARAMETERS OF RGLUCAGON & ANIMAL IV, IM, SC",
H7T-MC-B011,IMS Database Study,
"13219",FRD Eg5 AML trial ,
"13292",Phase 2a Indication exploration study other population 1,
H8O-MC-A031,Role of Exenatide in Atherosclerotic Placque ,
F3Z-JE-IOPU,JP_Humalog mixture_Ph4_Open trial,
H8Y-EW-HBCS,Sleep EEG Study,
H3S-LC-GGGV,"RALOXIFENE:  GENDER SPECIFIC METABOLISM, WITHIN SUBJECT...",
F1J-MC-B037,Retrospective Obs Claims DB Hepatic,
"11048",Analysis of enz and TGF-b inhibitor in colon cells and xenog,
H8O-MC-X034,Exen for weight loss in obese ins resistant ind,
"4592",rhrhelerjöelrjöelkrjöelj,
ZYY-MC-O002,Endothelial Function Methods Study,
"12153",QTc Study,
"12247",ADHD Post-launch observational study (CHANGE),
B9R-JE-GDGO,JP hGH P-III SGA,
B1Y-EW-E078,FLUOXETINE V CLOMIPRAMINE TREATMENT OBSESSIVE COMPULSIVE DIS,
F1K-US-X006,Current Approaches in Management of Septic Patients in US,
I2U-EW-H303,MDSS/Calorie Intake,
H3E-KL-B009,OS for pts receiving 2nd-line chemo after 1st-line doublet,
"12337",LTB4 MDSS,
"12362","2 year add-on to metformin",
H3E-US-X075,Phase II Study of Alimta + Cisplatin in Cervical Carcinoma,
"12412",Placeholder Forsteo Device IIT Germany,
"12461",placeholder PRA thales observatory,
"12482",PLACEHOLDER DUMMY TRIAL - Local IITs  --ITALY,
"12502",PoC/Phase 2 CIAS (combo therapy),
H8O-MC-O008,NASH study,
"12523",IIT - Pr Raymond SU11248 + Alimta,
I2T-MC-LADC,OA Efficacy/Dose Finding,
H6D-MC-LVIR,MOA-BPH blood perfusion,
H6U-US-O009,MDD Remission Scale Validation study 1,
H3S-LC-GGHY,RALOXIFENE HCL: 30MG BIOEQUIVALENCE STUDY,
H7T-EW-TAEE,Switching to Pras. after Clop loading dose & before PCI,
B7A-MC-A016,Role of prot kin Cß inhib in tx ex diab cardiomyo,
H6U-MC-B003,GERAS:Cost and Resource Use of Alzheimer's Disease in Europe,
H9X-EW-GBDM,A Study by Scintigraphy to Evaluate the Effect of GLP-Fc o,
"13642",Phase 3,
"13680",mGlu5 Potentiator Effort 3 SDSS,
F1J-AY-O044,The Safety of Duloxetine for Breast feeding Infant,
B7A-MC-A026,Characterization of Endothelial Cell-Specific PKC bet,
H3E-MC-V147,Biomarker - Head and Neck - drug sensitivity/resistance,
H6Q-MC-A035,Pre Clinical -Akt pathways - colorectal carcinoma,
I4L-MC-ABEG,Ph III T2DM Non- inferiority Study for IMCT,
H7T-US-X010,Allergic Reaction,
H3Z-BP-JNAF,LY295501-PHASE I CLINICAL AND PHARMACOKINETIC EVALUATION,
H6Q-MC-V024,Enz resistance and efficacy in combo in cancer cell lines,
H9P-EW-LNCT,Biopharm DDI Sertraline Study,
H9P-EW-LNCW,Pilot QTC study - Part II,
H8Y-MC-HBCH,Hepatic impairment,
H2Q-EW-LZZR,TRANSDERMAL XANOMELINE:TOLERANCE/KINETICS FOLLOWING DOSE ESC,
"12753","3rd pain indication (undecided at this time)",
"12904",Olanzapine Early Response Validation Tool,
I1R-FW-GLBL,Fasting/Exercising Study,
I4D-MC-JTJA,"FHD, Chk1 II, Ph1 (Single Agent)",
"13135",Relative Bioavailability,
F1J-CA-O037,Duloxetine treatment of major depression in midlife women,
B4Z-SB-O026,Evaluation of a Psychoeducation Program for Parents ,
H4S-CA-O082,Hosp Upstream Abciximab Administration in PCI Transfers,
B1Y-EW-S001,FLUOXETINE SURVEILLANCE STUDY,
"13368",QTc,
F1D-SB-O328,Efficacy of early antipsychotic switch vs maintenance,
I5K-MC-DGAA,SAD/MAD study of LY2883255,
H6N-MC-LEAY,Renal Impairment,
"12731",iGluR5 GI Transit,
H3S-JE-202J,EXTENSION STUDY OF LY13948 HCL,
H9P-MC-LNDU,Taste study for pediatric formulation prototypes,
H4Z-MC-GJBF,Raloxifene to Arzoxifene Sequential Trial,
H3S-LC-GGHC,PK. OF ORAL RALOXIFENE HCL IN CIRRHOTIC PTS & NOR.VOL.,
"13442",Mexican PK Study,
I3U-MC-GRCC,Multiple Dose Study,
"13463",PK/PD Bioequivalence in T1DM,
B3D-MC-GHDO,"Hip Fracture, Phase III",
F3Z-CR-IOQD,Insulin Intensification  (Asia/China Need),
"13506","1-year efficacy in patients with comorbidity",
B7A-MC-V005,Effects of ruboxistaurin on vasc cell inflammation,
I2R-MC-BIDC,China MAD,
H9P-MC-LNDX,China MDD IMCT,
H7T-SB-O006,Prasugrel on peripheral NO dependent vasomotor function ,
B9E-GH-O511,Gem+Cis VS Gem+Pac as 1st line treatment in Adv Breast Ca,
H6Q-MC-A023,Enz and multiple myeloma,
I4V-MC-JADD,Phase II BID study,
I5S-EW-EFJA,PCSK9 Antibody Effort 2 Single Ascending Dose,
"14007",DPNP China IMCT,
I4V-MC-JADG,Open Label single dose C-14 study for LY3009104,
"14048",Asian Antiplatelet Obs Study in ACS Patients undergoing PCI,
B9E-GH-O510,Individualized 1st line chemotherapy for advanced NSCLC,
H6Q-MC-A048,Pre Clinical - Enz+Vori - intracranial glio xenograph,
"14158",Retreatment study,
H7T-FR-O013,MIMI study,
I2Y-EW-GHFV,Phototoxicity and photoallergenicity,
H4G-EW-LIAE,LY303870 PK COMPARISON OF TWO FORMULATIONS,
F3Z-US-X035,Diabetes Remote Care Management System,
H4M-LC-NRRA,LY307640: PK/PD IN GERD,
I4X-JE-JFCM,JP_Ph1b/2-Necitumumab+Gem-CDDP vs Gem-CDDP-Sq NSCLC-1st Line,
"14462",Tx of very insulin resistant obese patient with T2DM,
I5U-MC-ANBE,TQT,
H4Q-SB-V006,"LY333328 - GLYCOPEPTIDE, PHARMACODYNAMYC EVALUATION",
I1C-MC-JLBH,R-Ph II/III-GemPro vs Best Sup Care-2nd line-Mesothelioma,
H8C-MC-LQBQ,OA Pain #2: Double blind pbo cntrlld 3 arms (2 LY),
"12747",iGluR5  OA Pain 10 (PhIII),
H2Q-MC-LZZI,MUSCARINIC MECH. IN NEUROCARDIOVASCULAR CONTROL: XANOMELINE,
I3K-EW-LAEA,SDSS (FHD) mGluR5 Antagonist ,
F1J-MC-HMGH,MDD w/ comordity Chronic Low Back Pain,
H7T-MC-TADJ,"2C19 in MD clop vs. pras",
H3E-MC-JMAA,"LY231514 PH I, BOLUS INFUSION EVERY 21 DAYS",
"12971",Fistulating Crohn's Disease,
I1F-MC-RHBA,PS PH3-2LY vs Enbrel vs Plc 12wk primary Superiority,
"12983",Fistulating Crohn's Disease,
F3Z-CA-O072,Is GDM a Risk Factor for Cardiometabolic Syndrome?,
I1V-JE-EIAE,JP CETP Inhibitor Phase 2,
"13056",IIT place holder Arzoxifène,
F1D-US-A155,The Role of Accumbens Acetylcholine in Antipsychotic-Induced,
H3E-MC-JMBB,PHASE II TRIAL IN REFRACTORY COLORECTAL PATIENTS,
I3R-EW-HMID,mGlu2 ph2 #2 MDD,
F3Z-EW-IOPY,Comparison of PK and GD Profiles of U200 and U100 Humalog,
H6L-AY-S001,GP Education and Audit to improve diagnosis ,
"13459",Aura C2 Study,
"13470",Peritrochanteric Study 1,
I1L-MC-GAED,SAM:  Thorough QTc Study,
I3T-MC-PRAC,Trial for Progesterone Receptor Modulator PoC,
H6D-MC-LVIX,DRUG ONLY_Ph IV- 1st line Combo/Mono Ambrisentan+Tadalafil  ,
H7T-SB-O010,Early Thienopyridine treatment (ETAMI-Study),
I4T-IE-JVBD,REGARD-CP12-0715:R-Ph3-1121B+BSCvsPlacebo+BSC-Gastric-2nd ln,
I5B-IE-JGDA,CP15-0802: Ph 2 - 3G3 - Ovary,
H3Z-SB-JNAE,"CLIN/PHARM EVAL OF LY295501 ORAL/DAILY, 14 DAYS, METAS./CANC",
H6Q-MC-A046,Pre Clinical - PKC theta graft vs host & anti leukemia respn,
H8L-MC-IQAV,"""Memoir vs Luxura in Patients with Dose Forgetfulness.""",
H7T-DS-TAEL,Switching AntiPlatelet Agents-ticagrelor to prasugrel,
"14045",R-Ph II - Alimta vs Iressa - NSq EGFR + Mutation - NSCLC,
"13473",Lumbar Vertebra Study 2,
H8L-MC-IQAN,KwikPen simulated injection study,
H3E-MC-S132,Ph II-alimta+Carboplatin or Cisplatin+Erbitux-Head & Neck,
I5M-MC-FABB,FED Ferroportin Antibody HRA in MM,
H3S-LC-GGHT,RALOXIFENE HCL-WARFAARIN DRUG INTERACTION STUDY,
"13535",FED Randomized Phase 2 Study in Patients w/Met BC,
H8Y-MC-HBDB,MTD Study,
H3S-MC-GGGJ,EVALUATIONS OF EFFECTS OF RALOX. ON MARKERS REPRO. ENDOCRINE,
H7T-KL-B013,Prasugrel PMS (Post Marketing Surveillance) in Korea,
H8O-MC-A033,Role of Exendin-4 on transcription factors ,
H3S-MC-GGHG,"COMP OF RALOX, ESTROGEN & PLACEBO: UTERINE EFFECTS",
I4O-MC-BACC,BACE Inhibitor II (Phase IB/2A),
H6Q-MC-V053,Pre Clinical - Enzastaurin/Erlotinib Combo (invitro/Xenograf,
B3D-MC-O026,IIT: Efficacy of Teriparatide in Patients with New Forms of ,
H3E-US-I033,BATTLE-FL Biomarker-Integrated Study PtwNSCLC Tx-FL setting,
I4T-MC-JVBA,REVEL-CP12-1027:R-Ph3-1121B+Docet vs Docet+Plcb-NSCLC-2nd Ln,
"13666",GPR119 MAD,
H6D-EW-LVIS,Patient's choice of ED therapy on patient outcomes,
H8K-MC-JZAV,Renal Impaired ,
H7L-MC-MDAC,Exploratory study evaluating muscle atrophy and recovery,
I4J-MC-HHBA,Biomarker Study of Smoothened Pathway in Healthy Volunteers,
H6Q-MC-V061,Pre Clinical  - endometiral carcinoma cell lines,
H3S-JE-A009,Combination therapy with raloxifene and eldecalcitol in rats,
"13836",Bioequivalence Study,
H3E-MC-V149,Pre Clinical- Anti-metastasis role for Alimta in NSCLC,
I5A-IE-JAED,CP13-0708: Ph 2 - A12-mCRC-2nd Line,
"13975",Differences in anti-insulin antibody binding (Humulin -R) ,
"14029",QW/BID in severely insulin resistant pts who require insulin,
H4A-EW-XBAA,"ORAL SINGLE DOSE ESCALATION, PK AND SAFETY",
I4V-MC-JADZ,Ph 3 RA - MTX naiive patients,
H6Q-MC-V078,Pre Clinical - epithelial carcinoma xenograph and cell lines,
I5M-FW-FABA,FHD:Ferroportin Antibody (LY2928057) SAD study,
I5J-MC-NOAJ,RBA Exploratory Study,
H9X-MC-GBGC,Pediatric Study 2,
H4G-EW-LIAA,"LY303870,PHASE 1,SINGLE ORAL DOSE KINETICS,SAFETY,DYNAMICS",
I5E-MC-TSAN,Ph II Randomized 2-way crossover to PK steady state,
I5A-IE-X018,ADVL1221: PhII - A12 - Solid Tumors,
H3E-MC-V156,In Vitro Pre-clinical Study,
I4V-MC-JADP,Phase 2 Study of Patients with Moderate to Severe Psoriasis,
I4E-BR-JXBF,BMS CA225-346: Ph II-Erbitux+Cis+Vinorelbine-NSCLC-1st Line,
I3X-MC-JHTD,C14 in healthy male subjects ,
B3D-US-GHDV,Effects of osteoporosis on markers of bone formation,
I1V-MC-EIAP,Effect of Evacetrapib on Oral Contraceptive PK in H F Subj,
H8O-MC-X036,"Prosp study of patterns, predictors, and mech of weight loss",
H4S-MC-X005,DUKE UNIVERSITY MONITORING PROGRAM,
I3X-MC-A001,"Preclinical evaluation of L Y2784544, alone and in combinati",
F1J-MC-B050,"2012_200_Dosing and Daily Pharmacy Costs of Dulox Treatment ",
H4Y-MC-LJAM,Dose comparison of LY334370 vs placebo (liquid),
I4V-JE-JADM,JP JAK Phase1,
I3P-JE-GKBD,Japan Ph1 study w/Glucokinase activator II,
"14110",Phase IIB-MDD dose-ranging study,
I5A-MC-JAEO,R-PhIII-Gemzar+Tarceva +/-A12 - Pancreas-1st Line,
I3P-MC-GKBF,Phase 2 - Fixed Dose,
H4G-EW-LIAC,LY303870 SINGLE ORAL DOSE IN FEMALE VOLUNTEERS,
H8O-CY-O027,IIT-EXECUTIVE,
I5L-MC-TCAC,"767 Ph. 3 L.Term Safety in CF exocrine pancreatic Insuff.",
H8L-MC-IQBC,Safety and Tolerability Study of the Auto Injector in Health,
I5S-EW-EFJB,Multiple Dose Safety Study,
I5E-MC-TSAS,Body Composition trial - Testosterone Solution,
H9P-EW-LNEB,Biopharm Effect of Clarithromycin on NERI PK Study,
I3P-GH-GKBK,China Ph1 for GKA II (LY2608204),
H8Y-MC-HBDI,Long-term Safety Study Adolescent for LT trt. from other stu,
H9S-JE-JDCI,JP_Ph I - LA294+Bortezomib - MM,
"15329",Blosozumab Formative Human Factors Study #2,
I6M-MC-SSAC,BAFF/IL-17 Bispecific Ab Single Ascending Dose Study in RA,
H9X-MC-V001,ID of GLP-1 Target cells w/in gastrointestinal tract,
I4J-MC-HHBG,"SAD Single Ascending dose study with food effects, RBA, PPI",
I6A-MC-A002,Eval. FDG-PET as a PD after admin. of PI3/mTOR,
I4O-MC-BACM,Absolute Bioavailability,
H9H-MC-V005,TGFb RI Inhibition in Melanoma,
I6T-MC-AMAA,"FHD IL-23 Antibody II, Ph1 Psoriasis",
H6O-FW-S013,PK and PD effects of Intranasal Insulin in HV and MCI ,
I6U-MC-GHRB,POC T2DM,
I7I-JE-XNAC,JP MAD,
I6W-MC-TNAB,"TNFa/IL-17 Bispecific, Phase 1B",
I5S-MC-EFJJ,HeFH ,
"1513",Levodopa-Sparing Capacity of LY300164 in Parkinson's Dis.,
B3D-MC-B022,"2012-082_Study of Forteo Patients after Hip Fracture",
I7D-MC-SGAD,C14 STUDY,
"1525",Alternative formulation trial,
H3E-MC-JMIY,Ph II-Alimta+Carboplatin+Erlotinib-NSCLC-1st line,
H6D-SO-V016,Molecular mechanisms behind glucose uptake in muscle cells i,
I7E-AV-_A05,Evaluating the safety & imaging characteristics of 1451,
"15593",C14  ,
B4Z-US-B030,Chart Review Study of Atomoxetine Hydrochloride Monotherapy ,
"15672",Hepatic Impaiment,
H8L-MC-IQCW,Dulaglutide Supplemental Summative Study,
H7T-MC-V041,VerifyNow PRUTest to monitor inhibition of platelet function,
B1Y-HL-0006,FLUOXETINE IN BIGE-EATING OF OBESE BULIMIC PATIENTS,
I7E-AV-_A14,"18F-AV-1451-A14",
I4E-IE-W837,"Protocol CA225-094; A II STUDY OF OXALIPLATIN, CAPECITABINE,",
I4E-IE-W843,"Protocol CA225-251; A RANDOMIZED III TRIAL OF CETUXIMAB, BEV",
I4E-IE-W855,Protocol CA225-009; A II Study of  cetuximab/Paclitaxel/Carb,
I4E-IE-W864,Protocol CP02-9504; Ib/IIa Evaluation of Anti-Epidermal Grow,
"1598",Pediatric ADHD Open Label,
I8D-MC-AZEL,Particle Size,
B3D-LC-GHBD,Blood Draw in Uremic Patients,
I4T-IE-JVBN,CP12-0402: Ph1-1121B- Advanced Solid Tumors - 2nd line,
I4T-IE-JVBO,CP12-0604:R-Ph2-1121B +/- Dacarbazine -Melanoma,
H8O-MC-X026,Compliance & Adherence in Diabetes Pts: An ADA/Medco Study,
H3Z-MC-JNAC,PHASE I CLINICAL AND PHARMACOKINETIC EVALUATION LY295501,
"13961",FED Randomized Phase 2 Study in Pts w/prostate CA,
I1F-JE-RHAT,JP Phase III for Psoriasis (Switch to PMCT after J-approval),
I5E-MC-TSAC,Cialis PRN +Testosterone -Global,
H3E-JE-O063,JP_Ph II-Chemoradiation + Alimta - NSCLC (Placeholder),
"14046",Anti-inflamm effect of pras in ACS patients treated by PCI,
H6Q-MC-A047,Pre Clinical - Enzastaurin effect on PKD activation,
F1J-MC-HMGW,Double blind Fibro Adolescent study,
F3Z-FR-V010,IIT Chevenne,
H6O-EW-S008,Aromatase 5-alpha Reductase EET,
B3D-JE-GHDS,JP Teriparatide Phase 3 Fracture Healing,
F1J-US-X059,Dulox in reduction of pain in pts w/Syst Lupus Erythematosus,
H6U-EW-S012,Assessment of Cognitive Testing Methods,
I1R-MC-GLDF,PK DDI Study - Atorvastatin,
I4L-MC-ABEL,China IMCT T1 trial ,
H3E-UT-O066,Predictive markers for ALIMTA in patients with NSCLC,
B4Z-US-A014,Atomox microinject into prefrontal cortex delay discounting,
H3E-US-X086,PHII PlatinumbasedChemoNSCLC switch nonresponders NEOSCAN,
H6Q-MC-V081,Pre Clinical - TS gene copy and methylation status,
B9R-US-V008,Study of origin of irreversible endotherm:hGH&human insulin,
"14365",Ph II-Erbitux + Xeloda +Cisplatin - Gastric - 1st Line,
I4E-IE-I003,MED P02-06004:R-Ph II-Gem+Cis +/-Cetuximab-Urothelial,
H8O-MC-B016,UK PEMS,
I4V-MC-JADR,Placebo-Controlled Study Of Efficacy & Safety for Psoriasis,
H3E-US-I036,PHI/II Eval Panitumumab/Pem/RX then Panitumumab/Pem Thyroid,
I2M-MC-GSDH,Bridging Study for the Device,
I4V-MC-JAGD,Oral Contraceptives,
H4S-FP-EHHA,ADMIRAL:ABCIXIMAB BEFORE ANGIOPLASTY AND STENTING IN AMI,
"14668", NOP-1 and OPRA kappa PET RO with Buprenorphine,
I5E-MC-TSBB,Summative Human Factor Study-Production equivalent device,
I2R-MC-BIDH,PEG Vendor Study,
I1V-MC-EIAU,Bioequivalence of evacetrapib drug products,
H8O-MC-GWED,CN exenatide to existing insulin therapy,
H4S-MC-EFFA,ERASER:EVALUATION OF REOPRO & STENTING TO ELIMINATE REOSTENO,
H4S-MC-EWAI,EFFECT OF REOPRO AND TICLID WITH STENT PLACEMENT IN PTCA,
I4V-MC-JAGQ,"Phase 2, Double-Blind, Multi-site, Trial for DN",
B3D-IT-GHDX,The effect of Forsteo in Mid-head resection hip arthroplasty,
I6E-AV-_B04,Ph II/ III to eval dopaminergic degen. in mvmt disorders,
B3D-IT-O034,The effect of Forsteo in Mid-head resection hip arthroplasty,
H9D-MC-ITAI,T1DM Clamp,
I4O-MC-BACR,Definitive BE,
H4Z-LC-SDAA,"LY353381 HCl Single Dose, Dose Escalation in Healthy Women",
I2M-MC-GSDK,Phase 3 study of Blosozumab in Japanese severe OP patients,
I1F-MC-RHBM,Human Factor Study,
I6E-AV-_A04,"18F-AV-45-A04 ",
H4Q-MC-V001,LY333328 VS VANCOMYCIN--PHARMACODYNAMIC IN VITRO EVALUATION,
I6P-MC-FMRB,MAD-POC,
I4O-MC-BACK,Taste Study for BACE Inhibitor II,
H3E-EW-B014,"Retrospective, chart-based study of ALIMTA population",
H4Q-UT-V008,LY 333328 SURVEILLANCE OF RESISTANCE IN EUROPEAN ENTEROCOCCI,
I1R-MC-GLDB,Elderly PK Study,
H4S-MC-EEAB,REOPRO & PTCA IN FAILED THROMBOLYTIC THERAPY IN AMJ,
F1J-US-X063,Anal. 120 MRI scans from dulox vs placebo Tx chronic depress,
I6E-AV-RN08,France only IIT-Pilot study; PET imaging of early AD,
"14751",Ph. 1 AV-133 in healthy subj and subj with T1DM or T2DM,
I1V-MC-EIBE,CETP inhibitor - SIMCT Phase 3 MACE/China ,
"14810",Oral Sensory Eval of Intermediate Commercial Pediatric ,
H9H-MC-A007,TGFB signaling on the vasculature and vascular homeostasis.,
H9D-MC-ITAM,Safety & Effectiveness of Aura for BBT in Type 1 & 2 ,
H5M-SB-EIIB,Xipamide vs furosemide in pts. with coronary heart failure,
H4H-EW-LGAK,LY300164 vs. Placebo in Pts w Partial Seizures,
H4H-MC-I002,Effects of AMPA Recept. Blockade in Parkinson's Disease,
"15124",TQT,
I3O-MC-V001,Antitumor effect of LY2801653 or LY2940680 in BTC,
I6V-EW-S001,Early Exploratory for Thyrotropin Releasing Hormone,
"15080",Ph II - Ramucirumab + wkly Paclitaxel - MBC - 1st Line,
B1Y-FP-0738,FLUOXETINE LIQUID VS CLOMIPRAMINE TABLETS IN ELDERLY PATIENT,
H9H-MC-V010,melanoma cell plasticity and invasion,
I6I-JE-LMRG,FGF21vLA Japan Ph1 SAD/MAD,
B9E-MC-X032,Phase 2 Study of Gemcitabine in Biliary Tract Tumors,
H8L-MC-IQCK,BIL in reusable devices Summative Human Factors,
B9E-MC-X025,Phase 2 Study of Gemcitabine and Carboplatin,
I1D-MC-A003,Rational dev. of LY & irinotecan comb. in colorectal cancer,
I6K-EW-GLEG,CYP3A,
H3E-GH-B019,NSCLC Retrospective survey of Histological Diagnosis,
I7T-MC-RMAD,TQT Study,
H9H-MC-JBAY,Hepatic Impairment in noncancer patients,
"15558",Renal Impairment,
H3S-JE-O137,"Eff RLX vs EVL, comb in postmenopausal OP patients with CKD",
I2R-MC-BIDR,BIL vs. Degludec,
I3O-MC-A002,Targeting breast cancer metastasis using inhibitors of eiF4E,
I3G-MC-JGCF,Study of LY2584702 to probe for P70 S6K1 Inhibition,
H6Q-MC-V085,Therapeutic Targets for Cutaneous T-Cell Lymphoma (CTCL) ,
H3E-MC-B016,"2012-606_PhIV-Trtmt patterns/Cost Effect in1st Line-AdvNSCLC",
B4G-EW-LCCB,Efficacy of Pergolide in Restless Leg Syndrome (I),
F1D-MC-HGFI,Clinical and Economic Impact of Olanzapine in Schizophrenia,
I7J-EW-BCGC,MAD PK/PD AD,
I2I-MC-V016,Anaplastic Thyroid Carcinoma (ATC),
I4M-MC-MRAN,DDI Study w/ 3A4 Inducer,
I4M-MC-MRAO,TQT Study,
I8A-MC-URAB,Urocortin (LY3116168) MAD,
F3Z-MC-B018,"2013-569_Economic &/or safety outcomes assoc w/floor stock ",
I3X-MC-A002,aGvHD/murine Allo-HSCT models & human xeno-transplant models,
I8L-MC-IXAE,U100 Pilot PK,
F3Z-MC-IOGX,Lispro LM effect on overnight glycemic control in Type 2,
I2M-MC-GSDT,Formulation: Safety and Tolerability,
"2892",Renal impairment,
F1D-MC-X044,THE EFFECTS OF OLZ NV RX OF PSYCHOTIC SYMPTOMS WITH BPD,
I1R-MC-GLDM,Formulation Bridging Study,
I4T-JE-B001,JP_Ph IV - PMS - Gastric pts treated w/ Ramucirumab,
I6E-AV-I005,AV-45-IIT-005: Quantification of Brain Amyloid Burden,
H7T-MC-V038,Investigate Ticagrelor&Metabolite Binding to P2Y12 Receptor,
"15785",Evacetrapib- Lipid 2,
F3Z-MC-B020,U200 Risk Minimization Assessment Study - US #1,
H9H-MC-V017,ALK5 & Enza!utamide in Castration resistant prostrate cancer,
I6A-MC-E001,PhII- PI3 Kin/mTor Dual Inhib-Molecular Alloc-Urothelial,
I4E-IE-W806,Protocol CA182-003; BMS-582664 in Combination With Erbitux i,
I4E-IE-W848,Protocol CA225-117; II TRIAL OF FIRST-LINE THERAPY WITH GEMC,
I4E-IE-W922,Protocol CA225-109; EVALUATION OF THE ROLE OF EPIDERMAL GROW,
I8D-MC-AZEP,Absolute Bioavailability,
"16079",MAD-Taste,
H2Q-MC-LZYE,Behaviors in mod. Alzheimer's-global (B2),
F3Z-MC-IOQP,OPINION study using the QD IOQC Algorithm,
I7E-AV-E005,TAU IMAGING IN YOUNG-ONSET FOCAL DEMENTIA,
I7E-AV-E007,"PET Imaging of Tau Deposits in normal aging, MCI, and AD",
H9X-MC-B010,PMS EU PASS study 1 - Drug Utilization Study,
B4Z-MC-HFBK,Second Tomoxetine vs Pbo in Pediatric Outpatients with ADHD,
"1589",Pediatric ADHD-C,
I4E-IE-W908,Protocol CA225-101; A I study of CETUXIMAB in combination wi,
I4E-IE-W911,Protocol CA180-049; I TRIAL OF CETUXIMAB PLUS DASTINIB IN PA,
I6A-MC-V001,Comb. of LY & everollmus in pc model of hepatocellular cance,
F3Z-MC-IOQN,U200 Patient Preference Outcome - Claims,
I8D-MC-AZEB,DDI BCRP,
I8D-MC-AZEN,Renal Impairment,
I7E-AV-E020,"18F-AV-1451-EXIST-020",
I6E-AV-I021,AV-45-IIT-021: Multimodality Imaging of Cardiac Amyloidosis,
H6O-MC-GCEI,Early Exploratory Trial - Pain study with excipients,
I7E-AV-E021,"18F-AV-1451-EXIST-021",
I1V-MC-EIBU,BE,
I6F-MC-JJCF,C14,
I4V-MC-JAHF,Monotherapy in MTX-IR ,
I8B-FW-ITRG,URI-Citrate+Remodulin Ph1b T1DM PK/PD,
H2Q-MC-LZYC,Cognition in mild to mod. Alzheimer's-English speaking (C2),
I6E-AV-I038,AV-45-IIT-038: INSIGHT,
H9H-MC-JBEI,PK & ECG Study in Japanese and Non-Japapese HV,
I6E-AV-I026,AV-45-IIT-026: Italian DIAfN,
I6F-MC-JJCE,"Notch Inhibitor II. pH, food effect and QT SAD study",
I4L-MC-ABEU,BIV U100 new vial/BE study,
"16288",DDI Oral Contraceptive,
I4X-GH-JFCV,CN_Ph III - Neci + Gem + Cis vs Gem + Cis - Sq NSCLC,
"16331",Ph III - Ramucirumab + IO - Bladder - 1st/2nd Line,
F1D-HL-O341,A Nationwide Cohort Study of Oral and Depot Antipsychotics,
I8H-MC-BDCB,MAD Study,
J4A-LC-EZZL,Drug Interaction Study (renal),
I8L-MC-IXAN,Renal impairment,
"16474",Mechanistic biomarkers of glutamatergic intervention - POCM,
B1Y-MC-HCAM,FLUOXETINE / IMIPRAMINE OPEN LABEL BIPOLAR DIS.,
H9X-MC-B014,"2014-492 Early Truven RetroObsStudy Initial Dula Pts and Use",
I7E-AV-E030,"18F-AV-1451-EXIST-030",
I4E-US-X011,CA225-288 S0713 Oxal/Cape/Cet/RT Preop Therapy Rectal C,
"16291",China PK,
I4E-US-X017,CA225-223 R0522 ConcAcccRad+Chemo vs CAR+Chemo+Cetuximab H/N,
I1F-MC-RHCC,Ixekizumab Pediatric Psoriasis PK / Safety Study ,
I2V-MC-CXAD,"Ph Ia/Ib-CXCR4 + Anti-PD-L1 Combination-Pancreatic, Ovarian",
H9X-JE-GBGI,Dulaglutide 0.75mg vs Sita,
I7S-MC-HBEL,Ph2 Alzheimer’s Disease (AD) PoC,
B9R-MC-I018,IGF-IGFBP AXIS IN CHRONIC RENAL FAILURE,
I4X-JE-B004,JP_PMS-Ph IV - Necitumumab - NSCLC Sq - 1st Line,
I4V-JE-B006,Japan Akatsuki Dr-Pt Site-Based Observational Research ,
F3Z-MC-B025,Humalog U200 Patient and Physican Survey Study ,
J1E-MC-JZEA,FHD Ph 1 - PD-1/PD-L1 Bispecific - Unspecified tumors,
I4V-MC-JAJC,"1st Line POC in Crohn’s Disease",
B9R-BP-GDET,"GH WITHDRAWAL ON BODY COMPOSITION, EXERCISE AND WELL-BEING",
I1R-MC-GLBX, CV safety,
F1J-MC-B048,"2009-232-5_Amend- Cymbalta vs. Lyrica in Fibromyalgia",
"14830",Formative human factor study for IRMA,
I3X-MC-V001,Preclinical evaluation of L Y2784544 in acute lymphoblastic ,
I6N-MC-PTAA,Phase I: Ascending Dose,
I2I-MC-V004,"Inhib of DNA repair by Chk1in Diffuse Large B-cell Lymphoma,",
I6E-AV-_C02,Florbetapir (18F) PET providing amyloid burden info ,
"15090",Phase 2b MDD Comorbid AUD,
H6D-JE-B020,Post-marketing safety study of tadalafil treatment in Japane,
I2M-MC-GSDN,Renal (reduced) Study,
I6L-AV-_T01,uptake/retention: 18F-AV-133 in neuroendocrine/brain tumors,
H6D-CA-B021,Sexual QOL Questionnaire for men with Prostate Cancer,
I7J-JE-BCGG,MAD PK / PD AD - Japan Only,
H8L-MC-IQCL,BIL in Savvio Summative Human Factors,
H9X-MC-B003,Dulaglutide Risk Minimization (REMS) Assessment - 3 year,
I7E-AV-_A18,"18F-AV-1451-A18: A05 Extension",
I4V-MC-JAHT,axSpA ,
F1D-US-X158,Olz as an Adjunct to Antidepressant Pharmacotherapy for Comb,
I4V-MC-JAIC,DDI Study Pgp,
F1D-CA-O004,Gravidity of Women with Psychiatric Disorders 1989-1999,
"16757",Early Exploratory Trial- Triphosphate Excipient,
I7E-AV-E058,AV-1451-EXIST-058,
F3Z-MC-IOQV,Bravo Adherence Trial,
I8F-MC-GPGT,MOA Study - Hyperinsul+Gly Clamp in T2DM Pts,
H9X-MC-B020,Post marketing safety study of Dulaglutide w T2DM China,
I8F-MC-GPHI,"RBA: Thigh, Arm & Abdomen in low and high BMI HV",
"1726",LY396623 Infusion study,
B5K-MC-IBHJ,U500 Pump Safety Study,
I3Y-MC-B004,"2018-6963_GHO_Abema MBC:RWE-PH02 Flatiron spotlight/registry",
J1Y-MC-GZIA,SAD (SC) LY3487929 study in Healthy Subjects,
H8H-MC-LAIN,Effects of Daily Lasmiditan on Simulated Driving Performance,
B1Y-MC-HCJQ,Augmentation Obesity Trial,
B9E-MC-X048,PHASE 2 STUDY OF GEMCITABINE AND CISPLATIN IN BREAST CANCER,
J2G-OX-Y044,PhI-RET Inhibitor-NSCLC,
I6T-MC-AMBV,Miri Reformulation PK (RBA) HV,
J1O-MC-JZHG,AurA EGFRm NSCLC,
I4V-EW-B028,GPORWE (BSRBR-RA) - UK Retrospective Obs study,
J3F-MC-EZCA,FHD SAD,
J2G-OX-Y093,RET Inhibitor-NSCLC,
J2G-OX-Y140,RET Inhibitor-NSCLC,
J2G-OX-Y153,RET Inhibitor-MTC,
J2G-OX-Y162,RET Inhibitor-NSCLC,
J2G-OX-Y179,RET Inhibitor,
F1D-MC-I012,Parkinson's Disease,
J2W-NS-I001,ACTIV 2,
F1D-MC-X058,Olanzapine Treatment of Major Depression,
I8B-JE-B003,URLi Japan post marketing DBR,
I1F-MC-B016,"2019-9032: Persistance of anti-IL17 for tx of PsA in Spain",
I9R-MC-BSDB,LLY3374849 -MAD,
I6F-MC-JJCG,Absolute Bioavailability,
H7I-MC-S025,Use of digital hlth sol to improve migraine care UC,
I3O-MC-JSBJ,Ph II - Merestinib - NSCLC - 2nd Line - Exon 14 deletion,
H5H-MC-DDAC,LY355636 vs Metronidazole in CDAD,
I9E-MC-LAGB,Long Acting Glucagon Agonist SAD (LY3324954),
I4V-MC-JAHR,AS - bDMARD naive and TNF-IR,
"16609",PsA phase 2,
I3Y-MC-E013,Ph II - Abemaciclib+Necitumumab-Altered Sq Cell Cancers,
"16623",PsA cDMARD-IR ,
B3N-MC-EUAT,SR Dose Response,
I9G-MC-CCBB,MAD ,
I4V-JE-JAID,Japan-Eval immune response of Live Zoster Vaccine in RA Pats,
I4V-MC-JAIL,Maintenanc Study in pts with Moderate to Severe CD,
I5S-MC-EFKA,Autoinjector Self-Administration Efficacy Study,
B1Y-IT-0006,FLUOXETINE V IMIPRAMINE IN ATYPICAL DEPRESSION,
I4V-MC-JAIT,Mechanistic Study,
I8H-MC-BDCH,"12 Week BIF/High Dose Dula Phase 2 Study",
J2X-MC-PYAH,"Exploratory Low Dose 555, JS016 Combo in Mild-Mod COV-19 Pts",
H6O-AV-S014,ADDI Confirm EET,
B5K-SB-IBEC,USER-FRIENDLYNESS OF A NEW 3.0 ML PRE-FILLED INSULIN,
J2T-MC-KGBM,Long-Term Extension Study,
I8F-MC-B011,Study of annual incidence of Pancreatic malignancy,
"18598",OXM3 + LAGIPRA Combination Ph2,
"18649",treatment breast cancer,
J2G-NS-O011,LOXO IN COMB. WITH RITUXIMAB IN THE UPFRONT TRTX OF MCL,
B3N-MC-EUBA,Morbidity and Mortality of HTN patients Rx'd with moxonidine,
F1D-MC-HGGI,Olanzapine Relapse Prevention vs Placebo in the tx of schizo,
B9E-MC-I113,CHEMORADIOTHERAPY WITH GEMCITABINE BASED CHEMOTHERAPY,
B9E-MC-S039,Gem/Cis/ vs Tax/cis in ovarian-S039,
B9E-MC-S043,Ph lll Gem+Cis vs Gem in Panc,
H5P-MC-BWWC,PHASE II TREATMENT OF SIGNS AND SYMPTOMS IN RA,
H4Z-MC-JWWR,(JW11)  Phase 1 Prostate Biomarker Trial,
F3Z-CA-O010,Optimal Basal Regimen for NPH with Insulin Lispro,
"2208",S. pyogenes global surveillance study,
"2211",Postprandial control - Pt function/lifestyle impact,
H9X-MC-B004,Dulaglutide Risk Minimization (REMS) Assessment - 7 year,
H9D-MC-ITAN,URI via vasodilation w/ SNP,
"15431",Phase 2 Study #1,
I4T-JE-JVCW,JP - Ph II - Ramucirumab - Gastric - 1st Line,
I6S-MC-ASEE,Human c14,
"15497","MAD, with Part B OCP and Part C DDI cohort.",
I6E-AV-I022,AV-45-IIT-022: The Relationship Between Brain Iron Accumulat,
I7T-MC-RMAC,Food Effect Study,
I4X-MC-JFCP,Ph II-Necitumumab+nab-paclitaxel +Carbo- Sq NCLC-1st Line,
"15565",Adaptive Phase 3 Trial,
I4X-MC-JFCT,Ph I/II Necitumumab+Met mab2 - NSCLC - 2nd line,
H9X-JE-B005,Post marketing safety study of Dulaglutide w T2DM Japan,
F3Z-FW-ITCB,URI-Citrate Ph1b T1DM PK/PD,
H9X-MC-B006,"2014-130_UnderstandingHCP & patient inertia injectable thrpy",
H9H-MC-A033,Treatment of NF1-related plexiform neurofibromas with LY,
I3Y-JE-B008,JP PMS - Ph IV - Abema - mBC,
F3Z-MC-IORU,R6 Reimbursement Study,
H0P-MC-BP04,Intervention Specific Appendix - CLBP,
"17771",Crohn's Reformulation RBA HV,
J2G-OX-Y120,RET Inhibitor-MTC,
J2G-OX-Y130,RET Inhibitor-NSCLC,
I8S-MC-E008,Phase I/Ib study with the combination of RMC-4630 (SHP2 inhi,
J1I-MC-GZBF,Ph2a GGG Tri-Agonist obesity 48 wk trial with NAFLD addendum,
J2S-MC-GZMC,MAD POC 12-week study in T2DM Pts,
J2G-MC-JZJY,Dose Proportionality/HV,
H7I-MC-S022,EET Project MERLIN-Auto-Injector App HV,
I4V-NS-I005,WHO Bari-SolidAct,
"18317","Restore of Radioiodine Uptake by Selp, in Tyroid Cancer",
"18403","PF , AIIMIN-Autoimmune, Immunomodulators & Inflammatory",
"18454",N3PG IV Phase 3 trial		,
"18469",N3PG IV Dose Regimen Study,
J2G-OX-B006,"2021-10496:RETEVMO NSCLC-2L TC:multi-country retro chart ",
I9R-JE-BSDC,LY3374849 - J SAD,
I5B-MC-JGDT,China PK,
I9W-MC-IFDA,"SAD-Random,Double-blind,Placebo-Controlled,Single Ascending",
I5Q-MC-CGAY,China PK HV,
I6T-MC-AMBP,Drug-disease interaction study in patients with psoriasis,
F1D-LC-HGFN,OLANZAPINE:DRUG INTERACTION WITH ANTIHYPERTENSIVE AGENTS,
J1P-MC-KFAG,Phase 2 Trial in SLE,
"17293",MS Proof of ConceptStudy,
J1U-MC-JV01,Ph II - Lung Protocol Ram w/Doce Post IO/Platinum - NSCLC,
J1L-MC-JZGJ,Ph 1 - Pegilodecakin - 1L RCC (pembro + axitinib),
F1D-MC-X062,OLANZAPINE IN DEMENTED PATIENTS WITH BEHAVIORAL AGITATION,
B5K-MC-B014,"2018-7241 GHO TX Patterns Outcomes U-500R ",
J2E-MC-GZJA,SAD Study for LY3374849 in Healthy Subjects,
J2H-MC-IUAA,TANGO infusion set POC PK Pts,
H4W-LC-LLAN,"Bioavailability of Tablet vs Solution, Effect of Food",
B9E-MC-O007,"Phase     , Gem  & Cisplatin,  Nasopharyngeal Carcinoma",
B1Y-MC-HCCJ,FLUOXETINE/PLACEBO; FLUOX. OPEN LABEL ADOLESCENT,
B1Y-MC-HCJH,Assessment of the Effects of Antidepressants on Cognitive Fu,
B1Y-MC-HCCN,FLUOX COMPASSIONATE USE - OBSESSIVE COMPULSIVE,
B1Y-MC-HCCO,FLUOX VS PLACEBO IN OBESITY (PARALLEL; BLIND),
B9E-MC-S106,Gem+Ifosphamide / Ovarian,
B9R-MC-I021,Effect of GH and IGF-1 on children with short bowel syndrome,
B9E-MC-I090,ALTERNATING PHASE I/II OF TWICE WKLY INFUSION GEMCITABINE...,
"2572",Phase Curve Response,
B1Y-US-HCJD,"Fluoxetine, Paroxetine, and Sertraline Subjective Wellness",
"2599","PET scan (CNS, PK)",
F1D-US-A020,Effect of Olz. in the Fluid Percussion Model of Brain Injury,
F1D-US-V009,Olanzapine on NMDA Receptor-Mediated Neurotransmission,
"2657",Ph 1 Clin/Pharm Eval of LY309887 Admin Wkly in Metas Ca,
"2813",Investigator Initiated Studies Block for PTH,
"2838",Exploratory:  Use of Mixtures in Insulin Resistent Type 2,
"2897",GHRP: Oral Secretagogue First Human Dose,
H3E-MC-JMDC,PH III 1st line NSCLC,
I5Q-MC-CGAH,Ph3 acute episodic migraine prevention study #2,
I4E-IE-W814,Protocol CP02-0035; Anti-Epidermal Growth Factor Receptor (E,
I4E-IE-W905,Protocol N1047; III trial for adjuvant therapy with FOLFOX o,
A6J-SB-3066,VANCOMYCIN BY CAPD,
I8E-MC-APBC,PET,
I1R-MC-GLDO,CV Outcomes Trial 2,
F1J-MC-B055,Observational Trail for EUMA- not a clinical trial,
H9X-MC-B015,"2015-242 Evaluating Pts’ Prefs for Type 2 Diabetes TXs:Japan",
I8K-MC-JPDC,Ph2 POC in Sjogren's Syndrome patients,
I3Y-MC-JPCD,EXPANDED ACCESS-Ph II-Abemaciclib-Metastatic Breast,
I7S-MC-HBED,Taste Study,
I1V-MC-EIBS,Fixed Dose Combination Eva + Rosuvastatin,
H9X-KL-B017,Dulaglutide PMS - Korea,
B1Y-IT-0003,FLUOX VS IMIPRAMINE DBL MAJOR DEPRESSIVE DIS.,
I9C-MC-JZBA,FHD: Ph I - IDH1 Inhibitor - AML/MDS,
I8X-MC-JECB,LY3200882 C14 trial,
"18641",Relative Bioavailability HV,
"18643",Drug-Drug Interaction HV,
F3Z-US-X003,Preventing Post-prandial Hyperglycemia in Children,
B4G-EW-LCCW,Potential study in Cognition,
"18664",RBA/Food Effect Placeholder,
"18673",Loxo-PIK-23006-Ph1-PI3K-DDI: 2C8 Inhibitor,
"18674",Loxo-PIK-23007-Ph1-PI3K-Hepatic  Impairment,
"18695",PF QTc study,
H4Q-MC-ARRC,LY333328 Dose Escalation.  Gram-Positive Bacteremia,
H4A-MC-A008,Disseminated Candidiasis in Neutropenic Rabbits-Animal Study,
B1S-MC-I002,DOBUTAMINE ECHO VS PERSANTINE THALLIUM IN CAD,
B1Y-LC-HCCY,FLUOXETINE: CHRONIC HEPATIC DYSFUNCTION PATIENTS,
B9E-MC-JHQH,"Breast-Gemcitabine in Refractory Disease, Phase II--JH42",
B9E-MC-S018,Ph II/III Gem+Carbo vs. Carbo+MV/ Bladder ca,
B1Y-MC-X122,EFFICACY OF FLUOX & PLACEBO IN TX OF POSTPARTUM DEPRESSION,
B1Y-MC-HCAA,FLUOXETINE SINGLE BLIND INPATIENT,
H4Q-SB-V017,LY333328 neutrophil penetration & intracellular activity,
H4Z-LC-JWWF,Relative bioavailability of 20- and 50-mg tablets,
F1D-US-X090,olz. vs. hal. as initial treat. of adolescent-onset schizo.,
B5K-BP-S001,Atlas (HumaPen) Commercilisation Study in Type 2 Patients,
F1D-MC-X053,Augmentation of SSRIs Response in Refractory OCD using olz.,
J2G-OX-Y005,PhI-RET inhibitor-NSCLC,
"18443",Rest RadioI Uptake w Selp in RET Fus+ RadioI-Refrac Thyroid ,
J2G-OX-Y006,Ph1-RET Inhibitor-NSCLC,
J2N-OX-JZNC,LOXO-BTK-20006-Ph1-Pirtobrutinib-DDI ITZ/RIF,
F1D-MC-X068,Sleep &Cognitive Function in Psychosis Treated w/Olanzapine,
I1F-MC-B015,Phase 4 Psoriasis Pediatric,
J2G-OX-Y083,RET Inhibitor-MTC,
J2G-OX-Y090,RET Inhibitor-NSCLC,
J2G-OX-Y098,RET Inhibitor-NSCLC,
J2G-OX-Y108,RET Inhibitor-NSCLC,
"17971",SUT,
J2G-OX-Y181,RET Inhibitor,
I1F-NS-I010,Ixe in patients with COVID19 associated SARS,
J2G-OX-Y201,RET Inhibitor,
J2G-OX-Y206,RET Inhibitor,
J2G-OX-Y210,RET Inhibitor,
I4T-MC-B011,"2019-8681_GHO_ RAM 1L EGFR+ NSCLC (Korea)",
B9E-MC-JHDP,Gemcitabine in combination with RT in Stage III NSCLC,
B9E-MC-I036,"PHASE 2 STUDY OF GEMCITABINE, 5-FU, AND LEUCOVORIN",
B4G-EW-LCCG,RLS / Patch vs placebo,
B4G-EW-LCCH,Parkinson / Olanzapine + Pergolide (ClinPharm study),
B9E-MC-S065,Ph II Gem +Cis neoadjuvant to surgery; followed by XRT+Gem,
B9E-MC-S086,Gem+Cisplatin vs CMF / Breast,
B4G-EW-LCCY,Parkinson / Adjunct / patch vs placebo / E. morning dystonia,
B1Y-MC-HCDB,FLUOXETINE VS AMITRIPTYLINE DEPRESSED ADULT PTS.,
H3E-MC-JMDG,MTA +/- vitamins in Head and Neck Cancer,
H5H-MC-DDAD,LY355636 vs. Metronidazole in CDAD,
H5P-LC-BWWR,Particle Size,
F1J-LC-SBAO,Multiple Dose PK - Hormone Interaction Study,
H4W-LC-LLAP,Melatonin Bioavailability study,
F1J-MC-SBAU,European Open Label - Long Term Safety/Exposure(Trial #2685),
B1Y-MC-HCEK,FLUOXETINE VS. NORTRIPTYLINE IN MAJOR DEPRESSIVE DISORDER,
H4A-MC-XBAR,IV vs. AMB in Candidemia and Sys. Candidiasis in Neut. Pat.,
"2846","Study 1, Dose equiv, PK vs. NPH",
C2N-MC-JXAE,(J106) LY355703 plus Gemcitabine - Ph 1,
B5Q-TH-NCCL,The efficacy of Nizatidine in combination with amoxicillin a,
I8B-MC-ITRX,Drug drug interaction study,
F3Z-MC-IOHK,Insulin lispro LM and Oral Agent Combination in OHA failure,
I8L-MC-IXAR,BC3-CT015 T1DM pump PK/PD variability,
H3E-MC-B027,"2016-4207:Pt&PhysDecisionMaking&Attitudes-NSCLC-PtSvy",
"16734",Placeholder 1 for potential additional ClinPharm study,
H9D-MC-ITAR,EET (Clamp) with Lispro/Triphosphate,
I4V-MC-JAIK,Ph3 Induction Moderate to Severe CD Mixed Population,
I8B-FH-ITSE,Phase 3 T2DM URI vs Lispro,
"16837",Training Purposes only,
H8H-MC-LAHC,Evaluation of Lasmiditan PK in Migraine Patients ,
H8H-CD-LAHG,Driving Study(COL MIG-106),
H8H-CD-LAHI,Sumatriptan DDI (COL MIG-118),
"16943",Ph3-Olara+Gem+Doc vs Gem+Doc-Soft Tissue Sarcoma,
I5B-MC-JGDV,Ph3-Olara+Dox+Ifos-Soft Tissue Sarcoma,
I4V-MC-B013,RA-BELIEF OUS Observational Study,
J1B-MC-FRCH,Ph2b CSU study,
B3N-EW-EUCI,Pharmacokinetics of a 'Fourth Generation' SR tablet,
J1S-MC-JV03,Ph2-Radiotherapy+Abema+TMZ vs Radiotherapy+TMZ-HGG,
I9Y-OX-JDHM,LOXO-IDH-22012-Ph1-IDH1-QTc,
"18675",Loxo-PIK-23008-Ph1-PI3K-Renal Impairment,
"18742",Ph3 young adult TZP metabolic study,
"1901",Petty-Olanzapine and Learned Helpness (animal study),
B1Y-IT-M004,FLUOXETINE MAJOR DEPRESSIVE DISORDER,
B1Y-MC-X141,FLUOXETINE IN THE TREATMENT OF BINGE EATING,
B1Y-JE-1001,FLUOXETINE: PHASE I CLINICAL STUDY - SINGLE DOSE,
B9E-MC-S025,Gem+Dox(nav?) vs CMF in breast-S025,
B1Y-LC-HCCZ,FLUOXETINE VS AMITRIPTYLINE:ETHANOL INTERACTION,
F1J-JE-323G,JP P-III dulo DBT vs Mianserin Shionogi,
B1Y-MC-X140,PHARMACOTHERAPY IN PTS. WITH BORDERLINE PERSONALITY DISORDER,
H4Z-MC-JWWL,(JW23)  LY353381HCl in Premenopausal High Risk Population,
H3Z-MC-JNAT,P-II Eval of LY295501 in Treatment of 3rd Line Colorectal Ca,
I6T-MC-AMBO,Pain and Tolerability of Large Volume Delivery,
B9E-MC-JHPC,Phase 3 trial of gemcitabine in metastatic NSCLC,
I9Z-MC-OFBB,SD-PET and MD,
I8F-MC-GPGQ,Hepatic Impairment Pts,
J1H-MC-LAJA,SAD and Multiple Dose for PACAP38 Antibody,
B1Y-MC-B004,SSRI and Cardiac Valve Disorders,
"17149",Ph IV- Neci Ram Pem Gem - NSCLC,
"17200",Renal,
"17201",QTC,
J1P-MC-KFAA,SAD,
F1D-MC-V007,EFFECTS OF ACUTE AND CHRONIC TREATMENT W/OLZ ON NMDA AND AMP,
I6Q-MC-BIFF,EET Rosacea study Pts,
I4V-MC-B018,SLE Primary Data Collection Observational Study (Survey),
I7E-AV-E082,"18F-AV-1451-EXIST-082",
J1L-MC-JZGH,Cyto1000L/Gen3 PK Formulation Bridging Study,
"17353",Ph 1a/b - Basket Trial Pegilodeca + Chemo - Multiple Tumors,
H3E-MC-JMCM,PH II MTA + 5-FU DeGramont 1st line CRC,
I8F-MC-GPHT,China PK ,
I4V-JE-B022,Outcome validation PM study using MDV data in Japan (SI/Mal),
J1X-MC-GZHB,Mini-MAD (Oral/Intestinal) HV ,
J1X-MC-GZHG,MAD 4-week (Gastric) study in T2DM Pts,
I3Y-JE-I022,Obs/TR_predict_toxicity_Abema-BC_KBCRN,
I8B-IN-B004,URLi India Post Approval Commitment Study,
J2T-DM-KGAJ,Vaccine Responses in pts w/ moderate to severe AD,
B9U-US-AZDJ,EFFICACY AND SAFETY OF HIGHER DOSES OF LORABID DIFFICULT,
B3T-MC-JTAD,Ph 1 Study of LY335979/Mitoxantrone,
I6E-AV-I060,AV-45-IIT-060: COGFRAIL,
J2G-MC-JZJV,DDI HV,
I4L-MC-YCAA,CGM-based basal titration study,
H3E-MC-JMAY,Phase II NSCLC MTA + Cisplatin,
"18187",VC 4.0 test trial,
F3Z-MC-B030,Evaluation of hypoglycemia as a result of incorrect data,
"2972",Olanzapine in Human Breast Milk after Single and Multiple,
B9E-MC-X194,Gemcitabine and Cisplatin Phase 1 Study,
B9E-SB-O026,"Phase I, Gemcitabine & Carboplatin In Ovarian Cancer",
"3041",Euro-Region -Olz vs contro conversion from typical neurolept,
B5K-FP-IBEQ,"ACCEPTABILITY OF A NEW LILLY 3.0 ML REUSABLE PEN, HUMAPEN",
B1Y-MC-HZAH,FLUOXETINE PLUS PINDOLOL VS. FLUOXETINE PLUS PLACEBO,
B1Y-MC-O004,ASSOC. BETWEEN SEROTONIN TRASPORTER GENE & AFFEC. DISORDR.,
"3151",Olz in Tx of Children/Adolescents w/Bipolar Disorder,
B9E-MC-X056,Phase 2 Study of Gemcitabine and Doxorubicin,
"3211",Food interaction study,
"3218",Polysonography Paradigm Development,
"3236",OLANZAPINE IN THE PROPHYLAXIS OF MIGRANE,
F1D-US-HGHH,Reduction of Hyperprolactinemia & Assoc. Med. Morbidity in,
F1D-MC-HGHY,Sibutramine & Topiramate in tx of wt gn in schiz pts on olz,
"3292",BUS. PLANNING FOR POTENTIAL ALLIANCE FOR ID,
B9E-MC-V009,Role of Membrane Transport in Gem Cytotoxicity in Hematologi,
"3359",Imaging study - ligand development mice,
"3383",Olanzapine and Fluoxetine vs. Placebo for treatment of MDD,
I9Y-OX-JDHG,Loxo-IDH-21006-IDH1 Inhibitor-LY Oral vs LY Oral+IV (hAME),
J3N-OX-JZRC,LOXO-BCL-23004-Ph1-BCL2 Hepatic,
B3L-MC-LWAO,LY354730 vs.Placebo and Lorazepam in the Treatment of GAD,
"18502",FHD SAD/MAD in Healthies (Include 1G Jpn +/- Native Chn),
F1J-JE-311G,JP dulo P-III long term/ psychosomatic,
"18628",RBA - Food effect - Tablet formulation,
"1867",Void,
J1A-MC-KDAH,Ph3 LTE Safety Efficacy Study Peresolimab Mod-Severe RA,
B3N-MC-EUBS,Metabolic Effects of Moxonidine SR in Pts. with HTN,
"18887",Clinical Trial (Ph3 Trial 1: AD DM; LY v Pbo w/OLE) LM,
B9E-MC-X132,PHASE 2 TRIAL OF GEMCITABINE IN SMALL CELL LUNG CANCER,
B9E-MC-X062,PHASE 2 TRIAL OF GEMZAR IN ADVANCED SARCOMAS,
B9E-MC-X104,GEMCITABINE AND CISPLATIN IN CERVICAL CANCER,
B1Y-LC-HCJO,multiple dose steady state switch,
"1944",VOID,
F1D-EW-LOAT,Study of the Safety & Efficacy of IM Olanzapine in Patients,
B9E-MC-S026,Gem+Dox vs Tax+Dox in Breast- S026,
B9E-MC-S045,Gem vs Gem/Cis in Panc--S045,
B9E-MC-I099,Gemcitabine and Pre-Op RT for Pancreatic Cancer,
F1D-US-A023,Exam of Effects of Acute and Chronic Anti-Pyschotic Treatmen,
B1Y-BP-HC23,FLUOXETINE EFFICACY/SERUM LEVELS GERIATRIC PT.,
B9E-SB-O052,"Ph II, Gemcitabine & Carboplatin Neoadjuvant, In NSCLC",
"3820",Treatment of diabetic patients w/stable angina,
B3L-CA-LWAX,LY354740 in Patients with Early Parkinson's Disease: Tolerab,
"3867",PHASE 2 GEMZAR IN REFRACTORY/RELAPSED LOW GRADE NHL,
B1Y-MC-X081,HYPOCHONDRIASIS:  A CONTROLLED STUDY,
B3L-MC-LWAZ,LY354740 vs. placebo in GAD,
B3L-MC-LWBF,MGlur2 - Abuse Potential,
B9E-IN-O093,"Gemcitabine,Paclitaxel and cisplatin In chemo naive ovarian",
H6E-MC-GLAB,ACTOS vs. placebo,
"3992",CTNR Grant:  HOE901 Offense,
"4178",Timing for Lispro injection,
"4208",IIT Block Grants,
B9E-MC-V046,Determine chemosensitivity of ovarian carcinomas for gem,
B9E-MC-V052,Define cellular and molecular interactions of drug combinat.,
B1Y-MC-HCKF,JP fluox P-III PKPD Bridg CLCR,
"5801",Phase II Rand. NSCLC/LY317615,
"2191","Safety and Efficacy of IM olanzapine, acute non-organic psyc",
B1Y-MC-HCAI,FLUOXETINE / DOXEPIN OPEN LABEL,
B9E-MC-S060,"Ph III, Gem+Cis vs Gem+Carbo,  NSCLC Stage IIIb and IV",
F3Z-SB-S003,USE OF INSULIN LISPRO LOW MIXTURE IN HUMAPENS,
F1D-US-X097,Olanzapine in Childhood and Adolescent Schizophrenia,
"2385",A BIOEQUIVALENCE STUDY OF TWO FORMULATIONS OF CEPHALEXIN 125,
B9E-MC-S066,Ph II Gem q 3 wks vs q 4 wks/ NSCLC,
B9E-MC-S105,Ph II Gem+Cis - Ovarian Cancer,
F3Z-MC-IOMV,Lispro Mixtures Use During Ramadan (Asia Pacific),
B1Y-MC-HCDP,FLUOXETINE VS PLACEBO: LONG TERM TREAT. OBESITY,
B5K-EW-IBER,HumaPen (Atlas) Commercialisation II,
"2711","Smoking Cessation-LY354740 vs Placebo,Dose-Response Evaluati",
B3N-SB-EUBV,Mox. vs Metoprolol on Glycemic Control in HTN and NIDDM,
"2812",Competitive Response Studies Funding,
"2893",MGlur2 - Benzodiazepine interaction,
"2963",Additional Phase 2 trial - design unknown at this time,
B9E-MC-X181,Gemcitabine and Weekly Paclitaxel in Ovarian Cancer,
B9E-MC-X192,Gemcitabine (Bi-Weekly) and Doxorubicin in Advanced Breast C,
B1Y-MC-HCHJ,FLUOXETINE VS SERTRALINE AND PAROXETINE IN DEPRESSION,
B4G-BX-S001,PERGOLIDE IN THE TREATMENT OF OLD PARKINSON PATIENTS,
B9E-MC-V059,Investigate brain pharmacokinetics of gem in rats,
H6D-MC-LVCJ,SSRI- Treated ED Patients,
B9R-CA-GDC1,Extension to GDCT:  Humatrope:Tx to final height in Turners,
"4480",Olanzapine vs Resperidone Clinical Outcomes in Women,
B9E-MC-S154,Ph II gem + Doxil in recurrent ovarian cancer,
F1D-US-HGIZ,olanzapine vs. haldol in treatment of delirium,
"4552",MGluR2 - Food Interaction,
B4Z-JE-LYAN,JP atom P-I SDSSl/MDSS,
"4609",Rfsh - Safety of LY444301 in Hyper-reactive Airways,
B9E-MC-V072,Characterizing radiolabeled gem using PET,
B1Y-KL-O009,DEVMT OF TECHNIQUE TO PREDICT  RESPONSE TO SSRI,
B9E-MC-S179,Ph II Gem+Carbo+Taxol neoadjuvant followed by surgery-NSCLC,
H3E-MC-JMEU,Ph II Alimta in Bladder 2nd line therapy,
B9E-US-S188,Randomized Ph III Gem/Txtr v Txtr/Cape in 1st & 2nd Line MBC,
B9E-US-S189,Ph II Gem+Taxane+Herceptin Breast Neo Adj,
B9E-MC-S200,Ph II Gem+Dox Breast 1st line Metastatic,
B9E-MC-S208,Ph II Gem+Oxali->Tax Ovary 1st line,
B9E-MC-S209,"Gemcitabine Single Agent (Bladder, intravesical)",
B9E-BP-A006,Characterizing radiolabelled gemcitabine using PET,
B1Y-MC-HCKX,Fluoxetine Versus Celexa and Venlafaxine XR Differentiation,
B9E-MC-X280,"Phase I Trial of Gemcitabine, Cisplatin, and XRT in Pancreas",
B9E-MC-X300,gem/cyclophosphamide/dox./vincristine/pred in Nonhodgkin's,
B1Y-TW-0005,FLOUXETINE AND MAPROTILINE W PATIENTS W/MDD MULTI-CENTER,
H6D-MC-LVCW,Effect on Anxiety,
"4558",Cefaclor vs. Amoxycillin/Clavulanate in AECB,
"4983",FHD:  Single dose safety - Lilly Clinic,
"5029",R-Fluoxetine -- MDD in Elderly,
"5042",GAD / PANIC Efficacy Trial,
"5095",LY333328 S Pneumonia Model in Mice,
"5097",LY451395 Japan - first human volunteer study,
F1D-MC-HGJL,DNA Banking (weight change),
H6D-EW-LVDK,Multiple Dose Study (20mg),
F1K-MC-EVBC,Compassionate use for Sepsis,
H5N-MC-GFFK,Safety and Tolerability study in type 2 diabetics,
"5345",light therapy vs. antidepressants in SAD,
B9E-MC-V107,Determine mechanism of drug resistance to gem,
F1D-US-HGGV,OLANZAPINE IN BEHAVIORAL DISTURBANCES AND/OR PSYCHOSIS,
B9E-MC-S047,Gem + topotecan - SCLC,
F1D-MC-HGHD,Olanzapine vs Haloperidol in the Treatment of Acute Mania,
B4G-EW-LBBA,Pergolide patch in healthy volunteers (Clinpharm),
B5K-MC-IBEK,"Efficacy, Linearity, and Dose Response",
H3S-MC-GGIS,Ralox Male Study (Hypogonadal and Normal Men),
H3E-MC-JMAU,MTA + Carboplatin Phase I,
B1Y-MC-HCAG,FLUOXETINE / IMIPRAMINE OPEN LABEL,
"2248","Phase II, MTA _ GEM in 1st line Pancreas",
A6J-MC-O001,Vancomycin-Loaded Bone Grafts,
B1Y-MC-HCCK,FLUOXETINE/PLACEBO ALCOHOLISM,
B9E-MC-S102,Gem+Carbo+Tax vs TbA / Ovarian,
B9E-SB-O018,"Phase II, Gemcitabine &  Vinorelbine In Patients w/  NSCLC",
B4G-EW-LCDG,Parkinson Patch / Regulatory C (ClinPharm study),
B4Z-MC-LYAD,Adult Abuse Potential Study,
B1Y-MC-HCDR,FLUOX V PLACEBO OBESE ADOLESCENTS:PARALLEL/BLIND,
H4Y-BD-LJBD,Propranolol interaction,
F1K-LC-EVAL,APC Renal Study 3,
H4Z-LC-JWXB,CYP2D6 Drug Interaction Study,
F1D-US-A052,Antipsychotic Medications and Cortical Circuitry: olz vs.hal,
H7B-MC-LXAD,"iv proof of concept in Migraine,  LY293558 & pb as controls",
"5407",FED,
"5437",Safety and Efficacy of Buccal Insulin in Type 2 Diabetes,
B1Y-GH-HCLE,Fluoxetine in different departments in general hospital,
B9E-GH-O221,Gemzar+Cisplatin in Breast Cancer,
B9E-CP-O207,A ph I/ II of Tax + Gem as 2nd line treatm of pt w advan BC,
B9E-MC-X321,PhII carboplatin/gemzar in untreated ext small cell lung,
B9E-UT-V068,Effectiveness of Gemcitabine combined with hyperthermia,
B9E-MC-X326,PhII Gemzar/Irinotecan for previously treated CUP,
H3S-CY-O110,Raloxifene after alendronate in postmenopausal osteoporosis.,
"5666",Fellowship for Dr. Leticia Rao (FEL-052b),
B9E-US-V125,reactivation of the p53 pathway in cervical neoplasia,
B9R-HL-O011,Growth horm treatment in familial hypophosphataemic rickets,
F1J-LC-SBBN,Duloxetine - High Dose Mechanistic Study,
F1D-AY-O121,Olanzapine versus risperidone in early phase Schz,
B9E-BL-O241,"Neoadj therapy Gem, Vinorelbine and Cis in NSCLC IB,II,IIIA",
"5740","Patients formerly on Evista or Fosamax, put on active PTH",
H6N-MC-LEAG,Phase 2 study in patients with Alzheimer's disease - AMPA II,
H6P-MC-A001,Neurobiological basis of olz aug SSRI in TRD,
B1Y-MC-HCLH,Switching pts from flx 40 to twice weekly flx 90,
H6D-MC-LVEL,Eastern Europe Regional Trial,
F1D-TW-O130,Retrospective study in Taiwan,
B9R-XM-O022,STUDY OF PATIENTS WITH GH DEFICIENCY ON CHILDHOOD.REEVALUATI,
H3S-XM-O018,Ultrasound osteoporotic fracture prediction,
"6008",Major Depressive Disorder with Comorbid Anxiety,
"6052",Investigation of an fMRI method to study nicotinic agents in,
B1Y-MC-HCKB,Pharmacological Treatment of Fluoxetine-Assoc. Sex Dysfunc.,
H4S-MC-EWBD,ReoPro Stroke Phase III (Trial #1),
H5N-EW-GFFO,GLP-1 analogue - Formulation bioequivalence 1,
B9E-MC-S274,"DBL BLD Phase 3 Placebo,Postop Gem in SF TCC Bladder",
B9E-SB-O272,Gem/Docetaxel vs. seq. Gem and Docetaxel Phase II/III,
B4G-JE-YI01,COMPARISON OF PERGOLIDE AND BROMOCRIPTIN IN P.D.,
H3E-MC-S025,Placeholder for NSCLC,
"6205",Painful Neuropathy II,
H3E-MC-S029,Placeholder for Breast,
H3E-MC-S032,Placeholder for Breast,
H7N-MC-ECBA,Urine desmosine,
B4G-SB-LBAI,LOW-DOSE PERGOLIDE IN THE TREAT. OF TARDIVE DYSKINESIA,
H7R-LC-GCBF,PPAR Gamma Special Poplulations,
H3E-MC-JMCU,PH II MTA + Cisplatin Weekly,
B1Y-MC-HCFO,FLUOXETINE EFFECTS ON PSG OF DEPRESSED PATIENTS,
B9E-MC-I115,"Gemcitabine, Docetaxel, and Carboplatin in Bladder Cancer",
B9E-MC-X133,Gemcitabine and Vinorelbine in Breast Cancer,
B9E-MC-X204,Gemcitabine and 5-FU in Advanced Colorectal Cancer,
B9E-MC-X205,Gemcitabine and 5-FU/Phase 2/Pancreatic Cancer,
H6N-BD-LEAK,Fed Fasted/MDSS 395,
"3049",Dementia w/Psychotic Features:European Comp Trial,
B1Y-MC-HCHF,FLUOXETINE IN DEPRESSED PATIENTS WHO FAILED SERTRALINE,
"3051",Olz in treatment of substance abuse,
"3060",MTA + Low dose 5-FU C.I. 1st line CRC,
B1Y-MC-X162,Treatment of Obesity w/Phentermine and Fluoxetine,
B9E-SB-O030,"Phase I, Gemcitabine & Radiotherapy,  Pancreatic Cancer",
B9E-MC-I096,Gemcitabine and Cyclophosphamide  in Breast Cancer,
H3S-CA-GGJH,Health Related Quality of Life after Raloxifene Initiation,
F1J-MC-SBBH,"Duloxetine vs. Alternative Treatment ""Anchoring Studies""",
B9E-JE-N31D,Phase 3,
B1Y-BP-HC20,FLUOXETINE VS DOTHIEPIN D.B. PARALLEL STUDY IN MDD,
B9E-MC-X162,"Phase 1/2 Study of Gemcitabine, Cisplatin, and Decadron",
F1D-MC-HGIR,Depot Fixed dose study--No active comparator,
B9E-MC-S116,Ph 1 Gem + Taxol + Herceptin - 1st line breast,
B9E-MC-S124,Ph 2 Gem - adv recurrent adenoid cystic; Mar98SE103,
"3220",Neuroimaging Paradigm Development,
B9E-MC-X229,Phase 2 Gemcitabine/T Cell Lymphoma,
B5K-MC-I008,IMDIAB VI-MULTICENTER DOUBLE BLIND TRIAL,
B1Y-MC-X004,A DOUBLE BLIND PLAC CONTROL TRIAL OF PROZAC IN HUNTINGTON DI,
F1D-MC-O011,Temp cortex dysf in Neurodev. model of schizophrenia,
B9E-MC-X237,Gemcitabine for Elderly PPS NSCLC,
B1Y-MC-X009,FLUOXETINE IN POST-HERPETIC NEURALGIA,
H4A-JE-101L,ECB P-I SINGLE INTR,
H6C-LC-GKAA,"SD, dose escalation in healthy volunt.with MD component",
B9E-MC-V014,To determine the chem. shift of Gemcit. Metabolite,
H4Y-BD-LJBL,"multiple dose (II, high dose)",
H6C-LC-GKAC,MD Safety/PD dose-ranging in patients with obesity,
F1D-SP-HGID,Pharmacoepidemiology study of treatment of schizo in hospita,
B1Y-US-HCJY,U.S. SSRI Prospective Study,
B9E-MC-X242,Gemcitabine and Herceptin / NSCLC,
H6D-EW-LVAL,Food effect study on final formulation,
B4G-SB-LBAR,PERGOLIDE FROM COMB. LEVODOPA TO MONOTHERA. IN PROG. PARKIN.,
F3Z-SZ-O048,Self-adjusted Humalog doses for post-prandial control,
"6316",Observational study with Cialis. Spain,
H3S-BL-GGKT,CHOOSE LA - Evista versus bisphosphonates,
B5K-EW-E039,REGULAR INSULIN: SAF./EFFC.CARTRIDGES W/ COMPATI,
H7X-MC-JVAA,Rand Ph III (Regist) - Gem+Cisplatin +/- Affinitak - NSCLC,
H7X-MC-JVAB,Ph II -  Affinitak + Gemzar + Carboplatin - NSCLC,
"6463",Ph II - 5-FU + Affinitak - Pancreas,
"6483",Glucocorticoid Induced Osteoporosis,
B5K-MC-X007,EFFECTS OF INSULIN ON COUNTERREGULATORY RESPONSE,
B9E-MC-V149,PK Analysis of Gem and its Deaminated Metabolite,
B9E-MC-V150,Rxn of Two Generations of Cell Lines after Exposure to Gem,
B4Z-MC-LYBQ,Abuse Potential,
H4S-SB-O036,KOEBES: Acute Coronary Symdrome,
F1D-BP-O163,A naturalistic evaluation of atypical prescribing,
"3355",IPI pre-clinical studies,
"3476",Phase 1a pulmonary (new formulation),
"3494",NSAIDS interaction,
F1D-MC-I031,Effects of Olz on anticipatory cigarette craving,
B1Y-MC-X037,FLUOXETINE AND BUPROPION IN THE TREATMENT OF PMS,
H4Z-EW-V002,In Vitro evaluation of LY353381 in Breast Xenografts,
H5P-LC-BWWY,ELDERLY PK STUDY,
H6D-EW-LVAD,Single and Multiple dose study in Males and Femal volunteers,
B9E-BX-O047,"Phase II, Gemcitabine & Carboplatin , In Adv NSCLC",
B1Y-MC-X052,FLUOXETINE AND CUE EXPOSURE TO REDUCE ALCOHOL CRAVING,
F1K-LC-EVAR,LY203638 (rhAPC) Blinded Headache Study,
B9E-VI-O054,ErbB Receptor as Predictor of Response to Gem & Cis in NSCLC,
H6D-MC-LVBT,Pilot bioequivalence and food effect study (Glaxo study),
H6D-MC-LVBI,PD Study,
H6D-MC-LVBQ,Physiology Study,
H5Z-MC-LUAG,R-fluoxetine Open-Label Exposure study,
B1Y-BP-HC25,FLUOXETINE/IMIPRAMINE MAJOR DEPRES. (GUY HOSP.),
F1J-JE-312G,JP dulo P-III elderly pts psychartry Sionogi,
H6D-EW-LVAR,Nizatidine Interaction Study,
H6D-EW-LVAZ,Interaction study with Rifampicin,
B9E-MC-S139,Ph 2 Gem+Docetaxel vs Gem + Paclitaxel in NSCLC- Dec98SU104,
H6D-MC-LVBG,Dose ranging efficy in MED with daily dosing,
B9E-VI-O075,"Phase II, Gemcitabine & Vindesine, In Advanced NSCLC",
B9E-FP-O089,IIT-NSCLC  NON RESACLE -WITH A BI-MONTHLY CHEMIOTHERAPY,
B4G-SB-LCDJ,Efficacy of Pergolide vs. Bromocriptine as Adjuncs to Levodo,
H3E-MC-JMDU,Ph I/II ALIMTA + Epirubicin - MBC,
B9E-TW-O099,Gem plus Ifosfamide as second-line treatment for SCLC,
H5Z-LC-LUAP,R-fluoxetine Bioequivalence and Food Effect Studyi,
H5Z-LC-LUAN,R-Fluoxetine/Omeprazole Interaction Study,
"4157",C 14 Trial,
B9E-MC-X263,Sequential Gemcitabine/Carboplatin/Tirapazamine - NSCLC,
B9R-EW-GDFR,comparison of pk of Humatrope in Japanese (bridging study),
"4225",Commercial form bioequivalence,
F1D-DI-O057,Naturalistic Study of Cogn Funcn in Pts switched to Olanz.,
"4271","2nd Psychotic Depression study",
"7840",Hyperprolactinemnia Switch,
B9E-SB-O083,Gemcitabine vs. Docetaxel in NSCLC / determined second line,
"3819",Treatment of non-diabetic patients with inter claudication,
F1D-US-X151,Olanzapine in the Tx of Anorexia Nervosa,
"3853",Effects of Lispro Insulin on circulating leptin concentratio,
B9E-MC-X261,"Phase I Trial of Gemcitabine, CPT-11, and Taxotere",
B9E-IN-O094,Cisplatin and Gemcitabine in head and neck cancer,
B7A-LC-MBCK,ECG Composite Analysis,
H3S-IT-V004,In Vitro study on Raloxifene and Arthritis,
F1D-MC-X156,Olanzapine in Syndromal/Sunsyndromal Bipolar Disorder,
H6E-VI-GLAE,ACTOS vs. metformin,
F1D-BD-HGIO,Olanzapine Short-Acting IM Kit Testing,
F1J-MC-HMAW,Diabetic Neuropathy Pain,
B1Y-MC-X115,FLUOXETINE IN  DEPRESSED ADOLESCENT INPATIENTS,
B1Y-BP-HC29,FLUOXETINE/CLOMIPRAMINE 12WK IN MDD,
B1Y-MC-X120,FLUOXETINE FOR CHILDREN ANXIETY DISORDER,
B3M-GH-S023,Ceclor vs Augmentin in treatment of Otitis Media,
H3S-CA-O002,Double-Blind Trial of Evista as Adjunct Treat for Psychosis,
F1D-BP-O062,Typical & atypical neuroleptics and bone mineral density,
F1D-US-A043,Olanzapine Effects on Abuse Liability Properties of Amphetam,
"6598",Placeholder for local Zyprexa studies,
"6616",Placeholder for Alimta IITs,
B5Q-LC-NBBP,NIZATIDINE:EVAL. OF POSS. DRUG INTERACTION WITH ALCOHOL,
"6626",Early Stade Therap Alliance Zyprexa,
B1Y-MC-HCLM,Assessing the effects of fluoxetine during early treatment i,
"6676",Placeholder for Humatrope IITs,
B7A-MC-MBBC,SAFETY AND PHARMACOKINETICS OF LY333531 IN DIABETIC PATIENTS,
B9E-CA-JHPA,PHASE II STUDY OF GEMCITABINE/CISPLATIN  IN BLADDER CANCER,
B9E-MC-V167,Investigate possible synergybetween genistein & gemcitabine,
"6843",PH II CHF Exercise Tolerance,
"6853","Ph III Systolic HTN Elderly, ACE comparator",
F1D-KL-S037,Clinical effectiveness of switching to Zyprexa,
B9E-KL-S306,"Gemzar OS,  Bladder",
B1Y-GH-O025,"Comparison of characteristics,treatment reaction and economi",
B9E-MC-I049,PH. I TRIAL OF GEMCITABINE AND 5-FU IN REFRAC. SOLID TUMORS,
B9E-XM-O326,Gem-5Fu in continuous infusion in advance colorectal cancer,
H3E-SB-JMFT,"Ph I Dose-Escalating, ALIMTA+Gem+Cis in adv./met. cancer",
B4Z-MC-LYBY,Comorbid Substance Abuse in Adults,
"2680",Lithuanian Translation of the Zung Self Rating Depresn Scale,
B9E-MC-X041,Gemcitabine in Stage III and IV Non-Small Cell Lung Cancer,
B1Y-BP-0002,FLUOXETINE IN OBESE DIABETICS OVER THE AGE OF 60 YEARS,
"2840","LM vs. 30/70:  Testmeal study in Type 2, blinded",
"2847","Study 2, In/out-patient overnight BG",
C2N-MC-JXAD,(J105) LY355703 with Carboplatin - Ph 1,
"2862",Phase II Extension (SC Mealtime),
"2890",MGluR2 - Alcohol interaction,
B1Y-MC-HCJU,Fluoxetine and zatosetron in sexual dysfunction,
"2933",Efficacy Trial II - Depression,
H4Y-MC-LJBC,cohort,
B9E-MC-X199,"Gemcitabine, Carboplatin, Docetaxel, Vinorelbine/NSCLC",
B9Z-PH-AQBX,DIRITHROMYCIN TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA,
F1D-US-X095,Hyperprolactinemia in Premenopausal Women Treated w/Risp,
F1D-US-HGHG,Olz. vs. Risp. Treatment of Negative Symptoms in Older Schiz,
B1Y-MC-I005,FLUOXETINE IN PANIC DISORDER,
B1Y-MC-X157,LONG-TERM SSRI TREATMENT OF DEPRESSION,
F3Z-JE-M32H,Mix Open,
"3314",Phase II of ECB,
"3354",Void,
B1Y-SB-3048,FLUOXETINE COMPARED TO PSYCHOTHERAPY IN BULIMIA NERVOSA,
H6D-MC-LVCE,Pivotal On-Demand Therapy,
B1Y-SB-4017,FLUOXETINE 40MG ENDOGENOUS DEPRESSION VS AMITRIPTYLINE 100MG,
B1Y-SB-4018,"FLUOXETINE VS. MIANSERINE, DOUBLE-BLIND",
B9E-AY-O187,Phase 2 cisplatin & gemcitabine in malignant mesothelioma,
"4467","MTA Synergy, MTA & Gemcitabine",
"4468",MTA Assay,
"4627",Placeholder,
"4492",STERIOD INDUCED OSTEOPOROSIS,
B3M-PL-S012,Cefaclor vs Zinnat in AECB,
B3M-PU-S020,Cefaclor vs. Zythromax in AECB,
B9E-SB-O143,Gemcitabine intra-arterial in liver metastasis,
B1Y-FP-S006,Patient satisfaction with antidep. treatment fluo vs parox,
B1Y-BP-HC33,FLUOXETINE/IMIPRAMINE POST NATAL DEPRESSION,
"4615","Evaluation of IGF-I, IGFBP2/3  and VEGF",
F1K-LC-EVAX,LY203638 (rhAPC): Dose response and QTc interval,
F1D-US-X180,studying drug efficacy in specific schizophrenic behaviors,
B1Y-VI-HCKO,Fluoxetine in the treatment of PTSD in Turkey,
F1D-SN-LOBD,Effectiveness and Safety of Olanzapine in Asian Population,
F1D-US-A046,A Comparison of Olanzapine to Other Drugs in the Morris Wate,
B3D-US-X003,Investigator Initiated Trial,
"7164",Formulation BA#1,
F1D-OE-O187,Reduction of Zpyrexa induced weight gain by drug interventio,
"7226","Placeholder IIT, Buy Up for 2003, 2004",
F1D-HL-S054,RAIM,
"7332",Zyprexa Endocrine Disturbance,
"7359",placeholder local study dulox,
"7384",Placeholder for IIT Evista : X-rays screening,
B9E-MC-JHET,PHASE I GEMCITABINE AND CARBOPLATIN IN NSCLC,
"7414",Duloxetine Observation Trial,
"7463",Xigris Compasionate Use Study,
"7476",SCLC Phase II trial place holder,
F1K-FP-T001,ATU Xigris,
"7575",Effectiveness ot combination therapy of Actos and insulin,
B9E-MC-X011,PHASE II GEMCITABINE IN BREAST CANCER,
"7726",Xigris in Leptospirosis,
"7777",First break patient,
"7789",IIT Cialis 2004 (3),
B9E-MC-V213,PK evaluation of patients,
F3Z-SB-O026,"Metabolic recompensation, insulin resistance.",
B1Y-CA-O008,Eff. of Maternal Fluox During Lactation on Breastfed Infants,
F1D-US-HGIY,High-Dose Olanzapine,
B9E-AY-O191,Phase I gemcitabine & oxaliplatin in solid tumours,
B9E-FP-O136,ITT - FOLFOX- GEMZAR IN LOCAL.ADV.ORMETAST.PANCREATIC CANCER,
B7A-FW-MBCJ,Pharmacokinetics of  LY333531 in anephric patients,
"4550",MGluR2 - C14 study,
B9E-MC-V071,Characterizing gem + metabolites in bladder mucosa,
B1Y-SO-0703,FLUOXETINE: OPEN STUDY ON PATIENTS WITH MDD,
B1Y-SO-0705,FLUOXETINE V LOFEPRAMINE IN PATIENTS WITH MDD,
B9E-MC-S190,GemCarbo --> Tax vs Carbo/Tax --> Gem/Oxali (NSCLC),
F1D-US-A047,Olanzapine Reversal of Haloperidol and Risperidone Induced,
H4S-SB-O010,FAST-Hamburg Acute Stroke Treatment,
B1Y-MC-X208,Relapse Prevention in Anorexia Nervosa,
B9E-MC-V083,Use of in-vitro (neoadjuvant) chemo incl gem hydro-lung canc,
"7876",IIT Schizophrenia-2004,
"7921",Placeholder trail Pergolide NL,
"7943",CTNR: Gem + Alimta + Affinitak - Pancreas,
F1J-US-HMCR,Duloxetine vs. Escitalopram and Placebo in MDD,
B9E-JE-JHSJ,JP Bladder Cancer,
H6D-MC-LVFI,CV Observational Cohort Study,
B9R-XB-O031,Iodine nutritional situation and goitre prevalence in child,
B9E-US-S334,Rand Ph II Gem/RT with Gem/Carbo cons in IIIb/IV NSCLC,
F1K-US-V004,Factor Va Interactions Regulating Prothrombin Activiation,
"8112",PPAR CoAG Piolot Formulation-Bridging Study,
"8127",CV Safety Study,
B9F-MC-MBBF,PHARMACOKINETICS/SAFETY IN SUBFOVEAL AMD,
H8S-MC-A002,[11C] MPBM  Dosimetry Study in Monkeys,
H3S-VI-S045,Transition from HRT to Evista,
"8308",Dobretsov-Effect of LY on tactile hyperalgesia in rats,
B9R-JE-T01A,hGH P-III non-GHD turner,
F1D-US-HGLF,Zyprexa use in Higher Doses,
B5K-GH-O441,Effect of Humulin & TZD on Serum Ferritin in Type2 DM,
F1D-UT-O022,Olanzapine in Huntington Disease,
"3421",To determine the effects of administering continuous combine,
H5Z-MC-LUAA,Kinetics of R-fluoxetine in the Brain Using MRS,
B1Y-MC-X021,FLUOXETINE VS PLACEBO IN BULIMICS NONRESPONSIVE TO DESIPRAMI,
B9E-MC-S133,Ph lll - EU Adjuvant - Oct98SU94 - Pancreatic,
B1Y-MC-X033,FLUOXETINE IN MOOD DISORDERS FOLLOWING STROKE,
H4S-SB-EWAX,Stent vs PTCA in Small Coronary Vessels,
B9R-MC-I020,DIABETIC AND CARDIOVASCULAR RISK MARKERS IN OBESE GIRLS,
F1J-MC-HMBT,Diabetic Neuropathic Pain Open Label Exposure Study,
B1Y-MC-X045,FLUOXETINE TREATMENT OF DYSTHYMIC DISORDER IN OLDER PATIENTS,
H6D-EW-LVAE,Ethanol Interaction Study,
H6D-EW-LVAF,Interaction study with midazolam,
B1Y-MC-X168,Exercise vs. Fluoxetine in the Treatment of Fibromyalgia,
H6D-EW-LVBC,LY450190 Interaction study with an ACE inhibitor,
H6D-MC-LVBF,Dose ranging efficacy in MED with on demand dosing,
B9R-CA-O002,Cardiovascular Function in Adults with Growth Hormone Def.,
B1Y-SP-E063,FLUOXETINE VS CLOMIPRAMINE MAJOR DEPRESSIVE DISORDERS,
F1D-FP-S011,SCOPE Obs study on schizophrenic patients with acute state,
F1D-US-X188,olz treatment of marijuana and/or cocaine abuse among sch su,
F3Z-MC-IONS,Humalog Use During Pregnancy Retrospective Observational,
"4954",Dissolution study,
B9E-MC-V097,Gem as a substrate for cellular and recombinant deoxynucleos,
B5K-MC-IBFP,Use of PI in patients with asthma,
F1D-MC-HGJJ,Olanzapine + Sibutramine/Placebo in weight gain treatment,
B1Y-UT-0391,EFFECT OF FLUOX ON SYMPTOMS OF CHRONIC FATIQUE SYNDROME,
F1D-MC-HGJN,Olanzapine + Amantadine/Placebo in weight gain treatment,
H4Q-LC-ARRS,LY333328 Pharmacokinetics in Pediatric Patients,
H3E-MC-JMEN,R-Ph 3- ALIMTA+BSC vs BSC-NSCLC,
B1Y-VI-0004,FLUOXETINE/MAPROTILINE MAJOR DEPRES. DISO. OTPTS,
F1D-US-X192,Weight control on atypical antipsychotic meds.,
"5263",MDSS,
B3M-MC-AIKM,Cefaclor Pediatric Population Pharmacokinetic Study,
F1D-SB-0236,PET in preliminary and early stage of schizophrenia,
B9E-SB-S348,Gem + Carbo vs. Gem + Carbo split dose in NSCLC,
H3E-US-JMGS,Single Agent Alimta in Cervical Cancer,
B9E-MC-V228,Gem+2-Methoxyestradiol in Pancreas Cancer,
"8422","Ph III, ALIMTA vs. Capecitabine in Breast Cancer",
"8449",Pilot POC Alcohol Study,
H8Z-MC-A003,Labeling Survivin ASO,
H7Q-MC-EABD,GED-aPC Phase Ib/IIa POC Study,
"8532","Ph II, ALIMTA + Taxane in  Breast Cancer",
B9E-FP-O397,IIT-Breast B9E-FP-O397 GELYX / ICL,
"8570",Proof of Concept Type 2 Diabetes,
"8571",Obesity Ph 2,
B3D-EW-B002,European Forsteo Observational Study-EFOS,
H3E-SB-S041,Ph II ALIMTA-Pretx Pts w/ Unresectable/Met Pancreatic Cancer,
"8716",Expanded ED Benefits,
B9E-US-S366,Ph II - Gem+Rituxan relapsed pts after transplant - Lymphoma,
"8763","Ph I, 1st Line High Dose ALIMTA + Ca in NSCLC",
"8777",Ph II ALIMTA in Lymphoma,
H3E-MC-V010,Mechanism of Cell Death Induced by ALIMTA,
B9E-MC-S197,Ph II Gem+Paclitaxel vsGem+PaclitaxelvsGem+Docetaxel Breast,
B9E-MC-S202,Ph II - Gem + Oxaliplatin -  2nd line Ovarian cancer,
H6R-BD-LXAC,"PHASE 1b, SINGLE I.V, PROOF OF CONCEPT IN MIGRAINE",
B9E-FR-O158,ITT-Chemotherapy with gemzar-Amifostine-Cisplatin in advance,
B9E-SN-O162,Gem plus carbolatin in patients with Ovarian CA as 1st line,
B1Y-SZ-BN37,FLUOXETINE IN THE TREATMENT OF MAJOR DEPRESSION DISORDER,
B9E-MC-X290,"Ph2 induct.gem/cpt-11,2xwk inf.gem w/radiation in Pancreatic",
B9E-MC-S172,Ph II - Gem -Cisplatin - NSCLC,
B1Y-SZ-WA42,PROZAC IN DAILY PRACTICE IN FRENCH WEST AFRICA,
"9102",Oral Dissolve Proof of Concept,
"4925",Ph 1 Trial of LY335979,
"4929",Lower Dose R-Fluoxetine/Desipramine Interaction Study,
"4935",Monotherapy - Oral Failure,
H6P-MC-HDAI,TRD Maintenance Study,
B9R-UT-O005,"Growth, body composition, and GH treatment in Prader-Willi",
H6S-LC-GMAA,"Single dose, dose escalation followed by multiple dose study",
"5013",Phase 2 schizophrenia,
"5037",Multiple Dose Safety Study,
B9E-SB-O115,"5-FU/Folinic Acid/Gemcitabine in Colorectal Cancer",
B1Y-MC-X197,Pharmacotherapy of Adolescent Body Dysmorphic Disorder,
"3846",pulmIns P-I PK,
"3865",Registration phase ReoPro with low dose lytic,
B9E-MC-X259,Phase I/II Trial of Gemcitabine and Capecitabine,
F1D-CA-LOAS,cerebral effts of olanz after discont of typical neuroleptic,
B3M-FW-AJBD,Bioequivalence of Cefaclor CD 500mg & Reference Formulation,
B9E-TW-O098,Gemcitabine for advanced and  Metastatic hepatoma,
H5P-MC-BWXL,Phase I Allergen Challenge Asthma Trial,
H4S-SZ-O003,ReoPro in PTA,
B9E-MC-V027,Combined administration of gem + XRT,
B9E-BL-O111,PHASE II COMBINATION CHEMOTHERAPY WITH GEMCITABINE AND DOCET,
B9E-BL-O112,PEDIATRIC PHASE II STUDY OF GEMCITABINE IN CHILDREN AND,
B3M-SN-AJBE,Acute Bronchitis Study (no comparator),
F1D-US-X168,Impact of healthly lifestyle with serious psy disabilites,
B4Z-MC-LYAI,Long-term Open Label extension,
F1D-BP-O067,Rehabilitation for 'difficult to place' patients,
F3Z-CA-O032,Compare Health Care Costs on Insulin Treated Patients,
B4Z-XV-O003,Frontal disfunction in ADHD,
B9U-SB-AZCZ,LORACARBEF IN PHARYNGOTONSILLITIS,
H3S-SR-B004,Obs Study of Transition from HRT to Evista,
H7T-MC-TABG,CS 747 Phase III Secondary Prevention CVA,
H3E-US-S047,Ph I/II A/Carbo or A/Cis + XRT follow by A,
"9061",Perl/Hantman-Effect of PKC beta on the excitability...,
F1J-JE-HMDZ,JP Dulo P-I PK study using PET manage by Shionogi,
B9Z-MC-V024,EXPANDED STUDIES OF DIRITHROMYCIN AGAINST H. INFLUENZAE,
F1D-EW-E005,LY170053: OPEN LABEL SAFETY & DOSE RANGING STUDY,
"9197",Optimal duration Olanzapine treatment after maniac episode,
B3D-US-X006,Teriparatide Treatment for Low Bone Mineral Density Among In,
B9E-US-X423,PhIII Random Gem/CPT-11+Iressa vs Pac/Carbo/Etop+Iressa CUP,
"9238",Microneedle (Mixture) PK/PD Trial,
F1D-EW-HGBW,OLANZAPINE BIOEQUIVALENCE CAPSULES VS GRANULES,
F1D-EW-LOAC,SAFETY TOLERANCE PK PD OF IM OLANZAPINE VS ORAL IN VOLUNTEER,
B9R-UT-O012,"hGH, Oxandrolone, and estrogen treatment in Turner Syndrome",
H3S-US-X014,Comparison of Histomorphometry and microCT in Bone Biopsies,
B3D-EW-GHAG,"LY333334:COMPARISON OF PULMONARY,SC AND BUCCAL PLACEBO DELIV",
B3M-BL-S026,Cefaclor vs amox+clav vs levofloxacin in sinusitis,
"5429",Safety Using PI at mealtimes in type 2 pts,
F3Z-US-X008,Regular Insulin:  Enteral insulin use in preterm Infants,
B9E-FP-O212,IIT-NSCLC B9E-FP-O212 IFCT,
B9R-AY-O008,Modulation of Protein Anabolic Effects of Testosterone by GH,
"5627",Gem + Cys in Patients with Advanced Ovarian Cancer,
B9E-IS-JHRV,"randomised, open-label, phase IV",
B3M-MC-AJAP,CECLOR VS CEFTIN IN AOME AMOXICILLIN FAILURES,
H7F-FP-V001,Benzothiophenes and growth factor activities,
F1D-US-A107,Atypical Antipsychotics & Sensory Inhibition,
"5816",Japanese PK Bridging study,
"5817",Japanese PK Bridging Study,
B9E-MC-X338,PhIII Rdmize Gem/Carbo/Taxol v Gem/Vinorbline 1st line NSCLC,
H6D-MC-LVEC,ED Patients on Antihypertensives,
H6D-MC-LVEK,Pan-Arabic Regional Trial,
H7A-EW-LNAB,Single Dose Safety Study,
F1D-JE-304E,LY170053 PHASE 3 (LONG TERM) STUDY - QUALITY OF LIFE,
F3Z-XM-O059,Prevalence of metabolic syndrome/nutritional habits/CV risk,
F1J-MC-SBCT,Mechanistic Study (CHMP),
F1D-LC-HGAU,ORAL OLAN: SAFETY & P'KINETIC STUDY IN PTS. WITH CIRRHOSIS,
H8O-MC-GWAT,Long term effect on glucose control with Exenatide,
F1D-LC-HGAX,OLANZAPINE:SAFETY AND PHARMACOKINETIC STUDY IN ASIANS,
F3Z-JE-PV02,JP lispro mixture PMS Special population,
"9696",Nasal Study,
F1D-US-X266,Ph II Zyprexa & Aloxi for prevention of chemo induced N&V,
B9E-US-X441,Ph II Gem/Capecitabine/Bevacizumab in renal cell carcinoma,
H3E-MC-S076,"RPh II, ALIMTA -> Gem vs. Gem -> ALIMTA in Pancreas Cancer",
F1K-MC-X005,PC Profile Study in Acute Renal Failure,
B9E-US-X443,Ph II Evaluation Gem + Docetaxel & Filgrastim in soft tissue,
H3E-XM-O004,Alamo 3,
F1D-GH-LOBY,IM olanzpaine PK study,
"9983",MDSS in Treatement-resistance Depressed patients,
H9W-BD-GBEA,FHD (25-Oct-05): CB1 Antagonist SDSS,
B3M-PL-S011,Cefaclor 375 BID vs Augmentin 625 BID in ac Pharyngotonsil.,
F1D-XB-O075,Observational study about the weight increase associate,
F1D-US-X189,olz fir corticosteroid-induced mood changes,
F3Z-SB-O031,Study for the evaluation of Diabetes of the Elderly,
"4680",Antidepressant & gene modification,
B9E-MC-S181,Ph III-Adj Gem+Cis or MVAC or High Dose MVAC,
B1Y-SO-E033,FLUOXETINE-BIOCHEMICAL EFFECTS,
B9E-MC-S212,Ph III Carbovs.Taxoterevs.Carbovs.Gem+Taxoterevs.CarbovsGem+,
B9E-MC-S220,Gem single agent in Gallbladder cancer,
B9E-MC-JHRK,Gem Single agent in gallbladder cancer,
B9E-MC-S224,Ph I/II - Fixed dose Gem + Cis - Hepatocellular,
B9E-BX-O157,Gemcitabine and docetaxel in advanced TCC of the bladder,
B1Y-ME-HCKQ,Comparative study  of MDD in HIV positive patients,
B9E-MC-X285,"Gemcitabine, Cisplatin, & Methotrexate for Adv Bladder Ca",
F1D-BX-LOBG,schizophrenia outcome survey (obs. study vs. risp/haldo),
B9E-MC-X297,neoadjuvant gem/cisplatin in pt w/advanced bladder CA,
"4903",Schizophrenia PK/PD trial,
F1K-MC-EVBQ,EXTEND Biomarkers in 4 vs 7 days therapy,
"6005",Comorbid Anxiety in Alcohol Use Disorder,
H7T-EW-TAAE,CS-747 - Aspirin interaction study,
H7U-MC-IDAD,First Take Home Study,
B9E-US-S270,Ph II Gen/Trastuzumab in Pts w/HER2 Overexpressing MBC,
B9E-MC-S374,Ph III Gem intravesical vs observ in superficial bladder CA,
H3E-MC-JMFD,"Ph 2/3 1st Line NSCLC, ALIMTA/Cis vs Gem/Cis vs ALIMTA/Gem",
F1J-MC-HMCA,Fibromyalgia (second study or another pain indication),
H4Q-MC-ARRU,PHII Endocarditis Dose Finding,
B4G-SB-LBAP,PERGOLIDE VS.LISURIDE AS AN ADJ.TO L-DOPA IN S.D.P.IN PARKI.,
B9E-SB-O309,Phase II: Simultanous Radiochemotherapie in NSCLC,
B3D-MC-GHBY,Post-Approval Surveillance Case-Control Portion,
B1Y-MC-HCLK,void,
"6405",Olanzapine in the Treatment of Bipolar II Hypomania,
"6411",IIT Placeholder for CT Material Shared Stock,
B3N-SB-S004,Drug surveill. in pts. with hypertension and metabol. syndr,
F1D-IT-O032,Obs. study with RAIM in Emergency Dept.,
H6D-MC-LVDG,Period of Responsiveness,
"5082",Registration Pain,
B9E-MC-JHRO,Rand Ph II Gem+pacli vs Gem+carbo in met breast cancer,
"5173",GAD2:  mGluR2 Prodrug vs placebo,
H6D-EW-LVDM,Interaction of 20 mg IC351 with a statin,
F3Z-GN-O036,Use of CGM during CSII or MDI therapy in children (Type 1),
"5240",PPAR alpha phase I safety,
F3Z-JE-PV01,JP lisp PMS Hypoglycemia QOL(24w),
"5297",Bioequivalence study (powder to capsule LY404039),
F1D-FW-LOBI,PK/PD comparison of Olanzapine RAIM in asians & caucasians,
H7V-MC-GPAC,Phase II Efficacy Trial for Obesity,
"5415",MDSS,
"5443","Olanzapine treatment effectiveness,QoL and comlpiance in PK",
B3D-MC-GHAC,LY333334 IN TREATMENT POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS,
"5475",Central Penetration,
H4S-CA-O015,Leukocyte Adhesion Study,
B5K-MC-IBFW,Effects of acute hyperglycemia on cognitive function,
B3M-CA-V013,CEFACLOR IN VITRO GLOBAL SURVEILLANCE STUDY,
B9E-MC-O223,EVALUATE EFFICACY/TOXICITY OF GEM+CIS IN REFRAC DCL LYMPHOMA,
H3R-MC-I004,pEEG Profile of LY293558 and Narcotic Analgesics in Humans,
B9E-TW-O170,Weekly Gem with a Fixed dose-rate infusion for HCC,
"4946","Humalog or High Mix vs NovoRapid, equivalency clinical study",
H5Z-MC-LUAU,R-Fluoxetine Relapse Prevention,
H6Z-EW-LPBA,Single Dose Safety Study,
H7C-MC-LMBD,mGluR2 Prodrug vs placebo in Panic subjects,
F1J-MC-HMBR,General Anxiety Disorder,
B1Y-UT-0388,FLUOXETINE: EFFECT ON INSULIN ACTION IN OBESE NIDDM/CONTROLS,
B3T-MC-JTAN,IV short course LY335979 in AML,
H6T-XB-EOAC,Bioequivalence Trial for B-acetyldigoxin,
B1Y-MC-HCLD,Extension for Open Label HCKN,
"5245",A Phase II/III Study Sivelestat,
"5277",JP gem P-II Bladder,
"5281",Gemzar + 5FU combination study,
B9E-KL-O206,Gem-Cis in NSCLC  multicenter trial,
B3H-MC-L007,PH II RHB1.1 VS ALLOG BL IN ELECT SURG PTS WHO ANH,
F3Z-SB-IONN,PP microvas. blood flow post sc LP or HR vs healthy subjects,
B9E-ME-O224,Neoadjuvant Carboplatin/Gemcitabine in LANSCLC,
B9E-US-V124,Brain PK of GEM using microdialysis,
H4S-SB-O024,BRAVE 1:Pretreatment Reteplase plus Abciximab vs ABX in AMI,
H7Q-EW-EABB,aPC-II - Phase Ib Trial,
B9R-US-X034,Metabolic and hormonal characteristics of boys,
"5852",Bioequivalency Study,
F1D-KL-O127,One Year Longitudinal Follow up Study of Schizophrenia.,
H6D-MC-LVEF,US/Puerto Rico Regionial Trial,
H6D-MC-LVEG,EU Regional Trial,
B3N-MC-EUAU,LY326869 SUSTAINED RELEASE DOSE RANGING STUDYIN CHF,
B9E-XB-O256,Pharmacogenomics of gem-cis in NSCLC stages IIIb-IV,
B9E-XB-S280,Ph. II gem-oxali in advanc. bladder ca. in unfit pat.,
F3Z-XB-O038,FEATURES OF POSTPRANDIAL LIPAEMIA IN TYPE 2 DIABETIC SUBJECT,
"7445",Asian Duloxetine observational study on depression,
"5983",ph II gem-hercept. in metastatic breast ca.,
H6P-MC-HDAN,OFC Primary Care Physician Study,
F1K-US-EVBS,Pharmacokinetics in the Obese Patient,
F3Z-PL-O047,Humalog + NPH vs R+NPH in obese Type 2 patients,
H4S-SB-O029,RIO-ReoPro and Peripheral Arterial Intervention,
B4G-EW-LBAG,PERGOLIDE VS LEVODOPA AS MONOTHERAPY IN PARKINSON'S DISEASE,
"6078",Observational study Olanzapina RAIM,
H6N-MC-LEAJ,Screening Patients for Probable AD/MCI,
H4S-IT-O038,CARESS: Abciximab in Acute Myocardial Infarction,
B3M-GH-S030,Ceclor SR versus Cefzil in Treatment of AECB,
B9E-BX-JHLP,PHASE 4 STUDY GEMCITABINE COMPARED TO CISPLATIN/VINDESINE,
B9E-CA-JHDE,PH 1 STUDY OF GEMCITABINE/CISPLATIN/ETOPOSIDE IN SCLC,
"6760",PD study with 395,
B9E-IT-JHLS,GEMCITABINE AND RADIOTHERAPY IN LOCALLY ADVANCED NSCLC,
B9E-SB-O314,Gemcitabine and liposomal Daunorubicin in non-Hodgkin lympho,
"6902",Ph III HTN ESRD in renal patients,
B9E-MC-I012,"PHASE 1/2 GEMCITABINE, TAXOL, AND CARBOPLATIN IN NSCLC",
B9E-CY-O319,phase II Gem+Taxol 3-line testicular (germ cell) tumor,
B9E-US-X359,Ph II wkly Gem comb. w/ mo Doc in pts w/ Adv. Breast CA,
"7043",SSRI/SNRI Transition Study,
"7048",ASD Pilot in Burn Unit Patients,
H3E-US-JMFS,"Phase I, ALIMTA + Radiation in NSCLC",
H6D-EW-LVEW,LY450190 - Alpha blocker in BPH patients,
H7U-MC-IDAT,Pulmonary Insulin in Asthma,
F1J-MC-HMCL,Duloxetine pediatric depression (acute study #1),
"6339",Clin Pharm Special Population Study,
H4S-UT-O025,beta-radiation investigation with direct stentin and galileo,
"5732","Phase II, biweekly gem & docetaxel, bladder cancer",
B9E-MC-X335,Ph.II Wkly Docetaxol/Gem/Epirubicin Local Adv/Inflam Breast,
"5802",Postmenopausal women with MIs,
B9R-US-X033,Investigation of GHD in pts with OA and Short Stature,
"5845",PPAR-gamma Agonist Drug/Drug Interaction #1,
H6D-MC-LVEA,Scheduled Intermittent Dosing,
B9E-MC-S273,Ph III Gem + Txt vs Txt + Capecitabine - Breast,
B4G-JE-CS01,PERMAX:SPECIAL INVESTIGATION I FOR LONG-TERM TREATMENT OF PD,
B9E-MC-S278,Adjuvant - Ph II Gem+Cis - Cervix,
B9R-BX-O026,The Genetics of Growth Hormone Deficiency,
"6156",Oritavancin Other Study ( a placeholder study),
B1Y-BP-HC51,FLUOXETINE/AMITRIPTYLINE/PLACEBO  ALCOHOL INTERACTION,
B4G-PL-LBAM,EFFICACY/SAFETY PERGOLIDE:ADJUNCTIVE TX TO LEVODOPA-PARKINSN,
H7C-MC-LMBN,Cerebrospinal Fluid (CSF) Penetration,
H6P-MC-HDAO,Olan plus FLX in combination for TRD w/o psychotic features,
H3E-MC-JMFO,Ph I G FDR + Alimta Pancreas,
"6295",PPAR Coagonist Special Population,
H3E-MC-S019,"Ph2  ALIMTA + Carbo (AUC 6), 1 at Line NSCLC",
H6U-UT-LRAE,Cognitive Processes in Patients With OCD,
B7A-MC-MBDA,Effect of LY333531 on vascular beds (proteinuria),
F1D-MC-HGKL,Borderline Personality Disorder; Variable Dose Registration,
H6R-BD-LSAB,Placeholder study (visual symptomatology),
B7A-MC-MBDR,Non-Painful SDPN Treatment,
"6387",GLP 1 - analogue - Drug/drug interaction 5,
F3Z-MC-O049,Impact of Humalog on Post Prandial Lipaemia,
B9E-MC-V145,Yeast as a Model Organism to Study Mechanism of Gem Action,
"7436",Safety Register,
B9E-IT-JHSC,GEM TXT in 2 diff. comb. and GEM Cis f.wed by TXT in NSCLc,
B5K-SE-9184,HUMULIN MIXTURE CLINICAL TRIAL,
F1J-BP-SBBW,Duloxetine SUI Study,
"6612", SERT Trial  /  SSRI Dose-Occupancy Curve using SPECT Ligand,
"6615",Placeholder for Gemzar IITs,
F1D-UT-O166,"Olanzapine versus Risperidone, adol.",
H8F-EW-LGCA,Single Dose Safety Study - SDSS,
H6N-MC-LEAM,FED in Alzheimer's,
"6782","Schizo Care and Assessment Prog (SCAP), Global Data Pooling",
B4Z-SB-LYDE,Local  German Atomoxetine Study with adolescents,
B9E-US-X365,Prolonged Inf Gem & Mitoxantrone in Relap/Refrac AML,
B9E-MC-V205,peptide transporter targeting of gemcitabine,
H8L-MC-IQAA,Comp. of Inj. React. w/ Needle-Free vs. Conv. Needle/Syr.,
B9E-US-X368,Ph II Gem & Cis Unres. Met Biliary Tract & Gallbladder CA.,
F1D-FP-S045,dvlpmt. and valid° of an outcome instrmt. in schizophrenia,
B9E-MC-JHEK,GEMCITABINE & CONC.RADIATION IN ADVANCED HEAD & NECK CANCER,
"7366",In Vitro Study Prof. Rotella,
F1J-SB-S010,Duloxetine vs. Comparator in MDD,
"7453",Gem-Platinum as 1st-line in locally advanced NSCLC,
H3E-FP-S044,Neoadjuvant mesothelioma phase II,
"7516",Pergolide vs Ropinirol:sleepiness § watchfullness assessment,
H6K-MC-IIAH,Phase 2 - LY452504 in diabetics,
B9E-AG-B001,Gemtro Observational Study,
"7568",Borderline Personality Disorder Maintenance Trial,
B1Y-BP-X087,THE ROLE OF 5-HT IN COGNITION AND MOTOR CONTROL,
"7622",Gemzar in Breast Cancer,
"6808",Multi-dose safety study,
B9E-IT-JHPF,GEMCITABINE-VINORELBINE-IFOSFAMIDE IN NSCLC,
B3D-LC-GHCE,Bioavailability trial for teriparatide for needleless SQ,
"6830",Capsule/tablet bridging study,
H6K-MC-IIAG,Single-Dose Safety Study in Diabetics,
B9E-MC-I004,PH I STUDY OF GEMCITABINE IN PTS. WITH ORGAN DYSFUNCTION,
B3M-KL-AJBT,Ceclor III syrup- influence treatment behaviors and actively,
B9E-LC-JHSG,SDSS/MDSS for gemcitatbine HCV,
F1J-AA-HMCV,Duloxetine MDD IMCT- Local Registration Trial,
B9E-XM-O320,ph II gem-vin-cis followed surgery-rdt-docetaxel NSCLC,
"6951",GI Regional Absorption Study,
H7U-MC-IDAJ, Upper Respiratory Infection Pulmonary Insulin Trial,
A5K-LC-ABBB,SEROMYCIN: BIOEQ OF A MARKETED VS NEW FORMULATION,
H3S-FP-O026,relation between the BMD and osteoporotic fracture incidence,
"7042",Benzodiazepine Transition Study,
B9E-MC-I059,"GEMCITABINE, ADJUVANT RADIAT., & 5-FU FOR PANCREATIC CANCER",
B4Z-MC-LYBT,BID vs QD in Stimulant Nonresponders,
B4Z-MC-LYBV,Functional Outcomes in Adults,
B4Z-MC-HFBC,SAFETY & PK STUDY OF TOMOXETINE IN PEDIATRIC OUTPATIENTS,
"6375",C-14 Study LY450108,
"6386",GLP-1 analogue - Drug/drug interaction 4,
B9E-MC-S284,"Ph I - Gem + CHOP, 14 day - Lymphoma",
A3Q-FW-AFBN,"250 mg Cephalexin bioequivalence study",
H7X-MC-JVAF,Rand Ph II - Gemzar + Cisplatin +/- Affinitak - NSCLC,
F1J-US-HMBY,"Dose Escalation, 2-Blind tx with Dulox QD for Safety in MDD",
"6516",Phase II Trial of Carbopltn/Gem and Bexarotene in Tx of NSCL,
F1J-UT-S004,Observational study.,
H6M-MC-LDAP,In-pt Pk/PD MDSS in MCI pts with LY450108,
"6684","Placeholder for GeNeSIS, B9R-EW-GDFC, Impact No 2712",
F1D-XM-O168,Olanzapine's efficacy in treating of delirium,
F1K-MC-EVBR,Study of low-dose heparin in patients with severe sepsis,
"6801",SD/MDSS in healthy subjects,
B9E-US-X350,Ph II Trial of Gem as Single Agt in Refrac/Relpse Mltpl Myel,
B9E-US-X362,Ph I Irinotecan w/ Gem given fixed dose rate infusion.,
B9E-US-I150,"Ph II Ind Chemo w/ Carb, Gem & exisulind for early stg NSCLC",
"7037",Imaging Study (C-13 Glucose  Part B),
B9E-US-S311,Gem/Herceptin vs Gem in Metastatic Breast Cancer,
"7227",UK Duloxetine UI IIT - Protastectomy,
B9E-MC-V195,Prove whether chemotherapy induces NF-KB activation in human,
B9E-TW-O335,Phase II of GV vs PGV for NSCLC (VGH-TP),
"7307",Hgh,
F1D-US-X224,A Randomized Double-Blind Placebo Controlled Clincial Study,
F1K-FP-EVCN,Xigris safety for surgical severe sepsis patients,
"7367",In Vitro Study - Prof. Ceriello,
"7370",Gemzar in NSCLC Ph II (Scagliotti proposal),
"7401",Commercialisation study,
F1J-SB-S011,Duloxetine Experience Trial,
"7427",Olanzapine Bipolar study for acute mania - maintenance (AO),
B9E-XM-O339,PHASE II STUDY WITH A FIXED DOSE RATE INFUSION OF GEMCITABIN,
H3E-AA-S038,Phase 1/2 study of LY231514-Cis 1st-line in adv Gastric Ca,
"7585",Time to Heal No. 1; 4 arm/1cycle,
"7593",Untitled IIT for Evista in 2003,
"7610",MDSS,
"7652",Canadian Open Label Dul SUI Tx study,
"7699",The Effect of Self Monitoring of Blood Glucose,
B9E-MC-X040,RANDOMIZED PHASE III TRIAL IN METASTATIC NSCLC,
"7688",IIT / Fellowship / Chair Placeholder for Evista,
"7695",Gemcitabine in LYMPHOMA,
F1D-PL-O203,"Efficacy of oral olanzapine in agitated pts, acute psychosis",
"7767",Local Registry observational study,
B9E-MC-V207,HPLC of gemcitabine,
"7818",Length of therapy continued improvement,
"7849",McGill Fellowship,
B9E-SB-V003,Gemcitabine In Renal Cells Treated w/  Hyperthermy,
H3S-BL-GGKZ,Evista vs. TRH (SHE),
B3D-VI-GHCK,Bone Effects of SC Teriparatide Following Alendronate,
F1K-SB-S003,Obs. study on Drotrecogin alpha activated in Germany,
"7996",Epidemiologic Study on Prevalence of MUI and SUI,
B9E-XB-V218,Gap junctions with Gemzar in vivo,
H8R-MC-A001,[18F] Radiotracer Development and Animal Validation for NK-1,
F1D-AY-O218,Prevention of relapse from early psychosis,
H6U-AY-O003,Muscarinic receptors in the pathology of schizophrenia,
B9R-CA-GDCT,HUMATROPE: TREATMENT TO FINAL HEIGHT IN TURNERS SYNDROME,
H6U-MC-V002,Pharmacodynamic CSF/plasma protein profiling,
H3E-MC-V020,Radiation + Alimta in pancreatic adenocarcinoma,
B9E-AY-O352,Gem&Carbo induct followed by Cis& IMRTnasopharyngeal ca,
F1D-PL-O208,Sexual disorder in hyperprolac. Pts on atipicals.,
"7839",HOMA Risperidone Vs Olanzapine,
"7863",Placeholder for Gemzar Breast/Lung IIT,
F1K-BL-B002,Sepsis Health Outcomes Study,
"7887",Alimta + Cisplatine in advance Gastric,
"7915",Evista vs physical exercise - prevention of osteoporosis,
B4Z-LC-LYCB,Tolerance and Safety of Multiple Dose in PM Subjects,
B4Z-US-LYCC,AM/PM Dosing,
"10151",Thyroid Ca GemPaccPhase I/II,
H7C-LC-LMCM,Hepatic Impairment Study,
F1J-US-A001,Duloxetine on Expression of BDNF and Neurogenesis in rats,
H7G-MC-PDAI,LY582563 & Lamivudine Interaction Study in LAM-R HBV Pts.,
H3S-GV-S044,Compliance with raloxifene therapy in post-menopausal women.,
H7R-FW-GCBL,Relative Bioavalability Study,
B9R-MC-C006,IMPACT OF HGH ON IMMUNE FUNCT. OF HGH DEF. CANCER SURVIVORS,
"8423",Phase I/II Taxotere+ALIMTA in Prostate Cancer,
F1D-US-A054,Evaluation Olz reversal of Haloperidol in TD in Rat Model,
"8654",Cialis: Ketaconazole,
H8E-FW-KBAC,Oral-Labial Safety Study,
"7095",Pulmonary Insulin in Sulfonylurea Failures,
B9E-MC-JHBR,GEMCITABINE+CISPLATIN VS ETOPOSIDE+CISPLATIN IN NSCLC,
B4Z-LC-LYCM,Definitive Bioequivalence/Adult Fed/Fasted 100 mg,
H3S-FP-O114,"raloxifene, type 2 diabetes and nephropathy",
F1K-BP-V003,In-vitro study of effects of rhAPC on neutrophil function,
B9E-US-S319,Ph II Gem/RT in NSCLC,
B9E-SO-O377,Phase II Gem comb Carbo +/- docetaxel NSCLC,
"7288",IIT placeholder for Alimta,
"7312",Placeholder for local PKC Beta Inhibitor support,
B9E-MC-JHEE,"GEMCITABINE,LV,5-FU IN ADVANCED,RECURRENT,&/OR SOLID TUMORS",
"7379",Alimta-Cyclophosphamide in II line breast cancer,
B9E-VI-S327,neoadjuvant Gemcitabine Cisplatin for operable NSCLC,
B9E-MC-JHFA,PH1 GEM/RAD COMB. IN LOCAL. UNRESECTABLE PANCREATIC CANCER,
F1J-MC-HMCM,Lilly's Emotional and Physical Symptoms of Depression,
"7459",PTH in Male Osteoporosis,
"7481",Phase 2 Neoadjuvant Alimta in Meso,
B9E-MC-JHFV,GEM/TAXOL PH.1 DOSE-FINDING IN PTS W. PERS/RECUR. OVARIAN CA,
"7547",Multi focal ERG,
F1J-MC-HMDG,EU SSRI Switch,
H6D-EW-LVGM,Cialis: alpha blocker interaction study (2),
"8697",Progressive Treatment Algorithms,
H8L-FW-IQAB,Microneedle Confirmatory PK/PD Trial,
F1K-MC-EVCX,Treatment in Emergency Room,
"8738",SHS in combination with orals compared to glargine,
"8761",Ph I/II - ALIMTA + CPT-11+ novel agents(PKC-beta) - CRC,
"8780","Ph II, 1st Line ALIMTA+Carbo+XRT -> Surgery in adj. NSCLC",
"8810",Placeholder  --  [F19] MRI Validation Study for NK-1,
B9E-US-X416,Ph II Capecitabine & Gem in pts w/metastatic colorectal CA,
"8858",SSRI switch,
"8863",dummy trial,
"8877",Nicotinic alpha7 pot biomarker study,
H7R-LC-GCBO,Renal Impairment Study 2,
H7R-MC-GCCI,Effects on Insulin sensitivity/visceral adiposity,
"9079",Phase II GAD Low-Dose #1 (Buy-Up),
B9Z-PH-0007,IN-VITRO EVALUATION OF DIRITHROMYCIN IN SINGAPORE,
H6D-MC-B006,Observational Study Continued Use of Cialis in Men with ED,
ZYY-LC-GQAB,Methods - menstrual symptoms premenopausal w.tubal ligation.,
"8288","Effect of Alchol, Drugs & Stimulants on Course, Outcomes",
B9R-JE-C004,HUMATROPE PMS IN PITUITARY DWARFISM,
F1J-MC-HMCY,Lilly's Emotional and Physical Symptoms of Depression,
"8315",Prospective Urinary Incontinence Research in Europe (PURE),
B9E-MC-V229,Chemosensitizing effect siRNAs in pancreatic carcinomas,
"8387",Isales-Angiotensin II-Induced JAK/STAT Pathway in Diabetes,
H3E-US-S042,"Ph I, ALIMTA+Gem (q2w, targeting ovarian & solid tumors)",
H6D-EW-LVGP,Cialis: bioavaillability/bioequivalence,
H3E-MC-JMGX,"Rand-Ph III, 2nd Line ALIMTA 500 vs 900 in NSCLC",
"8441",Bioequivalence LY333531 (64 mg),
H3S-IS-O130,EFFECTS OF RALOXIFENE ON URINARY NTx,
B4Z-LC-LYDI,Relative bioavailability pediatric liquid formulation,
H4Z-LC-GJAH, Hepatic Impairment (ClinPharm),
F1D-MC-X243,The effect of olz in combination w/lithium & divalproex & vo,
"8564","5-HT2c  Phase 2A/Obese with no co-morbidities",
F1D-CY-B005,Mania and Olanzapine Treatment (MANOLA),
"8589",Renal/Creatin Study,
F1K-US-X003,Use of PslCO2 to reflectSeverity//Response to Treat Sepsis,
F1D-EW-E006,LY170053: FIXED DOSE SAFETY & EFFICACY STUDY VS HALOPERIDOL,
"9210",IIT Placeholder - Zyprexa (Poland),
H9F-MC-GYAC, PET Study--OpRA,
F1D-MC-HGMC,IM Olz Depot:  Schizophrenia Comparator Trial no. 2,
ZYY-LC-GOAE,Food Intake Feasibility Study,
B9E-FP-O419,IIT-NSGCT B9E-FP-O419 GETUG / IGR,
"9482",GP II B IIIA'S IN Percutaneous Coronary Intervention,
"7723",IIT GEmzar 2004,
"9518",Cialis: antihypertensive study (placeholder),
H6D-MC-LVGO,Cialis: 6-month  visual safety study,
H7U-MC-IDAP,Minimal vs Intensive training for HIIP usage,
"9527",Special Populations study in Prostatectomy Patients,
"9536",GLP -1 Analog IV-FC Phase II,
F1K-US-A010,Pot. Mit. of Reperfusion Injury in Skeletal Muscle using APC,
H3E-US-X019,Ph I dose escalation of Alimta in head + neck cancer pts,
B4Z-MC-LYDJ,Initiation of Atomoxetine following treatment for MPH,
"7564","5HT1d Phase IIb Comparison of Efficacy and Safety",
B9E-LD-O343,Gemcitabine plus Carboplatin in metastatic breast cancer,
H6E-KL-O009,IIT animal study,
B9E-PK-O344,Phase II trial of Gem+Dox in MBC as 1st line Chemotherapy,
"7638",Gemcitabine Observational Study for Lung,
"7641",IIT / Fellowship / Chair Placeholder for Prozac,
B9E-XM-O401,Gem-oxaliplatin in Ovary,
B9E-MC-S335,"Ph II Rand G-CHOP 21d vs. CHOP, NHL, 1st Line",
B9E-US-X379,Ph I/II Prolonged IV Gem & Oral Cap in Adv renal cell CA,
B9E-MC-X045,GEMCIT. & VINORELBINE FOR STAGE IV NSCLC AND BREAST CANCER,
"7770",GemCis Combination in patients with ovarian cancer,
B9E-MC-V209,Effect of Gem loaded novel cationic liposomes,
B9E-SB-JHLE,"GEMCITABINE AN INTERFERON ALFA-2B, A DOSE-FINDING STUDY",
B9E-HU-JHSI,"Gemzar in Lung, Pancreas and Bladder Cancer",
"7835",Compliance and Satisfaction with Forteo Treatment,
F1D-BL-HGKJ,HEALTH OUTCOMES IN MANIA EPISODE AND STABILIZATION,
"7873",Entreeve/ Duloxetin UI,
"8745","Ph II ALIMTA + Gem FDR or SI, 1st & 2nd line Colorectal",
B9R-SB-GDDT,INFLUENCE OF EXOG. GH ON ENDOG GH LEVEL,
F1D-TW-B006,Olanzapine vs Risperidone in health outcome of schizophrenia,
F1D-US-HGLR,Switching to quetiapine in overweight/obese pts,
ZYY-FW-GCBY,Exploratory Biomarker Trial with Non-Lilly Compound,
"9014",JP Arxoxifene P-1 SDSS,
F1D-MC-X249,Impact of Olanzapine Treatment on Insight in Schizophrenia,
"9070",Follow-up study of B9R-EW-E001 patients,
"9101",Daily Dosing Clin Pharm Study #2,
H6D-MC-LVGC,Dose ranging study of tadalafil in treating LUTS in men wBPH,
F1D-EW-E001,LY170053: OPEN LABEL SAFETY & DOSE RANGING STUDY,
H3E-MC-V025,"Preclinical Testing w LY231524. LY338913, LY247292",
H3E-MC-V028,Invitro Alimta studies w Iressa in meso cells,
H6D-FP-O002,IIT - Effect of association Tadalafil and testosterone,
"9274",Actos IIT Placeholder study for S. Korea,
B5K-GH-B003,Glycemic control target achievement in 70/30 HumaPen Users,
F1K-MC-A005,Effects Xigris Burn Depth Conversion/Microvascular Perfusion,
F1D-JE-203E,LY170053 LONG-TERM STUDY ( CONT. FROM LATE PHASE 2 ),
H3E-MC-V044,Cytotoxic effects of pemetrexed in gastric cancer cells,
"9733",Micro needle,
B9E-US-X439,Feasibility trial of Neo. Gem/Cisplatin in pts.w/ Bladder CA,
"9768",PLACEHOLDER_B9E-MC-S298 TRIAL,
H9S-MC-JDCF,"FHD, Phase I Clinical Trial of LA294 for Oncology",
H3E-MC-S100,"Ph II, 2-stage ALIMTA+Carbo in  2nd Ln Plat Sensitive Lng CA",
"10008",Placeholder for IIT of TOGA group,
H6D-MC-LVGU,Tadalafil for the Tx of Subjects with Mild to Moderate HTN,
H6E-UT-O013,Pioglitazone in glucocorticoid-induced resistance,
"10158","Coagulation Response in heat stroke, Baboon model",
B9E-MC-V264,Cytarbine Triphosphate in Leukemic cells Resistant,
B3D-SB-O007,Bone histology/histomorphometry under teriparatide BBB study,
H3E-US-I003,"Ph I Alimta & Carboplatin, Radiation Therapy for NSCLC",
B3D-US-X013,New Imaging Technology for the Assessment of Trabecular Micr,
F1J-AY-O011,Depression and physical illness - pain CV risk factors & ost,
H3E-US-X058,PhII Alimta in Stage IIIB/IV for Bronchioloaveolar Carcinoma,
"7888",Alimta in 2nd line w or w/o dexa and dose escal in NSCLC,
B5K-AG-S006,Treatment schemes for 30/70 in OHA failure in T2 diabetes,
"7924",Phase II Study,
"8012",Duloxetine placeholder - SUI,
F1J-XB-O003,validation of ICIQ-Short Form,
B9F-MC-I027,C-PEPTIDE: EFFECT ON INSULIN SECRETION IN NORMALS/NIDDM,
B9E-MC-V221,Gem Diphosphate as an inhibitor of the recombinant parasite,
B9R-EW-GDDY,HYPOPITUITARY DEVELOPMENTAL OUTCOME STUDY,
B4Z-MC-LYCL,Dosing study in suboptimal responders,
ZYY-LC-S001,Continuous ECG in Healthy volunteers,
B9R-IT-GDDK,HGH IN PREVENTION OF BONE MASS LACK IN ADULT GH DEFICIENT P.,
B9E-US-X396,Ph II Capecitabine with Gem in Prostate CA prev w/Taxanes,
B9R-JE-C005,hGH P-IV Turner,
F1J-MC-HMDB,Prevalence of painful physical symptoms in outpts with MDD,
"8305","Lee, Hon-Chi Effects of LY on Hyperpolarizing and Ca channel",
F1J-MC-A003,MPBM and MADAM Autoradiography with Duloxetine Pretreatment,
"8340",Effect of Humulin & TZD on serum Ferritin in Type2 DM,
F1K-BP-V008,Effect of Xigris on end organ injury in acute pancreatitis,
"9354",Gemzar study in MBC,
F1D-JE-204E,LY170053 LONG-TERM STUDY/TREATMENT RESISTANT SCHIZOPHRENIA,
"9425",CS 747 Standard vs High Dose Clopidogrel in Stable ACS,
H9M-BD-LGEC,LY2059436  Proof-of-Concept for Alzheimer's Disease,
F1K-US-B006,Mercury 2,
B4Z-SB-LYDD,Local German Atomoxetine Study with Children,
H3E-US-X017,Ph II Alimta + Gem for Adv. Soft Tissue Sarcoma,
H3E-US-X018,Pemetrexed in poor-risk pts. w/ adv. head & neck cancer,
H7U-MC-IDAV,Type 1 efficacy,
"9651",Adult GHD Postmarketing Surveillance,
H9O-BD-MAAG,FHD(22-Jun-05):MC4R Agonist  Single-dose Safety Study (SDSS),
"9749",Ph 3 Neo-adj adding Cape/Gem to Txt seq w/ 6 arms - Breast,
F1J-US-X005,Assessment of Cognitive Function before and after Treatment,
B9E-US-X444,Ph II trial of Gemcitabine and Triapine in Advanced Sarcoma,
H7Q-LC-EABE,MDSS 24-hour infusion of LY458202,
H9U-MC-MDBE,Depression POC-Add-on therapy,
F1D-MC-HGBS,OLANZAPINE VS. RISPERIDONE IN SCHIZOPHRENIA,
F1K-XM-EVCV,Epidemiologist study: sepsis + distress,
"8415","Ph II, ALIMTA + Cisplatin in Breast Cancer",
"8494",Ph I ALIMTA + Gem q 2wk ovary,
H7Q-LC-EABC,SDSS 8-hour infusion of LY458202,
H9G-LC-GXAB,"5-HT2c  MDSS 1B",
"8663",QCT of the Spine and Hip During Treatment with shPTH(1-34),
"8740",SHS or glargine + Humalog in Type 1 Diabetes,
"8749",Ph II - Gem+Navel-Ifosfamide - relapsed Hodgkin's - Lymphoma,
"8759",Ph II - ALIMTA + Gem q 2 wks - CRC,
H3E-MC-V032,Preclinical Evaluation of TK Inhibitors (human lung+breast),
H3E-MC-V009,Pre-clinical research of ALIMTA,
F1D-IT-B023,Obs. Study on therapy adherence in bipolar disorder (EPHAR),
"8869",BACE Biomarker Study #2,
"8874",mGluR pot/CysL T2 antag Biomarker Study,
"8880",triple reuptake inhibitor II Biomarker study,
H7T-FW-TAAQ,CS-747: Asian PK,
H3E-FR-O025,IIT-H3E-FR-O025 maintenance study,
B9E-SB-S354,Phase III bladder instillation study,
B4Z-US-LYCV,adolescent risk behavior,
"9047",JP 5HT1d P1 SDSS,
F1J-JE-HMEA,JP Dulo P-II open-label study manage by Shionogi,
"9077",JP hGH C24 mg and C12 mg bioequivalence,
B9E-AA-B004,Gem-platinum OS (smoking vs outcome) for 1st-line NSCLC,
"9134",Atomox Dummy Drug Order,
"9154",Olanzapine/Xanomoline,
F1D-MC-X253,Comparison of Brain Morphology Changes in Prodromal Patients,
H6U-SU-I001,Prevalence Study on ED among Male Adults in San Juan-PR,
F1K-US-V014,Genetic Predisposition to the hypercoag. state in sepsis,
"9239",Gem.+ Carboplat. Prosp. Obs. Study in Relapsing Ovarian Ca,
H8D-LC-EMBE,"Dose Ranging Study, formerly known as dose de-escalation",
B9E-MW-S369,Gem+Cis followed by radiotherapy in Cervix cancer,
H6O-FW-GCAR,Measure Insulin Senstivity Via Pharmacological Intervention,
H8I-EW-HQAK,ID/SSRI: MDSS with LY628535,
F1D-JE-305E,OLANZAPINE PHASE 3 LONG-TERM STUDY FOR SAFETY EVALUATION,
"9455",Placeholder for Yentreve in CH,
H3S-XM-O126,Trabecular bone structure using fractal analisys with RLX,
H7T-MC-TABU,CVA Study #1,
"9557",PPAR alpha agonist 2nd generation,
ZYY-LC-BFAB,Sleep Study,
"9687", MC4R Agonist  Multiple-dose Safety Study (MDSS),
"9688",MC4R Agonist-- Caloric Intake Study,
B9E-FP-RTAA,Placeholder _ Radiotherapy packet (JHQG_S273_JMEV_JMES_JVAA),
F1D-LC-V002,HUMAN PLACENTAL TRANSPORT OF OLANZAPINE,
H9P-EW-LNBB,NERI IV: PET Proof of Concept (Aepodia),
"9810",Multi-Dose Caloric Intake Study,
"10146",Placeholder for CTNR H3E-PL-S051,
H6Q-MC-JCBF,R-Ph III-Enzastaurin versus Lomustine in Glioblastoma,
H6Q-MC-S028,Ph II-R-CHOP vs. R-CHOP+Enza-DLBCL,
"9851",assessment of beta cell function in type 2 diabetic patients,
"9886",Collection of Joint Replacement Specimens for OA Research,
H6Q-MC-JCBA,DDI Interaction Study w/ Rifampin [hv],
H9U-BD-MDBB,QTcStudy,
F1D-MC-X269,Zonisamide pts with olanz-associated weight gain & obesity,
B4Z-US-X033,Can Strattera Produce a False Positive UDS for Drugs of Abus,
I1E-LC-ESAC,MDSS,
F1D-MC-HGBX,OPEN LABEL OLANZAPINE,
H3E-MC-S095,Ph II Alimta/Carbo+XRT in limited disease SCLC,
F1D-MC-HGCM,OLANZAPINE IN CLOZAPINE REFRACTORY SCHIZOPHRENIC PATIENTS,
"10107",Epidemiology study to assess the SUI prevalence,
"10133",Placeholder for local support NSCLC Targetted with Gemzar,
F1D-MC-HGDM,OPEN-LABEL OLANZAPINE TREATMENT,
H3E-MC-V041,Cyclooxygenase II Inhibitors and ALIMTA in Meso Cell Lines,
"10156",Prevention of T2 Diabetes & CV Risks in African Americans,
H3E-MC-V061,Alimta and Doublet Screening of Chemotherapeutic agents,
H4S-SZ-O063,EURO Heart Survey,
H8K-MC-JZAF,Phase II: Malignant Melanoma,
F1D-MC-X007,OLANZAPINE EFFECT ON WATER IMBALANCE IN SCHIZOPHRENIA,
H3E-US-I007,Ph II Immunomodulation in Pancreas Cancer both Gem/Alimta,
H6D-MC-LVHI,BPH LUTS Phase 3 Open-Label Extensions,
F1J-MC-X015,"PET imaging, vulnerability to relapse of depression, dulox",
F1J-MC-X016,"fMRI, duloxetine in Chronic Pain and Depression",
H6Q-US-S004,Alimta/Carbo vs Alimta/Carbo + Enzastaurin vs Taxotere/Carbo,
F1D-CA-O288,Olz as an Adjunctive Treatment for Anorexia in Youth - Pilot,
F1D-EW-HGMK,Olz+Flx vs Flx+lithium vs Placebo bipolar depression,
F1D-MC-HGCG,OPEN LABEL EXPERIENCE WITH OLANZAPINE,
F1D-MC-X273,Double-blind placebo controlled of amantadine retarding wt,
"10045",Placeholder for IITs (US),
ZYY-MC-KDAA,Blood & Urine Biomarkers in Stage III/IV Chronic Kidney Dis.,
H6D-MC-V001,In Vitro Tadalafil and Alpha Blockers on Resistance Vessels,
"10079",Drug interaction study (placeholder),
B1Y-CA-P002,FLUOXETINE MAJOR DEPRESSIVE DISORDER-INPATIENTS,
F1D-MC-HGEP,OPEN-LABEL OLANZAPINE,
H4S-BP-O065,BCIS 1-Balloon-pump assisted Coronary Intervention,
A6J-MC-ASCA,VANCOMYCIN DBL-BLIND PLACEBO COMP. ANTIBIOTIC ASS. DIARRHEA,
H6Q-MC-A008,Study of the effect of enzastaurin alone or in combination,
H8O-MC-B003,INSTIGATE: EU Pre-launch obs study on Type 2 Diabetes,
B4Z-US-X041, The effect of Atomoxetine of ADHD related Insomnia in Child,
"10048",Placeholder for Strattera IIT,
"10044",Cymbalta Vs triciclico,
F1J-US-X013,Duloxetine for Depression in Parkinson's disease,
H6Q-MC-V012,Determination of the in vitro toxicity of enza on  CLL cell,
F3Z-US-IOOV,Durability of Two Starter Insulin Regimens,
B9R-IT-O041,Prevalence of Hypopituitarism in patients with TBI and SAH,
B9R-SO-O044,Bonemineralisation and bodycomposition in children,
F1D-MC-X022,OLAN VS. HALDOL IN PTS WITH SCHIZO. AND SUBSTANCE DEPENDENCE,
B9E-US-S377,Rand Ph II Gem+Taxol+Avastin vs Taxol+Avastin in MBC,
F1K-TW-O037,Clinical Efficacy of Xigris in Leptospiral Infection,
B7A-MC-MBDV,Diabetic Retinopathy Open Label,
F1D-US-HGMM,Usual Care vs. Algorithm Weight Mngt of Zyprexa in Schizo Pt,
H6U-US-S003,Disease Management OR,
F1D-VI-HGCQ,OLANZAPINE VERSUS CHLORPROMAZINE IN TURKEY,
"10895",Void,
B9E-AY-O480,myelotoxicity of Rituximab in comb. for relapsed lymphoma,
H7L-SO-O002,"Incidence of fractures and CV disease hypopituitarism, GHD",
"10977",ENZASTAURIN DDI w/CYP2D6 Inhibitor,
H3E-MC-V121,Vitro and In vivo Experiments with LY-231514 compared to sim,
H8O-MC-A002,Studies for Exenatide Therapy for Type 1 Diabetes,
H3E-US-X043,Early Positron Emission Tomography in Chemo for NSCLC,
H8O-MC-GWAZ,Patient Preference for LAR,
H3E-SB-S089,Ph II Alimta+Cis vs Alimta+Carbo - adjuvant NSCLC Ib-IIa-IIb,
H3S-IS-S046,bone marker study,
F1D-MC-HGCW,EFFICACY AND SAFETY OF OLANZAPINE AS ADD-ON THERAPY,
F1D-MC-HGCY,OPEN-LABEL EXPERIENCE WITH OLANZAPINE,
I1K-BD-GLUB,LP10152 MDSS in Pts with Type 2 Diabetes,
H9U-MC-MDBH,"2C19 poor metabolizer/3A4 inhibition (Drug/Drug interaction)",
B9E-MC-V253,Intracellular assay measure Phosphorylated Gem metabolites,
ZYY-KW-B002,"Diabcost Australia: Burden of illness, type 1 diabetes",
B4Z-MC-X040,Atom children with attentional disorders in acute leukemia,
H6Q-MC-A026,Angiogenesis therapies,
H6Q-MC-V015,Enzaastaurin and human lymphoma cells,
B7A-MC-V017,Westfall- Protein kinase C-beta in cardiac myocyte Perf.,
H3E-MC-V063,Pemetrexed and gem in combination with radiation invitro,
F1K-FP-O033,IIT-AI effects aPC in septic pts & healthy volunteers,
F1D-XM-O287,"Glutamate transporters - BDNF in schizo,bipolar - other psyc",
"10475",Placeholder for Cymbalta MDD trials NL,
F1D-MC-HGDJ,OLANZAPINE VS. HALOPERIDOL IN FIRST EPISODE SCHIZOPHRENIA,
H3E-MC-V057,"Bronchioloalveolar Carcinoma, Adenocarcinoma Lung",
H9Z-MC-RKAA,MDSS (PoC) DPP-IV Inhibitor Analog I,
B4Z-AY-O007,Atmx and Dex on cog functioning in bys & grls w ADHD.,
H6D-MC-LVGZ,Tadalafil PAH Tracecleer Interaction Study,
"10354","Placeholder for H3E-MW-JMGJ study, impact #7771",
B7A-LL-V001,Rahimian-Involvement of protein Kinase C-beta,
I1I-EW-GECA, FHD: SDSS GLP-I Analog V-PEG,
"10401",RBA Study DPP IV Inhibitor,
H3E-MC-V066,Genetic determinants assoc. w Pem res and tox,
B7A-MC-V024,Ha-Research on pathophysiology of diabetic nephropathy,
H3E-MC-JMHX,Ph II-Alimta pts w/ 3rd space fluid-NSCLC/Meso-2nd line,
F1D-MC-X003,TREATMENT OF RISPERIDONE PARTIAL RESPONDERS WITH OLANZAPINE,
F1J-ME-O012,Cognitive functions in subjects w Major Dep,
B1Y-CA-P005,FLUOXETINE COMPASSIONATE USE FOR MDD,
B9E-US-I154,Ph II Gem/Carbo/Bevacizumab in Ovarian/Fallopian/Peritoneal,
F1D-MC-X013,STUDY RE: MOTOR DISFUNCTION IN SCHIZ PATIENTS,
B9E-MC-S378,Ph II Gem plus Oxaliplatin in Pediatric cancer,
F1D-US-HGMN,Risperidone Fail First transition to Zyprexa in Schizo Pts.,
B9E-MC-V322,T-cell biomarker assay for the oral Gemzar FHD study,
F1D-VI-HGCH,Efficacy & safety of olz vs fluphenazine in LT trt of schizo,
F1D-CA-O293,Cerebral Mechanism in Appetite Increase in Schizophrenia Pts,
"10863",OpRa I Drug - Drug interaction study,
F1J-FR-HMFD,Duloxetine in MDD  old old patients with or without MCI,
F1J-US-X023,The Impact of treatment with duloxetine (Cymbalta) on Alertn,
F1D-FW-LOCA,BE Study to Support Zydis Local Registration in China,
H3E-IT-O026,Alimta 2° Line Cervical Cancer,
H8C-MC-LQBD,CHORUS Study:Validation Protocol for the BTS Pain Experiment,
B9E-IS-V329,invitro efficacy zoledronic acid w gem/cis in lung cancer ce,
F1D-IT-A133,Olanzapine favoring insuline-resistance,
H6Q-MC-V021,Enz and tgf beta in colon cells and xenografts,
"11103",Sample request,
"11134",In Vitro toxicity of Gemcitabine and the metabolite difluor,
B9E-IT-V349,Gemzar in pancreatic carcinoma: in vitro study,
F1J-MC-HMFG,Osteoarthritis knee pain,
F1D-MC-X017,OLANZAPINE THERAPY IN ELDERLY PATIENTS WITH SCHIZOPHRENIA,
I1S-MC-GSCA,"562653 SPPARM (SDSS) in Healthy Subjects",
H8O-EW-GWBT,Exenatide:  Inhaled FHD Study,
H6D-MC-LVHV,PAH Pediatric Study for patients >= 6months of age,
H7T-MC-TABK,MSCT in ED Early ID of ACS Patients,
H7T-EW-TABP,PPI on Chronic Prasugrel Therapy,
H3E-MC-V085,"Cell Line Studies with Gemzar, Alimta and Enza",
"10682",Cytarbine triphosphate  leukemic cells reisitant to Cytarbin,
"10770",Ph 2 Alimta vs Taxotere in 2nd Line Bladder Cancer (EORTC),
F1D-US-X116,Olz. to Relieve Opiod Induced-Nausea In Cancer Pain Pts.,
F1D-VI-S067,PREFERENCE: 12-Wk open label Olz Orodispersible vs Olz,
H3E-MC-V124,A Phase I study of Intraperitoneal ALIMTA,
F1D-MC-X289,Olz vs. Plc for Adult and Adolescent Outpatients w/ Anorexia,
"11029",Phase I/II MAK Tumor 4,
"11063",Pain Model study,
F1J-JE-104G,BIOEQUIVALENCY STUDY:  L10*2 VS L20,
I1R-MC-GLBE,Glucagon-R Phase 2a Safety and Tolerability Study,
F1D-JE-V017,Effect of ola on Microglial Cell Activity,
F1D-US-X292,Risk of Cerebrovascular Events Associated with Antipsychotic,
"10488",CTNR Cymbalta,
"10557",Pulmonary hGH: Phase III Pediatric Idiopathic Short Stature,
H3E-MC-V068,ALIMTA interaction with Cytokine Gene Therapy,
B9E-MC-V288,Analyses of DNA Polymerase B Mutations and Efficiency of Gem,
B9E-MC-V282,Cell Death Pathways Triggered by Cisplatin anf Gem,
"10589","562653 vs Rosglitazone: Phase 2 study in type 2 diabetes",
"10592",Preference of Inhaled vs Subcut. Growth Hormone in Ped Pts.,
B9E-MC-V294,Analysis of Gemcitabine (dFdU) in human plasma,
H3E-MC-V107,Cyto & Nucleo Effects of Pem Colon Cancer Cells,
H6Q-MC-A015,Alimta and enzastaurin against neuroblastoma,
"10672",LOCAL PLACEHOLDER FOR B9E-MC-S346,
F1D-US-X284,Relapse Prevention:  Long-acting atypical anti-psychotics,
B7A-MC-A020,Distrubed cytosolic Ca homeostasis in sensory neurons,
H3E-MC-V106,ALIMTA + Gemzar Sequencing,
"10832",FHD trial for future compd FC000068,
F1D-CA-O292,Difference in Olz-Fluox Efficacy in Unipolar and Bipolar,
"10865",OpRa I Food effect pilot study,
F3Z-US-X023,Prevalence of MODY 3 in children w/atypical diabetes,
"10885",Local trial for NPL registration in Russia,
H3E-US-X061,PhII Alimta & Cetuximab in Colorectal Adenocarcinoma,
ZYY-MC-S003,ERbeta Biomarker Methods & Exploration Study in Male Subject,
H6D-MC-LVHK,Cialis Urodynamics Safety Study for BPH LUTS,
H6L-MC-LFBL, DDI: Acetaminophen,
H6L-MC-LFBC,A Beta Lowering Efficacy in Alzhiemers Patients Phase III #2,
F1D-CY-A137,Subchronic olan.tx in neuroinfectious animal model of SCH,
"11305",Platelet Adhesion Assay,
"11341",OA phase III Knee (Structural Signs & Symptoms) LY2189102,
F1J-MC-SAAH,A STUDY OF DULOXETINE HYDROCHLORIDE VS. PLACEBO IN PATIENTS,
H8O-MC-I010,Effects of Exen 4 in patients w/left ventric. dys.,
H6D-MC-A002,Does tadalafil affect the release of nitric oxide from auton,
H6D-MC-V004,Investigate the distinct components of the NOS-cGMP-PKG sign,
ZYY-CA-O001,GATC Genotype Specific Approaches to Therapy in Childhood,
F1J-US-X036,Swtch to Dulox to Ameliorate SSRI induced Sexual Dysfuntion,
"11472",Alimta-carbo + RT,
H6Q-MC-S041,Ph II trials ENZ + Revilmid in multiple myeloma,
H6Q-MC-S057,Phase II ENZ in heme/B-cell malignancies,
H9V-MC-GFRB,MDSS/POC in stage 3/4 CKD due to type 2 diabetes,
H6L-MC-LFAW,Statin Drug Interaction,
B9R-IT-O047,GH IGF-1 axis and ascular risk,
"11280",Cellular uptake of antifolates in human tumor cell models in,
B4Z-PL-O012,Prevalence of ADHD in children/adolescents in reformatories.,
H9P-MC-LNDI,ADHD pediatric NERI-IV fixed doses (2) vs. PBO,
"11338",RA Ph3 LY + DMARD vs DMARD; TNF Failures; 6mo S&Sx,
H9C-MC-BBDI,OA POC LY2189102 Anti-IL 1 Beta,
H3E-US-V131,Sequence-Dependent Anti-Tumor Effects of Erlotinib & Alimta,
H6O-FW-GCEA,"11beta-hydroxysteroid dehydrogenase type 1 (11HSD1) study",
I1C-JE-JLBB,JP Gem Prodrug P-I,
F1J-MC-A007,Antinoceptive effects of dulox on allodynia induced neruropa,
F2P-LC-LCAI,AMESERGIDE: INTERACTION STUDY WITH DIAZEPAM,
"11522",Ph 3  Enzastaurin Placeholder for Planning #1,
F1J-MC-X038,Dulox in pts with SOD,
H3E-US-V133,Comparison of cytotoxic effects of novel anti-folate agents,
H3E-CA-O032,chart reveiw of outcomes of patients with MPM at TOHRCC,
"11780",PhIII/IV - LY+TNF vs TNF (TNF PR; DAS28),
H9B-MC-BCDG,Phase II Placebo Controlled RA (MTX Background)   LA294,
H6Q-MC-V033,Enzastaurin in lymphoma,
H6Q-MC-A029,Enzastaurin and avastin in several cancer types,
H6D-MC-A010,Evaluation of the effects of tadalafil on urodynamic functio,
F1K-MC-EVAB,APC DOSE RANGING IN HEREDITARY PROTEIN C DEFICIENT PATIENTS,
H7T-MC-V009,In Vitro TEG,
B4Z-US-X053,Effects of Strattera Therapy on the Home and School Behavior,
H3E-US-I018,PhII Alimta & Carboplatin in Head&Neck Squamous Cell Cancer,
B3N-SP-EUCV,Bioequivalence of Two Moxonidine IR Formulations,
F2P-LC-LCAC,LY237733: ORAL MULTIPLE DOSE STUDY,
"11524",Ph 3  Enzastaurin Placeholder for Planning #3,
"11535",Phase 1 Gem prodrug bioavailability,
H9X-MC-GBCP,D/D Interaction-Statin,
B4Z-EW-LYDY,ADHD LIFE: Long Term Open Label study of Strattera vs SCT,
F1J-XB-O023,"Neurochemistry, pharmacology and genetics in depressión",
B4Z-EW-LYEA,Pilot Thorough QT Study (Aepodia),
B9E-PU-O494,"A Genomic, Proteomic and Pharmacogenomic Correlative Study",
"12484",IPO Vado Approach,
H6D-PL-B011,Sexual life of Poles aged+50. - epidemiological study,
F1D-US-A147,"Antipsychotics, Temporal Effects on Cognitive Function",
I2P-MC-GAAD,Proof of concept,
I1C-MC-JLBE,Ph 1 LY2334737 Alternate Dosing Regimens,
I1C-MC-JLBC,Ph I LY2334737 + Capecitabine,
H8C-MC-LQBG,Phase 2 Osteoarthritis (OA) Knee Pain Study,
H7T-MC-V025,In vitro platelet effect of active prasugrel metabolite ,
F1D-MC-A101,Action Mechanism of Olanzapine,
I1F-MC-RHAG,Psoriasis Proof of Concept for LA426,
I2I-MC-JMMC,FED PhIb/II study of LY2603618 plus gemcitibin in Pancreas,
I1I-MC-GECE,QTc Study,
H6D-MC-V011,Influence of tadalafil on electrophysioogical parameters,
F3Z-SF-IOFE,EFFECT OF PRE-MEAL VS POST-MEAL SUBCUTANEOUS INJECTION,
"12380",Chronic Insomnia PSG w/young end elderly-6wks,
F1D-US-X309,Retrospectiv of Metabolic Syndrome in pts with schizophrenia,
H9P-MC-LNDL,"Peds reading disorder trial, NERI-IV fixed dose vs. PBO",
F1K-US-X008,Protein C and Endothelial Cell Dysfunction in Sepsis,
F3Z-BP-IOEA,ASSESS SUITABILITY POST MEAL ADMINISTRATION OF LISPRO,
F1J-US-X041,Open Label Dulox in the Trmt of IBS w/out MDD,
H9X-MC-GBCW,Drug-drug interaction trial with OHAs,
"11657",Depression POC add on therapy-Restart,
"11662",Zyprexa vs Paliperidone in schizophrenia,
"11665",OP Depot Antipsychotic Naturalistic Study,
H7O-MC-S001,Collection of Blood Samples from subjects with CLL,
I2E-MC-BSAC,RA Safety Study Follow up - B Cell Recovery,
"11812",NPL/AIR,
"11918",DDI-Oral Hyperglycemic Agents,
H7T-MC-TACP,Intensive PD monitoring w/Accumetrics in pts undergoing PCI,
H3S-JE-S02J,JP EVS QOL,
F1D-MC-V021,Effect of atypical neuroleptic drugs on adipogenesis,
H8G-MC-EPBI,Human C14,
F1D-OE-V022,Second Generation Antipsychotic Drugs And Insulin Resistance,
I2W-MC-DMAB,POC acute treatment of migraine,
H8O-JE-GWCW,JP Exenatide TDP Phase 1,
I1D-MC-JIAF,FED Ph II p38 Breast Cancer LY + SOC,
I3A-MC-LLBB,PET Receptor Occupancy,
H8O-MC-A013,Effect of Exenatide on intimal hyperplasia ,
I2B-MC-GACB,MD/POC study in postmenopausal women symptomatic for HFs (fi,
H2Q-EW-LKAB,XANOMELINE-TTS INTERACTION STUDY WITH THEOPHYLLINE,
B3D-US-X020,NMR Imaging and Stereological Analysis of Trabecluar Bone,
H7T-EW-TADC,Food Effect,
I3K-MC-LAED,SD PET mGluR5 Antagonist I,
H9P-JE-LNDJ,"JP_NERI IV_P-III depression, open label extension",
H2Q-MC-LZZS,"XANOMELINE, METHSCOPOLAMINE TO REDUCE GI EFFECTS IN ALZ PTS",
"12906",AMPA Phase 3,
H6D-US-LVIB,PK/PD in Adult PAH,
H7T-MC-TADE,Cangrelor Pre-Trt PK/PD,
H4Z-MC-GJBA,Sensory evaluation of placebo for arzoxifene combo,
F1J-MC-B035,"Duloxetine, SUI, and Suicidality - (GPS Obs Study)",
I3P-LQ-GKBB,MDSS for LY2608204,
I2Q-FW-GMAN,Definitive QTc Study for LY2599506,
"10899",placeholder- french addendum to F1J-MC-HMEM,
"10926",ph III Gem/Cis adj. vs neoadj. NSCLC,
B9E-MC-V347,Test Crystallization of Gemcitabine,
H6Q-MC-JCBZ,Enzastaurin Thorough QTc Study,
ZYY-MC-GOAI,Validation of qNMR Body Composition Analysis Methodology,
B9E-MC-V345,Combination of LY309887 with L-Alansoine on Soft tissue Ca,
F1J-MC-A006,Gene microarray analysis of duloxon gene expressions in rats,
B4Z-CR-S018,Strattera Functional Outcomes in Asia,
I1R-FW-GLBC,Phase I Glucagon Infusion Study with LY2409021 dose,
F1J-MC-X029,Suicidality Association with Antidepressants Ttmt-Retrospect,
F1J-XM-B023,Early response in prognosis of good outcome in MDD,
F1D-US-X299,Outcome study for Solutions for Wellness and Team Solutions,
H6L-MC-LFBH,IV-Tracer Absolute Bioavailability Study,
B9E-IT-O487,Phase II trial of Gemcitabine or epirubicin/mmc bladder K,
I1Q-MC-JDDD,"FHD - SDSS, dose escalation  (Myostatin Antibody)",
"11294",Multiple-dose PoC (Myostatin Antibody),
H9P-EW-LNBT,Definitive QTc Study,
F1J-XB-O024,Efectivity/ tolerability of duloxetine in MDD.,
H6Q-US-S036,Enz/Alimta vs Alimta/Amgen drug vs Alimta in NSCLC 2nd line,
"11661",OP depot Switching study,
F1D-MC-B034,Post-Injection Syndrome in Patients with Schizophrenia ,
H6D-IT-V008,Activity of Tadalafil on the endothelial progenitor Cells,
H8Z-MC-JACV,Ph2 Gastric Combo,
"11801",Local Resources for External Research for CV,
F1K-BP-O045,Changes in Sublingual Microcirculation in Early Sepsis,
F3Z-MC-IOPC,NPL PK/PD 1,
"11852",Local Resources for External Research for Endo,
I2G-FW-ALBA,Intrasubject diurnal HPA-axis variability,
ZYY-MC-GOAJ,(CRU +) Non-clinical to Clincal Obese and Laren Phenotype,
"11964",Psychotic Symptoms with dementia,
"12054",Asian A Beta Antibody Single Dose Safety in Healthy,
H8G-MC-EPBP,Special Population - Renal,
F3Z-MC-IOER,HYPOGLYCEMIA WITH HM/NPL VS HUMULIN R/NPH IN TYPE I DIABETES,
I2R-MC-BIAN,T1DM 18mo Basal Bolus v. Glargine w/6mth primary endpoint,
H3E-GH-O048,China NSCLC IIT,
I2Y-MC-GHFD,Ph.1 Transdermal Patch,
"13103",Ph III - 2nd line - NSCLC,
H8O-MC-A022,Therapeutic possibility of GLP-1 in exp DN,
B1Y-EW-HCHQ,FLUOXETINE VS CLOMIPRAMINE VS PLACEBO IN PANIC DISORDER,
I2Q-FW-GMAL,Bridging Study,
H3E-EW-O055,DRUG ONLY-Phase II Pem+Pazopanib vs Pem+Cis 1st line NSCLC,
H7T-IT-V028,Non-Clinical JRT trial ,
H7T-EW-TADZ,Definitive BE with PPI,
H9X-CR-GBDK,Pan Asian Ph3 Combination Therapy vs Glargine ,
F1D-CP-A163,Effect of Tesofensine on Olanzapine Induced Changes in Body ,
B7A-MC-V020,Pkcb1 stabilize Il-2 mRNA,
B5K-IT-V017,Role of proinsulin ad a ligand of isoform A of the IR-A,
"13703",sTM SAD,
H6Q-MC-V060,Pre Clinical - Melanoma Cell lines,
H6Q-MC-V068,Pre Clinical - B-Lymphoma cell lines,
H8R-MC-HJAO,Pharmacokinetic Interactions of LY686017 (NK-1) & Alchohol,
F1K-BP-O049,The use of Xigris in Severe Acute Pancreatitis,
"12458",Vit D deficiency altering dopaminergic signaling in adults,
F1J-SB-B031,EMPATHY Obs. study Cymbalta for DPNPain,
I2Z-MC-LAFB,MAD Kappa OpRA w/ EtOH interaction study,
"12522",IIT - Pr Duffaud Alimta chondrosarcome,
H9P-EW-LNCR,Biopharm Abuse Potential Study,
H9P-EW-LNCS,Biopharm Absolute Oral Bioavailability Study,
H9P-EW-LNDE,Biopharm Relative BA Study (Japan),
I2K-MC-ZZAS,"8 Week Mid-Term Non-Elderly (2)",
H8Y-MC-HBBT,Acute treatment Adolescent,
H8Y-EW-HBCR,DDI:Probenecid (OAT),
H8O-MC-O010,GI motility,
"12750",Radicular Pain Open Label,
H8L-MC-IQAF,Leakage Device Study,
I3E-BM-MSAE,Mindset-01,
"11333",Randomized Confirmatory Phase III,
"11343",Randomized Phase II/III Pancreatic Cancer,
"11362",Phase III Alcohol Dependence Efficacy,
H9X-MC-GBDB,Ph III Reg Trial - Add on to Met + SU,
B1Y-EW-E012,FLUOXETINE COMPARING THREE DIFFERING DOSAGE REG.,
H6D-MC-A005,Effect of tadalafil on penile apoptosis after cavenosal nerv,
F1D-FR-O299,IIT-F1D-FP-O299-Olanzapine plasmatic level-Dr ,
H6Q-MC-S050,Ph II Targeted patients population in recurrent GBM for 2008,
"11508",Ph 1 ENZ + ZD6474 in solid tumors,
H6Q-MC-S060,Ph II ENZ + Taxotere vs ENZ + Placebo in 2nd line NSCLC,
F1K-SB-O041,Microcirculatory effects of rhAPC in the human intestine,
B1Y-EW-E070,FLUOXETINE VS PLACEBO IN OBESITY,
H3E-US-I022,Ph II trial of Pem/Gem/Bevacizumab or Pem/Carbo/Bevacizumab,
H3E-EZ-S114,Front line treatment of advanced NSCLC with Alimta / Cisplat,
"11849",Alcohol Withdrawal/Dose Ranging Study,
F3Z-MC-IOAM,SAFETY MONITORING OF PTS TRTD WITH LY275585 IN UK,
H6D-MC-LVHU,PAH Compassionate Use Trial,
I4L-MC-ABED,Pk/PD Pilot Variability Study,
"13847",SDSS (FHD) CGRP Neutralising Ab I,
F1D-JE-CS07,Olanzapine Trials for Japan,
I5A-IE-JAEL,CP13-0605: Ph2 - A12 - mCRC - 2nd Line,
I4V-MC-JADV,Ph 3 MTX IR Signs and symptoms study,
F3Z-MC-IOQF,Lispro in pumps vs MDI in T2DMs,
I2Y-EW-GHFT,China Study,
I6E-AV-ADN2,Alzheimer's Disease Neuroimaging Initiative 2 (ADNI 2),
I4E-US-I001,Expl Study of H/N Preoperative Tx w Cetuximab and IMC-A12,
H8O-MC-A035,Potential amplification of MI size limiting eff of exenatide,
I4X-IE-JFCF,CP11-1009:PhIb-Necitumumab(11F8)+Gem+Cis-NSCLC-1st Line,
B9R-US-X050,ANALYSIS OF HIGHER ORDER COGNITIVE FUNCTION IN GROWTH HORMON,
I5B-IE-JGDH,CP15-1008:Ph II-3G3-Gastrointestinal (GIST),
I3W-MC-HHAL,RBA/Food Effects Study,
I5E-MC-TSAO,"MTE06 - Phase II, random. 4-way crossover -steady state PK",
H9B-MC-BCED,Bioequivalence Study in Patients with RA,
H3E-MC-V155,Pre-Clin Gene microarray identify predictive markers,
B3D-JE-GHDT,JP Forteo Osteo safety trial of concomitant treatment with a,
H4Q-FP-V007,IN VITRO ACTIVITY/MECANISM OF ACTION LY333328/ENTEROCOCCI,
H4Q-LC-ARRA,SAFETY AND PK OF SINGLE IV DOSES OF LY333328 IN HEALTHY VOL,
H6D-XM-A017,Oral Tadalafil + stem cell after cavernous nerve injury,
B1Y-JE-HCLV,JP Prozac P-III Bridging study,
H9B-MC-BCEF,Phase 3 Autoinjector Trial,
"14641",Pain Raters,
I5E-US-TSAY,Transition from injectable testosterone to Axiron therapy,
I4H-MC-V002,Preclinical analysis S6K1 inhibitors for suppressing cancer ,
I6K-FW-GLEA,Single Ascending Dose Study for LY2922470,
I5S-MC-EFJH,Bioequivalence Study,
H4W-MC-L001,CHRONOBIOTIC EFFECT OF LY156735 VS PLACEBO AFTER A 9 HR SHIF,
"14947",PhIV-1121B-target population/treatment patterns-HCC-2nd Line,
I6E-AV-_A02,"18F-AV-45-A02 ",
I6E-AV-TW01,Taiwan Ph. I,
"1517",Efficacy of LY300164 in pts with Lennox-Gastaut Epilepsy,
"13464",T1DM non-inferiority,
"11937",Multiple Dose Safety study,
F3Z-MC-IOBS,INSULIN LISPRO:PHARMACOKINETIC OF INTERMED-ACTING FORMULATIO,
"11948",CETP Inhibitor - Phase III - IVUS,
H7T-MC-V015,Effects of rifampicin on plt aggregation inVitro,
H7T-MC-TADT,PROMUS,
I1I-MC-GECC,Phase 2 Obesity,
"12044","Genetic characteristic of schizophrenia, mood, and obsessive",
I1F-MC-RHAJ,Phase 2 - Psoriasis,
B4Z-JE-LYFI,Jp atomo FG Ph-III,
I2R-MC-BIAP,T2DM double-blind 6mo Insulin Naïve v. glargine,
B3D-US-I004,A Phase II Study of Short-term Teriparatide in the Treatment,
H3E-XM-S122,PemetrexedCb concomitant RT following Pemetrexed in NSCLC,
F3Z-MC-V004,METABOLISM OF LISPRO INSULIN ANALOG,
H6D-MC-A014,Reagent to impair myeloid suppressor cells in mice,
"12261",MAD/PH2 GLP ANALOG PEG 80 kDA,
"12263",Kubler,
"12383",LY2364596 Phase 2 Parkinson's Disease Progression,
H9P-MC-LNBP,Pilot QTc,
H8O-EW-GWCU,IVIVC,
F1J-US-HMGB,Flexible Dosed Duloxetine vs. Placebo in Fibromyalgia,
B5K-US-X009,CSII and U500 insulin IIT ,
H6L-MC-LFBE,Safety and Tolerability of increased dose,
H7T-EW-TACV,Prasugrel: Multiple Dose Assay Control Study (placeholder),
B7A-MC-A024,Role of PKC beta in endo dysfunction,
"12320",FXR Antagonist MDSS,
"12389",Phase II Injection Experience with the Aura Device,
H6U-US-O008,Portfolio Project Triage Tool - Phase 2,
I3B-FW-GRAA,Study 1 POC,
H8O-US-X010,Exenatide IIT - Short Bowel Syndrome,
F3Z-VI-IODB,SAFETY A. EFFICACY OF INS. LISPRO IN PATIENTS WITH DM,
F1J-KL-B033,Post Marketing Surveillance on Cymbalta DPNP,
H8Y-MC-HBCK,Abuse liability,
H8Y-MC-HBCM,Tailoring - targeted gene therapy,
B1Y-FP-0701,FLUOXETINE:  USE IN PROPHYLAXIS OF RELAPSES,
H8A-WU-LZAY,DIAN: Effect on those known to have dominantly inherited AD,
"15178",Pt-derived xenograft models of human ACC in mice,
H6Q-MC-JCCE,R-PhII-Enza vs plcbo-Pediatric pts w/Bcell-1st remission-NHL,
I3Y-MC-JPBI,PH II - CDK 4/6 Dual Inhib-Braf wt&Braf mutant-Melanoma,
I7G-EW-HLBE,Sleep EEG,
F3Z-US-X038,Inpatient Diabetes on Corticosteroids,
B4Z-JE-B027,"24 Hour Efficacy Observational",
I7R-EW-HPBA,SAD,
B9E-MC-X061,"Phase 1/2 study of Gemcitabine, 96 hour infusion",
B3M-MC-V014,CEFACLOR IN VITRO CANADIAN SURVEILLANCE STUDY,
I3Y-MC-V004,Anti-cancer efficacy of LY in HNC cells invitro,
I6F-MC-A006,LY IN SIGNAL/maintenance of stem-like cells/TRIPLE NEG. BC,
I6E-AV-I006,AV-45-IIT-006: Effects of Aerobic Exercise on Alzheimer's,
"15786",Evacetrapib- Lipid 3,
I4E-IE-W816,Protocol No. CA225-111; II TRIAL OF ERBITUX TWO WEEKS THEN A,
I4E-IE-W847,Protocol CA225-115; A II STUDY FIRST-LINE THERAPY WITH BEVAC,
I4E-IE-W937,CA225-086:E1504 Ph II-CETUXIMAB in Adv BAC/AdenoBAC Features,
"3159",SIAM - Drug interaction,
H9P-MC-LNBJ,pk/pd Child Safety Study,
F1K-PL-O048,Sepsis bundles,
B1Y-EW-E079,"FLUOXETINE: 20, 40, 60 MG V PLACEBO OBSESSIVE COMPULSIVE DIS",
F3Z-VI-IOBR,SAFETY AND EFFICACY OF LISPRO,
H8O-UT-O007,Byetta vs glargine on cardiac funct in T2DM w/CHF,
I2R-MC-BIAE,"Type 2 patients, phase 2  (insulin naïve)",
H9P-EW-LNCV,Biopharm Alcohol Interaction Study,
I4C-MC-JTBG,Ph II c-Met Antibody + 3rd Generation TGFR TKI-NSCLC-2 Ln,
I2K-MC-ZZAO,"6-month Safety Study ",
H3E-US-V143,Anti-tumor activity of Pemetrexed combined with EGFR TKIs in,
"12755",iGluR5 DDI EtOH,
H3E-US-X078,PhII Concurrent Pemetrexed/Radiation Poor-Risk St III NSCLC,
I2K-MC-ZZBV,Warfarin,
H2Q-MC-LZZF,OPEN-LABEL EXTENSION OF LZZA: LY246708 TARTRATE IN AD,
I2K-MC-ZZCK,Definitive Food Effect,
B4Z-US-LYEM,Strattera vs. compartor 24 hour efficacy and missed dose,
"12953",IIT Placeholder - Cialis,
H3S-MC-GGGM,RALOXIFENE VS ESTROGEN: HISTOMORPHOLOGIC EFFECTS IN BONE,
F3Z-MC-IOPS,Comparison of ILPS bid glargine qd in T1DM patients on bolus,
H8O-MC-A017,The effects of GLP-1 agonist on b-cells of Islet trans,
I2K-MC-ZZCG,Pediatric Study,
I3J-MC-LACH,BACE Phase 2 Biomarker ,
F1J-US-HMGO,Neurobiology of Depression,
"12999",DDI for LY2608204,
F1D-MC-V025,Olanzapine on the T-type Ca channels,
H8O-MC-V007,Effects of GLP-1 and Exenatide on HDL Cholesterol,
"13222",GPR119 DDI Study (Phase 1),
B3D-US-X023,PTH on Accelerating Lower Extremity Stress Fracture Healing,
I2Q-MC-GMAJ,Phase 2 Dose Titration vs SU,
"13311","Japanese FHD Study; safety, tolerability, PK/PD in healthy ",
H3E-US-I030,PhII Cisplatin/Pemetrexed/Rx in pts w/ StageIIIA NSCLC,
H9P-MC-LNDT,API/resinate taste evaluation for child formulation devel.,
H3S-LC-GGGI,METABOLISM AND PHARMACOKINETICS OF 14C RALOXIFENE (LY139481-,
H9B-EW-BCDU,China Lupus Phase I/ PK Trial ,
H9B-MC-BCDQ,China RA Phase III,
I4D-MC-V005,Cancer models to id specific subsets of human cancer patient,
I1F-MC-RHBQ,Moderate to Severe Psoriasis with Genital Involvement,
I1F-MC-RHBS,PS PH3b-Ixe vs Stelara 12wk Primary Endpt NonInf & Superior,
"1606",Duloxetine on electromyography of pelvic floor (Benson),
I1R-MC-E001,ExIST Trial to examine the effect of GRA I on GIGD Incretin,
H2Q-MC-LZYH,Disease progression in mild to mod. Alzheimers (P2),
I8B-MC-ITRL,U100 Pilot PK,
I8K-MC-JPDA,Phase 2 POC in Rheumatoid Arthritis PLUS long-term extension,
I7E-AV-E015,"18F-AV-1451-EXIST-015",
I4V-MC-B001,Corrona Contextualization,
"16290",TQT,
"16295",Hepatic Impairment,
I8V-MC-LODA,SAD/MAD,
"16649",Monotherapy in Atopic Dermatitis,
B3N-MC-EUBC,Morbidity and Mortality,
I5P-MC-CKAA,"CDK 7/9 Dual Inhibitor, ph 1 in AML patients",
"13515",PTH-anti RANKL Antibody ,
H8O-CA-O020,Exenatide Regulation of Lipoprotein Particle Prod in Humans,
H3S-MC-GGGR,EFFECTS OF RALOXIFENE ON BONE REMODELING IN POSTMENO. WOMEN,
I4G-MC-ABDB,T1DM non - inferiority,
"13704",sTM MAD,
B7A-MC-V023, Nitric Oxide Signaling in Diabetic Retina,
"13729",Translating diet & exercise data to improve R-A dosing,
H3S-MS-GGHQ,DIGOXIN-RALOXIFENE INTERACTION STUDY,
I3I-MC-GFBB,Teplizumab compared with placebo in treatment of psoriasis,
I4T-IE-JVBR,CP12-0711: Ph2-1121B-Ovarian,
I5A-IE-JAEF,CP13-0811: Ph2 - A12- NSCLC adv - 1st Line,
H8O-MC-A034,Effects of Exenatide Therapy in a Large Animal Model - NASH,
I5A-MC-JAEN,R-PhII-A12+Gem+Cis vs Gem+Cis-Squamous-NSCLC-1st line,
H4A-CA-V012,IN VITRO LY303366:1)SYNERGY 2)MULTIPLE DOSE PD 3)HUMAN SERUM,
I1F-MC-RHBB,Ph 3 Palmoplantar Psoriasis,
I4S-MC-HHCG,Phase 2 POC study in Alz Psychosis,
H2Q-MC-LZZD,LY246708 TARTRATE: SAFETY&TOLERANCE STUDY IN AD PTS,
I2K-MC-ZZBN,Absolute BA,
"12845",Phase 2 Depression #1 mGluR5 Antagonist I,
F1J-MC-HMGG,Cymbalta Low Dose Study for Fibromyalgia,
"12877",Opiate Sparing,
"12903",OLAI safety & efficacy (continuity of care),
"12931",Ph1 study for Notch in leukemia,
I3K-EW-LAEC,Sleep EEG Study,
H4H-LC-DDAA,VOID,
F1D-MC-LOCB,PK Characterization of Olanzapine LAI in Adolescents,
H7T-MC-TADR,Oral Sensory Evaluation and Flavor Characterization,
H3E-MC-JMAP,PHASE1 OF LY231514 A. CISPLATIN IN LOC.ADV. A. METAST.SOLID,
"13098",Treatment trends in obese type 2 DM patients,
I3S-MC-JABA,"FHD/FED, Hepcidin, ph 1",
"13173",Phase 2,
B4Z-US-X061,Atom. as a Neuroprotective agent in Alzheimer's,
I2Y-JE-GHFF,JP Forteo_TD Phase 1,
"13346",CMC Formualtion Development,
B5K-US-A002,Li Wen: Pro Insulin study in mice,
H6D-KL-O015,Cialis OAD PMS study in Korea,
I1F-MC-RHAZ,PS - PH3: Plc trial 12 wk endpt w/ long term eff. 2 LY doses,
"12984",PS-12wk to primary endpt-placebo ctrld vs 2LY doese 5 yr ,
F1D-US-X317,Prevention of Weight Gain and Dyslipidemia by Green Tea,
H3E-MC-JMAR,PH I TRIAL LY231514 AND 5-FU IN LOCALLY ADVANCED OR MET CA,
I3W-MC-HHAH,"5-HT2a POC study #1",
"13139","5-HT2a POC #2",
H6D-US-X010,PDE5I to Prevent ED Following Radiotherapy For Prostate Ca,
H8O-MC-I014,Effects of Exenatide on Hypothalamic Obesity,
H8O-MC-A030,Exenatide in Islet Cell Tx in Primate Model - 12 mos,
I1A-MC-BPAI,ERbeta RBA Study,
H6N-MC-LEAV,Digoxin Interaction (PgP),
H6E-AY-O018,The effects of pioglitazone in acromegaly ,
H3E-MC-V145,Pre Clinical - Response and toxicity,
I2Y-EW-GHFL,TQTc Study ,
"13465",T2DM non-inferiority,
"13531",prasugrel in-lab loading vsclopidogrel flexible preloading,
"16720",FHD_Ph Ia/Ib - Tie2 Antibody - Solid Tumors,
H4A-LC-XBAW,LY303366:SAFETY AND PK STUDY IN HEALTHY AND HIV-INFECTED SUB,
I7E-AV-_A19,"18F-AV-1451-A19",
I7E-AV-E060,AV-1451-EXIST-060,
H8H-CD-LAHJ,SAMURAI Acute Treatment of Migraine (Lasmiditan vs Placebo) ,
H8H-CD-LAHO,Oral Lasmiditan in Acute Treatment of Migraine ,
"16954",Ph2-Abema Right Sequence-mBC (Eric Winer Alliance Foundation,
"17006",Human Abuse Liability,
I1F-MC-RHCN,Hidradenitis suppurativa (HS) trial 2 ixekizumab vs placebo,
B9E-MC-JHMQ,Phase 3 Trial of Gemcitabine + Cisplatin in NSCLC,
I1F-MC-RHCP,PPP registration trial 2,
B9E-MC-X053,PHASE I/II TRIAL OF GEM AND RT IN PANCREATIC CANCER,
J1O-MC-JZHC,Ph1b - AurA Kinase Inhib - MBC,
I1F-GH-RHCX,"A Multicenter, Open-Label Study to Evaluate the Efficacy and",
J2D-MC-CVAA,SAD/MAD,
"14157",Pediatric study of Teplizumab,
H3E-US-B013,CHART REVIEW_ALIMTA Cost/Clinical Outcomes-Comorbidities ,
I1N-JE-CDBF,JP mGlu2Pot/CytLT1 antag I P-I,
H9H-MC-JBAJ,"FED Ph 1B/2, TGFb RI Kinase Inhibitor Pancreas",
"13678","2B6 DDI Placeholder",
B4Z-GH-O032,strattera,
H6Q-MC-V054,Pre Clinical - Mol. mechanism of apoptosis induced by Enz,
I2R-MC-BIAI,Renal Study,
I2Y-EW-GHFR,Environmental Conditions,
I5A-IE-JAEA,CP13-0813: JP-Ph1 - A12 - Solid Tumors,
H7T-MC-B014,Prasugrel Active Surveillance Study ,
"14011",B'pharm Metformin DDI Study,
I4V-MC-JADE,"PhI JAK plc multidose, Healthy Volunteers Incyte 102",
B9R-SO-O056,Minimax,
I4V-MC-JADL,Renal Study,
F3Z-MC-IOQG,CREED Retro Ob Study of mgt & outcomes diab pts in ramadan,
H6Q-MC-V079,Pre Clinical - PKC Beta development in CLL,
J2K-MC-JZKA,KRAS G12C Phase I FHD,
B9R-FP-GDES,EFFICACY AND SAFETY OF GH TO FINAL HEIGHT. NVSS-2,
J1W-MC-JZH1,AMBIANCE - Ph II - MultiCmpd BC Aurora Kin -Post CDK 4/6 mBC,
B1Y-IT-0077,FLUOXETINE MAJOR DEPRESSIVE DISORDER,
I9N-MC-FCAD,Ph2a EoE Study,
"17606",Ph I/II-PEG+TIM3-(post-IO post-platinum) NSCLC,
J2G-OX-Y009,PhI-RET Inhibitior+Crizotinib-NSCLC,
I7E-AV-E105,ExIST-120: Tau Burden Among Mexican Americans,
J2G-OX-Y051,RET Inhibitor-MTC,
J2G-OX-Y079,RET Inhibitor-NSCLC,
J2G-OX-Y152,RET Inhibitor-MTC,
J2G-OX-Y203,RET Inhibitor,
J2G-OX-Y205,RET Inhibitor,
I1F-NS-I011,Consortium trial testing multiple compounds for COVID-19 eff,
"18102",Rosuvastatin DDI HV,
"18111",Efficacy and safety of fruquintinib for mCRC ,
J2G-OX-B002,China PMSS-PhIV-RET Inhibitor-NSCLC+MTC+Thyroid,
H7T-CR-TAEN,Taiwan Safety Study,
"14163",Relative Bioavailability,
I1A-JE-BPAJ,JP ER beta P-II BPH　,
"14239",CP11-1012: R-Ph3 - Gem+CiS+Necitumumab vs Gem+Cis-Sq NSCLC,
H8O-EW-GWEA,TQT Study for QW - Infusion,
I2R-MC-BIDD,Doubled Dose Trial,
"14948",Ph IV-Target Population/Treatment Patterns-MBC-1st Line,
I1F-MC-RHBE,Psoriatic Arthritis Phase 3 Biologic Experienced Pts.,
F1J-US-A013,Effect dulox in rat mod neuropathic spinal cord injury pain ,
H7T-FR-O014,Normal vers tailored dose of Prasugrel in patients >75 years,
I5U-MC-ANBB,SAD,
I5A-IE-X004,"8792: Ph II - A12 - Mesothelioma",
H7T-UT-O017,Rijnmond CCR,
I5A-IE-X022,E4508: Ph II - A12+Carbo+Paclitaxel - NSCLC,
H8K-MC-JZAY,"2C19",
H4Q-MC-V002,LY333328--MIC/MBC TESTING OF GRAM+ BACTERIA & KILLING CURVES,
I1F-MC-RHBG,China PK Study,
I3P-MC-GKBI,C14,
I4T-IE-JVBW,CP12-1026: Ph1b - Ramucirumab - Gastric,
B4Z-JE-B017,NSOS for Strattera in Japan (Japanese QCD study),
"14213",Tadalafil PRN + Testosterone Solution,
H8O-EW-GWDZ,Pilot TQT Infusion Study,
I7Z-JE-FLAF,Japan Combo Ph3 ,
H6D-MC-LVJC,PPHN safety and efficacy study,
I5L-MC-TCAE,"TC-1A Open Label, Dose ranging Safety and Tolerability",
I5X-MC-PFAC,Single Dose PET Receptor Occupancy Study ,
I5E-US-TSAX,Determinants of Convenience of Axiron Application Method,
I5L-MC-X001,Measurement of Fat Uptake in Serial Blood Samples,
I1R-MC-GLDC,Hepatic Impairment Study,
B1Y-FP-0730,PROZAC IN GERIATRIC DEPRESSION,
F1J-JE-HMHB,JP Cymbalta P-III Long term safety FM,
B1Y-JE-HCLX,Japan PhaseI study,
H8K-MC-V002,Pre Clinical Cyto toxic mechanism/Target ID,
F1J-XV-A015,Dulox activation brain regions in animals,
H7T-US-TAEO,Prasugrel vs Ticagrelor,
I2M-MC-GSDI,Bridging Study,
I1R-MC-GLBT,Renal Impairment PK Study,
"14615",FRD mBC phase 3,
I5J-MC-NOAE,Drug-Drug Interaction Study - Itraconazole,
H8A-MC-LZAW,Mexico PK Study,
I4L-MC-ABEP,PK/PD Bioequivalence BIV (Aura),
I6M-MC-SSAB,POC Study,
I5S-MC-EFJE,PCSK9 Ph 2 Dose Ranging/Statin Add-on,
"14862",PCSK9 Ph 2 Open Label Extension,
I2R-MC-BIDL,PK/PD Elderly Study,
I2R-MC-BIDP,"Transcapillary Transport, Microdialysis Study",
I4E-US-X002,Eval of Biomarkers Ph2b Erbitux Combo w Platinum-based Chemo,
I6O-JE-BHBF,BIL Humalog Mixtures Jp Ph1,
I6R-MC-DLAB,MAD SARM III,
"14970",spinal cord injury (MOA) trial,
"1499",LY315920:PHARMACOLOGY STUDY IN ACTIVE RHEUMATOID ARTHRITIS,
B5K-FW-IBFH,Ethnic variability in vascular response to humulin,
F3Z-MC-IOQB,Comparison of Insulin and exenatide QW on cIMT progression,
H6U-US-O012,MDD Remission Validation Study 4,
H3E-MC-JMIO,Ph II-Alimta+/-TKI-NSCLC-NSq-Feasibility,
F1J-MC-B038,Drug Utilization Study by age groups,
"13527",Internalising Symptoms observational study,
"15657",DDI - Contraceptive,
H8K-MC-JZAS,PK Study to support Tasisulam local China Registration,
F1J-MC-HMGT,Adolescent Fibromyalgia,
"13546",lumbar spine BMD in pts with glucocorticoid-induced osteopor,
B7A-MC-A018,Role of PKCbeta in atherosclerotic plaque formation in ,
B9R-IT-O054,Prevalence of SHOX mutation inan Italian ISS population,
H7T-MC-TAEG,China IMCT study for ACS MM indication,
F1J-CA-O043,"Dep, Anx Disorders and Insomnia in Pts Visiting Pain Clinic",
I1F-MC-RHAO,"Ph3: AS in bDMARD Naive Pts 16k endpoint, 2 LY doses",
"13660",iGluR5 Opioid DDI (placeholder),
I1V-MC-EIAJ,Confirmatory Relative Bioavailability(RBA)Study Healthy Subj,
"13728",Effects of Atomox. on binge-like drinking in C57BI6J mice,
H3S-MC-GGHU,"COMP OF COMBO FLUO/RALOX,FLUO ALONE TREAT POSTMENO OSTEOPORO",
I6B-MC-HZBH,RBA,
H7T-MC-B018,Prasugrel Active Surveillance Study,
I4J-MC-V001,Testing of efficacy in an in-vitro model of esophagal cancer,
I4O-MC-BACL,Hepatic Impairment,
I4V-MC-JAGT,Taste study for pediatric formulation,
I4H-MC-JWAC,PhIb/II study of LY2780301 with paclitaxel in breast cancer,
H9H-MC-JBAQ,Ph III - Galunisertib+Sorafenib vs Sorafenib - HCC1L ,
H4H-MC-LGAG,Extension of H4H-MC-LGAC (ALS Trial),
B3D-OE-O040,Effects of Parathormone (1-34) on Periprosthetc Fractures,
I6E-AV-_657,AV-657 (Binding properties and safety of 18F-AV-657),
I3Y-MC-A003,Tyrosine kinase inh. in models of ped. high-grade glioma,
I6O-MC-B004,"2012-607 Efficacy and Safety of Humalog® Mix75/25™",
H6D-CA-A021,Small Molecule Therapy and survival in renal transplantation,
B7A-MC-MBEA,Ruboxistaurin (ExIST Study)in New York Heart Failure,
H6Q-MC-V064,Pre Clinical - EBV positive gastric cancer cell lines,
"13884",Phase 3 Placebo Controlled Trial of Teplizumab,
I5B-IE-JGDE,CP19-0801: R-Ph2 - 3G3 or 1121B - Glioblastoma,
I4L-MC-ABEH,BIV-use in Pediatric subjects,
H9B-MC-BCEB,China Ph III Lupus Study,
"14066",Pre Clinical - Enz+Vor - Intracranial Glio Xenograph,
"1649",LY354740 in Social Phobia,
I2Z-MC-LAFH,C14 study,
H4A-MC-V014,LY303366--MORPHOLOGICALLY ALTERED ASPERGILLUS AFTER EXPOSURE,
"14190",Basal Switch Study,
H4F-MC-L006,LY303932 IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS,
H4G-MC-CBAB,A COMP STUDY OF ANAL EFFECT OF LY303870 IN PT WITH OSTEO,
F1J-JE-HMHA,JP Cymbalta P-IV DPNP,
I5A-IE-X005,"8832: Ph II - A12 - Uveal Melanoma",
F1D-CR-HGNC,CN Zyprexa O+F Regional IMCT ph 3 BPD,
H9P-EW-LNEF,Dose Linearity Study for Japan Submission,
I4V-JE-JAGP,JP_JAK_Ph2_PS,
I4T-CR-JVCH,CN -R-Ph III-Ramucirumab+FOLFOX4 vs FOLFOX4 - HCC - 1st Line,
H4S-MC-EWAK,INTRACORONARY STENTING OF OLD SAPHNEOUS VEIN GRAFTS,
F1J-CA-A014,Neuropathic pain in the rat,
I6E-AV-_A17,Ph III subjects with progress. cog. decline post Florbetapir,
I6E-AV-_A20,Ph II study- PET imaging in focal dementia syndromes,
I2H-MC-V001,Deter. of in vitro activity in Chronic Lymphocytic Leukemia,
I8L-MC-IXAH,Injection Site,
H8L-MC-IQBD,Formative human factor study for IRMA,
"14869",Post marketing surveillance study,
I2R-MC-BIDM,Counter Regulatory Study,
I6A-MC-A001,Pi3K1mTOR inhibitor in in vivo & in vitro models Esophagea,
I5S-EW-EFJD,MD Statin PCSK9,
I4T-MC-JVCK,R-Ph III-1121B+Eribulin vs Eribulin-mBC,
H7T-MC-V035,Examine reversibility of ticagrelor effect on human platelet,
I2I-MC-V010,Invest. the in-vitro efficacy of LY2606368 in HNSCC,
"15027",QTC study,
I4O-MC-BACS,Phase II Open Label Extension,
I4O-MC-BACV,CSF Biomarker Multiple Dose ,
I6S-MC-ASEB,Multiple Ascending Dose,
"15074",HTN Study,
I2I-MC-V012,Dissect. the role of CHK1 in hepatocellular carcinoma invitr,
I4O-MC-BACU,CSF Biomarker Single Dose,
"15112",Ph III - Chk-1 Inhib II (placeholder),
I4O-MC-BACY,Organoleptics Assessment of LY2886721 and Placebo,
I7P-MC-DSAA,Phase 1 SAD in Healthy Subjects,
"1518",North American  ALS  Registration Trial,
I6I-MC-LMRC,RBA,
I6O-MC-B003,"2013-064_Diabetes Mellitus, Chronic Kidney Disease",
I3O-EW-JSBC,C14 Study,
H8L-MC-IQCJ,BIV 80 KwikPen Summative,
B1Y-MC-A001,Effects of Withdrawal following Chronic Fluox. Adm. in Rats,
B1Y-MC-X121,Antidepressant Half-Life and Mania,
F3Z-US-X006,Lyspro & Ultralente bid in type 1 children and adolesent,
H9H-MC-V011,Testing of TGFb compounds in adult glioblastoma,
H7T-CA-O021,In-vitro Immunogenetic Safety of Platelet Inhibitors,
I3X-MC-JHTG,JAK-2 Food effect study,
I1R-MC-GLDI,BP study,
H3E-MC-B018,"2013-388_CN - Ph IV - Alimta - NSCLC",
I7J-EW-BCGB,MAD HV,
I7N-MC-BDPA,Phase I SAD/MAD to POC,
I5B-JE-JGDK,JP_Ph Ib - Olaratumab + Doxorubicin - Soft Tissue Sarcoma,
H7T-MC-B021,Physician Survey to Assess Effectiveness of Risk Minimisatio,
"15429",C14 STUDY,
F3Z-US-IOGF,Long term efficacy of insulin lispro usage in type I DM,
I7D-FW-SGAF,O-glycoside study,
I3Y-MC-A005,Assess. the sensitivity of esophageal carcinoma and melanoma,
I6F-MC-A004,Assessment of LY in pt. derived xenograft models of T-ALL,
I4D-MC-V001,Cytotoxic Mechanism and Potential Mechanisms of Resistance,
I7T-MC-RMAA,LY900013 CP Human c14 Study,
B9E-MC-JHPD,Phase 2 study of Gemcit in Stage 3 & Non-Small Cell Lung Can,
I3Y-MC-JPBU,Food Effect study in Healthy Subjects,
"15548",Hepatic Impairment in noncancer subjects,
J2G-OX-Y136,RET Inhibitor-MTC,
I4M-JE-MRAS,MRIII plus Tadalafil Phase 1 Japan,
I3Y-MC-A006,Combo of inhibs w/LY to overcome feedback induced loss of G1,
H3F-CA-O001,efficacy of single and dual hormone during exercise type 1,
I8B-FW-ITRA,URI-Vasodilator Ph1 HV Study,
I7Z-EW-FLAJ,Renal Impairment,
I8L-MC-IXAF,BE (U200),
H9H-MC-V015,Evaluation of TGFb inhibitor (L\Y2157299) in gastric cancer,
H7T-US-X021,Pharmacodynamic profiles of prasugrel in patients with ST el,
I4V-MC-JAHD,Pharmacodynamic study  ,
I4E-IE-W811,Protocol CA183-013; II TRIAL OF VINFLUNINE AND CETUXIMAB IN ,
I4E-IE-W825,Protocol CA225-063; A II TRIAL OF ERBITUX FOR RECURRENT AND ,
I4E-IE-W827,Protocol CA225-065; AN EXPLORATORY PHARMACOGENOMICS STUDY OF,
I4X-MC-JFCQ,Phase1b/expansion cohort – neci + PD1 in stage IV NSCLC,
H3E-MC-V160,"LY, LOX, COX-2 & recptor tyrosine kinase inh./Mesothelioma",
"15712",Anti-cancer efficacy of LY in HNC cells in vitro,
B1Y-US-HCIW,Pharm. Treatment of Fluoxetine-Assctd. Sexual Dysfunction,
I4D-MC-V003,Devel. of comb. therapeutics with CHEK1 inhibitor in ovarian,
H4Z-MC-A001,Test the activity of SERM-analogues against Leishmania,
I6A-MC-CBBE,Ph II - PI3 Kin/mTor Dual Inhib + Necitumumab - Sq NSCLC,
"15845",FED_Ph Ib/II - Olaratumab+Sorafinib-Tumor Type TBD- lst Line,
I4E-IE-W866,Protocol CP02-9607; Ib/IIa Study of Anti-Epidermal Growth Fa,
I4E-IE-W899,Protocol CP02-9816C; II Study of Anti-Epidermal Growth Facto,
I4E-IE-W900,Protocol Non-BMS/UPC 05-005; A I TRIAL OF CETUXIMAB (C225) A,
I4E-IE-W925,Protocol CA225-118; A PILOT II STUDY WITH CETUXIMAB AND RADI,
I8D-MC-AZEK,DDI Oral Contraceptive,
I3Y-MC-JPCA,Abemaciclib SAD,
I4T-MC-JVDJ,PhIa/Ib -Ramucirumab+MEDI4736 - Gastric-Esophageal-NSCLC-HCC,
I3O-MC-JSBE,Ph II - c-Met Inhibitor + Novel Compound - Melanoma,
"6933",Abeta CSF over 6 Hr.,
"1588",Pediatric ADHD-B,
I4E-IE-W861,Protocol CP02-9401; I Study of C225 in Patients with Advance,
I4E-IE-W873,Protocol CA225-074; A Randomized III Trial of Oxaliplatin (O,
I4E-IE-W903,Protocol Non-BMS/3G-03-4; II STUDY OF OXALIPLATIN AND XELODA,
I8D-MC-AZEU,Open Label Extension,
I7E-AV-E010,"18F-AV-1451-EXIST-010",
I8H-MC-BDCA,Basal Insulin-Fc SAD study (Using LY3209590 Only),
I6E-AV-I043,AV-45-IIT-043: Kinetic Modelling,
I8K-MC-JPDD,SAD/Food Effect/MAD,
I4V-MC-JAHH,Phase 2 POC SLE,
H9X-MC-GBGG,Phase 3b Trans Launch Conc Start w SGLT2i,
I4E-US-X018,CA225-261 UCDCC177 PhI/II Erotinib+Cetuximab NSCLC,
I8B-MC-ITRO,URI Vaso/Citrate Phase III T1DM Pump,
I8F-MC-GPGB,Phase 2,
"16337",Nail Psoriasis,
I8R-MC-IGBE,Evaluate effect of Nasal Congestion from common cold ,
B3D-LC-GHAW,PK & acute PD of PTH when admin with Furosemide in renal ins,
B7A-MC-MBBO,"Erectile Dysfunction- US IND 55,999",
H3E-MC-JMCB,"Phase I, MTA + Taxol weekly",
H3E-MC-JMCC,A phase I trial of MTA + Ifosfamide,
H3E-MC-JMBZ,"Phase II, MTA + Cisplatin in NSCLC (NCIC)",
H3E-MC-JMCG,"Phase II, MTA + 5FU daily in 1st line CRC",
F1D-US-X088,olz. treatment of Pychotic Features Associated with PDD,
H3E-MC-JMCH,"Phase III 1st Line Mesothelioma, ALIMTA/Cis vs. Cis",
B1Y-MC-HCAN,FLUOXETINE OPEN LABEL PANIC ATTACK,
B9E-SB-O012,"Phase  I/II, Gemcitabine & Epirubicin In Pancreatic Cancer",
"2475",Safety and pharmacology of pulmonary insulin,
B9E-MC-I107,"PHASE 1/2 TRIAL OF TAXOL, METHOTREXATE, AND GEMCITABINE",
B1Y-MC-HCDH,FLUOXETINE VS TRAZODONE DEPRESSED GERIATRIC PTS.,
"2540",Phase I MTA + GEM,
H4Y-FW-LJBJ,Ergotamine interaction,
"2609",LY334370 in patients with hypertension,
"2723",LY354740 Relapse Prevention in Smoking Cessation:Chronic Dos,
B1Y-MC-HCEG,FLUOXETINE V PLACEBO:LONG-TERM TREAT OBESE NIDD,
H4Q-MC-ARRD,LY333328 vs vancomycin--complicated skin infections,
I4X-MC-B002,Ph IV - Necitumumab - sq NSCLC,
"1635",LY333013-LC-xxxF Hepatic Impaired,
"1636",LY333013-LC-xxxG C14 Metabolism,
I8V-MC-LODC,EO PET,
"16406",Ph II - Ramucirumab - High Risk Adj Bladder,
I8W-MC-PDBA,LY2775240 FHD SAD in HV,
"1648",LY354740 in PMS,
I8B-MC-ITRP,U200 feasibility study for citrate/vaso,
I8H-MC-BDCE,"12W Phase 2 Study",
"16531",TNF IL-23 Phase II archetype,
I9E-MC-LAGA,Combined SAD/MAD Long Acting Glucagon Agonist  (LY3324954),
I4V-MC-JAII,Ph3 UC Maintenance Study,
I4T-MC-B007,"2016-3909:Sequence of treatments in NSCLC",
"16608",Psoriatic Arthritis Phase 2,
F3Z-MC-IOQW,TANGO Feasibility Study 2a,
"5998",Ph3 Safety & Efficacy in Acute Ischemic Stroke,
I7E-AV-_A01,AV-1451-A01,
H3E-MC-JMIX,Ph III-Alimta+Carbo-NonSq NSCLC-1st line Maintenance PS2,
B4Z-MC-B026,Atomoxetine Drug Utilization Study Part 4,
I2V-MC-A002,CXCR4 antagonist inhibiting metastases dev. in solid tumors,
H4W-LC-LLAH,Disposition after Oral Administration,
H7T-MC-B023,"2014-229 RWE-Comparative safety & effectivenes Effient v Bri",
I6S-MC-ASED,Phase 2 ASI in CKD ,
I7S-EW-HBEB,Sleep Study,
I5Q-MC-CGAF,Phase 2 PoC of LY2951742 in Osteoarthritis,
I7T-MC-RMAF,RBA Study,
B1Y-HL-0001,FLUOXETINE AND PLACEBO IN BULEMIA,
B3M-MC-AJAU,Cefaclor AF vs Amoxicillin/Clavulanate in Acute Bronchitis,
F3Z-FW-ITCC,URI-Citrate Ph1b T2DM PK/PD,
I6E-AV-I011,AV-45-IIT-011: Amyloid accumulation in pre-clinical AD,
I7E-AV-E006,Tau Imaging of Chronic Traumatic Encephalopathy,
H9H-MC-A034,Preventing BC via depleting mammary epithelial progenitors,
I7S-MC-HBEG,RBA Study,
I8F-JE-GPGD,Japan Ph2 (monotherapy),
I8Y-MC-CRBE,Ph2 Abortive dose ranging study,
I8M-MC-BIXC,Formultation PK Study,
I4V-MC-JAIG,Ph 3 LY vs PBO moderate to severe UC Conventional IR Group,
I5S-MC-EFJO,ASCVD study,
F3Z-MC-IOHH,Insulin lispro HM in MDI Therapy:  An Optimization Study,
"16683",TANGO Peds Pivotal Study,
I9L-MC-JZCC,RBA/Food Effect/ABA,
I9J-MC-DIPA,Pilot PK HV,
"16980",China IMCT,
B1Y-IT-0008,FLUOXETINE VS IMIPRAMINE CHRONIC DEPRESSIVE DISORDER,
H8H-CD-LAII,Phase II trial,
I1F-JE-RHCV,Japan Post Marketing Clinical Trial for EP/GPP,
I5Q-MC-B002,EU Drug Utilization -Retrospective Study (Database study) ,
J1A-MC-KDAC,MAD in Psoriasis Pts,
"5168",Bioavailability study of B-acetyldigoxin,
B3M-BP-S024,Colonization Resistance Day Care Study,
H4A-MC-XBAS,Oral - Chronic Aspergillus Pilot,
"2910",Multiple Dose,
F3Z-SB-O020,IIT PK/PD of Lispro in Type 1 w/ Nephropathy,
H4Q-MC-A002,LY333328 endocarditis loading and relapse studies in rabbits,
H3E-MC-JMD3,PH I MTA + 5-FU DeGramont,
H3E-MC-JMCQ,PH II MTA +Taxol 1st line NSCLC,
H3E-MC-JMH1,PH II MTA + Taxol 2nd line NSCLC,
"2974",Invest Initiated -Block Strategic Support Studies-Vancomycin,
B9E-MC-X182,Gemcitabine in a Multi-Modal Treatment Approach,
B1Y-MC-X136,PINDOLOL EFFECTS IN TREATMENT OF MAJOR DEPRESSION,
B4G-IN-LCDI,Parkinson/non-responder to conventional Tx/no comparator,
J2G-OX-Y151,RET Inhibitor-MTC,
I4V-MC-B031,SLE Patient Preference Study,
J2Z-MC-PGAB,PK subcutaneous dosing,
H7I-MC-S021,Detect Oculomotor Changes During a Migraine Attack,
"18286","Three arms: zagotenemab, donanemab and a combo-arm",
B5K-SB-IBEG,POST MARKETING SURVEILLANCE: A NEW PRE-FILLED INSULIN PEN,
"1595",Adult ADHD Efficacy - B,
I8B-FH-ITSD,Phase 3 TIDM URI vs Lispro,
I8B-MC-ITSK,Ph3 URI U200 Pump Safety Study,
B9E-MC-X060,PHASE 1/2 STUDY OF GEMCITABINE AND CYCLOPHOSPHAMIDE,
"17025",Lasmiditan Subcutan ph3,
"17028",AV-1451-EXIST-085,
I4V-MC-JAIV,Phase 2 Study of Patients with Primary Biliary Cholangitis,
I8H-MC-BDCL,Injection Naive T2DM,
I9V-JE-IFBE,SAD/MAD Japan study,
I3Y-MC-I041,PhII Min Resid Diseases Study of Abema w/ Endo Therapy-MIRA,
I8F-MC-GPGS,RBA Study (AI vs PFS) and injection site assessment,
I1F-MC-RHCT,Ixe Reformulation PK (RBA),
S2C-LC-G2AA,LY396623 Dose Escalation in Obese Healthy Volunteers,
F3Z-MC-IORF,Pump Safety Study ,
J1P-MC-KFAC,MAD Psoriasis Pts,
I5Q-MC-S002,Digital Bio-marker Study in Migraine,
J1O-MC-JZHE,An Open-Label Taste Assessment of AK-01 in Healthy Panelists,
I5B-MC-JGDO,FED_R-Ph Ib/II - Olaratumab +/- Dox - mBC                  ,
I4E-IE-W804,"Protocol CA225-006; A III Randomized, open-label, multicente",
I4E-IE-W833,Protocol CA225-019; II Evaluation of C225 in Combination wit,
I4E-IE-W838,Protocol Number CA225-098; II trial of induction cetuximab (,
I4E-IE-W871,Protocol CA225-047; A III Trial of Irinotecan/5-Fu/Leucovori,
I4E-IE-W895,Protocol CP02-0036; II Study of Anti-Epidermal Growth Factor,
"16028",BIV U200 BE study,
F1J-MC-SAAX,VOID,
I8D-AZ-AZEY,AZD PK (DDI) Study (D5010C00004),
B9E-MC-X173,Gemcitabine and Docetaxel in Advanced Solid Tumors,
I4L-MC-B003,"2014-826-3 Reasons behind insulin treatment persistence",
I7E-AV-E032,"18F-AV-1451-EXIST-032",
H2Q-MC-LZYG,Disease progression in mild to mod. Alzheimers (P1),
H3E-US-B023,Retro Analysis Genomic Landscape NSCLC prior to Pemetrexed,
B5K-MC-B012,KwikPen U500 Risk Minimization Study,
I7U-MC-GAHC,Glucagon Analog Agonist Micro Dose Study for LY3185643,
I1V-MC-EIBY,Simvastatin DDI Study in Caucasian Subjects,
"16411",Ph III - Ram + Pembro - Bladder 1st/2nd Line,
F1K-LC-GUAI,F1K-LC-GUAI Bolus Injection,
I3Y-JE-JPCQ,Ph 1b - Abema+Oncolytics - Solid Tumor or Hematologic,
F1D-CA-HGGO,Olanzapine rapid-disintegrating tablet  with schizophrenia,
J2Y-MC-JZSB,Japan ph1 Sintilimab-advanced solid tumor,
I8B-MC-ITSV,Hepatic Glucose Production,
B7A-MC-MBBM,Phase II/III Severe Nonproliferative Diabetic Retinopathy,
"17307",SLE Observational Study,
"18462",Taste Study,
J1V-MC-SSMA,Appendix 1 of Master Protocol for BAFF/IL-17,
I4V-JE-B019,Database study of baricitinib with RA in Japan (Serious Inf),
"18571",N3Pg4 Preclinical Ph 3,
"17350",Ph II - Pegilodecakin - 1L NSCLC PDL1 Low,
"18609",PF: RBA Placeholder,
B1Y-MC-X126,PSYCHOTHERAPY AND MEDICATION FOR BINGE EATING DISORDER,
B1Y-MC-HCJG,DC of SSRI - Effects on Cognitive Funct. & Psychomotor Perf.,
I8S-MC-E002,Ph 1/2 - ERK Inhib - B-cell Malignancies,
H3Z-MC-JNAS,Phase II Eval. of LY295501 for Treatment of Prostate Cancer,
I7E-AV-E092,"18F-AV-1451-EXIST-092",
I1F-MC-B012,"2018-7913 GHO_Pt survey of tx goals & mgmt of pso arthritis ",
J1T-MC-GZEA,FHD SAD/MAD HV,
F3Z-MC-IORO,Tango MDI Feasibility,
J2G-OX-JZJF,LOXO-292 CQT Gating Trial,
F3Z-MC-IORS,R4 OUS Registration Study,
H0P-MC-OA04,Intervention Specific Appendix - OA,
F1D-MC-X055,A PILOT STUDY OF ZYPREXA IN POSTTRAUMATIC STRESS DISORDER,
B9R-JE-H02A,LY137998: OPEN TRIAL 3GIU IN DWARFISM,
J2N-OX-JZND,LOXO-BTK-20008-Ph1-Pirtobrutinib-DDI/MDZ,
H9X-MC-GBGP,Ph IV China Dulaglutide 1.5 mg + Met with CGM,
I4T-MC-B009,"2020-9135_GHO_ RAM 2L LUNG: TREAT-LUNG Pooled EMR Study...",
J2G-OX-Y050,RET Inhibitor-NSCLC,
J2G-OX-Y054,RET Inhibitor-MTC,
J2G-OX-Y064,RET Inhibitor-NSCLC,
J2G-OX-Y087,RET Inhibitor-NSCLC,
J2G-OX-Y099,RET Inhibitor-MTC,
I8R-MC-IGBA,"Safety, Efficacy, PK/PD in T1D with Insulin Induced Hypoglyc",
I8R-MC-IGBF,Randomized Parallel Safety Study to Evaluate Immunogenicity,
I4X-MC-JFCY,Ph II - Neci - Sq Esophageal,
I7E-AV-E047,AV-1451-EXIST-047,
H4Z-MC-JWWA,Ph1:Esc Doses. Pop: Recurrent/Metastatic Breast/Endometrial,
I7E-AV-E104,AV-1451-EXIST-108,
I6T-MC-AMAJ,Trial I: Active controlled Psoriasis phase 3,
I4T-JE-B008,Ph IV - Ramucirumab - Obs Japan pts CRC,
I7W-MC-JQBD,R - Ph II - Angiopoietin2 + Ram + Paclitaxel - Gastric,
B9E-MC-X123,"TAXOL, CARBOPLATIN, AND GEMZAR IN OVARIAN CANCER",
H4S-MC-EWAM,DOSE FINDING WITH rPA (SPEED),
F3Z-MC-IOHG,Pilot Study: Frequency of Hypoglycemia,
B9E-MC-X094,PHASE 2 GEMCITABINE AND CARBOPLATIN IN NSCLC,
J2G-OX-JZJT,LOXO hADME (C14),
"16600",Evaluating a standardised serial CSF collection methodology,
I1F-MC-B017,"2019-8496 Real World Outcomes in Taltz psoriasis patients fr",
H6O-MC-O016,Early Exploratory Trial (EET) HV,
J2N-OX-B004,"2021-10187: Loxo 305 MCL Conert Adm Claims Study",
"18320",Strategy Targeted Inhibition Pancreatic Ductal Adenocarcinom,
"18354",PF |  | DIAB-Diabetes,
B1Y-IT-E045,FLUOXETINE VS IMIPRAMINE DBL MAJOR DEPRESSIVE DISORDER,
"18407", DDI Midazolam study,
B9E-MC-X082,"PHASE 2 STUDY OF GEMCITABINE, CYTOXAN, AND DOXORUBICIN",
B9R-US-GDER,A COMPARISON OF VARIOUS PROVOCATIVE TESTS AND INDICES,
"18622",DDI- Acetaminophen - Gastric pH,
"18625",C14 Trial with LY3556050,
I5Q-MC-CGBE,Registration Trial for India,
"1884",Pilot  Eff. - Breast Cancer,
H3S-MC-GGJJ,Comparison of Ralox HCL & Continuous Combined HRT.,
H4Q-SB-V009,STUDY ON CURRENT STATUS OF RESISTANCE OF THE MOST COM. PATHO,
B9E-MC-X087,PHASE 1/2 TRIAL OF GEMCITABINE AND TOPOTECAN,
B9E-MC-S044,Gem vs Gem/5FU in Panc-S044,
H5P-LC-BWWP,drug interaction (digitalis),
F1D-MC-HGEO,OLAN. VS HALOPERIDOL WITH 31PHOS. NUCLEAR MAGNETIC RESONANCE,
J2G-OX-Y101,RET Inhibitor-NSCLC,
J2G-OX-Y105,RET Inhibitor-NSCLC,
J2G-OX-Y143,RET Inhibitor-MTC,
J2T-DM-KGAI,PK HV,
J2G-OX-Y150,RET Inhibitor-NSCLC,
H7K-GH-O002,Phase II trial of Fruquintinib with Sintilimab in treating Refractory Metastatic Colorectal Cancer patients with TMB-high and Non-MSI-High,
J2G-OX-Y212,RET Inhibitor,
F1D-MC-X052,Treatment Efficacy of Olanzapine for Tourette's  Syndrome,
J2X-MC-PYAG,SC PK HV,
H8H-MC-B004,"2020-9134:REYVOW US daily activities survey study",
B9E-MC-JHDR,JHDR,
B9E-JE-P11D,LY188011 GEMCITABINE PHASE 1 STUDY (PANCREAS),
J2N-NS-I002,Ph2-Loxo 305+VEN-CLL (Thompson/Wierda),
"18404",Hepatic study,
"18410", RBA CMC study 1,
H3E-US-I041,Ph II High-Dose Pemetrexed for Chordoma,
B1Y-MC-X124,FLUOXETINE FOR THE TREATMENT OF DEPRESSION IN PARKINSON'S DI,
H4S-MC-EWAE,ReoPro plus low dose lytics in Acute MI,
I5S-MC-EFJS,Clinical Pharmacology Bioavailability,
I8M-MC-BIXD,T1DM Cross-Over Study ,
I9H-MC-FFAA,HV SAD/MD w/ Pso Pt SD cohort(s),
I6T-MC-AMBE,BE Study to evaluate PK of LY PFS 1ml to Auto-Injector(Bolt),
F3Z-MC-IOQY,Connected Pen System,
I8K-MC-JPDL,PK/PD,
I7S-EW-HBEI,Human Abuse Liability HV,
F1D-MC-HGGU,Ol z vs Risp & Placebo in Psychosis with Dementia,
H8H-MC-LAIB,Absolute Bioavailability of Lasmiditan,
I6Q-MC-BIFD,Matrix Study,
"17202",DDI,
"17289",PMSS for China,
I9S-MC-BTAD,SLE Proof of Concept Study,
J1U-MC-JZG2,PhII - Lung Protocol Pegilo w/Pembro Post IO/Platinum -NSCLC,
I7E-AV-E091,"18F-AV-1451-EXIST-091",
F3Z-MC-IORN,Callisto connected pen meal-tagging study,
J2G-OX-JZJE,LOXO-292 Renal Impairment Trial ,
J2G-MC-JZJI,LOXO-AZ Orchard NSCLC - Non Sponsored Collab with AZ,
J2G-OX-Y002,PhI-RET Inhibitor-MTC,
J2G-OX-Y018,PhI-RET Inhibitor-PTC,
J2G-OX-Y020,PhI-RET Inhibitor-MTC,
I1F-NS-O009,InToDerm QoL in young children w derm diseases,
"2214",Postprandial control - Improved physiologic function,
B3T-MC-JTAG,Ph 2 Study of LY335979/Doxorubicin in Soft Tissue Sarcoma,
J2G-OX-Y188,RET Inhibitor,
J2G-OX-Y199,RET Inhibitor,
J2N-OX-JZNQ,LOXO-BTK-20021-Ph1-Pirtobrutinib-Digoxin DDI,
H7I-AV-S027,ADDI Confirm EET – Lilly SF,
B9E-MC-I082,GEM PLUS 5FU AND G-CSF IN GI AND NSCLC,
H6O-MC-GCEJ,GIP/GLP Coagonist Peptide II,
J1S-MC-JP03,Ph2-Radiotherapy+Abema+TMZ vs Radiotherapy+TMZ-HGG,
"18491",HumaPen PMCF study,
B3N-MC-GRRF,Normalization of glycemic control in type 2 DM,
F1J-LC-HMBI,IV Absolute bioavailability,
"3212","14C Radiolabelled study in healthy subjects",
B7A-BD-MBBZ,PK study - to be defined.,
H3S-JE-302J,DB fracture Osteoporosis : Cooperation with Chugai Pharm,
H4S-MC-X008,Stent Implantation Post Rotational Atherectomy Trial,
H6A-EW-HAAD,Single Dose Safety Studies for Concord,
B9E-MC-V011,HPLC Anal. as Ref. Comp. in Lab.,
B9E-SB-O037,"Phase II, Gemcitabine &  Interferon Alpha 2B Renal Carcinoma",
H3R-MC-I002,migraine study,
B9E-MC-I108,Gemcitabine Combination Chemotherapy in Anal Cancers,
"3470",GEM+VINORELBINE METASTATIC BREAST CANCER PHASE II,
"3496","Pet Scan (Cardiac, PD)",
B1Y-BP-HC22,FLUOXETINE/DOTHIEPIN GEN. PRACTICE UNIPOLAR MDD,
F1D-US-HGHO,"The Efficacy of Olanzapine and Adjunctive Lorazepam, as need",
F1D-MC-O031,Visuo-Manual testing to detect EPS in OLZ vs RIS,
F1D-US-HGIA,Zydis in the Treatment of Acutely Ill Non-Compliant Patients,
"3549",GEMCITABINE FOR RESISTANT LYMPHOMA,
F3Z-FP-O018,EFFICACY OF LISPRO IN YOUNG IDD CHILDREN TREATED BY PUMP,
B1Y-MC-X039,FLUOXETINE EFFECTS ON DEPRESSION & IMMUNE STATUS IN HIV,
B1Y-IT-M006,FLUOXETINE V MIANSERIN D.B. DEPRESSED PATIENTS,
B9E-MC-X085,PHASE 1/2 STUDY OF GEMCITABINE IN NHL,
B9E-MC-S057,Gem in soft tissue sarcoma-JH13,
F1K-LC-EVAJ,F1K-LC-EVAJ APC/Heparin/Hemofiltration Study,
"2098",Oral xanomeline PET study,
B3L-MC-LWAR,LY354740 vs placebo vs paroxetine in panic disorder,
H5P-LC-BWWJ,asthma (probe),
H4Y-MC-LJBA,Comparison study LY334370 vs naramig,
F3Z-SB-IOMG,MIMICKING ICT WITH INSULIN LISPRO MIXTURES,
B3L-MC-0001,Rat model of panic disorder,
B1Y-MC-X151,Fluoxetine in Dysthymic Disorder in Children and Adolescents,
B1Y-MC-HCCI,FLUOX / BENZPHETAMINE / PLAC ANTI OBESITY,
B9U-IT-AZDL,BIOEQUIVALENCE STUDY OF TWO FORMULATIONS OF LORACARBEF 100,
B9U-IT-AZDM,BIOEQUIVALENCE STUDY OF TWO FORMULATIONS OF LORACARBEF 200,
B1Y-MC-HCCM,FLUOX VS PLACEBO IN PRIMARY DEGEN. DEMENTIA,
B1Y-MC-HCDG,FLUOXETINE V TRAZODONE DEPRESSED ADULT PATIENTS,
B1Y-MC-HCDS,FLUOXETINE/PLACEBO HYPERTEN./DIABETIC OBEST PTS.,
"2602",Single dose PK - renally impaired,
B9E-BP-O044,"Ph II, Gemcitabine & Flutamide, In Adv Pancreatic Cancer",
H5Z-LC-LUAQ,Single & multidose R-fluoxetine Phase I Sepracor studies,
B1Y-MC-X043,FLUOXETINE IN POST PARTUM DEPRESSION,
B4G-SB-LCCA,"Open pilot study, effect of pergolide to parkinsonian Tremor",
"3818",Claudication - Comparison of LY to Trental and Pletal,
B9E-MC-X161,Gemcitabine CNS Pharmacokinetic Studies,
"3835","open-label, olanzapine versus risperidone",
B5Q-US-S002,Prokinetic efficacy of Nizatidine in patients with GERD:,
"2957",Raloxifene - Skin Collagen Effects,
B1Y-MC-X093,ADJUNCTIVE PINDOLOL IN FLUOXETINE TREATED PATIENTS WITH OCD,
F3Z-MC-I030,Retrospective: Use of Humalog Insulin During Pregnancy,
"4014",Phase 3 painful neuropathy,
"4055",Phase II Gem + (oxa)platinum in Head and Neck,
B9E-TW-O100,Gem plus vinorelbine for Anthra- and Taxane- refrac MetaBC,
F1J-MC-HMAV,Diabetic Neuropathic Pain,
"4099",Phase I for pamoate formulation,
"4144","Single Dose/Multiple Dose Safety, PK, PD (FHD)",
B9E-MC-V037,Analysis of DNA uptake of H3-gem by cell culture,
F1J-LC-HMBA,Ethanol interaction study,
B5K-EW-IBEO,Prefilled Humalog/Humulin pen (turbo) II - next generation,
B1Y-MC-HCEA,FLUOXETINE VS DESIPRAMINE IN-PATIENTS WITH MDD,
"2674",Phase 2 Trial of LY309887 in Patients with Pancreatic Cancer,
F1D-US-X113,Olz and Eye Movements in Childhood-Onset Schizophrenia,
"2698",Gem vs. paclitaxel vs. gem+ paclitaxel (JH44) in brca,
B3M-MC-S005,Cefaclor AF vs Augmentin BID in AECB-CTNR,
"2831",Exploratory Snacking Study in Patients with Type 2 Diabetes,
C2N-MC-JXAF,(J107) LY355703 plus Doxorubicin - PH1,
B9E-MC-X186,Gemcitabine and Paclitaxel for NSCLC,
B1Y-MC-HCHB,FLUOXETINE/PLACEBO IN SUBSYNDROMAL SYMPTOMATIC DEPRESSION,
B9E-MC-X217,Phase 2 Study of Gemcitabine and Docetaxel in Uorthelial Can,
"3133",Comparison of LY334370 vs rizatriptan,
"3152",Depot phase 1a for SRI 65:35 formulation,
"3219",Neuroimaging Ligan Development (Animal and Human),
B4Z-BD-HFBN,Hepatic Failure,
H4Y-MC-LJBH,Dose response moderate/severe (1 migraine),
B1Y-MC-X008,FLUOXETINE TREATMENT OF BORDERLINE PERSONALITY DISORDER,
B1Y-LC-HCFA,EFFECTS OF FLUOXETINE EX VIVO PLATELET FUNC. NORMAL FEMALES,
"2111",Phase 2 Randomized Double Blind in Women with Met Breast Ca,
B1Y-MC-E003,FLUOXETINE:MDD MULTIINFARCT OR ALZHEIMERS DEMENT,
"2180",LY300164 in Parkinson's pts w L-Dopa induced Dyskinesias,
"2213",Postprandial control - Improved psychometric performance,
F1D-MC-X092,Effect of Olanzapine on Cognitive Function and Psychiatric,
F1J-LC-SAAZ,Single Dose C-14 Radio-labelled Distribution,
B3M-CA-V041,Mechanisms of Cefaclor Resistance in H.Inf.,
F1D-MC-HGHK,Olanzapine Switching Study in Asia-Pacific Region,
B4G-EW-LCCK,Parkinson / Monotherapy / Patch (Extension of Patch #3 & #5),
B3D-EW-GHBF,MD Safety inhaled and rel.bioavail. vs sc,
F3Z-MC-IOHY,"Poland local registration study, type2 diabetes, LM vs 30/70",
B1Y-MC-HCDK,FLUOXETINE VS. IMIPRAMINE IN DEPRESSED PATIENTS,
H3E-MC-JMDH,single arm mesothelioma,
"2559",D/K Backup Study,
"2566",Drug Interaction H2 Blocker,
"2569",Dual Diagnosis Open-Label peds,
B1Y-MC-X169,IS FLUOXETINE'S ANTIDYSPHORIC EFFECTS MEDIATED BY NEUROSTERO,
"2583",JP pulm hGH P-I SDSS,
B1Y-MC-HCDX,FLUOXETINE/PLACEBO:FIXED DOSE ALCOHOL MODERATION,
"2663",combination phase 1 with LY309887,
"2706",Smoking Cessation - Study #1,
"2722","LY354740:  Chronic Dosing, Relapse in Smoking Cessation",
H3S-US-GGIW,"A RANDOMIZED, PARALLEL TREATMENT STUDY OF DOUBLE-BLIND RALO",
"2763",Drug Interaction,
"2815",Single dose safety,
"2842",Use of Humalog Mixtures during Ramadan (Mid East),
F3Z-MC-IOMR,MM/MM/LM vs 30/70 BIDin patients with type 2 diabetes,
"2845",Humalog Mixtures:  Investigator Initiated Study Grants,
H3S-MC-GGIU,Comparison of Raloxifene and Placebo in Postmenopausal Women,
"2864",Phase III (SC Mealtime),
B9R-US-GDFG,Growth Velocity of Young Girls,
"2898",MGlur2 - antidepressant interaction,
B1Y-MC-HCFI,"FLUOXETINE VS IMIPRAMINE IN PATIENTS WITH MDD, AGITATED",
"2940",Comparison of Ralox HCl and Placebo in Postmenopausal Women,
H3E-MC-JMCW,PH II MTA + Navelbine 1st line NSCLC,
B9E-MC-X177,"Ph II  Gemcitabine, 5-Fu, & Interleukin 2, Renal Cell Cancer",
B1Y-MC-HCKJ,Differentiation Trial,
A2E-EW-E003,A BIOEQUIVALENCE STUDY OF DISTALGESIC VS DISTALGESIC NOVUM,
B9E-MC-X190,Gemcitabine and Intensity Modulated Radiation Therapy,
B1Y-MC-HCHR,FLUOXETINE VS PLACEBO IN OCD RELAPSE PREVENTION,
B1Y-BP-E084,FLUOXETINE EFFECT ON APPETITE & THE PATTERN OF FOOD CONSUMP.,
B9E-MC-X151,Phase 2 Study of Gemcitabine in Soft Tissue Sarcomas,
B9E-MC-S112,Gem + Vin v Gem + Tax- NSCLC; Jun98SU68,
"3250",LM vs. 30/70: Comparative study in ~380 Japanese Patients,
"3396",Glycopeptide Phase III Local Registration Trial - China,
"3397",Moxonidine Phase III Local Registration Trial - China,
F1D-MC-A029,Novel Mechanisms of Action of Antipsychotic Drugs,
B9E-MC-V012,Dev. of Anal. Methods for the Det. of Gem. and dFdU in plasm,
H3S-US-GGJN,Pilot Study of Treatment after bone density,
H3E-MC-JMDM,ALIMTA in capecitabine failures,
H3S-MC-I003,Raloxifene pilot study in untreated normal men,
H6D-EW-LVAH,Formulation  assessment study in healthy male and females,
"3837",decision phase for ReoPro plus lytic in AMI,
B1Y-MC-X083,BULIMIA NERVOSA:  THE TREATMENT OF CBT NON-RESPONDERS,
"3915",PK BRIDGING STUDY [JAPAN AND US FORMULATION],
B9E-MC-X052,"Phase 2 Gemcitabine, Cisplatin, XRT for Stage IIIA/B  NSCLC",
B9E-SB-JHPK,"Phase III, Gem & Cisplatin vs Gem, In Pancreatic Cancer",
"3335",Oral delivery - multiple dose,
"3340","Phase II, MTA + Gem, 2nd line Breast",
"3381",Ulrich Ebert Animal Study in epileptogenesis,
"3394",Antifungal Phase II Local Registration Trial - China,
"3418",New Anti depressant Product Team Planning 1999,
B9E-XM-JHPR,"Phase II, Gemcitabine &Taxol, Metastatic Breast Cancer",
B1Y-MC-I014,Liquid Fluoxetine vs Placebo in Child/Adolescent Autism,
B1Y-MC-X188,Effect of Prozac TX in Patients with OCD,
B9E-BX-O048,"Phase II, Gemcitabine  & Paclitaxel, In Advanced NSCLC",
B9E-VI-O073,"Phase II, Gemcitabine  & Cisplatin, in NSCLC",
"3847",pulmIns P-II  type 2 DM,
H5N-MC-GFFH,Phase 2 Dose finding for the administration of LCS LY307161,
"3893",LY354740 vs. placebo vs. paroxetine in panic disorder,
"3897",LY354740 in Parkinson's Disease: Neuroprotection,
B9R-US-X028,Recombinant GH in the treatment of dilated cardiomyopathy in,
"4026","a pop study on gravidity of women w/psych disorders, 1989-99",
B9E-MC-JHRQ,Phase II Gem+Platinum+Taxane/MTA in Advanced H/N CA,
F1D-US-A110,long term effects of olanzapine on rat brain regions,
F1D-CA-O058,Delirium in Intensive Care Setting,
H4Q-LC-ARRO,Effect of Single Dose LY333328 on QTc Interval,
B9E-GH-O150,Gemzar + Cisplatin in treatment of breast cancer,
B9E-GH-JHRD,"Gemzar+Cisplatin in treatment of NSCLC (21d, 28d)",
F1D-AY-HGIX,Australian Bipolar Study,
F1D-MC-V010,Novel Mechanisms of Action of the Antipsychotic Drug Olanzap,
H6L-LC-LFAD,"Clin Pharm Multiple Dose study, placebo controlled",
"4416",R-fluoxetine GAD study - comparison to venlafaxin,
F1J-LC-HMBE,CYP2D6 STUDY,
B9E-AY-O190,Gemcitabine & Liposomal Doxyrubicin in Ovarian Cancer,
B9E-XB-O141,"PHASE II DOCETAXEL, CIS, GEM IN NSCLC NEOADJUVANT",
"4537",estudio,
B1Y-SE-9286,CLINICAL EXPERIENCE EVALUATION OF PROZAC 20,
"4616",Evaluation of IGF-I,
"4631",LY354740 in Panic Disorder,
F1D-CA-O083,Olanzapine and Placebo in Treatment of Trichotillomania,
B9E-MC-V070,Tumor up-take and matabolism of gem in solid tumors of rats,
F1D-US-X182,Management for risk of relapse in schizophrenia,
F3Z-FP-O030,Regular insulin IV versus humalog SC in type 2 diabetics,
B7A-MC-MBCM,Phase III Diabetic Retinopathy Study,
"4838",Japan PK comparison LY307161 (SR-V8-GLP-1),
H6H-MC-JEAM,LY293111/Gem/Cis in NSCLC,
B1Y-SZ-IS38,DISCONTINUATION OF FLUOXETINE IN OCD,
F1D-XB-O094,"Olanzapine,Risperidone,haloperidol in cognitive funtion",
B9E-MC-X295,Ph2 Evaluation of Gemcitabine in Met. Choriodal Melanoma,
H6Q-JE-JCAF,JP PKC-II P-I SDSS,
H6P-MC-HDAJ,TRD European Regulatory Study,
B3D-HL-O014,The effectiveness of teriparatide in the clinical practice,
A3Q-MC-C002,ACUTE PUNCTURE WOUNDS TO THE FOOT -- KEFLEX,
"5107",MGlur2 - Japan Multiple Dose,
H6U-BD-LRAB,Cognition exploratory study,
"5174",Japan SDSS,
B9E-CP-O173,Ph II Sekv Carb + Gem foll Pac to untreat NSCLC pt,
F1D-US-A051,Brain Metabolic and Behavioral Respons to actute ,
B1Y-VI-0083,FLUOXETINE VS PLACEBO IN OBESITY/DIABETIS MELLITUS TYPE II,
B1Y-SZ-O016,Effect of Fluox on Thyroid function in dep. borderline pat.,
F1D-JE-BAMA,JP ola P-II/III Bipolar Bridging,
H6D-MC-LVDR,Open Label Study #4,
B9E-TW-O271,Gem/Cis for HCC at CGMH-LK,
B9E-MC-V112,Humane myelmoma cell lines sensitivity to gem dex,
B9E-EW-JHRX,First Human Dose,
B5K-GH-O003,The relationship of serum CD30 and beta cell function in LAD,
F1J-UT-O002,Influence of drug interfering in the cAMP/PKA transduction p,
B9E-FP-O213,IIT-NSCLC B9E-FP-O213 GERCOR,
"5563",Fellowship for Dr. Lesley McKarney (FEL-058),
B9E-MC-X316,PhI/II Thalidomide/Gem/Cis of Met Transitional cell bladder,
F1D-FP-S020,STUDY ON SEDATION PRACTICES,
B3T-MC-JTAO,"LY335979/Daunorubicin/Cytarabine in elderly AML, ECOG",
B9E-US-S244,Ph II Gem+Irinotecan+Etoposide in SCLC,
B9E-US-S253,FDR Gem/Carbo vs Gem/Carbo plat sens. late relapse Ovarian C,
B9E-US-S258,Breast - Ph 2 Gem/Taxotere - Ellis,
"5819",Comparioson of Intra-Stentintimal Hyperplasia Volumes in Dia,
H6D-MC-LVDY,China Local Registration Trial,
B9E-FP-O255,ITT-Evaluation comb Gem-Pacli in NSCLC stade IIIb+IV,
B3N-MC-LNAA,MOXONIDINE VS. PLACEBO: PILOT STUDY FOR SMOKING CESSATION,
F3Z-XM-O040,ANALYSIS OF GENETIC FEATURES OF DIABETIS MELLITUS MODY,
"5965",NEW IITS PROPOSAL FOR 2002 YEAR,
F1D-CA-O133,Open Label Bipolar Dis. Rapid Cycling Olz & Risp Adjunctive,
"6050",fMRI model for detecting drug induced cognitive enhancement,
"4069",ACTOS vs. Amaryl,
"4100",Patient pharmacology study for pamoate,
B1Y-MC-X107,FLUOXETINE EFFECTS ON DIABETES SELF-CARE IN DEPRESSION,
"4114",omeprazole drug interaction study,
H5M-SB-EIIE,Efficacy Check Aquaphor (xipamide),
H4W-MC-LLAQ,Sleep Latency with Comparator,
B9E-MC-V050,Intravesical Gem for BCG refract. superf. carcin. of bladder,
H4H-MC-LGAN,Adjunctive Therapy,
B1Y-SB-1001,FLUOXETINE/LITHIUM PHARMACOKINETIC INTERACTIONS,
B9E-MC-X267,Phase I/II Study of Intravesical Gemcitabine,
B5K-MC-IBFN,Efficacy & safety in type 2 patients failing TZD therapy,
F1D-MC-LOBC,Low dose Zyp combo therapy with Chlopromazine in Chinese Pts,
B9E-MC-X272,Phase 2 Gemzar/Taxol/Carboplatin in Bladder Cancer,
"4466",Invitro MTA study - cancer cell lines,
B9E-AY-O189,Lung XRT - Phase I (gemcitabine & RT in NSCLC),
H6E-US-GLAJ,efficacy of pioglitazone in polycystic ovary sydrome,
B1Y-SB-7053,FLUOXETINE IN OBESE PATIENTS,
"1954",Type 2: Humalog bolus vs NPH BID (in NPH users),
B9E-MC-S036,Ph I Gem/5FU CI in breast,
B9E-MC-S001,Ph II/III Gem q 3wks vs Gem q 4wk in poor performance status,
B9E-MC-S010,Ph III Gem + Cis --> XRT vs Cis + XRT in NSCLC,
B1Y-LC-HCFJ,FLUOXETINE: EFFECT ON DISPOSITION OF NICOTINE IN SMOKERS,
B9E-MC-X010,"GEMCITABINE IN OVARIAN, FALLOPIAN, AND PERITONEAL CANCER",
H5P-LC-BWWL,fed/fasting,
B1Y-MC-HCAD,FLUOXETINE VS IMIPRAMINE OUTPATIENT,
B3D-MC-GHAQ,Intranasal delivery phase II (GHAQ),
"2276",Oral delivery - dose ranging,
B1Y-MC-HCCH,FLUOXETINE/PLACEBO ONSET OF ACTION,
B4G-EW-LCCI,Parkinson / Monotherapy,
B4G-IT-LCCN,Parkinson / Switch Bromocriptine to Pergolide (S3),
B1Y-MC-HCCL,FLUOXETINE MULTIPLE DOSE STEADY STATE STUDY,
B9E-MC-S099,Gem+Carbo vs. Gem+Tax / Ovarian,
B9E-MC-X118,PHASE 2 STUDY OF GEMCITABINE AND TAXOL IN MULTIPLE MYELOMA,
B9E-MC-I140,PHASE I STUDY OF GEMCITABINE AND DOXIL,
B9E-MC-X075,PHASE II STUDY OF GEMCITABINE TRMT. NON-HODGKIN'S LYMPHOMA,
"6098",GLP-1 analogue - Absolute bioequivalence,
B4G-FP-LAAX,PERGOLIDE ENDOCRINE COMPASSIONATE USE EUROPE,
F1D-FP-S022,Survey on schizophrenic pat. social integration,
F1D-UT-O134,IM Olanzapine vs IM Haloperidol,
H7C-MC-LMBG,Impact on Psychomotor Performance and Sleep,
F1D-CA-O135,Lifestyle & Wt Mgmt in Psych Pts: Prospective Study,
B9E-US-X340,Gemzar IIT Program / United States,
"6385",GLP-1 analogue - Formulation bioequivalence 2,
A6J-JE-XR35,JP vanc P-III PRSP pediatric area,
B9E-MC-V138,MBT-2 Model for Induction of Blad Tum in C3H/eb Female Mice,
F1D-BP-S028,Observational study of IM olanzapine,
"6558",VOID,
F1K-MC-EVBP,Global Pediatric Severe Sepsis,
F1D-XB-O171,factors in patients with a 1º schizophrenic episode,
H6K-MC-O002,A Pilot Glucose Clamp Study Comparing 25% and 0% Co-crystal,
"6742",differentiating unipolar depression from bipolar depression,
F1D-SB-O175,Neurophysiological recordings in schizophrenic patients,
"6816",Concomitant Use of Teriparatide and Raloxifene,
B1Y-MC-X203,Fluoxetine and Interferon Beta-1a in the Treatment of MS,
B9E-MC-S206,"Ph II/III Rand, Gem f/b Gem + XRT vs control - Pancreas",
H6H-MC-JEAK,"Phase I, LY293111 + CPT-11 (irinotecan), NCIC",
B1Y-ME-HCKV,Effect of fluoxetine tx in cerebral perfusion of diabetic,
B9E-MC-V089,Evaluate Gem action assoc w/apoptotic drugs,
B3D-MC-GHBM,PTH vs. Alendronate,
"4952",Mix25/Mix50 bid vs glargine once daily + oral/orals,
"4997","LY900002 PHASE II, 12 WEEK EFFICACY STUDY",
B4Z-MC-LYAX,Atomoxetine for treatment of co-morbid ADHD and depression,
"5011",Phase 2 Alzheimer's disease,
B1Y-UT-0287,FLUOXETINE-EFFECT NEUOENDOCRINE REG. ON OBESITY,
"5053",mGLUR prodrug bioequivalence study,
"5063",Duloxetine Depression,
"5128",LY333328 Skin Blister Study,
"5132",Clinical pharmacology C14 study,
B1Y-UT-E034,FLUOXETINE VS MAPROTILINE IN TREATMENT OF MDD,
F1D-US-V012,Olz on glucose metabol in Neuron cells,
F3Z-SB-O035,Insulin Lispro vs Regular:  Continuous Glucose Monitoring,
"5273",JP lisp P-III High Mixture,
"2563",Pediatric B,
B5K-CA-O001,NPH dosing study-characterization of activity profile-IIS,
B9R-MC-GDEH,hGH use in heart transplant patients,
B3N-EW-EUAY,Single Dose PK Study of the Final Moxonidine SR Formulation,
B7A-BD-MBBV,To determine safety and pharmacokinetics and dose ranging,
"2819",Mechanism of action study 1,
B1Y-MC-HCEQ,FLUOXETINE V PLACEBO:LONGTERM TREAT.BULIMA NERVO,
H4A-MC-XBAL,vs TMP/SMX in PCP (Therapy),
F3Z-MC-IOME,NPH (1-2 times daily) vs. LM in patients with type 2 diabete,
"2841",Hoechst Depo H25/75 vs LM study in Type 2,
H3E-MC-JMAZ,"Randomized Ph II, ALIMTA+ CPT-11 vs. CPT-11/5-FU/LV",
B9E-MC-X200,Gemcitabine and Cisplatin in Advanced Mesothelioma,
"3046",SIAM-efficacy dose for trxt of agitation in patients w/ demt,
B1Y-MC-HCHG,FLUOXETINE/PLACEBO IN PANIC DISORDER,
F1D-US-X102,Olanzapine in the Treatment of Trichotillomania,
B3N-MC-EUDA,Effects on CNS (Solvay),
B9E-SB-O027,"Phase II, Gemcitabine & Radiotherapy, in Head/Neck Tumors",
B9E-MC-X219,"Gemcitabine, 5-FU, Leucovorin, CPT-11 in Colorectal Ca",
"3164",Multiple oral dose in volunteers (tablet),
B1Y-GH-O027,The outcome of depressive disorders in old age,
ZYY-LC-GOAB,Obesity Biomarker - Method Study #2 - Obese Humans,
H6D-MC-LVFN,US Big Trial,
"7012",Ph II - CPT11 + Oxaliplatin + Affinitak - CRC,
B9E-MC-I057,"STUDY OF GEMCITABINE, 5-FLUOROURACIL, & INJECTION",
B9E-MC-I058,RAD. & GEMCIT. IN LOC. ADV. OR METAST. TUMORS OF G.I. TRACT,
"7059",NGHSS Market Uptake,
"7060",Clin Pharm Registration Package (PLACEHOLDER),
B9E-MC-V181,Evaluation of Pathology Specimens of Breast Cancer Tissue fo,
"7152",Definitive Bioequivalence/Adult Fed/Fasted 120 mg,
H3E-US-JMFX,Ph II Single Arm Study of Gem/Alimta in 1st line NSCLC,
B9E-US-S322,Ph II Carbo/Taxol/Herceptin followed by Gem/Taxol/Herceptin,
H3S-FP-S038,vertebral Fracture Impact Study in rheumatologists (EMERAUDE,
B9E-MC-V199, induce apoptosis in adenocarcinoma cells,
"7299",HSV Transmission Study,
F1D-US-X223,Influence of olanzapine on lamotrigine pharmacokinetics in h,
B9E-US-X367,Rand. Trial of Gem VS Gem + Doc for Unresec. Soft Tissue Sar,
F1D-IT-HGLI,A 5-months cross sectional study in SPDC (Progetto Perseo),
F3Z-IT-IONX,Humalog Mix 25 vs Humulin 30/70 in Type 2 diabetes patients,
B1Y-VI-5000,"FLUOXETINE: IN ACUTE DEPRESSION, USSR-REGISTRATION",
"5303",Serotonin Transporter Radioligand - Validation in Humans,
"5319",Phase III Bipolar Acute Mania - Japan,
B1Y-VI-MH01,FLUOXETINE 20 MG STUDY,
B9R-SB-O006,Effect of HGH treatment on cardiac funct. and glucose metab.,
B9E-MC-V117,HPLC method for analysis of gem & its metabolite,
F1D-XB-O111,cognitive disfuntion neuropsicological evaluation,
H7T-MC-V021,Pras AM and ASA Platelet Inhibition via TEG  ,
B1Y-BP-HC44,FLUOXETINE VS LOFEPRAMINE AND LITHIUM AUGMENTATION,
"5640",Fellowship: Dr. Paul Links,
B1Y-BP-HC45,FLUOXETINE VS. CLOMIPRAMINE AND PLACEBO IN PANIC ATTACKS,
B3N-EW-EUAW,MOXONIDINE:HF CAPSULE INTESTINAL ABSORPTION SITE STUDY,
B9E-US-S246,Gemcitabine in PS 2 NSCLC Patients,
"5851",Drug Interaction Study 4,
"5932",LY450139 QTc Pilot,
"5933",Drug Interaction Study #3,
B9R-XM-O019,CALCIUM AND FOSFOLIPIDIC METABOLISM ROLE ON CELULAR DESENSIB,
F3Z-XM-S013,QUESTIONNAIRE VALIDATION *HYPOGLICAEMIC FEAR,
B9E-XM-S294,NSCLC three chemoth. arms (ONCOPAZ),
F3Z-MC-IOMY,Combination Therapy of Insulin Lispro Lox mix w/ oral agents,
B4Z-LC-LYAM,Bioequivalence_antacid_IV_EM Subjects,
B3M-PH-S002,Cefaclor CD 375 mg for tx of tonsillopharyngitis,
B1Y-MC-X119,SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) IN LACTATION,
"4204",Single dose trial using 5-HT2c,
"4218",Oral contraceptive interaction,
F1J-FW-HMBB,Antacid or H2 antagonist interaction,
B9E-SB-O122,Pre-Irradiation Gemcitabine/Treosulfan-chemotherapy in Gliom,
H4Q-MC-V018,LY333328--testing of disk diffusion assay,
B9E-VI-O128,Phase II GET (75) in MBC,
B7A-MC-MBCI,PKC INHIBITOR FOR ERECTILE DYSFUNCTION,
F1D-US-X175,The Effects of Olanzapine on Work Performance in Schiz,
F3Z-MC-IOMU,HM Trial to Support Registration in Europe,
H4Q-LC-ARRN,Effects of Multiple Dose LY333328 on the QTc Interval,
H6D-EW-LVCP,Treadmill Study in Non-ED subjects with CAD,
B9E-MC-S156,Ph III Gem+Cis+Paclitaxel vs observ in bladder cancer,
B3M-HU-S013,Cefaclor (suspension) in tonsillopharyngitis vs amoxiclav.,
B1Y-SE-1361,FLUOXETINE: PROZAC CLINICAL EXPERIENCE EVALUATION OPEN-LABEL,
"3334","Phase II, MTA in Cervix Cancer",
B1Y-MC-X012,FLUOXETINE PHENELZINE AND PLACEBO IN OCD,
F1D-UT-O028,Olanzapine in Behavioral Disturbances in Elderly.,
"3386",Ligand development - Baboon trial,
F3Z-SX-IOMF,SAFTEY AND EFFICACY OF HUMALOG VS HUMULIN R IN DM PATIENTS,
"3469",OL slow metabolizers,
"3480",Lindsay Study,
B5K-MC-IBFL,Compare pre-meal PI to Lispro,
"3501",definitive bioequivalence,
F1D-US-X134,Schizophrenia Treatment Guideline Implementation Project,
A6J-MC-X005,Vanco vs Metronidazole in VRE colonization,
B9E-BP-O041,"Ph I,  Gem, Docetaxel, & Cisplatin, Bladder Metastatic TCC",
F1D-MC-X139,Olz as sole therapy for bipolar disorder,
B9R-MC-X010,ASSESSMENT OF POSSIBLE GH INSUFFICIENCY USING NOCTURNAL SERI,
H3S-US-V003,A comparative study of Evista and sex hormones on proteoglyc,
B9E-MC-I088,Phase I Study of Gemcitabine and Irinotecan,
H6D-EW-LVAK,Hepatic impairment study,
H6D-EW-LVAN,Study to assess the effects of LY450190 on vision,
H6W-MC-MCAA,A Phase II/III Study Sivelestat,
H6E-XM-S001,Efficacy on HDL elevations/long term efficacy and safety dat,
ZYY-FW-GCAK,Monoamines - Effect of SD of SSRI on plasma prolactin conc,
"6051",Validation of short duration intensive serial MRI scans for,
B4G-EW-LBAO,PERGOLIDE VS PLACEBO AS MONOTHER. IN EARLY-STAGE PARK'S DIS.,
B9E-TW-O268,Gem/Cis for Hepatoma at PTH,
H7U-MC-IDAH,"Ph 3, Safey Study, Pulmonary Insulin",
F1J-MC-SBBQ,Nursing Home Study,
"6199",Pivotal trial for ART - II,
H6U-UT-LRAC,STOP,
H7C-MC-LMBJ,mGluR2 vs placebo in GAD at select US sites,
"6269",CS-747 - Gastric pH,
"6291",PK Bridging Study (Prodrug to Parent),
F1D-MC-X210,Glucose Metabolism in Drug Naive Patients with Schizophrenia,
"6326",Post-launch study-Spain,
B4G-UT-LBAY,OPTIMAL PERGOLIDE ADD-ON THERAPY IN PT. WITH PARKINSON DIS,
"6362",Sequential Use of Foteo and Evista ECG Addendum,
B9E-SB-O293,Gemcitabine and peginterferon-alpha in renal cell carcinoma,
B5K-SB-IBDZ,BERLINSULIN DRUG MONITORING,
B1Y-SE-8290,FLUOXETINE: THREE MONTH OPEN LABEL STUDY,
F1D-SZ-S008,Switch to olanzapine,
"4607",C14 Study,
F1D-US-A045,ability of olz to prevent the funtional hyperactivity of NMD,
B9E-BL-O185,Neoadjuvant chemother Gem plus Docet in stage IIIA in NSCLC,
F1D-SB-O085,Modulation of neuronal networks due to Olanzapine in compari,
H3S-MC-GGKC,Prevention of Glucocorticoid-induced Osteoporosis,
B9E-MC-JHRJ,Ph III Gem/MTA vs Gem - Pancreas,
B1Y-SP-0004,BIOEQUIVALENCE STUDY BETWEEN FLUOXETINE 20 MG SACHES VS CAPS,
F1D-MC-X184,Efficacy of Olz in Treatment-Refractory Bipolar Disorder,
F1D-US-X185,risperidone response:therapeutic complications from genetic,
H6D-MC-LVCV,"5mg, 10 mg Daily Dosing",
B1Y-UT-0189,"EXPERIENCE WITH FLUOXETINE IN DEPRESSION,PSYCHIATRISTS,OPEN",
H7D-EW-GNAA,Oral PTH - Oral administration of carrier,
"5000",Olanzapine Fluoxetine Combination PK Study II,
H6D-MC-LVDD,Phase II/III Safety and Efficacy Post-Menopausal FSAD,
"5034",Pilot Bioequivalence #2 for Line Extension,
F1D-FP-S012,OLANZAPINE PRESCRIPTION SURVEY IN SCHIZOPHRENIA,
B9E-BP-O195,"Pilot of 6 patients, Gem/Cisplatin, Cervix cancer",
H3S-MC-V006,"Effect of Raloxifene on VEGF Thrombospondin-1, and TNF",
B9E-GN-O202,Gem+Epi+Docetaxel in pat. with locally adv. breast cancer,
B3M-GH-S027,Ceclor RTU vs Amoxicillin/Clavulanate for LRTI in children,
F1D-UT-O105,olanzapine vs risperidone psychomotor function/cognition,
H6U-UT-O004,Psychometrische evaluatie van de vragen lijst voor subjectie,
B9E-MC-V120,Infusional gem in comb w/carbo,
B9E-MC-X329,PhI/II Gem/Cis + RT in periampullary cancer of pancreas/non,
B9E-MC-X333,PhII Gem/5FU/leucovorin in biliary tract & gallbladder cance,
H4R-GH-O001,Acceptance and function comparison of HumaPen in NovoPen Use,
B9R-US-I027,hGH and T Supplementation in Hospitalized Older Men,
H6E-CP-GLAR,Actos effect on HbA1c and lipids and PPARgamma polymorphisms,
B9E-MC-X336,Ph.II Dose-Rate Gem in Pts. with Relasped Mullerian Tumor,
ZYY-US-X001,Osteoporosis in orthopedics,
B9E-US-S248,FDR Gem + XRT in Unresectable pancreas (phase 2),
B9E-MC-O245,Phase II study of Gem-Cis as neadjuvant for pennis carcinoma,
H4S-US-V004,Detection of Platelet Surface CD40L and Soluble CD40L,
"5910",Tic/Movement Disorder,
ZYY-FW-GCBJ,hormone response to oral citalopram in healthy subjects,
B9E-US-X372,Ph II Gem + Doc pts w/ rec or adv CA of endometrium,
F1J-BP-HMCP,Duloxetine MDD Secondary Care local UK study,
F1K-FR-O024,Pulmonary blood flow in pigs - Pr ,
F1K-FR-O023,CV organ failure in rats - Pr Nevierre,
"7537",NL Observational Trial with pioglitazone,
"7543",Progression of DR/ME using Fundus Fluorescein Angiography,
F3Z-MC-IOHO,Local Registration Trial in India,
B9E-MC-JHFX,PHASE 1 STUDY OF GEMCITABINE/RADIOTHERAPY IN PANCREATIC CAN.,
F1D-GH-LOBV,olanzapine versus lithium carbonate in the treatment of bipo,
B9E-GH-S357,Gemzar combined with Vinorebline in Breast Cancer,
"7668",TA alternant with Gem-cape,
"7725",Atomoxetine in ADHD in children with Autism (Wray),
"7807",Dulox SUI Health Outcome Studies,
F1D-AY-B004,Open label bipolar maintenance Zyprexa vs mood stabilisers,
B9E-SB-JHLU,GEMCITABINE IN PTS WITH PANCREATIC CANCER,
F1D-HU-O209,Weight Control of Patients Treated with Olanzapine,
"7879",IIT - 2004 (1),
"7885",IIT - 2004 (~11),
H6L-MC-LFBF,Open Label Extension of Phase III Trials,
H3S-XM-O017,Raloxifene in postmenopause. Perioxidative&cardiovascular,
"6021",gem-carbo-taxol vs carbo-tax in ovarian cancer,
B9E-TW-O270,Gem/Cis for NPC at CGMH-LK,
H3E-US-JMFE,ALIMTA Treatment IND,
B1Y-BP-HC50,FLUOXETINE/AMITRIPTYLINE MAJOR DEPRESSIVE DISORDER,
F3Z-IT-O008,Early Use of Humalog in NIDDM,
H7U-FW-IDAE,IFR Pulmonary Insulin Clamp,
H3E-MC-S030,Placeholder for Breast,
H8G-EW-EPBA,FHD for Factor Xa Inhibitor 2nd Generation,
H7C-MC-LMBL,Imaging Study (C-13 Glucose),
F1D-MC-HGKK,Borderline Personality Disorder Fixed Dose Trial,
B4G-SB-LBAS,FAST VS SLOW UP-TITR. OF PERGOLID AS ADJUN. TREAT. TO L-DOPA,
"6304",Miscellaneous IIT- Prozac (Primary Health Care + NS),
B5K-BD-IBEA,HUMAN INSULIN DELIVERY IN AUTOPEN TYPE DEVICES,
H7X-MC-JVAG,Ph II - Aron Inh + Affinitak - Breast,
B9E-MC-V156,Evaluation of Gem in Therapy of Lymphoma-PET Method,
F1D-UT-O155,Tardive Dyskinesia,
B9E-SB-V162,Treatment of liver metastases in rat with Gemcitabine,
B5K-JE-HN02,PATIENT'S EXPERIENCE PROGRAM,
B1Y-MC-X075,"19F MAG. RES. SPECT. MEASUREMENT OF FLUOX. EVELS IN BRAIN",
"3832",LATE PHASE 2,
B4Z-MC-LYAH,Double blind active comparator study,
B9E-VI-O091,Gem in Combi with Doxorubicin in Metastatic Breast Cancer,
F1D-VI-HGIK,Olanzapine in Schizophrenic Patients in Iran,
"3968",Multiple dose PK/PD (opioid antagonist),
F3Z-FW-IOMM,Postprandial glucose profiles in Asian ethnic groups,
B9E-MC-I127,Phase I Gemcitabine and Cisplatin/Pediatric Patients,
B1Y-MC-X112,FLUOXETINE AND CBT TREATMENT OF BINGE EATING DISORDER,
"4153",Single Dose Safety Study,
B3M-MC-S007,Acute Otitis Media (Cefaclor Susp vs Augmentin) - Regional,
"4299",Cephalexin vs cotrimoxazole in treatment of UTI,
B1Y-PH-0004,FLUOXETINE: IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDERS,
B9E-BX-V058,IN VITRO GEMCITABINE + RADIOTHERAPY,
F1D-MC-HGIV,OLZ VS PLACEBO IN ALZHEIMERS PSYCHOSIS AND BEHAVIORAL DIST,
F1J-BD-HMBF,Theophylline Interaction,
H3S-US-X003,The Effects of Raloxifene on Nitric Oxide,
F1D-SU-HGLH,PRiSMA - Cost Effectiveness,
H8R-MC-HJAF,Motility Study,
H6D-SO-LVFR,Sweden (GP-LiSat),
B1Y-GH-HCLP,The Prevalence of Depression and Anxiety Disorders in Women,
F1D-US-X233,Olanzapine Zydis as a PRN for acute agitation in patients,
H8O-MC-GWAP,TZD AMIGO (exenatide vs placebo in pts on TZD),
"7099",Beta cell Actos clamp study,
H7C-LC-LMCJ,Digoxin Interaction Study,
"8092",first episode obsevational trial,
H3S-GN-S043,"Hot flashes,Compliance with gradual\rapid initiation of Evis",
B9R-US-GDGE,Genetic relationship to short stature CTNR,
"8224",PK Study Q-Weekly,
"8234",Clin Pharm Registration Study CP8 - Placeholder,
B9E-US-X393,Ph II of Taxotere + Gem & Cisplatin in Urothelial CA,
H3E-MC-JMGU,"Ph II, 1st Line ALIMTA + CPT-11 in Colorectal Cancer",
F1D-US-X238,Retrospective Chart Review Inpatient Antipsychotic Use,
F1D-MC-X239,The Psychoeducation of Borderline Patients,
B9E-SX-O380,Ph II Gem+Carbo follow by concur Gem + Radiation in NSCLC,
"8406",Ph II - 2nd Line - ALIMTA - Superficial Bladder (EU),
"8417","Ph I/II, ALIMTA + Oxaliplatin in Breast Cancer",
"6534",ReoPro IIT - Place Holder,
F1D-UT-O156,Subjectivewell-being and compliance,
H3S-XM-S008,Primary Care Study,
"6575",Ph I Study - Escalating Doses of Fixed Rate Intrahepatic Gem,
B9E-CY-S289,Ph II Study Gem+Docetaxel+Cis 1st line advanced ovarian ca.,
F1D-US-HGKH,An Observational Trial of the Transition from IM to PO Olanz,
F1D-SB-S030,"Olanzapine vs. Ziprasidone, Subjective well-being",
B4Z-UT-S005,Observational study - Atomoxetine,
"6682",Placeholder for Gemzar study,
"6709",Humalog mix 25 vs insulin mix 40/60 w/child w/type 1 DM,
H7B-MC-LXAG,"POC Migraine, 3-period xover, sumatriptan comp, 2 LY",
H7B-BD-LXAF,"Parallel, plcb-controlled LY466195 effect on visual function",
B9E-US-X352,Intrapleural Gem Thpy For Malignant Pleural Effus: Ph 1 & PK,
B9E-IT-JHPG,GEMCITABINE IN ELDERLY PT. WITH STAGE III-IV NSCLC,
"6849",Ph III HTN CV Outcomes,
F1K-CA-EVCD,Sepsis Treatment and Response (STAR) Registry,
F3Z-MC-O053,Holman Postprandial Lipemia Type I Diabetes,
B9E-BP-O321,Gemcitabine/Carbo +/- Thalidomide in Adv/metastatic NSCLC,
B9E-MC-X345,Ph I Study - escalating Doses of Fixed Rate Intrahepatic Gem,
F1D-BP-O162,UK IIT Zyprexa vs Geodon,
B1Y-BP-HC55,DIAGNOSIS & TREAT. DEPRESSION ELDERLY PHYSICALLY ILL PATIENT,
"6646",determine risk of DVTin med surg ICU pts,
B1Y-SK-O023,Fluoxetine in specific phobia - double blind placebo control,
H8R-MC-V001,PET Ligand Prep,
H8M-FW-HTAC,AMPT Study,
"6855",Placeholder trial for Duloxetine Local Trials,
B9E-TW-O318,"24-hour Inf of 5-FU/ fro Avanced Pancreatic Adenocarcinoma",
B9E-MC-S307,Ran Ph III-Gem+Paclitaxel+Carbo vs Paclitaxl+Carbo-ovary,
H8B-EW-EJBC,Food Effect & BA Polymorph,
B4Z-MC-LYBR,Asian ADHD Pediatric,
H7X-MC-JVAL,Ph II - Gem + Carbo + Affinitak - (7day infusion) NSCLC,
"6938",Local Registration Trial for Atomoxetine,
"7082",placeholder,
B9E-MC-JHBO,PHASE 2 STUDY GEMCITABINE PLUS ETOPOSIDE EXTENSIVE SCLC,
"7122",Cancelled study,
"7125",Phase 2 Edema Study,
B1Y-SB-5044,"FLUOX EFFECTS ON IND OF EMOT,CORT&AUTON AROUSAL",
F1D-US-X103,Dbl blind estrogen schizo post menopausal women,
F1D-EW-LOBE,Olanzapine pamoate single/multi depot injection in patients,
B3M-PK-V045,Cefaclor indicated bacteria Surveillance Study,
B9E-FP-O147,IIT-Biliary ducts B9E-FP-O147 /CHU Dijon,
"4583","CT Lot#4, Microspheres market batch",
H3S-MC-GGKA,Registration trial for treatment of osteoporosis in China,
H4S-FP-O009,PEARL - CONCOMITTANT USE OF ABCIXMAB AND LMWH,
B9E-XB-O152,Phase I-II prolonged inf. gem+doxorubicin in sarcomas,
B4Z-MC-LYAR,Adult Open Label,
B9E-MC-S225,Ph II Gem + Cis in Nasopharyngeal cancer,
B9E-BP-V076,Affects of tumour suppressor expression with gemcitabine.,
H6U-UT-O003,cannabis en schizofrenie,
F3Z-CA-IONG,Use of Humalog Mix25 in a Clinical Practice Setting,
"4819",LY353381 omeprazole interaction study,
B9E-MC-X284,"Gemcitabine, Irinotecan, and Cisplatin Phase 1 Study",
B1Y-TW-0002,FLUOXETINE: IN THE TREATMENT OF DEPRESSION,
B1Y-BP-HC37,FLUOXETINE VS PLACEBO: ANXIETY,
H3E-MC-JMGV,Ph II - ALIMTA + Doxorubicin - Metastatic Breast,
B9E-US-X407,"Ph II Gem, Carbo, Exisuland in early NSCLC",
"8513",Efficacy and safety of olz. following previous typical IM,
"8544",Maddox-Prevention of obesity-linked renal disease by PKC inh,
B9R-MC-S001,EFFECT OF SUPPORTIVE INTERVENTION IN CHILDREN W/ SHORT STATU,
"8588",Formulation PK Comparison,
F1J-MC-HMDF,G3 - EU Duloxetine vs Duloxetine Plus Non-Pharmacological,
H3E-MC-S090,Ph II  ALIMTA + Avastin in 2nd Line NSCLC,
"8644",Exendin-4: Interaction 1,
H3E-FP-S057,"Ph II of ALIMTA + CPT-11, q 2wk Schedule in CRC (France)",
"8685", AKT-1 Animal Biomarker PET Study (b),
"8707",LY544344 Imaging Study,
H6D-MC-LVGB,Hypertension Phase 2A Proof of Concept,
"8730",Prevention of Radiation Induced Enteropathy,
B9R-SB-GDDE,SOMATROPIN: CORRELATION OF BONE MARKERS AND GROWTH VELOCITY,
F1D-FP-B008,SEXAP: sexual dysfonction in schizophrenic patient,
H3S-XM-O120,Osteoporosis prevalence in La Safor (Osteosafor),
F1J-IT-HMEL,Pharmacogenetics and Duloxetine,
"7010",FSD Phase 2 Study,
B9E-SB-O325,Gemcitabine in children with Solid Tumors,
"7030",Gem/Herceptin vs Gem in Metastatic Breast Cancer,
F1D-MC-HGLD,High Dose Olanzapine Registration Study,
"7062",SHOX Japan Study,
F1D-MC-HGLO,IM Olz Depot:Safety/Efficacy in Bipolar Disorder (2nd study),
"7097",Micro Needle Injection Definitive PK,
B1Y-BP-HC62,FLUOXETINE VERSUS PLACEBO IN FACIAL PAIN,
B9E-MC-S329,PhII-seq neoadj gem+doxo & gem+cis in operable LABC,
"7126",Dyslipidemia Proof of Concept Study,
B9E-UT-O332,"Gemcitabine vs paclitaxel in elderly pts, NSCLC, a QoL study",
H6D-EW-LVFB,LY450190- QT study with positive control in healthy male sub,
B3D-MC-GHCH,Treatment Protocol,
B9E-MC-JHDS,"GEM. + CISPLAT. VS MITOMYCIN, IFOSAMIDE & CISPLATIN IN NSCLC",
"7315",Placeholder for PKCi trials (Buy-up),
H4S-MC-X018,Revascularization and Abciximab Facilitate Treatment in ACS,
"7457",Renieved Strenght Study,
B9E-MC-V180,Isolated lung perfusion for the treatment of pulmonary metas,
H5Z-MC-LUAV,R-fluoxetine Transition from Fluoxetine,
"5088",Formulation/Particle-Size,
B9E-MC-X306,Rituximab & Gemcitabine for pts with relapsed Hodgkins,
H3S-US-X013,Neurophysiological and Neuropsychological Correlates of Meno,
"5305",Mutliple-dose cognition exploratory study,
F1K-MC-EVCC,Clinical Evaluation Committee support data to EVAD,
H6D-EW-LVDO,"20 mg IC351 Interaction with Alcohol",
"9020",Phase I/II Stage III a/b NSCLC Alimta/Cis/XRT,
B1Y-BP-HC42,FLUOXETINE VS LOFEPRAMINE IN GERIATRIC MDD,
X1A-MC-QA02,Alzheimer's PK/PD with LY450108 and LY451395,
H3S-US-X019,Role of a SERM on Markers of Renal Function in Diabetic Wome,
B3D-MC-GHBT,Commercialization/Observ. Study Osteoporosis Pt. Registry,
B9E-SX-O218,Phase II Gemzar and Cisplatin in biliary tract CA,
"5659",Fellowship for Dr. John Dick (FEL-041),
B3M-MC-V013,CEFACLOR GLOBAL SURVEILLANCE STUDY,
B3D-MC-GHBU,"Patients formerly on Evista or Fosamax, put on active PTH",
B9E-SB-O237,Gemcitabine/Vinorelbine vs. Taxol/Carboplatin in NSCLC,
H6U-UT-O005,Quality of Life  in first onset of Schizophrenia,
B3N-HH-EUAD,"24hour ECG under moxonidine",
"5856",Clin Pharm - Drug Interaction Study,
F1D-XM-O131,Experimental study about cognitive funtion,
"8864",observational secondary failure,
"8929",Diagnostic criteria ADHD adolescents,
"8961",Eval. ability of Xigris to block lymph. cell death in vitro,
H7T-EW-TAAX,CS-747: Digoxin interaction,
B4Z-US-X015,Atomox in adolescents w/comorbid ADHD & nicotine dependence,
B4Z-US-X007,Strattera use in poor stimulant responders,
"8997",IIT Placeholder for Yentreve,
B9E-SB-O404,Gem + Carbo in pretreated and metastatic breast cancer,
"9054",Placeholder for Olanzapine (BYE UP),
B9E-XM-S356,EFFECT OF GEM IN CACHEXIA MEDIATORS IN PANCREAS CANCER,
F1D-CA-P022,OLANZAPINE/HALOPERIDOL/RISPERIDONE IN SCHIZOPHRENIA,
B9E-SN-JHSO,Cis+RT with/without induction CX with Gem+Carbo+Pac in NPC,
F1D-EW-E004,LY170053: OPEN LABEL SAFETY AND DOSE RANGING STUDY,
F1D-MC-HGLT,DNA Banking for SOHO Trial,
B9E-MC-V270,Effect of HSP90 disruption on gemcitabine cytotoxicity,
B4Z-US-X012,Medication Effects on Brain Activation During Inhibitory Con,
F1D-EW-HGCE,OLANZAPINE: HEALTHY ELDERLY COGNITION AND PSYCHOMOTOR STUDY,
B9E-FP-O368,IIT -ACUP B9E-FP-O368 GEFCAPI02 / IGR,
"7548",Prevent Sensation Loss in Diabetic Peripheral Neuropathy,
H8S-MC-A001,[18F] MeNER Radiotracer Development,
H6U-MC-A002,"5-HT2C Radiotracer Development and Animal Validation",
"7559",NK-1 PET Validation in Monkeys using [11C] GSK Tracer,
"7586","Time to Heal No. 2; 2 arm, 3 cycle",
H4S-MC-X019,Interdependent Cytokine & Plt Activaction during PCI for ACS,
H8V-BD-LTBA,SDSS,
H6L-MC-LFAN,Alzheimer's Disease Progression Study (FED),
"7671",Human insulin IIT placeholder,
"7687",Fellowship/Chair Placeholder for Gemzar,
"7722",Atomoxetine in ADHD comorbidities - Anxiety,
"7737",Severe Osteoporosis Health Outcomes Study,
B9E-AG-O361,Gemcitabine in relapse lymphomas.,
B4Z-MC-LYCH,Attentional symptoms in Autism/Asperger's,
B9E-VI-JHDJ,GEMCITABINE IN PATIENTS WITH NCSLC,
F1J-EW-SBCC,European Safety and Efficacy Study,
B9E-GH-O366,Gemzar plus Cisplatin chemotheraphy on Immune Function,
B9E-MC-JHBU,PHASE 2 GEMCITABINE IN PRETREATED EPITHELIAL OVARIAN CANCER,
"7208",Gem-myocet,
"7234",Cefaclor UK Placeholder,
B9E-US-S323,Ph II Gemcitabine + Trastuzumab in HER2  2+ met breast ca,
"7314",Placeholder study for PKC,
B9E-MC-JHDZ,GEMCITABINE & CISPLATIN IN PTS WITH ADVANCED OVARIAN CANCER,
H3S-FP-O028, miscelleaneous  Evista IITs (france),
B9E-FP-O360,IIT-NSCLC B9E-FP-O360 Soulié GEM-PC / CAC Paul Papin,
B4Z-XM-S007,Study on the impact of the illness in children with ADHD,
B9E-IN-S328,Gemcitabine Hcl in Breast Cancer,
"7640",Placeholder for Cymbalta- Local Plan Spain,
B9E-MC-X019,PHASE 2 STUDY OF GEMCITABINE IN RELAPSED CLL,
"7721",Obs. Inv/Patient Expectations Non Small Lung Cancer,
"7749",Fellowship - Dr. Huot,
B9E-MC-V208,Gem Iressa Affinitac study,
B9E-MC-V211,Monitor Gem PK in HSV-kinase overexpressing tumors,
H3S-AG-O115,Raloxifene and diabetes,
B1Y-BP-X111,POSTNATAL DEPRESSION - PHARMACOPROPHYLAXIS,
B5K-SE-9283,HUMULIN CLINICAL EXPERIENCE EVALUATION STUDY:  OPEN LABEL,
H7T-EW-TAAA,CS-747 - Multiple Dose Safety Study -1 v Clopidogrel,
H3S-XM-O021,BMD/SPANISH POPULATION *CLINICAL EVOLUTION*,
B9R-XM-S006,INCIDENCE OF SHOX DEFICIENCY IN SHORT CHILDREN,
B4Z-LC-LYBJ,Once daily dosing in PM Adult Subjects,
"6088",mGluR2 Health Economics Study for Pricing Support,
H6E-MC-GLAT,Insulin Combination Study,
B4G-IT-LBAU,PARKINSON / MRI EVAL.OF NIGRAL DEGENERATION,
B9E-MC-S272,"1st line - Rand Ph III Docetaxel + Gem  --> Gem -  Breast",
H3E-US-JMEZ,Ph 2 ALIMTA  + Carbo AUC 6. 1st Line NSCLC,
F1J-MC-SBBR,Dose Escalation / De-escalation of Duloxetine in SUI,
B4G-JE-YI13,STUDY ON L-DOPA REDUCTION IN PATIENTS WITH PARKINSON'S DIS.,
H4Q-MC-ARRT,PHIII Bacteremia Registration Trial,
F1J-MC-SBBU,Korea Local Registration Trial,
B9E-LD-O278,Ph II Gem+Carbo in relapsed metastatic Breast cancer,
A6J-JE-XR34,JP vanc P-III PRSP internal medicine area,
B5K-MC-IBDG,HUMAN INSULIN DELIVERY WITH A NEW 3.0ML B-D REUSABLE PEN,
"6482",MDSS 2 (patients with LMR),
F1D-BL-B012,SOHO 2004 Brazil relapse rate,
"9368",This is a pilot study - test for the Atomoxetine Com - 618,
F1D-JE-205E,"LY170053:  BIOEQUIVALENCY OF CAP. AND TAB., EFFECT OF MEAL",
H3E-US-S054,Phase I Alimta/Gemzar/Oxaliplatin in GI Malignancies,
H3E-US-S055,Phase II trial of Alimta in Hepatoma,
F1D-UT-O259,Cognitive functioning and bipolar disorder.,
B9E-SB-O422,Ph IIb - Gem/Cis/5-FU/FA (A) Gem (B) +/- Heparin - Pancreas,
F1D-JE-P200,LY170053 MULTIPLE DAILY DOSES TO 3 DAYS IN HEALTHY VOLUNTEER,
F1D-LC-HGAN,OLANZAPINE/ETHANOL DRUG INTERACTION TRIAL,
H8D-MC-EMBH,Blood Pressure,
F1D-LC-HGAQ,OLANZAPINE: INTERACTION STUDY WITH IMIPRAMINE,
"9615",Insulin treated type 2,
F1D-JE-RAPK,JP ola PK RAIM,
B4Z-MC-I002,A study of the Efficacy of Atomoxetine in Treating the Inatt,
"9700",Placeholder 3,
H3E-US-X023,Ph II Alimta & Gem as First Line Chemo for pts. w/ NSCLC,
"9833",PK/PD NPL vs NPH,
"9850",Thorough QTc Study,
H7C-LC-LMCL,Urinary pH Study,
H8O-EW-GWAI,Exendin-4: Definitive BE,
F1D-XM-O224,Neuromagnetic discovery in bipolar,
H8F-EW-LGCE,Single Oral Dose Study to Assess Safety and Pharmacokinetics,
H8I-EW-HQAF,Effect of SD SSRI on GH resp to Zolmitriptan,
B9E-US-X440,"Ph I & pk of gem, oxaliplatin & capecitabine w/solid tumors",
B9R-MC-I013,rhGH STUDIES IN RENAL FAILURE PATIENTS,
B5K-MC-IBEL,Insulin Delivery Using a New 3.0ml Prefilled Pen,
F1D-US-A118,"Olz on behavior, acetylocholine + neuroprotection in rodent",
H4Z-MC-GJAN,Absolute Bioavailability-IV (ClinPharm),
"8586","Fed/Fast, single dose, HV, PK, safety",
F1J-BI-SBCM,Community Dwelling Elderly Study,
"8675","Ph II, ALIMTA (D1) Gem/Cis (D2) q 15d in Pancreas Cancer",
H9F-BD-GYAD,Single Dose Caloric Intake,
ZYY-FW-GCBM,Antioxidant effects of Vit. C in healthy subjects,
B9U-MC-AZCV,LORABID VERSES CEFTIN:  SINUS TISSUE PENETRATION,
H7R-LC-GCBR,Drug-Drug Interaction Study (CYP3A4),
B5K-GH-O015,Effect of insulin on B cell in type 2 DM,
"8436",Pilot Bioequivalence for LY333531 (64 mg),
B9E-MC-V217,Characterize gem cytotox profile w/tannic acid in vitro,
I3Y-KL-B002,Korea PMSS - Abemaciclib mBC,
A6J-JE-C001,VANCOMYCIN HYDROCHLORIDE I.V.;PMS IN MRSA INFECTIONS,
F1D-MC-A113,Role of NT system in antipsychotics properties OS Olz.,
"8020",Proof of Concept (Phase 1b) Study,
F1D-US-X229,A Non-Tapered Switch from Quetiapine to Olanzapine in Psychi,
H7U-MC-IDAO,Pulmonary Insulin Phase 2 Type 2 study,
B9E-MC-V010,HPLC Anal. as Ref. Comp. in Lab.,
"8136",Raloxifene vs bisphosphonates observational,
F3Z-CA-O058,Healthcare Economic Study for the Diabetic foot,
"8144",Gem+Alimta lung (Ceresoli proposal),
"8146",Alimta-Cyclophosphamide in II line breast cancer,
H6P-MC-X004,Retrospective Chart Review on the Efficacy of Olanzapine,
B9R-EW-GDED,SAFETY AND EFFICACY OF HUMAN GROWTH HORMONE REPLACEMENT THER,
B9E-US-X397,"Ph II Gem, Carboplatin, Herceptin w/metastatic breast CA",
"8345",Duloxetine vs. Comp. in MDD plus painful physical symptoms,
F1K-MC-O015,CRRT: Xigris vs Heparin in non-sepsis induced ARF,
"8419","Ph II, ALIMTA + Doxil in Breast Cancer (US Oncology)",
"8420",ALIMTA + Gemzar (Biliary),
F1K-SB-EVBL,E/S of rhAPC in Pts. w/ Sepsis Undergoing Peritoneal Lavage,
H8A-MC-LZAM,LY2062430 A Beta Antibody Efficacy in AD Subjects,
H4S-US-X015,Safety & Efficacy of ReoPro in PCI Pts with Prior Stroke,
H8B-EW-EJBA,"SDSS/MDSS, PK/PD",
"6823",Tx pts w/rec/ref hodkin's dis w/wkly Gem & Vrb,
"6834",Drug Interaction - Diuretic,
ZYY-FW-GCAN,zolmitriptan and 5-HT1D receptor,
F1D-MC-X216,A Double-Blind Randomized Controlled Trial of Olanzapine VS,
B9E-MC-I030,TO DETERMINE THE MTD OF THE COMBINATION OF GEM & TAXOTERE,
"6986",Investigation of Pathogenic Spectrum of CAP in Chinese Urban,
H7C-MC-LMCR,Open-Label Long Term Exposure Study,
F1D-US-I037,A Controlled Study of Olanzapine in Children with Autism,
B9E-MC-V187,Combination effect between Gemcitabine and ZD1839 (Iressa) o,
H6M-MC-LDAR,LY450108 vs Placebo--Efficacy & Safety--Parkinson's Disease,
"7268",Placeholder Cialis non-study related local support work,
B3D-EW-GHCI,Observational Study for Severe Osteoporosis,
B9E-MC-V201,For PK analysis of the study:  Intravesical Treatment with G,
"7351",CCK,
"7374",Pharmacogenomic study (Scambia proposal),
B9U-SB-AZDF,LORACARBEF:INFLUENCE ON INTESTINAL MICROFLORA,
B4Z-US-LYCW,Effect of tx on parent w/ADHD & looking @ family functioning,
F1D-GH-HGMI,RAIM Olanzapine versus Haloperidol i.m. in acute schizophren,
F1D-RO-B010,Local Obs Study - Zyprexa - Romania,
"9157",CS-747: Plavix switching study,
F1D-MC-X252,Application of Shape Analysis of Subcortical and Cortical St,
B3D-VI-B005,Forteo observational study in CEE/AMEA,
B9E-EW-B005,OASIS - Observational study in metastatic breast cancer,
B4Z-SB-O005,ADHD Profile Study II,
F1J-JE-HMEC,JP Dulo P-III DB study managed by Shionogi Co.Ltd.,
"9428",Bucket - Melbourne Academic Psychiatrist Consortium Studies,
B3D-IT-B007,Pain in Non-responder OP Obs Study (PROOS),
F1D-AY-O265,Managing neurocognitive deficits in schizophrenia,
F1D-MC-O267,Olanzapine augmentation therapy in treatment-resistent depre,
B4Z-CA-S012,Atomoxetine in children/adolescents with ADHD - Peds study,
"9701","Ph I, ALIMTA+Abraxane in Breast Cancer",
B4Z-CA-S013,ADHD outcome in French-speaking children,
F1J-SB-B009,PADRE Obs. Study Germany Cymbalta,
F1J-MC-HMFK,Duloxetine Bioequivalence Study for 20% and 32% pellets,
F1D-VI-B019,Efficacy of weight education programs,
"9909","RPH2, 1st line, Gem/Pacli/Her vs. Gem/Carbo/Her in MBC",
F1D-MC-HGBM,OPEN-LABEL OLANZ. IN PTS WITH POS. OR NEG. SYMPTOMATOLOGY,
H8C-MC-LQBB,Single and Divided Oral Dose - Safety/Tolerability/PK,
I1E-MC-ESAE,POC-HTN,
H3E-US-X036,PhII Alimta & Gemzar in Cisplatin Refractory Germ Cell Tumor,
"10094",Cytotoxicity and antitumor activity of gem,
"10145",Placeholder for local support of B9E-MC-S132,
"10147",Opra III Formulation Bridging,
H3E-MC-V046,Preclinical Stusies with ALIMTA,
B9E-MC-V252,Cytotoxicity and antitumor activity of gem,
H3E-MC-V052,Folate Receptor Binder for Rheumatoid Arthritis,
B9E-KL-O460,Phase II Study of adjuvant Gemcitabine and cisplatin,
B4Z-MC-LYDT,oral solution taste study evaluating flavor levels,
H8D-JE-EMBJ,JP PPAR-alpha P-1 SDS/MDS,
B9E-RO-O393,"Gem, oral Cycloph. and Methotrexate in relapsed or met. BC",
F1D-US-X247,Evaluation of Antipsychotic Use in Children Restrospective,
F1K-US-V011,Anti-Inflammatory & Anti-Apoptotic effects of Xigris,
H3S-XM-O119,Raloxifene effects on the OPG/RANKL system,
F1K-CA-O017,Studies of Act.prot C in Cancer patients with severe sepsis,
F1J-MC-SBCJ,Sphincter Hypertrophy,
"8631",Placeholder for CRC,
"7648",Atom Adult - Post launch Tx study in adults with ADHD,
B5K-GH-O013,Change of cytokine in T2DM and effect of intensively insulin,
"8647","1d/ssri: GI regional absorption",
"8681","Ph I/II, 2nd Line ALIMTA + Taxotere in Bladder Cancer (US)",
"8756","Ph I/II, ALIMTA+Gem (qo wk) - refractory Leukemia/Lymphoma",
H3E-MC-V006,ALIMTA in tritated form (multiple samples),
F1D-XM-HGLW,OPTIMAL LENGTH OF CONTINUATION TXT W OLZ AFTER MANIC EPISODE,
"8907",CS-747: Metabolism II,
B9E-UT-O431,NSCLC:Gem/Carbo 3wk comparing 2 schedules (Carbo:d1 vs d8),
H7R-LC-GCBX,EKG Controlled Study,
B9U-MC-X001,OUTCOME ANAL. OF ENDOS. SINC. SURG. FOR CH. SIN: A RAND. CON,
B4Z-US-X009,Atom treatment of Binge-Eating Disorder,
B9R-US-X038,National Collaborative Study,
H6E-XV-O012,Metabolic Syndrome - Diagnosis Criteria for NCEP,
"9775",Disease-based Proteomics POC,
H6Q-MC-JCBT,R-Ph II ENZ Alimta vs Placebo+Alimta-2nd line-NSCLC,
F1J-IT-O009,Neutrophic factors in Duloxetine-treated rats and mice,
F1J-US-B011,Observational Study of Women Taking Dulox HCl for SUI,
H3E-US-S082,Biweek A/Gem or A vs A/Carb or A in relapsed NSCLC,
I1B-MC-NDAA,FHD: Single Dose Safety Study for OpRA III,
F1K-MC-I003,Safety & Dosing of Xigris in ESRD treated with HD,
I1A-MC-BPAE,Phase II Trial in Men with BPH,
F1J-ME-MPAA,Explorat Assestment of effectiv and tolerabilty of 60 mg,
"10489",MDD OBS Cymbalta,
I1F-MC-RHAC,RBA - Relative Bioavailability (LY2439821) IV vs SC in NHV,
F1K-BP-O035,Effects of Drotrecogin om severe sepsis Observational,
F1D-MC-X015,OLANZAPINE ACTION ON KETAMINE-INDUCED RCBF CHANGES,
F1D-MC-X021,OLANZAPINE TREATMENT OF PSYCHOSIS IN PARKINSON'S DISEASE,
B9E-US-X369,"Ph II Gem, Capecitabine, & CP-461 in pts w/ref ren cell CA.",
B3D-MC-GHCJ,Teriparatide/Risedronate in men with osteoporosis,
"7403",MOA Guinea Pig Model No. 1 Trial-Resiquimod,
B9E-AA-O389,R-PhII-Concurrent Chemo RT->Gem vs Gem+Carbo-IIIa/IIIb NSCLC,
"7478",Phase 3 Alimta in NSCLC - UK,
B7A-MC-B001,Amrami-Endoneurial Blood Flow-MRI study,
H6D-EW-LVFG,LY450190 - Alpha blocker in healthy male subjects,
B9E-US-X375,"Ph II Gem, Rituximab & Dexamethasone pts w/Non-Hodgkins Lymp",
F1D-VI-B007,Olanzapine in acute mania in CEE-AMEA Region,
B9E-MC-X039,GEMCIT. & LEVCOVORIN MODULATED 5-FU IN COLORECTAL CARCINOMA,
B9E-US-X378,Ph II eval efficacy of combo Gem & Vinorelbine sarcoma,
"7769",GET Combination in patients with breast cancer,
"7788",Cialis vs Vardenafil in ED,
B9E-MC-V210,PK & PD determination,
B9E-MC-S330,PH I/II liposomal doxorubicin + Gem Breast,
"7882",Forte Compassionate Use Study,
"7904",Evista in Osteoporotic cohort with Uterine Miomatosis,
"8994",ALIMTA-CPT 11 in Colon - Pr De Gramont,
"9038",OUS DMC Trial,
B4Z-US-LYCX,executive functioning in adult population,
"9060",Ambrosio-Mechanisms of cell degeneration in DR,
"9106","Phase 4 ""Weekend"" Trial",
H6D-MC-LVFY,Safety and Efficacy of Cialis in SCI,
F1D-BP-HGEZ,OPEN-LABEL OLANZAPINE VS. SERTINDOLE SPECT STUDY,
"9158",Gemcitabine & COX-2 inhibitors,
F1D-MC-A121,Dynamic changes in regional glucose metabolism in brain,
"9253",Placeholder for HMDD local headcount,
B3D-US-X010,Using teriparatide to build bones in osteogenesis imperfecta,
F1J-XM-O006,socioeconomics costs of mental disorders in Spain,
F1D-JE-2001,LY170053 EARLY PHASE II CLINICAL STUDY,
H6E-AY-O010,Actos study of NZ ethnic groups,
H6L-MC-LFBB,QTc study - Gamma Secretase single dose,
"9440",LY2059346 Biomarker Study,
"7913",Zyprexa-relapse prevention - schizo,
H4S-SB-O060,Repair AMI,
"9488",Platelet Leukocyte MPO Study,
"9493",Decres Platelet Activ vs. Clopidogrel 300/600mg aft 2b3a adm,
B9E-BX-O423,RT + gemci/oxali in pancreatic and biliary tract cancer,
H9J-EW-EPCA,FHD Study for LY680697,
H3E-MC-S014,Ph I/II - ALIMTA in Patients with Relapsed Leukemia,
B5K-GH-O443,Polymorphism of GLUT2 promoter effect bcell function in T2DM,
"9663",Second study- ped comorbid ADHD + ODD,
F1K-MC-EVDB,Severe Sepsis pts. at high risk of death with PC deficiency,
F1D-CA-S060,Olanzapine at higher doses for refractory schizophrenia,
B4Z-MC-LYDL,Sensory study part 2 for child-friendly formulation,
F1D-MC-HGAD,LY170053 VERSUS PLACEBO/HALOPERIDOL IN SCHIZOPHRENIA,
H6Q-MC-S006, Pharmacodynamic Study of Enzastaurin in Prostate Carcinoma,
F3Z-FW-IOOS,PK/PD NPL vs Detemir vs Glargine vs NPH,
F1D-FP-O295,IIT - F1D-FP-O295 - Pr fMRI study ola,
"8700",Exenatide compared to an insulin comparator in pat. w/type 2,
B9E-SZ-JHLM,GEMCITABINE IN HORMONE REFRACTORY PROSTATE CANCER,
H7X-JE-JVAP,JP Affinitac Phase I,
B4Z-US-LYCE,ADHD + LD + Cognition,
H6E-IS-S005,Actos Add-On Efficiency Study,
"8145",Gem+Alimta Colon study (Amadori proposal),
"8214", Inhibition of PKCa in HER2 overexpressing breast cancer,
B9R-US-X036,A Trial of Growth Hormone and Leuprolide to Improve Final He,
B9R-IT-GDDO,NEW BONE AND COLLAGENE MARKERS AS GROWTH PREDICTORS IN T.SIN,
B9E-SZ-O372,Capecitabine and Gemcitabine for biliary tract cancer phII,
B9E-MC-S346,Ph II wkly Gem F/B TURB,
B9E-BP-O384,Phase II Gem/Carbo ovarian- platinum resistant/refractory,
B9E-GH-O391,Phase II Gemzar & Cisplatin Treat Advanced Breast Cancer,
B9E-OL-O411,Vinorelbin/Carbo vs Gem/Carbo in advanced NSCLC,
H9B-MC-BCDE,LA294 Bioavailability SQ-IV formulation bridging study,
"8624",Placeholder,
H3E-MC-JMHA,"Ph I, ALIMTA+Avastin+CPT-11 or Oxali",
H8I-EW-HQAI,"1d/ssri: Food effect",
B3D-US-GHCW,Forteo use in Osteoporosis evaluated by MRI bone biopsy,
B9E-US-X445,Ph II Carboplatin/Gemcitabine plus Bevacizumab in NSCLC,
F1D-MC-HGBO,OLANZ: COST-EFFECTIVENESS IN TREATMENT RESIST. SCHIZOPHRENIA,
F1J-MC-X008,Does Duloxetine Reduce Opioid Requirments in Non-Depressed,
H6L-MC-LFBA,LFBA - #11259 - DDI: Plavix (2C19),
H7T-MC-TACE,Prasugrel IMCT ACS PCI study,
"11344",Randomized Phase II/III Pancreatic Cancer,
H8O-MC-O003,"Effect of Exex on satiety, etc. in Type 2 Diabetes",
F1J-MC-X034,Psych Resil + Correl w Blockade of Sero + Nor Transporter,
"11478",Effect of Ruboxistaurin in Patients with CSME,
B9E-US-X462,"PhII Gem, Abraxane & Bevacizumab in Metastatic Breast Cancer",
H6Q-MC-S043,Ph II ENZ in Neoadjuvant Breast Cancer (NSABP),
H6Q-MC-S039,Phase II ENZ before and concom XRT --> maint.-newly diag gbm,
I1W-EW-GBFA,Single-dose safety study (SDSS),
F1D-MC-X303,Metformin to prevent metabolic SE of olz,
B9E-MC-V340,Personalized Pedication for Gemcitabine in Clinical Settings,
H8S-MC-LIBB,MeNER Validation Trial Using Reboxetine,
"8709",Psychomotor Impairment vs Pregabalin,
"8741",Ph III- Carb+Doxil vs Carb+Taxol vs Carb+Gem -2nd line Ovary,
"8847",GEMZAR + CISPLATIN ADJUVANT TREAT. IN NSCLC,
F1D-US-HGLU,Effect of olanzapine in pts with pre-existing diabetes,
"8899",Zydis for Agitation in Elderly Patients,
H7R-LC-GCBS,Drug-Drug Interaction Study (CYP2C9),
H7R-LC-GCBT,Drug-Drug Interaction Study (LY/metformin),
F1J-US-HMDY,DNP,
"9000",Conservative Management of Women with Severe SUI,
H7U-JE-IDAQ,JP Pulmonary Insulin SDSS (Clamp),
"9050",placeholder for humulin local support,
"9095",ICR pre-launch Comparator Cymbalta,
B1Y-CA-C019,FLUOXETINE: TREATMENT OF LATE LUTEAL PHS. DYSPHORIC DISORDER,
"9116",Stroke Trial (Place Holder),
H3E-MC-V030,ALIMTA to be used as Positive Control for invitro assays,
H6U-BD-HGLX,Olanzapine/Atomoxetine Augmentation POC in Europe,
F1J-JE-102G,LATE PHASE II STUDY ( B GROUP ),
B4Z-VI-B004,Obs. Study of Treatment Regimen & QoL in ADHD in CEE & Asia,
B9E-SN-O416,MBC IIT - Serum Protein Profiling for Gem Sensitivity,
F1D-GH-B016,Olanzapine in the treatment of schizophrenia and related dis,
"9325",Prozac in depression with fatigue symptoms in general hospit,
"9351",Egypt affiliate local trial Glustin vs Avandia,
H3E-US-X006,Ph II Pemetrexed 2nd line for Hormone Refrac Prostate CA,
H3E-US-S062,Phase I Alimta + Doxil,
B1Y-MC-HCLS,Impact of fluoxetine on growth in children and adolescents,
"9494",Anti-Inflam effects of CS747 Compared to 300/600mg Clopidogr,
B9E-US-X434,Ph I study of biweekly carboplatin & Gem in pts. w/ adv. CA,
"9513",PK/PD in STEMI patients--IPA to Outcomes (Topol),
H3E-US-X013,Ph II of Alimta vs. Alimta & Erbitux in 2nd line chemo NSCLC,
H7U-MC-IDAW,Concordance Protocol - HIIP,
F1D-BP-O262,Comp Prolactin/sex hormone axis/BMD in pts on Olz and Risp,
F1K-IT-V015,Effect of rhAPc on white cells apoptosis in vitro study,
H9D-MC-ITAB,Apollo pen trial,
F1D-US-X268,"Drug Only -Double-blind, rand comparison clozapine vs olz",
H6Q-MC-JCAZ,Single Doses-Absolute BA Biopharm Study,
B9R-BP-O037,Transition of Endocrine Care from the child to the adult,
H7T-EW-TABD,PCI Study,
"9807",Exenatide: Statin steady state,
F1K-US-EVDA,Hemodynamic Study in Septic Shock,
"9962",Terminal insomnia,
H6O-IS-O002,Evaluation of Beta Cell Reserve in Newly Diagnosed Type 2 DM,
H3E-MC-JMHY,Ph 1-Cis +/- Alimta-HNC,
B4Z-US-X045,Atomoxetine for Attention Deficits in Adults with Mild Hunti,
H6Q-MC-S022,Ph Ib ENZ in CLL pgx trial,
"10764",Young-In Chi ExNCR,
B9E-MC-V304,Synergy of Gemzar + clusterin ASO in bladder cancer,
F1J-MC-I005,"dulox with chronic fatigue syndrome, rand, db placebo",
"10928",Ph III randomized Gem/Carbo vs Gem/Caelix Ovarian Cancer,
B4Z-ME-B008,Attention Deficit Hyperactivity Disorder (ADHD) Prevalence,
"10931",Ph I/II Alimta + SU11248 2° Line NSCLC,
F3Z-BP-IOBW,LY275585-NEED FOR SNACKS USING AN INTENSIVE INSULIN REGIMEM,
F1J-MC-HMFO,Pediatric depression dose finding study,
F1J-US-X043,A Comparison of Antidepress in Women w and w/out PPO of MDD,
B9E-IT-O496,Gem+Campath in t-CELL lynphoma,
F1D-IS-O302,The effect of omega-3 on the time to remission ,
H8O-MC-GWCD,HR & BP Monitoring of Patients on Exenatide,
F1D-US-X306,Augmenting Zyprexa with Naltrexone:  Normalization of the We,
B3D-CR-B013,ICR Forteo OS study,
"11851",Monotheraphy compared to Polypharmacy in treatment of DPNP,
F3Z-MC-IOAO,LONG TERM MONITORING OF SAFETY IN PTS CURR TREATED W/ LYSPRO,
F1D-AY-V019,Signalomics: Sys Approach to study func of neuro disease,
F3Z-MC-IOBH,METABOLIC EFFECTS & QOL OF LY275585 VS ACTRAPID IN IDDM,
I1C-MC-JLBD,P1 LY2334737 in Comb. w/Docetaxel in Pts w/Adv Solid Tumors,
H8O-FW-GWCL,QW PK,
H6D-CP-O012,Cialis IIT Dr Laursen,
H8O-IT-O004,Beta cell damage and regeneration,
B1Y-VI-HCHL,PROZAC EXPERIENCE PROGR. IN CZECK AND SLOVAK REP.,
F1J-BL-O021,Open dulox trial on comorbid depression and chronic headache,
F1K-US-A021,Therapeutic role of APC in the hamster model of hantavirus,
F1K-XM-EVDL,Characterization of Neutrophil Apoptosis in sepsis,
B9E-KL-O483,Randomized trial of preoperative vs. postoperative Gem+Cis,
F1J-JE-1009,LATE PHII STUDY ON DEPRESSION AND DEPRESSIVE STATE,
F1J-JE-HMFE,JP Dulox P-II Double-blind DPNP Study (Shiognogi),
F3Z-VI-B001,Hypnotice - Safety of premixed insulin analogues,
B9E-AY-V352,Test Crystallisation of Gemcitabine,
H6Q-MC-V027,Enz in myeloma disease and apoptosis in myeloma cells,
F3Z-US-X026,IMMEDIATE Trial,
B9E-US-X461,PhII Bortezomib w/ Gem in Nasopharyngeal Carcinoma,
F1J-MC-HMAI,DULOXETINE VS PLACEBO AND CLOMIPRAMINE IN MAJOR DEPRESSION,
H6L-MC-LFAZ,"Renal Interaction w/probenecid, metformin",
I1C-MC-JLBJ,R-Ph II-Dbl Blind-GemPro vs Taxotere-NSCLC-2nd line,
H6Q-MC-S048,Ph II Lower Grade Glioma Study for EU n recurrent GB,
"11523",Ph 3 Enzastaurin Placeholder for Planning #2,
H9X-MC-GBCM,Renal Impairment,
F1D-US-A041,Regulation of Transcription Factors by Olz and Hal Treatment,
F1D-MC-X011,CLINICAL OUTCOME AND COST-EFFECTIVENESS STUDY,
F1D-MC-X018,TEXAS MEDICATION ALGORITHM PROJECT,
H6D-EW-LVHO,PAH Clin Pharm Interaction Study #3,
"10611",Cialis Couples Trial,
H6L-MC-LFAP,LY450139 and Renal Dysfunction,
H6Q-MC-S009,PII enz vs Obs former smokers-chemo prevention/insitu NSCLC,
B3D-US-GHDD,Preos PK Study,
F1J-US-X020,An Open Label of Duloxetine for the treatment of pain and de,
B4Z-US-X046,Atomox for ADHD in Adolescents w/Substance Abuse Disorder,
B9E-MC-V328,Antitumor effects on Interferons on pancreatic cancer,
B9E-SB-O477,"Gem/Docetaxel seq. vs Gem/Carbo, combined with Cetuximab",
"10884","CHIP- ADHD children- achievement, satisfaction, comfort",
F1D-VI-HGDU,SAF.&EFF. OF OLANZ. IN PT. WITH SEV. HALOPERIDOL SIDE EFFECT,
B9E-US-X456,PhI Abraxane w/ Gem for Solid Tumors,
F1D-MC-X288,efficacy and safety of co-admin of mifepristone and olz,
"11028",Transdermal permeation of nucleosides,
H9B-MC-BCDF,Safety and Efficacy of IV LY2127399 in Patients with RA,
F1J-US-HMFT,Duloxetine Vs Gen SSRIs in the Treatment of  Severe Depressi,
F1D-XB-O303,OLZ vs Velotab. Influence on weight and BMI,
F1K-AY-V025,Investig Host Inflamm Factors Affecting Sepsis,
F3Z-MC-IOAN,LONG-TERM MONITORING SAFETY PTS CURR TRTD WITH LY275585,
F1J-IT-A009,Changes in the rats' brain by chronic Dulexetine adm,
I2I-MC-JMMB,FHD Dose Escalation Study of IC83 plus Pemetrexed,
"11950",CETP Inhibitor - Phase III - Outcomes,
H8A-JE-LZAK,JP Abeta AB P-II Local study,
H3E-US-X072,Ph II Study of Alimta + Carboplatin + Avastin in NSCLC,
H9P-JE-LNBH,JP NERI-IV PhI MDSS,
F3Z-MC-IOET,BIOEQUIVALENCE OF INSULIN LISPRO MM:  CT07806 VS CT07807,
F1K-FR-A026,AsfarSeptic rat induced-microparticles: their role in the he,
F3Z-PL-IODW,INSULIN LISPRO: FIT FLEXIBLE INSULIN THERAPY EDUCATION TRIAL,
H8Y-EW-HBBK,Alcohol Interaction,
"12281","11bHSD1 Biopharm DDI",
I4E-IE-W933,Protocol CA225-278; II study of single-agent cetuximab for t,
H6Q-MC-A020,Enz and irradiation effects in bone cancer,
F1J-JE-107G,LY248686 GERIATRIC STUDY (PHASE I) BY SHIONOGI,
"11187",DPP IV MDSS,
H4S-SB-O071,Retrospective Analysis Dr. Wöhrle,
H6O-MC-GCAX,Effect of sibutramine on body comp meas variability w/ qNMR,
H8O-MC-V001,"Increasing beta-cell growth, prolif. & reducing apoptosis",
H9T-MC-NABL,Drug- Alcohol Interaction Study (OpRa II),
H8O-MC-A010,Role of GLP-1 signaling ins secr and islet mass,
I1X-MC-BDAD,Phase II Adults with Plaque Psoriasis,
"14172",C14 Metabolism Study,
B4Z-SB-O013,Atomox and a standardized behavior therapy in adult ADHD,
B9E-IT-O500,Ph III randomized of Neoadj/Adj therapy Gem+Cispl NSCLC,
F3Z-BD-IOEG,EXPERIENCES WITH LISPRO THERAPY IN IDDM PATIENTS,
F1K-BP-O043,A study of the effects on short and long term outcomes of th,
I1O-BD-S001,Temporal Summation Human Pain Methods Validation study,
"11679",PK to Eval. LY2181308 in Pat. w/ Adv. Hepacelluar Carcinoma,
"11690",Evaluation of the anti-tumoral effect of a combination Meso,
"11697",Placeholder local Forteo study,
F2X-LC-HIAE,LY210448 HC1: STUDY OF EFECT OF FOOD ON BIOAVAILABILITY IN,
H8O-MC-X003,"Early clin exp w/Byetta, real world setting",
B9E-IT-O498,Molecular predictive determinants to CT response in NSCLC,
F1D-GH-O300,effects of different antipsychorics on menstruation of women,
H6O-MC-GCED,PET RO Study using Rimonabant and [11C]MePPEP for CB1 target,
"11624",CB1 Antagonist II Phase II Efficacy Study,
B5K-SB-O453,Effects of Insulin on the central nervous system via fMRT,
I2D-FW-GIBA,SDSS in heatlhy volunteers,
H3E-SB-O033,Alimta/Carbo plus or minus Sorafenib in first line NSCLC,
B9R-CA-O049,GH therapy and bone quality in pediatric osteoporosis,
F3Z-IT-GVAB,EFFECT OF LISPRO TREATMENT ON MICROALBUMINURIA TYPEII PAT.,
F1D-HL-O301,Solution for Wellness - impact on metabolism,
F1D-US-A145,Drug Only: Effects of Olanzapine and Haloperidol on Rat Brai,
B4Z-PH-B010,Post Marketing Surveillance Study on Strattera (Atomoxetine),
B1Y-EW-E072,FLUOXETINE V PLACEBO OBESITY TYPE II DIABETICS,
H8Y-EW-HBBL,Relative Bioavailability and Food Effect Study,
H7T-EW-TACT,Prasugrel:Biopharm FE Study,
"12321",Teriparatide vs biphospohates. Effeft of Teriparatide on BMD,
H9B-MC-BCDH,"RA Ph2 Dose expansion MTX INR, TNF Naive (IV)",
H9P-MC-LNDN,Peds reading disorder w/ ADHD flex doses LY vs. PBO,
F1J-GH-B032,Local Major Depressive Disorder,
I2C-MC-BABB,Multiple Dose Study of Safety and Pharmacology (LY2328382),
"12562",FED trial for LY2090314 (Tumor Type TBD),
I2T-MC-LADD,Human C14 Trial,
H9P-EW-LNCP,Biopharm Haemodynamic and vital signs study,
H9P-EW-LNCQ,Biopharm GENERIC PLACEHOLDER STUDY,
H9P-EW-LNCX,Biopharm Oral Contraceptive Study,
I2Y-MC-GHFA,Phase 2 Transdermal Patch ,
H8Y-MC-HBCQ,DDI: Pgp (Digoxin) ,
B4Z-BP-O023,Atomox vs Methylphenidate and placebo on the brain activatio,
H7T-MC-TACY,"5 mg Pras. PK/PD in Elderly Patients",
B9R-XM-S005,QOL QUESTIONNAIRE*LOCAL VALIDATION*,
F1J-SB-O030,Duloxetine and deep somatic pain/C-fiber function in MDD,
"11932",Omega3 Fatty Acids for Olanz. Related Hypertriglyceridemia &,
H7T-MC-V014,Effect of AM pras on aggregometry using Multiplate,
F3Z-MC-IODM,LISPRO MM AND LISPRO LM VS HUMULIN 50/50 AND HUMULIN 30/70,
F3Z-MC-IODR,OVERNIGHT GLYCEMIC CONTROL FOLLOWING EVENING ADM. OF NPL,
F3Z-MC-IOEI,LISPRO IN PATIENTS W/ TYPE II DIABETES & RENAL IMPAIRMENT,
H6P-MC-HDAX,Tx of major depressive episodes assoc w/bipolar in peds,
"12158",PEG Distribution Study,
F3Z-MC-IOFY,INSULIN LISPRO MM VS. HUM 50/50: TEST MEAL STUDY IN TYPE I,
B1Y-EW-E075,FLUOXETINE V PLACEBO/FOOD INTAKE AND SUBJECTIVE HUNGER,
B9E-MC-V356,Effect of Gemcitabine on Tumor associated macrophages myelo,
H6D-CR-S024,Phase III/IV Cross-over Tadalafil OaD vs PDE5 inhibitors PRN,
"12318",FXR Antagonist SDSS,
H7T-MC-TACX,Phase 2 Pediatric Dose Ranging Study,
ZYY-FW-O003,Continuous Glucose Monitoring Methods Study,
F3Z-SB-IOGP,INSULIN LISPRO IN COMBINATION WITH ORAL AGENT (DM TYPE II),
"12368","2-year diabetes add-on to metformin + pioglitazone",
H2Q-MC-LZZP,EFFECTS OF METHSCOPOLAMINE ON THE ORTHOSTATIC INTOLERANCE,
I2Y-MC-GHFB,Teriparatide Transdermal Phase 3 Bridging Study PMW,
"12907",QEEG study,
F1D-US-A154,Olfactory Span: A new technique to study drug effects on ,
H7T-MC-X005,HCRI: DAPT Stent Study,
F1K-SB-V027,Effects of activated Protein C on Contractile Forces Sepsis ,
H8O-SB-O012,KADIS prediction for Byetta therapy,
"13027",IC Forteo vs. bisphosphonates in PM women with osteoporosis,
"13106",CRH-1 Antogonist II C14 study,
I3R-EW-HMIE,mGlu2 Potentiator SDSS,
B4Z-US-X060,Atx in Adolescents with ADHD and SUD,
F1J-BI-HMGN,DPNP +/- Co-morbid MDD (BI),
H3R-LC-ERRB,"LY293558:DOSE-RANGING, SAFETY AND PRELIMINARY PK.(II)",
I4C-MC-JTBA,FHD/FED c-MET Antibody ,
H3S-JE-102J,PHASE 1 CLINICAL STUDY OF RALOXIFENE(EFFECT OF MEAL),
I1V-MC-EIAG,Relative bioavailability study in healthy volunteers,
H9G-LC-GXAA,"5-HT2c",
B3D-EW-GHDK,MOVE Terip vs Rised in pts w low BMD & recent hip fx,
F3Z-TW-IOBA,LY275585 VS HUMULIN R PREMEAL THERAPY IN TYPE I&II DIABETES,
"12513",Kappa OpRA ph2/POC Alcohol Dependence,
"12576",MCHR-1 QTc Study,
H9P-EW-LNDF,Biopharm GENERIC PLACEHOLDER STUDY,
H9P-EW-LNCY,Biopharm GENERIC PLACEHOLDER STUDY,
H3S-US-X037,CEA of Mammography,
F3Z-MC-IOCL,INSULIN LISPRO VS HUMAN INSULIN R: TWICE A DAY IN DIABETES,
F1D-KL-V024,Protective eff of olz agst MPP+-indcd apoptos in PC12 cells,
H9D-SB-ITAE,Evaluation of Memoirpen versus Luxurapen ,
"12732",iGlR5 Definitive QTc,
F3Z-MC-IOPQ,Comparison of timing of ILPS dosing when switching from glar,
"12766",Ease of initiation study in insuli- naive type 2 diabetes,
I2K-MC-ZZCJ,Dose Equivalence,
I3K-EW-LAEB,MDSS mGluR5 Antagonist I,
"12876",Lyrica Combination,
"12896",Gem Prodrug - Absolute bioavailability,
H8O-MC-GWDH,QW in DPP4 Failures,
"13338",Midazolam Interaction,
F1D-AY-O325,MoodSwings an online Intervention for bipolar disorder,
H8O-US-GWDO,Effect of Exen. QW on 24 hr Glucose Profile,
"13409",QD & Other Formulation Feasibility,
ZYY-FW-O005,Epigenetics in Obesity/Metabolic Syndrome,
I2Y-EW-GHFK,Special Population (BMI) ,
"13520",Moderators and mediators of Strattera response,
B7A-MC-A021,Effect of PKCß inhibitors on atherosclerosis ,
H8O-FR-O021,IIT - Joubert,
H8O-MC-X021,Impact of exenatide on sleep and circadian func,
B7A-MC-V021,The role of protein kioase C (PKC) isoforms in the cy,
H8C-EW-LQCC,igluR5 Elderly Study (Placeholder),
F1D-CR-HGNB,O+F TRD for China Registration,
H7T-MC-V031,Cattaneo: Effect of thienopyridine AMs on MK function,
F1J-XM-O046,Duloxetine in MDD. Efficacy on fibromialgia,
H6Q-MC-V072,Pre Clinical - Chondrosarcoma and Enzastaurin,
H7T-CA-O009,Statins and Proton pump inhibitors on clopidogrel antiplatel,
F1J-US-V003,Impact of Serotonin Transporter Mutation I172M on Duloxetine,
"12985",PS-Ly vs comparator vs placebo Study has 5 yr ext,
I3O-MC-JSBA,"FHD, Ph I in c-MET",
"13057",IIT Placeholder Exenatide ,
"13096",Efficacy Ex QD at breakfast on diurnal hyperglycemia,
I3W-EW-HHAB,SAD,
H3E-US-S126,Ph III Alimta in NSCLC (Stage IB-IIIA) ,
F1J-SZ-O036,BDNF serum level changes with MDD patients,
I3W-EW-HHAE,SD PET study 5-HT2a,
I2Y-MC-GHFE,Transdermal Teriparatide CS-82-000-04,
H7T-MC-B010,Sweden Post Launch Observational Study (SCAAR Registry),
I3E-BM-MSAK,Kinetic profiles of CSF anti-MBP in MS patients Phase 1,
I3F-MC-JSRB,"FHD PH 1 Trial for LY900009, Notch-1 Inhibitor",
F1D-AY-O326,Prevention of weight gain with second generation antipsychot,
H7T-MC-V026,Hirata: Japan Non-Clinical P2Y12 Smooth Muscle Study ,
"13394",Adult ADHD fixed dose vs. PBO ,
"13477",Escalation from basal #2 iplan 3633,
F1D-IS-O310,the neuroprotective effect of antipsychotic drugs,
"12071",VTE Prophylaxis #1 (Hip),
I1Y-MC-JFBC,Phase I study of LY2523355 in AML,
H3E-JE-S118,JP ALM P-II Combination,
B9R-US-V003,Regulation of STAT5 Phosphorylation by Growth Hormone in Hum,
I2R-MC-BIDF,Injection Site study,
B3D-AY-O016,PTH 1-34 reverses osteonecrosis of the jaw or mandible,
ZYY-MC-S004,(CRU+)Large Molecule Immunogenicity Clincl Follow-up Survey,
B3D-US-X017,Anaylsis of MrOS Study,
H6O-MC-S002,PET [11C]MePPEP test/retest for CB1,
"12470",NK1 RBA/Dose Ranging Study,
F1D-UT-O320,TOPFIT (outcome of pychosis and fitness ther),
H8O-MC-GWDC,bSafety of Once Weekly in T2DM w/TZD or TZD+Met,
I4C-JE-JTBD,Ph I - C-Met Antibody PI Japan - Solid Tumors,
I1Q-MC-JDDG,FED Ph 2 in pts w/pancreatic cancer receiving chemo,
"14640",CSF Fractalkine (FKN) and mediator levels in painful v nopai,
I3G-JE-JGCC,JP_p70S6_Phase_1,
"13891",Relative Bioavailability,
I5B-IE-JGDD,CP15-0805: Ph2 - 3G3 - Prostate - 2nd Line,
H3E-IT-O061,Pem/cis followed by Pem vs carbo/paclitaxel followed by beva,
"13987",Placeholder- Ph2 Testosterone handwashing plus elderly pK,
H4A-EW-XBAU,LY303366:IV MULTIDOSE SAFETY AND PK STUDY IN HEALTHY SUBJECT,
I1V-MC-EIAN,CETP Inhibitor - Phase III - MACE rACS,
H6D-JE-LVJF,Japan TDL BPH Phase III,
I3P-FW-GKBE,Phase 1b (Dose Extension,
I4O-MC-BACH,French Brain Imaging Initiative SOC study,
H4A-SB-V004,"LY303366 IN VITRO ACTIVITY,INFLUENCE ON PHAGOCYTOSIS",
"14240",CP11-1013:R-Ph3-Alimta+Cis+NecitumumabvsAlimta+Cis-NSq-NSCLC,
H6Q-MC-V080,Pre Clinical - PKCb as a therapeutic target in B Cell ALL,
I5E-MC-TSAI,MTE09 - Phase III OLE of Phase III OL Titration Trial,
I5W-EW-LBCB,MAD,
H8Y-MC-HBDF,mGlu (LY2140023) Physical Dependence Assessment Study,
H8Y-MC-HBBI,Schizophrenia Monotherapy Dose-ranging Study,
H7U-FW-IDBN,HIIP PK China,
H3E-SB-B007,PERFORMANCE Alimta Obs. study in Germany,
H9R-MC-JKAG,PD Trial of LY2275796 in pt w/localized prostate cancer,
F1D-FH-O306,Olanzapine's effective in social cognition of schizophren,
F1K-MC-EVDP,"28day mortality; Xigris v Placebo in Adult Septic Shock",
B4Z-CA-O017,GATC: Genotype Specific Approaches to Therapy in Childhood,
B1Y-EW-E073,FLUOXETINE NAMED PATIENT,
"12028",Cialis IIT DK,
"12080",A-fib Stroke (Phase 3),
H8G-MC-EPBO,Biopharm Geriatric,
I2I-MC-JMMD,"FED, Ph II, LY2603618 plus Pemetrexed for NSCLC",
H8O-MC-X007,Effect of Pioglitazone w/ & w/o exen,
I2R-MC-BIAO,T1DM 12mo Basal Bolus v. Glargine,
H6U-US-O010,MDD Remission Scale Validation Study 2,
H6U-US-O011,MDD Resmission Scale Validation study 3,
"13508","1-year efficancy in patients with Type 2 Diabetes Mellitus",
B4Z-JE-LYEO,BE study with Japan child-friendly formulation vs. capsule,
B7A-MC-A027,Inhibition of Protein kinase C sensitizes  ,
F1D-GH-O333,Olanzapine to improve congnition of Mania patients ,
H9X-MC-GBDN,"The Effect of LY2189265 on Blood Pressure and Heart Rate, as",
I4I-MC-SNAA,Phase 1 single dose study of LY2878735,
F1D-MC-B042,Obs Risk Study of Cardiac Mortality in Atyp Antipsych Users,
I4P-MC-GPFC,C14,
I2Y-EW-GHFP,Special Pop Male PK,
I5A-IE-JAEE,CP13-0710: Ph2-A12-Islet Cell,
I4Y-IE-JCDB,CP20-0801: Ph2 - 18F1 - mCRC - 2nd Line,
H7T-CP-O011,TAILOR,
H8L-MC-IQAX,Safety & Effectiveness of Aura for BBT in Type 1 & 2 ,
I1Y-MC-JFBH,Eg5 Inhibitor:  CYP3A DDI ,
H9X-JE-GBDY,JP GLP-Fc Ph3 H2H Glargine,
I4T-IE-JVCD,CP12-1134:R-Ph2-1121b+Eribulin vs Eribulin-Breast-3rd line,
I4X-MC-JFCG,Ph I - 11F8 - Solid Tumors,
"14440",Non-drug Device Trial,
H8O-MC-B017,UK Thyroid Neoplasm and Pancreatic Cancer database study,
B4Z-IT-B018,Retrospect study of atomox in children and adult ADHD,
I4V-MC-JAGA,Open Label Trial for Autoinflammatory Syndromes,
"1734",LY396623 - PK in premenopausal women,
H9H-MC-V002,Pre Clinical:  GI Cancer Cell Lines,
I1R-MC-GLBR,POC target to show GRA I (T1DM) leads to reduct. of insulin,
I1R-MC-GLDE,DDI Study w/Lisinopril PK/PD,
I1V-JE-EIAY,Bioequivalence of 65mg tablet and Japan Food Effect,
H8O-JE-GWEE,JP EX suspension P1b,
H9H-MC-JBAM,TGFb R1 Kinase:  Healthy volunteers,
H4S-MC-X001,REOPRO AND HEPARIN AS AN ALTERNATIVE TO THROMBOLYTICS IN AMI,
I6E-AV-_A14,Ph II Eval of FLORBETAPIR in compaion IIT's,
H6D-MC-LVHW,PAH Pediatric Sensory Eval Study,
F4A-SB-A002,centralnervous effects of proinsulin,
I1Y-MC-JFBD,"FED, LY2523355, PHII, SCLC",
"12256",MDSS w/food effect,
H6D-MC-A015,Treatment of Chronic Heart Failure Following MI with Tadalaf,
B9E-US-S380,Ph II Gem + Ixabepilone in MBC (Taxane Failures),
H8K-MC-JZAW,Randomized PhII - Tasi/Gem- 2nd/3rd line-Soft Tissue Sarcoma,
"12432",Obesity Phase 2,
"12433",Excessive Sleepiness Phase 2,
"12475",CRH-1 Relative Bioavailability,
H8C-MC-LQBI,Elderly pk study,
H8Y-MC-HBBU,Elderly,
"12700",Single-dose drug-drug interaction study for LY686017,
H3E-US-X077,Ph II Pemetrexed/Bevacizumab Recur Ovarian&Peritoneal Cancer,
I2K-MC-ZZBE,Benzo Interaction/Lorazepam,
H8Y-MC-HBCX,Elderly Study,
I3L-MC-LABA,Single Dose Safety Study/PET,
H8O-MC-GWDJ,HC Claims Data to Est Incidence of Acute Pancreatitis (GPS),
"14073",Pre Clinical/PGx - TS expression LCC NSCLC,
"14118",Treadmill Pain Model method study,
H4A-MC-V010,LY303366--ASPERGILLUS IN VITRO TESTING SYSTEM,
I5L-MC-TCAK,Acute Chronic Pancreatitis and pancreatectomy,
I2R-MC-BIAW,PK/PD Variability,
I4C-MC-JTBC,"p2, 2nd line NSCLC (Erlotinib refractory patients)",
F1J-CA-O051,A Prospective Study on Concomitant Depression and Neuropathi,
H9V-JE-GFRG,JP TGFb PhIb MDSS,
I5U-MC-ANBA,RBA #1 - Japan SD/MD,
I5E-MC-TSAT,"Impact of testosterone on TT levels, sex drive and energy",
I4T-IE-JVCE,CP12-1135:R-PhII-Ramucirumab_Gem vs Gem-Breast,
I4K-MC-GPED,Sarm I/Tadalafil for Erectile Dysfunction in Incomplete Resp,
H6D-US-LVJG,Tadalafil once-daily confidence study,
"14522",Placeholder - Diabetic Nephropathy Phase 2b Study,
I4V-MC-JAGH,Cyclosporin DDI,
I1V-MC-EIAX,Effect of Food on the Pharmacokinetics of Evacetrapib (LY248,
I5J-MC-NOAC,Phase 2a signal detection trial for MDD,
"14813",Relative bioavailability of Commercial Pediatric formulation,
I6O-FW-BHBB,Phase IB PK/PD Trial in T2DM Patients,
H9H-JE-JBAN,Japan_Ph1 monotherapy for solid tumors ,
F3Z-US-X036,FLuctuATion reduction with inSUlin and Glp-1 Added togetheR,
"14876",Summative Human Factors (Usability Validation) Study for Hum,
H6O-SB-B003,icroRNA changes in diet thru lifestyle changes,
I6E-AV-_A01,"18F-AV-45-A01 ",
I6E-AV-_A03,"18F-AV-45-A03 ",
I4H-MC-JWAB,Ph1b study of LY2780301 with gemcitabine in adv/met. cancer,
"12588",MCHR1 Phase 2b,
"15071",Thrombogenesis Method's Study - EET,
H9P-MC-LNCB,Taste evaluation of NERI-IV solution,
I1R-MC-GLDG,GRA + DPP4 +/-MET vs. DPP4 +/-MET+PBO,
H3E-MC-JMAM,PH II TRIAL OF LY231514 IV Q 21 DAYS IN PTS W/CERVICAL CA,
I4A-FW-GQBA,SADS (Single Ascending Dose Study),
H7T-US-X004,Platelet Function and Bleeding: Theinopyridine & Cor CABG,
"13198",Hypnion PET study,
H8O-MC-A026,Evaluation of Four Pathways (part II),
"13226","1-yr Trial - GLP-PEG 40 Monotherapy vs. Metformin +1 Oral",
I4M-JE-MRAD,JP MR Antagonist Phase 1,
I1V-MC-EIBC,Blood Pressure,
H3E-US-X081,Phase II Alimta/Carboplatin/Avastin advanced NSCLC Pts>70yrs,
"13255",Enzastuarin + Vorinostate Gliboblastma Xenografts,
"13260",GPR119 Phase II,
H8Y-MC-HBCU,Formulation:absolute BA,
I7D-FW-SGAC,Hypoglycemia Recovery Study,
H7T-EW-TADW,Clinical Pharmacology in Healthy Mexican Subjects,
I3G-MC-V006,Role of p70 S-6 Kinase in Regulation of Hepatic Lipid Synthe,
H4Z-MC-GJBG,Chewable/Swallowable (TBC) BE Study,
I2T-MC-LADE,LDI in Healthy Subjects,
B3D-XM-O009,Biphasic effects of parathyroid hormone on human oteoblast,
H7T-EW-TABZ,Prasugrel: Ethnic comparison study of PD/PD in healthy vols,
"11232",Drug Interaction Study: Second generation thiazolidinediones,
"11240",Ph 2 Alimta/cb -> ENZ  or Placebo in ext SCLC,
H6L-MC-LFBK,#11263 - Dimabon/memantine ,
I1Q-MC-JDDA,Cancer Cachexia Methods Study in Prostate Ca Patients,
"11337","RA Ph3 LY + MTX vs placebo + MTX; MTX Failures; S&Sx, Struct",
H6D-MC-V005,Expression and activity of phosodiesterase type 5 in vas def,
B1Y-EW-E026,FLUOXETINE VS AMITRIPTYLINE SLEEP STUDY,
H9C-MC-BBDH,OA Proof-of-Concept Study,
H3E-US-I019,PhII Alimta/Carbo/RT & Bevacizumab for NSCLC,
F1D-MC-HGMR,Maint of Effect of Olz in Peds with PDD,
I2H-MC-JWYA,FHD Ph 1 Combination with a Platinum-Containing Doublet,
F1D-MC-X304,Topiramate vs placebo to prevent wt gain in olanzapine pts.,
F1J-MC-HMFP,Duloxetine -Warfarin Pharmacodynamic Study,
I1R-JE-GLBS,Japan Ph2,
H4S-MC-A002,EFFECTS OF CTE3 IN AN ATHEROSCLEROTIC NONHUMAN PRIMATE MODEL,
I2R-JE-BIDK,Single Dose Biopharm Study,
H8A-MC-B001,GERAS II- Observational Alzheimer Disease study,
B3D-JE-B016,JP Forteo Observational Study (JFOS),
I6E-AV-VMAT,PH 1 FLORBETAPIR: VMAT in at-risk populations,
I1D-MC-A001,Radiosensitizers of Prostate Cancer/endothelial cells & radi,
H4S-MC-X004,REOPRO IN PERCUTANEOUS CORONARY INTERVENTIONS-A REGISTRY,
H6O-XM-B002,MORBIDITY/MORTALITY/GENOTYPIC CHARACTERISATION IN SEGOVIA ,
B3D-MC-B019,"2012-105_Forteo adherance in Japan",
I5S-MC-EFJC,PCSK9 Screening Protocol for MD Study,
H9D-MC-ITAJ,SNP Insulin (Ultra rapid Insulin by vasodilation),
I4O-MC-BACQ,Definitive Food Effects,
I4V-MC-JAGU,Liquid Formulation,
I2I-MC-V007,Chk 1 Inhibitor + cytarabine in AML cells,
H9H-MC-V007,Preclinical Study of TGFb in hepatocarcinoma models,
F1D-JE-O339,Preventing CI induced nausea and vomiting,
H8C-MC-LQBP,OA Pain DB Pbo cntrlld + 9 mon open label extension,
A3Q-ME-AFBQ,Mexico Keflex Bioequivalence Study of Keflex Liquid,
"12771",Aura 4 (11718),
I1V-MC-EIBN,Warfarin Drug Interaction #2,
H7T-MC-B022,"2014-228 RWE- Comparative Effectiveness: Effient vs Plavix",
H9D-MC-ITAO,URI via vasodilation w/ treprostinil,
I4V-MC-JAGY,CANDLE Registration Trial,
"15487",Urocortin (LY3116168) DKD Study,
H9H-MC-JBEC,CYP3A (Placeholder formely known as Particle Size),
F3Z-FP-IOGD,HUMALOG VERSUS HUMULIN R IN PONCTUAL HYPERGLYCEMIAS,
H9H-MC-A029,Enhancing NK-Cell Based Immunotherapy by LY in Neuroblastoma,
F3Z-FW-ITCD,URI-Citrate Ph1b T1DM Pump PK/PD Variability,
"15667",TQT,
"15681",URI-Excipient OTHER-Ph1b T1DM PK/PD,
H8L-MC-IQAY, ( CT-3) PK/ PD Study.,
I3P-MC-GKBC,Phase 2 - Dose Titration,
I5J-MC-NOAA,"SD and MD, safety, tolerability and PK study of LY2940094",
B3D-MC-X028,Natural progress of fracture healing delineated by RSA in pa,
H7T-US-X011,AA Genetic,
H8O-MC-GWDU,Safety and Efficacy of EOW in T2D pts fasting during Ramadan,
"5239",PPAR alpha phase I safety,
I6C-MC-FRCB,MAD,
I4O-MC-BACG,Bridging capsule Tablet RBA Study,
H4G-JE-101K,"LY303870, PHASE I SINGLE ORAL DOSE",
H3E-MC-S136,GHO - Cost-effectiveness of Alimta in 1st Line NSCLC,
I5Y-MC-DDBC,Sleep Methods study assessing wake promoting effects,
I5Y-MC-DDBA,SAD,
I5Y-MC-DDBB,MAD,
H4G-MC-LIAP,COMPARISON OF LY303780 & PLACEBO IN LONG TERM PROPHYLAXIS OF,
B4Z-SZ-O033,Effect of Atomoxetine on executive functioning and functiona,
I6B-MC-HZBA,First Human Dose-Single Ascending Dose study,
I5A-IE-X009,"8129:  Ph I/II - A12+Temsirolimus - Breast",
"14441",Phase 2a:  POC in diabetic patients with kidney disease,
"14516",PLACEHOLDER_Ph III-JAK-2_ 2nd Line,
I6E-AV-_A05,Safety/Imaging characteristics 18F-AV-45-healthy MCI&AD    ,
I6E-AV-NIMA,Ph 1 multi modal neuroimaging in AD,
B5K-US-IBHC,Two Treatment Approaches of Human Regular U-500 Insulin,
H9H-JE-JBAP,Japan_Ph1b combo for HCC,
I5L-MC-TCAL,Liprotamase Compassionate Use,
H6Q-MC-A050,Evaluate In Vivo Affects of Enzastaurin,
I6R-MC-DLAA,SAD SARM III,
H5M-SB-EIIC,Safety and efficacy of xipamide,
H8L-MC-IQBO,HF EU PEDs - Formative,
I6L-AV-PFIZ,PET Imaging of pancreatic beta-cell mass in obese/prediabeti,
"1510",Italian Epilepsy Proof of Concept Trial,
"1514",Neuroprotection in Patients with Alzheimer's Disease,
H8L-MC-IQBX,ePFS Ixekizumab and Tabalumab formative HF1,
I6A-EW-CBBB,RBA/Food effect,
"15760","2014-236 [OUS-1a] RWE comp effectiveness between pras clopi ",
I4E-IE-W809,Protocol CA225-064; A I STUDY OF CETUXIMAB IN COMBINATION WI,
I4E-IE-W812,"Protocol CA225-082; II STUDY OF CAPECITABINE, OXALIPLATIN AN",
I4E-IE-W818,Protocol CP02-9811; Compassionate Use of Anti-Epidermal Grow,
I4E-IE-W913,"Protocol CA180-123; I/II STUDY OF , CETUXIMAB, CISPLATIN AND",
I4E-IE-W929,Protocol CA225-240; II /ERBITUX IN HEPATOCELLULAR (CRG),
I4E-IE-W931,"Protocol CA225-262; A MULTI-CENTER, OPEN LABEL, NON-RANDOMIZ",
B1Y-IT-0013,FLUOXETINE: TREATMENT OF DEPRESSED PATIENT WITH M.S.,
F1J-JE-DL04,PMSS Long term CLBP,
I7E-AV-E009,AV-1451-E009,
I6E-AV-I030,AV-45-IIT-030: FAIR-AD,
I6M-MC-SSAD,MAD Study for Sjogren's Syndrome LY3090106 vs PBO,
B3L-LC-LWAH,LY354740 concentrations in CSF,
F3Z-MC-ITCG,URI Citrate Phase III T1DM ,
I4X-MC-B003,Ph IV-Necitumumab-Risk Minimization Assessment/EU-NSCLC,
I4E-MC-B002,"2016-3797:Patterns of care w/ elderly head & neck cancer pts",
"16629",Hepatic Study,
"16655",sJIA,
"15069",Ph II mPGES-1 Inhib 1 in OA in Japanese,
I6F-MC-A001,In vitro/in vivo testing of LY3039478 in human T-ALL,
I2M-MC-GSDM,RBA,
I3Y-MC-JPBE,CDK4/6 CYP3A4 Inh Drug-Drug Interaction study in cancer pts,
I7A-MC-EACA,SAD MAD,
H9H-MC-A015,Effects of TGFbeta inhs in MDS & AML stem & progenitor cells,
I4T-CR-JVCQ,Ph Ib-1121B+5-FU/FA+Oxaliplatin (FOLFOX4)-Adv HCC,
H9H-MC-A016,Inhibition of TGF-beta signaling in mesenchymal colon cancer,
B4Z-US-A015,The Effects of Methylphenidate and Atomoxetine on Glutamate ,
I6A-MC-A004,Developing the PI3K/Akt inhibitor LY3023414 in human bladder,
I6O-MC-BHBC,Phase III QD Trial vs Glargine in T2DM Patients,
H9H-MC-A020,Decrease the Treg population in primary bone marrow cultures,
I2M-MC-GSDR,China Registration - Active Comparator BMD Trial,
I5Q-MC-CGAE,Phase 1 randomized study of LY2951742 in healthy subjects,
I3Y-MC-JPBO,PhII-CDK4/6 Dual Inhib-Brain Met- >2nd line Lung/mBC,
B9E-MC-I026,Phase 1/2 Study of Gemcitabine and Strontium-89,
I2K-MC-ZZBI,Metabolism/Transporter #2,
I2K-MC-ZZBK,Renal,
I3J-MC-LACG,BACE C14 Study,
H7T-MC-TADI,PK/PD of 5mg Pras in low body weight,
H9X-EW-GBDL,GLP-Fc Phase 1 China SDSS,
B5K-US-V013,Measuring Insulin/Proinsulin Autoantibodies with a Europium ,
H6U-MC-S006,Evaluate & compare PO & IV self-admin of alcohol  method,
H7T-MC-TADN,TAXUS Liberte Stent Study,
"12970",CD-4week induction and 12 month maintenance & Opel label Saf,
F1D-MC-I042,Exenatide for Tx of Weight Gain Assoc. w/Olanz (IND Exempt),
H8Y-MC-HBCN,Schizophrenia,
H9T-MC-NABN,CYP2D6 DDI Study OpRa II,
H7T-MC-B008,German Obs Study (ALKK PCI Registry in Germany) ,
H8O-CP-O013,Effect of Exenatide on glucose metabolism in brain and ,
"13314",Phase II Combo Trial,
H6N-JE-LEAT,J-Ph1 (SDSS/MDSS),
I5S-JE-EFJV,Japan Ph3 Study 2,
I8M-JE-BIXF,Japan MAD Study in T2DM,
I4V-MC-JAIJ,Ph3 Induction Moderate to Severe CD Conventional IR Pts,
"16784",Investigator Initiated Trial,
"16813",R-PhII-Alimta+Carbo+/-Truncated Demcizumab-Sq NSCLC-1st Line,
I8D-MC-AZFE,Ante-Amyloid Prevention of AD Trial ,
I7E-AV-E076,AV-1451-EXIST-076,
"16902",SAD/LDI,
H8H-MC-LAHY,EET Taste HV,
I5B-JE-JGDU,Ph1a/b-Olara in Combo-Advanced Cancer,
I9V-MC-IFBC,"Ph2a-Double-blind,Placebo-controlled,Randomized study",
I7S-MC-HBEJ,PRESENCE 2: First Ph3 global registration study in LBD,
J1G-MC-LAKA,SAD (Healthy vols)/MAD (patients),
H5O-LC-G1AA,Beta 3 / Single dose safety in normal volunteers,
J1B-MC-FRCE,Experimental derm model for CD200R,
I8R-MC-IGBM,User experience study,
I7T-MC-RMAB,DDI Study w/ 3A4 Inducer,
I3Y-MC-JPBT,TQT study,
H9H-MC-V012,Combination of LY and mDX400 in syngeneic tumor models,
I7V-MC-JNEA,FHD-Ph I/Ib - VEGFR2/Ang 2 Bispecific - Solid Tumors,
"15614",Thrombogenesis Method's Study - EET,
F1D-MC-HGGC,OLTrial of Olanzapine in Children w/ Bipolar Disorder,
I7Z-EW-FLAH,Human C14,
"15662",DDI - Antidepressant,
I1F-MC-B002,"2014-100 Electronic health records pilot study: QOL/Res Use ",
F1D-MC-V003,Olanzapine/valproate interaction in human liver microsomes,
"15782",JP Phase 1 SAD/MAD ,
F3Z-MC-B019,U200 Risk Minimization Assessment Study,
F1D-MC-A008,Olanzapine and mood stabilizers as molecular targets,
I4J-MC-E001,Ph I/II - Hedgehog/SMO Antagonist + Paclitaxel - Ovarian,
H9D-FW-ITAQ,Early Exploratory Trial: Treprostinil effects in T2DM ,
I4E-IE-W822,Protocol CA225-041; ANTI-EPIDERMAL GROWTH FACTOR (EGFR) ANTI,
H3S-JE-T01J,ANTIGENICITY STUDY OF LY139481 IN GUINEA PIG,
"13378",Role of 5-HT2A/mGluR2 in mechanism of action of OLZ,
H7T-EW-TADY,ExVivo 60mg Prasugrel Platelet transfusion(Healthy Volunt),
"13428",LY Vs Placebo Trial in Psoriasis,
"13471",Peritrochanteric Study 2,
H4Z-MC-GJBI,Digoxin-Arzoxifene DDI study,
H3S-LC-GGHS,RALOXIFENE HCL: 60MG BIOEQUIVALENCE STUDY,
"13537",Strattera Use in ADHD pt in Combination with Stimulant,
H7T-MC-TAEF,Oral Sensory Evaluation for LY640315,
H7T-MC-V029,PAM & CAM activity w plt thiol isomerases,
H9P-JE-LNDW,Japan Ph 2 ADHD pediatric trial,
I1F-JE-RHAM,JP IL17 Ph 1 extension study,
H7T-DS-TAEI,Smoking Study,
"13674",Chemical: Global Ph 3 or Asian IMCT + Local PK iGluR5,
H8K-MC-JZAX,Hepatic Impaired ,
I1F-MC-RHBC,PS PH3-2LY vs Enbrel vs Plc 12wk primary Superiority,
"13694",Hospital Hyperglycemia Study.,
"1591",Pediatric Open Label Safety,
I4E-IE-W879,Protocol CA225-060; II TRIAL OF INDUCTION CETUXIMAB (IM-C225,
I4E-IE-W897,Protocol MED-PO2-06118; A II Study of Mitoxantrone vs. Mitox,
I4E-IE-W909,"Protocol CA225-259; A Multi-center, Open Label, Non-randomiz",
I8B-FW-ITRE,URI-Citrate+Remodulin Crossover Ph1 HV Clamp,
I8D-MC-AZED,Definitive Food Effect,
"1600",Adult Bipolar Proof of Concept,
I8D-MC-AZEH,Food Effect and BE,
I4L-GH-ABES,China Ph3 T1DM BIV vs. Lantus,
I1R-JE-GLDN,Japan Ph2/3 ,
I4L-MC-B004,"2014-883-2 Reasons behind insulin tx persistence(Pt Survey)",
I8F-MC-GPGA,SAD/MAD,
I6E-AV-I032,AV-45-IIT-032: MAPT,
I6E-AV-I037,AV-45-IIT-037: MAPTEPAV,
I6E-AV-I045,AV-45-IIT-045: Main Aging Study,
"16187",Hepatic Fat with Imaging ,
"16286",DDI Donepazole,
F3Z-MC-B029,Tango EP Study,
"17198",Bioequivalent,
I8S-MC-JUAD,C14,
"17209",Tirzepatide Risk Minimization (REMS) assessment - 7 years,
"17276",Japan SAD/MAD,
I8B-MC-ITST,Recovery from Hyperglycemia Compared PK Pts,
B1Y-IT-0011,FLUOXETINE VS PLACEBO IN BULIMIA,
J1X-MC-GZHE,RBA Proximal-Distal Food/Water Effects (Intestinal) HV,
B3D-MC-GHDQ,Femoral Neck Fx Healing ,
I8B-MC-ITTB,Pump Dose Optimization study,
J3D-MC-FNAD,C14 and absolute bioavailability study,
J3Q-MC-KJAA,FHD | SAD | HV,
"18325",HumatroPen Post Market Clinical Followup,
I2V-MC-A001,CXCR4 blockade with anti-CXCR4 peptide LY2510924 in AML,
ZYY-MC-B004,"2013-339 Further Examination of TTO and SG Methods for Direc",
H8L-MC-IQCD,BIL 60 KwikPen Summative Human Factors ,
A3Q-ME-AFBO,Mexico Keflex Bioequivalence Study of  Keflex Tablets ,
I2Z-MC-E001,FAST-MAS1 - ExIST 2 week daily dosing of LY2456302,
I2R-MC-BIDU,BIL and Glargine Clamp-Meal Tolerance Type I DM,
I6A-MC-A005,Eff/in vivo and in vitro models of Esophageal Adenocarcinom,
J2J-MC-JZLE,C14 HV,
B5Q-ME-NCCM,Efficacy of Nizatidine in combination with Clarythromycin an,
H9H-MC-A028,Effect of TGF-b blockade In recurrent NF2 vestibular Schwann,
I2H-MC-A002,GSK3 regulation of melanocyte antigen expression,
I8L-MC-IXAM,Blinded mealtime dosing study in type 1 patients,
H9H-MC-A032,Testing LY with radiation in preclin mouse models of cancer,
I2M-MC-GSDU,Injection Volume ,
I4T-MC-B002,"2014-419: Ramucirumab Treatment Patterns in US-Lung",
"15802","2014-858 SHIRLOC Examination relationship btwn quality of pr",
H9X-MC-B013,PMS EU PASS Study 1 Retrospective Study,
"1634",LY333013-LC-xxxE Drug Interaction Studies,
B5K-MC-B013,U500 Dedicated Syringe Risk Miniization Study,
"16361",Glucagon Analog Agonist Micro Dose Study for LY3143753,
I1V-MC-EIBW,Relative Bioavailability of Reformulated Eva Tablets,
I8S-MC-JUAB,FHD_Ph I - ERK Inhibitor - Solid Tumors,
"16435",Dose-ranging study,
I7E-AV-E048,"18F-AV-1451-EXIST-048",
I3O-GH-JSBI,CN_Ph II - Merestinib - NSCLC (Harboring NTRK Fusion),
I6T-MC-B001,Patient Preference in Psoriasis,
I6T-MC-AMAG,Phase II Crohn's study in patients,
I8D-MC-AZFC,Human Abuse Potential,
I6T-MC-AMAQ,PK after Subcutaneous Inj 2 x 1ml PFS vs 1 x 2ml PFS ,
I6T-MC-AMAR,BE Study to Evaluate PK of LY PFS (2x1ml) to AI (Tella),
F3Z-MC-IOHL,Insulin lispro LM:  Effects on between meal snacking-type II,
J2X-MC-PYAF,Pediatric PK Study,
H3S-MC-GGHD,"COMP OF RALOX, HRT & PLAC IN EARLY POSTMENOPAUSAL WOMEN",
H8L-MC-IQAS,Aura C2 Study,
I5B-IE-JGDB,CP15-0804:R-Ph2-3G3+Pacl+Carbo vs Pacl+Carbo-NSCLC-1st LN,
I5B-IE-JGDF,CP15-0907: Ph1 - 3G3 - Adv Solid Tumors,
B1Y-MC-B003,Meta analysis of epi data for potential congenital risks,
H6Q-MC-A045,Pre Clincial - Effect of PKCb inhibition in Ewing Tumors,
I5E-MC-TSAE,Testosterone- Sex Dys/Energy ,
I5E-MC-TSAA,Testosterone Ph2 Special population pK,
"14004",T1DM Dawn Phenomenon,
"14017",B'pharm DDI with Ritonovir,
"14028",QW in elderly patients,
"14033",Pem follow by Pem maintenance in Asians with advanced NSCLC,
I4T-MC-JVBT,CP12-0918: Ph II - Ramucirumab(1121B) +/- FolFox 6 - Gastric,
I5T-MC-AACB,Single and Multiple Ascending Dose Study in AD Patients,
I4L-MC-ABEI,PK/PD Pilot Relative Bioavailability Study,
I2Z-MC-LAFG,Hepatic impairment,
I4E-IE-W823,Protocol CA225-046; A II Trial of Single-agent Cetuximab Dos,
I4E-IE-W842,Protocol CA225-247; A II SAFETY AND EFFICACY TRIAL OF LETHAL,
I4E-IE-W876,CA225-056: Ph II-Cetuximab+Biweekly Capcitabin+Oxali - Colon,
"1593",Adult ADHD Proof of Concept,
I4E-IE-W910,Protocol CA180-048; DUAL INHIBITION OF EGFR AND C-SRC BY CET,
I4E-IE-W928,Protocol CA225-228; II FIRST-LINE RT/ERBITUX THEN RT/ERBITUX,
"1599",Pediatric ADHD Proof of Concept,
I4T-CR-JVDI,CN:R-PhIII-Ramucirumab+Gefitinib vs Gefitinib+placebo-NSCLC,
H2Q-MC-LZYB,Cognition in mild to mod. Alzheimer's -US/Canada (C1),
F3Z-MC-IORT,R6 Registration Study,
I8B-JE-ITRK,URI-Citrate+Remodulin combo Japan Ph1 Trial,
I7E-AV-_A11,"18F-AV-1451-A11 Tau Imaging in Professional Fighters",
F3Z-GH-IOQO,China Humalog Ped Ph3 Study for LRT,
I6E-AV-I039,AV-45-IIT-039: NIDECO,
I6E-AV-I042,"18F-AV-45-IIT-042 (DIAfN)",
I8K-JE-JPDB,Japan Phase 1 Study,
I1F-MC-RHBY,Ph3 AS & nr-axSpA Long Term Extension ,
H8H-MC-B005,Safety & Utilization for migraine patient tx with Lasmi,
H9H-MC-JBEH,Ph1b -Galunisertib+IMCgp100-Metastatic Melanoma,
"16204",EET: Pain on SC injections,
I7E-AV-E019,"18F-AV-1451-EXIST-019",
H3E-MC-B026,Ph IV-Safety Outcomes - NSCLC - 1st line plantinum chemo,
I7E-AV-_A16,"18F-AV-1451-A16: Phase 3 Autopsy Study",
I4E-US-X003,CA225-088 CALGB80403 E1206 study/ECF-C IC-C Folfox esoph ca,
I4E-US-X007,CA225-331 09-038-A Chemo+Cetuximab then Surgery in Thymoma,
F3Z-MC-ITCI,URI Citrate Phase III T1DM PUMP,
B9E-MC-I066,Phase 2 study of gem and carboplatin in NSCLC,
I8F-MC-B001,"2015-196-1:Concept elicitation interviews w T2 Diabetes Pts",
"16410",Ph III - Ram+Nivo v. Nivo - NSCLC - 2nd Line,
I8R-MC-B002,Observational Study to Eval home and school in severe or Mod,
F1J-MC-B057,Pregnancy Registry Obs/Retro DB Study (Harvard),
I8I-MC-JY02,Myostatin Antibody - CONTINUED ACCESS - Solid Tumors,
I8W-MC-PDBB,LY2775240 MAD Study in T2DM,
F3Z-MC-IOQS,TANGO Feasibility Study 1,
"16713",error,
I8B-MC-ITSC,Ph1b Exploratory Study in T1DM Patients on CSII Therapy,
I4V-MC-JAIB,DDI OAT3,
F1D-MC-A011,Efficacy of Olanzapine in an Animal Model of Mania,
B3C-MC-JQAF,PH2 Trial of Ly309887+F.A. in Pts with Breast CA,
B3D-MC-B028,"2016-3340:Outcomes in Severe OP Patients in China and Mexico",
B1L-MC-FAAE,MELBEX FOR PSORIASIS LONG TERM SAFETY STUDY CONT,
"17008",FHD-Ph I-EZH2-Solid Tumors,
I9Z-MC-OFBC,C14,
B1Y-IT-0009,FLUOXETINE EVALUATION IN MULTICENTER STUDY (CGI),
F3Z-MC-IORA,Meal-centric bolus development study,
"17132",POC (Phase 2A),
I1F-MC-RHCW,Mosquito Device-Safety and Tolerability Study,
I8F-MC-GPHC,Tirzepatide and Warfarin DDI Study in Healthy Subjects,
"17211",IMCT H2H Sema,
"17591", LY3528037 exposure and food effect,
I8Z-MC-APCA,Glucagon Analog Agonist Micro Dose Study for LY3185643 ,
B9E-GH-O513,Predictive biomarker analysis in advanced triple negative br,
I4L-MC-B006,"2016-0238:Eff Strat for Accepting Ins Tx for reluctant T2DM ",
I4V-MC-JAHK,Ph III - Baricitinib - Acute/Chronic GVHD Prevention,
I4T-CR-JVDO,CN_Ph III - Ramucirumab - Gastric - 1st line,
"16631",PPI Study,
H4Z-LC-SDAD,LY353381 HCL PIILOT FOOD EFFECT STUDY  IN HEALTHY WOMEN,
I8B-MC-ITSR,Pivotal Pump Trial,
I4V-MC-JAIW,"1, 2 mg trial",
I8F-JE-GPGP,Tirzepatide Japan Combination Safety (Add on to Orals) ,
J1I-MC-GZBA,SAD,
I4T-MC-I012,Ph2 - Ram+Carbo+Pac - NSCLC,
F3Z-MC-B028,Tango Feasibility Study 3 (b&C),
F3Z-MC-IORH,TANGO Peds Early Feasibility,
F3Z-MC-IORK,TANGO Infusion Set POC ,
I6T-MC-AMBS,Miri Reformulation PK (RBA),
J1U-MC-JEEE,Ph II - Multi-Compound Lung Protocol - NSCLC,
I8F-MC-GPHW,Obese Pediatric PK 12-17 yo,
I8F-MC-GPHY,MoA 18FDG PET and Hyperinsulinemic Clamp Study in T2DM Pts,
J2G-OX-JZJG,LOXO-292 CQT  Trial,
S2B-LC-LSSB,LY368975:  Oral Dose-Ranging Study II,
H0P-MC-OA02,Intervention Specific Appendix - OA,
B9E-MC-JHCA,GEMCITABINE COMPASSIONATE USE IN PT WITH NSCLC - OUS,
J2S-MC-GZMA,FHD Japan SAD HV,
J2G-OX-Y055,RET Inhibitor-MTC,
J2G-OX-Y061,RET Inhibitor-NSCLC,
F3Z-VE-IOGC,Effects on glycemic control and lipid profile in children,
J2G-OX-Y077,RET Inhibitor-MTC,
J2G-OX-Y111,RET Inhibitor,
H3E-MC-JMBR,Phase 2 Trial of MTA in Patients with NSCLC who are Platinum,
B3T-MC-JTAC,Ph 1 Study of LY335979/Paclitaxel in Refractory Solid Tumors,
J2G-OX-Y133,RET Inhibitor-NSCLC,
J2T-DM-KGAT,Lebri for pts w/ severe corticosterois dependent asthma,
"18100",Hepatic Pts,
I8F-MC-GPHG,MoA: Hyporecovery Clamp Study in T2DM Pts,
I8R-MC-IGBN,Paediatric,
I3Y-MC-JPCT,Ph1b - Abema+Cetux+Pembro - H&N,
I3Y-MC-JPCX,Ph IV - Abema - Breast Cancer Poor Prognostic Factors,
I3Y-MC-B007,"2017-6494 GHO - Abema - Pts Experience with Diarrhea in MBC",
F3Z-BP-O002,Preprandial Lispro vs Once Daily NPH in Type 2,
I9N-MC-FCAE,Safety and Tolerability / PH Bridging Study,
J2G-OX-Y052,RET Inhibitor-Anaplastic Thyroid,
B3T-MC-JTAF,Ph 1 Dose Ranging Study of LY335979/Docetaxel,
J2T-DM-KGAZ,Evaluation in Japanese vs Caucasian HV (GB25741),
J3I-MC-OFAA,FHD SAD HV,
"18107",RBA/Food Effect HV,
"2281",Alternate delivery Phase III: BMD #1,
I4E-MC-S001,CP02-0554: R-PhII-Cetuximab+Bevacizumab+Paclitax+Carbo-NSCLC,
H7T-CA-B012,Canadian Observational ACS-PCI Trial (COAPT),
I2I-MC-JMMH,Human C14 Study (in cancer patients),
H7T-MC-TAEC,MD (high-dose ASA vs. low-dose ASA and PPI vs. no PPI) ,
B7A-MC-V025,Rho GTPases in Diabetic Nephropathy,
F3Z-US-X032,Development of Insulin dosing for pts on MDI,
F1J-JE-DL01,DLX MDD Special investigation,
H6Q-AY-A031,PKC beta inhibition- autoimmune B lymphocytes elimination,
H6Q-MC-A037,Pre Clinical - Central Nervous System Lymphoma,
H6Q-MC-A044,Pre Clinical - Head and Neck Squamous Cell Carcinoma Xeno,
H6L-MC-LFBM,SMG - Hormone Study,
F1J-CA-O047,A Survey and Needs Assessment in Sexual Pain and Related Iss,
H8O-FR-O025,IIT - GLP-1 role cardiac change gastric bypass,
I4X-IE-JFCD,CP11-0602:Ph2- 11F8 - CRC - 1st line,
I5A-IE-JAEH,CP13-0501: Ph1 - A12-Adv Solid Tumors - 2nd Line,
H3E-EW-S133,Home delivery of Alimta as maintenance treatment,
"9335",RAIM IN AGITATED PATIENTS,
I9Y-OX-JDHL,LOXO-IDH-22011-Ph1-IDH1-BCRP ,
H7I-AV-S031,CertuitAD Clinical Utility,
B3N-MC-EUDD,Moxonidine vs Active Comparator -BP primary measurement (#2),
H3Z-MC-JNAQ,Phase II Eval. of LY295501 in Treatment of Breast Cancer,
F1D-EW-LOAR,Olanzapine SAIM in patients with non-organic psychosis,
"1911",Noda-animal study-olanzapine effects on phencyclidine,
F1D-US-X089,Open Trial of Olanzapine in Adolescents with Schizophrenia,
B3N-EW-EUCN,Moxonidine: Laxative interaction study,
B9E-MC-JHQF,"Bladder-Gemcitabine + Taxol, Phase II- - JH26",
B9E-MC-S015,Gem+Cis vs. Taxol+Carbo vs. Gem+Taxol,
B7A-MC-MBBL,Age Related Macular Degeneration (Phase 1b),
"2143",Phase 2 Breast Cancer Biomarker Trial,
H4Y-MC-LJAZ,Comparison study LY334370 vs zolmatriptan,
H4Y-MC-LJBE,Coronary angiography in Normal Coronary Arteries,
H5H-MC-DDAI,LY355636 vs Metronidazole in CDAD,
"2294",LY333334 effect on immobilized patients (larger study),
F1D-MC-A013,Long Term APD traetment on Basal Ganglia Function in Rats,
F1D-MC-A025,Olanzapine and learned helplessness,
B4G-EW-LCCJ,Parkinson / Monotherapy / Patch (Patch #5),
B4G-EW-LCCO,RLS / Pergolide vs Clonazepam,
H3S-US-X038,Improve Adherence to Cancer Control Guidelines in Minority W,
H9S-MC-JDCG,FRD: R - Ph II - LA294 + Bortezomib - Multiple Myeloma,
I4T-IE-JVBX,CP12-1028: Ph1b - Ramucirumab - Breast,
B3D-UT-O029,Osteoporosis Guideline Study of Vertebral Fractures,
I5L-MC-TCAF,"TC-1B Open Label, dose, Safety, Tolerability & Activity",
I3G-FW-JGCE,p70 S6 Kinase SAD + RBA study in healthy subjects,
I5X-MC-PFAB,"Multiple Ascending Dose Safety, Tolerability & PK Study",
F1J-JE-HMGZ,JP Cymbalta P-III FM,
H9P-EW-LNEC,Biopharm Fluvoxemine PK DDI study,
H9P-EW-LNED,Biopharm UGT involvment in the CL of LY Study,
H4H-MC-LGAC,ASSESSMENT OF EFFICACY & SAFETY OF LY300164 IN ALS,
I4O-MC-BACJ,High dose SAD/MAD Trial,
I4F-MC-CCAE,"3A4 DDI",
F1J-JE-B043,Japan Epi study prevalence of PPS ,
I1V-MC-EIBH,Primary Hypercholesterolemia,
B1Y-AY-0004,OPEN LABEL SAFETY & EFFICACY OF FLUOXETINE IN OCD,
J2G-OX-Y011,PhI-RET Inhibitor+Osimertinib-NSCLC,
B3N-EW-EUCC,Moxonidine: Radiolabel Metabolism Study in Healthy Subjects,
"17693",Eval Adhesive Properties on Skin of Healthy Human Subjects,
F1D-MC-X065,OLANZAPINE IN ADOLESCENTS WITH PSYCHOTIC ILLNESS,
H7K-GH-O003, Phase II study of  therapy with Fruquintinib in the patient,
J2G-OX-JZJP,DDI Itraconazole/Rifampin ,
J2G-OX-Y080,RET Inhibitor-NSCLC,
F1D-MC-X042,EFF OF OLN FOR TREATMENTS OF COMORBID MOOD DISTURBANCE,
J2G-OX-Y180,RET Inhibitor,
"18138",Controlled Release CR Pilot,
B9E-MC-JHEZ,JHEZ,
F1D-EW-HGGP,OLAN. VS. PLAC. FOR TREATMENT-ASSOC PATIENTS WITH PD,
J2X-MC-PYAJ,Prospective cohort study of bamlanivimab,
I3Y-MC-B011,"2020-10005:  Treatment pattern for MBC in Japan",
I9Y-OX-JDHE,LOXO-IDH-21004-Ph1-IDH1-Pilot FE + PPI,
J2N-OX-B005,"2021-10186: Loxo 305 MCL Adm Claims Study",
"18392",China PK study,
J3N-OX-JZRB,LOXO-BCL-22002-Ph1-BCL2-CYP3A4Inhib/Inducer,
I8P-MC-OXAF,OXM Phase2 study for chronic weight management,
B3L-MC-LWAN,LY354740 vs. Placebo and Lorazepam in the Treatment of GAD,
I8F-MC-B009,Study for women exposed to TZP during pregnancy/lactation ,
J1I-MC-GPS1,Chronic Weight Management -1 (without T2DM) PCOS DSA,
"18681",Loxo-FG3-23004-Ph1-FGFR3-Hepatic Impairment,
F1D-MC-X070,OLANZAPINE IN TREATMENT OF PTS. WITH PSYCHOTIC DEPRESSION,
B3N-EW-EUCM,Moxonidine: Metaclopramide Interaction Study in Healthy Vols,
B9E-MC-I103,GEMCITABINE AND VINORELBINE FOR NSCLC,
B9E-MC-S023,Ph ll Gem+Dox(Day 1) q3wks in Breast,
B9E-MC-S031,Gem/5FU vs Gem/Nav in atra ref breast- S031,
H5P-LC-BWWO,drug interaction (H2 blocker),
H3E-MC-JMCF,"Phase II, MTA + Gemcitabine in 2nd line Breast cancer",
H3S-MC-GGIZ,Raloxifene in postmenopausal women with Type II diabetes,
H8Y-MC-HBDJ,Food Effect,
I6P-MC-FMRA,SAD,
H8O-MC-A036,IMMUNOMODULATORY ROLE OF EXENDIN4 in Autoimmune animal model,
"14579",Absolute Bioavailability Study,
I1V-MC-EIAW,Effect of pravastatin on the PK of evacetrapib,
I4P-JE-GPFE,JP GPR40 Phase 1,
I1V-MC-EIBA,CM&C Development (Particle size Bioequivalence) ,
I1V-MC-EIBF,Pitavastin Drug Interaction Study,
H3S-US-X039,Combination Therapy in Postmenopausal Women,
B3C-MC-JQAD,A Phase 2 Trial of LY039887,
I2R-MC-BIDJ,Basal Switch Trial,
H4S-MC-X002,SANDBAG (A NURSING SUB STUDY OF THE EPILOG STENT TRIAL),
I6J-FW-PRBA,Single Ascending Dose Study for GPR40 Agonist II ,
H4W-LC-LLAB,MELATONIN:  EFFECT ON BODY TEMPERATURE AND PHARMACOKINETICS,
I4V-CR-JAGS,China IMCT MTX-IR RA,
H9H-MC-A009,Eff. of TI3RI/BMPRI inhs./glioblastoma & glioma-initiating ,
B4G-EW-LCCP,RLS/ Pergolide vs L-Dopa,
J3A-RM-C103,PHASE 1 STUDY OF SAFIGNOL ALONE AND 1 HR BEFORE ADRIAMYCIN,
H8L-MC-IQBJ,Axiron Gen III Formative Human Factors #2 ,
H8L-MC-IQBP,HF EU PEDs - Summative,
I2M-MC-GSDL,"2 Year Open label Alendronate",
J4A-MC-EZZG,Rheumatoid Arthritis (RA) Pilot Efficacy,
F3Z-SF-IOFA,IIS IM insulin lispro in treatment of diabetic ketoacidosis,
I5S-MC-EFJL,PCSK9 in Recent ACS MACE Outcomes Trial,
"15118",Japan Local NSOS for Adult ADHD,
H6O-FW-O009,EET - DPPIVi/PDE4i ,
H8L-MC-IQBQ,U500 Formative Human Factors #1,
B4Z-US-X062,ATX for treatment of exec. dysfunction in mild Parkinson's,
I7C-MC-FEAA,SAD,
I4C-MC-V002,transendothelial migration of anti-tumor neutrophils,
F3Z-MC-B015,CHRYSTAL - Costs and QOL study for type I children in Spain,
H8A-EW-LZBB,diagnostic shift from dementia to prodromal stages-scale val,
B4Z-US-LYEQ,"2013-168 Dosing Patterns Assoc Outcomes ADHD for Strattera ",
I8A-MC-URAA,Urocortin (LY31161680) SAD,
I4T-MC-JVCZ,Ph II - Ramucirumab - Gastric - 2nd Line,
I4T-MC-JVDA,Pediatric_Ph I - Ramucirumab - Solid Tumors,
I4X-MC-JFCU,Ph Ib/expansion cohort Neci+Abema stage IV nsqNSCLC 2nd line,
F3Z-FW-ITCA,URI-Citrate Phase 1 healthy subject PK/PD,
I7Z-EW-FLAG,RBA,
I6A-MC-A006,Targeting APC and PIK3CA Mutant Colorectal Cancer ,
I3G-MC-JGCG,"12 wk txt assessing safety & efficacy in dyslipidemia pts",
"15791",Japan Combo,
I6A-MC-CBBG,R-Ph II/III-PI3k/mTor - mesothelioma - 2nd line,
I1D-MC-V002,Molecular tar. for the treatment of cutaneous T cell lymphom,
I4E-IE-W850,Protocol CA225-230; RANDOMIZED II TRIAL OF RADIATION THERAPY,
I4E-IE-W872,Protocol CA225-055; A Study conducted by a sponsor other tha,
I4E-IE-W877,Protocol CA225-057; A II TRIAL OF MODIFIED FOLFOX 6 AND C225,
A3Q-IT-AFBJ,BIOEQUIVALENCE STUDY OF TWO FORMULATIONS OF CEPHALEXIN 250,
B9E-MC-S076,Gem+Dox vs Gem+Taxotere/Breast,
B9E-MC-S081,Gem+Taxtotere / Breast,
B9E-MC-I135,PHASE I STUDY OF GEMCITABINE+PALLIATIVE RADIATION THERAPY,
H4Y-LC-LJBN,"Single dose PK - African, Asian, Hispanic descent",
"2607",Single dose PK - adolescents,
"2647",In vitro (Animal) Host Defense Study - Cefaclor,
H4Z-LC-JWXE,relative bioavailability study of 2 formulations of LY353381,
F1J-MC-SBAX,Global - Single Dose Vs. Placebo,
H5U-EW-HSAC,Evaluation as a 5HT2a receptor antagonist in vivo using SPET,
"2697",Gemcitabine single agent in refractory breast cancer (JH42),
B3N-EW-EUCJ,Effect of food on the pk profile of the final SR formulation,
B3M-PH-AJBB,CEFACLOR AF TX OF 2NDARY BACTERIAL INF. OF ACUTE BRONCHITIS,
H4A-MC-XBAT,Oral vs. Fluconazole in Vaginal Candidiasis,
B1Y-MC-HCEU,FLUOXETINE/PHENELZ. IMIPRAM. RESIST.PTS WITH MDD,
"2871",VOID,
B1Y-MC-HCFB,FLUOXETINE PKE IN DIALYSIS/NONDIALYSIS DEPRESSED PATIENTS,
"2901","GHS: Dose ranging in elderly, Phase 2/3",
A3Q-VE-AFBH,"PROSPECTIVE, SINGLE-BLIND COMPARISON CEFALEXIN VS CEFADROXIL",
B4G-EW-LCCL,Parkinson / Adjunct / Patch (Patch #6),
B4G-UT-LCDA,Parkinson / Neurodegeneration / SPECT (S5),
B4G-EW-LCCV,Parkinson / Adjunct / Pergolide vs Pramipexole,
F1D-US-X109,Olz Treatment of Children with Severe Emotional Disturbance,
B1Y-AY-AS01,FLUOXETINE VS AMITRIPTYLINE IN MAJOR DEPRESSIVE ILLNESS,
B9E-MC-S103,Gem+Taxol vs Cis+Taxol  / Ovarian,
F1D-US-I025,Zyprexa in Treatment of Video Pathological Gamblers,
B5K-MC-IBEX,Safety of PI in type 2 on insulin therapy,
B1Y-MC-HCDD,FLUOXETINE VS PLACEBO: FIXED LOW DOSE-DEPRESSION,
A6J-FH-V011,EPIDEMIOLOGIC STUDY OF THE INCIDENCE OF NOSOCOMIAL INFECTION,
B4Z-MC-LYAA,Adult registration study,
B9R-EW-GDFV,Pulmonary hGH; FHD,
F1D-US-X115,Olz. for Treatment of Psychosis in PD pts. with Dementia,
"2774",Otitis Media Ceclor 40 mg/kg/d vs Clarithromycin,
C2N-MC-JXAH,(J109) LY355703 for Adv NSCLC - 2nd line - Ph 2,
B1Y-MC-HCFF,FLUOXETINE PLACEBO IN GERIATIC PATIENTS WITH MDD,
H3E-MC-JMCJ,Breast PK/PD study,
H3E-MC-JMBD,MTA in Carcinoid Ph II,
I8D-MC-AZEG,Dose Proportionality,
I4D-JE-JTJK,JP_FHD_PhI - Chk-1 Inhib II - Solid Tumors,
B9E-MC-X084,"Phase I Study of Gemcitabine, Taxotere, and G-CSF",
I7X-MC-LLCD,RBA\Food Effect,
B3D-GH-A010,"teriparatide, zoledronic or combination in rat spine fusion ",
I5Q-MC-CGAO,Formulations bridging lyophilized w/prefilled syringe ,
I7E-AV-E014,"18F-AV-1451-EXIST-014",
H9X-MC-B011,"2015-509 Disutility associated w/ diabetes delivery devices",
H8A-MC-LZBD,China PK study,
"16309",BIL MOA Metabolism Study BIL vs Glargine vs Healthies,
I3Y-MC-JPCJ,Ph II - Abemaciclib + TBD - Pancreas - 2nd Line,
H7I-MC-S012,EET – Yale SV2A Synaptic Density Study Pts,
"16484",Ph II - Abemaciclib+Enzalutamide - Prostate,
"16488",R-Ph II - MET/EGFR Bisp Antib - Colon,
H8L-MC-IQDD,Tella Device Safety and Tolerability Study (No LY),
I7E-AV-E040,AV-1451-EXIST-040,
I4V-MC-JAHS,NR axSpA,
I4V-MC-JAHM,Ph3 vs PBO Mod to Severe AtD Adults,
I8B-MC-ITRT,Injection site,
I4C-MC-JTBI,Ph III - Emibetuzumab - NSCLC,
"16735",Placeholder 2 for potential additional ClinPharm study,
B5K-US-X014,Severe Insulin Resistance Treatment Approaches with U500,
"16793",Crohn's Disease Open Label Extension Study,
I9P-MC-JKDA,Ph I - Tgfb RII (TR1) II - Solid Tumors,
I7E-AV-_A20,"18F-AV-1451-A20",
I6T-MC-AMBJ,Crohn's Disease Peds PK E-R (Phase II),
I9Q-MC-AOIA,SAD/MAD,
I9V-MC-IFBD,MAD-Titration Study,
J2G-OX-Y166,RET Inhibitor,
I8F-MC-GPGH,GIP/GLP-1 Vs Basal,
"17020",Alzheimers Patient Study,
I9O-MC-AABC,Pain and Tolerability of Large Volume Delivery,
I4L-MC-ABEW,Switching study,
B1Y-MC-HCFN,FLUOXETINE IN NON-DEPRESSED POST-STROKE PATIENTS,
B9E-MC-JHQJ,"Ph 3, Gem + Carbo v Carbo/Adv Ovarian Ca",
F1D-MC-HGHX,SAIM-treating agitation in dementia patients,
"3072",SR Moxonindine versus Active Comparators,
B9E-MC-X224,Phase 2 Study of Gemcitabine and Cisplatin (MPBC),
F1D-EW-LOAZ,DEPOT PHASE 1A FOR PAMOATE SUSPENSION,
"3165",Exploratory analgesia #1,
"3210",Proof of Efficacy,
B9E-JE-N14D,Phase 1,
"3294",BUS PLANNING FOR POTENTIAL ALLIANCE FOR ONCOLOGY,
B1Y-MC-X014,FLUOXETINE VS PLACEBO IN THE TREATMENT OF KLEPTOMANIA,
B1Y-MC-X016,FLUOX ADDED TO NEUROLETIC IN TRTMT RESISTAN SCHIZOPHRENIA,
B1Y-MC-X183,Fluox Treatment of OCD in Children and Adolescents,
B1Y-MC-X022,FLUOXETINE VS. PLACEBO IN PREMENSTRUAL SYNDROME,
B9E-MC-V013,To use Gemcitabine and Eval. it's cytotox. effect on cancer,
"17231",PK Bridging Study,
H0P-MC-BP02,Intervention Specific Appendix - CLBP,
B1Y-IT-9001,FLUOXETINE VS AMITRIPTYLINE IN ELDERLY DEPRESSED PATIENTS,
F3Z-US-X001,HUMALOG AND HUMULIN U BID IN IDDM CHILDREN AND ADOLESCENTS,
B5K-MC-B016,GHO_2019-8638_Effectiveness&Safety of U-500 among Patients ,
I8F-MC-GPIC,MoA 18FDG PET Validation Study in T2DM Pts,
H4W-LC-LLAO,Safety and Pharmacokinetics of the Tablet in Healty Elderly,
I7W-MC-UDAA,Angiopoietin2 Antibody,
J2G-OX-Y070,RET Inhibitor-NSCLC,
J2G-OX-Y072,RET Inhibitor-NSCLC,
J2G-OX-Y076,RET Inhibitor-NSCLC,
J2G-OX-Y154,RET Inhibitor,
J2G-OX-Y165,RET Inhibitor,
J2G-OX-Y183,RET Inhibitor,
J2G-OX-Y189,RET Inhibitor,
J2T-DM-KGBF,Multiple IV Dose-Escalation in Pts w/ Asthma (ILR4395G),
B9E-MC-JHFI,GEMCITABINE PLUS PACLITAXEL IN UROTHELIAL CANCER,
B9R-MC-GDFI,Humatrope use in hip fractures: European Support Study,
B9E-MC-X212,Phase 2 Trail of Gemcitabine and Paclitaxel,
B9E-MC-X218,Phase 1/2 Study of Gemcitabine and Topotecan,
B1Y-MC-O002,TRIAL COMPARING FLUOXETINE TO ELECTRO-ACUPUNCTURE,
B9E-MC-S119,Phase 2 Gem + Taxol - 1st breast; JUL98SU81,
F1J-MC-SBBD,Incorporate SAAW Data into Markov Model,
B9E-MC-X227,"Gemcitabine, Cisplatin, and Ifosfamide in Bladder Cancer",
F1D-MC-X122,OLZvs RIS; cerebral flow and emotional processing,
"3346","Phase II, MTA + Taxotere, 2 cohorts",
F1D-SE-9832,Switching from previous antipsychotics to Olanzapine,
B1Y-MC-X163,Effects of Fluox Treatment for Panic Disorder,
H5Z-MC-LUAD,R-fluoxetine (>40mg)  vs Placebo for Major Depression,
F1D-US-A033,"Effect of Clozapine, Olanzapine, and other atypical (3H-Cloz",
"3493",CYP1A2/smokers (induction),
"3500",bioequivalence (60 mg vs 120 mg),
H3S-US-GGJM,Therapy Management Program,
B9E-SB-O082,GEMCITABINE SECOND LINE IN ADVANCED GASTRIC CANCER,
B9E-VI-O043,"Phase III, Gem & Cis vs. Etoposide & Cis & RT, NSCLC",
J2T-DM-KGAR,Lebri for pts w/mild to moderate asthma,
J2G-OX-Y198,RET Inhibitor,
"18206",PF ONC-Oncology DDI Victim trial,
F1D-MC-X047,Olanz vs Neuroleptics on Service Utilities and Health,
J2N-OX-JZNS,LOXO-BTK-20017-Ph1-Pirtobrutinib-SAD,
J2G-OX-B007,"2020-9610-Loxo292:effective of selp in real world clinc prac",
B1Y-IT-M001,FLUOXETINE/CLOMIPRAMINE DBL MAJOR DEPRESSIVE DISORDER,
B3N-FW-EUCL,Moxonidine SR in Renal Insufficiency,
B9E-MC-X086,PHASE 2 STUDY OF GEMCITABINE & PACLITAXEL IN SCLC),
B1Y-LC-HCDC,FLUOXETINE:  MORPHINE INTERACTION,
B4Z-MC-HFBF,Long Term Open Label,
B1T-MC-EAAB,APRINDINE TREATMENT,
"2218",OLANZAPINE VS RISPERIDONE(POST-PSYCHOTIC DEPRESSION),
B1Y-MC-HCAE,FLUOXETINE VS AMITRIPTYLINE,
H3E-MC-JMDL,"Phase II, MTA/Gem(alternate schedule) in pancreatic cancer",
B9E-MC-X028,PHASE 2 TRIAL OF GEMITABINE IN PATIENTS WITH BREAST CANCER,
B1Y-MC-A006,Electrophysiology of Fluoxetine in Aging Rats,
B4G-EW-LCCD,Parkinson / Patch (Clinical Pharmacology Study),
B9E-MC-I102,Phase I study of Gemcitabine and Hydroxurea,
B9E-CA-JHQR,Gemcitabine and Carboplatin in Patients with bladder cancer,
F1D-MC-I027,Olz vs. Ris in Treatment Refractory Schizophrenia (Buckley),
B9E-VI-O063,"Phase II, Gemcitabine, Study in Transitional Cell Carcinoma",
H6D-MC-LVBD,"2 yr. open label study of""On demand"" therapy w/ IC351(1.5yr)",
F1D-MC-HGIG,Olanzapine Concentration in Blood Components Over Time,
F1D-US-I029,Clozapine and Olanzapine in Violent Schizophrenics,
B9E-MC-X250,"Gemcitabine with either Herceptin, Taxol, or Navelbine",
B3L-MC-LWBB,LY354740 Exposure Study,
B9E-MC-X253,Gemcitabine and Radiation for Brain Tumors & Brain Mets,
"4027",inv of effects of antipsychs on 5-HT2c rec in pts w/schiz,
H6D-LC-LVBY,Long and short acting nitrate study,
A5K-MW-ABBC,Safety and Efficacy of Cycloserine in Intensive Phase of Che,
ZYL-LC-Z034,methods development for beta-adrenergic agents,
F1D-CA-O054,Olanzapine and OCD,
B9E-MC-V044,Use gem-dFdCTP as standard for analysis of nucleotide pool,
B1Y-NZ-0001,FLUOXETINE: PREMENSTRUAL SYNDROME ANTIDEPRESSANT TRAIL,
"4278","Schizophrenia care and assessment program, Australia",
F1D-US-X165,dbl bld place contr of olz trx of outpts with patho gambling,
F1D-MC-I030,Effects of Olz on Physiological & Behav Measures of stimulat,
B9E-BP-O040,"Ph I, Gemcitabine & Taxol, In Advanced Metastatic NSCLC",
F1D-US-X040,Is Partical Response to SZ Patients to Neuroleptics Mediated,
B7A-JE-101M,PKC1 P-I sngl oral dose fasted,
B9E-MC-X241,Gemcitabine and Herceptin / Breast Cancer,
B1Y-MC-X062,FLUOXETINE IN ALCOHOLICS WITH DEPRESSION AND PANIC,
B9E-VI-O070,"Phase II, Gemcitabine Mono, In Pancreatic Cancer",
"3751",Interaction study with Digoxin,
F1D-MC-HGIH,A dose-ranging study of Olz vs placebo in Migraine preventio,
F3Z-US-I014,IIT Retrospective studies,
B3L-MC-LWBJ,LY354740 vs. chlordiazpoxide vs. placebo in GAD,
"3898",LY354740 in PTSD,
"3909",Performance Anxiety,
B9E-MC-X258,Gemcitabine/XRT/Surgery in Ib/IIa Cervical Carcinoma,
H4S-MW-O001,REOPRO IN PAT WITH HIGH RISK CORONARY ANGIOPLASTY,
B9E-MC-X105,"Gemcitabine, Cisplatin, & Surgery IN Stage IIIA NSCLC",
H3S-MC-GGJY,Continuing Outcomes Relevant to Evista (CORE),
F1D-CA-O001,pilot on effects of olanz on 1H MRSpect. & functional MRI,
H4Z-MC-JWWY,(JW15)  Ph 3 Trial of LY353381.HCl in Ovarian Canc,
J2A-MC-GZGG,Atorvastatin and Bicarbonate in Healthy Volunteers,
H8H-MC-B007,Lasmiditan Exposure and Driving in Europe,
I5Q-JE-B008,Validation study of serious hypersensitivity definition,
J2N-OX-JZNT,LOXO-BTK-20021-Ph1-Pirtobrutinib-Digoxin DDI,
I8H-MC-BDCZ,BIF Ph3 T2DM 6 month Insulin Naïve on GLPs,
J2N-OX-JZNV,LOXO-BTK-21050-Pirtobrutinib-RBA,
B9E-MC-X021,PHASE II STUDY OF GEMCITABINE IN PTS WITH HEAD AND NECK CANC,
"18620",DDI - Study 1 (perpetrator) - CYP3A,
"1887",Histomorphometry-Raisz,
B9E-MC-S021,Gem+Cis+Taxol in Bladder cancer- S021,
B1Y-LC-HCCV,FLUOXETINE INTERACTION WITH DIAZEPAM,
B9E-MC-S029,Gem+Epi vs Gem or Gem/Nav in Breast-S029,
B9E-MC-S013,Ph II Gem + Nav in NSCLC,
B3N-MC-EUCY,MOX Effects Sympathetic Nervous System/Central Hemodynamics,
B3N-MC-EUCZ,Open Label Long Term Safety in Hypertension,
F1D-SN-HGGQ,Pharmacokinetic Study in Caucasian & Asian Subjects,
H4Q-MC-V012,LY333328 in vitro activity against vancomycin resistant MRSA,
B3C-MC-JQAG,clinical assay development,
B1Y-PH-0001,FLUOXETINE: TREATMENT FOR MAJOR DEPRESSIVE DISORDERS,
"4359",INVESTIGATOR INITIATED STUDIES FOR OFC STUDIES,
B5K-MC-IBFM,Efficacy & safety of PI in new onset type 2 patients,
B9E-MC-V065,Modulation of Gemcitabine Sensitivity in Pancreatic Cancer,
B9E-MC-X276,Phase 2 Gemcitabine and Taxotere/Hepatocellular Carcinoma,
"4489",Zyprexa vs zeldox effect on QTc and prolactins,
"4490",FOSAMAX TO EVISTA SWITCH STUDY,
B9E-XB-S153,Phase II in NSCLC with induction Chemo followed by Gem-RT,
B4G-JE-PX14,JP Perg P-IV dysuria w/Parkinson,
B3M-MC-AIEU,CEFACLOR VS AMOXICILLIN  IN ACUTE SINUSITIS,
B1Y-SB-HCIQ,DRUG SURVEILLANCE STUDY FLUOXETINE,
B3L-MC-LWBI,LY354740 in geriatric patients with GAD,
"4563",LY354740 in pediatric patients with GAD,
B9E-SB-O163,Preoperative Chemotherapy (Gemcitabine) in NSCLC,
B9E-MC-S166,"Gemcitabine, cisplatin and paclitaxel in advanced ovarian ca",
B9E-MC-S207,Ph II Carbo+Tax->Gem+Oxal Ovary 1st line,
B9E-MC-V077,Is gem incorp into DNA predictive of extent of radiosensitiz,
B9E-MC-X279,Phase 1 Study of Dose Rate Gemcitabine in Elderly NSCLC,
B9E-MC-S079,Gem+Epi / Breast,
B9E-MC-I063,"Phase II, Gem & Paclitaxel, In Prev Treated  NSCLC",
B4G-EW-LCDC,Parkinson Patch / Bioequivalence (place holder) CPharm,
B9R-MC-GDFB,Humatrope bioequivalency in burned adult patients,
"2670",Phase 1 combination with LY309887,
F1J-MC-SBAY,US Open Label - Long Term Safety/Exposure,
B9R-MC-GDFM,Humatrope in Pediatric Pts with ISS (Global Study),
"2709",Smoking Cessation (OUS) - Study #3 (OUS),
"2891",Hepatic impairment,
F1K-MC-EVAN,Treatment of Meningococcemia with rhAPC,
F3Z-CA-O016,IIS Humalog-Basal Education & Late or EarlyExercise ,
"2958",Raloxifene Arthritis Effects,
B9E-MC-X202,Gemcibtaine and Monthly Docetaxel/1st Line/NSCLC,
H3E-MC-JMDJ,MTA + Taxol 2nd line Breast,
B9E-MC-X163,Gemcitabine and Interferon in Renal Cell Carcinoma,
F1D-EW-HGHU,Depot Phase 1 75:25,
F1D-MC-X121,Anti-cholinergic prop of olz:comp risp & cloz;polysomn study,
H5N-EW-GFFF,First Human dose administration of the LCS formulation,
S2C-LC-G2AC,Multiple Dose Safety and PK,
"2253",Nasal MD or Buccal Polyox/Alginate (bridging),
B3D-MC-GHAO,Pulmonary Phase Ib (GHAO),
B3M-MC-V039,M. catarrhalis and H. influenzae Global Surveillance Study,
F1J-LC-SBAA,Food and Diurnal Effects of Duloxetine,
B9E-MC-S089,Gem+Doxil / Breast,
B9E-MC-S109,Ph II Gem single agent - Hepatoma,
B9E-SB-JHMT,"Phase II, Gemcitabine In Patients w/ Hepatocellulr Cancer",
B9E-SB-O014,"Ph II, Gemcitabine In Breast Canc Relapse After High Dose CT",
B9E-MC-I041,GEMCITABINE IN NON-SMALL CELL LUNG CANCER,
B9E-MC-I136,"PHASE 1 STUDY OF GEMCITABINE, CISPLATIN, AND RADIOTHERAPY",
B9E-MC-I123,PHASE I STUDY OF INTRATUMORAL METABOLISM OF GEMCITABINE,
B9E-MC-X054,PHASE II TRIAL TO STUDY EFFICACY OF GEMCITABINE IN MYELODYSP,
H5P-LC-BWWS,Interaction with Methotrexate,
F1J-LC-SBAC,Warfarin Interaction,
"2716",Humatrope Depot Formulation in Japanese Ped.Pts with GHD,
B3M-MC-V044,H. flu and M. cat surveillance study,
H4Z-MC-JWWV,(JW18)  Breast Cancer Primary Prevention Trial,
B9E-FP-O165,ITT-Adjuvant Gemcitabine and radiation for pancreatic cancer,
"4852","Phase I, Patient Trial for MRP Modulator",
"4912",Void,
ZYY-LC-LKAG,A Beta Basal Levels in Plasma and CSF,
H5Z-LC-LUAS,Sepracor 41-004,
B9E-SB-O171,Tirapazamine+Cisplatin+Gemcitabine in NSCLC,
H6P-FW-HDAK,Olanzapine Fluoxetine Combination Bioequivalence Study,
"5083",Registration Pain,
"5094",LY333328 Septic Arthritis Animal Model Study,
B5K-MC-IBFQ,Use of PI in type 2 patients with COPD,
B1Y-UT-0689,"ERP IN AGING,DEMENTIA AND DEPRESSION. CORTISOL DYNAMISM",
H3S-US-GGKF,Effects of Raloxifene HCl vs Placebo on Free Testosterone,
B9E-MC-I149,Phase I Trial of Intrathecal Gemcitabine,
B4Z-MC-LYBB,second open label tomoxetine,
F1D-IT-LOBH,Assesment of cognitive functions in residual patients,
H3S-US-X012,Use of electron micrography to study BMD on bone biopsies,
"5246","Phase II dose finding, placebo-controlled, active comparator",
B9E-MC-X305,Ph IV Two schedules Gemcitabine in metastatic solid tumors,
B1Y-VI-HCHK,PROZAC EXPERIENCE PROGRAM IN ROMANIA,
B9E-AY-S143,P. II Gemcitabine (G) & Docetaxel vs G & Carboplatin in TCC,
H5P-MC-BWXM,Phase 1 Asthma Trial sPLA2 Lung,
H4Z-LC-JWXI,absolute bioavailability study,
B1Y-ME-0003,"FLUOXETINE: EFFICACY, SAFETY, TOLERANCE IN MAJOR DEPRESSION",
B9E-BL-O113,GEMCITABINE IN ADVANCED PANCREATIC CANCER: CORRELATION,
B9E-BP-O119,PHASE I/II GEMCITABINE AND RALTITREXED IN PANCREATIC CANCER,
B9E-MC-V048,Comb. chemo and gem w/paclitaxel in bladder  cancer,
B9E-MC-V055,Gemcitabine in treatment of hepatocellular carcinoma,
H6E-US-GLAI,Pioglitazone versus rosiglitazone in subjects with type 2 DM,
B9E-MC-S150,Gem+Cis vs Gem in treatment of advanced pancreas cancer,
"4484",Olanzpine p,
B9E-MC-S155,Ph I/II GAT in 1st line metastatic breast cancer,
B1Y-MC-HCKN,Cardinal Open Label Switching Study,
H3S-SB-O004,Primary prevention of mammary carcinoma,
"4591",PMDD,
B1Y-SO-0704,FLUOXETINE: THE INFLUENCE OF THE SEROTONERGIC SYSTEM/METABOL,
B9E-US-S194,Rand P III Combo Gem/Carbo f/b gem VS support care in NSCLC,
"2918","Proof of Efficacy, Study II",
B9E-MC-I109,"Gemcitabine, 5-FU, and Folinic Acid in Colorectal Cancer",
B9E-SB-O021,"Ph II,Palliative Treatment, Bladder Cancer, Patients  >70 Yr",
H3E-MC-JMDK,MTA + taxane vs MTA + the other taxane,
H3S-MC-GGJV,China Local registration Study,
F1D-EW-HGIL,Depot phase 1b,
"3155",Use of cereb.blood flow to pred diff eff of olz/risp emot pr,
"3209",Drug Interaction Study,
"3307",CNS Penetration Determination,
"3342","Phase II, MTA + Cis, 2nd line breast",
"3361",Human Imaging study,
B9E-MC-I055,"Gemcitabine, Cisplatin, and Radiotherapy (pancreatic ca)",
B3L-MC-LWAU,LY354740 in Schizophrenia,
B9E-MC-I091,"Gemcitabine, CIsplatin,a nd Ifosfamide in Bladder Cancer",
B9E-UT-JHQL,"Phase III,  Gem & Epirubicin vs Gem & Cisplatin, in NSCLC",
H3S-US-GGJP,Hormone Replacement Therapy Project Phase I: Instrument Deve,
F1D-MC-X146,Effects of Olanzapine on Brain Function: An fMRI Study,
H3S-AY-GGJW,Raloxifene combined with low dose transdermal oestrogen,
H3S-MC-A005,Estrogen Compared with raloxifene on fracture healing,
F3Z-AG-IONO,Mix25 BID in oral combination therapy of Type 2 pts with OHA,
F1D-JE-LOBK,JP ola P-I RAIM IM vs PO,
F1D-US-X199,Developmental Pharmacokinetics of Psychotropic Drugs,
"5403",PET Ligand Validation Study,
"5512",Phase 2 Alzheimer's,
F3Z-SB-IONQ,"24 hr glucose levels in pts on Mix25 BID vs glargine qd",
B9E-MC-X319,PhI Intrathecal Gemzar for Leptomeningeal neoplasms,
B9E-IH-O234,Gem+Cis as Induction Chemo. in Recurrent NPC,
B3M-IH-AAZD,CLINICAL EFFICACY/DISTACLOR EMPIRICAL TREATMENT INFECT/PHARY,
B9E-FP-O230,ITT-chimiotherapy(gem+vino) + radiotherapy in stage III,
F1D-US-X206,Long Term Outcomes of OLZ treatment of rehab in CMHC,
B9E-MC-V129,p53 gene sensitivity to gem in ov cell lines,
B9E-MC-V132,HPLC determinations of gem + metabolites,
B9E-IT-JHRY,Gemcitabine + Oxaliplatin in NSCLC,
B3N-EW-EUBM,FIRST DOSE TOLERABILITY AND PK OF MOXONIDINE,
B9E-US-S242,Ph I/II Gem+Carbo+Etoposide in extensive stage SCLC,
H3E-JE-NS01,JP ALIMTA P-II NSCLC,
B9E-US-S250,Gem/Carbo+Iressa vs Gem/Cis+Iressa Rand. Ph 2 GU Cancer,
F3Z-XM-S016,BETTER GLICAEMIC CONTROL USING MIX25,
F1J-MC-SBBI,Affiliate Initiated Health Outcomes Study,
"3251","3 open-label non-comparator studies in~530 Japanese patients",
H3S-JE-301J,JP ralo P-III Bridge osteoporosis,
"3293",BUSINESS PLAN FOR POTENTIAL ALLIANCE FOR CARDIOVASCULAR,
B4G-UT-O005,Pergolide D1/D2 Agonist Efficacy in Deep Brain Stimulation,
B1Y-MC-X185,TRIAL OF FLUOX TX FOR PTSD IN CHILDREN & ADOLESC,
H4A-MC-XBBC,Superficial Mucocutaneous Candidiasis-IV Pilot Safety Study,
H3S-US-GGJL,Provision of an economic model that can evaluate postmenopau,
F1D-MC-X138,Open-Label Olanzapine in Severe Bipolar Depression,
F1D-US-A034,Microdialysis Study:  Effect of Olanzapine on Acetylcholine,
B9R-US-X024,"Sex steroids, GH, IGF-I; metabolic regulation in puberty",
H6D-EW-LVAI,Pilot food effect study in Healthy Subjects,
B9E-VI-O068,"Phase III, Vinorelbine & CDDP vs Gem & CDDP, In NSCLC",
B9E-VI-O069,"Phase II, Gemcitabine & Cisplatin, In NSCLC",
B9E-MC-X247,Phase II Trial of Weekly Gemcitabine and Paclitaxel,
H6D-MC-LVBR,Phase 2 Questionnaire and end-point validation,
B9E-MC-V231,HPLC assay of gemcitabine and its metabolite dFdU,
B1Y-MC-X196,Fluoxetine Treatment of Vestibular Dysfunction and Anxiety,
"3815",Treatment of Sexual Dysfunction in Diabetic Women,
"3841",decison plan for LY314366,
B9E-MC-S215,Gem vs Gem+5FU in Pancreas Cancer,
B1Y-SP-0001,EFFICACY AND SAFETY OF FLUOXETINE IN PROPHYLAXIS OF MAJ. DEP,
F3Z-BP-IONC,Humalog and Mix25 Three Times Daily vs 30/70 BID in Type 2,
B1Y-MC-HCKY,Prozac vs. Reboxetine,
B9E-MC-X301,ph2 gem/docetaxel in recurr/persist leiomyosarcoma uterus/GI,
"4906",Depression exploratory trial,
B4Z-US-LYAV,Tomoxetine effect on sleep/cognition,
H5Z-MC-LUAZ,R-Fluoxetine -- Sleep in Major Depressive Disorder,
"5038",PET / PD study #1,
H7C-EW-LMBB,MGLUR prodrug MD study plus rel bioavailability,
"5065",Duloxetine Depression,
H3E-MC-JMER,MTA with folic acid supplementation in 1st line gastric canc,
H3E-MC-JMES,Ph 3 - Gemzar+ALIMTA vs Gemzar - Pancreas,
B1Y-UT-1089,IDE EFFECTS OF ANTIDEPRESSANTS IN PAT.WITHSOMATIC DISEASES,
F1D-XM-HGJK,Randomized naturalistic of olanzapine and risperidone,
B9E-SB-O051,"Phase II, Gem & Liposomal Doxorubicin vs Gemcitabine,",
H4S-SB-V003,Lab. Analyt. Monitor. of Antithromb. Effects of Abciximab,
H6D-EW-LVAM,Metaclopramide and Biscodyl Gastric motility study,
F3Z-BP-O023,TRAIN study-FIBRINGEN LEVEL IN TYPE 2 DIABETIC PAT W RECENT,
F1D-SB-O035,Effects of Classical and Atypical Neuroleptics on Anhedonia,
"3941",ReoPro in Acute Coronary Syndromes- A Meta Analysis,
F1D-CA-O038,Does Olanzapine reduce aggression and EPS - chart review,
F1D-CA-O040,Olanzapine Tx of Aggression in Tourettes Syndrome,
"4046",Mix 25 BID: Use in Dual Agent Failure,
H3E-MC-JMEB,ALIMTA + herceptin,
H3E-MC-JMEG,MTA in 2nd line CRC,
H6E-MC-GLAD,ACTOS vs. glimiperide,
B1Y-MC-X105,FLUOXETINE EFFECTS ON HOSTILE PERSONALITY,
H4S-SN-O002,ReoPro Asia-Pacific Observational Registry(RAPOR),
B9E-XB-O103,MOLECULAR BASIS: SENSIBILITY TO GEMZAR; HUMAN PANCREAS TUMOR,
B9E-MC-S145,Phase II Gem+Epi+Tax in first-line metastatic breast cancer,
B1Y-GH-HCKI,Fluoxetine in treatment of Cardiac patients,
H6E-MC-GLAK,Korean registration trial,
H6E-MC-GLAP,pio+SU vs metformin + SU (EC409),
F1D-JE-LOBJ,"JP ola P-I RAIM, vs Caucasian",
B2A-SB-ASSA,TOBRAMYCIN PK INVESTIGATION ON DAILY SINGLE DOSAGE,
B9E-MC-V108,Realtime metabolic activity of tumor cells,
H7E-MC-IABA,Pharmacology of Buccal Insulin,
F1D-MC-O107,A Study of Olz and Cognitive Behaviour Therapy for Psychosis,
B3L-EW-LMAA,LY354740 ORAL SAFETY KINETICS & DYNAMICS IN HEALTHY VOLUNTEE,
F1D-US-X201,Double-Blind Study of Sibutramine for Treatment of Weight Ga,
B3L-MC-LWAA,LY354740 VS. PLACEBO & LORAZEPAM IN GENERALIZED ANXIETY DIS,
F1D-US-X204,Effectiveness of behavioral intervention on weight gain,
F1D-JE-SW01,JP ola P-IV Switch,
B9E-MC-V130,gem effect on cachexia in Hu panc canc xenografts,
H6Q-MC-JCAJ,Phase II Glioblastoma/LY317615 NCI,
B7A-LC-MBDC,PKC Clin Pharm Trial--Relative Bioavailability,
"5861",Combination Therapy for Obesity  (POC),
H6D-MC-LVEE,Ethnic Diversity,
H6D-MC-LVEI,Mexico/Greece Regional Trial,
B9R-XM-O017,GROWTH HORMONE MODE OF ACTION IN ANTITUMORAL THERAPY,
H6F-LC-PAAD,LY466700 Dose Refinement,
B1Y-MC-X125,Effect of Fluoxetine on Female Infertility,
H6D-EW-LVCN,Volunteer visual study v sildenafil v IC351,
B9E-MC-X269,Phase 2 Gemcitabine in relapsed Hodgkins and NHL,
F1D-EW-LOBO,Olanzapine depot metabolism study,
B9E-BP-O142,Phase I/II Gem/Cisplatin in Pancreatic Cancer,
"4553",Open label Exposure in Pediatric Patients,
F1D-XB-O076,COGNITIVE VARIABLES IN NEGATIVE SCHIZOPHRENIC PATIENTS,
B1Y-SE-9333,PROZAC EFFICACY IN SLEEP DISORDER ASSOCIATED WITH DEPRESSION,
F1D-US-X179,nimh funded study of neuroleptic induced movement disorders,
B9E-TW-JHQY,Gem+Dox for HCC registration trial,
B9R-IT-O004,r-hGH in chronic respiratory failure,
B1Y-SO-0706,FLUOXETINE VS CHLORIMIPRAMINE TREATED PANIC DISORDER,
B9E-MC-S186,Ph III Gem+Cis vs AG-TP Bladder 1st line,
H3S-CA-O006,Vasomotor Symptoms and Endothelial Function,
B1Y-SP-E062,FLUOXETINE VS CLOMIPRAMINE MAJOR DEPRESSIVE DISORDERS,
"4833","Formulation:CT Lot#3, microspheres",
"4835","Multiple dose, dose ranging in Type 2",
"4395",LY354740 vs. placebo and Fluoxetine HCl in depression,
H5P-MC-BWXE,European Phase III RA Trial,
B4Z-LC-LYAL,Definitive Bioequivalence/Adult Fed/Fasted,
"3886",Japan Comparator Study,
B1Y-MC-X089,USE OF FLUOXETINE IN MGMT OF OBSTRUCTIVE SLEEP APNEA,
"3967",First human dose (opioid antagonist),
B1Y-MC-X094,FLUOXETINE IN ADULT STUTTERING,
B1Y-MC-X095,FINDING & TREATING DEPRESSION IN ALZHEIMER'S PATIENTS,
B1Y-MC-HCKE,Differentiation Trial,
F1D-SZ-O049,Olanzapine + Valproate in the treatment of mania,
B9E-MC-V030,Cell kinetics of Gemzar + Docetaxel,
F3Z-CA-V007,Lispro Transport Across the Perfused Human Placental Lobule,
A3Q-MC-AFBL,CEPHALEXIN VS DURACEF IN ACUTE PHARYNGOTONSILLITIS,
"4318",Gemcitabine in Hepatoma in Asia Pacific,
B9E-MC-X266,"Gemcitabine, Carboplatin, and Radiotherapy",
"4344",ITT-GEMZAR in transitional Cell Carcinoma of the Urothelium,
H6D-MC-LVCD,Chronic Dosing for Safety & Efficacy of IC351 (Testes),
B9E-MC-V061,Biochem pharmacology of gem in CEM cells,
"4428",Multidose study,
F1D-MC-HGKB,Open Label Extension for olanzapine pamoate depot,
"6076",Observational RAIM _ Olanzapine Spain,
H3E-MC-T001,"ALIMTA, Single-agent Treatment IND",
H3E-US-S018,Ph 2 ALIMTA + Cyclophosphamide after A/T,
H7T-EW-TAAD,Phase II Study in Atherosclerosis Patients,
"6261",Phase 3 Prevention,
H7G-FW-PDAG,Relative Bioavailability/Food Effect Study,
F1D-CA-O142,"2nd Gen. Neuroleptic Wt Gain: Early Intervention Strategies",
"6399",Set of SNRTs with local support,
F1D-MC-HGLN,IM Olz Depot:Safety/Efficacy in Bipolar Disorder (1st study),
"6417",Sepsis in Immunocompromised Patients (Transplant),
B5K-MC-IBDV,EVAL.OF PHARMACOK.& PHARMOCOD.INS.AEROSOL DEL. BY ORAL INH.,
B9E-MC-X343,Ph II trial of carboplatin + gemcitabine in recur breast ca,
F1D-UT-O152,Olanzapine Mania,
"6578",ALIMTA IITs in Germany,
B9E-GH-JHSE,comparing Gem+Cis 3-week regimen vs 4-week regimen in NSCLC,
"6702",Olanzapine's  Effectiveness and Health Outcomes in Mania,
B1Y-GH-S013,Prozac in depression with tired fatigue unmotivated symptoms,
H3E-MC-JMEI,"Ph. III 2nd Line NSCLC, ALIMTA vs Docetaxel",
B3L-BD-LWBD,Fear-Potentiated Startle - Europe:  LY354740 vs benzo vs pla,
"5044",Schiophrenia Phase II study,
"5069",Phase 2 Study - Safety and Efficacy in Type 2 Diabetes,
"5087","Phase Ib, Single I.V. , PROOF OF CONCEPT IN MIGRAINE",
"5092",LY333328 Pan European Study (In Vitro Surveillance),
F1D-US-X190,Olz in Patients with Schizophrenia and Comorbid Substance us,
F1D-US-S016,"""The ASAS-COG in Patients with Schizophrenia Treated w/Conv",
H6E-XM-GLAN,Efficacy of pioglitazone combined with glibenclamide,
"5201",MGlur2 - Prodrug FHD Japanese PKJ study,
H3S-BL-O009,Hemost factors/art compl postm use conjug eq estrog or ralox,
B9E-XM-JHRS,R - Ph III - Gem-vin vs. vin - MBC,
H3S-RI-O010,Eff of Ral on markers of bone turnover in women above 80 yrs,
B7A-JE-MBDD,JP PKC1 P-II DBS neuropathy,
B9R-JE-K02A,JP hGH P-III adult long term,
B9E-BP-O196,"Phase I, Gem/Cisplatin/RT, NSCLC stage IIB/III",
"5321",Bridging study - SAIM Japan,
F1D-US-A105,Long-Term Effects of Olanzapine on Rat-Brain...Komoroski,
B9E-MC-X277,"Gemcitabine, Taxotere, and Herceptin in Pancreatic Cancer",
F1D-US-X173,olz for the reduction of irritability in BPD,
B3M-LD-S017,local marketing trial comparing Cefaclor and Augmentin,
B3M-PU-S018,Cefaclor vs Clarithromycin in Acute Uncomplicated Bronchitis,
B9E-SB-O144,Gemcitabin in unknown Primary Tumor,
F1D-KL-O078,Serum prolactine & sexual dysfuction of olanzapine,
"4611",Cardiac Pilot Study,
H4S-UT-EWBA,Effect Glycoprotein IIb/IIIa Inhibition Platelet Activation,
B9E-XM-O155,Phase II gem-vin biweekly first line breast,
F1D-IT-LOBF,Olanzapine Vs Haloperidol in First Episode,
B1Y-MC-X209,COMBINED PHARMACO-THERAPY IN DEPRESSED ALCOHOLICS,
H3S-US-X007,Treatment of systemic lupus erythematosus with Evista,
"4845",LY293111+ Gemcitabine in patients with HRPC,
B9E-MC-X293,Phase I Gemcitabine and Capecitabine,
B1Y-SZ-TR35,FLUOXETINE: IN THE TREATMENT OF MAJOR DEPRESSION,
B9E-SB-V092,Instillation Therapy with Gemzar in mouse with urothel CA,
H5N-JE-I001,v8g1 P-I SDSS,
H6D-MC-LVCZ,Sperm Assessment 20mg,
B3C-MC-JQAC,PH.I CLIN/PHARM. EVAL. OF LY309887 ADMIN. WKLY IN METAS. CAN,
B1Y-MC-X214,Flx vs Placeo for TX of Fatigue in Primary Biliary Cirrhosis,
B4G-GH-L001,Combining treatment fo pergolide in parkinson's patients,
B9E-MC-V118,Targeting gem to tumor site by attaching to carrier,
F1K-MC-EVBF,Open Label Study of rhAPC in Patients with Severe Sepsis,
B5K-GH-O004,Humapen switch and QOL,
B9E-FP-O214,IIT-Radiotherapy and Gem+Cisp in patient with NSCLC,
F3Z-SB-IONP,Early Humalog or Mix50 therapy tid vs Lantus (glargine) qd,
B9E-MC-X324,PhII Gem/carboplatin in Adv/recurrent carcinoma of cervix,
"5630","Japan, On-Demand, Randomized, Double-Blind",
B9E-US-S245,Immediate vs Delayed Gemcitabine - 2nd line Therapy - NSCLC,
"5810",Gem PK-intra-art route-Pancreatic,
B4Z-MC-LYBI,Atomoxetine vs comparator,
B9E-MC-X339,PhII weekly Gem/Herceptin in Metastatic Breast Cancer,
F3Z-SB-S012,Efficacy of Humalog dependent on the pretherapy,
B3N-MC-EUAL,ACUTE HEMODYNAMIC EFFECTS OF SINGLE LY326869 DOSES IN CHF,
F3Z-XM-O044,Revision of clinical files-hypoglycemia,
"5997",Phase 2 trial determine Xigris dose in acute ischemic stroke,
"602",PH 1 DOSE ESCALATING STUDY OF IV LY335979 AND DOXORUBICIN,
"6164",Graft vs Host Disease,
H3E-US-S088,"RPh II, A/Carbo+C225+XRT vs A/Carbo+XRT loc adv NSCLC",
H3E-MC-S024,"Ph. II 1st Line NSCLC, Gem/Cis seq w/Alimta/cis",
B1Y-MC-HCLJ,Dose occupancy/ PET scans in Japanese patients,
F1D-MC-HGKY,IM Olz + IM Ativan transition to Oral Olz,
F1D-PL-O139,Subj and Obj Eval of olz treatment of pts with schizophrenia,
B1Y-XM-HCLL,Observational study . Weekly Prozac. Primary Health Care,
B3D-MC-GHBX,Post approval surveillance study,
B9E-FP-O284,IIT-In vitro Gem cytotoxicity inhibi Cytoplasmic 5''nucleoti,
"6380",J-SDSS 395,
B5K-MC-I006,ORAL INSULIN IN NEW ONSET IDDM PATIENTS,
"6395",MDSS 108,
F1D-SB-S026,Prospektive Unters z. Zusammenh. zw. neurol. Med. u. d.Rauch,
"6419",An observation of effect of drug therapy on,
H8K-MC-JZAA," Phase I, FHD Dose Esc. Study of LY573636, IV every 21d",
B9E-UT-A007,gemcitabine/cisplatin and radiation in exp. NSCLC in rats,
B9E-US-S287,Phase II Adjuvant Gem in Genomically Selected NSCLC Patients,
"4989",Muti-Dose Safety Study (PK/PD),
"5014",Phase 2 depression,
H3E-MC-JMEP,ALIMTA + oxaliplatin in 1st line CRC,
H6D-MC-LVDJ,Pivotal Study in Canada (20mg),
F1D-US-X191,Olz treatment in Huntington's Disease,
B1Y-BP-HC39,FLUOXETINE/PLACEBO MAINTENANANCE AND PROPHYLAXIS DEPRESSION,
B1Y-VI-0010,FLUOXETINE VS CLOMIPRAMINE IN MDD,
F1D-US-X193,Olz in treatment of agitation due to brain injury,
"5284",Japanese PK/PD Bridging Study,
B1Y-VI-CZ01,COMP.OF CHANGES IN ECG PARAM.IN PAT. TREAT.WITH FLUOX/DOSULE,
B4Z-MC-LYBE,DNA banking protocol,
F3Z-PU-S009,switching from Insulin  R to Humalog (observational trial),
F3Z-XM-IONK,Mix 25 vs NPH Twice Daily:  ppBG Control in Type 2,
X1A-BD-QA03,Schizophrenia PK/PD with LY450108 and LY451395,
B9E-MC-S234,Ph II - Gem+Dexamethasone+Cis - Relapsed/Refractory Lymphoma,
F1D-SB-O104,Is olanzapine as effective in the treatment of acute schizop,
B9E-SB-O215,Gemcitabin + Oxaliplatin in Pancreatic Cancer,
B9E-SB-V122,Gemcitabine in vitro in Plasmozytom,
F1D-GH-L001,Olanzapine in acute schizophrenia and other psychotic disord,
B9E-MC-JHSF,Pilot Ph I study to determine bioavailability of oral gemcit,
"6773",Prospective Long Term Follow-up/Episodic Nucleoside Study,
"6793",CSF study,
B9E-MC-V170,Gem pk analysis,
F3Z-MC-O054,Holman Postprandial Lipemia in Type 2 Diabetes,
"6956",phase II gem+carboplatin NSCLC,
H3S-XM-O025,Raloxifene at the osteoclastogenesis in postmenopausal women,
H6D-MC-LVFD,Period of Response,
"7013",Ph II - Gem + Affinitak - Non-Hodgkins Lymphoma,
B9E-SZ-O327,Phase II Oxaliplatin and Gemcitabine NSCLC 1st line,
B9E-MC-V184,In Vitro study of effects of anti-cancer drugs in cancer cel,
F1D-XB-O179,risk factors associated with diabetes in schizophrenia,
"7195",IIT placeholder for Atomoxetine,
B1Y-BP-HCHS,FLUOX VS PLACEBO/PHS THERAPY IN FACIAL ARTHROMYALGIA (PAIN),
B9E-MC-JHCL,GEMCITABINE - NAME PATIENT SUPPLY,
"7229",PKC UK Placeholder,
B9E-MC-V197, resistance intrinsic in cell lines of brest carcinoma,
"7348",Local depot study,
B9E-MC-JHEN,"GEMCITABINE IN MALIGNANT MESOTHELIOMA, PHASE II",
B1Y-BP-HC48,EFFECT OF FLUOX IN SEASONAL AFFECTIVE DISORDER & NORM SUBJEC,
B3N-TS-EUBH,"1HE EFFFICACY AND SAFETY OF ORAL MOXONIDINE THERAPY",
"6002",Ph2b Bridging dose-finding Japanese trial,
B9E-SB-O261,Gemcitabine + Carboplatin + Taxol in ovarian ca.,
F1D-US-X214,Effic and Tolerab of Open Lbl Olz in children/Adl with Toure,
"6041",Effect of SD SSRI on GH resp to zolmitriptan,
H5N-EW-GFFN,GLP-1 analogue - Gastric motility,
H3E-MC-JMFF,Ph 3 ALIMTA+Cis v Taxol+Carbo/Taxol+Cis or GEM+Cis) 1st Line,
H3E-US-S013,Phase 2 ALIMTA + Taxotere in Breast,
B4G-JE-YI09,PERMAX SPECIAL INVESTIGATION II:TITRATION,
F1D-MC-HGLC,High oral dose Olanzapine,
H7C-MC-LMBM, Acute Stress Disorder/PTSD Prevention  at NIMH,
"6267",Glargine vs Humalog +Glargine in Poorly Controlled Patients,
H6Q-LC-JCBB,Lilly Clinic C14 Study,
F1D-PL-O138,Obs-Comp Sympt during Olz & Typ Antipsy Trt-Compar Study,
"6325",Olanzapine in elderly - publication studies,
"6356",Diagnostics and Treatment Trial,
B5K-GH-O008,Effect of high FFA on GSIS and mRNA expression,
"6437","6 m BID Insulin (Study B)",
F1D-MC-O148,Olanzapine-induced augmentation SSRIs resistant depression,
B3D-EW-GHCA,EUROFORS: Cont PTH/fu treatment with/w/o Rlx in sev osteop,
F1D-BP-O165,Zyprexa IM HO Study (Pereira),
B5Q-SE-1205,NIZATIDINE: CLINICAL EVALUATION STUDY IN PEPTIC ULCERS,
H6D-VI-LVEQ,Local Regional Trial:  Vienna,
B9E-AY-JHLI,PHASE 2 GEMCITABINE IN STAGE III OR IV NSCLC PATIENTS,
F1D-XM-O172,Schizophrenia: genes analysis,
H7G-MC-PDAE,Non-China Open Label Extension Phase Study,
"6837",C-14 Study,
H6X-LC-GBBD,MDSS PK safety study,
H6D-EW-LVDN,PD Drug Interaction of 20mg IC351 with short acting nitrates,
"6924","chronic non-organic headache,its psychological status and tr",
H3E-US-JMFP,ALIMTA Access for Previously Treated Patients,
B9E-MC-I047,"STUDY OF GEMCITABINE, VINORELBINE AND MITOMYCIN-C IN NSCLC",
"7016",Smoking vs Non-smoking GHD Adults Treated with Pulmonary hGH,
H3E-MC-JMFR,"Phase II, 2nd line CRC, ALIMTA + Oxaliplatin",
"7105","Anxiety #2, 3 arm relapse prevention study with comparator",
"7191",DIMITRI: PKC in early diabetic rethinopathy/neuropathy,
B9E-MC-X330,PhI/II carboplatin/gemzar/exisulind in advanced NSCL cancer,
B9E-ME-O228,Phase II Neoadj Gem+CDDP in untreated penile Ca,
H6D-EW-LVDT,IC351 Pharmacokinetics in Patients with Renal Dialysis,
F1D-US-X207,Open trial of Olz for Bipolar Disorder w/ Alcohol abuse,
B9E-FP-O243,IIT-NSCLC B9E-FP-O243 GEMFIX Baclesse,
B9E-US-S247,Ph. II Full-Dose Gemzar/RT in Pancreatic Cancer,
B9E-US-S251,Gem+Carbo+Taxol Muscle Invasive TCC Node Negative,
B1Y-BP-HC46,PROZAC: QUALITY OF LIFE STUDY IN DEPRESSED PATIENTS,
B1Y-MC-HCLG,Switching Pts from Sertraline & Paroxetine to Once Weekly,
B1Y-MC-X219,Treatment of Childhood Social Phobia,
B9E-AY-O264,Gemcitabine and Carboplatin in Carcinoma of Unknown Primary,
F1D-TW-O129,An observational study in TW,
H7V-BD-GPAB,"MDSS, dose escalation in overweight, healthy subjects",
B9R-XM-O018,GLUCOCORTICOIDE MODE OF ACTION UPON HUMAN GROWTH  CARTILAGE,
B5K-BC-L005,Berlin Chemie oberservational trial to support humulin regul,
B3N-VI-EUAK,MOXONIDINE- OPEN CLINICAL STUDY FOR THE EVALUATION OF THE ..,
H7T-EW-TAAF,CS-747 - BE Formulation selection,
B4Z-MC-LYBL,ADHD Comorbid Seizure Disorder-Peds,
"7385",Phase I/II Dose Escalation ALIMTA/GEM in NSCLC patients,
F1J-BP-HMCO,Duloxetine MDD Primary Care UK local study,
B9E-MC-JHFQ,GEMCITABINE IN PATIENTS WITH NSCLC,
"7587",Visual acuity (borderline ME),
H9M-BD-LGEB,MDSS in Elderly Male and Female Subjects,
H3S-IS-S042,raloxifene efficacy,
B9E-XM-O400,Gem-capecitabine in Breast cancer non chemonaive patients,
"7711",IIT / Fellowship / Chair Placeholder for Dul SUI,
"7782",Manitoba Cancer Care for Gemzar,
"7787",Regional Cymbalta Open Label Trial,
"7867",Cancer Pts with severe sepsis assay,
F1D-AG-S048,SC RAIM Study,
F1D-CA-O213,ACCORD II:Long Term Assessment of Cog. Impairment & Dementia,
F1D-MC-HGLB,Olanzapine vs Aripiprazole in the Treatment of Schizo Dis,
F1D-XM-O214,Internet addiction,
"8093",Placebo controlled crossover study in a single patient,
H8O-EW-GWAH,Exendin-4: OHAs,
H6X-LC-GBBF,PPAR Co-Agonist II SDSS (2) in Healthy Volunteers,
B9E-MC-V141,To Deter Gem Transport Cap of Gem-Resist Cell Lines,
B9E-MC-X342,Phase II Trial of Carboplatin/Gem &Baxarotene in Tx of NSCL,
F1J-SB-SBBV,Duloxetine in Mixed UI - QoL & S/E study at urologist,
"6647",Consequences of dexamethasone therapy in premature infants,
F3Z-US-IOOH,Glargine at bedtime vs Humalog Mixtures,
H3E-AA-S037,A Single Arm Phase II Study of Pemetrexed for NSCLC.,
B9E-KL-S292,"Bile-duct cancer, Phase II",
B3M-GH-S032,Ceclor SR in Treatment of Acute Bronchitis,
B7A-MS-MBBD,SINGLE/MULTIPLE DOSE SAFETY PHARMACOKINETICS OF LY333531,
"6728",Pharmacological Dose PET Study,
F1D-CA-O173,Assessing Sexual Functioning in Atypical Pts,
"6756",PD Study in Healthy Males,
F1D-CA-O174,D-Serine Augmentation of Olz in 1st Episode Psychosis,
B9E-US-X356,Ph II Gem & Carb Metastatic Breast CA,
"6838",p450 Study,
B9E-XM-S315,"2nd line gem-cis in long infusion in non Hogdkin lymphoma.",
B9E-MC-I006,"PHASE 1/2 GEMCITABINE, TAXOL PLUS CARBOPLATIN IN NSCLC",
"6903","Ph III HTN in African Americans, ACE comparator",
H5M-SB-S001,Drug surveill. in pts. with hypertension,
"7258",Hamilton IIT in Canada,
F1J-CP-O014,"Duloxetine, Sleep Phase Advance and Bright Light Therapy",
B5K-GH-O435,Value of CPH autoantibodies for diagnosis LADA,
B9E-MC-JHEA,GEMCITABINE/CISPLATIN IN PTS WITH ADV. OVAR. CA. (1ST LINE T,
F3Z-ME-IOOL,Comparison of two Insulin Therapies: Insulin lispro Low MixV,
H8E-MC-KBAF,Follow-up extension study to 3M's 1442,
"7424",PKC I in Microvascular Diabetic Complications,
"7431",Plasma levels of Ospeoprotegerin,
"7499",Phase I/II Bladder Gem Cis RTH concomitant,
H8N-MC-A002,mGluR2 ANTAGONIST Radiotracer Development,
B9E-MC-X034,PH I GEMCITABINE & CISPLATIN IN ADVANCED HEAD & NECK CANCER,
"7707",Radiologic assessment of bone quality for pts on PTH,
"7728",OFC in TRD,
H3S-HU-GGKY,Evista Bone Efficacy,
"7877",IIt Schizophrenia-2003,
"7878",IIT - 2003 (3),
"7894",Placeholder for  IITs,
F1K-MC-EVCP, Ph2 Study in Japan,
F1J-MC-SBBO,Mixed Incontinence Contingency,
F1J-MC-HMCK,Duloxetine pediatric depression (acute study #2),
F1D-EW-LOBQ,Vistaril,
B1Y-PU-S012,Fluoxetine hydroclorate with enteric cover one a week  in Ma,
A6J-JE-CS04,JP vanc P-IV infusion elder pts,
"6367",Phase Ib MDSS in RA patients,
B9E-ME-O285,L.A. Cervical Cancer with Chemo/Radio with Gem+CDDP vs CDDP,
"6400",Alimta compassionate use (Spanish affiliate),
H3E-SB-V001,MTA + Gem in liver mets of Colorectal CA in rats,
H7X-MC-JVAE,Ph II - Gemzar+Carboplatin+Affinitac,
H3S-MC-V007,Raloxifene Regulation of FAS Ligand Expression in BrCa,
H8H-BD-LACA,"5-HT1F Single Dose Safety Study",
H4S-SB-O037,Shakespeare: Patients Undergoing PC - GP IIb/IIIa Receptor,
"6587",Management and Treatment of Anorexia,
B4Z-UT-S001,"ADHD, Dyslexia and atomoxetine (ADA)",
"6644",Lispro SC vs lispro via Antares device,
F3Z-SU-S017,Mix75/25 Twice daily vs NPH Twice Daily in Clinical practive,
H6U-MC-HGLL,Olanzapine Augmentation Safety in Pts,
F1K-SB-V007,Study on the effect of activated protein C on monocyte funct,
B1Y-MC-HCLR,The Affects of Fluoxetine on Growth in Children/Adolesents,
"8304",CS-747: Multiple Dose pH study,
B9E-US-X400,Rand Ph II for pts w/ relapsed/refractory Hodgkin's disease,
F1D-BX-S032,Early Schizophrenia and Therapeutic Alliance with Zyprexa,
F1J-US-SBCD,Dulox HCI in Wmn of Diff. Ethnicities and Co-morbid w/ SUI,
F1D-OE-O238,D2 receptor occupancy in manic pat. treated with Olanzapin,
"8412","Ph I, Gem + ALIMTA + MEPM in Pancreas Cancer",
B4Z-US-X002,Atomox fMRI in children with ADHD,
F1D-MC-X242,Diabetes Prevalence Estimates in Schizophrenia & Risk Factor,
B1Y-BX-9401,EFFECTIVENESS PROZAC 20 MG VS AMYTRIPTILINE 150 MG IN MDD,
F1J-BI-HMDH,EU Pain Enriched,
F1J-BI-HMDK,Diabetic Neuropathic Pain,
B9R-MC-X004,EFFECT OF HGH THERAPY ON PATIENTS ON PERITONEAL DIALYSIS,
B9E-US-X415,Ph II Cisplatin/Gem w/tumor Grade III metastatic breast CA,
B1Y-BX-9402,TREATMENT FOR RECURRENT DEPRESSION IN GENERAL PRACTICE,
B9E-US-X358,Tx of pts w/recur/refrac hodgkin's dis w/wkly Gem & Vrb,
H7U-FW-IDAM,Smoker Study,
F1K-XM-EVCG,EPCR increase fibrinolytic effect of PC,
ZYY-LC-PCAC,Methods: Lilly Neuropsychology Test Battery in Elderly,
"7020",Cialis Pulmonary Hypertension,
"7047",ASD Phase III #2,
"7079",Bipolar II Depression Registration,
H6D-EW-LVEZ,LY450190 - QTc,
B9E-US-S313,Phase II Trial of FFG vs 5FU/Cis in Metastatic Esoph Ca,
B9E-MC-JHDB,PHASE I TRIAL OF GEMCITABINE/CISPLATIN/IRRADIATION IN NSCLC,
H3S-FP-S010,Multiple Risk assessment in Rheumatology,
H3S-FP-S012,Multi Risk assessment in Gynecologists,
"7347",Placeholder for duloxetine,
"7360",PKC in retinopathy (placeholder),
H4S-SZ-O043,ASTERICS-Abciximab versus Aspirin for Prevention of Stroke,
"7371",Gem intravescical lesion marker,
H3E-US-JMGD,Ph II Trial of Alimta Plus Gem or Carbo in mesothelioma,
"7503",Observational trial to promote insulin initiation by PCPs,
"7569",Bipolar Acute Mania with Zyprexa,
F1D-SB-O226,Memory and attentional processes in psychiatric patients,
H6L-MC-LFBJ,#7896 Bridging Study ,
"7941",CTNR: Cis+Etop+Affin+XRT vs Carbo+Tax+Affin+XRT-NSCLC,
"7942",CTNR: Gem+Cis+Iressa+Affin vs Carbo+Tax+Iressa+Affin - NSCLC,
H7U-MC-IDAN,HIIP (Pulmonary Insulin) COPD Trial,
H3E-JE-NS02,JP alimta Phase II NSCLC,
H3E-US-S073,Ph. I/II Gemzar + Alimta in Biliary/Gallbladder Cancer,
B9E-BP-O365, Randomised Ph. II Gem vs Gem/Fragmin in Pancreas,
ZYY-LC-PCAE,Evaluation of a Novel Diabetic Biomolecule (LP10152) in,
"8063",Genetic Prediction of Response to Tiazolidinediones in T2DM,
B9E-LC-JHSK,SDSS/MDSS for gemcitabine for HCV,
H4S-MC-I017,Carotid Angioplasty & Stenting:  Saftey & Efficacy,
H7H-SO-O001,A pilot study for tx of hyperglycemia in critically ill pts,
B1Y-BX-8709,FLUOXETINE V PLACEBO WGT LOSS NIDDM OBESE PTS,
B3D-MC-X004,Risedronate/FORTEO combination trial in male OP,
B9E-GH-O376,Gemcitabine plus Cisplatin Chemtherapy breast cancer,
H9K-MC-TWAA,PPAR Co-agonist IV SDSS,
"8303",CS-747: Statin interaction,
B9E-BP-JHLC,FEASIBILITY OF DOMICILIARY ADMINISTRATION OF GEMCITABINE,
"6763",Multiple Dose Crossover Study (donepezil- like) 108,
"6776",Scheduled Dosing,
B9E-MC-S297,"Ph II, First Line G + Alimta + Carbo Ovary",
"6797",Cognitive Battery Pilot Study in Patients with Alzheimer's,
"6826",Phase I 14C Study,
B9E-CA-O312,Phase I/II multicenter trial with carbo gem radiotherapy,
B9E-MC-V172,PK of Gem+Paclitaxel,
B9E-MC-I003,PHASE I STUDY OF GEMCITABINE IN PEDIATRIC SOLID TUMORS,
B9E-US-S301,Phase III Gemzar vs. Doxil in Plat. Resist. Ovarian Cancer,
F1D-MC-X218,Olanzapine in Anorexia Nervosa,
"7040",GAD Benzodiazepine Comparator,
H7C-MC-LMCP,Human Stress Model -  Cardiac Biomarker,
H6D-EW-LVEU,LY450190 - Ketoconazole drug interaction,
"7086",Pulmonary Insulin in CO:PD,
"7089",Pulmonary Insulin in COPD,
B9E-FP-O330,IIT-Breast B9E-FP-O330 TAXGEM / AERO,
B9E-MC-JHCB,GEMCITABINE COMPASSIONATE USE IN PATIENTS WITH BREAST CS(OUS,
B9R-OL-0005,SOMATROPIN-HYPOPITUITARY DWARFISM (SALES),
B9R-SB-2019,HUMATROPE DRUG MONITORING,
"8743",Placeholder,
B9R-SB-GDDQ,HYPOCCS DRUG MONITORING,
"8764",Ph I/II - ALIMTA+ novel agents (ASAP + PKC-beta) - CRC,
"8779","Ph II,1st Line ALIMTA+Cis or Carbo Neoad (genomic ) NSCLC",
H6O-LC-GCAP,Obesity Biomarker - Method #3 - Lipids,
"8853",Placeholder for IIT Zyprexa,
"8947",PLACEHOLDER Stratterea for joined dyslexia project with NL,
F1D-US-X254,Atom for Weight Management in pts tkg Clozapine orOlanzapine,
"9088",Placeholderstudy for Yentreve AT 2004/5,
H3E-MC-V018,"Invitro & Invivo ALIMTA combination w Gem in pancreas, NSCLC",
H8I-MC-HQAJ,"5HT1d/SSRI SERT Occupancy Trial - DASB",
F1D-EW-E007,HALOPERIDOL BIOAVAIL 5MG TAB (MCNEIL) V 5MG CAP (HALOPERIDOL,
F1D-SB-O253,Optimal lenght of Olanzapine as Add-on therapy in MD,
F1D-SB-O254,"A randomized, single blind prospective trial with emergency",
F1K-VI-B005,OS for pt with severe sepsis-Time to drotrecogin alfa treatm,
B5K-CY-B002,Patient`s Assessment of The HumaPen Ergo (PATH),
"9254",Placeholder for HMDG Local Headcount,
F1K-CA-O013,recombinant protein C in pre-eclampsia,
H4Z-LC-GJAC,Identify a once weekly safe and effective dose,
H6D-FR-B002,Representative Observatory of Mgmt of ED by SpecialistsB002,
"8326",Placeholder for duloxetine trial,
F1D-HL-O235,Orlistat in Clozapine - and olanzapine - induced weight gain,
H3E-US-JMGT,Single agent Alimta in Endometrial Cancer,
B9R-JE-YI45,HUMATROPE:CARDIAC RISK FACTORS IN GHD PTS. TREATED WITH HGH,
H4Z-LC-GJAI, Formulation Study,
I1D-MC-JIAC,"Ph1, FHD trial, P38 Map Kinase",
"8687",JP PPAR-gammma agonist Phase II,
H3E-MC-V003,Study of cytotoxic activity-ALIMTA on established cell lines,
B9E-SZ-O402,SAKK 36/03 Gemzar in Mantle Cell Lymphoma,
B9U-SB-3058,LORACARBEF DRUG MONITORING,
H7T-EW-TAAO,CS-747: Renal impairment,
"8996",IIT ALIMTA - PLACE HOLDER (TREDANIEL + others),
B9Z-CA-V013,DIRITHROMYCIN EFFECTIVENESS AGAINST PURTUSSIS (INVITRO),
"9100",Daily Dosing Clin Pharm Study #1,
B9E-AY-O407,OPTIMUM TIMING OF GEMCITABINE AND CONCURRENT RADIATION THERA,
"7583",Health Outcomes Study (Pre & Post Approval),
B9E-US-X381,Ph II Gem in Combo w/ Capecitabine in Adv Cholangiocarcinoma,
"7732",Non small cell lung CA,
"7796",Placeholder for Olanzapine IIT RIDE vs UCP,
"7797",W2000,
B9E-RM-JHBZ,GEMCITABINE VS EPIRUBICIN IN ELDERLY PTS WITH MET BREAST CA,
"7907",Adderall vs Methadate vs Straterra,
B9E-UT-V215,Are DNA repair enzymes predictive for OS IIIb/IV NSCLC,
F1D-FP-HGKZ,Antipsychotic medication in MPC in France,
"7936",CTNR: Affinitak - Hepatoma,
B9E-VI-JHDH,GEMCITABINE IN NSCLC,
B9R-AY-O029,GH Tx of protein wasting induced by glucocorticoid therapy,
H6E-MC-O007,Lipotoxicity in Human Pancreatic Islets,
F3Z-FP-IOON,Safety of Humalog in the Treatment of Pregestational DM,
F1D-SB-S051,Assesment of QoL in outpatients with schizophrenia,
"8030",Drug Interaction Study,
H8O-MC-GWAU,Long term durability,
B9F-MC-I026,EFFECT OF PORTAL VS SYSTEMIC INSULIN DELIVERY IN PKT PATIENT,
F1D-AY-O219,Supp. community agen. manage young people mental health prob,
H8O-MC-GWAR,Study 114:  Heine clamp,
"9290",Placeholder for IIT,
H3S-IS-O128,effects of Rlx on Cv markers,
B9E-US-X426,Ph I Gem w/Mitoxantrone pts w/first relapse AML,
B9E-US-S359,Ph II Gem+Carbo+Herceptin in MBC,
F1D-MC-X261,A prospective randomized double-blind trial of olz 10mg IM,
H6O-PU-O001,multicenter multinat.obs study fract,
F1D-LC-HGAA,"LY170053:  DOSE-RANGING, SAFETY & DISPOSITION STUDY",
H3E-MC-JMHH,"Ph I/II, ALIMTA + Carbo in platinum-sensitive Ovarian cancer",
"9616",Compliance protocol #1,
H3E-JE-GI01,JP MTA P-II gastric,
H3E-MC-JMHN,"Ph III, 1st Line ALIMTA in Bladder Cancer",
"9699",TZD Synergy,
"9713",PTH plus Alendronate: effect on bone,
"9870",IIT Dr Chabane: fluoxetine solution in infantile autism,
F3Z-US-X020,TODAY (Trtmt Opt for type 2 Diab in Adolescents & Youth),
"9911",Ph1; 1st line Alimta / Carbo,
B9E-FP-O448,IIT-Cervical carcinoma B9E-FP-O448 GEMCOL / COL,
B9E-US-X424,Ph II Gem+paraplaint+Herceptin in Her2+ Met Breast Cancer,
"9263",Placeholder study for TAAD financial reporting,
B3D-US-X011,Treatment of osteoporosis in young adults with CF,
"9275",Blood Archiving in the CPMC Breast Health Cohort,
B3M-GH-B006,Ceclor SR for the treatment of AECB,
B9E-MW-S368,Gem+Cis as first line therapy in ovarian carcinoma,
F3Z-US-X017,Effects of Insulin Resistance on CV Disease in T2 DM,
"9419",Multicenter Multinat obs. study fract post menop. women,
"9450","Scopolamine reversal study, Double blind, pbo controll",
"9467",GH in postmenopausal women and elderly men with reduced BMD,
H7T-EW-TABT,Multi-dose PPI + atorvastatin + CMD or PMD,
F1J-US-X014,A Pilot Study of Duloxetine in Social Anxiety Disorder,
H8D-MC-EMBG,HDL Kinetics Phase 1b,
F1D-LC-HGAW,OLANZAPINE IN SUBJECTS WITH OR WITHOUT CHRONIC RENAL FAILURE,
H3S-JE-S01J,JP EVS P-IV long-term open-label (Osteo),
F1D-MC-O266,Improvement in Brain Energy Metabolism by Olz as Com,
B9E-MC-JHSS,Gem plus Taxol vs. Taxol in MBC,
B3D-FW-GHDA,Pulmonary Bioavailability Trial Phase 1,
F1D-PH-HGLG,Olanzapine in the Acute Treatment of Bipolar Mania,
"8232",Schmidt-Blockade of PKC Beta and Atherosclerosis,
H3E-MC-V031,ALIMTA + GEM or Ionizing Radiation/CRC-PANC,
H8U-BD-HEAB,Single Dose Safety Study,
H6D-EW-LVFT,LY450190 - alpha blocker,
"8292",PPAR Co-agonist IV MDSS,
F1D-US-X236,Prevalence of hyperprolactinemia with antipsychotic drugs,
B9E-US-X402,Ph II fix rate Gem 2nd line ther adenocarcinoma of pancreas,
H3S-HL-O116,Biodegradable drug-coated vascular stents,
H3E-US-JMGQ,Ph II - Single Agent Alimta in Platinum-Sensitive -Ovarian,
H8O-JE-GWBB,JP Exenatide P-III Placebo controlled study(SU failure),
B3D-JE-GHCS,Phase 2 Japan trial for registration in Japan,
H3S-US-X028,Investigation of Hot Flashes Among Women Treated for Prevent,
F1J-LC-SBCH,Pilot Safety and Tolerability Study,
H6P-MC-HDAU,OFC in the Treatment of Bipolar II Depression,
B9R-MC-I014,IDPN AND RGH IN UNDERNOURISHED PATIENTS ON HEMODIALYSIS,
"8545",Wan-The biogenesis of lipid bodies in human leukocytes,
B9E-US-X363,Clinicopathological corr enzyme expr w/operable bladder CA.,
"7200",Patient acceptability of auto-insert device for HP-3,
B9E-MC-JHCM,EMERGENCY USE OF GEMCITABINE,
"7349",Placeholder for Alimta CTNRs,
"7368",GEM/Cis + iressa Vs GEM + iressa,
"7381",Atomoxetine in Adults,
F1J-FP-SBBZ,symptoms vs underlying conditions,
B9E-MC-JHEQ,PHASE 2 RAND. TRIAL OF GEMCITABINE OR COMB. OF CISP.& ETOPO.,
"7458",PTH Epidemiologic Trial,
ZYY-FW-GCBI,H2O2 Excretion and oxidative stress in diabetic subjects,
B9E-MC-JHFH,PH2 GEMCITABINE IN PTS. WITH ADVANCED MULLERIAN CANCER,
F1D-SB-O193,Prophylactic efficacy of olanzapine in bipolar patients,
B7A-US-MBDW,RBX vs. Placebo combolaser,
"7618",Ceclor SR versus Levofloxacin in treatment of Acute Bronchit,
"7643",European study- Duloxetina IU,
"7646",Burden of the illness,
B9E-EW-JHMU,ACTION (Observational study of Gemzar in NSCLC),
"7731",Second line usage vs primary competitor in breast CA,
F1D-MC-HGBJ,"DOUBLE-BLIND, OLANZAPINE VS PERPHENAZINE IN SCHIZOPHRENIA",
H3S-IS-O127,effects of RLX treatment on serum NTX level,
"9988","LY545694 Single Rising Dose, Safety, PK/PD Study",
B9E-AU-O390,"Triplet Gem, Pac, Carbo followed by 5FU+FA for Met NPC",
"7798",testing,
"7910",Locally advanced and metastatic breast cancer,
B9E-VI-JHMD,PHASE II:  GEMCITABINE IN STAGE III & IV NSCLC.,
H9A-BD-GSBA,GLP-1 Analog II- Phase 1 (SDSS),
B4G-SB-S005,German drug utilisation observation study pergolide,
F1D-MC-X231,Pharmacotherapy of Psychotic Depression,
B9R-CA-O032,Macrophage lipoprotein lipase expression in GHD patients,
H7R-LC-GCBK,"14-C Study LY519818",
H8O-EW-GWAB,Exendin-4: Renal Impairment,
"8124",General Drug Interaction,
B9E-MC-S342, Ph II-Gem/Cis-Biliary Tract Carcinoma,
"8256",Battle-LY379196-STAT signaling of chronic leukemia,
B9E-US-X388,Ph II Study Gem & Irinotecan in Unresec or Metastatic Renal,
B9E-US-X392,Ph II of Capecitabine + Gem in pts w/Renal Cell CA,
"8385",Ph I - ALIMTA + XRT (RTOG) - Pancreas,
H7T-EW-TAAJ,CS-747: Clopidogrel differentiation study,
"8587","Dosing Study QD/BID, 2 doses, HV, possible male/female",
"8625",Placeholder,
"8649","1d/ssri: C14 study",
"8751",Ph II-Gem-->maintenance PKC-beta inhib- mantle cell Lymphoma,
"8768",Ph I/II - ALIMTA + CPT-11 + C225 - CRC,
"8775",Ph I/II - ALIMTA + novel agents (PKC-beta) - CRC,
H3E-MC-V039,Alimta as a Positive Control for Invitro Assays,
"8807",A Beta RBM samples,
"8829",IBS POC,
H7R-LC-GCBW,Drug-Drug Interaction Study (EtOH),
B9U-SB-AZCI,LORACARBEF LIQUID DRUG MONITORING,
B4Z-US-X016,Atomoxetine for ADHD in Adolescents with SUD,
B3D-MC-GHCY,Effect of Teriparatide  Compared w/ Risedronate on Back Pain,
H8R-JE-HJAL,JP NK-1  P1 SDSS,
F3Z-US-IOOQ,Lantus Failure Trial,
B9E-JE-MB21,Jp Gem P-II Breast (A),
F1D-MC-X256,"Mechanism of weight gain with Olazapine, Quetiapine, & Rispe",
H6D-MC-B009,US Co-Presciption Observational Study,
H9U-MC-MDBF,Depression Disorder Combination Therapy,
B9E-MC-V240,Evaluation of Gemcitabine Modulation of Cisplatin Drug Resis,
F1D-US-A125,Facilitating Action of Olanzapine on Glutamatergic Transmiss,
B9R-MC-C007,DIFFERENTIAL EFFECT OF INSULIN RESISTANCE IN OBESITY,
H4Z-LC-GJAJ,Desipramine trial (ClinPharm),
H3E-ES-S085, Ph 1/2 Alimta + Cis (bi-wkly) in 1st line bladder,
B7A-MC-MBDP,RBX Transition Study,
"8723",PK in Severe DIC,
H3E-US-S068,Ph 1 ALIMTA/Cetuximab (C225) in 2nd line NSCLC,
B9R-US-GDEO,THE EFFECT OF CHRONIC SOMATROPIN TREATMENT ON SPINE BMD,
"8831",GEMZAR NEOADJUVANT IN BREAST CANCER,
"8841",Place Holder for Yentreve Local studies Spain,
"8957",Placeholder - UK Olanzapine IIT's,
"9039",Glucocorticoid induced osteoporosis - Europe,
B1Y-CA-C023,PSYCHOTHERAPY PHARMACOTHERAPY PSYCHOEDUCATION FOR BULIMIA,
F1D-AY-O252, Psychotherapy in Young People  with Bipolar Disorder,
"9214",IIT Placeholder - Gemzar (Argentina),
"9232",Japan Phase I- MDSS,
H8L-FW-IQAD,Mixtures PK/PD,
H3E-US-X002,Alimta IIT Program/United States,
A6J-GH-B001,Vancocin for Treatment of MRSA/MRSE infections Post Surgery,
H4S-FP-O058,MISTRAL,
F1D-EW-HGCC,OLANZAPINE ELDERLY MULTIPLE DOSE KINETICS,
H3S-MC-X031,Blood Archiving in the CPMC Breast Health Cohort,
F1D-US-X257,Retrospective - Effect of Antipsychotic drugs in pts w schiz,
H8I-EW-HQAL,"5HT1D/SSRI: MD/PK study",
"9487",Pre TX vs. no Pre TX prior to Percutaneous Coronary Interven,
"9491","300/600mg Clopidgrel vs. 60mg CS747 Loading Dose in NHV",
H4Z-LC-GJAG,Bioequivalence study Form III vs Form V(Clin Pharm),
H8D-JE-EMBL,JP PPAR-a P-II Dose finding,
F1K-US-A011,"Act,. Prot. C Regulation of Leukotriene Pathways in Monocyte",
"9638",JP ola P-IV Zydis acute,
H7T-EW-TABC,CS747: Elderly PK (placeholder),
H6D-EW-LVGN,Daily Dosing Tadalafil and Tamsulosin Alpha Blocker Study,
H8R-MC-HJAK, Phase 1 14C study,
F1D-MC-X265,An Open-Label Trial of an HMG-CoA Reductase Inhibitor for th,
F1D-SB-O269,Program evaluation to prevent weight gain and adipositas,
H8Y-BD-HBBD,Schizophrenia Monotherapy POC,
H6Q-MC-S013,Ph II R-Gem+Ox + ENZ in relapsed DLBCL,
H9G-MC-GXAC,PET Receptor Occupancy (5HT2c),
H9R-MC-JKAF,"Ph I, FHD trial of eIf-4E-ASO",
H8L-FW-IQAE,Skin Tolerability Microneedle Study,
F1D-LC-HGAE,INTERACTION OF LY170053 AND DIAZEPAM,
B1Y-SE-V002,Effects of fluoxetine HCl on neuronal injury,
H9L-LC-PSAA,A Single Dose Study to Evaluate the Safety of LY570977,
H8D-MC-EMBF,LY/Statin Comparator,
B9E-XM-O435,Gemcitabina + taxol (Toledo),
B7A-JE-MBDU,JP PKC1 PK Study,
B4Z-MC-LYDO,hAdult relapse prevention study,
F1J-US-X006,Pilot Study Assessing Dulox Efficacy in Atypical Depressives,
H8R-MC-HJAJ,IBS Phase II Study,
F1D-MC-HGBB,OPEN-LABEL EXPERIENCE WITH OLANZAPINE,
B3D-BP-O003,Pharmacoginetic studies of acute response to PTH injection,
F1D-MC-HGBF,"DOUBLE-BLIND, OLANZAPINE VERSUS CLOZAPINE I.T.TREATM. OF SCH",
F3Z-US-X021,Placeholder for Financial Reporting,
F1K-MC-EVDD,Severe Sepsis Patients Post Liver Transplant,
F3Z-BP-S018,Mix25 vs glargine in UK primary care,
"9950",Chronic sleep disorder dose ranging,
"9961",Sleep On-set /Terminal Insomnia Study,
B5K-IS-O450,Endothelial and Leucocyte Adhesion Molecules and Proteinurea,
"9976",Fellowship: Salivary Cortisol Resp-Child. of Bipolar Parents,
"9996",Can Strattera Produce a False Postiitve UDS for Drugs of Abu,
H6D-US-LVGS,Initiation Trial (Daily Dosing to PRN),
H3E-EW-O008,ALIMTA+cis in neoadjv mesothelima,
F1D-IT-O272,Olanzapine in animal models of fear,
F1K-SB-A015,Microhemodynamic and cellular mechanisms of APC action,
,Clinical Trial (SAD/MAD) SM non-Oncology,
J1H-MC-LAJB,Dose Ranging/POC for PACAP38 Antibody,
,Clinical Trial (Renal),
J2T-MC-KGAK,Vaccine Responses in pts w/ moderate to severe AD,
,Clinical Trial (RBA/BE),
,Clinical Trial (Ph2 Trial: AD DM; LY v Pbo Dose Finding & POC) SM,
,Clinical Trial (Japan Mad),
,Clinical Trial (DDI 3),
,Clinical Trial (SAD/MAD incl. JP/CN HVs) LM non-Oncology,
,Clinical Trial (SAD/MAD incl. JP/CN HVs) SM non-Oncology,
J3G-MC-O002,Clinical Trial (Defecation detection),
J3E-MC-EZDD,Relative Bioavailability Study HV,
,Clinical Trial (SAD/MAD incl. JP/CN HVs) LM non-Oncology,
I5T-MC-B004,PMR1-US Registry (ARIA),
,Clinical Trial (Special Population),
,Clinical Trial (C14+ABA),
,Clinical Trial (Hepatic),
,Clinical Trial (SAD/MAD incl. JP/CN HVs) SM non-Oncology,
,Clinical Trial (SAD/MAD incl. JP/CN HVs) LM non-Oncology,
,Clinical Trial (SAD/MAD) LM non-Oncology,
,Clinical Trial (SAD/MAD) LM non-Oncology,
,Clinical Trial (BE/Device Bridging),
,Clinical Trial (RBA/Bridging) non-Oncology,
,Clinical Trial (SAD/MAD) SM non-Oncology,
,Clinical Trial (SAD/MAD) SM non-Oncology,
,Clinical Trial (SAD/MAD incl. JP/CN HVs) SM non-Oncology,
,Clinical Trial (SAD/MAD) SM non-Oncology,
I6T-JE-AMCF,Clinical Trial (J-Ph3) investigating acrodermatitis continua of Hallopeau,
J5P-MC-GZ01,Clinical Trial (ISA #1 Non-PAP),
J5P-MC-GZ02,Clinical Trial (ISA #2 PAP),
,Clinical Trial (Ph3 PK/PD trial) LM,
J2T-JE-B001,Japan Lebrikizumab-AD PMSS,
I8I-MC-JY09,LOXO-NGR-21001 JZTA continued access,
I1F-MC-RHDE,Clinical Trial (Ph4 observational study with ixekizumab and tirzepatide in PsA),
,RBA Placeholder,
,Clinical Trial (Renal),
I5Q-US-I002,"A Pilot Study to Assess the Effect of Galcanezumab in Reducing the Frequency of Post-Traumatic, Migranous Headaches",
,Clinical Trial (SAD/MAD incl. JP/CN HVs) LM non-Oncology,
I8P-MC-OXAH,Clinical Trial (Ph2 Alcohol Use Disorder AUD),
I1F-MC-RHDD,Clinical Trial (Ph4 observational study with ixekizumab and tirzepatide in PsO),
,Clinical Trial (PK Co-Formulation),
W8M-MC-GN01,Clinical Trial non-T2D (CWMM) Ph2b 48 Weeks,
J5G-MC-KOAA,FHD SAD/MAD LM non-Oncology HV,
I4V-US-I009,Randomized double-blind placebo-controlled trial EValuating baricitinib on pERSistent nEurologic and Cardiopulmonary Symptoms of Long Covid (REVERSE-LC) study,
J2A-MC-GZPP,DDI Quinidine HV,
I8B-MC-ITTA,Lyumjev India Ph4 Study,
I6T-US-X001,Pouchitis,
I5T-MC-AACS,Real World Donanemab phase IV US,
J5P-MC-GZRA,Glp-1 Receptor Non-peptide Ag I (ly3502970),
J4G-OX-JZVG,Renal Impairment Loxo-FG3-23005-Ph1-FGFR3 HV,
J5C-MC-FOAD,SAD/MAD no costs,
I6T-NS-O002,Visceral hypersensitivity and persistent symptoms after mucosal healing in Ulcerative Colitis patients: a prospective cohort study 	,
J1I-MC-GZBK,Chronic Weight Management -2 (with T2DM),
J3H-MC-GZNF,Incretins in Imm- GIP-GLP study in mild to mod pts,
J3G-MC-E001,Validation of Dreemband for measurement of sleep disturbance relative to PSG in atopic dermatitis patients followed by feasibility of Dreemband for at home data collection.,
J4G-OX-JZVF,Hepatic Impairment Loxo-FG3-23004-Ph1-FGFR3 HV,
I8I-MC-JY08,LOXO-BCL-20001 JZRA continued access,
I3Y-US-X027,A Phase I Pilot Study of Abemaciclib in Combination with Concurrent Neoadjuvant Radiation Therapy in Patients with Retroperitoneal Liposarcoma.,
I3Y-MC-X024,"A Phase Ib Study of Concurrent Abemaciclib and Radiation Therapy (RT) for Patients with Metastatic Hormone Receptor positive, HER2 Negative Breast Cancer",
I5E-MC-X001,"Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial",
B3D-US-X035,The Role of Teriparatide For Healing of Atypical Femoral Sha,
B3D-US-X037,Denosumab and High-dose Teriparatide Administration Study,
I3Y-NS-X025,"A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer",
J4G-OX-JZVE,DDI CYP 3A4 Inhibitor/Inducer Loxo-FG3-23002-Ph1-FGFR3 HV,
B3D-CA-O028,Systematic follow up for osteoporotic fracture,
F1J-CA-O053,Analgesic Properties of Duloxetine,
B3D-US-X030,Forteo in Spinal Cord Injury,
B3D-US-I007,Spinal Fusion in Forteo,
B3D-US-X031,Optimizing Teriparatide and Denosumab Sequences for Treatment for Osteoporosis,
H7T-CA-O022,Reassessment of Anti-Platelet therapy using InDividualized,
H3F-CA-O002,"Three-way, cross-over study  assess efficacy of single-hormone closed-loop strategy,dual-hormone closed-loop strategy&conventional pump therapy  during 60 hrs in patients w type 1 diabetes",
H3F-CA-O004,"Five-way, cross-over efficacy of single-&dual-hormone closed-loop operations combined w carb counting or simplified qualitative estimation &sensor-augmented pump therapy pts w t-1 diabetes",
H3F-CA-O005,Closed-loop plus carb counting or simplified qualitative meal-size estimation & sensoraugmented pump therapy regulating glucose levels in children&adults w type 1 diabetes,
J1O-MC-E001,"A phase Ib/II trial to evaluate safety, tolerability and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer",
J2I-MC-JZMA,A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Malignancies,
H9H-MC-E007,Phase I study of LY2157299 in patients with myelofibrosis,
I8X-MC-E001,galunisertib combined with chemotherapy in chemotherapy resistant colorectal cancer,
J1V-MC-IMMA,Master Protocol for SLE,
J4T-MC-OLAB,Ph1 Biodistribution Study,
J2R-MC-YAAB,FHD SAD MAD,
,Clinical Trial (Ph3 preclincal AD Epidemiology Study),
J1V-MC-BT01,Appendix 1 of Master Protocol for BTLA,
,Clinical Trial (Ph2 Trial 2: POC CLBP) SM,
J6G-MC-OYAA,Clinical Trial (SAD/MAD incl. JP/CN HVs) LM non-Oncology,
J2S-MC-GZML,Clinical Trial (Hepatic),
I4V-JE-B039,Japan All-Cases data Additinal Alaysis,
I5T-MC-B006,Clinical Trial (Brain Bank Study),
J4C-OX-JZUB,LOXO-PIK-22003-Ph1-PI3K DDI: CYP3A4 Inhib/Inducer,
,Clinical Trial (Trial # 1: Ph3 Adjunct Therapy for Relapse Prevention),
J1B-GH-FRCI,China Phase 1 PK study HV,
J2N-OX-JZNA,"LOXO-BTK-18001-BRUIN-Ph1/2-Pirtobrutinib-CLL, SLL, & NHL",
J4C-OX-JZUE,Loxo-PIK-23005-Ph1-PI3K-AME,
J3M-OX-JZQE,LOXO-RAS-23003-Ph1-KRAS-ADME,
J5E-OX-JZXA,Clinical Trial (Ph1a/b Trial: 200 pts 6 cyc 30 sites 36 mo Model B),
J3M-OX-JZQK,PH1-Kras-RBA,
J2S-MC-GZMM,Clinical Trial (Renal),
J5I-OX-JZYA,Clinical Trial (Ph1a/b Trial: 200 pts 6 cyc 30 sites 36 mo Model B),
,Clinical Trial (Ph2/3 Adjunct Therapy for Mood Episode Relapse Prevention),
I8F-MC-GPIU,Clinical Trial (CN Early Therapy),
J2S-MC-GZMN,Clinical Trial (Injection Site/ABA),
H9H-MC-JBAH,"FHD PH1 Trial, TGFb R1 Inhibitor Glioblastoma Multi-Form",
,Clinical Trial (Bari T1D New Onset),
,Clinical Trial (Bari T1D Prevention/Delay),
J4Z-MC-GIDH,Clinical Trial (China PK) LM,
,Clinical Trial (Trial # 2: Ph3 Adjunct Therapy for Relapse Prevention),
,Clinical Trial (Ph2 Adjunct Therapy for Relapse Prevention) LM,
J2A-JE-GZPD,GLP-NPA Ph3 study in Japan for Chronic Weight Management,
J1I-MC-GZQB,Clinical Trial (Triumph-6) Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals with Obesity,
J2A-MC-GZPL,A Master Protocol for Orforglipron in Participants with Hypertension and Obesity or Overweight: (ATTAIN-HYPERTENSION),
I8H-MC-BDDB,BIF PK Study T1DM Pediatric Pts,
J6B-MC-YKAA,FHD SAD/MAD Pts/HV,
I8F-MC-GPJE,TZP Gastric Retention PMR in T2D and CWM,
J3H-MC-GZND,Incretins in Imm- GLP1-NPA2 in mild to moderate pts,
I3Y-US-I029,Phase II study of stereotactic radiation and abemaciclib in the management of HR+ brain metastases,
J3G-MC-O001,Assessing PD in HV with a skin model,
,Clinical Trial (SURMOUNT-REAL OUS UK),
J2N-MC-JZNY,Clinical Trial (Rollover Master),
I9X-MC-MTAG,Clinical Trial (MTAG  Monotherapy Ph3 Ph3),
,Clinical Trial (Ph3 H2H w/ Erda  Functionally Sourced),
I4D-MC-E011,A Phase I Study of Prexasertib Alone and in Combination with Irinotecan and Temozolomide in Patients with Relapsed or Refractory Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma,
J6E-MC-KWAD,Clinical Trial (Ph2b Trial: UC) No forecast alias only,
J6E-MC-KWAB,Clinical Trial (Ph2b CD),
J2S-MC-GZMD,MAD study in Participants with Obesity or Overweight Pts,
J3G-MC-S005,EET Hercules HV,
J4P-MC-IYAB,SAD PoC Pts/HV,
J1I-MC-GZQD,Clinical Trial (Ph 3 for CLBP),
J2N-NS-X001,Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome (EPCORE™ CLL-1)),
I8S-MC-E009,"SHERPA Trial: Phase I/Ib study with the combination of RMC-4630 (SHP2 inhibitor) and LY-3214996 (ERK inhibitor) in metastatic KRAS mutant CRC, PDAC and NSCLC",
J2V-MC-GZLC,Hyporecovery Clamp study PT,
J2V-MC-GZLB,MAD POC Pts,
J2V-MC-GZLA,FHD SAD HV,
I7P-MC-DSAH,Incretins in Imm- eltrekibart/mazutide combo,
J5B-MC-FHAE,DDI #2 no costs,
,Clinical Trial (Reta T2D Peds aged 10 to <18 years),
H8H-JE-LAIP,Lasmi Japan PMSS,
J1I-MC-GZQC,Clinical Trial (Triumph-1 Extension),
,Clinical Trial (Ph2a POC in SLE),
I6T-MC-AMCB,BE Study in HV,
I6A-MC-E003,Pediatric Molecular Analysis for Therapy Choice (MATCH) - Phase 2 subprotocol of LY3023414,
J2V-MC-GZLD,SAD/MAD 12-week HV,
I9A-MC-JLDA,FHD - Ph I - TIM-3 Antibody - Solid Tumors,
I5Q-IN-CGBF,Registration Trial for India,
I4V-US-X009,Study to Evaluate the Efficacy of Baricitinib in Adults of African Descent of with Biopsy-proven Central Centrifugal Cicatricial Alopecia (CCCA),
I4V-US-X008,Baricitinib in neurological Degos disease ,
I3Y-MC-E008,A phase II study of abemaciclib for Rb+ metastatic triple-negative breast cancer,
J2A-JE-GZPM,Japan capsule-capsule BE study,
,Clinical Trial (Ph3b Template High Burden),
I8F-XX-XXXX,Observational retrospective study of the ABCD Tirzepatide Registry,
,Clinical Trial (Ph3 Reduction in risk of relapse),
H9X-MC-GBGT,Dulaglutide Gastric Retention PMR in T2DM,
I4V-NS-O043,JDORE-BARI,
I8F-NS-I007,The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women with Obesity: A Pilot Study,
I6T-NS-E001,"Effectiveness of mirikizumab in the management of ulcerative colitis: A German observational, retrospective, single-center study. 
The MURI (Munich UC miRIkizumab) trial",
J5C-MC-FOAH,Clinical Trial (RBA),
J1R-MC-GZFD,Clinical Trial (Effect of PYY as add-on to incretin) Prism Req 1224,
I3Y-MC-B017,ABemaciclib persistence and outcomeS In patients with early breast cancer treateD in clinical practicE in Spain,
J3J-AV-_001,"18F-LY3546117-01",
J4G-OX-JZVB,Loxo-FG3-23003-Ph1-FGFR3-ADME HV,
J2N-US-I005,"A phase 2 study of pirtobrutinib, rituximab and venetoclax combination therapy for patients with previously untreated mantle cell lymphoma",
J2N-US-I004,"Phase I Study of LV20.19 CAR T-cells in combination with Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",
J2N-NS-O002,PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously untreated symptomatic chronic lymphocytic leukemia (CLL),
J6E-MC-KWAC,RBA HV,
J1S-MC-JV02,CAMPFIRE - PhII - MultiCmpd Ped Ram+Doce+Gem - SS,
J5J-OX-JZZA,Clinical Trial (Ph1/2 Trial: 200pts  4 cycle 35 sites 32mo  Model A),
,Clinical Trial (IBD Algorithm Development),
,Clinical Trial (Assess utiltiy of RetiSpec AI),
J2N-NS-O001,PROPOSAL FOR A STUDY OF PIRTOBRUTINIB IN COMBINATION WITH RITUXIMAB IN THE UPFRONT TREATMENT OF INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA (MCL),
J5L-MC-YHAA,FHD SAD/MAD (Combined) Overweight Pts/HV,
,Clinical Trial (Ph3 Reduction in alcohol grams consumed per day),
I1F-JE-RHCB,Post-marketing safety study of IXE for long term use Japan,
J4C-OX-JZUC,LOXO-PIK-22004-Ph1-PI3K Pilot FE,
I3Y-MC-JPBA,FHD Trial for LF2835219 CDK 4/6 Dual Inhibitor,
I9Y-OX-JDHF,LOXO-IDH-21005-Ph1-IDH1-DDI (Itra/Carba),
I4V-JE-B005,Phase 4 RA Safety,
I6T-MC-AMCG,Clinical Trial (BE/Device Bridging) LM HV,
J4P-MC-IYAC,Clinical Trial (Ph2 Trial 1: T2DM 6 Mo Tx) LM,
,Clinical Trial (Ph3 Smoking cessation study #2),
,Clinical Trial (Ph3 Trial 1: AD DM; LY v Pbo w/OLE) LM,
J5Z-MC-OTAA,FHD SAD/MAD,
I8F-MC-GPHK,Weight Management in non-T2DM,
J4U-MC-KTAA,FHD SAD/MAD HV,
I3Y-US-X026,Neoadjuvant Abemaciclib with concurrent radiation in patients with locally advanced breast cancer,
I4V-JE-B024,HO Observational Study to generate OLM RWD,
I8H-MC-BDDE,PK Study Hypo risk #2 Pts (Degludec),
,Non-Interventional Safety Study of JP Patinets with ped-AA,
J2N-MC-E006,Phase 2 study of Combination Pirtobrutinib (LOXO-305) and Venetoclax in CLL Patients with Resistance to Covalent BTKi,
,Clinical Trial (BE),
,Clinical Trial (Ph2/3 Reduction in alcohol grams),
,DHT Acute Pain Comparison,
I8F-MC-GPJD,Clinical Trial (2nd Phase 3 trial),
I4V-NS-O016,Exploring analgesic effects of the JAK-inhibitor Baricitinib by inhibiting IL-12 signaling and furin induction,
J1I-MC-GZQI,Clinical Trial (Ph3 Trial) req Dec 6 2024,
H3E-KL-O068,Randomized Phase II Study Comparing Pemetrexed Plus Cisplatin followed by Pemetrexed Until Progression versus Pemetrexed Alone Until Progression in NSCLC Patients failed Firsr Line EGFR-TKI,
I3Y-MC-E022,EndoMAP: A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer; Cohort 7,
I4V-NS-O022,"Interventional, open-label, phase I/II prospective trial of participants with moderate to severe COVID-19 infection.",
,Clinical Trial (Ph2/3 Smoking cessation study #1),
J3M-MC-JZQH,Ph3 KRAS G12C NSCLC Adjuvant,
J4Z-VR-G015,LBM and physical performance after surgical treatment of hip fracture,
J4Z-VR-G014,PoC in obesity and type 2 diabetes,
J4Z-MC-GIDA,Safety and efficacy of bimagrumab and semaglutide in adults who are overweight or obese,
J4Z-MC-GIDG,RBA Bridging Ph2 to Ph3 + Coadmin to EP Coform | HV,
J2G-JE-B008,Post Marketing Safety Study of Selpercatinib Among Japanese,
,Clinical Trial (evaluate the safety and tolerability of AAVAnc80-antiVEGF and Akouos delivery device),
J5K-MC-OQAA,FHD SAD/MAD HV/Pts,
J2T-NS-X004,Evaluating the Efficacy and Speed of Response of Lebrikizumab in High-Burden Atopic Dermatitis Patients: A Phenotype-Based 52-Week Study with Objective Scratch Monitoring,
H6O-NS-X003,A single-center pilot study to establish a novel hypoglycemic clamp procedure to assess the time to spontaneous recovery from hypoglycemia in people with and without diabetes,
J3M-OX-JZQA,LOXO-RAS-20001-Ph1-FHD,
J5C-MC-FOAE,ADME/aba no costs,
J4M-MC-PW01,Pediatric (Age 12-17),
J5Y-OX-JQDA,Clinical Trial (Ph1a/b SM St Dose Esc/Expan: 400 pts 20 cyc 52 sites 25 mo Stand,
J3O-MC-LSBC,C14/ABA in Healthy Participants,
H9H-MC-JBAL,"FED Ph2, Glioblastoma",
I8F-NS-O002,"The IDEAL-COR study: The effects of tirzepatIDE on coronAry pLaque lipid content and myocardial microvascular function in overweight and obese patients, with or without diabetes, and stable CORonary disease",
J6D-MC-JSDA,Clinical Trial (Ph1/2 LM St Dose Esc/Expan/Reg: 240 pts./25 cyc/35 sites/28 m,
,Clinical Trial (Ph1a/b SM St Dose Esc/Expan: 240 pts 20 cyc 35 sites 25 mo Stand,
J6H-MC-KXAA,FHD SAD HV,
I8S-MC-E004,"Open-label Phase Ib/II Study of Cetuximab Administered in Combination with LY3214996 (ERK 1/2 Inhibitor) or LY3214996 Plus Abemaciclib in Patients with Metastatic, Cetuximab-Refractory Colorectal Cancer and an Acquired RAS Mutation",
I8B-NS-I003,Alleviating Carbohydrate Counting Using Weekly Subcutaneous Semaglutide Injections in People with Type 1 Diabetes on Closed-Loop Insulin Therapy: a 2x3 Factorial Randomized Placebo-Controlled Trial,
,Clinical Trial (Orfo ISA for OLE of peds MP),
,Clinical Trial (TZP ISA for OLE of peds MP),
,India PMSS (observational prospective study) for Retevmo,
W8M-MC-LAA2,Clinical Trial Combo QW,
J3R-JE-YDAB,MAD Early Exploratory Trial HV,
J6C-OX-JKFA,J6C-OX-JKFA GRPR+ Advanced Solid Tumors,
J2T-MC-KGCD,Clinical Trial (Ph3 Lebrikizumab vs PBO in Atopic Hand Eczema to support section 14 label update),
I3Y-US-I002,Combining abemaciclib with immunotherapy in patients with metastatic or recurrent head and neck cancer,
I3Y-US-I017,"A Multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer",
I3Y-US-X023,A Phase 1/2 Study of Neoadjuvant Abemaciclib in Combination with Radiation Therapy for High-Risk Adipocytic Retroperitoneal Sarcomas,
I3Y-US-X019,Single cell immune and non-immune correlates of response to neoadjuvant abemaciclib and letrozole in hormone receptor positive breast cancer,
I4X-US-I002,UCLA L-08: A Phase Ib/II Study of Combined HER Inhibition Adding Necitumumab and Trastuzumab to Osimertinib in Patients with Refractory EGFR-Mutated Lung Cancer,
I4T-US-I020,"S1922, Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma",
I3Y-US-X017,Evaluation of the effects of endocrine therapy and abemaciclib on host and tumor immune cell repertoire/function in advanced ER+/HER2- breast cancer,
I3Y-US-X005,Phase II Study of the Combination of Abemaciclib and Pembrolizumab in Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149,
I3Y-US-I024,Abemaciclib in metastatic or locally advanced Anaplastic/Undifferentiated Thyroid Cancer,
I3Y-US-I006,"A single-arm, open-label, phase II study of abemaciclib in patients with recurrent oligodendroglioma with CIC mutation",
I3Y-US-X014,"A Phase II Pilot Trial of ABemacicliB, HydroxYchloroquine, or the Combination to Target Minimal Residual Disease in Breast Cancer Patients (“ABBY”)",
I3Y-US-I020,A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination with Endocrine Therapy in Patients Age 70 and Older with Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition,
I3Y-US-X002,"Phase 2, single-arm study of Abemiciclib for advanced, non-liposarcoma, bone or soft tissue sarcoma, selected by CDK pathway genomic alteration.",
I3Y-US-X016,Pilot Study of Abemaciclib with Bevacizumab in Recurrent Glioblastoma Patients with Loss of CDKN2A/B or Gain of CDK4/6,
I3Y-US-X006,A Pilot Phase II Study of Neoadjuvant Fulvestrant plus Abemaciclib in Women with Advanced Low Grade Serous Carcinoma,
I3Y-US-I019,Pilot study of abemaciclib in hormone receptor positive ovarian and endometrial cancer,
I3Y-US-X004,Phase II Trial of Abemaciclib and Nivolumab for Advanced Hepatocellular Carcinoma,
I3Y-US-I003,Phase I-II Trial of Abemaciclib and Nivolumab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RMHNSCC),
I4E-US-X019,Targeted Agent and Profiling Utilization Registry (TAPUR) Study,
I4E-US-X029,"Open-label, Phase 2 Study of VS-6766 (RAF/MEK Clamp) and VS-6063 (FAK inhibitor) in combination with Cetuximab in Patients with Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer ",
J5C-MC-FOAG,DDI #1 no costs,
J6A-MC-OUAA,FHD SAD/MAD Pts/HV,
,Clinical Trial (Hepatic Impairment),
,Clinical Trial (Ph3 LY vs. IL-17; 24 wks treatment + continued access),
J2A-MC-GZP1,"Participants with Obesity and Overweight and At 
Least 1 Weight-Related Comorbidity (Excluding Type 2 Diabetes)",
J2A-MC-GZP2,"Participants with Obesity and Overweight and 
Type 2 Diabetes",
J3K-MC-KIAC,Clinical Trial (Ph2 OL Trial: POC),
I4T-JE-O030,A single-arm phase IIa study of neoadjuvant therapy with ramucirumab plus pembrolizumab (MK-3475) followed by surgery for stage IB-IIIA non-small cell lung cancer,
J3L-MC-EZEB,Phase 2 study in partcipants with elevated Lp(a),
I3Y-NS-I048,"A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, 
Pharmacokinetics, and Efficacy of INX-315 in Patients with 
Advanced Cancer",
J2N-OX-JZNN,LOXO-BTK-20020-BRUIN-321-Ph3-Pirtobrutinib-CLL,
J2J-MC-JZLF,China Phase 1 - MBC,
J2J-MC-JZLB,Ph1b - SERD Window Study,
J5M-OX-JOXA,Clinical Trial (Ph1/2 Trial: 200pts  4 cycle 35 sites 32mo  Model A),
J2J-MC-JZLA,Ph1a/b - Sel Estrogen Rec Degrad - Breast Cancer,
J2J-OX-JZLC,Ph3-SERD-MBC,
J2J-MC-JZLD,Food Effect PPI DDI Pts,
I4T-US-I015,"LungMAP: S1800A A Phase II Randomized Study of Docetaxel, Ramucirumab Plus Pembrolizumab versus Docetaxel, Ramucirumab Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched SubStudy)",
I4T-JE-O018,"A multicenter, single-arm, phase II study of ramucirumab plus FOLFIRI with 150 mg/m2 irinotecan, standard Nippon dose, as the second-line treatment for Japanese patients with metastatic colorectal cancer  (Study rindo)",
I5T-KL-B008,"This is a single-country, prospective, non-interventional PMSS of patients in Korea receiving Kisunla(Donanemab) for improving mild cognitive impairment or mild dementia stage of disease to collect AE-SAE/AESI and to evaluate the proportion of patients meeting efficacy endpoints (CDR-SB, ADAS-Cog13, ADCS-iADL, MMSE)",
I8F-NS-E001,Weight Reduction in Asthma Programme with Tirzepatide (WRAPT): clinical efficacy and mechanisms of action,
I8F-NS-X005,Combination Tirzepatide - Pioglitazone Therapy in T2DM,
J4T-MC-OLAA,FHD SAD/MAD AD Pts,
I7P-MC-DSAG,Clinical Trial (Ph2 Trial: (Adaptive for Linking),
J2N-MC-JZ04,ISA 4,
J3M-OX-JZQF,Loxo-RAS-23004-Ph1-KRAS-Hepatic Impairment HV,
J2N-MC-JZ01,ISA 1,
H7I-MC-S033,EEG vs PSG devices for sleep disturbance in Alzheimer’s patients,
J4X-JE-LWCA,SAD/MD/drug-drug interaction (DDI) with rosuvastatin HV,
J3M-OX-JZQJ,Loxo-RAS-23007 (DDI2 Perpetrator Cocktail),
J3M-OX-JZQD,LOXO-RAS-22002-Ph1-KRAS-CYP3A4 Inhib/Inducer,
J3M-OX-JZQG,Loxo-RAS-23005-Ph1-KRAS-Renal Impairment,
,"Post Approval Safety Study (Preg, Safety,  etc) - US",
I8F-MC-GPJC,Clinical Trial (China PK RBA KP vs YP),
J3M-MC-JZQB,Ph3-KRAS G12C+pembrolizumab-NSCLC,
J2N-MC-JZ02,ISA 2,
I5T-NS-E001,Ultra-rapid MRI for Alzheimer’s disease: ‘real-world’ application for trials and practice,
I8F-NS-I005,Efficacy of Tirzepatide in the treatment of weight regain after bariatric surgery.,
J3H-MC-GZNI,Clinical Trial (Healthy Weight Trial),
J2N-US-I010,A Clinical Trial of Pirtobrutinib and Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma,
W8M-MC-GN02,Clinical Trial T2D (CWM) Ph2b 32 Weeks,
J2N-MC-JZ06,ISA 6,
J4Z-MC-GIDI,Clinical Trial (Ph2 CWM T2D 36 weeks),
J2N-MC-JZ03,ISA 3,
I5Q- MC-B009,China prospective/non-interventional/one arm study,
I5T-JE-B005,Ovservational study_Japan VEO study,
I9S-MC-E001,"A Phase 2, Open Label Study of Anti-BTLA Agonist Therapy in Subjects with Primary Sjogren’s Syndrome",
J2T-NS-X002,"A Phase 2a Open-Label Study to Assess the safety, efficacy and tolerability of Lebrikizumab in Reducing Pruritus in Adults with Prurigo Nodularis",
I6T-NS-X002,INTESTINAL ULTRASOUND PREDICTS RESPONSE TO THERAPY IN ULCERATIVE COLITIS PATIENTS TREATED WITH MIRIKIZUMAB,
J2J-NS-E001,A quality of life associated sub-study to the EMBER-4 trial: comparing vaginal health and sexuality in patients using Imlunestrant Versus Standard Endocrine Therapy,
J5S-MC-CEAA,FHD SAD/MAD,
I7E-AV-E144,Minimally invasive detection of early Alzheimer's disease pathology at the eye clinic using blood tests and eye scans: the BeyeOMARKER study,
I7E-AV-E143,"Synaptic density and tau pathology in Alzheimer's Disease (""SYNAPSE"")",
J2J-NS-X001,Phase II minimal residual disease study of selective estrogen receptor modulator imlunestrant with CDK 4/6 inhibitor abemaciclib in patients with ER+ breast cancer (MIRI),
H8H-MC-LAHV,Ph3 Lasmiditan vs Placebo in Peds and Adolescents,
,Clinical Trial (RBA/BE),
,Clinical Trial (Ph3 PBO and Active Comparator Study (2LY:1Sotyktu: 1PBO),
I7E-AV-E109,Lithium As a Treatment to Prevent Impairment of Cognition in Elders (LATTICE),
I7E-AV-E141,"Timely, Accurate, and Personalized Diagnosis of Dementia (""TAP-Dementia"")",
I7E-AV-ADN3,Alzheimer's Disease Neuroimaging Initiative 3 (ADNI-3),
I7E-AV-E139,Impact of Semaglutide in Amyloid Positivity (ISAP),
J5D-MC-FPAB,FHD SAD/MAD LM non-Oncology HV,
J3S-MC-YEAA,FHD  Dose Escalation  Hybrid Pt/HV  Obese,
I1F-NS-O019,"Detailed assessment of axial and peripheral entheses and joints in axial spondyloarthritis and psoriatic arthritis patients treated with ixekizumab – a 2-year study applying whole body MRI, MRI-based synthetic CT and CT.",
,Clinical Trial (OUS Efsitora Tempo Device) Prism Req 1225,
J3H-JE-GZNG,Japan MAD study,
I5Q-MC-CGAT,Adolescent chronic migraine prevention study,
W8M-MC-LG01,Clinical Trial (CWM non-T2D LAGIPRA + eloralintide Combo),
J3R-MC-YDAE,RBA Ph2 vs Ph3 EP and coformulation with TZP vs coadministration with TZP HV,
J2T-MC-KGBV,China PK Study HV,
J2A-MC-GZL2,A Master Protocol for Orforglipron in Participants with Hypertension and Obesity or Overweight: (ATTAIN-HYPERTENSION) ISA GZL2,
I4E-NS-L001,"An Open-Label, Multicenter, First-in-Human,
Dose-Escalation and Dose-Expansion, Phase 1/2
Study of BBI-825 and BBI-825 in Combination
With Select Targeted Therapies in Subjects With
Locally Advanced or Metastatic Solid Tumors
With Resistance Gene Amplifications",
,Clinical Trial (Ph2 Reduction in Craving Promote BUP Adherence),
I5T-JE-B003,Observational study_Japan PMSS,
I3Y-NS-O026,"A study of Niraparib in combination with Abemaciclib for late line treatment of ovarian cancer: a monocenter, open label, single arm, phase I/II trial",
J2N-JE-B008,Observational Study Japan PMSS_Pirtobrutinib_MCL,
J2O-MC-EKBG,Clinical Trial (Ph3 Trial 2: HF CVOT) SM,
I8R-JE-B005,Post Marketing Japan Nasal Glucagon Study for Ped. DM pts,
J5W-MC-OSAA,Clinical Trial (Ph1/2 CSF1R-related Adult-Onset Leukoencephalopathy) Gene Therapy,
I3Y-NS-O003,Abemaciclib combined endocrine therapy in patients with symptomatic metastatic breast cancer,
J2A-MC-GZPQ,Mechanism of Action and Body Composition HV,
J3X-MC-LYGC,DDI,
J5Q-OX-JRDA,Clinical Trial (Ph1a/b Trial: 200 pts 6 cyc 30 sites 36 mo Model B),
J3H-GH-GZNH,China PK Pts,
J4M-MC-PW02,Pediatric (Age 6-11),
,Paediatric participant study (12 - <18 years) w/obesity,
J2P-MC-LXBC,C14 Study HV,
J2A-MC-GZL1,A Master Protocol for Orforglipron in Participants with Hypertension and Obesity or Overweight: (ATTAIN-HYPERTENSION) Future ISA GZL1,
I3Y-NS-JPEA,"An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts",
I8F-MC-GPJB,Clinical Trial (China PK BE KP vs YP),
I8F-NS-I001,"The Effects of Tirzepatide on Adolescents and Young Adults with PWS, Hypothalamic Obesity and General Non-Syndromic Obesity",
J2N-MC-JZ05,ISA 5,
J6E-MC-KWAA,Clinical Trial (China PK),
I4V-CA-B042,Cross-Sectional Survey of Rheumatologists and Dermatologists to Assess the Effectiveness of the Baricitinib Additional Risk Minimization Measures in Canada,
J1B-MC-FRCC,FHD SAD/MAD HV POC Atopic Derm Pts,
"27381","A Prospective Observational Cohort Study Evaluating Lebrikizumab Therapy in the Management of Adult and Pediatric Patients 12 Years of Age and Older with Moderate-to-Severe Atopic Dermatitis in Asia, Latin America and the Middle East.",
"7986",Olanzapine - H1 Receptors Imaging Trial,
H9X-MC-B001,Medullary Thyroid Carcinoma Surveillance,
I6T-MC-AMAP,Ulcerative Colitis Long Term Extension study,
I8H-MC-BDCX,BIF Ph3 T2DM Insulin Naïve 12 month vs Degludec,
J3Z-MC-OJAC,PRV-GD2-EAP; GD Type 2  Center 1,
I1F-US-I007,Ixekizumab in the treatment of Lichen Planus,
B5K-NS-I013,"develop, study, and introduce to pharmaceutical market an investigational transdermal spray-on insulin delivery technology, INS-2301",
I8I-MC-JYAA,Single Protocol-cont access to study drug-mult compounds,
I8B-MC-ITSU,Protection from Exercise Induced Hypoglycaemia Pts,
H8A-MC-LZAZ,A4 - Anti-Amyloid Treatment in Asymptomatic AD,
I4V-MC-JAIP,"PK, Effi & Safety adolescent mod-severe atopic derm",
I3Y-MC-JPCP,Food Effect and Tolerability,
H9X-JE-GBGQ,Japan Ph3 for Dulagltuide 1.5mg,
J1X-MC-GZHI,Intestinal Distal Formulation Study HV,
J2U-MC-YBAC,SAD/MAD Japanese HV,
J3L-MC-EZEE,"PK study, HV, Healthy",
J2A-JE-GZPE,GLP-NPA Ph3 study in Japan for Type 2 Diabetes Mellitus,
J5B-MC-FHAH,SAD/MAD JP Ph1 in PsO Pts,
J3P-MC-FTAA,POS for Ps,
J2A-MC-GZPC,Renal Impairment Study Pts,
J4H-MC-KNAB,"J/C PK, RBA, Food Effect, High Dose Study",
J3P-NS-FTB1,"This was a PhI SAD/MAD study that was performed by Rigel, before the molecule was in-licensed by Lilly.  The study is fully completed, with a final CSR date in Feb 2021.",
I7E-AV-_A26,High Tau Reader Study,
I8P-MC-OXAK,RBA Formulation Bridging Study HV,
,Intervention Specific Appendix,
I6E-AV-X001,Alzheimer’s Disease Digital Biomarker Discovery: Framingham Cognitive Aging and Dementia Study,
I6T-NS-E003,Early IBD ESCR - Ulcerative Colitis part 1,
I4V-NS-O021,BARICITINIB IN THE TREATMENT OF COVID-19,
I4V-MC-E002,"Baricitinib in Relapsing Giant Cell Arteritis (GCA):  A Phase II, Single-Institution, Open-label Pilot",
I4V-MC-E003,Phase II proof of concept study of Baricitinib in individuals who are considered at risk of developing Inflammatory Arthritis,
I6T-MC-AMCA,PK Miri Lactation Trial,
J4Z-VR-G012,PoC study of BYM338 in inclusion body myositis (IBM),
I6T-KL-B007,Post-Marketing Safety Study on OMVOH (Mirikizumab) for Adult Patients in Korea with Moderately to Severely Active Ulcerative Colitis,
J1O-MC-JZHD,Ph1b - AurA Kinase Inb - Pediatric Neuroblastoma,
I3Y-MC-B009,China PMSS - Ph IV-Abemaciclib-mBC,
H7K-MC-O005,EET Bolus Injector Study Pts,
J2T-MC-KGBG,BE Prefilled Syringe vs AutoInjector HV,
J2J-MC-JZLH,Imlunestrant Adjuvant Trial in ER+HER- Early Breast Cancer,
J3Z-MC-OJAB,PRV-GD2-101 Ph I/II PR001A GD2,
I3Y-MC-JPBZ,R-Ph II-Abema+Traz+/-Fulvest vs SOC+Traz - HR+/HER2+ mBC,
I4E-NS-I023,,
I8F-KL-B008,"This is an observational study, post-marketing safety study protocol, to be implemented in Korea only. 
Post-Marketing Safety Study on Mounjaro (Tirzepatide) for Adult Patients in Korea requiring improving glycemic control in Type 2 Diabetes Mellitus or Chronic Weight Management.",
J4F-MC-CYAA,FHD SAD/MAD HV,
W8M-MC-OXA1,CWM Master Protocol - Mazdutide Ph2,
J2N-JE-B010,Japan PMSS_Pirtobrutinib_RR CLL monotherapy,
I1F-MC-RHBT,Ixekizumab North American Registry,
I4V-MC-B025,Survey assessment of risk minimization activities,
J3H-MC-GZNB,MAD and T2D Pts,
I8R-MC-B003,China Post-Marketing Safety Surveillance,
J1I-MC-GZQE,PK Small Intestine Transit Time HV,
J2A-MC-GZGI,Phase 2 Obesity GLP-1 Non-Peptide Ag 1,
J3N-OX-JZRA,LOXO-BCL-20001-Ph1-BCL2-NHL,
I5T-MC-AACR,Real World Donanemab phase IV OUS,
I6T-MC-B005,Clinical Trial (Observational Study),
"25969","A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of LY3885125 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single-Ascending Dose in Participants with Dyslipidemia and Repeat-Doses in Participants with NAFLD.",
,Clinical Trial (Ph2 Trial: Ph2 Healey MP) SM,
I3Y-MC-JPBL,Monarch 2_R-PhIII-CDK 4/6Dual Inh+Fulv vs Fulv+Plcb-MBC,
I4V-MC-B009,IBU & CA Site-based Prospective Obs Study,
I5Q-KR-CGAZ,Galcanezumab Migraine PMSS- Korea,
I6T-MC-AMBU,Peds UC Open Label PK Study,
I6T-MC-AMBY,Crohn's Reformation BE HV,
J1I-MC-GZBE,China Ph1 PK Study Pts,
J3K-MC-KIAA,Safety FHD SAD/MAD with HV Study,
H6O-MC-O015,CNCD Call Back Sample collection protocol,
J1S-MC-JP04,Ph2-Abema+TMZ+IRN vs TMZ+IRN-Ewings Sarcoma,
J4Z-VR-G009,Skeletal muscle in sarcopenic adults with mobility limitations,
J2A-MC-GZGL,A DDI investigating effect of cyclosporine on the PK of LY,
I5Q-MC-B010,Emgality Device Post Market Clinical Follow Up (PMCF) Survey Study,
J4G-OX-JZVA,LOXO-FG3-22001-Ph I/II-FGFR3-Genitourinary,
I6F-JE-JJCC,JP_FHD - Ph I - Notch Inhib II - Solid Tumors,
